data_2jvu_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2jvu _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -79.89 -21.73 43.65 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.475 -0.765 . . . . 0.0 110.549 -179.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 28.5 m120 -88.48 0.13 56.61 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.933 -1.105 . . . . 0.0 109.424 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.8 t -112.74 127.54 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.553 -0.717 . . . . 0.0 109.42 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.478 ' CG ' ' HG ' ' A' ' 13' ' ' SER . 12.1 t0 -79.04 130.92 68.2 Favored Pre-proline 0 N--CA 1.488 1.444 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 178.642 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -74.49 -10.65 22.21 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 121.706 1.604 . . . . 0.0 111.832 -179.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.478 ' HG ' ' CG ' ' A' ' 11' ' ' ASP . 82.7 p -69.96 -29.34 66.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.301 -0.874 . . . . 0.0 109.505 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 62.9 tt0 -90.07 -19.52 24.26 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.228 -0.92 . . . . 0.0 109.502 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.811 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 48.8 t -66.34 -33.5 75.86 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.089 -1.007 . . . . 0.0 109.846 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.5 pp -119.35 132.11 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -113.98 142.87 45.61 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -96.01 127.24 41.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.422 -0.799 . . . . 0.0 110.024 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 49.5 m -115.67 124.24 50.39 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.62 -103.12 0.11 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.4 m -129.76 30.5 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.086 0 O-C-N 121.559 -0.965 . . . . 0.0 109.188 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 14.2 tt0 -129.43 153.04 48.32 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.397 -0.815 . . . . 0.0 110.453 -178.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -114.34 136.42 53.0 Favored 'General case' 0 N--CA 1.499 1.99 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.193 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 36.9 p -135.36 145.37 47.31 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.338 -0.851 . . . . 0.0 109.553 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 45.6 t80 -80.13 124.46 28.79 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.2 m120 -82.82 86.96 6.82 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.01 -1.056 . . . . 0.0 110.267 -179.087 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.409 ' C ' ' H ' ' A' ' 29' ' ' VAL . 13.8 m -79.61 -13.69 59.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.044 -1.035 . . . . 0.0 109.145 179.422 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -65.78 -3.68 16.66 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.409 ' H ' ' C ' ' A' ' 27' ' ' SER . 2.0 t -102.93 126.91 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 96.7 p -59.92 -40.12 87.79 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.076 -1.015 . . . . 0.0 111.279 -178.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.447 ' CG2' ' N ' ' A' ' 32' ' ' CYS . 16.2 m -60.56 -44.3 96.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 120.878 -1.139 . . . . 0.0 110.638 -178.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.811 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 89.3 m -60.14 -43.36 95.76 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.099 -1.001 . . . . 0.0 110.563 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 95.2 mmm -84.33 -12.76 54.02 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.721 -1.237 . . . . 0.0 109.121 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 -60.12 -47.44 85.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.889 . . . . 0.0 108.604 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.86 -45.04 17.85 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.2 tp -60.18 -40.01 88.47 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.242 -1.152 . . . . 0.0 109.449 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -66.13 -39.95 90.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.319 -0.863 . . . . 0.0 110.363 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -75.62 -6.17 49.03 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.071 -1.018 . . . . 0.0 109.978 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.93 26.81 73.3 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -101.13 -5.47 25.62 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.443 ' CG1' ' H ' ' A' ' 43' ' ' GLY . 77.2 t -134.95 159.82 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -179.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 65.0 mtp180 -122.73 -5.93 8.59 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.443 ' H ' ' CG1' ' A' ' 41' ' ' VAL . . . 137.76 -164.92 25.43 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 108.429 -1.868 . . . . 0.0 108.429 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.0 t -120.34 130.0 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.226 -1.161 . . . . 0.0 109.545 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.3 t -83.17 133.79 35.01 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.189 -0.944 . . . . 0.0 108.726 179.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.5 p -129.96 134.22 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.59 -0.694 . . . . 0.0 109.434 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 25.5 p -124.83 146.59 49.19 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.473 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -138.27 140.55 11.23 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 98.2 t -126.53 129.85 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.675 -0.897 . . . . 0.0 109.143 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -101.44 117.2 34.45 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 39.1 m-85 -91.96 122.61 34.64 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.403 -0.811 . . . . 0.0 109.079 -179.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.402 ' C ' ' H ' ' A' ' 54' ' ' ASP . 98.7 m-85 -104.99 136.16 44.99 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.575 -0.703 . . . . 0.0 109.771 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 -57.27 -11.63 1.88 Allowed 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 11.2 t70 -74.46 2.16 10.19 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.59 21.21 69.78 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.1 p -120.47 147.02 45.66 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.405 -1.056 . . . . 0.0 110.127 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 71.8 p -130.01 140.95 50.8 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.673 0.749 . . . . 0.0 110.066 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.6 t -116.96 140.83 49.0 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 106.641 -1.614 . . . . 0.0 106.641 178.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 49.0 m-20 -129.96 116.69 18.97 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.035 -1.04 . . . . 0.0 109.727 -179.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -116.57 124.38 49.68 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -114.18 146.05 40.87 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -163.96 168.31 38.4 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.159 -1.576 . . . . 0.0 109.159 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.3 t -110.39 127.32 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.535 -0.98 . . . . 0.0 109.363 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.3 t -89.59 118.89 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.375 -0.828 . . . . 0.0 109.792 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.593 ' HG1' ' H ' ' A' ' 68' ' ' THR . 30.1 p -128.25 149.97 72.79 Favored Pre-proline 0 N--CA 1.494 1.732 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 178.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.89 -16.12 3.86 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 121.276 1.318 . . . . 0.0 111.414 -179.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 84.2 p -108.21 -13.2 14.96 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.393 -0.817 . . . . 0.0 110.697 -179.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.593 ' H ' ' HG1' ' A' ' 65' ' ' THR . 56.8 m -132.55 106.87 13.07 Favored Pre-proline 0 N--CA 1.505 2.286 0 O-C-N 121.086 -1.009 . . . . 0.0 110.561 -179.378 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -88.28 162.43 6.95 Favored 'Trans proline' 0 N--CA 1.49 1.293 0 C-N-CA 122.267 1.978 . . . . 0.0 111.833 178.329 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.5 t -120.17 128.49 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.158 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -104.64 128.77 52.77 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.124 -0.985 . . . . 0.0 111.324 -178.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 74' ' ' GLN . 1.1 p -90.05 0.09 57.31 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 177.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -67.9 60.43 0.07 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-O 121.556 0.693 . . . . 0.0 109.143 -179.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.494 ' N ' ' O ' ' A' ' 72' ' ' THR . 7.3 tt0 -68.79 -106.5 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.169 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -103.6 94.47 5.48 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.009 -1.057 . . . . 0.0 109.74 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 79.5 mt -74.46 -29.82 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.013 -1.054 . . . . 0.0 109.698 179.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -59.94 -42.63 94.42 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.809 -1.182 . . . . 0.0 108.186 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 84.2 tttt -65.27 -42.16 93.49 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.277 -0.889 . . . . 0.0 108.749 178.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.599 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.4 OUTLIER -69.75 -42.7 73.54 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.562 -0.711 . . . . 0.0 110.179 -179.132 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -63.51 -32.76 74.3 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.168 -1.582 . . . . 0.0 109.233 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.0 tttt -69.81 -47.38 63.03 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 110.735 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.4 p -112.2 -27.55 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 O-C-N 121.504 -0.747 . . . . 0.0 111.661 -177.126 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.599 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 88.61 169.7 45.04 Favored Glycine 0 N--CA 1.49 2.244 0 O-C-N 120.715 -1.241 . . . . 0.0 110.452 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.473 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 23.5 t -115.43 129.67 71.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.892 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -80.07 -67.46 0.76 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.071 -1.018 . . . . 0.0 110.297 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -116.51 140.12 49.71 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.508 -0.745 . . . . 0.0 110.846 -179.102 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 68.9 t80 -119.96 131.8 55.3 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -131.53 132.6 44.3 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.08 -1.012 . . . . 0.0 110.788 -178.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.52 137.1 54.84 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.802 -0.561 . . . . 0.0 109.551 179.266 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 44.7 tp -117.16 133.32 56.14 Favored 'General case' 0 N--CA 1.502 2.167 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 p -129.08 122.18 29.39 Favored 'General case' 0 N--CA 1.503 2.215 0 CA-C-O 121.708 0.766 . . . . 0.0 110.733 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -132.35 152.75 51.3 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.891 -0.506 . . . . 0.0 109.846 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 78.0 m95 -70.21 139.89 52.37 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.048 -1.033 . . . . 0.0 109.07 178.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 59.7 t -112.53 120.83 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.156 0 O-C-N 121.383 -0.823 . . . . 0.0 109.397 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.487 0 N-CA-C 109.189 -1.564 . . . . 0.0 109.189 179.844 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.653 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . 0.414 ' O ' ' OD1' ' A' ' 8' ' ' ASP . 61.1 t0 -92.13 -27.47 17.71 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.234 -0.917 . . . . 0.0 109.555 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -95.15 4.08 54.01 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.392 -0.817 . . . . 0.0 110.099 -179.276 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 19.7 t -110.61 134.08 54.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.5 -0.75 . . . . 0.0 109.88 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -90.81 131.61 37.07 Favored Pre-proline 0 N--CA 1.49 1.526 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.49 -14.16 22.5 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 121.747 1.631 . . . . 0.0 111.592 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 59.8 p -67.22 -35.83 80.42 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.518 -0.739 . . . . 0.0 109.867 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -90.05 -11.62 40.9 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.208 -0.933 . . . . 0.0 110.313 -179.095 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.816 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 8.2 t -69.63 -29.4 66.89 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.974 -1.079 . . . . 0.0 108.471 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.4 pp -120.62 145.47 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 61.1 mttp -127.09 154.14 45.09 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.402 -0.811 . . . . 0.0 110.032 -179.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.441 ' NE2' ' OH ' ' A' ' 23' ' ' TYR . 83.4 mt-30 -96.07 120.01 35.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.463 -0.773 . . . . 0.0 109.692 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 5.9 t -110.34 115.14 29.14 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.87 -111.09 2.25 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.4 m -117.33 20.69 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.241 0 O-C-N 121.466 -1.02 . . . . 0.0 109.959 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -127.26 160.53 31.02 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.348 -0.845 . . . . 0.0 111.081 -177.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . 0.441 ' OH ' ' NE2' ' A' ' 18' ' ' GLN . 12.5 m-85 -111.33 134.17 53.11 Favored 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.567 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 37.9 p -132.74 145.48 51.06 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.284 -0.885 . . . . 0.0 108.986 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -82.87 127.26 33.33 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.387 -0.821 . . . . 0.0 108.999 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -84.56 80.52 9.21 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.024 -1.047 . . . . 0.0 109.119 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.555 ' C ' ' H ' ' A' ' 29' ' ' VAL . 92.0 p -83.73 -8.35 59.27 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.413 -0.804 . . . . 0.0 109.485 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.67 -2.74 0.2 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.159 -1.177 . . . . 0.0 110.159 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.555 ' H ' ' C ' ' A' ' 27' ' ' SER . 34.9 m -108.32 131.35 59.03 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.328 -1.101 . . . . 0.0 108.442 179.165 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 82.8 p -63.68 -30.23 71.36 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.287 -0.883 . . . . 0.0 111.278 -178.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 p -59.9 -39.9 81.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 120.87 -1.144 . . . . 0.0 110.415 -179.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.816 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 56.3 m -59.93 -40.17 87.99 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.95 -1.094 . . . . 0.0 110.077 -179.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 9.0 mmt -79.73 -14.31 58.83 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.0 -1.062 . . . . 0.0 109.415 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 -60.76 -40.56 92.98 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.876 -1.14 . . . . 0.0 108.451 179.323 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -82.99 -51.22 4.29 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.5 mt -58.27 -40.07 80.88 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.919 -1.341 . . . . 0.0 108.832 -179.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -59.93 -40.02 87.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.342 -0.848 . . . . 0.0 109.497 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 60.3 mm-40 -76.8 -6.76 53.64 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.989 -1.069 . . . . 0.0 109.87 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.35 32.56 68.37 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 120.066 -1.064 . . . . 0.0 110.646 178.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -102.81 -9.65 19.77 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.462 HG12 ' H ' ' A' ' 43' ' ' GLY . 5.8 t -134.19 158.16 41.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -179.087 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -117.33 -11.08 10.63 Favored 'General case' 0 N--CA 1.501 2.087 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 178.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.462 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 146.09 -157.33 27.34 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 107.879 -2.088 . . . . 0.0 107.879 -179.175 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 77.2 t -120.01 128.42 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.281 -1.129 . . . . 0.0 108.538 179.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.8 m -86.17 132.78 33.94 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.118 -0.989 . . . . 0.0 108.351 179.454 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 13.2 p -132.52 132.46 60.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.592 -0.693 . . . . 0.0 109.779 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.3 m -128.47 141.1 51.5 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 178.395 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.426 ' O ' ' OD1' ' A' ' 59' ' ' ASN . . . -130.87 149.6 19.16 Favored Glycine 0 N--CA 1.505 3.272 0 C-N-CA 120.21 -0.995 . . . . 0.0 110.872 -178.621 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 38.2 t -125.04 129.99 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.824 -0.809 . . . . 0.0 108.825 179.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.539 ' CE2' ' O ' ' A' ' 72' ' ' THR . 50.0 m-85 -105.45 121.89 44.86 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.475 -0.766 . . . . 0.0 109.567 179.285 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 45.8 m-85 -95.76 121.59 37.65 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.045 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.444 ' C ' ' N ' ' A' ' 54' ' ' ASP . 93.3 m-85 -106.28 128.61 54.11 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.236 -0.915 . . . . 0.0 109.271 179.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.473 ' C ' ' H ' ' A' ' 55' ' ' GLY . 51.9 t30 -48.77 -17.13 0.15 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.067 -1.021 . . . . 0.0 109.199 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.444 ' N ' ' C ' ' A' ' 52' ' ' TYR . 62.7 m-20 -67.99 3.28 1.62 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.407 -0.808 . . . . 0.0 109.115 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.473 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 77.68 19.77 75.21 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 178.655 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.1 p -117.79 147.67 42.78 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.383 -1.069 . . . . 0.0 109.952 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 24.3 p -130.57 127.96 40.1 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.703 -0.623 . . . . 0.0 109.543 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 30.6 t -118.39 154.49 32.31 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . 0.426 ' OD1' ' O ' ' A' ' 48' ' ' GLY . 57.9 t-20 -141.53 133.15 27.02 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.796 -1.19 . . . . 0.0 110.149 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.438 ' CZ ' ' NE2' ' A' ' 74' ' ' GLN . 58.6 m-85 -116.46 124.41 49.91 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.304 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 62.9 tttm -114.36 143.4 44.96 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.15 172.46 43.38 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 49.0 t -114.74 128.67 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.629 -0.924 . . . . 0.0 109.156 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 75.7 t -98.08 123.02 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.218 -0.927 . . . . 0.0 109.515 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.465 ' HG1' ' CB ' ' A' ' 68' ' ' THR . 17.0 p -121.55 151.0 56.16 Favored Pre-proline 0 N--CA 1.496 1.856 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_exo -34.49 -34.0 0.08 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.399 2.066 . . . . 0.0 113.191 -179.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.403 ' N ' ' O ' ' A' ' 65' ' ' THR . 63.4 m -106.76 -0.55 23.4 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.379 -0.825 . . . . 0.0 111.78 -178.626 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.465 ' CB ' ' HG1' ' A' ' 65' ' ' THR . 4.1 m -124.39 106.86 30.05 Favored Pre-proline 0 N--CA 1.508 2.437 0 O-C-N 120.945 -1.097 . . . . 0.0 111.527 -178.5 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -92.61 161.2 2.89 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 C-N-CA 122.712 2.275 . . . . 0.0 111.025 177.126 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 91.1 t -134.64 139.88 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.238 0 O-C-N 120.952 -1.092 . . . . 0.0 109.825 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -95.43 138.72 32.72 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.165 -0.959 . . . . 0.0 109.158 179.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.539 ' O ' ' CE2' ' A' ' 50' ' ' PHE . 5.8 t -110.93 -33.83 6.4 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.321 -0.862 . . . . 0.0 109.419 -179.769 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.508 ' ND2' ' CD1' ' A' ' 76' ' ' ILE . 9.6 t30 -92.1 32.32 1.17 Allowed 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.218 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.438 ' NE2' ' CZ ' ' A' ' 60' ' ' PHE . 13.8 pt20 -54.13 -22.56 11.43 Favored 'General case' 0 N--CA 1.499 2.011 0 C-N-CA 120.276 -0.57 . . . . 0.0 112.246 -178.056 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -107.37 71.9 0.85 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 120.702 -1.249 . . . . 0.0 109.735 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.508 ' CD1' ' ND2' ' A' ' 73' ' ' ASN . 45.7 mm -70.1 -40.35 78.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.335 -0.853 . . . . 0.0 111.332 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -60.12 -46.9 88.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.629 -1.294 . . . . 0.0 108.551 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 29.6 ttmt -60.08 -50.03 75.33 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.293 -0.879 . . . . 0.0 108.864 179.092 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.568 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.3 m -62.36 -42.8 99.69 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.79 -0.569 . . . . 0.0 110.625 -178.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -60.47 -35.28 75.5 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.561 -1.337 . . . . 0.0 110.027 179.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 14.7 tmtt? -67.07 -48.55 67.91 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.089 -1.007 . . . . 0.0 111.079 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -113.45 -26.88 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.183 -0.948 . . . . 0.0 111.572 -178.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 90.07 168.11 42.61 Favored Glycine 0 N--CA 1.491 2.323 0 O-C-N 120.54 -1.35 . . . . 0.0 110.173 179.737 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.05 124.58 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -79.92 -65.64 0.98 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.094 -1.004 . . . . 0.0 110.286 -179.169 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 44.3 tptt -115.38 142.28 46.91 Favored 'General case' 0 N--CA 1.504 2.23 0 O-C-N 121.415 -0.803 . . . . 0.0 110.526 -178.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.0 t80 -121.13 132.1 54.65 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 -135.01 127.18 29.98 Favored 'General case' 0 N--CA 1.503 2.199 0 O-C-N 121.126 -0.984 . . . . 0.0 110.358 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.87 134.63 52.63 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.654 -0.653 . . . . 0.0 110.017 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.6 tp -118.51 133.45 55.86 Favored 'General case' 0 N--CA 1.503 2.192 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.2 p -129.2 126.36 39.0 Favored 'General case' 0 N--CA 1.503 2.198 0 CA-C-O 121.53 0.681 . . . . 0.0 110.678 -179.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 58.2 mm-40 -134.4 158.46 43.79 Favored 'General case' 0 N--CA 1.504 2.235 0 CA-C-O 121.488 0.661 . . . . 0.0 110.599 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 71.9 m95 -71.15 139.21 50.15 Favored 'General case' 0 N--CA 1.494 1.774 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 178.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 44.6 t -112.41 118.79 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.289 -0.882 . . . . 0.0 109.335 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.504 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.318 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -66.72 -73.3 0.14 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.758 -0.589 . . . . 0.0 110.234 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 64.8 t-20 -145.45 47.05 1.29 Allowed 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 179.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 2.6 m -81.17 139.75 17.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.538 -0.726 . . . . 0.0 109.077 -178.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.447 ' OD1' ' N ' ' A' ' 11' ' ' ASP . 2.0 m-20 -76.66 130.01 77.71 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.906 . . . . 0.0 109.981 -178.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -81.55 -19.96 7.2 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.22 1.947 . . . . 0.0 112.079 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 81.9 p -64.87 -36.53 84.64 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.437 -0.79 . . . . 0.0 110.572 -179.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -68.99 -24.66 64.26 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.132 -0.98 . . . . 0.0 109.715 -179.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.814 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 50.1 t -65.56 -35.16 80.03 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.331 -0.856 . . . . 0.0 109.775 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -117.09 140.42 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.063 0 O-C-N 121.436 -0.79 . . . . 0.0 109.149 -179.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -117.82 147.17 43.3 Favored 'General case' 0 N--CA 1.5 2.026 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -93.77 122.22 36.01 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.172 -0.955 . . . . 0.0 109.746 -179.429 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.479 ' O ' ' N ' ' A' ' 21' ' ' VAL . 26.3 t -110.67 123.71 50.53 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.117 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.42 -94.28 0.01 OUTLIER Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.479 ' N ' ' O ' ' A' ' 19' ' ' SER . 24.7 m -139.4 28.03 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.945 0 O-C-N 121.236 -1.155 . . . . 0.0 109.833 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.6 pt20 -131.42 163.65 27.45 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.318 -0.864 . . . . 0.0 110.035 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 54.0 m-85 -115.69 139.97 49.63 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 76.6 p -134.15 148.67 50.98 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.388 -0.82 . . . . 0.0 109.021 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 52.1 t80 -87.54 124.92 33.99 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.441 -0.787 . . . . 0.0 110.007 -178.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -84.39 84.93 7.47 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.33 -0.856 . . . . 0.0 109.732 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 92.4 p -77.22 -9.44 58.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.141 -0.975 . . . . 0.0 109.679 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -72.9 -1.91 56.42 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -98.89 131.64 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.159 -1.2 . . . . 0.0 108.431 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 27.3 t -59.97 -42.58 94.46 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.324 -0.86 . . . . 0.0 110.643 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.402 ' CG1' ' N ' ' A' ' 32' ' ' CYS . 9.9 p -59.95 -40.15 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.711 -1.243 . . . . 0.0 110.327 -179.061 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.814 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 90.2 m -61.95 -48.29 81.07 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.014 -1.054 . . . . 0.0 111.244 -178.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 1.2 mmt -77.64 -24.67 49.43 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.735 -1.228 . . . . 0.0 111.358 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -60.06 -40.05 88.12 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.709 -1.244 . . . . 0.0 109.498 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -72.44 -44.2 42.53 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.2 mt -66.2 -42.58 88.58 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.309 -1.112 . . . . 0.0 109.629 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -60.88 -40.08 91.67 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.07 -1.019 . . . . 0.0 110.212 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -78.66 -12.49 60.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.354 -0.841 . . . . 0.0 109.907 -178.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.02 29.27 70.8 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 41.9 mmtm -103.26 -5.39 23.14 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.435 HG13 ' H ' ' A' ' 43' ' ' GLY . 72.4 t -135.13 160.26 40.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 93.4 mtt-85 -120.95 -5.96 9.56 Favored 'General case' 0 N--CA 1.501 2.095 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.435 ' H ' HG13 ' A' ' 41' ' ' VAL . . . 132.59 -158.58 23.09 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 107.939 -2.064 . . . . 0.0 107.939 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 81.3 t -121.98 128.1 75.53 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.222 -1.164 . . . . 0.0 110.194 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.6 t -83.13 134.98 34.97 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 178.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 7.7 p -131.22 134.57 61.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.38 -0.825 . . . . 0.0 109.963 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.8 p -125.35 141.6 51.98 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -129.61 138.1 10.01 Favored Glycine 0 N--CA 1.503 3.107 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -178.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.15 125.01 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.61 ' CG ' ' NE2' ' A' ' 74' ' ' GLN . 26.3 m-85 -102.31 121.78 42.95 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 77.2 m-85 -94.61 129.28 41.53 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 120.984 -1.072 . . . . 0.0 109.517 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.47 ' OH ' ' NE2' ' A' ' 74' ' ' GLN . 68.4 m-85 -109.34 130.48 55.49 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.613 -0.679 . . . . 0.0 110.433 -179.693 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 43.1 t30 -50.61 -16.72 0.41 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.347 -0.846 . . . . 0.0 108.971 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.419 ' N ' ' C ' ' A' ' 52' ' ' TYR . 29.6 t0 -73.26 1.3 9.7 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.332 -0.855 . . . . 0.0 109.352 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.16 18.98 70.62 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 179.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.4 p -117.34 146.74 43.18 Favored 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.482 -1.01 . . . . 0.0 110.106 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.3 p -130.23 140.25 50.73 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.65 0.738 . . . . 0.0 110.384 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 65.3 p -118.14 143.95 46.07 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 178.235 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -137.79 119.73 15.38 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.876 -1.14 . . . . 0.0 109.933 -179.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -115.61 125.24 52.68 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -110.55 143.5 40.83 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -161.89 161.46 33.34 Favored Glycine 0 C--N 1.284 -2.319 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 32.2 t -108.12 125.85 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.347 -1.09 . . . . 0.0 109.049 -179.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 55.5 t -91.77 116.7 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.318 -0.864 . . . . 0.0 109.417 -179.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 67' ' ' SER . 22.3 p -135.89 149.93 70.08 Favored Pre-proline 0 N--CA 1.494 1.73 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 179.244 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_exo -41.47 -18.03 0.07 OUTLIER 'Trans proline' 0 C--N 1.313 -1.307 0 C-N-CA 121.908 1.739 . . . . 0.0 112.039 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.526 ' N ' ' O ' ' A' ' 65' ' ' THR . 68.7 m -69.96 -52.12 27.05 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.277 -0.889 . . . . 0.0 111.139 -179.002 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 60.1 p -149.64 151.75 33.61 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 120.731 -1.231 . . . . 0.0 110.064 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -85.38 165.72 10.84 Favored 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.728 2.285 . . . . 0.0 112.422 178.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 68.8 t -111.23 134.05 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.219 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -102.36 131.78 48.76 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.121 -0.987 . . . . 0.0 112.048 -177.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.401 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.3 OUTLIER -111.01 20.07 17.85 Favored 'General case' 0 N--CA 1.503 2.217 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 177.694 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.492 HD21 ' N ' ' A' ' 73' ' ' ASN . 0.0 OUTLIER -77.07 55.73 1.17 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.575 -0.703 . . . . 0.0 110.383 -178.782 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.61 ' NE2' ' CG ' ' A' ' 50' ' ' PHE . 13.2 pt20 -49.0 175.04 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.366 -0.834 . . . . 0.0 108.884 178.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -55.19 107.71 0.34 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.819 -1.176 . . . . 0.0 108.64 179.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 72.2 mt -79.36 -13.83 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.181 -0.949 . . . . 0.0 110.019 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -59.94 -45.18 93.47 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.87 -1.144 . . . . 0.0 109.254 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 1.3 ptpp? -66.23 -38.53 88.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.93 -1.107 . . . . 0.0 108.905 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.601 ' O ' ' N ' ' A' ' 83' ' ' GLY . 3.7 m -59.96 -50.06 75.25 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.577 -0.702 . . . . 0.0 110.095 -179.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -60.48 -36.4 78.21 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 120.498 -1.377 . . . . 0.0 108.852 179.046 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 22.3 tttp -69.37 -47.29 64.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.405 -0.809 . . . . 0.0 110.929 -179.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.7 p -111.98 -29.72 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.18 0 O-C-N 121.245 -0.909 . . . . 0.0 111.817 -177.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.601 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.62 164.49 40.14 Favored Glycine 0 N--CA 1.49 2.279 0 O-C-N 120.705 -1.247 . . . . 0.0 110.696 179.053 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 82.6 t -109.86 130.82 62.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 48.0 tp60 -79.94 -67.37 0.77 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.228 -0.92 . . . . 0.0 110.254 -179.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -115.35 146.24 41.74 Favored 'General case' 0 N--CA 1.503 2.184 0 O-C-N 121.453 -0.78 . . . . 0.0 111.152 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -119.73 131.67 55.44 Favored 'General case' 0 N--CA 1.499 1.989 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 14.0 tpp85 -137.62 136.15 37.24 Favored 'General case' 0 N--CA 1.504 2.266 0 O-C-N 120.932 -1.105 . . . . 0.0 111.057 -178.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.97 137.69 54.57 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 10.4 mp -119.84 126.17 50.33 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 16.9 p -127.01 125.09 40.84 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.301 -0.874 . . . . 0.0 110.447 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -132.13 147.44 52.43 Favored 'General case' 0 N--CA 1.5 2.039 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 75.1 m95 -70.72 139.27 51.11 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.913 -1.117 . . . . 0.0 109.593 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.8 t -111.37 123.76 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.976 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.444 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.652 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -179.693 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.162 0.506 . . . . 0.0 109.655 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 34.0 p-10 -86.49 -20.06 28.62 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.038 -1.039 . . . . 0.0 109.172 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 57.0 t30 -95.36 1.68 54.39 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.411 -0.806 . . . . 0.0 109.045 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.6 t -116.41 126.19 73.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.749 -0.594 . . . . 0.0 109.903 -178.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -83.49 139.83 41.4 Favored Pre-proline 0 N--CA 1.489 1.499 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 178.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -75.65 -14.17 19.86 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 121.762 1.641 . . . . 0.0 111.868 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 77.6 p -60.21 -39.96 88.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.367 -0.833 . . . . 0.0 109.722 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 88.6 mm-40 -84.24 -11.88 55.72 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.139 -0.976 . . . . 0.0 109.725 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.813 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 29.9 t -69.69 -31.45 69.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.146 -0.971 . . . . 0.0 108.677 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.5 pp -123.58 146.15 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.413 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.5 mttt -111.31 145.18 39.26 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.285 -0.884 . . . . 0.0 109.885 -178.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.454 ' NE2' ' CZ ' ' A' ' 87' ' ' TYR . 63.3 tt0 -97.65 114.81 26.84 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.438 ' O ' ' N ' ' A' ' 21' ' ' VAL . 48.0 m -115.13 130.12 56.84 Favored 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.67 -98.27 0.01 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.438 ' N ' ' O ' ' A' ' 19' ' ' SER . 3.9 m -137.57 27.46 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.369 -1.077 . . . . 0.0 109.836 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 -130.72 162.98 28.27 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 121.196 -0.94 . . . . 0.0 109.956 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -116.95 140.02 49.96 Favored 'General case' 0 N--CA 1.5 2.07 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.028 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 71.3 p -130.53 145.75 51.92 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.38 -0.825 . . . . 0.0 109.446 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -80.78 126.18 31.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.189 -0.944 . . . . 0.0 108.521 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -85.76 83.48 7.84 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.176 -0.953 . . . . 0.0 110.422 -179.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.9 p -81.07 -9.07 59.88 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.132 -0.98 . . . . 0.0 109.614 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -57.42 -39.18 90.14 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.5 m -80.84 136.89 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.106 -1.232 . . . . 0.0 108.984 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 24.1 t -67.54 -30.28 69.89 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.359 -0.838 . . . . 0.0 111.178 -178.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.1 p -60.0 -40.06 82.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.818 -1.176 . . . . 0.0 110.419 -178.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.813 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 67.3 m -64.17 -40.17 95.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.786 -1.196 . . . . 0.0 110.14 -179.806 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 97.1 mmm -86.36 -14.96 41.95 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.892 -1.13 . . . . 0.0 109.77 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 30.1 tt0 -60.21 -40.27 89.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.985 -1.072 . . . . 0.0 108.127 179.146 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -79.2 -45.48 8.85 Favored Glycine 0 N--CA 1.485 1.902 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.9 tp -60.42 -43.67 96.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.243 -1.151 . . . . 0.0 109.737 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -67.32 -39.81 85.92 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.202 -0.936 . . . . 0.0 110.055 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -60.39 -31.09 70.03 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.03 -1.044 . . . . 0.0 109.349 -179.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.52 23.42 23.97 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 64.5 mmtt -109.73 -0.57 18.44 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 178.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.414 HG13 ' H ' ' A' ' 43' ' ' GLY . 86.9 t -135.37 158.12 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 121.671 0.748 . . . . 0.0 109.259 -179.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 67.4 mtp180 -119.9 -9.66 9.63 Favored 'General case' 0 N--CA 1.497 1.925 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.414 ' H ' HG13 ' A' ' 41' ' ' VAL . . . 137.75 -159.96 25.11 Favored Glycine 0 N--CA 1.497 2.72 0 N-CA-C 108.009 -2.037 . . . . 0.0 108.009 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 90.1 t -118.61 129.73 74.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.143 0 O-C-N 121.18 -1.189 . . . . 0.0 109.315 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.2 t -85.91 138.76 31.79 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.324 -0.86 . . . . 0.0 108.883 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.7 p -130.13 132.49 65.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.785 0.802 . . . . 0.0 109.544 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.4 p -123.78 146.06 48.59 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -141.77 138.7 8.82 Favored Glycine 0 N--CA 1.5 2.954 0 C-N-CA 119.362 -1.399 . . . . 0.0 111.471 -178.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 55.1 t -120.11 122.6 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 178.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.518 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 0.3 OUTLIER -100.06 126.18 46.23 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 179.875 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -98.53 121.39 40.4 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.156 -0.965 . . . . 0.0 109.444 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.532 ' O ' ' N ' ' A' ' 54' ' ' ASP . 91.7 m-85 -105.47 125.58 51.14 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.382 -0.824 . . . . 0.0 109.356 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.645 HD21 ' NE2' ' A' ' 85' ' ' GLN . 20.9 t-20 -45.53 -16.62 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.147 -0.971 . . . . 0.0 109.49 179.543 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 52' ' ' TYR . 7.4 t70 -67.79 2.52 1.91 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.378 -0.826 . . . . 0.0 109.275 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.44 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 77.39 18.83 77.47 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.529 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 16.3 p -116.65 148.36 41.07 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.555 -0.968 . . . . 0.0 110.067 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 69.6 p -129.99 138.07 50.63 Favored 'General case' 0 N--CA 1.496 1.872 0 CA-C-O 121.589 0.709 . . . . 0.0 109.665 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.5 t -118.65 142.37 47.71 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 107.224 -1.399 . . . . 0.0 107.224 178.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . 0.439 ' OD1' ' O ' ' A' ' 59' ' ' ASN . 39.7 p-10 -135.05 117.04 15.28 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.025 -1.047 . . . . 0.0 109.691 -179.443 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -116.83 130.43 56.71 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 27.2 ttpp -113.69 141.95 46.61 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -160.08 161.29 32.35 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 49.1 t -108.74 124.17 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.47 -1.017 . . . . 0.0 108.769 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 53.3 t -97.64 119.18 45.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.326 -0.859 . . . . 0.0 110.214 -179.147 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.65 ' O ' ' N ' ' A' ' 67' ' ' SER . 15.4 p -137.36 159.15 70.62 Favored Pre-proline 0 N--CA 1.491 1.616 0 N-CA-C 107.043 -1.466 . . . . 0.0 107.043 178.562 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_exo -51.2 58.73 0.02 OUTLIER 'Trans proline' 0 N--CA 1.504 2.147 0 C-N-CA 122.247 1.965 . . . . 0.0 113.688 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.65 ' N ' ' O ' ' A' ' 65' ' ' THR . 3.1 m -140.98 -64.07 0.46 Allowed 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.762 -1.211 . . . . 0.0 109.417 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 30.4 p -141.76 149.97 55.2 Favored Pre-proline 0 N--CA 1.5 2.064 0 O-C-N 121.212 -0.93 . . . . 0.0 109.501 179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -84.57 164.11 12.44 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 122.707 2.271 . . . . 0.0 112.717 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.5 t -122.26 130.12 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 74.6 m-80 -96.77 136.08 37.82 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 120.806 -1.184 . . . . 0.0 111.11 -178.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.495 ' O ' ' CZ ' ' A' ' 50' ' ' PHE . 1.6 p -81.11 -51.55 8.34 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 178.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.466 ' N ' ' OG1' ' A' ' 72' ' ' THR . 78.9 m-20 -81.46 56.1 2.83 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 66.4 tt0 -47.69 -47.23 29.81 Favored 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 119.843 -0.743 . . . . 0.0 109.553 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -106.12 97.68 7.46 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 82.2 mt -80.31 -23.83 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.228 -0.92 . . . . 0.0 109.834 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 22.9 m120 -60.13 -48.82 80.11 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 120.95 -1.094 . . . . 0.0 109.537 -178.265 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 13.8 ptpt -68.28 -38.63 81.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.676 -1.265 . . . . 0.0 109.223 179.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.609 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.4 OUTLIER -62.2 -45.7 92.21 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.012 -1.055 . . . . 0.0 108.834 179.47 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 9.5 t-20 -60.05 -34.17 73.03 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.63 -1.293 . . . . 0.0 109.499 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.3 tmtt? -64.86 -50.02 68.26 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.197 -0.939 . . . . 0.0 110.727 -179.055 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.4 p -113.2 -27.66 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.229 -0.919 . . . . 0.0 111.545 -178.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.609 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.37 157.69 26.82 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 179.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.0 t -103.52 116.49 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 179.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.645 ' NE2' HD21 ' A' ' 53' ' ' ASN . 97.7 mt-30 -70.9 -47.83 57.01 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.101 -1.0 . . . . 0.0 111.904 -178.641 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 58.6 tttp -115.58 142.81 46.23 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.239 -0.913 . . . . 0.0 110.798 -178.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.454 ' CZ ' ' NE2' ' A' ' 18' ' ' GLN . 62.3 t80 -120.66 130.07 53.96 Favored 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 178.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 2.2 tpp180 -139.44 127.51 22.38 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.082 -1.011 . . . . 0.0 110.422 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -125.45 135.36 52.26 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.875 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 9.8 mp -119.93 129.7 54.46 Favored 'General case' 0 N--CA 1.504 2.231 0 O-C-N 121.306 -0.871 . . . . 0.0 108.745 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 25.2 p -129.28 127.33 40.96 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 121.267 -0.896 . . . . 0.0 110.821 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -133.15 156.21 47.89 Favored 'General case' 0 N--CA 1.502 2.157 0 CA-C-O 121.222 0.534 . . . . 0.0 110.169 179.479 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 69.0 m95 -70.4 138.45 51.3 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.201 -0.937 . . . . 0.0 108.679 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 27.7 t -111.26 120.03 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.382 -0.824 . . . . 0.0 109.89 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 179.573 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.662 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -60.9 -39.76 90.56 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.754 -0.591 . . . . 0.0 111.346 -179.079 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -84.27 0.33 49.38 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.861 -1.149 . . . . 0.0 110.195 -178.095 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.4 t -106.1 131.54 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.252 -0.905 . . . . 0.0 108.703 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.522 ' O ' ' N ' ' A' ' 13' ' ' SER . 4.3 m-20 -99.91 108.61 52.53 Favored Pre-proline 0 N--CA 1.492 1.662 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 179.634 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -44.72 -12.01 0.05 OUTLIER 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 121.931 1.754 . . . . 0.0 112.35 -179.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.522 ' N ' ' O ' ' A' ' 11' ' ' ASP . 88.1 p -69.59 -38.61 77.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.258 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.51 ' N ' ' HG ' ' A' ' 13' ' ' SER . 98.7 mm-40 -91.14 -6.79 53.1 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 120.947 -1.095 . . . . 0.0 109.967 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.811 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 22.4 t -70.66 -24.89 62.78 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.191 -0.943 . . . . 0.0 109.804 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -120.8 151.25 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.152 0 O-C-N 121.569 -0.707 . . . . 0.0 110.27 -179.059 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -118.58 137.15 53.45 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.766 -0.584 . . . . 0.0 109.61 -179.54 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -100.35 121.63 41.81 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.205 -0.934 . . . . 0.0 110.353 -179.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 83.5 p -121.21 127.56 51.58 Favored 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.73 -111.13 1.72 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.6 m -127.88 36.51 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.084 0 O-C-N 121.451 -1.029 . . . . 0.0 109.605 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -131.6 160.02 36.57 Favored 'General case' 0 N--CA 1.5 2.051 0 CA-C-O 121.646 0.736 . . . . 0.0 110.62 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -119.67 139.96 51.4 Favored 'General case' 0 N--CA 1.498 1.966 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 80.7 p -134.94 151.13 50.58 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.328 -0.857 . . . . 0.0 109.825 -179.2 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 48.3 t80 -87.51 122.88 31.79 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.393 -0.817 . . . . 0.0 109.311 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -82.66 88.28 6.7 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.344 -0.847 . . . . 0.0 109.77 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 59.7 p -80.5 -9.9 59.75 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.106 -0.996 . . . . 0.0 109.626 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -56.66 -31.8 60.89 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -84.24 114.23 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.06 -1.259 . . . . 0.0 107.989 179.281 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.545 ' O ' ' N ' ' A' ' 34' ' ' GLN . 59.7 m -60.05 -40.04 88.04 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.237 -0.914 . . . . 0.0 111.132 -178.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 6.1 m -52.09 -40.69 30.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 120.946 -1.096 . . . . 0.0 110.653 -178.115 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.811 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 55.3 m -69.97 -44.51 69.33 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.818 -1.176 . . . . 0.0 109.869 -179.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 31.1 ttm -81.07 -13.0 59.18 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.023 -1.048 . . . . 0.0 109.623 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . 0.545 ' N ' ' O ' ' A' ' 30' ' ' SER . 62.5 tt0 -61.44 -40.03 92.98 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 179.207 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.33 -39.96 29.79 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.0 tp -59.84 -43.52 94.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.14 -1.212 . . . . 0.0 108.407 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 44.5 t30 -62.15 -40.22 95.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.507 -0.745 . . . . 0.0 109.775 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -69.07 -26.56 65.01 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.361 -0.837 . . . . 0.0 110.308 -179.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 91.17 18.07 47.99 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.854 -1.165 . . . . 0.0 110.804 179.147 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 40.1 mtmt -97.92 -0.75 44.34 Favored 'General case' 0 N--CA 1.495 1.793 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 178.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.451 HG13 ' H ' ' A' ' 43' ' ' GLY . 59.7 t -136.12 156.72 37.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 115.021 -0.99 . . . . 0.0 108.511 -179.669 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -115.74 -10.17 11.8 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.273 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.451 ' H ' HG13 ' A' ' 41' ' ' VAL . . . 139.55 -152.14 22.34 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 108.298 -1.921 . . . . 0.0 108.298 -179.566 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.5 p -125.06 129.44 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 121.068 -1.254 . . . . 0.0 109.647 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 t -87.42 134.6 33.57 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.1 p -130.06 131.18 66.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.405 -0.81 . . . . 0.0 109.359 179.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 53.1 p -121.21 149.72 42.41 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -140.49 144.4 14.77 Favored Glycine 0 N--CA 1.502 3.051 0 C-N-CA 119.603 -1.284 . . . . 0.0 110.751 -178.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 96.0 t -126.37 128.9 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.513 -0.993 . . . . 0.0 109.429 178.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -102.21 120.4 40.4 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -95.5 126.34 40.72 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.246 -0.909 . . . . 0.0 109.314 -179.74 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.51 ' O ' ' N ' ' A' ' 54' ' ' ASP . 55.0 m-85 -109.51 126.5 53.61 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.383 -0.823 . . . . 0.0 109.257 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.447 ' C ' ' H ' ' A' ' 55' ' ' GLY . 17.9 t-20 -45.94 -17.3 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.123 -0.986 . . . . 0.0 109.167 179.263 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.51 ' N ' ' O ' ' A' ' 52' ' ' TYR . 39.9 t0 -67.67 0.96 2.74 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.501 -0.75 . . . . 0.0 109.013 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.447 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 77.76 27.77 58.19 Favored Glycine 0 N--CA 1.494 2.5 0 O-C-N 121.206 -0.934 . . . . 0.0 110.769 178.689 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.5 p -123.15 150.02 43.81 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.389 -1.065 . . . . 0.0 109.78 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 39.6 p -132.58 133.99 44.37 Favored 'General case' 0 N--CA 1.501 2.101 0 CA-C-O 121.618 0.723 . . . . 0.0 109.669 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 48.3 t -119.89 142.82 48.35 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 178.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 37.9 t-20 -132.49 125.72 31.3 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 120.994 -1.066 . . . . 0.0 109.488 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -117.72 128.27 54.73 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.0 ttpm? -110.82 143.78 40.86 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -158.03 159.34 29.91 Favored Glycine 0 C--N 1.285 -2.282 0 N-CA-C 108.763 -1.735 . . . . 0.0 108.763 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 56.0 t -109.55 124.27 66.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.487 -1.007 . . . . 0.0 108.789 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.9 t -90.21 118.94 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.421 -0.799 . . . . 0.0 109.321 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.549 ' C ' ' H ' ' A' ' 67' ' ' SER . 30.6 p -132.89 151.57 78.27 Favored Pre-proline 0 N--CA 1.492 1.659 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 178.637 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -48.75 -5.51 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 121.295 1.33 . . . . 0.0 111.39 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.549 ' H ' ' C ' ' A' ' 65' ' ' THR . 19.7 t -75.62 -57.33 3.95 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.152 -0.968 . . . . 0.0 110.422 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 56.4 p -147.68 151.82 39.95 Favored Pre-proline 0 N--CA 1.502 2.142 0 O-C-N 120.855 -1.153 . . . . 0.0 110.107 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -84.67 167.33 11.55 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.939 2.426 . . . . 0.0 112.265 178.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.2 t -102.74 131.09 51.68 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -97.39 122.98 41.06 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.334 -0.853 . . . . 0.0 111.976 -177.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 1.2 p -93.37 -0.21 56.66 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 178.125 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.43 ' OD1' ' O ' ' A' ' 73' ' ' ASN . 41.3 t-20 -75.4 54.03 0.71 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.57 -0.706 . . . . 0.0 109.254 -179.631 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -62.96 -87.18 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -114.35 84.41 2.05 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.497 -0.752 . . . . 0.0 109.226 178.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 10.1 tp -70.11 -32.85 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.121 -0.987 . . . . 0.0 109.727 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -60.02 -47.39 86.04 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.1 -178.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.421 ' CG ' ' N ' ' A' ' 79' ' ' THR . 15.1 ptmt -63.63 -39.82 95.33 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.707 -1.246 . . . . 0.0 108.215 179.288 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.582 ' O ' ' N ' ' A' ' 83' ' ' GLY . 2.0 m -59.96 -40.71 89.96 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -179.614 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -66.59 -31.8 72.74 Favored 'General case' 0 C--N 1.295 -1.792 0 O-C-N 120.579 -1.326 . . . . 0.0 109.382 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 7.6 tmtm? -69.84 -44.28 70.22 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.915 -1.116 . . . . 0.0 110.378 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -110.58 -26.44 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.377 0 O-C-N 121.206 -0.934 . . . . 0.0 111.349 -178.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.47 164.29 37.6 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 71.4 t -111.21 128.16 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 93.1 mm-40 -81.27 -65.5 1.0 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.086 -1.009 . . . . 0.0 110.996 -178.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 45.1 tptt -113.92 141.76 46.97 Favored 'General case' 0 N--CA 1.503 2.181 0 O-C-N 121.438 -0.789 . . . . 0.0 110.639 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -120.17 131.25 54.93 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 95.5 mtt180 -131.8 130.8 42.27 Favored 'General case' 0 N--CA 1.508 2.432 0 O-C-N 121.094 -1.004 . . . . 0.0 110.524 -179.231 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -122.68 137.89 54.77 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.675 -0.64 . . . . 0.0 109.894 179.649 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 60.3 tp -120.01 133.31 55.58 Favored 'General case' 0 N--CA 1.506 2.355 0 O-C-N 121.298 -0.876 . . . . 0.0 109.058 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.9 p -128.7 126.11 39.39 Favored 'General case' 0 N--CA 1.504 2.227 0 CA-C-O 121.581 0.705 . . . . 0.0 110.485 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -133.24 159.21 40.88 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.759 -0.588 . . . . 0.0 110.198 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 50.7 m95 -75.66 136.46 40.42 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.372 -0.83 . . . . 0.0 108.775 178.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 21.4 t -106.79 120.81 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.485 -0.759 . . . . 0.0 109.304 -179.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.537 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 -179.771 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.61 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -93.11 -25.7 17.77 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.113 -0.992 . . . . 0.0 110.759 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -90.05 4.83 49.07 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.846 -1.159 . . . . 0.0 109.916 -179.18 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.9 t -118.16 131.05 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.379 -0.826 . . . . 0.0 109.686 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 59.0 m-20 -81.96 133.91 50.71 Favored Pre-proline 0 C--N 1.301 -1.512 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 177.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -74.79 -15.34 21.34 Favored 'Trans proline' 0 N--CA 1.494 1.535 0 C-N-CA 121.848 1.699 . . . . 0.0 112.12 -178.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 79.8 p -69.05 -28.83 66.9 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.51 -0.744 . . . . 0.0 110.4 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -78.94 -11.32 60.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.121 -0.987 . . . . 0.0 109.307 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.812 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 11.7 t -69.93 -39.89 75.85 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.062 -1.024 . . . . 0.0 109.81 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -121.38 142.22 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.108 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 179.504 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -115.85 147.48 40.99 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.476 -0.765 . . . . 0.0 109.697 -178.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -85.05 113.0 21.14 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.43 -0.793 . . . . 0.0 108.953 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.5 m -103.36 120.04 40.03 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.92 -99.78 0.04 OUTLIER Glycine 0 N--CA 1.488 2.148 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 -179.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 t -128.32 20.2 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.456 -1.026 . . . . 0.0 109.195 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -129.61 167.88 17.27 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 121.357 -0.839 . . . . 0.0 110.732 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -124.31 145.21 49.55 Favored 'General case' 0 N--CA 1.501 2.079 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 40.5 p -136.8 153.65 50.76 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.272 -0.893 . . . . 0.0 110.051 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.414 ' HH ' ' CD1' ' A' ' 36' ' ' LEU . 44.2 t80 -85.59 123.28 30.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.584 -0.698 . . . . 0.0 109.695 -179.062 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -88.5 83.83 6.8 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.301 -0.875 . . . . 0.0 110.139 -179.578 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 77.7 p -79.85 -4.89 54.15 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 120.991 -1.068 . . . . 0.0 108.989 179.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.73 -40.1 96.14 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.0 m -72.97 139.97 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.008 -1.289 . . . . 0.0 108.862 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 55.2 p -69.04 -25.55 64.53 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.394 -0.816 . . . . 0.0 110.587 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 54.0 t -60.03 -43.11 91.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.011 -1.056 . . . . 0.0 110.089 -179.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.812 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.0 m -60.99 -39.95 91.62 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.067 -1.02 . . . . 0.0 110.464 -179.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.2 mmt -80.47 -14.44 58.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.934 -1.104 . . . . 0.0 110.037 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -61.07 -42.56 98.72 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.058 -1.026 . . . . 0.0 108.914 179.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.2 -47.42 9.17 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.414 ' CD1' ' HH ' ' A' ' 25' ' ' TYR . 11.7 mt -61.26 -41.66 97.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.074 -1.251 . . . . 0.0 110.14 -179.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -65.52 -39.86 92.31 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.166 -0.959 . . . . 0.0 109.333 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -66.86 -29.66 69.62 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.379 -0.826 . . . . 0.0 109.494 -179.601 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.28 22.29 54.76 Favored Glycine 0 N--CA 1.494 2.557 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 31.2 ttmt -107.61 -3.51 19.21 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 179.218 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 43' ' ' GLY . 86.3 t -133.68 160.27 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.305 -179.183 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 81.5 mtt85 -121.79 -8.1 8.97 Favored 'General case' 0 N--CA 1.499 2.023 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 178.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.426 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.34 -152.86 23.14 Favored Glycine 0 N--CA 1.499 2.86 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 99.2 t -126.53 130.0 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.322 0 O-C-N 121.066 -1.255 . . . . 0.0 109.667 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.1 t -84.43 137.86 33.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.319 -0.863 . . . . 0.0 109.608 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 7.5 p -132.7 134.19 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.43 -0.794 . . . . 0.0 108.943 179.034 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 86.7 p -121.93 146.91 46.67 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 179.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -135.99 131.24 5.64 Favored Glycine 0 N--CA 1.498 2.811 0 C-N-CA 119.964 -1.112 . . . . 0.0 110.525 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 53.7 t -120.96 127.02 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.43 ' CE1' ' OG1' ' A' ' 72' ' ' THR . 23.8 m-85 -105.47 116.05 31.3 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -92.97 137.53 32.28 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.361 -0.837 . . . . 0.0 109.879 -178.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.42 ' OH ' ' OE1' ' A' ' 74' ' ' GLN . 74.0 m-85 -120.11 137.08 54.35 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.367 -0.833 . . . . 0.0 109.676 179.347 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.422 ' C ' ' H ' ' A' ' 55' ' ' GLY . 18.7 t-20 -47.29 -21.32 0.27 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.475 -0.766 . . . . 0.0 109.531 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.414 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 10.4 t70 -68.47 0.95 3.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.267 -0.896 . . . . 0.0 109.208 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.422 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 75.61 17.93 79.94 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.09 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.9 p -111.65 154.39 24.98 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.444 -1.033 . . . . 0.0 108.932 179.329 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 32.7 p -140.44 148.01 40.53 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.38 -0.825 . . . . 0.0 110.525 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 54.9 m -117.86 147.58 42.94 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 106.046 -1.835 . . . . 0.0 106.046 177.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -139.97 116.17 10.5 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.974 -1.079 . . . . 0.0 109.705 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -115.99 122.42 45.2 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 178.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -112.26 145.57 39.71 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -165.92 178.9 40.42 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 -179.466 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 30.4 t -119.42 127.53 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.487 -1.008 . . . . 0.0 109.593 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 t -89.46 118.9 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.436 -0.79 . . . . 0.0 109.875 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.45 ' O ' ' N ' ' A' ' 67' ' ' SER . 26.6 p -138.14 150.05 65.7 Favored Pre-proline 0 N--CA 1.494 1.727 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -44.55 -19.7 0.28 Allowed 'Trans proline' 0 C--N 1.311 -1.4 0 C-N-CA 121.111 1.207 . . . . 0.0 111.414 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.45 ' N ' ' O ' ' A' ' 65' ' ' THR . 69.9 m -70.05 -46.16 65.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.512 -0.743 . . . . 0.0 111.441 -178.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -148.47 141.31 15.25 Favored Pre-proline 0 N--CA 1.504 2.235 0 O-C-N 120.664 -1.273 . . . . 0.0 110.945 -178.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -86.95 165.09 8.74 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.087 2.524 . . . . 0.0 112.229 178.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 72.6 t -113.09 128.34 69.9 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.203 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -104.52 140.61 37.73 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.285 -0.885 . . . . 0.0 111.818 -177.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.43 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.0 OUTLIER -109.9 19.17 19.36 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.024 -1.473 . . . . 0.0 107.024 177.502 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 46.5 t-20 -71.05 55.39 0.19 Allowed 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.637 -0.664 . . . . 0.0 109.522 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.42 ' OE1' ' OH ' ' A' ' 52' ' ' TYR . 55.0 tt0 -49.61 169.35 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.051 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -59.07 123.77 17.72 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.713 -1.242 . . . . 0.0 108.939 -179.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 43.3 mm -80.16 -21.61 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.433 -0.792 . . . . 0.0 110.694 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -60.01 -47.73 84.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.673 -1.267 . . . . 0.0 110.069 -179.009 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 9.9 ptpt -64.14 -39.26 93.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.966 -1.084 . . . . 0.0 108.488 179.206 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.549 ' O ' ' N ' ' A' ' 83' ' ' GLY . 30.2 m -60.0 -45.04 94.03 Favored 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.683 0.754 . . . . 0.0 109.438 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -62.01 -36.16 80.7 Favored 'General case' 0 C--N 1.293 -1.887 0 O-C-N 120.949 -1.095 . . . . 0.0 109.972 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 15.0 tmtt? -70.31 -44.83 67.5 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.102 -0.999 . . . . 0.0 111.119 -178.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.6 p -117.51 -29.04 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.416 0 O-C-N 121.135 -0.978 . . . . 0.0 111.543 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.549 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.0 158.26 33.92 Favored Glycine 0 N--CA 1.497 2.702 0 O-C-N 120.616 -1.302 . . . . 0.0 110.571 179.35 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 56.1 t -100.04 123.44 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -77.69 -65.0 1.02 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.181 -0.949 . . . . 0.0 111.365 -178.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -115.96 152.45 33.45 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.124 -0.985 . . . . 0.0 111.814 -178.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 64.8 t80 -120.94 130.92 54.05 Favored 'General case' 0 N--CA 1.5 2.033 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -136.86 130.2 31.38 Favored 'General case' 0 N--CA 1.507 2.39 0 O-C-N 120.814 -1.179 . . . . 0.0 110.843 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.68 135.44 53.05 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.2 tt -119.77 129.1 54.31 Favored 'General case' 0 N--CA 1.504 2.228 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.5 p -129.1 121.59 28.13 Favored 'General case' 0 N--CA 1.505 2.279 0 O-C-N 121.414 -0.804 . . . . 0.0 111.433 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -133.32 159.82 39.14 Favored 'General case' 0 N--CA 1.502 2.165 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.176 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -73.6 144.06 46.13 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.918 -1.113 . . . . 0.0 109.278 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.9 t -114.2 123.71 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.344 -0.848 . . . . 0.0 109.326 179.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.681 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.621 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -93.62 -28.38 16.04 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.298 -0.876 . . . . 0.0 109.914 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -90.57 0.09 57.48 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.187 -0.946 . . . . 0.0 109.397 -179.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.5 t -109.04 127.8 65.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 O-C-N 121.495 -0.753 . . . . 0.0 109.801 -179.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 60.4 m-20 -87.06 132.12 42.66 Favored Pre-proline 0 N--CA 1.489 1.515 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 178.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -72.84 -14.51 26.73 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 121.633 1.555 . . . . 0.0 112.154 -178.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 30.3 t -61.57 -40.17 93.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.142 -0.974 . . . . 0.0 110.364 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 65.4 mt-30 -81.46 -11.29 59.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.043 -1.035 . . . . 0.0 110.302 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.801 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 35.5 m -70.11 -30.02 67.11 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.948 -1.095 . . . . 0.0 108.939 179.273 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -122.11 140.51 45.79 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -123.95 143.3 50.48 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.528 -0.732 . . . . 0.0 109.398 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -87.5 130.68 34.62 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.086 -1.009 . . . . 0.0 109.456 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 53.6 m -118.9 128.41 54.4 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 46.48 -107.12 0.17 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.7 m -121.78 19.9 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.67 -0.9 . . . . 0.0 109.977 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -130.68 164.99 23.81 Favored 'General case' 0 N--CA 1.503 2.19 0 O-C-N 121.389 -0.819 . . . . 0.0 110.266 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -117.6 140.67 49.33 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 79.2 p -139.94 150.93 45.12 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.305 -0.872 . . . . 0.0 109.044 178.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 8.8 t80 -78.53 128.78 34.03 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.375 -0.828 . . . . 0.0 109.371 -179.412 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -85.69 83.12 7.96 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.341 -0.849 . . . . 0.0 109.257 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.479 ' C ' ' H ' ' A' ' 29' ' ' VAL . 97.6 p -79.08 -5.05 53.12 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.199 -0.938 . . . . 0.0 109.3 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.17 -11.73 0.69 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.479 ' H ' ' C ' ' A' ' 27' ' ' SER . 29.0 m -108.9 127.39 65.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.518 -0.989 . . . . 0.0 108.776 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 64.5 m -70.07 -27.48 64.66 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.42 -0.8 . . . . 0.0 110.451 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.7 m -60.01 -40.3 82.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.036 -1.04 . . . . 0.0 111.204 -178.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.801 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 97.1 m -66.39 -40.24 89.54 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.546 -1.347 . . . . 0.0 110.074 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 70.5 mtp -80.98 -10.08 59.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.953 -1.092 . . . . 0.0 109.603 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -61.23 -40.46 94.1 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -80.46 -51.27 4.99 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.9 tt -60.14 -41.53 92.92 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.105 -1.232 . . . . 0.0 109.726 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 -60.1 -40.22 88.85 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.018 -1.051 . . . . 0.0 109.736 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -79.01 -6.04 55.37 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.348 -0.845 . . . . 0.0 109.487 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.56 29.25 49.37 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.941 -1.123 . . . . 0.0 110.374 178.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -104.48 -9.54 18.31 Favored 'General case' 0 N--CA 1.496 1.848 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.444 ' CG1' ' H ' ' A' ' 43' ' ' GLY . 70.9 t -136.15 161.2 37.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . 0.427 ' N ' ' CG1' ' A' ' 41' ' ' VAL . 57.9 ttm-85 -122.95 -7.65 8.38 Favored 'General case' 0 N--CA 1.495 1.8 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.444 ' H ' ' CG1' ' A' ' 41' ' ' VAL . . . 138.3 -161.16 25.63 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 95.0 t -122.5 130.13 74.74 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.335 -1.097 . . . . 0.0 109.103 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.8 m -86.3 136.79 33.02 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.051 -1.03 . . . . 0.0 108.303 179.364 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 6.0 m -132.08 133.45 60.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.644 -0.66 . . . . 0.0 109.543 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 57.3 p -122.65 142.46 50.64 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 179.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -131.3 143.06 14.48 Favored Glycine 0 N--CA 1.503 3.151 0 C-N-CA 120.085 -1.055 . . . . 0.0 111.113 -178.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 92.6 t -126.25 129.99 72.03 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.852 -0.793 . . . . 0.0 109.405 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -103.97 120.05 40.23 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 62.6 m-85 -96.64 123.22 40.24 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.354 -0.842 . . . . 0.0 109.405 -179.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.58 ' CD1' ' NZ ' ' A' ' 78' ' ' LYS . 96.9 m-85 -109.03 128.03 54.61 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.607 -0.683 . . . . 0.0 109.634 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.474 ' C ' ' H ' ' A' ' 55' ' ' GLY . 0.5 OUTLIER -45.58 -17.27 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.27 -0.894 . . . . 0.0 109.324 179.149 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 52' ' ' TYR . 22.1 t0 -67.42 1.54 2.21 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.474 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 75.36 23.42 73.65 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.346 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.9 p -121.76 149.85 42.69 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.499 -1.001 . . . . 0.0 110.002 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.1 p -134.01 138.08 45.16 Favored 'General case' 0 N--CA 1.499 2.016 0 CA-C-O 121.824 0.821 . . . . 0.0 110.174 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.8 t -119.78 143.2 47.97 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 58.6 t-20 -134.44 129.84 35.89 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 120.624 -1.297 . . . . 0.0 110.127 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -117.06 128.69 55.4 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -113.98 142.7 45.83 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -165.42 170.58 40.39 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.9 t -113.96 126.45 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.112 0 O-C-N 121.544 -0.974 . . . . 0.0 109.408 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 72.5 t -96.45 117.92 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.075 -1.015 . . . . 0.0 109.906 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.52 ' O ' ' N ' ' A' ' 67' ' ' SER . 24.3 p -126.69 150.12 70.25 Favored Pre-proline 0 N--CA 1.501 2.088 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 179.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_exo -37.41 -22.39 0.05 OUTLIER 'Trans proline' 0 N--CA 1.49 1.306 0 C-N-CA 122.227 1.951 . . . . 0.0 112.984 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.52 ' N ' ' O ' ' A' ' 65' ' ' THR . 9.0 t -114.1 -16.06 12.16 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.275 -0.891 . . . . 0.0 111.556 -178.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 98.5 m -119.6 106.53 41.99 Favored Pre-proline 0 N--CA 1.502 2.156 0 O-C-N 120.976 -1.077 . . . . 0.0 110.193 -179.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -91.41 163.48 3.62 Favored 'Trans proline' 0 N--CA 1.492 1.416 0 C-N-CA 122.657 2.238 . . . . 0.0 112.347 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.8 t -127.22 130.03 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.293 0 N-CA-C 108.714 -0.846 . . . . 0.0 108.714 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -100.16 132.31 45.61 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 121.209 -0.932 . . . . 0.0 111.873 -178.094 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.436 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.0 OUTLIER -105.33 19.96 19.69 Favored 'General case' 0 N--CA 1.498 1.938 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.602 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -67.44 54.37 0.06 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.777 -0.577 . . . . 0.0 109.651 -179.256 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.449 ' NE2' ' O ' ' A' ' 75' ' ' ASP . 0.0 OUTLIER -48.0 166.71 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.285 -0.885 . . . . 0.0 108.831 179.517 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.449 ' O ' ' NE2' ' A' ' 74' ' ' GLN . 78.3 m-20 -57.09 117.83 4.41 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.006 -1.058 . . . . 0.0 109.538 -178.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 47.7 mm -69.59 -39.48 78.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.768 -0.582 . . . . 0.0 109.582 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -56.15 -41.47 75.44 Favored 'General case' 0 N--CA 1.488 1.425 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.58 ' NZ ' ' CD1' ' A' ' 52' ' ' TYR . 28.3 tttm -62.84 -49.47 74.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.317 -0.865 . . . . 0.0 108.884 178.323 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.582 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.0 OUTLIER -67.61 -42.16 82.84 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.535 -0.728 . . . . 0.0 110.062 -179.099 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -60.96 -34.21 74.39 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 120.641 -1.287 . . . . 0.0 110.902 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -70.99 -43.54 67.79 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.887 -1.133 . . . . 0.0 111.243 -178.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.1 p -115.98 -27.78 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.39 -0.819 . . . . 0.0 111.231 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.87 166.01 40.9 Favored Glycine 0 N--CA 1.488 2.162 0 O-C-N 120.675 -1.266 . . . . 0.0 110.371 178.742 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.9 t -111.06 124.91 68.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -81.34 -64.19 1.24 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.162 -0.962 . . . . 0.0 111.073 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -114.22 143.17 45.27 Favored 'General case' 0 N--CA 1.509 2.48 0 O-C-N 121.167 -0.958 . . . . 0.0 111.299 -178.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 74.4 t80 -120.5 134.43 55.27 Favored 'General case' 0 N--CA 1.505 2.291 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 178.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 78.9 mtp180 -136.45 129.0 30.47 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 120.968 -1.083 . . . . 0.0 110.944 -178.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.66 132.66 53.39 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.729 -0.607 . . . . 0.0 109.672 179.047 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 7.7 mp -108.83 129.46 55.4 Favored 'General case' 0 N--CA 1.503 2.206 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 179.138 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.9 p -124.2 121.46 35.15 Favored 'General case' 0 N--CA 1.507 2.384 0 O-C-N 121.313 -0.867 . . . . 0.0 110.575 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 53.4 tp10 -133.84 150.95 51.41 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.772 -0.58 . . . . 0.0 110.163 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 70.9 m95 -66.95 141.55 57.57 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.992 -1.067 . . . . 0.0 108.737 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 62.0 t -119.3 130.16 74.32 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.177 0 O-C-N 121.503 -0.748 . . . . 0.0 109.989 -179.204 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.501 3.0 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.338 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 33.5 p-10 -72.81 -20.13 61.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.34 -0.85 . . . . 0.0 110.708 -178.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.7 m120 -99.52 6.71 45.79 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.098 -1.001 . . . . 0.0 109.783 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 29.2 t -119.98 129.97 74.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.47 -0.769 . . . . 0.0 109.905 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.96 140.28 43.1 Favored Pre-proline 0 N--CA 1.489 1.486 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.21 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -71.48 -22.39 24.82 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 121.806 1.671 . . . . 0.0 111.975 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 76.9 p -69.32 -38.93 78.45 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.313 -0.867 . . . . 0.0 109.781 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 56.6 tt0 -70.04 -23.93 63.18 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.304 -0.873 . . . . 0.0 109.739 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.797 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 22.0 m -68.44 -28.54 67.14 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.888 . . . . 0.0 109.685 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.4 pp -116.49 139.1 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.402 -0.811 . . . . 0.0 109.227 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -118.04 147.84 42.84 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.553 -0.717 . . . . 0.0 109.731 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.681 HE22 ' N ' ' A' ' 22' ' ' GLN . 64.2 tp60 -99.58 117.73 34.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.649 -0.657 . . . . 0.0 109.266 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.464 ' O ' ' N ' ' A' ' 21' ' ' VAL . 14.6 t -110.45 118.29 35.88 Favored 'General case' 0 N--CA 1.497 1.902 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 179.023 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.03 -92.42 0.02 OUTLIER Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.727 -1.749 . . . . 0.0 108.727 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.464 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.4 t -140.41 30.52 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 O-C-N 121.328 -1.101 . . . . 0.0 109.564 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.681 ' N ' HE22 ' A' ' 18' ' ' GLN . 89.1 mt-30 -127.46 158.07 38.35 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.271 -0.893 . . . . 0.0 110.334 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . 0.528 ' CZ ' ' OE1' ' A' ' 18' ' ' GLN . 26.9 m-85 -119.74 134.73 55.12 Favored 'General case' 0 N--CA 1.498 1.963 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.1 p -139.97 150.45 44.5 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.225 -0.922 . . . . 0.0 109.833 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.6 t80 -78.99 127.5 32.06 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 57.9 t30 -82.81 81.52 8.51 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.068 -1.02 . . . . 0.0 109.777 -179.442 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 49.9 m -78.31 -5.98 53.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.168 -0.957 . . . . 0.0 109.068 179.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -58.36 -37.43 87.56 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.829 -1.308 . . . . 0.0 109.829 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.2 m -84.32 132.38 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.036 -1.273 . . . . 0.0 109.492 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.9 m -60.09 -39.42 86.04 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.642 -0.661 . . . . 0.0 111.622 -178.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 19.7 m -57.62 -42.99 82.56 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 120.849 -1.157 . . . . 0.0 111.369 -177.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.797 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 93.0 m -67.05 -39.99 87.05 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.45 -1.406 . . . . 0.0 109.412 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.1 tpt -79.99 -11.72 59.76 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.008 -1.058 . . . . 0.0 108.419 179.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 61.2 tt0 -65.41 -39.85 92.65 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.07 -46.59 15.79 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 23.7 mt -60.04 -50.11 75.02 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.213 -1.169 . . . . 0.0 109.943 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -61.08 -39.99 91.98 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.076 -1.015 . . . . 0.0 110.0 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.437 ' OE2' ' NZ ' ' A' ' 40' ' ' LYS . 79.3 tt0 -64.55 -29.82 70.85 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.331 -0.855 . . . . 0.0 109.297 -179.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 91.25 26.54 20.95 Favored Glycine 0 N--CA 1.496 2.638 0 O-C-N 121.161 -0.962 . . . . 0.0 110.765 179.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.437 ' NZ ' ' OE2' ' A' ' 38' ' ' GLU . 96.3 mttt -110.04 -1.86 17.35 Favored 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.444 HG12 ' H ' ' A' ' 43' ' ' GLY . 72.5 t -133.71 160.2 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 CA-C-O 121.756 0.788 . . . . 0.0 109.056 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . 0.51 ' HE ' ' CG1' ' A' ' 94' ' ' VAL . 44.9 ttp180 -125.25 -5.98 7.18 Favored 'General case' 0 N--CA 1.494 1.772 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.673 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.444 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 134.09 -164.42 24.49 Favored Glycine 0 N--CA 1.503 3.136 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 94.6 t -120.07 130.01 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.4 0 CA-C-N 118.747 1.273 . . . . 0.0 110.126 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 38.0 t -79.63 134.08 36.43 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 14.7 p -130.04 131.3 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.382 -0.824 . . . . 0.0 109.684 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 60.7 p -122.56 147.03 46.88 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 179.288 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -142.36 136.01 6.97 Favored Glycine 0 N--CA 1.503 3.118 0 C-N-CA 119.409 -1.376 . . . . 0.0 111.04 -179.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.537 ' CG1' HH12 ' A' ' 88' ' ' ARG . 65.0 t -123.45 133.77 68.22 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.311 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -111.06 124.31 51.92 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.603 -0.686 . . . . 0.0 109.185 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.607 ' CD2' ' NH2' ' A' ' 88' ' ' ARG . 23.4 m-85 -95.1 126.06 40.17 Favored 'General case' 0 N--CA 1.504 2.266 0 O-C-N 120.807 -1.183 . . . . 0.0 109.247 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.452 ' C ' ' H ' ' A' ' 54' ' ' ASP . 37.3 m-85 -111.04 131.47 55.03 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -53.13 -14.61 0.67 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.907 -1.121 . . . . 0.0 108.184 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.452 ' H ' ' C ' ' A' ' 52' ' ' TYR . 34.2 t0 -68.72 -4.77 17.05 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.2 12.43 80.8 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.0 p -110.57 159.45 17.54 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.541 -0.976 . . . . 0.0 110.025 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 78.4 p -140.43 143.82 35.8 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.449 -0.782 . . . . 0.0 110.487 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.0 t -114.98 130.01 56.84 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 177.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 12.3 m-20 -130.55 116.94 18.85 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.946 -1.096 . . . . 0.0 109.594 -178.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.532 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 54.5 p90 -117.09 120.69 39.11 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 178.511 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.9 ttpt -110.09 144.06 39.23 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -173.39 -175.35 41.08 Favored Glycine 0 C--N 1.286 -2.226 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 66.3 t -120.53 129.77 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.658 -0.907 . . . . 0.0 109.702 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.432 ' O ' ' CG1' ' A' ' 64' ' ' VAL . 4.3 p -96.89 124.23 49.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.207 -0.933 . . . . 0.0 109.462 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.0 p -135.58 150.13 71.21 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_exo -40.77 -24.8 0.17 Allowed 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.012 1.808 . . . . 0.0 112.845 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.2 t -102.84 -22.78 13.83 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.26 -0.9 . . . . 0.0 110.983 -178.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 41.5 m -123.17 107.1 32.97 Favored Pre-proline 0 N--CA 1.504 2.255 0 O-C-N 121.146 -0.971 . . . . 0.0 109.945 -179.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -89.2 163.09 5.7 Favored 'Trans proline' 0 N--CA 1.491 1.337 0 C-N-CA 122.453 2.102 . . . . 0.0 112.445 179.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.2 t -120.04 127.66 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 -103.99 130.89 51.67 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.306 -0.871 . . . . 0.0 110.805 -178.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.27 9.68 41.6 Favored 'General case' 0 N--CA 1.5 2.057 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 178.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 48.7 t-20 -76.36 56.81 1.11 Allowed 'General case' 0 N--CA 1.486 1.338 0 O-C-N 121.598 -0.689 . . . . 0.0 109.878 -179.004 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.508 ' NE2' ' N ' ' A' ' 75' ' ' ASP . 0.0 OUTLIER -63.96 -156.07 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 178.544 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.508 ' N ' ' NE2' ' A' ' 74' ' ' GLN . 76.2 m-20 -73.4 101.39 3.46 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 120.575 -1.328 . . . . 0.0 108.583 179.571 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 90.6 mt -79.95 -9.34 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.493 -0.754 . . . . 0.0 109.959 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -59.12 -43.85 91.97 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.98 -1.075 . . . . 0.0 109.337 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 10.1 ptpt -69.94 -39.2 76.23 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.947 -1.096 . . . . 0.0 109.648 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.593 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.8 OUTLIER -60.14 -47.85 84.17 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.764 -1.21 . . . . 0.0 108.266 179.808 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 44.6 t-20 -60.04 -35.07 74.31 Favored 'General case' 0 C--N 1.296 -1.718 0 O-C-N 120.825 -1.172 . . . . 0.0 108.501 178.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 83.4 tttt -64.37 -51.52 62.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.407 -0.808 . . . . 0.0 110.817 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.4 m -115.94 -26.59 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.395 0 O-C-N 121.139 -0.976 . . . . 0.0 111.803 -178.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 93.49 166.31 37.79 Favored Glycine 0 N--CA 1.492 2.43 0 O-C-N 120.65 -1.281 . . . . 0.0 110.328 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 59.7 t -110.8 130.02 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.945 -0.738 . . . . 0.0 109.127 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 36.2 tt0 -80.0 -66.57 0.86 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.119 -0.988 . . . . 0.0 110.462 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -115.71 139.98 49.63 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 121.26 -0.9 . . . . 0.0 111.48 -178.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.446 ' CA ' ' HE ' ' A' ' 88' ' ' ARG . 80.6 t80 -121.84 133.38 54.88 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.724 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.607 ' NH2' ' CD2' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -138.5 134.07 33.48 Favored 'General case' 0 N--CA 1.507 2.415 0 O-C-N 120.933 -1.104 . . . . 0.0 110.655 -179.874 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.64 136.2 53.72 Favored 'General case' 0 N--CA 1.498 1.927 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.52 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.28 131.91 56.34 Favored 'General case' 0 N--CA 1.505 2.292 0 O-C-N 121.365 -0.834 . . . . 0.0 109.427 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 40.3 p -127.09 125.31 41.05 Favored 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.358 -0.839 . . . . 0.0 110.579 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -133.18 151.61 51.96 Favored 'General case' 0 N--CA 1.504 2.242 0 O-C-N 121.783 -0.573 . . . . 0.0 110.338 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 71.0 m95 -70.37 140.73 52.19 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.146 -0.971 . . . . 0.0 108.882 178.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.51 ' CG1' ' HE ' ' A' ' 42' ' ' ARG . 38.4 t -117.03 124.8 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 O-C-N 121.399 -0.813 . . . . 0.0 109.315 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.434 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.66 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -84.3 -26.34 28.61 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.27 -0.894 . . . . 0.0 110.362 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.449 ' ND2' ' O ' ' A' ' 9' ' ' ASN . 0.9 OUTLIER -86.32 1.7 50.05 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.103 -0.998 . . . . 0.0 110.077 -179.307 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 2.0 t -118.15 126.92 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.483 -0.761 . . . . 0.0 109.332 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -77.91 140.33 62.5 Favored Pre-proline 0 C--N 1.3 -1.583 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 178.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -75.21 -13.74 20.89 Favored 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 121.347 1.365 . . . . 0.0 111.549 -179.275 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 38.3 t -60.73 -40.35 92.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.639 -0.663 . . . . 0.0 110.917 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -81.97 -10.03 59.38 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.0 -1.062 . . . . 0.0 109.673 -179.254 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.796 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 18.3 t -70.93 -30.9 67.34 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.125 -0.984 . . . . 0.0 109.335 179.357 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -123.86 151.89 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.204 0 O-C-N 121.443 -0.785 . . . . 0.0 109.318 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.423 ' HZ3' ' HG1' ' A' ' 24' ' ' THR . 20.9 pttp -130.85 148.22 52.59 Favored 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.502 -0.749 . . . . 0.0 109.374 179.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 62.7 tt0 -100.7 124.95 47.03 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.203 -0.935 . . . . 0.0 109.673 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.525 ' O ' ' N ' ' A' ' 21' ' ' VAL . 34.4 p -111.8 121.53 45.31 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.68 -92.87 0.01 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.67 -1.772 . . . . 0.0 108.67 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.525 ' N ' ' O ' ' A' ' 19' ' ' SER . 4.6 m -137.24 30.6 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.356 -1.085 . . . . 0.0 109.264 179.293 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -129.55 159.67 35.6 Favored 'General case' 0 N--CA 1.504 2.226 0 CA-C-O 122.03 0.919 . . . . 0.0 111.029 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -119.89 139.95 51.6 Favored 'General case' 0 N--CA 1.499 2.004 0 N-CA-C 108.404 -0.962 . . . . 0.0 108.404 178.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.423 ' HG1' ' HZ3' ' A' ' 17' ' ' LYS . 77.0 p -138.32 147.42 43.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.28 -0.888 . . . . 0.0 109.001 179.423 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -83.17 125.65 31.76 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.606 -0.684 . . . . 0.0 109.38 -178.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.6 m120 -84.91 90.34 7.78 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.208 -0.933 . . . . 0.0 109.555 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 79.8 p -89.52 -0.87 57.8 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.223 -0.923 . . . . 0.0 108.851 179.352 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -68.33 -2.12 24.89 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.0 m -113.71 130.06 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.546 -0.973 . . . . 0.0 109.363 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 80.5 p -60.45 -28.0 67.96 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.703 -0.623 . . . . 0.0 110.497 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 71.2 t -61.22 -44.31 98.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 120.948 -1.095 . . . . 0.0 110.338 -178.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.796 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 86.1 m -69.83 -39.81 76.24 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.101 -0.999 . . . . 0.0 110.109 -179.034 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.4 mmt -74.95 -20.86 59.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.092 -1.005 . . . . 0.0 109.495 179.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -60.42 -39.61 88.03 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 120.985 -1.072 . . . . 0.0 109.073 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.97 -49.13 7.2 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 17.8 mt -62.64 -39.92 95.37 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.333 -1.098 . . . . 0.0 109.737 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -66.46 -39.91 89.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.055 -1.028 . . . . 0.0 109.496 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 77.0 tt0 -67.12 -30.1 70.01 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.058 -1.026 . . . . 0.0 109.348 -179.406 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.32 22.41 27.13 Favored Glycine 0 N--CA 1.497 2.743 0 O-C-N 121.112 -0.992 . . . . 0.0 110.688 179.07 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.1 mtpt -104.47 -1.52 26.57 Favored 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 178.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.438 HG12 ' H ' ' A' ' 43' ' ' GLY . 78.3 t -131.08 158.4 43.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-O 121.639 0.733 . . . . 0.0 109.447 -179.53 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . 0.404 ' N ' ' O ' ' A' ' 94' ' ' VAL . 62.5 ttm-85 -123.38 -6.84 8.17 Favored 'General case' 0 N--CA 1.498 1.965 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.438 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.54 -163.19 26.52 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 108.563 -1.815 . . . . 0.0 108.563 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.8 t -119.42 128.37 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.278 -1.131 . . . . 0.0 108.684 179.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.411 ' H ' ' HG ' ' A' ' 45' ' ' SER . 4.1 p -85.16 137.35 33.07 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.098 -1.001 . . . . 0.0 108.716 179.523 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 13.4 p -130.19 131.83 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 54.7 p -125.88 142.1 51.67 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -141.08 139.15 9.35 Favored Glycine 0 N--CA 1.497 2.731 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.317 -178.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 56.0 t -120.02 119.83 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -92.72 117.64 30.22 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -90.37 120.33 31.4 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -105.83 139.16 40.82 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.588 -0.695 . . . . 0.0 110.491 -179.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.529 ' C ' ' H ' ' A' ' 55' ' ' GLY . 45.0 t-20 -61.29 -14.7 28.52 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -66.48 0.82 1.97 Allowed 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.529 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 79.34 16.02 78.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 179.098 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.7 p -123.19 148.21 46.04 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.382 -1.069 . . . . 0.0 110.264 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 63.9 p -127.24 140.04 52.5 Favored 'General case' 0 N--CA 1.496 1.856 0 CA-C-O 121.648 0.737 . . . . 0.0 109.423 179.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.5 t -116.98 147.57 42.18 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 178.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -132.08 119.12 20.55 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.078 -1.014 . . . . 0.0 109.42 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.526 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 51.7 p90 -116.19 120.83 40.24 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.725 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -114.37 145.14 42.19 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 -179.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.4 171.35 43.1 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 72.7 t -110.83 126.94 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.458 -1.025 . . . . 0.0 109.966 -179.676 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 89.2 t -93.13 120.19 42.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.232 -0.918 . . . . 0.0 109.669 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.613 ' HG1' ' H ' ' A' ' 68' ' ' THR . 23.3 p -126.57 151.23 72.72 Favored Pre-proline 0 N--CA 1.495 1.811 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.038 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -53.99 -8.65 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 121.449 1.433 . . . . 0.0 111.615 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.416 ' H ' ' C ' ' A' ' 65' ' ' THR . 70.2 m -111.16 -18.65 12.94 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.476 -0.765 . . . . 0.0 110.243 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.613 ' H ' ' HG1' ' A' ' 65' ' ' THR . 10.3 p -133.91 109.37 11.86 Favored Pre-proline 0 N--CA 1.505 2.321 0 O-C-N 121.106 -0.996 . . . . 0.0 110.799 -179.016 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -86.91 163.58 8.91 Favored 'Trans proline' 0 N--CA 1.497 1.691 0 C-N-CA 122.556 2.171 . . . . 0.0 112.229 178.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 61.6 t -119.05 130.18 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.421 0 O-C-N 121.256 -0.902 . . . . 0.0 109.76 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 64.9 m-20 -100.58 123.63 45.05 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.34 -0.85 . . . . 0.0 110.717 -178.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.492 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.6 OUTLIER -90.87 0.59 57.45 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.832 -1.167 . . . . 0.0 108.665 179.051 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 -66.2 50.35 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.287 -0.883 . . . . 0.0 110.072 -179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.492 ' N ' ' O ' ' A' ' 72' ' ' THR . 98.9 mm-40 -55.04 -98.04 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.126 -0.984 . . . . 0.0 109.755 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -103.42 85.46 2.48 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.156 -0.965 . . . . 0.0 109.227 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.452 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 9.5 tp -67.38 -39.73 83.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.54 -0.725 . . . . 0.0 109.914 -179.751 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.452 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 97.6 m-20 -59.61 -40.15 86.55 Favored 'General case' 0 C--N 1.297 -1.716 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 -179.58 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 13.0 ttmm -66.71 -41.33 88.16 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.594 -0.691 . . . . 0.0 109.495 178.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.618 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -65.07 -52.3 56.42 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.281 -0.887 . . . . 0.0 110.836 -177.638 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.448 ' ND2' ' O ' ' A' ' 77' ' ' ASN . 0.5 OUTLIER -62.31 -28.17 69.55 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 119.808 -1.807 . . . . 0.0 108.976 179.677 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . 0.426 ' N ' HD21 ' A' ' 80' ' ' ASN . 34.6 ttmt -64.6 -51.09 64.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.129 -0.982 . . . . 0.0 110.496 -179.296 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 m -116.42 -22.04 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.274 0 O-C-N 121.353 -0.842 . . . . 0.0 110.72 -179.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.618 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 83.44 165.96 39.11 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 179.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 28.2 t -108.31 120.45 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -69.79 -55.08 10.82 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.998 -1.064 . . . . 0.0 110.051 -179.364 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -116.84 148.79 40.94 Favored 'General case' 0 N--CA 1.502 2.148 0 CA-C-O 121.863 0.84 . . . . 0.0 111.75 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 66.6 t80 -119.65 133.89 55.45 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 178.411 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 74.7 ttt180 -139.62 121.6 15.64 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.856 -1.152 . . . . 0.0 110.613 -178.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -125.34 137.84 54.05 Favored 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.135 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.0 tp -120.55 130.99 54.46 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 23.1 p -129.24 119.8 24.63 Favored 'General case' 0 N--CA 1.508 2.469 0 CA-C-O 121.817 0.818 . . . . 0.0 111.168 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -132.8 160.5 36.71 Favored 'General case' 0 N--CA 1.504 2.269 0 O-C-N 121.666 -0.647 . . . . 0.0 110.211 179.102 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 90.2 m95 -69.42 142.98 53.75 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.432 -0.793 . . . . 0.0 110.426 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.404 ' O ' ' N ' ' A' ' 42' ' ' ARG . 41.0 t -115.94 123.42 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 178.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 2.88 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 179.929 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.648 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . 0.448 ' O ' ' OD1' ' A' ' 8' ' ' ASP . 55.1 t0 -90.34 6.74 41.82 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.654 -0.654 . . . . 0.0 110.715 -178.725 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.43 ' OD1' ' N ' ' A' ' 9' ' ' ASN . 21.5 p-10 -137.83 17.74 2.86 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 120.913 -1.117 . . . . 0.0 109.048 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 35.0 m -126.02 129.76 72.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -94.94 142.48 24.69 Favored Pre-proline 0 N--CA 1.494 1.772 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.44 -18.05 23.28 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 121.91 1.74 . . . . 0.0 112.145 -179.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 87.9 p -70.13 -30.18 67.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 110.187 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -89.25 -14.98 34.67 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.959 -1.088 . . . . 0.0 109.952 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.811 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 35.7 t -72.44 -27.61 62.43 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.304 -0.872 . . . . 0.0 109.648 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.1 pp -118.21 132.52 67.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.534 -0.729 . . . . 0.0 109.087 -179.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -120.05 138.18 53.68 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.369 -0.832 . . . . 0.0 109.094 -179.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 -100.02 123.67 44.52 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.566 -0.709 . . . . 0.0 110.409 -178.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t -125.37 83.81 2.21 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.473 -0.767 . . . . 0.0 109.413 179.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.49 ' O ' ' N ' ' A' ' 22' ' ' GLN . . . 98.13 73.43 1.11 Allowed Glycine 0 N--CA 1.501 2.981 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.429 ' C ' ' O ' ' A' ' 20' ' ' GLY . 15.2 m 34.47 32.41 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.183 0 O-C-N 121.946 -0.738 . . . . 0.0 110.817 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.49 ' N ' ' O ' ' A' ' 20' ' ' GLY . 14.1 pt20 -130.86 161.02 32.75 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.569 -0.707 . . . . 0.0 109.55 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -124.38 131.49 53.51 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 38.7 p -134.27 152.52 51.86 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.336 -0.853 . . . . 0.0 109.381 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 39.1 t80 -81.79 130.67 35.14 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.514 -0.742 . . . . 0.0 109.256 -179.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -81.86 77.41 8.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.917 -1.114 . . . . 0.0 109.93 -179.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 54.3 p -79.57 -8.34 59.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.092 -1.005 . . . . 0.0 109.358 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.9 -39.86 96.07 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.414 ' CG2' ' SG ' ' A' ' 32' ' ' CYS . 27.0 m -82.25 138.34 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.046 -1.267 . . . . 0.0 109.305 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.744 ' HG ' HE21 ' A' ' 34' ' ' GLN . 32.6 t -63.2 -34.64 78.08 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.488 -0.758 . . . . 0.0 110.868 -179.255 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.1 t -56.83 -40.04 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.832 -1.168 . . . . 0.0 109.556 -178.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.811 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 49.1 m -63.08 -39.89 96.04 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.047 -1.033 . . . . 0.0 110.059 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 96.5 mmm -88.94 -16.8 30.91 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.769 -1.207 . . . . 0.0 110.974 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . 0.744 HE21 ' HG ' ' A' ' 30' ' ' SER . 50.3 mt-30 -60.23 -42.68 95.74 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 120.616 -1.302 . . . . 0.0 108.984 178.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -80.34 -41.68 11.37 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.0 tp -59.99 -47.08 87.3 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.312 -1.11 . . . . 0.0 109.241 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 45.0 t30 -65.52 -39.86 92.31 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.285 -0.884 . . . . 0.0 110.184 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.5 -31.98 71.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.249 -0.907 . . . . 0.0 109.423 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.74 18.77 46.63 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 -179.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.3 tttp -97.56 -9.09 27.65 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 178.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.431 HG12 ' H ' ' A' ' 43' ' ' GLY . 97.1 t -134.72 159.87 41.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.038 -0.983 . . . . 0.0 108.665 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . 0.472 ' N ' ' O ' ' A' ' 94' ' ' VAL . 57.9 ttm-85 -125.04 -1.69 7.74 Favored 'General case' 0 N--CA 1.497 1.917 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 179.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.431 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 129.65 -163.96 22.59 Favored Glycine 0 N--CA 1.499 2.855 0 N-CA-C 107.719 -2.153 . . . . 0.0 107.719 -179.236 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 47.5 t -120.56 129.79 75.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.124 0 CA-C-N 118.881 1.34 . . . . 0.0 109.486 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 63.6 p -77.43 141.94 39.47 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.456 -0.777 . . . . 0.0 108.959 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.9 p -127.38 125.32 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 CA-C-O 121.947 0.88 . . . . 0.0 108.727 179.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 2.4 p -128.06 146.65 50.61 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -154.66 147.44 16.57 Favored Glycine 0 N--CA 1.494 2.56 0 C-N-CA 118.306 -1.902 . . . . 0.0 111.237 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 53.2 t -126.4 126.28 68.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -100.56 125.82 46.95 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.267 -0.896 . . . . 0.0 108.773 179.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -95.28 126.92 40.92 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.493 -0.754 . . . . 0.0 109.965 -178.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.535 ' C ' ' H ' ' A' ' 54' ' ' ASP . 98.2 m-85 -114.02 130.33 56.55 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.543 -0.723 . . . . 0.0 109.918 -179.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -53.02 -8.19 0.09 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.507 -0.746 . . . . 0.0 109.328 179.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.535 ' H ' ' C ' ' A' ' 52' ' ' TYR . 41.3 t0 -74.44 0.81 13.42 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.773 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.68 14.55 79.63 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.2 p -123.15 147.86 46.36 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 121.487 -1.008 . . . . 0.0 109.788 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 53.0 p -129.68 140.35 51.15 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 85.0 p -107.45 155.88 19.57 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 30.1 p-10 -146.53 116.07 7.14 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.874 -1.141 . . . . 0.0 109.674 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -118.51 121.82 41.19 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -113.17 153.67 27.91 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -174.82 -177.25 43.78 Favored Glycine 0 C--N 1.282 -2.464 0 C-N-CA 119.337 -1.411 . . . . 0.0 110.847 -179.505 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -119.7 127.36 75.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.971 -0.723 . . . . 0.0 109.375 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.1 t -92.3 120.26 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.199 -0.938 . . . . 0.0 110.519 -179.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.7 p -135.76 152.08 75.35 Favored Pre-proline 0 N--CA 1.492 1.639 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.011 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -54.54 -10.18 2.18 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 121.613 1.542 . . . . 0.0 111.687 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.2 t -103.04 -26.97 12.87 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.324 -0.86 . . . . 0.0 111.23 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 78.2 p -133.34 108.87 12.38 Favored Pre-proline 0 N--CA 1.505 2.283 0 O-C-N 120.911 -1.118 . . . . 0.0 110.295 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -85.09 163.18 11.58 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 C-N-CA 122.068 1.845 . . . . 0.0 111.897 178.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.4 t -120.61 127.53 75.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.467 -0.77 . . . . 0.0 109.07 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -105.48 130.22 53.6 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.189 -0.944 . . . . 0.0 111.303 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.518 ' C ' ' H ' ' A' ' 74' ' ' GLN . 0.6 OUTLIER -92.61 4.87 52.79 Favored 'General case' 0 N--CA 1.499 1.983 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 177.703 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 48.2 p-10 -73.3 21.09 0.08 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.731 -0.605 . . . . 0.0 109.78 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.518 ' H ' ' C ' ' A' ' 72' ' ' THR . 73.5 tp60 -42.85 -83.49 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.479 -0.763 . . . . 0.0 110.744 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -113.62 74.38 0.86 Allowed 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.338 -0.851 . . . . 0.0 110.597 -179.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 83.1 mt -70.21 -34.26 58.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 120.945 -1.097 . . . . 0.0 109.303 178.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 71.3 m-20 -52.78 -43.25 65.73 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.064 -1.023 . . . . 0.0 108.698 -179.15 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 47.4 tttp -62.82 -46.37 88.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.412 -0.805 . . . . 0.0 109.051 178.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.585 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.3 OUTLIER -60.3 -46.7 88.96 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.528 -0.732 . . . . 0.0 110.103 -178.998 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -61.0 -36.75 80.28 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 120.255 -1.528 . . . . 0.0 109.406 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 38.0 tttm -66.38 -50.08 64.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.494 -0.754 . . . . 0.0 110.827 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.9 p -111.42 -26.98 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.544 -0.723 . . . . 0.0 111.805 -176.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.585 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.09 161.52 35.42 Favored Glycine 0 N--CA 1.492 2.372 0 O-C-N 120.678 -1.264 . . . . 0.0 110.294 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.46 ' CG2' ' HG1' ' A' ' 79' ' ' THR . 16.5 t -106.99 120.97 59.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.916 -0.755 . . . . 0.0 109.27 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 61.7 tt0 -72.04 -58.2 3.64 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.155 -0.966 . . . . 0.0 110.951 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 32.7 ttmt -114.81 146.39 41.08 Favored 'General case' 0 N--CA 1.509 2.476 0 O-C-N 121.226 -0.921 . . . . 0.0 111.038 -178.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -121.59 130.36 53.45 Favored 'General case' 0 N--CA 1.501 2.098 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 21.9 mmm180 -137.29 121.68 18.24 Favored 'General case' 0 N--CA 1.505 2.312 0 O-C-N 120.929 -1.107 . . . . 0.0 109.913 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.24 133.9 53.39 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.632 -0.668 . . . . 0.0 109.387 179.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 65.5 tp -117.87 131.46 56.54 Favored 'General case' 0 N--CA 1.5 2.068 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 11.3 p -128.19 124.55 37.07 Favored 'General case' 0 N--CA 1.502 2.139 0 CA-C-O 121.39 0.614 . . . . 0.0 110.334 -179.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -132.67 151.13 52.05 Favored 'General case' 0 N--CA 1.505 2.312 0 O-C-N 121.617 -0.677 . . . . 0.0 110.748 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 58.1 m95 -71.2 139.04 50.0 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.31 -0.869 . . . . 0.0 109.007 179.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.472 ' O ' ' N ' ' A' ' 42' ' ' ARG . 47.3 t -111.08 119.41 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.427 0 N-CA-C 109.261 -1.535 . . . . 0.0 109.261 179.834 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.623 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . 0.407 ' O ' ' OD1' ' A' ' 8' ' ' ASP . 34.0 t0 -88.44 -28.07 21.11 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.33 -0.856 . . . . 0.0 109.566 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 53.5 t30 -89.97 -0.0 57.34 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.522 -0.736 . . . . 0.0 109.556 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.8 t -110.87 129.98 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.569 -0.707 . . . . 0.0 109.868 -178.771 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -89.14 135.07 31.96 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.147 -0.97 . . . . 0.0 108.593 179.288 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -73.37 -14.27 25.33 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 121.695 1.597 . . . . 0.0 111.603 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 23.2 t -60.64 -40.12 90.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.57 179.489 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 27.5 mt-30 -82.54 -12.97 57.39 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.989 -1.069 . . . . 0.0 109.865 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.796 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 44.3 t -64.27 -37.81 88.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.049 -1.032 . . . . 0.0 109.268 179.721 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -118.23 148.63 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 20.3 ptmt -130.61 155.07 47.16 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 121.497 -0.752 . . . . 0.0 109.508 -179.078 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -98.95 117.46 33.52 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.414 -0.804 . . . . 0.0 110.521 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.5 t -126.37 85.71 2.42 Favored 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.605 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.81 62.52 1.37 Allowed Glycine 0 N--CA 1.497 2.739 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.9 m 40.01 35.74 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.746 -0.855 . . . . 0.0 110.556 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 80.3 mt-30 -132.32 162.84 30.03 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.61 -0.681 . . . . 0.0 109.401 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 41.8 m-85 -120.03 136.34 54.6 Favored 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 178.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 49.3 p -139.57 149.76 44.24 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.411 -0.806 . . . . 0.0 109.925 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.61 ' CZ ' ' SG ' ' A' ' 32' ' ' CYS . 44.1 t80 -80.47 125.21 29.67 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -84.41 84.2 7.73 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.113 -0.992 . . . . 0.0 110.577 -178.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 83.1 p -83.18 -7.0 59.68 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.128 -0.982 . . . . 0.0 109.538 179.321 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.58 -37.76 68.76 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.4 m -85.53 136.46 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.272 -1.134 . . . . 0.0 108.719 179.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 82.9 p -69.88 -40.0 75.95 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.322 -0.861 . . . . 0.0 111.442 -178.617 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 33.7 m -50.23 -42.75 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.773 -1.204 . . . . 0.0 110.647 -178.084 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.796 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 18.9 t -61.17 -42.0 97.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.875 -1.14 . . . . 0.0 110.111 -179.505 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 18.0 mtp -82.12 -12.73 58.03 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.61 -1.306 . . . . 0.0 110.829 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 12.5 mm100 -60.18 -40.0 88.46 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.629 -1.295 . . . . 0.0 108.387 178.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.92 -50.61 6.3 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 62.6 tp -60.24 -41.31 92.87 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.279 -1.13 . . . . 0.0 109.446 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -60.19 -40.05 88.68 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.169 -0.957 . . . . 0.0 109.738 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -74.24 -9.51 58.68 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.156 -0.965 . . . . 0.0 109.999 -179.435 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.65 26.42 67.47 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 179.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 45.7 mmtm -100.17 -5.54 27.58 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 178.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.491 ' CG1' ' H ' ' A' ' 43' ' ' GLY . 55.7 t -133.3 161.01 42.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . 0.412 ' N ' ' CG1' ' A' ' 41' ' ' VAL . 74.3 ttt180 -122.05 -6.82 8.92 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.564 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.491 ' H ' ' CG1' ' A' ' 41' ' ' VAL . . . 135.42 -164.95 24.84 Favored Glycine 0 N--CA 1.498 2.785 0 N-CA-C 108.082 -2.007 . . . . 0.0 108.082 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.3 t -120.03 129.41 75.49 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.091 -1.241 . . . . 0.0 109.415 179.593 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.9 t -83.71 135.99 34.35 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.312 -0.868 . . . . 0.0 108.768 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.0 p -131.45 133.17 62.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 CA-C-O 121.603 0.715 . . . . 0.0 109.813 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.8 p -124.73 151.12 45.45 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 178.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -146.17 147.01 17.68 Favored Glycine 0 N--CA 1.5 2.926 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.803 -179.029 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 75.0 t -129.67 127.18 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.803 -0.822 . . . . 0.0 108.989 179.32 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -102.64 112.88 25.83 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.472 ' HH ' HH21 ' A' ' 88' ' ' ARG . 23.7 m-85 -81.44 128.57 34.01 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.091 -1.006 . . . . 0.0 109.374 -179.222 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -114.72 134.21 55.27 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.481 -0.762 . . . . 0.0 109.499 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.447 ' C ' ' H ' ' A' ' 55' ' ' GLY . 95.9 m-20 -61.84 -9.34 6.46 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.262 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.442 ' OD2' ' OG1' ' A' ' 56' ' ' THR . 46.1 p-10 -68.05 0.15 3.87 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.326 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.447 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 88.27 14.38 62.24 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.247 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.442 ' OG1' ' OD2' ' A' ' 54' ' ' ASP . 35.0 p -136.03 156.75 48.27 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.03 -1.277 . . . . 0.0 110.652 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 37.3 p -131.23 132.94 45.0 Favored 'General case' 0 N--CA 1.498 1.937 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 83.7 p -91.59 160.01 15.61 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 6.0 p30 -152.15 115.01 4.62 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.822 -1.174 . . . . 0.0 109.985 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -118.01 127.77 54.13 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 178.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 78.7 tttt -115.44 145.71 42.31 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.155 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.71 170.07 42.09 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.2 t -110.56 127.53 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.521 -0.987 . . . . 0.0 109.574 -179.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 69.3 t -94.0 118.07 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.086 -1.009 . . . . 0.0 109.491 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.518 ' O ' ' N ' ' A' ' 68' ' ' THR . 12.0 p -125.62 146.25 54.16 Favored Pre-proline 0 N--CA 1.497 1.916 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 178.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_exo -35.9 -27.85 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.344 0 C-N-CA 122.433 2.089 . . . . 0.0 112.884 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.474 ' N ' ' O ' ' A' ' 65' ' ' THR . 5.8 t -106.81 -10.57 16.01 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.433 -0.792 . . . . 0.0 110.528 -179.657 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 65' ' ' THR . 88.7 m -126.33 106.58 24.33 Favored Pre-proline 0 N--CA 1.505 2.31 0 O-C-N 121.04 -1.038 . . . . 0.0 110.981 -179.175 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -90.44 162.48 4.46 Favored 'Trans proline' 0 N--CA 1.487 1.107 0 C-N-CA 122.404 2.069 . . . . 0.0 111.351 177.568 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 78.4 t -119.84 128.06 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.239 0 O-C-N 121.229 -0.92 . . . . 0.0 108.91 179.318 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -101.25 135.15 43.2 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.298 -0.876 . . . . 0.0 110.16 -179.206 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.486 ' C ' ' H ' ' A' ' 74' ' ' GLN . 0.1 OUTLIER -106.02 19.68 20.15 Favored 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 178.332 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.583 HD21 ' N ' ' A' ' 73' ' ' ASN . 1.6 m120 -64.28 42.88 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.848 -178.628 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.486 ' H ' ' C ' ' A' ' 72' ' ' THR . 25.2 mm100 -51.48 170.27 0.05 OUTLIER 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.106 -0.996 . . . . 0.0 109.114 179.213 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -53.05 114.0 1.3 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.054 -1.029 . . . . 0.0 109.621 -179.242 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 97.5 mt -86.46 -16.06 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.384 -0.823 . . . . 0.0 110.246 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -59.84 -39.66 85.92 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 179.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 71.1 mttt -63.0 -50.23 71.57 Favored 'General case' 0 N--CA 1.492 1.634 0 CA-C-O 122.496 1.141 . . . . 0.0 109.551 179.436 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.587 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -59.96 -50.68 72.79 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.515 -177.33 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -61.39 -36.11 79.35 Favored 'General case' 0 C--N 1.292 -1.9 0 O-C-N 120.208 -1.558 . . . . 0.0 109.031 178.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -65.58 -50.27 65.75 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.447 -0.783 . . . . 0.0 111.093 -179.312 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.3 m -115.77 -24.77 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.3 0 O-C-N 121.271 -0.893 . . . . 0.0 111.609 -177.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 91.52 166.55 40.23 Favored Glycine 0 N--CA 1.492 2.413 0 O-C-N 120.71 -1.244 . . . . 0.0 110.068 179.372 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.419 ' CG2' ' HG1' ' A' ' 79' ' ' THR . 49.0 t -106.96 128.54 61.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.926 -0.749 . . . . 0.0 109.057 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -79.99 -66.59 0.86 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.945 -1.097 . . . . 0.0 109.838 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 57.4 mttm -116.55 140.85 48.93 Favored 'General case' 0 N--CA 1.504 2.255 0 O-C-N 121.291 -0.881 . . . . 0.0 111.051 -179.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 70.5 t80 -121.05 132.75 55.07 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 178.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.472 HH21 ' HH ' ' A' ' 51' ' ' TYR . 42.6 mtm105 -136.85 129.97 31.07 Favored 'General case' 0 N--CA 1.504 2.258 0 O-C-N 121.119 -0.988 . . . . 0.0 110.743 -179.409 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.31 135.47 54.22 Favored 'General case' 0 N--CA 1.499 1.983 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.9 mt -118.51 130.28 55.84 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.427 -0.796 . . . . 0.0 109.599 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 20.1 p -128.61 125.07 37.41 Favored 'General case' 0 N--CA 1.503 2.218 0 CA-C-O 121.677 0.751 . . . . 0.0 110.645 -179.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -132.96 154.37 50.53 Favored 'General case' 0 N--CA 1.502 2.159 0 CA-C-O 121.412 0.625 . . . . 0.0 110.638 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 80.2 m95 -69.87 142.08 53.09 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 35.4 t -116.61 120.81 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.133 0 O-C-N 121.332 -0.855 . . . . 0.0 109.202 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.179 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.978 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.736 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . 0.555 ' CG ' ' H ' ' A' ' 9' ' ' ASN . 11.3 p-10 -47.74 -79.74 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.787 -0.571 . . . . 0.0 111.367 -178.533 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.555 ' H ' ' CG ' ' A' ' 8' ' ' ASP . 13.9 m120 -144.42 37.66 1.24 Allowed 'General case' 0 N--CA 1.497 1.899 0 O-C-N 120.898 -1.126 . . . . 0.0 109.885 -178.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -81.49 152.55 4.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 120.94 -1.1 . . . . 0.0 108.398 -179.11 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.6 m-20 -78.63 131.5 67.72 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.179 -0.951 . . . . 0.0 109.879 -178.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -80.61 -15.08 11.16 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.128 1.885 . . . . 0.0 111.812 179.438 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 94.2 p -64.46 -35.75 81.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.48 -0.763 . . . . 0.0 110.506 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -69.98 -23.7 63.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.162 -0.961 . . . . 0.0 109.812 -179.249 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.8 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 60.8 m -68.26 -27.66 66.54 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.209 -0.932 . . . . 0.0 109.64 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.7 pp -118.49 133.0 66.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.498 -0.751 . . . . 0.0 109.19 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -112.05 142.15 44.84 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.544 ' CD ' ' H ' ' A' ' 18' ' ' GLN . 0.1 OUTLIER -97.55 128.48 44.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.257 -0.902 . . . . 0.0 109.694 -179.411 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.549 ' O ' ' N ' ' A' ' 21' ' ' VAL . 25.3 t -107.4 118.6 37.15 Favored 'General case' 0 N--CA 1.495 1.825 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.42 -78.81 0.01 OUTLIER Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.549 ' N ' ' O ' ' A' ' 19' ' ' SER . 9.8 p -156.7 32.95 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.319 -1.106 . . . . 0.0 108.629 179.268 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 46.3 tt0 -129.22 161.56 29.86 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 -179.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -115.19 135.06 54.58 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.322 -0.861 . . . . 0.0 109.261 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 23.9 p -135.8 150.01 49.3 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 35.8 t80 -83.79 122.09 28.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.347 -0.846 . . . . 0.0 109.663 -179.039 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -84.55 83.63 7.94 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.362 -0.837 . . . . 0.0 109.742 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 96.3 p -78.48 -4.91 50.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.231 -0.918 . . . . 0.0 109.091 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -56.68 -39.01 85.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 -179.437 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.5 m -81.06 133.46 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 120.877 -1.366 . . . . 0.0 109.741 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.5 m -63.33 -34.47 77.77 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.544 -0.723 . . . . 0.0 111.929 -178.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.2 p -59.98 -40.01 81.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 120.608 -1.307 . . . . 0.0 110.796 -177.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.8 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 77.6 m -66.25 -40.04 89.92 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.657 -1.277 . . . . 0.0 109.719 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 7.7 mmt -78.69 -19.14 53.15 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.008 -1.058 . . . . 0.0 109.123 179.607 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -60.75 -41.04 94.62 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.216 -0.928 . . . . 0.0 108.958 179.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -73.59 -43.61 35.85 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 2.1 mt -65.85 -39.98 91.27 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.254 -1.145 . . . . 0.0 108.94 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.32 -40.03 94.98 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.07 -1.019 . . . . 0.0 109.82 179.05 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -76.63 -10.79 59.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.214 -0.929 . . . . 0.0 110.086 -179.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.28 28.49 69.86 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.404 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -103.64 -6.01 22.05 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.435 HG11 ' H ' ' A' ' 43' ' ' GLY . 45.9 t -133.72 159.88 42.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 115.51 -0.768 . . . . 0.0 108.987 -179.251 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . 0.508 ' N ' ' O ' ' A' ' 94' ' ' VAL . 70.3 mtp85 -120.91 -7.71 9.47 Favored 'General case' 0 N--CA 1.5 2.053 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.355 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.435 ' H ' HG11 ' A' ' 41' ' ' VAL . . . 138.73 -159.85 25.51 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -179.035 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.4 t -120.67 129.74 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.145 0 O-C-N 121.297 -1.12 . . . . 0.0 109.32 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.0 t -86.65 140.02 30.22 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.303 -0.873 . . . . 0.0 108.98 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.9 p -131.9 132.46 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.74 0.781 . . . . 0.0 109.829 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 81.9 p -123.29 148.79 45.57 Favored 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -144.64 144.33 13.15 Favored Glycine 0 N--CA 1.5 2.962 0 C-N-CA 119.219 -1.467 . . . . 0.0 111.375 -178.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 85.6 t -121.59 130.01 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.545 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.531 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 9.9 m-85 -106.79 119.89 40.53 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.783 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -98.67 120.82 39.76 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.422 -0.799 . . . . 0.0 109.07 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.529 ' O ' ' N ' ' A' ' 54' ' ' ASP . 94.1 m-85 -105.56 131.33 53.09 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.345 -0.847 . . . . 0.0 109.164 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 49.2 t30 -46.6 -15.56 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.245 -0.909 . . . . 0.0 109.166 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 52' ' ' TYR . 35.9 t0 -69.71 -0.81 7.59 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.578 -0.701 . . . . 0.0 109.392 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.4 23.19 65.89 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 120.047 -1.073 . . . . 0.0 110.611 179.135 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.2 p -118.76 150.27 40.06 Favored 'General case' 0 N--CA 1.504 2.256 0 O-C-N 121.297 -1.12 . . . . 0.0 110.046 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 63.9 p -135.27 128.98 32.87 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.501 -0.75 . . . . 0.0 109.783 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 45.9 t -118.7 145.87 45.17 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 55.9 t-20 -135.8 128.08 30.12 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.753 -1.217 . . . . 0.0 109.796 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -117.15 122.15 43.27 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 178.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -107.52 144.5 34.41 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -162.68 170.99 38.4 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.634 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.7 t -113.98 125.39 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.555 -0.967 . . . . 0.0 109.42 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -90.26 117.9 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.368 -0.833 . . . . 0.0 110.232 -179.152 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.517 ' O ' ' N ' ' A' ' 67' ' ' SER . 25.9 p -125.74 144.4 48.2 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.402 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -38.4 -21.29 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.157 1.905 . . . . 0.0 113.276 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 65' ' ' THR . 10.4 m -108.64 -11.37 15.1 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.197 -0.939 . . . . 0.0 111.296 -178.845 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 55.1 p -130.69 107.87 15.63 Favored Pre-proline 0 N--CA 1.504 2.242 0 O-C-N 121.011 -1.056 . . . . 0.0 110.392 -179.201 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -91.25 164.42 3.69 Favored 'Trans proline' 0 N--CA 1.49 1.314 0 C-N-CA 122.605 2.203 . . . . 0.0 112.135 178.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 48.9 t -124.42 130.15 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.127 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 31.3 m120 -100.77 138.19 38.16 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.082 -1.012 . . . . 0.0 110.502 -178.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -98.5 -19.37 17.69 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 121.02 -1.05 . . . . 0.0 109.021 179.17 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 44.4 p-10 -87.41 44.42 1.18 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.038 -1.039 . . . . 0.0 108.442 179.118 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -59.71 -49.18 78.74 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.519 -0.872 . . . . 0.0 108.741 -179.334 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -115.17 75.8 0.96 Allowed 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 107.845 -1.168 . . . . 0.0 107.845 178.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 10.4 tt -73.33 -28.64 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.28 -0.887 . . . . 0.0 110.116 -178.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -60.06 -49.66 76.79 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.61 -178.067 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.414 ' CG ' ' N ' ' A' ' 79' ' ' THR . 0.1 OUTLIER -61.08 -39.94 91.82 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.569 -1.332 . . . . 0.0 108.34 179.353 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.586 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.4 m -60.04 -43.96 94.99 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.397 0.618 . . . . 0.0 109.772 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -61.63 -38.5 87.89 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 120.596 -1.315 . . . . 0.0 109.987 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.4 ttmm -70.04 -44.85 68.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.139 -0.976 . . . . 0.0 111.224 -179.266 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.1 p -112.08 -28.75 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.075 0 O-C-N 121.311 -0.868 . . . . 0.0 112.098 -176.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.586 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.69 161.43 33.52 Favored Glycine 0 N--CA 1.491 2.339 0 O-C-N 120.66 -1.275 . . . . 0.0 110.177 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 90.0 t -109.51 124.85 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.14 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -80.05 -58.62 3.07 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.247 -0.908 . . . . 0.0 110.952 -178.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 35.4 ttpt -114.11 137.59 51.53 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.267 -0.895 . . . . 0.0 110.809 -178.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 54.9 t80 -123.78 125.89 45.5 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.129 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 76.0 mmt-85 -130.98 132.01 44.76 Favored 'General case' 0 N--CA 1.506 2.336 0 O-C-N 121.137 -0.977 . . . . 0.0 110.525 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -121.26 138.09 54.39 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 179.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.6 tt -119.95 131.17 55.1 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 22.1 p -126.59 126.3 43.39 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.507 -0.745 . . . . 0.0 110.706 -179.243 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 -133.5 154.57 50.71 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.855 -0.528 . . . . 0.0 109.793 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -67.58 139.4 56.9 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.163 -0.961 . . . . 0.0 109.051 179.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.508 ' O ' ' N ' ' A' ' 42' ' ' ARG . 41.4 t -111.84 121.29 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.323 -0.861 . . . . 0.0 109.013 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.739 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 179.461 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.48 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -69.87 -39.84 76.09 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.681 -0.637 . . . . 0.0 110.761 -179.223 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 32.7 m120 -84.38 3.56 35.37 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.004 -1.06 . . . . 0.0 110.4 -178.312 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.0 t -116.31 129.8 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.347 -0.846 . . . . 0.0 109.129 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 -84.68 138.3 38.11 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.016 -1.053 . . . . 0.0 109.212 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -76.63 -24.74 10.07 Favored 'Trans proline' 0 N--CA 1.494 1.531 0 C-N-CA 121.938 1.758 . . . . 0.0 111.673 179.314 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 55.4 m -60.26 -39.89 88.38 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.304 -0.872 . . . . 0.0 110.566 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.7 mt-30 -77.89 -19.82 54.06 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.182 -0.949 . . . . 0.0 110.287 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.812 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 49.6 m -65.66 -29.61 70.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.005 -1.06 . . . . 0.0 109.685 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -118.6 139.64 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.132 0 O-C-N 121.427 -0.796 . . . . 0.0 109.272 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -124.31 144.25 50.1 Favored 'General case' 0 N--CA 1.498 1.955 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 -179.731 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 64.8 tt0 -96.74 124.37 40.7 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.212 -0.93 . . . . 0.0 109.676 -179.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.497 ' O ' ' N ' ' A' ' 21' ' ' VAL . 70.3 m -109.52 129.95 55.54 Favored 'General case' 0 N--CA 1.498 1.967 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.36 -94.06 0.01 OUTLIER Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.497 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.8 t -137.17 28.84 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 121.427 -1.043 . . . . 0.0 109.319 -179.386 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -131.38 163.15 28.53 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.577 -0.702 . . . . 0.0 110.359 -179.571 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -118.76 139.94 50.75 Favored 'General case' 0 N--CA 1.503 2.183 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 70.9 p -139.82 157.01 46.43 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.272 -0.893 . . . . 0.0 109.651 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -89.65 121.69 32.07 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.539 -0.726 . . . . 0.0 109.103 -179.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 -82.47 86.09 6.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.129 -0.982 . . . . 0.0 110.105 -179.368 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.516 ' C ' ' H ' ' A' ' 29' ' ' VAL . 92.1 p -81.58 -7.04 59.54 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.243 -0.91 . . . . 0.0 109.38 179.391 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.66 -8.22 0.34 Allowed Glycine 0 N--CA 1.489 2.196 0 N-CA-C 110.162 -1.175 . . . . 0.0 110.162 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.516 ' H ' ' C ' ' A' ' 27' ' ' SER . 20.4 m -113.31 132.44 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.409 -1.054 . . . . 0.0 108.992 179.529 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.8 m -69.87 -30.07 67.45 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.426 -0.796 . . . . 0.0 111.107 -178.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 18.0 m -60.16 -40.34 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 120.672 -1.268 . . . . 0.0 110.583 -178.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.812 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 96.5 m -65.81 -40.02 91.47 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.83 -1.169 . . . . 0.0 110.01 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 35.3 mtp -84.37 -11.92 55.42 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.901 -1.125 . . . . 0.0 109.303 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 12.6 tm0? -61.66 -42.19 98.57 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.83 -42.68 24.97 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 179.16 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.5 tp -60.2 -41.23 92.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.276 -1.132 . . . . 0.0 108.96 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -62.61 -40.68 97.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.306 -0.871 . . . . 0.0 109.815 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -63.07 -28.27 69.97 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.342 -0.849 . . . . 0.0 109.873 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.69 17.96 57.4 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 92.4 mttt -100.84 -1.54 34.5 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.422 HG11 ' H ' ' A' ' 43' ' ' GLY . 97.4 t -132.3 157.75 43.14 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 115.189 -0.914 . . . . 0.0 108.713 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -119.99 -7.62 9.9 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 179.149 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.422 ' H ' HG11 ' A' ' 41' ' ' VAL . . . 135.7 -160.08 24.41 Favored Glycine 0 N--CA 1.5 2.934 0 N-CA-C 108.22 -1.952 . . . . 0.0 108.22 -179.564 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.1 t -119.98 128.03 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.16 -1.2 . . . . 0.0 108.795 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.493 ' H ' ' HG ' ' A' ' 45' ' ' SER . 1.5 p -82.56 139.64 33.72 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.147 -0.971 . . . . 0.0 108.924 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.7 p -120.05 127.62 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 CA-C-O 121.827 0.822 . . . . 0.0 108.878 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.0 p -128.06 149.86 50.2 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -168.92 159.44 32.53 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 117.922 -2.085 . . . . 0.0 111.682 -179.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 89.2 t -131.32 136.84 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.943 -0.739 . . . . 0.0 109.133 179.255 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.55 ' CZ ' ' OG1' ' A' ' 72' ' ' THR . 55.7 m-85 -108.18 123.71 49.16 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.006 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -95.91 126.51 41.21 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 120.735 -1.228 . . . . 0.0 109.751 -179.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.503 ' C ' ' H ' ' A' ' 54' ' ' ASP . 78.2 m-85 -112.0 129.79 56.08 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.453 -0.779 . . . . 0.0 109.913 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.435 ' C ' ' H ' ' A' ' 55' ' ' GLY . 31.9 t-20 -52.89 -10.83 0.18 Allowed 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 178.459 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.503 ' H ' ' C ' ' A' ' 52' ' ' TYR . 9.3 t70 -67.07 -2.68 5.82 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 84.56 19.0 60.89 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.114 178.633 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.4 p -133.46 152.07 51.86 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.022 -1.281 . . . . 0.0 110.812 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 68.9 p -130.33 142.39 50.53 Favored 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.419 0.628 . . . . 0.0 109.859 -179.476 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -117.55 140.83 49.1 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 178.681 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -125.28 116.24 21.63 Favored 'General case' 0 N--CA 1.496 1.839 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -117.49 121.04 39.93 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -113.22 149.8 33.23 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 179.502 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.2 -175.99 38.88 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.317 -1.421 . . . . 0.0 110.844 -179.53 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 66.8 t -122.49 127.82 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.915 -0.756 . . . . 0.0 109.944 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 21.8 t -99.3 118.61 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.365 -0.834 . . . . 0.0 110.256 -179.267 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.413 ' O ' ' N ' ' A' ' 67' ' ' SER . 29.9 p -118.89 149.83 47.4 Favored Pre-proline 0 N--CA 1.494 1.732 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.304 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -38.51 -28.02 0.12 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 121.845 1.697 . . . . 0.0 113.013 -179.552 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.413 ' N ' ' O ' ' A' ' 65' ' ' THR . 53.5 m -108.58 -3.58 17.89 Favored 'General case' 0 N--CA 1.503 2.225 0 O-C-N 121.345 -0.847 . . . . 0.0 111.677 -178.767 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 7.5 m -124.76 106.57 29.26 Favored Pre-proline 0 N--CA 1.508 2.452 0 O-C-N 120.84 -1.163 . . . . 0.0 111.008 -179.036 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -92.61 164.76 2.83 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 122.818 2.345 . . . . 0.0 111.562 177.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.8 t -119.88 130.04 74.69 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.19 0 O-C-N 121.261 -0.899 . . . . 0.0 108.802 179.62 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -99.91 121.7 41.72 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.304 -0.872 . . . . 0.0 109.997 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.55 ' OG1' ' CZ ' ' A' ' 50' ' ' PHE . 0.2 OUTLIER -100.45 5.45 44.22 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.075 -1.016 . . . . 0.0 108.855 179.41 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.422 ' O ' ' O ' ' A' ' 74' ' ' GLN . 47.9 p-10 -73.42 46.52 0.2 Allowed 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.323 -0.861 . . . . 0.0 109.649 -179.379 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.422 ' O ' ' O ' ' A' ' 73' ' ' ASN . 65.4 tt0 -47.72 -91.9 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.132 -0.98 . . . . 0.0 109.208 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -113.78 104.49 12.25 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.481 -0.762 . . . . 0.0 109.762 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 77.6 mt -80.07 -27.02 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 120.951 -1.093 . . . . 0.0 108.765 179.084 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.408 ' HA ' HD22 ' A' ' 80' ' ' ASN . 27.0 t-20 -59.71 -40.0 86.5 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 18.5 ttmm -69.59 -48.55 59.78 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.209 -0.932 . . . . 0.0 108.791 177.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.61 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.5 OUTLIER -61.84 -51.15 69.43 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.805 -1.184 . . . . 0.0 110.801 -178.551 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 81' ' ' LYS . 29.6 p30 -66.25 -27.11 67.7 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 119.656 -1.902 . . . . 0.0 108.925 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . 0.52 ' N ' ' OD1' ' A' ' 80' ' ' ASN . 37.4 tptt -69.94 -49.05 55.65 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.348 -0.845 . . . . 0.0 110.431 179.366 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.5 m -114.73 -26.04 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.351 0 O-C-N 121.039 -1.038 . . . . 0.0 110.859 -178.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.61 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.87 161.28 36.01 Favored Glycine 0 N--CA 1.493 2.46 0 O-C-N 120.712 -1.243 . . . . 0.0 110.41 179.097 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -100.92 117.52 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -74.75 -59.28 2.8 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.115 -0.991 . . . . 0.0 111.613 -178.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 54.3 mttp -114.29 135.41 54.1 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.33 -0.856 . . . . 0.0 110.983 -177.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 61.2 t80 -122.7 131.81 53.97 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.562 -0.711 . . . . 0.0 109.599 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -139.18 130.76 27.25 Favored 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.214 -0.929 . . . . 0.0 110.576 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -126.95 133.68 50.57 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.617 -0.677 . . . . 0.0 110.309 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 64.9 tp -120.05 131.29 55.05 Favored 'General case' 0 N--CA 1.503 2.181 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -130.48 131.13 44.99 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.528 -0.732 . . . . 0.0 111.181 -179.308 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.466 ' CD ' ' N ' ' A' ' 92' ' ' GLU . 4.6 pm0 -134.22 153.49 51.82 Favored 'General case' 0 N--CA 1.505 2.289 0 CA-C-O 121.35 0.595 . . . . 0.0 110.512 179.101 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 36.7 m95 -70.0 138.97 52.66 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.7 t -110.23 119.81 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.442 -0.787 . . . . 0.0 108.891 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.961 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.706 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -57.61 -72.04 0.09 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.677 -0.64 . . . . 0.0 110.892 -178.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.4 p-10 -147.38 42.33 1.08 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.051 -1.031 . . . . 0.0 108.22 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.3 m -80.5 139.95 17.4 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 O-C-N 121.463 -0.773 . . . . 0.0 109.301 -178.191 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -70.69 126.35 92.19 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.436 -0.79 . . . . 0.0 110.297 -178.442 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -82.91 -17.36 7.0 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.402 2.068 . . . . 0.0 111.53 178.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 57.3 m -60.04 -39.64 86.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.504 -0.747 . . . . 0.0 110.112 -179.427 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.3 mm-40 -65.98 -23.91 66.68 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.106 -0.997 . . . . 0.0 109.468 -179.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.816 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 36.0 t -65.26 -34.92 79.49 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.282 -0.886 . . . . 0.0 110.208 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -119.93 146.51 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.337 -0.852 . . . . 0.0 109.701 -179.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 53.4 mtmt -126.47 157.99 37.21 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 121.531 -0.73 . . . . 0.0 109.252 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -100.22 113.41 26.07 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.123 -0.986 . . . . 0.0 109.876 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.2 m -125.37 121.34 33.64 Favored 'General case' 0 N--CA 1.5 2.032 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.43 ' O ' ' N ' ' A' ' 22' ' ' GLN . . . 57.56 64.34 4.46 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' A' ' 20' ' ' GLY . 35.0 m 37.03 31.47 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.866 -0.785 . . . . 0.0 110.94 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.43 ' N ' ' O ' ' A' ' 20' ' ' GLY . 84.0 mt-30 -131.67 160.0 36.7 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.637 -0.664 . . . . 0.0 109.292 179.484 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 52.3 m-85 -119.32 140.09 50.88 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.074 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 33.7 p -135.14 148.09 49.65 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.525 -0.734 . . . . 0.0 109.314 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -84.24 120.02 25.73 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -86.23 105.85 16.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.096 -1.002 . . . . 0.0 110.516 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 79.3 p -90.78 -0.11 57.61 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.579 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -66.24 -9.75 49.93 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -103.78 124.72 58.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 179.138 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 44.1 t -59.94 -40.13 87.93 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.364 -0.835 . . . . 0.0 111.828 -178.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 p -53.51 -34.96 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.751 -1.218 . . . . 0.0 110.143 -178.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.816 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 22.1 m -61.31 -44.74 96.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.996 -1.065 . . . . 0.0 110.82 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.0 mmt -77.21 -23.48 51.39 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.838 -1.164 . . . . 0.0 110.857 -179.324 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -60.07 -39.99 87.94 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.708 -1.245 . . . . 0.0 109.748 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -74.84 -46.85 15.92 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.5 mt -66.26 -39.4 89.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.451 -1.029 . . . . 0.0 109.553 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -60.13 -39.95 88.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.262 -0.899 . . . . 0.0 110.147 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -81.5 -7.76 59.63 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.109 -0.994 . . . . 0.0 110.792 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.4 28.13 70.26 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 32.1 mmtp -101.05 -7.43 23.24 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 178.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.403 HG11 ' H ' ' A' ' 43' ' ' GLY . 41.6 t -131.93 156.98 43.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 84.3 mtp180 -118.33 -6.5 10.79 Favored 'General case' 0 N--CA 1.5 2.052 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 179.521 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.403 ' H ' HG11 ' A' ' 41' ' ' VAL . . . 137.19 -156.37 23.34 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 108.084 -2.006 . . . . 0.0 108.084 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.3 t -124.69 129.45 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 CA-C-N 118.644 1.222 . . . . 0.0 109.642 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.4 m -84.43 132.87 34.52 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.028 -1.045 . . . . 0.0 108.342 179.05 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 15.0 p -130.04 131.6 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.555 -0.715 . . . . 0.0 109.435 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 54.4 p -122.86 144.71 49.02 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.237 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -135.12 137.22 9.06 Favored Glycine 0 N--CA 1.5 2.958 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 96.4 t -123.41 130.56 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.694 -0.886 . . . . 0.0 109.321 179.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -102.82 122.47 44.58 Favored 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -98.2 127.87 44.37 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.367 -0.833 . . . . 0.0 109.149 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.522 ' O ' ' N ' ' A' ' 54' ' ' ASP . 93.1 m-85 -113.04 128.12 56.41 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.525 -0.735 . . . . 0.0 109.364 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.533 ' OD1' ' N ' ' A' ' 53' ' ' ASN . 0.8 OUTLIER -42.95 -19.83 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.528 -0.732 . . . . 0.0 109.786 179.796 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 52' ' ' TYR . 8.6 t70 -67.97 0.79 3.16 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.473 -0.767 . . . . 0.0 109.395 -179.08 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.424 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 77.72 23.35 67.35 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.554 179.011 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.5 p -119.98 146.35 45.92 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.364 -1.08 . . . . 0.0 109.617 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 38.8 p -130.89 140.01 50.17 Favored 'General case' 0 N--CA 1.497 1.884 0 CA-C-O 121.571 0.7 . . . . 0.0 109.998 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' SER . . . . . 0.434 ' C ' ' ND2' ' A' ' 59' ' ' ASN . 46.4 t -118.65 140.15 50.37 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 178.324 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . 0.673 ' N ' HD21 ' A' ' 59' ' ' ASN . 0.3 OUTLIER -129.99 118.66 21.95 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 120.973 -1.079 . . . . 0.0 109.756 -179.414 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -115.55 125.46 53.02 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 178.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -113.08 148.93 34.23 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.5 166.24 39.43 Favored Glycine 0 C--N 1.288 -2.095 0 N-CA-C 108.839 -1.704 . . . . 0.0 108.839 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.0 t -109.08 125.38 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.506 -0.997 . . . . 0.0 108.815 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.46 ' O ' ' CG1' ' A' ' 64' ' ' VAL . 3.4 p -94.35 121.8 45.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.41 -0.806 . . . . 0.0 109.984 -179.411 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.415 ' O ' ' N ' ' A' ' 68' ' ' THR . 8.2 p -127.75 149.97 71.94 Favored Pre-proline 0 N--CA 1.499 1.989 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.403 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -34.87 -38.55 0.16 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.52 2.147 . . . . 0.0 113.353 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.9 t -99.02 -6.52 28.39 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.039 -1.038 . . . . 0.0 111.026 -179.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.415 ' N ' ' O ' ' A' ' 65' ' ' THR . 34.7 m -128.07 106.89 19.93 Favored Pre-proline 0 N--CA 1.505 2.291 0 O-C-N 121.005 -1.059 . . . . 0.0 110.509 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -90.79 163.25 4.09 Favored 'Trans proline' 0 N--CA 1.488 1.201 0 C-N-CA 122.507 2.138 . . . . 0.0 111.624 178.171 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 58.6 t -120.43 130.13 74.78 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.297 0 O-C-N 121.275 -0.89 . . . . 0.0 108.783 179.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -101.33 127.78 47.8 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.126 -0.983 . . . . 0.0 111.495 -178.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.91 11.15 30.52 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 177.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.415 ' O ' ' O ' ' A' ' 74' ' ' GLN . 45.6 p-10 -77.97 57.88 1.84 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.514 -0.741 . . . . 0.0 110.214 -178.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.415 ' O ' ' O ' ' A' ' 73' ' ' ASN . 27.3 mt-30 -60.91 -158.84 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.048 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -63.68 102.13 0.42 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.722 -1.236 . . . . 0.0 108.717 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 96.8 mt -79.93 -18.1 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.422 -0.799 . . . . 0.0 110.398 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 -59.99 -40.68 90.0 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.883 -1.136 . . . . 0.0 108.413 -179.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 4.1 mtpm? -62.42 -47.93 81.94 Favored 'General case' 0 N--CA 1.495 1.786 0 CA-C-O 122.419 1.104 . . . . 0.0 108.78 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.583 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -60.04 -42.93 95.48 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.078 -0.964 . . . . 0.0 109.592 -178.284 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -62.55 -36.99 84.4 Favored 'General case' 0 C--N 1.293 -1.879 0 O-C-N 120.494 -1.379 . . . . 0.0 108.899 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 53.9 tttt -72.01 -44.49 63.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.091 -1.006 . . . . 0.0 111.107 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.3 p -112.88 -28.18 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.341 -0.85 . . . . 0.0 111.972 -176.61 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.77 165.25 40.68 Favored Glycine 0 N--CA 1.493 2.5 0 O-C-N 120.519 -1.363 . . . . 0.0 110.893 178.545 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.424 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 30.0 t -110.26 124.32 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.064 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 28.1 mt-30 -80.99 -65.17 1.05 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.004 -1.06 . . . . 0.0 110.121 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -114.77 139.94 49.31 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.363 -0.836 . . . . 0.0 110.899 -179.173 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 62.8 t80 -121.38 127.63 51.4 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.161 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -132.06 131.27 42.28 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 120.994 -1.066 . . . . 0.0 110.664 -179.424 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -122.09 131.02 53.76 Favored 'General case' 0 N--CA 1.501 2.12 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 179.229 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 8.7 mp -111.02 130.92 55.44 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.38 -0.825 . . . . 0.0 109.315 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.8 p -124.41 124.08 41.55 Favored 'General case' 0 N--CA 1.506 2.36 0 O-C-N 121.392 -0.817 . . . . 0.0 110.675 -179.625 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 -134.0 146.63 50.6 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.791 -0.568 . . . . 0.0 109.779 179.567 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 87.8 m95 -69.17 139.61 54.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.733 -1.229 . . . . 0.0 108.587 178.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 44.7 t -108.86 119.62 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.025 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.193 0 N-CA-C 108.345 -1.902 . . . . 0.0 108.345 179.872 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 121.509 0.671 . . . . 0.0 109.544 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -72.14 -36.91 69.49 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.302 -0.874 . . . . 0.0 110.51 -179.173 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -81.76 -0.91 45.23 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.922 -1.111 . . . . 0.0 109.784 -179.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.9 t -100.34 140.24 19.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.241 -0.912 . . . . 0.0 109.212 -179.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -102.04 106.44 47.75 Favored Pre-proline 0 N--CA 1.492 1.653 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -49.17 -14.42 0.49 Allowed 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 121.86 1.707 . . . . 0.0 112.066 -179.274 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.1 t -63.44 -38.51 91.43 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.465 -0.772 . . . . 0.0 110.083 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -85.22 -12.58 52.25 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.313 -0.867 . . . . 0.0 110.367 -178.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.814 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 39.2 t -68.88 -34.5 75.53 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.654 -1.279 . . . . 0.0 109.867 -179.542 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -119.82 145.43 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 11.4 ptmm? -131.57 152.58 50.67 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.226 -0.921 . . . . 0.0 108.96 -179.624 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -98.49 131.83 44.42 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.149 -0.969 . . . . 0.0 109.824 -179.591 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 29.3 t -117.71 120.07 36.87 Favored 'General case' 0 N--CA 1.496 1.871 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 178.51 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.64 -119.03 7.74 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 108.375 -1.89 . . . . 0.0 108.375 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.5 m -110.75 27.57 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.374 -1.074 . . . . 0.0 108.731 179.326 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 45.7 tt0 -128.99 155.72 44.93 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.572 -0.705 . . . . 0.0 110.244 -178.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 38.3 m-85 -118.41 138.56 52.36 Favored 'General case' 0 N--CA 1.498 1.966 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 73.3 p -138.64 153.15 48.58 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.227 -0.921 . . . . 0.0 109.359 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.569 ' CZ ' ' SG ' ' A' ' 15' ' ' CYS . 30.1 t80 -80.72 125.2 29.76 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -86.52 88.68 7.7 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.232 -0.918 . . . . 0.0 110.681 -178.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.481 ' C ' ' H ' ' A' ' 29' ' ' VAL . 7.7 m -79.66 -8.9 59.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.952 -1.093 . . . . 0.0 108.631 178.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.53 -8.12 0.78 Allowed Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.481 ' H ' ' C ' ' A' ' 27' ' ' SER . 0.1 OUTLIER -107.51 122.7 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.954 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 178.793 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 59.8 p -63.67 -37.29 86.78 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.655 -0.653 . . . . 0.0 111.613 -178.171 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.8 m -57.65 -36.93 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 120.841 -1.162 . . . . 0.0 110.622 -178.174 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.814 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 27.1 m -61.7 -42.08 98.46 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.805 -1.185 . . . . 0.0 110.461 -179.349 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 14.6 mmt -73.91 -20.63 60.33 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.965 -1.085 . . . . 0.0 110.685 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 79.6 mm-40 -60.16 -41.86 93.69 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.739 -1.226 . . . . 0.0 110.027 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.79 -47.02 8.98 Favored Glycine 0 N--CA 1.491 2.328 0 C-N-CA 119.166 -1.493 . . . . 0.0 109.872 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 20.9 tp -62.92 -43.45 98.77 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.496 -1.002 . . . . 0.0 110.822 -178.766 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -61.97 -39.7 93.07 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.975 -1.078 . . . . 0.0 110.304 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -74.95 -8.11 55.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.231 -0.918 . . . . 0.0 110.438 -178.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 73.45 24.83 74.17 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -97.86 -6.61 32.1 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 178.129 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 93.6 t -135.65 159.92 39.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.64 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 52.7 ttt85 -118.61 -8.47 10.42 Favored 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.526 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 138.34 -161.46 25.66 Favored Glycine 0 N--CA 1.502 3.081 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 90.8 t -120.62 127.23 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.023 -1.281 . . . . 0.0 109.529 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.1 m -85.29 138.28 32.42 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 10.3 m -132.32 134.29 59.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.374 -0.829 . . . . 0.0 110.148 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 51.7 p -125.33 147.8 48.99 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.514 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -151.7 142.23 9.27 Favored Glycine 0 N--CA 1.496 2.644 0 C-N-CA 118.996 -1.573 . . . . 0.0 110.836 -178.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 78.5 t -125.13 130.13 73.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.446 ' CZ ' ' OG1' ' A' ' 72' ' ' THR . 48.8 m-85 -104.52 122.01 44.67 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.451 -0.781 . . . . 0.0 108.914 -179.285 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 36.0 m-85 -92.37 125.86 37.21 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.258 -0.901 . . . . 0.0 110.488 -178.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.412 ' CB ' ' HZ2' ' A' ' 78' ' ' LYS . 97.9 m-85 -109.22 135.54 50.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.454 -0.779 . . . . 0.0 109.941 179.76 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.442 ' C ' ' H ' ' A' ' 55' ' ' GLY . 25.6 m120 -60.83 -13.86 18.16 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 179.041 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 11.3 t70 -68.72 0.68 3.97 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.442 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 82.87 15.41 72.89 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 179.059 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.2 p -119.18 152.71 36.12 Favored 'General case' 0 N--CA 1.51 2.531 0 O-C-N 121.367 -1.078 . . . . 0.0 111.153 -179.305 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 39.3 p -131.83 141.53 49.46 Favored 'General case' 0 N--CA 1.499 1.993 0 CA-C-O 121.433 0.635 . . . . 0.0 109.509 179.298 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 35.7 t -118.0 141.58 48.31 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 178.458 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -132.4 116.62 17.06 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.123 -0.986 . . . . 0.0 109.312 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.539 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 42.2 p90 -116.38 122.65 45.47 Favored 'General case' 0 N--CA 1.496 1.865 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.613 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -115.76 143.73 44.97 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.01 178.19 42.4 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.3 t -116.56 128.95 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 O-C-N 121.46 -1.023 . . . . 0.0 109.929 -179.458 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.0 t -95.81 112.0 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.151 -0.968 . . . . 0.0 109.922 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.571 ' O ' ' N ' ' A' ' 67' ' ' SER . 2.3 p -136.63 151.5 72.85 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 178.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_exo -41.14 -15.14 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.437 0 C-N-CA 121.704 1.603 . . . . 0.0 112.24 179.108 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.571 ' N ' ' O ' ' A' ' 65' ' ' THR . 67.3 p -61.53 -54.15 46.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.875 -1.141 . . . . 0.0 109.955 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -157.78 148.76 16.39 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 120.865 -1.147 . . . . 0.0 110.109 -179.649 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -82.55 163.53 16.68 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 122.23 1.953 . . . . 0.0 111.413 178.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 99.6 t -111.25 131.1 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.128 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . 0.468 ' O ' ' OD1' ' A' ' 71' ' ' ASN . 22.8 p30 -100.91 138.26 38.19 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.471 -0.768 . . . . 0.0 111.671 -177.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.458 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.1 OUTLIER -100.0 1.72 42.78 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 177.907 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 73' ' ' ASN . 0.7 OUTLIER -66.96 52.74 0.05 OUTLIER 'General case' 0 N--CA 1.488 1.461 0 CA-C-O 121.631 0.729 . . . . 0.0 109.345 -179.604 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.458 ' N ' ' O ' ' A' ' 72' ' ' THR . 77.2 mt-30 -64.82 -90.37 0.01 OUTLIER 'General case' 0 C--N 1.294 -1.824 0 O-C-N 121.456 -0.778 . . . . 0.0 109.667 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -112.04 74.83 0.88 Allowed 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.566 -0.709 . . . . 0.0 110.115 -179.563 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.441 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 10.7 tp -60.31 -38.87 79.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.441 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 17.0 t-20 -57.92 -41.19 82.17 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.412 ' HZ2' ' CB ' ' A' ' 52' ' ' TYR . 32.4 tttm -67.81 -43.33 79.9 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.365 -0.834 . . . . 0.0 109.098 178.548 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.572 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.3 OUTLIER -67.57 -40.84 84.89 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.088 -1.007 . . . . 0.0 109.445 -179.365 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -66.79 -25.92 66.7 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 120.441 -1.412 . . . . 0.0 109.156 179.336 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -68.63 -47.52 66.41 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 120.89 -1.131 . . . . 0.0 110.379 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.7 m -121.25 -18.8 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 121.337 -0.852 . . . . 0.0 111.669 -177.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.11 170.37 46.91 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.413 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 46.5 t -108.3 127.17 64.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 62.5 tt0 -80.45 -66.8 0.83 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 120.999 -1.063 . . . . 0.0 111.149 -179.381 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 34.8 ttpt -114.82 140.02 49.27 Favored 'General case' 0 N--CA 1.506 2.342 0 O-C-N 121.179 -0.951 . . . . 0.0 110.919 -178.267 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 84.5 t80 -120.97 136.26 55.02 Favored 'General case' 0 N--CA 1.505 2.293 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.24 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 -136.49 124.13 22.37 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.204 -0.935 . . . . 0.0 110.18 179.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -125.01 140.77 52.61 Favored 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.421 -0.799 . . . . 0.0 110.426 179.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.0 mt -118.93 129.82 55.38 Favored 'General case' 0 N--CA 1.504 2.26 0 O-C-N 121.501 -0.749 . . . . 0.0 109.464 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 31.8 p -126.57 117.18 22.28 Favored 'General case' 0 N--CA 1.508 2.439 0 CA-C-O 121.848 0.832 . . . . 0.0 110.29 179.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -132.56 156.12 47.42 Favored 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.154 -179.109 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -70.82 144.74 50.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.4 -0.813 . . . . 0.0 109.384 179.302 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 35.5 t -120.04 127.58 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.707 -0.621 . . . . 0.0 109.343 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.764 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -179.552 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' A' ' 8' ' ' ASP . 26.6 t0 -100.2 7.48 44.48 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.309 -0.869 . . . . 0.0 110.894 -178.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 71.6 m-80 -122.39 13.17 10.23 Favored 'General case' 0 N--CA 1.501 2.087 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.4 m -120.49 141.66 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 CA-C-O 121.343 0.592 . . . . 0.0 109.422 -179.175 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 36.0 t0 -103.97 111.94 65.34 Favored Pre-proline 0 N--CA 1.499 1.999 0 O-C-N 121.247 -0.908 . . . . 0.0 109.081 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_exo -40.78 -33.43 1.06 Allowed 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.232 1.955 . . . . 0.0 113.126 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 58.5 m -60.01 -39.93 87.5 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.036 -1.04 . . . . 0.0 110.711 -179.367 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 47.0 tt0 -70.03 -24.91 63.35 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.799 -1.188 . . . . 0.0 109.925 -178.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.817 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 37.3 t -68.31 -34.41 76.09 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.332 -0.855 . . . . 0.0 110.118 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.1 pt -117.17 145.88 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.409 -0.807 . . . . 0.0 109.153 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 52.7 mtpt -126.36 146.09 50.19 Favored 'General case' 0 N--CA 1.497 1.875 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 -179.47 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -87.0 119.73 27.51 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.543 -0.723 . . . . 0.0 109.208 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.512 ' O ' ' N ' ' A' ' 21' ' ' VAL . 39.3 p -102.07 119.54 38.96 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.404 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.81 -93.4 0.01 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.512 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.4 t -129.86 20.89 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.538 -0.978 . . . . 0.0 109.23 -179.641 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 75.2 mt-30 -128.55 167.93 16.42 Favored 'General case' 0 N--CA 1.5 2.067 0 CA-C-O 121.866 0.841 . . . . 0.0 110.695 -179.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 24.3 m-85 -119.74 135.15 54.96 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 107.888 -1.152 . . . . 0.0 107.888 178.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 60.9 p -131.32 149.74 52.43 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.345 -0.847 . . . . 0.0 109.753 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 48.5 t80 -86.89 128.76 35.06 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.468 -0.77 . . . . 0.0 109.871 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -88.27 81.53 7.28 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.105 -0.997 . . . . 0.0 110.552 -179.362 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.404 ' C ' ' H ' ' A' ' 29' ' ' VAL . 93.2 p -77.97 -16.64 57.99 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.936 -1.102 . . . . 0.0 109.599 179.396 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -64.1 -3.68 9.48 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.363 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.404 ' H ' ' C ' ' A' ' 27' ' ' SER . 2.7 t -98.6 129.35 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.261 -1.141 . . . . 0.0 108.321 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 80.8 p -60.06 -40.24 88.8 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 110.727 -178.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.1 p -60.67 -40.4 84.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.92 -1.112 . . . . 0.0 110.402 -179.246 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.817 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.9 m -61.37 -43.36 99.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.024 -1.047 . . . . 0.0 110.11 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 9.2 mmt -80.34 -16.83 53.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.897 -1.127 . . . . 0.0 109.824 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 55.9 tt0 -60.32 -40.28 90.02 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.053 -1.029 . . . . 0.0 108.744 179.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -78.49 -47.47 8.03 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 mt -64.86 -42.67 94.68 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.196 -1.179 . . . . 0.0 110.159 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -62.79 -40.39 97.2 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.015 -1.053 . . . . 0.0 110.002 -179.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 63.5 mm-40 -67.78 -29.29 68.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.199 -0.938 . . . . 0.0 109.61 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.02 22.75 44.01 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 110.09 -1.204 . . . . 0.0 110.09 179.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 17.2 mmmt -102.55 -0.31 32.32 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 178.475 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.427 HG11 ' H ' ' A' ' 43' ' ' GLY . 14.4 t -136.53 157.46 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . 0.512 ' N ' ' O ' ' A' ' 94' ' ' VAL . 70.7 mtp85 -118.18 -10.19 10.33 Favored 'General case' 0 N--CA 1.5 2.045 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 178.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.427 ' H ' HG11 ' A' ' 41' ' ' VAL . . . 141.55 -158.86 26.69 Favored Glycine 0 N--CA 1.497 2.717 0 N-CA-C 108.644 -1.783 . . . . 0.0 108.644 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.7 t -120.59 128.96 76.08 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.184 -1.186 . . . . 0.0 109.207 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.4 m -85.69 139.67 31.18 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.256 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 8.6 p -129.61 133.03 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 CA-C-O 121.808 0.813 . . . . 0.0 109.797 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 22.4 p -126.73 150.09 49.24 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 178.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -148.88 145.21 13.29 Favored Glycine 0 N--CA 1.494 2.548 0 C-N-CA 118.708 -1.71 . . . . 0.0 111.462 -178.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 95.4 t -118.16 125.98 74.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 178.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 2.1 m-85 -105.51 116.29 31.69 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.166 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.409 ' HH ' ' NH1' ' A' ' 88' ' ' ARG . 70.7 m-85 -91.76 124.75 36.13 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.45 -0.781 . . . . 0.0 109.137 -179.55 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.515 ' C ' ' H ' ' A' ' 54' ' ' ASP . 88.9 m-85 -109.31 134.68 51.49 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.439 ' C ' ' H ' ' A' ' 55' ' ' GLY . 86.2 m-20 -57.16 -5.96 0.34 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.905 -1.122 . . . . 0.0 108.767 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.515 ' H ' ' C ' ' A' ' 52' ' ' TYR . 46.2 t0 -73.64 3.59 6.14 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.439 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 76.59 27.41 61.21 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.286 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 22.7 p -130.12 150.87 51.19 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.416 -1.05 . . . . 0.0 110.864 -179.162 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 80.5 p -132.0 123.04 26.52 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.64 -0.663 . . . . 0.0 109.324 179.263 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' SER . . . . . 0.462 ' C ' ' ND2' ' A' ' 59' ' ' ASN . 23.2 t -104.46 153.2 21.42 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 179.23 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . 0.462 ' ND2' ' C ' ' A' ' 58' ' ' SER . 3.1 m120 -131.97 118.87 20.32 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 120.93 -1.106 . . . . 0.0 108.98 179.755 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -117.48 123.95 47.59 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.477 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -111.78 145.57 39.16 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -163.37 174.88 39.67 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.6 t -119.82 127.22 75.87 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.124 0 O-C-N 121.517 -0.99 . . . . 0.0 109.373 179.584 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 70.8 t -95.38 120.1 44.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.21 -0.931 . . . . 0.0 110.278 -179.202 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.537 ' C ' ' H ' ' A' ' 67' ' ' SER . 3.0 p -137.34 155.32 75.73 Favored Pre-proline 0 N--CA 1.492 1.635 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.097 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -49.69 -4.96 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.021 1.814 . . . . 0.0 111.624 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.537 ' H ' ' C ' ' A' ' 65' ' ' THR . 52.6 p -71.51 -52.1 20.12 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.201 -0.937 . . . . 0.0 110.414 -179.576 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.0 t -154.58 147.08 17.6 Favored Pre-proline 0 N--CA 1.497 1.902 0 O-C-N 120.843 -1.161 . . . . 0.0 110.235 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -80.89 163.91 20.47 Favored 'Trans proline' 0 N--CA 1.497 1.687 0 C-N-CA 122.373 2.048 . . . . 0.0 112.413 179.032 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 64.6 t -123.02 131.22 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.223 0 O-C-N 121.499 -0.75 . . . . 0.0 109.02 179.419 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -90.8 140.31 29.92 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 120.953 -1.092 . . . . 0.0 109.728 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.446 ' OG1' ' N ' ' A' ' 73' ' ' ASN . 1.2 p -80.34 -50.43 10.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.058 -1.026 . . . . 0.0 108.778 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.446 ' N ' ' OG1' ' A' ' 72' ' ' THR . 97.7 m-20 -79.5 58.32 2.64 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.483 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.484 ' NE2' ' OD1' ' A' ' 75' ' ' ASP . 0.0 OUTLIER -46.41 -39.56 10.68 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.965 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.484 ' OD1' ' NE2' ' A' ' 74' ' ' GLN . 95.3 m-20 -108.37 75.6 0.99 Allowed 'General case' 0 N--CA 1.496 1.841 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.739 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.425 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 9.2 tp -60.43 -39.85 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.456 -0.777 . . . . 0.0 110.435 -178.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.425 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 46.1 t30 -59.87 -46.28 89.79 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 119.02 -1.072 . . . . 0.0 108.142 -179.371 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 44.2 tttp -60.62 -50.14 74.72 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.164 -0.96 . . . . 0.0 108.938 178.345 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.535 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.1 m -62.11 -41.11 97.89 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.726 -0.609 . . . . 0.0 110.413 -178.513 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -64.92 -33.06 75.14 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 120.545 -1.347 . . . . 0.0 109.882 179.714 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 46.2 tttt -67.02 -49.86 63.93 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.116 -0.99 . . . . 0.0 110.662 -179.073 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.8 p -113.8 -26.16 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.67 -0.644 . . . . 0.0 111.967 -176.66 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 81.59 158.11 20.6 Favored Glycine 0 N--CA 1.493 2.436 0 O-C-N 120.494 -1.379 . . . . 0.0 109.713 179.703 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.5 t -105.03 120.38 55.52 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.764 -0.845 . . . . 0.0 108.988 179.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -70.0 -58.36 3.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.132 -0.98 . . . . 0.0 111.569 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -113.9 140.04 48.7 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.141 -0.975 . . . . 0.0 110.328 -178.228 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 71.6 t80 -120.24 127.75 52.7 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.409 ' NH1' ' HH ' ' A' ' 51' ' ' TYR . 99.2 mtt180 -130.78 127.12 38.06 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 121.212 -0.93 . . . . 0.0 109.869 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.68 142.83 51.1 Favored 'General case' 0 N--CA 1.505 2.296 0 O-C-N 121.557 -0.714 . . . . 0.0 110.314 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 mt -125.83 133.54 51.95 Favored 'General case' 0 N--CA 1.508 2.433 0 O-C-N 121.602 -0.686 . . . . 0.0 109.384 179.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 61.8 p -127.95 124.66 37.85 Favored 'General case' 0 N--CA 1.506 2.362 0 O-C-N 121.369 -0.832 . . . . 0.0 110.75 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -133.08 147.25 52.17 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.749 -0.594 . . . . 0.0 109.806 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 88.4 m95 -69.49 139.76 53.92 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 120.816 -1.178 . . . . 0.0 109.35 179.331 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.512 ' O ' ' N ' ' A' ' 42' ' ' ARG . 46.8 t -111.68 120.09 61.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.185 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 -179.986 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.692 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 -82.28 -26.16 33.37 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.465 -0.772 . . . . 0.0 110.947 -178.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -94.04 3.44 55.33 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 120.858 -1.151 . . . . 0.0 110.659 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.3 t -110.83 130.04 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.296 -0.878 . . . . 0.0 110.52 -179.076 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -88.0 131.94 41.44 Favored Pre-proline 0 N--CA 1.492 1.63 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.491 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -77.18 -19.58 13.44 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 121.801 1.668 . . . . 0.0 112.477 -179.217 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 55.2 m -59.92 -39.93 87.16 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.174 -0.954 . . . . 0.0 110.374 -179.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 90.2 mm-40 -83.71 -11.15 57.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.076 -1.015 . . . . 0.0 110.054 -179.454 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.813 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 45.5 t -69.67 -31.33 69.32 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.131 -0.981 . . . . 0.0 109.142 179.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -120.07 146.06 25.43 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 61.4 pttt -125.47 149.96 47.77 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.458 -0.776 . . . . 0.0 109.384 -179.406 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -99.85 122.03 42.18 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.357 -0.839 . . . . 0.0 109.827 -178.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.1 t -107.45 100.9 10.29 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 71.72 -94.52 0.59 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.1 m -133.2 23.28 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.204 0 O-C-N 121.285 -1.126 . . . . 0.0 110.413 -179.642 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -131.66 161.56 32.46 Favored 'General case' 0 N--CA 1.504 2.275 0 O-C-N 121.209 -0.932 . . . . 0.0 109.989 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -113.26 141.41 47.02 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 37.2 p -130.01 142.04 50.67 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.36 -0.838 . . . . 0.0 109.425 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.9 t80 -81.64 126.0 31.24 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.49 -0.756 . . . . 0.0 109.897 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -90.02 85.41 6.32 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.35 -0.844 . . . . 0.0 110.447 -179.611 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.2 p -85.54 -1.43 57.09 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.933 -1.104 . . . . 0.0 109.207 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.08 -31.56 77.16 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.511 ' CG2' ' SG ' ' A' ' 32' ' ' CYS . 24.4 m -83.64 132.48 31.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.152 -1.205 . . . . 0.0 109.138 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 71.1 m -60.08 -39.92 87.76 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.325 -0.859 . . . . 0.0 111.474 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.1 m -52.96 -38.19 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 120.719 -1.238 . . . . 0.0 110.588 -178.072 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.813 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.8 m -62.85 -39.93 95.91 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.73 -1.231 . . . . 0.0 110.016 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 10.0 mmt -80.07 -14.92 58.16 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.984 -1.073 . . . . 0.0 110.263 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 -64.84 -39.97 94.43 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.884 -1.135 . . . . 0.0 109.287 179.167 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.12 -49.11 8.82 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.97 -40.16 94.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.347 -1.09 . . . . 0.0 109.998 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -61.15 -40.01 92.23 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.936 -1.103 . . . . 0.0 110.043 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -76.7 -10.19 59.21 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.017 -1.052 . . . . 0.0 109.214 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 69.93 27.23 73.36 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 54.7 tttp -98.99 -7.52 26.8 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 178.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.45 HG12 ' H ' ' A' ' 43' ' ' GLY . 4.2 t -133.71 159.03 42.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-N 115.113 -0.949 . . . . 0.0 108.885 -179.591 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . 0.45 ' N ' ' O ' ' A' ' 94' ' ' VAL . 96.3 mtt180 -121.46 -5.96 9.28 Favored 'General case' 0 N--CA 1.504 2.265 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.211 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.45 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 142.66 -170.13 25.29 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 108.567 -1.813 . . . . 0.0 108.567 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 77.0 t -111.08 126.18 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.065 -1.256 . . . . 0.0 108.338 179.147 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.4 p -82.02 139.76 34.32 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.126 -0.984 . . . . 0.0 109.275 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.3 p -130.0 133.45 64.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 98.1 p -124.43 142.54 51.23 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.406 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -133.87 131.86 6.19 Favored Glycine 0 N--CA 1.502 3.068 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.108 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 74.4 t -121.58 129.26 75.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.732 -0.863 . . . . 0.0 108.999 178.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -104.76 122.54 45.92 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.209 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -96.16 129.82 43.37 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.284 -0.885 . . . . 0.0 109.454 -179.417 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.529 ' O ' ' N ' ' A' ' 54' ' ' ASP . 95.0 m-85 -114.66 127.57 55.84 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -179.67 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.402 ' C ' ' H ' ' A' ' 55' ' ' GLY . 49.1 t30 -43.12 -19.11 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.428 -0.795 . . . . 0.0 109.918 179.763 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 52' ' ' TYR . 50.1 t0 -68.25 1.32 2.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.459 -0.776 . . . . 0.0 109.752 -179.235 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.402 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 77.76 20.26 74.12 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.574 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.5 p -115.9 154.76 29.17 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.423 -1.046 . . . . 0.0 109.726 179.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 45.2 p -139.62 137.98 35.76 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.626 -0.671 . . . . 0.0 109.629 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 53.8 m -113.71 149.58 34.55 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 178.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 21.9 p-10 -140.79 119.07 12.08 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.023 -1.048 . . . . 0.0 110.119 -179.418 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 73.5 m-85 -114.11 121.52 44.05 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 107.678 -1.231 . . . . 0.0 107.678 178.349 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.0 ttpm? -113.17 147.33 37.63 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.64 169.2 41.55 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.4 t -110.04 127.32 67.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.416 -1.05 . . . . 0.0 109.594 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.5 t -91.3 119.99 39.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.423 -0.798 . . . . 0.0 110.017 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.515 ' O ' ' N ' ' A' ' 67' ' ' SER . 25.7 p -136.31 147.59 60.81 Favored Pre-proline 0 N--CA 1.493 1.688 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 178.515 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_exo -39.16 -21.86 0.07 OUTLIER 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 121.987 1.792 . . . . 0.0 112.538 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.515 ' N ' ' O ' ' A' ' 65' ' ' THR . 67.9 m -68.41 -45.82 71.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.115 -0.991 . . . . 0.0 111.413 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 5.8 t -154.75 142.8 14.26 Favored Pre-proline 0 N--CA 1.5 2.042 0 O-C-N 120.407 -1.433 . . . . 0.0 111.19 -179.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -81.95 166.84 16.67 Favored 'Trans proline' 0 N--CA 1.499 1.83 0 C-N-CA 122.993 2.462 . . . . 0.0 111.627 178.308 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 90.3 t -105.95 135.79 42.81 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.198 0 O-C-N 121.242 -0.911 . . . . 0.0 109.258 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 29.2 m120 -99.67 123.95 44.43 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.301 -0.874 . . . . 0.0 111.464 -178.258 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.462 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.3 OUTLIER -109.87 20.03 18.44 Favored 'General case' 0 N--CA 1.502 2.174 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.1 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.445 ' O ' ' O ' ' A' ' 74' ' ' GLN . 25.6 t-20 -78.69 60.23 2.7 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.47 -0.769 . . . . 0.0 109.927 -179.433 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.554 ' N ' ' OE1' ' A' ' 74' ' ' GLN . 0.0 OUTLIER -50.28 177.59 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 178.732 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 78.9 m-20 -66.08 119.81 12.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.469 -1.394 . . . . 0.0 108.464 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 94.5 mt -80.65 -13.11 12.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.506 -0.746 . . . . 0.0 110.409 -179.092 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 28.7 m120 -60.13 -43.89 95.33 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.827 -1.171 . . . . 0.0 109.036 -179.497 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 18.7 pttt -66.89 -40.09 87.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.877 -1.139 . . . . 0.0 109.271 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.598 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.9 OUTLIER -63.05 -41.13 99.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.239 -0.913 . . . . 0.0 108.777 179.473 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -62.19 -38.71 90.14 Favored 'General case' 0 C--N 1.295 -1.773 0 O-C-N 120.76 -1.213 . . . . 0.0 109.551 179.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 31.3 tttm -71.61 -42.51 67.61 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.07 -1.019 . . . . 0.0 111.148 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 p -112.12 -29.42 2.36 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.188 0 O-C-N 121.252 -0.905 . . . . 0.0 112.168 -176.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.598 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.98 161.09 37.15 Favored Glycine 0 N--CA 1.495 2.587 0 O-C-N 120.702 -1.249 . . . . 0.0 110.606 179.31 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 84.7 t -108.99 127.34 65.73 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.075 0 O-C-N 121.807 -0.82 . . . . 0.0 108.903 179.363 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -88.01 -63.12 1.35 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.08 -1.013 . . . . 0.0 111.181 -178.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -115.07 142.94 45.96 Favored 'General case' 0 N--CA 1.505 2.293 0 CA-C-O 121.872 0.844 . . . . 0.0 111.937 -178.002 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -120.08 130.87 54.86 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.07 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.91 128.62 32.93 Favored 'General case' 0 N--CA 1.505 2.325 0 O-C-N 121.067 -1.02 . . . . 0.0 110.104 -178.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.43 135.38 54.08 Favored 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 179.14 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -120.0 134.73 55.16 Favored 'General case' 0 N--CA 1.503 2.205 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 14.5 p -130.22 124.24 32.05 Favored 'General case' 0 N--CA 1.505 2.283 0 CA-C-O 121.571 0.7 . . . . 0.0 111.016 -179.181 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.29 156.98 47.48 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.762 -0.586 . . . . 0.0 110.131 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 65.6 m95 -69.61 149.51 48.06 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.707 -1.246 . . . . 0.0 108.135 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.45 ' O ' ' N ' ' A' ' 42' ' ' ARG . 31.7 t -117.95 123.11 71.2 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.171 0 O-C-N 121.353 -0.842 . . . . 0.0 109.394 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 2.77 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 179.627 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.682 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . 0.435 ' O ' ' OD1' ' A' ' 8' ' ' ASP . 39.2 t0 -99.19 6.09 46.51 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.296 -0.877 . . . . 0.0 111.427 -178.546 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.7 p-10 -130.01 9.3 5.3 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 120.843 -1.161 . . . . 0.0 108.908 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 2.2 m -124.68 129.96 73.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -89.81 148.25 39.41 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.016 -1.053 . . . . 0.0 108.759 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -80.15 -22.36 7.23 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.408 2.072 . . . . 0.0 111.937 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 56.0 m -60.24 -40.16 89.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.916 . . . . 0.0 110.411 -179.583 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -81.05 -13.77 58.48 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.031 -1.043 . . . . 0.0 110.239 -179.286 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.801 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 53.9 m -71.11 -29.06 64.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.11 178.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -120.46 135.05 61.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 64.0 mmtt -111.96 147.86 35.0 Favored 'General case' 0 N--CA 1.502 2.161 0 O-C-N 121.291 -0.88 . . . . 0.0 109.292 -179.318 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -97.11 119.86 36.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 108.796 179.516 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 47.8 t -107.56 116.08 31.3 Favored 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.56 -109.42 1.21 Allowed Glycine 0 N--CA 1.487 2.038 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 -178.681 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.414 ' CG2' ' HG1' ' A' ' 72' ' ' THR . 7.7 p -118.74 34.64 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.43 -1.041 . . . . 0.0 108.997 179.16 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -130.66 159.37 37.42 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 122.194 0.997 . . . . 0.0 111.567 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -120.8 136.79 54.81 Favored 'General case' 0 N--CA 1.496 1.825 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 26.5 p -137.25 154.44 50.14 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.245 -0.909 . . . . 0.0 109.279 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.8 t80 -87.67 128.06 35.29 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.266 -0.896 . . . . 0.0 109.597 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -86.01 83.21 7.83 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.929 -1.107 . . . . 0.0 109.92 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 86.4 p -84.65 -0.98 55.4 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.933 -1.104 . . . . 0.0 109.424 179.627 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.67 -39.96 95.87 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.089 -1.605 . . . . 0.0 109.089 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 33.4 m -81.83 135.28 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.332 -1.099 . . . . 0.0 108.774 179.433 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 34' ' ' GLN . 17.1 p -72.76 -26.8 61.68 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.182 -0.949 . . . . 0.0 110.873 -178.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.9 p -59.9 -40.85 83.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 120.841 -1.162 . . . . 0.0 110.774 -178.504 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.801 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 87.0 m -68.69 -39.9 80.3 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.839 -1.163 . . . . 0.0 109.228 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 99.5 mmm -80.09 -14.6 58.39 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.134 -0.979 . . . . 0.0 108.68 179.089 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . 0.421 ' N ' ' O ' ' A' ' 30' ' ' SER . 7.2 tt0 -60.62 -41.98 95.92 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.01 -41.2 28.1 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.378 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.3 tp -67.16 -40.26 86.63 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -1.128 . . . . 0.0 108.687 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -63.07 -40.03 96.47 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.48 -0.763 . . . . 0.0 110.539 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.537 ' N ' ' OE1' ' A' ' 38' ' ' GLU . 0.4 OUTLIER -75.09 -11.41 60.09 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.831 -1.168 . . . . 0.0 109.763 -179.403 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.24 21.5 70.16 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 119.901 -1.142 . . . . 0.0 110.443 178.654 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 62.3 mttm -98.66 -3.38 36.15 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.461 HG12 ' H ' ' A' ' 43' ' ' GLY . 94.0 t -134.91 159.28 41.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 95.0 mtt-85 -122.08 -7.13 8.89 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 179.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.461 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.78 -163.22 25.88 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 -179.504 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 87.8 t -119.39 129.19 75.6 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 121.322 -1.105 . . . . 0.0 109.115 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 5.4 m -86.36 139.19 31.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.861 -1.149 . . . . 0.0 108.897 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 10.6 p -131.25 133.76 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 53.5 p -125.42 149.42 48.21 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 179.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -143.51 138.12 7.96 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 119.574 -1.298 . . . . 0.0 110.062 -179.145 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 62.4 t -122.63 127.06 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 179.064 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.594 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 0.2 OUTLIER -100.87 119.8 39.2 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -179.858 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -94.41 119.92 33.86 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.164 -0.96 . . . . 0.0 108.661 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.482 ' O ' ' N ' ' A' ' 54' ' ' ASP . 93.4 m-85 -102.22 125.79 49.02 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.424 -0.797 . . . . 0.0 109.985 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.438 ' C ' ' H ' ' A' ' 55' ' ' GLY . 20.1 t-20 -47.2 -16.43 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.104 -0.997 . . . . 0.0 109.751 179.562 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.482 ' N ' ' O ' ' A' ' 52' ' ' TYR . 47.4 t0 -70.85 4.72 2.37 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.247 -0.908 . . . . 0.0 109.223 -179.533 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.438 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 77.08 22.76 70.49 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 178.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.4 p -123.54 150.81 43.54 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.33 -1.1 . . . . 0.0 109.339 179.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.1 p -135.33 139.79 44.58 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.583 -0.698 . . . . 0.0 110.152 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.1 m -117.92 144.5 45.41 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 178.352 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.6 m-20 -128.2 118.49 23.42 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.388 -0.82 . . . . 0.0 108.953 -179.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 66.3 t80 -116.76 126.47 53.16 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.256 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -113.74 144.9 42.19 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -159.16 167.83 35.02 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.83 128.58 74.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.599 -0.942 . . . . 0.0 108.694 -179.662 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 45.7 t -92.88 117.87 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.047 -1.033 . . . . 0.0 110.088 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.579 ' HG1' ' H ' ' A' ' 67' ' ' SER . 6.4 p -134.98 153.87 78.81 Favored Pre-proline 0 N--CA 1.492 1.633 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 178.643 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_exo -43.93 -10.13 0.03 OUTLIER 'Trans proline' 0 N--CA 1.494 1.543 0 C-N-CA 121.981 1.788 . . . . 0.0 113.204 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.579 ' H ' ' HG1' ' A' ' 65' ' ' THR . 87.1 p -67.6 -59.52 3.29 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.892 -1.13 . . . . 0.0 110.687 -179.236 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -155.4 150.75 21.21 Favored Pre-proline 0 N--CA 1.498 1.933 0 O-C-N 120.596 -1.315 . . . . 0.0 110.259 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -82.81 161.24 16.25 Favored 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.522 2.148 . . . . 0.0 112.523 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.5 t -110.78 130.5 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 15.7 m-20 -100.8 144.46 29.73 Favored 'General case' 0 N--CA 1.506 2.338 0 O-C-N 120.905 -1.122 . . . . 0.0 111.069 -178.355 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.414 ' HG1' ' CG2' ' A' ' 21' ' ' VAL . 0.1 OUTLIER -93.19 -0.06 56.99 Favored 'General case' 0 N--CA 1.504 2.244 0 O-C-N 121.059 -1.026 . . . . 0.0 108.607 178.531 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 52.2 p-10 -80.43 46.67 0.86 Allowed 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.239 -0.913 . . . . 0.0 109.832 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 62.1 tt0 -48.17 -81.04 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.957 -1.09 . . . . 0.0 110.012 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -112.93 94.9 5.12 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.41 -0.806 . . . . 0.0 109.938 -179.503 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 8.8 mm -68.63 -39.89 81.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.28 -0.888 . . . . 0.0 109.733 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -59.95 -40.97 90.81 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 107.74 -1.207 . . . . 0.0 107.74 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -66.51 -43.13 86.1 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.455 -0.778 . . . . 0.0 109.156 178.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.597 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.2 m -76.1 -47.95 22.55 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.524 -0.735 . . . . 0.0 110.227 -178.721 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -60.05 -32.11 70.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.248 -1.533 . . . . 0.0 109.783 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 18.7 tptt -67.49 -53.53 27.97 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.329 -0.857 . . . . 0.0 110.694 -178.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.12 -22.14 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.172 -0.955 . . . . 0.0 111.515 -178.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.2 167.3 43.39 Favored Glycine 0 N--CA 1.487 2.086 0 O-C-N 120.896 -1.128 . . . . 0.0 110.764 178.729 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 63.8 t -109.86 129.72 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -80.03 -67.08 0.8 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.768 -1.208 . . . . 0.0 110.34 -178.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -113.73 138.78 49.76 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.418 -0.801 . . . . 0.0 109.891 -178.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 63.2 t80 -121.99 126.88 49.53 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.205 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 38.6 ptt180 -133.71 134.7 43.37 Favored 'General case' 0 N--CA 1.502 2.151 0 CA-C-O 121.96 0.886 . . . . 0.0 110.023 179.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.8 136.04 54.16 Favored 'General case' 0 N--CA 1.495 1.798 0 CA-C-O 121.164 0.507 . . . . 0.0 109.749 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 4.0 mt -113.35 131.79 55.83 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.402 -0.811 . . . . 0.0 108.815 179.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 3.8 p -126.12 121.3 32.49 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.677 0.751 . . . . 0.0 109.82 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -133.66 154.46 50.9 Favored 'General case' 0 N--CA 1.498 1.926 0 CA-C-O 121.422 0.63 . . . . 0.0 110.087 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -72.94 138.44 46.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.394 -0.816 . . . . 0.0 109.01 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 39.7 t -109.97 116.31 51.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.752 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.551 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.286 0.565 . . . . 0.0 109.699 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . 0.425 ' OD1' ' N ' ' A' ' 9' ' ' ASN . 36.4 p-10 -85.13 -26.17 27.04 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.233 -0.917 . . . . 0.0 110.035 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.425 ' N ' ' OD1' ' A' ' 8' ' ' ASP . 22.7 m120 -91.71 1.46 57.14 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.295 -0.878 . . . . 0.0 110.067 -179.141 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.8 t -108.98 129.96 62.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.466 -0.771 . . . . 0.0 109.562 -178.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -90.02 127.6 53.05 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.103 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -76.57 -13.84 18.09 Favored 'Trans proline' 0 N--CA 1.497 1.702 0 C-N-CA 122.082 1.855 . . . . 0.0 112.648 -179.048 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 54.5 m -62.06 -40.01 94.33 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.133 -0.979 . . . . 0.0 110.43 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.416 ' CD ' ' N ' ' A' ' 14' ' ' GLN . 28.2 mp0 -83.35 -12.52 56.47 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.076 -1.015 . . . . 0.0 110.37 -179.2 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.814 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 36.6 t -64.62 -36.62 84.83 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.182 -0.949 . . . . 0.0 110.189 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -117.48 141.1 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 121.399 -0.813 . . . . 0.0 108.887 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 20.4 pttp -118.83 145.46 45.64 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -98.11 124.77 42.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.397 -0.814 . . . . 0.0 109.409 179.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.539 ' O ' ' N ' ' A' ' 21' ' ' VAL . 65.6 m -110.17 131.12 55.34 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.38 -93.68 0.01 OUTLIER Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 -179.235 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.539 ' N ' ' O ' ' A' ' 19' ' ' SER . 26.2 m -139.6 31.39 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.308 -1.113 . . . . 0.0 109.676 179.816 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -131.53 159.41 38.24 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.417 -0.802 . . . . 0.0 109.902 179.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -114.24 139.97 48.96 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.027 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.2 p -136.53 148.79 47.79 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.143 -0.973 . . . . 0.0 109.847 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -84.55 129.92 34.8 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.169 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -90.95 103.73 16.41 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.095 -1.003 . . . . 0.0 110.159 -179.6 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 88.1 p -92.08 -5.99 51.76 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.062 -1.023 . . . . 0.0 108.981 178.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.89 -36.43 90.06 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.8 m -79.0 136.89 22.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.214 -1.168 . . . . 0.0 109.263 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.9 m -68.37 -31.49 70.89 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.409 -0.807 . . . . 0.0 111.157 -178.693 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 85.4 t -59.98 -40.07 82.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.885 -1.135 . . . . 0.0 110.556 -178.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.814 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 68.3 m -59.84 -47.0 87.51 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.629 -1.294 . . . . 0.0 110.056 -179.321 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' MET . . . . . 0.416 ' O ' ' CB ' ' A' ' 37' ' ' ASN . 29.7 mmt -70.23 -34.13 72.49 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.304 -0.873 . . . . 0.0 110.657 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 18.7 mm100 -59.55 -41.53 90.32 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.02 -1.05 . . . . 0.0 110.765 -178.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.68 -49.5 7.14 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 30.6 tp -60.01 -43.71 95.04 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.416 ' CB ' ' O ' ' A' ' 33' ' ' MET . 39.9 t30 -61.47 -39.9 92.56 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.543 -0.723 . . . . 0.0 109.963 179.19 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 49.7 tp10 -60.2 -31.4 70.11 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.329 -0.857 . . . . 0.0 109.819 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.81 15.23 56.86 Favored Glycine 0 N--CA 1.497 2.737 0 N-CA-C 110.306 -1.117 . . . . 0.0 110.306 179.33 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -101.98 -1.16 32.46 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 106.628 -1.619 . . . . 0.0 106.628 178.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.437 HG12 ' H ' ' A' ' 43' ' ' GLY . 98.9 t -130.56 159.91 42.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-N 115.172 -0.922 . . . . 0.0 108.518 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . 0.511 ' N ' ' O ' ' A' ' 94' ' ' VAL . 42.0 ttm180 -123.71 -8.93 7.88 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.252 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.437 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.84 -159.1 26.43 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 108.215 -1.954 . . . . 0.0 108.215 -179.296 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 96.6 t -119.68 128.65 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.306 -1.114 . . . . 0.0 109.178 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.498 ' H ' ' HG ' ' A' ' 45' ' ' SER . 2.5 p -82.97 140.89 32.51 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.279 -0.888 . . . . 0.0 109.012 179.602 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 8.8 p -132.23 130.61 60.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.575 -0.703 . . . . 0.0 109.525 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 16.8 p -123.63 146.04 48.49 Favored 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -140.47 136.74 7.85 Favored Glycine 0 N--CA 1.499 2.84 0 N-CA-C 110.119 -1.193 . . . . 0.0 110.119 -179.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 90.9 t -121.39 129.1 75.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.791 -0.829 . . . . 0.0 108.973 179.113 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -100.72 119.96 39.37 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 179.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 63.6 m-85 -96.49 126.09 41.44 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.323 -0.861 . . . . 0.0 108.945 -179.535 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.545 ' CD1' ' NZ ' ' A' ' 78' ' ' LYS . 90.0 m-85 -111.45 129.42 56.04 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.446 -0.784 . . . . 0.0 110.021 -178.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.429 ' OD1' ' OE1' ' A' ' 85' ' ' GLN . 74.9 m-20 -45.46 -17.27 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.41 -0.806 . . . . 0.0 109.406 178.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.514 ' N ' ' O ' ' A' ' 52' ' ' TYR . 52.5 t0 -68.86 0.09 4.83 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.495 -0.753 . . . . 0.0 109.532 -179.552 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.55 23.96 63.86 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.019 -1.086 . . . . 0.0 110.431 179.219 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.3 p -122.76 147.47 46.46 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.37 -1.077 . . . . 0.0 110.127 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.5 p -131.56 136.27 47.69 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.608 -0.683 . . . . 0.0 109.771 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 41.2 t -118.64 142.73 47.37 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 178.439 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 35.1 p-10 -130.61 120.44 23.99 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.921 -1.112 . . . . 0.0 110.224 -179.224 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.436 ' CZ ' ' NE2' ' A' ' 74' ' ' GLN . 96.1 m-85 -114.71 120.16 39.16 Favored 'General case' 0 N--CA 1.498 1.963 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.52 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.8 ttpt -112.54 152.6 28.64 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 -179.43 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.57 174.67 43.27 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 67.6 t -115.7 126.27 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.623 -0.928 . . . . 0.0 110.04 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 38.2 t -91.23 117.76 35.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.514 -0.741 . . . . 0.0 110.013 -179.364 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.516 ' O ' ' N ' ' A' ' 67' ' ' SER . 21.7 p -121.28 150.92 55.11 Favored Pre-proline 0 N--CA 1.498 1.943 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 178.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_exo -38.34 -20.76 0.05 OUTLIER 'Trans proline' 0 C--N 1.312 -1.358 0 C-N-CA 122.01 1.807 . . . . 0.0 113.372 -179.466 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.516 ' N ' ' O ' ' A' ' 65' ' ' THR . 18.1 p -121.81 2.93 10.04 Favored 'General case' 0 N--CA 1.505 2.29 0 O-C-N 121.181 -0.949 . . . . 0.0 111.88 -179.004 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.44 ' OG1' ' OG1' ' A' ' 65' ' ' THR . 61.1 p -129.94 107.22 16.66 Favored Pre-proline 0 N--CA 1.51 2.537 0 O-C-N 120.768 -1.207 . . . . 0.0 110.687 -179.807 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -90.58 165.31 4.24 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 C-N-CA 122.781 2.32 . . . . 0.0 112.288 178.315 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.1 t -120.47 129.95 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 N-CA-C 108.79 -0.818 . . . . 0.0 108.79 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 30.1 m120 -99.99 121.65 41.68 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.22 -0.925 . . . . 0.0 111.154 -178.432 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -91.02 -0.02 57.64 Favored 'General case' 0 N--CA 1.497 1.914 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.211 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.438 ' O ' ' O ' ' A' ' 74' ' ' GLN . 51.5 p-10 -75.11 57.74 0.85 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.4 -0.813 . . . . 0.0 109.573 -179.218 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.438 ' O ' ' O ' ' A' ' 73' ' ' ASN . 9.4 tp-100 -55.47 -101.92 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.559 -0.713 . . . . 0.0 109.091 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -108.26 100.43 9.74 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 120.967 -1.083 . . . . 0.0 109.231 179.449 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.406 HG21 HD12 ' A' ' 76' ' ' ILE . 44.3 mm -69.86 -39.33 77.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.024 -1.047 . . . . 0.0 109.077 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 -58.29 -41.08 83.6 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.545 ' NZ ' ' CD1' ' A' ' 52' ' ' TYR . 54.5 tttm -60.12 -49.91 75.77 Favored 'General case' 0 N--CA 1.488 1.425 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.367 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.581 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.8 OUTLIER -63.29 -41.03 98.94 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.546 -0.722 . . . . 0.0 110.304 -179.113 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -60.4 -35.94 76.95 Favored 'General case' 0 C--N 1.294 -1.838 0 O-C-N 120.655 -1.278 . . . . 0.0 110.912 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 8.9 tmtm? -70.9 -43.94 67.28 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.701 -1.249 . . . . 0.0 111.463 -178.502 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 p -110.1 -26.0 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.281 0 O-C-N 120.872 -1.142 . . . . 0.0 110.924 -178.281 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.581 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 79.94 157.81 14.73 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.8 t -108.53 130.4 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.067 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.429 ' OE1' ' OD1' ' A' ' 53' ' ' ASN . 18.7 pt20 -97.43 -43.29 7.34 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.185 -0.947 . . . . 0.0 110.929 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -115.9 127.84 55.31 Favored 'General case' 0 N--CA 1.502 2.127 0 O-C-N 121.197 -0.939 . . . . 0.0 110.766 -178.804 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -122.17 123.62 41.94 Favored 'General case' 0 N--CA 1.499 2.003 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 93.8 mtt180 -132.2 133.75 44.54 Favored 'General case' 0 N--CA 1.507 2.387 0 O-C-N 121.073 -1.017 . . . . 0.0 110.799 -179.545 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.1 135.18 53.36 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.797 -0.564 . . . . 0.0 109.58 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 54.5 tp -117.32 137.48 52.41 Favored 'General case' 0 N--CA 1.505 2.316 0 O-C-N 121.421 -0.799 . . . . 0.0 109.73 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.7 p -129.72 123.58 31.43 Favored 'General case' 0 N--CA 1.504 2.25 0 CA-C-O 121.639 0.733 . . . . 0.0 111.241 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.4 tt0 -133.78 157.33 46.16 Favored 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.637 -0.664 . . . . 0.0 109.724 179.145 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 82.4 m95 -69.43 149.31 48.48 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.78 -1.2 . . . . 0.0 109.873 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 42' ' ' ARG . 21.7 t -122.48 127.28 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.549 -0.72 . . . . 0.0 109.629 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.502 3.097 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 178.847 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -98.07 5.31 48.82 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.48 -0.763 . . . . 0.0 110.546 -178.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -121.02 6.58 10.33 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -134.85 139.4 47.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -179.429 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 24.5 m-20 -85.02 148.47 50.72 Favored Pre-proline 0 C--N 1.301 -1.51 0 O-C-N 121.269 -0.895 . . . . 0.0 109.264 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -75.63 -20.98 15.15 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.258 1.972 . . . . 0.0 111.655 179.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.486 ' HG ' ' N ' ' A' ' 14' ' ' GLN . 84.0 p -61.48 -37.68 84.52 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.217 -0.927 . . . . 0.0 109.801 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . 0.486 ' N ' ' HG ' ' A' ' 13' ' ' SER . 5.1 tp-100 -70.1 -25.66 63.61 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.172 -0.955 . . . . 0.0 109.384 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.801 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 77.2 m -68.42 -30.67 69.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.119 -0.988 . . . . 0.0 109.903 -179.453 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -124.06 136.66 59.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -120.91 150.65 40.74 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.597 -0.69 . . . . 0.0 109.139 -179.545 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -91.99 119.77 32.02 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.037 -1.04 . . . . 0.0 109.639 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 54.9 m -124.4 131.72 53.51 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.419 -0.8 . . . . 0.0 109.073 179.732 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 46.6 47.99 17.46 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.896 -1.145 . . . . 0.0 110.504 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.4 t 56.92 29.6 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.208 -1.172 . . . . 0.0 110.363 179.451 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 25.3 mt-30 -130.76 164.85 24.22 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.287 -0.883 . . . . 0.0 108.708 178.494 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 39.1 m-85 -120.43 136.77 54.63 Favored 'General case' 0 N--CA 1.501 2.117 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.366 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 34.7 p -139.85 152.3 46.37 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.401 -0.812 . . . . 0.0 109.612 179.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 28.5 t80 -80.81 127.08 32.12 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.638 -0.664 . . . . 0.0 109.229 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -83.6 83.63 7.83 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.342 -0.849 . . . . 0.0 109.783 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 27.9 p -76.68 -8.91 58.17 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.223 -0.923 . . . . 0.0 108.988 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.01 -39.79 70.61 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.6 m -82.27 128.61 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.036 -1.273 . . . . 0.0 108.46 179.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.463 ' O ' ' N ' ' A' ' 34' ' ' GLN . 82.2 p -66.87 -25.0 66.19 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.174 -0.954 . . . . 0.0 110.445 -178.845 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 71.3 t -59.81 -49.24 84.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.242 -0.911 . . . . 0.0 109.937 -178.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.801 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 79.8 m -61.83 -40.08 94.04 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.949 -1.094 . . . . 0.0 109.305 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 5.3 tpt -79.97 -14.87 58.26 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.079 -1.013 . . . . 0.0 108.7 179.615 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . 0.463 ' N ' ' O ' ' A' ' 30' ' ' SER . 5.9 tp-100 -63.15 -40.04 96.43 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.05 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -73.17 -45.41 31.49 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.6 mt -61.02 -42.88 99.31 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.316 -1.108 . . . . 0.0 108.994 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -60.25 -39.91 88.42 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.622 0.725 . . . . 0.0 109.265 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -80.01 -10.01 59.74 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.627 -0.67 . . . . 0.0 109.455 -179.522 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.34 31.88 68.56 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -106.41 -5.89 18.64 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 179.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.436 HG13 ' H ' ' A' ' 43' ' ' GLY . 87.2 t -133.12 156.67 42.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 73.8 mtt85 -120.36 -7.03 9.8 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.253 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.436 ' H ' HG13 ' A' ' 41' ' ' VAL . . . 137.8 -166.02 25.21 Favored Glycine 0 N--CA 1.498 2.821 0 N-CA-C 109.042 -1.623 . . . . 0.0 109.042 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.7 t -119.95 126.18 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.282 -1.128 . . . . 0.0 109.239 -179.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 28.6 m -80.76 133.12 35.6 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.255 -0.903 . . . . 0.0 108.775 179.267 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 7.1 p -129.01 132.27 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.586 -0.696 . . . . 0.0 109.396 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.5 p -123.39 148.4 46.12 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -142.4 140.91 10.3 Favored Glycine 0 N--CA 1.503 3.157 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.981 -178.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 94.8 t -124.79 130.03 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.675 -0.897 . . . . 0.0 109.654 179.188 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 33.9 m-85 -104.18 114.36 28.55 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.823 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -86.28 131.68 34.16 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.041 -1.037 . . . . 0.0 109.192 -179.569 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.473 ' C ' ' H ' ' A' ' 54' ' ' ASP . 54.3 m-85 -116.32 134.18 55.18 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.465 -0.772 . . . . 0.0 109.713 -179.439 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.467 ' C ' ' H ' ' A' ' 55' ' ' GLY . 44.8 t30 -57.17 -11.38 1.63 Allowed 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 178.77 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.473 ' H ' ' C ' ' A' ' 52' ' ' TYR . 11.9 t70 -67.01 0.6 2.43 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.467 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 79.52 20.76 68.25 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.173 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 18.4 p -130.9 151.56 51.18 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.297 -1.119 . . . . 0.0 110.914 -179.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 79.2 p -130.05 137.58 50.3 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 56.9 m -116.24 148.89 40.01 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 179.105 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -137.49 127.33 25.58 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.302 -0.874 . . . . 0.0 109.715 179.77 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -116.41 129.13 56.07 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.013 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -114.06 144.95 42.28 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -167.44 164.54 37.99 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.1 t -109.95 128.19 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.535 -0.98 . . . . 0.0 108.932 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 21.2 t -91.91 119.1 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.191 -0.943 . . . . 0.0 110.088 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.448 ' C ' ' H ' ' A' ' 67' ' ' SER . 29.7 p -132.31 149.93 74.56 Favored Pre-proline 0 N--CA 1.492 1.639 0 N-CA-C 106.889 -1.522 . . . . 0.0 106.889 178.268 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -52.28 -9.23 0.48 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 121.443 1.429 . . . . 0.0 111.293 -179.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.448 ' H ' ' C ' ' A' ' 65' ' ' THR . 19.6 m -104.79 -24.93 12.84 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.513 -0.742 . . . . 0.0 110.31 -179.655 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 20.7 m -135.88 107.39 9.76 Favored Pre-proline 0 N--CA 1.506 2.356 0 O-C-N 121.113 -0.992 . . . . 0.0 110.652 -179.593 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -87.04 164.03 8.7 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 C-N-CA 122.148 1.899 . . . . 0.0 111.69 178.428 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.3 t -118.57 129.57 74.65 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.377 -0.827 . . . . 0.0 109.12 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -103.3 136.67 42.64 Favored 'General case' 0 N--CA 1.501 2.105 0 O-C-N 121.148 -0.97 . . . . 0.0 110.678 -178.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -93.12 -1.16 56.7 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 178.347 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.416 ' O ' ' O ' ' A' ' 74' ' ' GLN . 78.3 m-20 -70.31 51.73 0.13 Allowed 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.427 -0.796 . . . . 0.0 109.378 -179.554 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.416 ' O ' ' O ' ' A' ' 73' ' ' ASN . 59.1 tt0 -62.39 -108.47 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 179.507 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -106.32 96.12 6.24 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.137 -0.977 . . . . 0.0 108.384 178.278 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 90.4 mt -84.99 -15.22 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.0 -1.063 . . . . 0.0 110.305 -179.577 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 64.9 t-20 -59.89 -44.6 94.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.919 -1.113 . . . . 0.0 109.837 -179.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 9.7 ptmm? -68.77 -33.96 74.77 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.11 -0.994 . . . . 0.0 109.174 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.607 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.7 OUTLIER -62.89 -45.14 93.9 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.935 -1.103 . . . . 0.0 108.067 178.895 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -59.95 -35.17 74.38 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 120.776 -1.202 . . . . 0.0 108.843 178.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.4 tttp -63.99 -51.15 65.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.402 -0.811 . . . . 0.0 111.07 -178.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.9 m -117.01 -20.8 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.226 0 O-C-N 121.365 -0.835 . . . . 0.0 111.545 -177.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.607 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.28 167.48 42.84 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 179.412 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 53.6 t -108.62 126.49 65.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 57.1 tt0 -79.96 -65.33 1.02 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.892 -1.13 . . . . 0.0 109.958 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.8 tptm -114.38 140.18 48.88 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.52 -0.738 . . . . 0.0 110.554 -178.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 69.2 t80 -119.75 137.23 54.07 Favored 'General case' 0 N--CA 1.5 2.045 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.139 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -138.1 128.08 25.6 Favored 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.066 -1.021 . . . . 0.0 111.068 -178.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.57 133.43 53.29 Favored 'General case' 0 N--CA 1.503 2.177 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 59.4 tp -120.01 135.35 54.96 Favored 'General case' 0 N--CA 1.508 2.434 0 O-C-N 121.298 -0.876 . . . . 0.0 110.169 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 30.6 p -129.23 127.38 41.14 Favored 'General case' 0 N--CA 1.505 2.282 0 CA-C-O 121.679 0.752 . . . . 0.0 110.958 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -132.63 145.86 51.43 Favored 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.692 -0.63 . . . . 0.0 110.221 179.774 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 76.8 m95 -69.88 139.96 53.1 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 120.945 -1.097 . . . . 0.0 108.771 178.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 17.4 t -112.38 117.52 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.453 -0.779 . . . . 0.0 109.546 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.486 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 179.785 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.879 0 N-CA-C 119.587 2.595 . . . . 0.0 119.587 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.54 138.37 26.05 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 30.0 t -91.13 -3.53 56.99 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.249 -1.148 . . . . 0.0 109.614 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 108.07 -110.01 3.03 Favored Glycine 0 N--CA 1.499 2.897 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 20.2 t90 -61.88 136.56 58.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.229 -1.16 . . . . 0.0 110.6 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . 0.577 ' C ' ' H ' ' A' ' 8' ' ' ASP . 98.6 m-20 -131.57 124.42 29.98 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 177.047 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.87 -3.97 0.14 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.025 -1.047 . . . . 0.0 108.973 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.577 ' H ' ' C ' ' A' ' 6' ' ' ASN . 95.7 m-20 -79.89 -21.73 43.65 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.475 -0.765 . . . . 0.0 110.549 -179.442 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 28.5 m120 -88.48 0.13 56.61 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.933 -1.105 . . . . 0.0 109.424 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.8 t -112.74 127.54 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.553 -0.717 . . . . 0.0 109.42 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.478 ' CG ' ' HG ' ' A' ' 13' ' ' SER . 12.1 t0 -79.04 130.92 68.2 Favored Pre-proline 0 N--CA 1.488 1.444 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 178.642 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -74.49 -10.65 22.21 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 121.706 1.604 . . . . 0.0 111.832 -179.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.478 ' HG ' ' CG ' ' A' ' 11' ' ' ASP . 82.7 p -69.96 -29.34 66.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.301 -0.874 . . . . 0.0 109.505 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 62.9 tt0 -90.07 -19.52 24.26 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.228 -0.92 . . . . 0.0 109.502 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.811 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 48.8 t -66.34 -33.5 75.86 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.089 -1.007 . . . . 0.0 109.846 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.5 pp -119.35 132.11 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -113.98 142.87 45.61 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -96.01 127.24 41.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.422 -0.799 . . . . 0.0 110.024 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 49.5 m -115.67 124.24 50.39 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.62 -103.12 0.11 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.4 m -129.76 30.5 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.086 0 O-C-N 121.559 -0.965 . . . . 0.0 109.188 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 14.2 tt0 -129.43 153.04 48.32 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.397 -0.815 . . . . 0.0 110.453 -178.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -114.34 136.42 53.0 Favored 'General case' 0 N--CA 1.499 1.99 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.193 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 36.9 p -135.36 145.37 47.31 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.338 -0.851 . . . . 0.0 109.553 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 45.6 t80 -80.13 124.46 28.79 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.2 m120 -82.82 86.96 6.82 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.01 -1.056 . . . . 0.0 110.267 -179.087 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.409 ' C ' ' H ' ' A' ' 29' ' ' VAL . 13.8 m -79.61 -13.69 59.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.044 -1.035 . . . . 0.0 109.145 179.422 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -65.78 -3.68 16.66 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.409 ' H ' ' C ' ' A' ' 27' ' ' SER . 2.0 t -102.93 126.91 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 96.7 p -59.92 -40.12 87.79 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.076 -1.015 . . . . 0.0 111.279 -178.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.447 ' CG2' ' N ' ' A' ' 32' ' ' CYS . 16.2 m -60.56 -44.3 96.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 120.878 -1.139 . . . . 0.0 110.638 -178.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.811 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 89.3 m -60.14 -43.36 95.76 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.099 -1.001 . . . . 0.0 110.563 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 95.2 mmm -84.33 -12.76 54.02 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.721 -1.237 . . . . 0.0 109.121 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 -60.12 -47.44 85.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.889 . . . . 0.0 108.604 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.86 -45.04 17.85 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.2 tp -60.18 -40.01 88.47 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.242 -1.152 . . . . 0.0 109.449 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -66.13 -39.95 90.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.319 -0.863 . . . . 0.0 110.363 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -75.62 -6.17 49.03 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.071 -1.018 . . . . 0.0 109.978 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.93 26.81 73.3 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -101.13 -5.47 25.62 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.443 ' CG1' ' H ' ' A' ' 43' ' ' GLY . 77.2 t -134.95 159.82 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -179.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 65.0 mtp180 -122.73 -5.93 8.59 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.443 ' H ' ' CG1' ' A' ' 41' ' ' VAL . . . 137.76 -164.92 25.43 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 108.429 -1.868 . . . . 0.0 108.429 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.0 t -120.34 130.0 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.226 -1.161 . . . . 0.0 109.545 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.3 t -83.17 133.79 35.01 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.189 -0.944 . . . . 0.0 108.726 179.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.5 p -129.96 134.22 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.59 -0.694 . . . . 0.0 109.434 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 25.5 p -124.83 146.59 49.19 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.473 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -138.27 140.55 11.23 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 98.2 t -126.53 129.85 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.675 -0.897 . . . . 0.0 109.143 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -101.44 117.2 34.45 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 39.1 m-85 -91.96 122.61 34.64 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.403 -0.811 . . . . 0.0 109.079 -179.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.402 ' C ' ' H ' ' A' ' 54' ' ' ASP . 98.7 m-85 -104.99 136.16 44.99 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.575 -0.703 . . . . 0.0 109.771 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 -57.27 -11.63 1.88 Allowed 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 11.2 t70 -74.46 2.16 10.19 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.59 21.21 69.78 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.1 p -120.47 147.02 45.66 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.405 -1.056 . . . . 0.0 110.127 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 71.8 p -130.01 140.95 50.8 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.673 0.749 . . . . 0.0 110.066 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.6 t -116.96 140.83 49.0 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 106.641 -1.614 . . . . 0.0 106.641 178.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 49.0 m-20 -129.96 116.69 18.97 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.035 -1.04 . . . . 0.0 109.727 -179.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -116.57 124.38 49.68 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -114.18 146.05 40.87 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -163.96 168.31 38.4 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.159 -1.576 . . . . 0.0 109.159 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.3 t -110.39 127.32 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.535 -0.98 . . . . 0.0 109.363 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.3 t -89.59 118.89 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.375 -0.828 . . . . 0.0 109.792 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.593 ' HG1' ' H ' ' A' ' 68' ' ' THR . 30.1 p -128.25 149.97 72.79 Favored Pre-proline 0 N--CA 1.494 1.732 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 178.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.89 -16.12 3.86 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 121.276 1.318 . . . . 0.0 111.414 -179.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 84.2 p -108.21 -13.2 14.96 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.393 -0.817 . . . . 0.0 110.697 -179.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.593 ' H ' ' HG1' ' A' ' 65' ' ' THR . 56.8 m -132.55 106.87 13.07 Favored Pre-proline 0 N--CA 1.505 2.286 0 O-C-N 121.086 -1.009 . . . . 0.0 110.561 -179.378 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -88.28 162.43 6.95 Favored 'Trans proline' 0 N--CA 1.49 1.293 0 C-N-CA 122.267 1.978 . . . . 0.0 111.833 178.329 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.5 t -120.17 128.49 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.158 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -104.64 128.77 52.77 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.124 -0.985 . . . . 0.0 111.324 -178.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 74' ' ' GLN . 1.1 p -90.05 0.09 57.31 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 177.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -67.9 60.43 0.07 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-O 121.556 0.693 . . . . 0.0 109.143 -179.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.494 ' N ' ' O ' ' A' ' 72' ' ' THR . 7.3 tt0 -68.79 -106.5 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.169 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -103.6 94.47 5.48 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.009 -1.057 . . . . 0.0 109.74 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 79.5 mt -74.46 -29.82 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.013 -1.054 . . . . 0.0 109.698 179.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -59.94 -42.63 94.42 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.809 -1.182 . . . . 0.0 108.186 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 84.2 tttt -65.27 -42.16 93.49 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.277 -0.889 . . . . 0.0 108.749 178.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.599 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.4 OUTLIER -69.75 -42.7 73.54 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.562 -0.711 . . . . 0.0 110.179 -179.132 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -63.51 -32.76 74.3 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.168 -1.582 . . . . 0.0 109.233 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.0 tttt -69.81 -47.38 63.03 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 110.735 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.4 p -112.2 -27.55 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 O-C-N 121.504 -0.747 . . . . 0.0 111.661 -177.126 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.599 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 88.61 169.7 45.04 Favored Glycine 0 N--CA 1.49 2.244 0 O-C-N 120.715 -1.241 . . . . 0.0 110.452 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.473 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 23.5 t -115.43 129.67 71.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.892 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -80.07 -67.46 0.76 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.071 -1.018 . . . . 0.0 110.297 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -116.51 140.12 49.71 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.508 -0.745 . . . . 0.0 110.846 -179.102 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 68.9 t80 -119.96 131.8 55.3 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -131.53 132.6 44.3 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.08 -1.012 . . . . 0.0 110.788 -178.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.52 137.1 54.84 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.802 -0.561 . . . . 0.0 109.551 179.266 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 44.7 tp -117.16 133.32 56.14 Favored 'General case' 0 N--CA 1.502 2.167 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 p -129.08 122.18 29.39 Favored 'General case' 0 N--CA 1.503 2.215 0 CA-C-O 121.708 0.766 . . . . 0.0 110.733 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -132.35 152.75 51.3 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.891 -0.506 . . . . 0.0 109.846 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 78.0 m95 -70.21 139.89 52.37 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.048 -1.033 . . . . 0.0 109.07 178.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 59.7 t -112.53 120.83 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.156 0 O-C-N 121.383 -0.823 . . . . 0.0 109.397 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 145.46 -124.13 2.04 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.189 -1.564 . . . . 0.0 109.189 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 47.4 t -60.47 140.0 57.47 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.346 -1.09 . . . . 0.0 109.934 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 35.7 ttm180 -61.48 136.37 58.0 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.357 -0.839 . . . . 0.0 109.0 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.583 -179.919 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.936 0 N-CA-C 119.648 2.619 . . . . 0.0 119.648 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -86.58 162.42 34.56 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.5 t -78.68 141.54 37.85 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.358 -1.084 . . . . 0.0 109.458 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -135.64 64.18 0.58 Allowed Glycine 0 N--CA 1.5 2.909 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . 0.401 ' CB ' ' NE2' ' A' ' 34' ' ' GLN . 79.6 t90 -75.5 127.9 34.13 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.277 -1.131 . . . . 0.0 108.775 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 39.7 p-10 -134.06 18.28 3.77 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.522 0.677 . . . . 0.0 109.911 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 57.95 13.85 2.34 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.433 -0.792 . . . . 0.0 109.464 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.414 ' O ' ' OD1' ' A' ' 8' ' ' ASP . 61.1 t0 -92.13 -27.47 17.71 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.234 -0.917 . . . . 0.0 109.555 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -95.15 4.08 54.01 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.392 -0.817 . . . . 0.0 110.099 -179.276 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 19.7 t -110.61 134.08 54.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.5 -0.75 . . . . 0.0 109.88 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -90.81 131.61 37.07 Favored Pre-proline 0 N--CA 1.49 1.526 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.49 -14.16 22.5 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 121.747 1.631 . . . . 0.0 111.592 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 59.8 p -67.22 -35.83 80.42 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.518 -0.739 . . . . 0.0 109.867 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -90.05 -11.62 40.9 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.208 -0.933 . . . . 0.0 110.313 -179.095 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.816 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 8.2 t -69.63 -29.4 66.89 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.974 -1.079 . . . . 0.0 108.471 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.4 pp -120.62 145.47 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 61.1 mttp -127.09 154.14 45.09 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.402 -0.811 . . . . 0.0 110.032 -179.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.441 ' NE2' ' OH ' ' A' ' 23' ' ' TYR . 83.4 mt-30 -96.07 120.01 35.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.463 -0.773 . . . . 0.0 109.692 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 5.9 t -110.34 115.14 29.14 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.87 -111.09 2.25 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.4 m -117.33 20.69 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.241 0 O-C-N 121.466 -1.02 . . . . 0.0 109.959 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -127.26 160.53 31.02 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.348 -0.845 . . . . 0.0 111.081 -177.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . 0.441 ' OH ' ' NE2' ' A' ' 18' ' ' GLN . 12.5 m-85 -111.33 134.17 53.11 Favored 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.567 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 37.9 p -132.74 145.48 51.06 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.284 -0.885 . . . . 0.0 108.986 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -82.87 127.26 33.33 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.387 -0.821 . . . . 0.0 108.999 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -84.56 80.52 9.21 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.024 -1.047 . . . . 0.0 109.119 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.555 ' C ' ' H ' ' A' ' 29' ' ' VAL . 92.0 p -83.73 -8.35 59.27 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.413 -0.804 . . . . 0.0 109.485 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.67 -2.74 0.2 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.159 -1.177 . . . . 0.0 110.159 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.555 ' H ' ' C ' ' A' ' 27' ' ' SER . 34.9 m -108.32 131.35 59.03 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.328 -1.101 . . . . 0.0 108.442 179.165 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 82.8 p -63.68 -30.23 71.36 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.287 -0.883 . . . . 0.0 111.278 -178.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 p -59.9 -39.9 81.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 120.87 -1.144 . . . . 0.0 110.415 -179.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.816 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 56.3 m -59.93 -40.17 87.99 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.95 -1.094 . . . . 0.0 110.077 -179.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 9.0 mmt -79.73 -14.31 58.83 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.0 -1.062 . . . . 0.0 109.415 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.401 ' NE2' ' CB ' ' A' ' 5' ' ' TRP . 62.2 tt0 -60.76 -40.56 92.98 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.876 -1.14 . . . . 0.0 108.451 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -82.99 -51.22 4.29 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.5 mt -58.27 -40.07 80.88 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.919 -1.341 . . . . 0.0 108.832 -179.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -59.93 -40.02 87.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.342 -0.848 . . . . 0.0 109.497 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 60.3 mm-40 -76.8 -6.76 53.64 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.989 -1.069 . . . . 0.0 109.87 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.35 32.56 68.37 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 120.066 -1.064 . . . . 0.0 110.646 178.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -102.81 -9.65 19.77 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.462 HG12 ' H ' ' A' ' 43' ' ' GLY . 5.8 t -134.19 158.16 41.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -179.087 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -117.33 -11.08 10.63 Favored 'General case' 0 N--CA 1.501 2.087 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 178.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.462 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 146.09 -157.33 27.34 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 107.879 -2.088 . . . . 0.0 107.879 -179.175 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 77.2 t -120.01 128.42 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.281 -1.129 . . . . 0.0 108.538 179.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.8 m -86.17 132.78 33.94 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.118 -0.989 . . . . 0.0 108.351 179.454 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 13.2 p -132.52 132.46 60.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.592 -0.693 . . . . 0.0 109.779 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.3 m -128.47 141.1 51.5 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 178.395 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.426 ' O ' ' OD1' ' A' ' 59' ' ' ASN . . . -130.87 149.6 19.16 Favored Glycine 0 N--CA 1.505 3.272 0 C-N-CA 120.21 -0.995 . . . . 0.0 110.872 -178.621 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 38.2 t -125.04 129.99 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.824 -0.809 . . . . 0.0 108.825 179.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.539 ' CE2' ' O ' ' A' ' 72' ' ' THR . 50.0 m-85 -105.45 121.89 44.86 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.475 -0.766 . . . . 0.0 109.567 179.285 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 45.8 m-85 -95.76 121.59 37.65 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.045 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.444 ' C ' ' N ' ' A' ' 54' ' ' ASP . 93.3 m-85 -106.28 128.61 54.11 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.236 -0.915 . . . . 0.0 109.271 179.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.473 ' C ' ' H ' ' A' ' 55' ' ' GLY . 51.9 t30 -48.77 -17.13 0.15 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.067 -1.021 . . . . 0.0 109.199 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.444 ' N ' ' C ' ' A' ' 52' ' ' TYR . 62.7 m-20 -67.99 3.28 1.62 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.407 -0.808 . . . . 0.0 109.115 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.473 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 77.68 19.77 75.21 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 178.655 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.1 p -117.79 147.67 42.78 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.383 -1.069 . . . . 0.0 109.952 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 24.3 p -130.57 127.96 40.1 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.703 -0.623 . . . . 0.0 109.543 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 30.6 t -118.39 154.49 32.31 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . 0.426 ' OD1' ' O ' ' A' ' 48' ' ' GLY . 57.9 t-20 -141.53 133.15 27.02 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.796 -1.19 . . . . 0.0 110.149 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.438 ' CZ ' ' NE2' ' A' ' 74' ' ' GLN . 58.6 m-85 -116.46 124.41 49.91 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.304 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 62.9 tttm -114.36 143.4 44.96 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.15 172.46 43.38 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 49.0 t -114.74 128.67 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.629 -0.924 . . . . 0.0 109.156 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 75.7 t -98.08 123.02 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.218 -0.927 . . . . 0.0 109.515 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.465 ' HG1' ' CB ' ' A' ' 68' ' ' THR . 17.0 p -121.55 151.0 56.16 Favored Pre-proline 0 N--CA 1.496 1.856 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_exo -34.49 -34.0 0.08 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.399 2.066 . . . . 0.0 113.191 -179.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.403 ' N ' ' O ' ' A' ' 65' ' ' THR . 63.4 m -106.76 -0.55 23.4 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.379 -0.825 . . . . 0.0 111.78 -178.626 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.465 ' CB ' ' HG1' ' A' ' 65' ' ' THR . 4.1 m -124.39 106.86 30.05 Favored Pre-proline 0 N--CA 1.508 2.437 0 O-C-N 120.945 -1.097 . . . . 0.0 111.527 -178.5 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -92.61 161.2 2.89 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 C-N-CA 122.712 2.275 . . . . 0.0 111.025 177.126 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 91.1 t -134.64 139.88 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.238 0 O-C-N 120.952 -1.092 . . . . 0.0 109.825 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -95.43 138.72 32.72 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.165 -0.959 . . . . 0.0 109.158 179.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.539 ' O ' ' CE2' ' A' ' 50' ' ' PHE . 5.8 t -110.93 -33.83 6.4 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.321 -0.862 . . . . 0.0 109.419 -179.769 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.508 ' ND2' ' CD1' ' A' ' 76' ' ' ILE . 9.6 t30 -92.1 32.32 1.17 Allowed 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.218 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.438 ' NE2' ' CZ ' ' A' ' 60' ' ' PHE . 13.8 pt20 -54.13 -22.56 11.43 Favored 'General case' 0 N--CA 1.499 2.011 0 C-N-CA 120.276 -0.57 . . . . 0.0 112.246 -178.056 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -107.37 71.9 0.85 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 120.702 -1.249 . . . . 0.0 109.735 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.508 ' CD1' ' ND2' ' A' ' 73' ' ' ASN . 45.7 mm -70.1 -40.35 78.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.335 -0.853 . . . . 0.0 111.332 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -60.12 -46.9 88.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.629 -1.294 . . . . 0.0 108.551 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 29.6 ttmt -60.08 -50.03 75.33 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.293 -0.879 . . . . 0.0 108.864 179.092 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.568 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.3 m -62.36 -42.8 99.69 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.79 -0.569 . . . . 0.0 110.625 -178.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -60.47 -35.28 75.5 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.561 -1.337 . . . . 0.0 110.027 179.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 14.7 tmtt? -67.07 -48.55 67.91 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.089 -1.007 . . . . 0.0 111.079 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -113.45 -26.88 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.183 -0.948 . . . . 0.0 111.572 -178.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 90.07 168.11 42.61 Favored Glycine 0 N--CA 1.491 2.323 0 O-C-N 120.54 -1.35 . . . . 0.0 110.173 179.737 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.05 124.58 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -79.92 -65.64 0.98 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.094 -1.004 . . . . 0.0 110.286 -179.169 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 44.3 tptt -115.38 142.28 46.91 Favored 'General case' 0 N--CA 1.504 2.23 0 O-C-N 121.415 -0.803 . . . . 0.0 110.526 -178.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.0 t80 -121.13 132.1 54.65 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 -135.01 127.18 29.98 Favored 'General case' 0 N--CA 1.503 2.199 0 O-C-N 121.126 -0.984 . . . . 0.0 110.358 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.87 134.63 52.63 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.654 -0.653 . . . . 0.0 110.017 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.6 tp -118.51 133.45 55.86 Favored 'General case' 0 N--CA 1.503 2.192 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.2 p -129.2 126.36 39.0 Favored 'General case' 0 N--CA 1.503 2.198 0 CA-C-O 121.53 0.681 . . . . 0.0 110.678 -179.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 58.2 mm-40 -134.4 158.46 43.79 Favored 'General case' 0 N--CA 1.504 2.235 0 CA-C-O 121.488 0.661 . . . . 0.0 110.599 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 71.9 m95 -71.15 139.21 50.15 Favored 'General case' 0 N--CA 1.494 1.774 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 178.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 44.6 t -112.41 118.79 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.289 -0.882 . . . . 0.0 109.335 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -142.18 -117.48 1.3 Allowed Glycine 0 N--CA 1.494 2.504 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.318 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 28.6 p -85.83 118.82 25.56 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.053 -1.263 . . . . 0.0 109.337 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 35.3 ptt-85 -89.31 -9.52 50.21 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.071 -1.018 . . . . 0.0 109.616 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 36.6 t . . . . . 0 N--CA 1.5 2.028 0 CA-C-O 118.049 -0.976 . . . . 0.0 109.299 179.78 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.941 0 N-CA-C 119.475 2.55 . . . . 0.0 119.475 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 93.46 -32.92 5.43 Favored Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 38.1 t -100.1 121.42 41.38 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.342 -1.093 . . . . 0.0 108.875 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -54.9 -84.63 0.03 OUTLIER Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 -179.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 66.7 t90 -60.02 138.86 57.76 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.16 -1.2 . . . . 0.0 109.026 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -133.35 129.62 37.7 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.389 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -72.99 64.75 0.72 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.896 -1.127 . . . . 0.0 108.021 178.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -66.72 -73.3 0.14 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.758 -0.589 . . . . 0.0 110.234 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 64.8 t-20 -145.45 47.05 1.29 Allowed 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 179.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 2.6 m -81.17 139.75 17.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.538 -0.726 . . . . 0.0 109.077 -178.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.447 ' OD1' ' N ' ' A' ' 11' ' ' ASP . 2.0 m-20 -76.66 130.01 77.71 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.906 . . . . 0.0 109.981 -178.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -81.55 -19.96 7.2 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.22 1.947 . . . . 0.0 112.079 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 81.9 p -64.87 -36.53 84.64 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.437 -0.79 . . . . 0.0 110.572 -179.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -68.99 -24.66 64.26 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.132 -0.98 . . . . 0.0 109.715 -179.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.814 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 50.1 t -65.56 -35.16 80.03 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.331 -0.856 . . . . 0.0 109.775 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -117.09 140.42 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.063 0 O-C-N 121.436 -0.79 . . . . 0.0 109.149 -179.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -117.82 147.17 43.3 Favored 'General case' 0 N--CA 1.5 2.026 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -93.77 122.22 36.01 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.172 -0.955 . . . . 0.0 109.746 -179.429 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.479 ' O ' ' N ' ' A' ' 21' ' ' VAL . 26.3 t -110.67 123.71 50.53 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.117 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.42 -94.28 0.01 OUTLIER Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.479 ' N ' ' O ' ' A' ' 19' ' ' SER . 24.7 m -139.4 28.03 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.945 0 O-C-N 121.236 -1.155 . . . . 0.0 109.833 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.6 pt20 -131.42 163.65 27.45 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.318 -0.864 . . . . 0.0 110.035 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 54.0 m-85 -115.69 139.97 49.63 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 76.6 p -134.15 148.67 50.98 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.388 -0.82 . . . . 0.0 109.021 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 52.1 t80 -87.54 124.92 33.99 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.441 -0.787 . . . . 0.0 110.007 -178.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -84.39 84.93 7.47 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.33 -0.856 . . . . 0.0 109.732 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 92.4 p -77.22 -9.44 58.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.141 -0.975 . . . . 0.0 109.679 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -72.9 -1.91 56.42 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -98.89 131.64 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.159 -1.2 . . . . 0.0 108.431 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 27.3 t -59.97 -42.58 94.46 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.324 -0.86 . . . . 0.0 110.643 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.402 ' CG1' ' N ' ' A' ' 32' ' ' CYS . 9.9 p -59.95 -40.15 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.711 -1.243 . . . . 0.0 110.327 -179.061 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.814 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 90.2 m -61.95 -48.29 81.07 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.014 -1.054 . . . . 0.0 111.244 -178.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 1.2 mmt -77.64 -24.67 49.43 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.735 -1.228 . . . . 0.0 111.358 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -60.06 -40.05 88.12 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.709 -1.244 . . . . 0.0 109.498 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -72.44 -44.2 42.53 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.2 mt -66.2 -42.58 88.58 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.309 -1.112 . . . . 0.0 109.629 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -60.88 -40.08 91.67 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.07 -1.019 . . . . 0.0 110.212 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -78.66 -12.49 60.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.354 -0.841 . . . . 0.0 109.907 -178.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.02 29.27 70.8 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 41.9 mmtm -103.26 -5.39 23.14 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.435 HG13 ' H ' ' A' ' 43' ' ' GLY . 72.4 t -135.13 160.26 40.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 93.4 mtt-85 -120.95 -5.96 9.56 Favored 'General case' 0 N--CA 1.501 2.095 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.435 ' H ' HG13 ' A' ' 41' ' ' VAL . . . 132.59 -158.58 23.09 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 107.939 -2.064 . . . . 0.0 107.939 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 81.3 t -121.98 128.1 75.53 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.222 -1.164 . . . . 0.0 110.194 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.6 t -83.13 134.98 34.97 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 178.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 7.7 p -131.22 134.57 61.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.38 -0.825 . . . . 0.0 109.963 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.8 p -125.35 141.6 51.98 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -129.61 138.1 10.01 Favored Glycine 0 N--CA 1.503 3.107 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -178.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.15 125.01 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.61 ' CG ' ' NE2' ' A' ' 74' ' ' GLN . 26.3 m-85 -102.31 121.78 42.95 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 77.2 m-85 -94.61 129.28 41.53 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 120.984 -1.072 . . . . 0.0 109.517 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.47 ' OH ' ' NE2' ' A' ' 74' ' ' GLN . 68.4 m-85 -109.34 130.48 55.49 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.613 -0.679 . . . . 0.0 110.433 -179.693 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 43.1 t30 -50.61 -16.72 0.41 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.347 -0.846 . . . . 0.0 108.971 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.419 ' N ' ' C ' ' A' ' 52' ' ' TYR . 29.6 t0 -73.26 1.3 9.7 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.332 -0.855 . . . . 0.0 109.352 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.16 18.98 70.62 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 179.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.4 p -117.34 146.74 43.18 Favored 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.482 -1.01 . . . . 0.0 110.106 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.3 p -130.23 140.25 50.73 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.65 0.738 . . . . 0.0 110.384 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 65.3 p -118.14 143.95 46.07 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 178.235 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -137.79 119.73 15.38 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.876 -1.14 . . . . 0.0 109.933 -179.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -115.61 125.24 52.68 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -110.55 143.5 40.83 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -161.89 161.46 33.34 Favored Glycine 0 C--N 1.284 -2.319 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 32.2 t -108.12 125.85 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.347 -1.09 . . . . 0.0 109.049 -179.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 55.5 t -91.77 116.7 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.318 -0.864 . . . . 0.0 109.417 -179.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 67' ' ' SER . 22.3 p -135.89 149.93 70.08 Favored Pre-proline 0 N--CA 1.494 1.73 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 179.244 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_exo -41.47 -18.03 0.07 OUTLIER 'Trans proline' 0 C--N 1.313 -1.307 0 C-N-CA 121.908 1.739 . . . . 0.0 112.039 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.526 ' N ' ' O ' ' A' ' 65' ' ' THR . 68.7 m -69.96 -52.12 27.05 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.277 -0.889 . . . . 0.0 111.139 -179.002 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 60.1 p -149.64 151.75 33.61 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 120.731 -1.231 . . . . 0.0 110.064 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -85.38 165.72 10.84 Favored 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.728 2.285 . . . . 0.0 112.422 178.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 68.8 t -111.23 134.05 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.219 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -102.36 131.78 48.76 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.121 -0.987 . . . . 0.0 112.048 -177.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.401 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.3 OUTLIER -111.01 20.07 17.85 Favored 'General case' 0 N--CA 1.503 2.217 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 177.694 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.492 HD21 ' N ' ' A' ' 73' ' ' ASN . 0.0 OUTLIER -77.07 55.73 1.17 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.575 -0.703 . . . . 0.0 110.383 -178.782 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.61 ' NE2' ' CG ' ' A' ' 50' ' ' PHE . 13.2 pt20 -49.0 175.04 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.366 -0.834 . . . . 0.0 108.884 178.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -55.19 107.71 0.34 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.819 -1.176 . . . . 0.0 108.64 179.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 72.2 mt -79.36 -13.83 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.181 -0.949 . . . . 0.0 110.019 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -59.94 -45.18 93.47 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.87 -1.144 . . . . 0.0 109.254 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 1.3 ptpp? -66.23 -38.53 88.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.93 -1.107 . . . . 0.0 108.905 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.601 ' O ' ' N ' ' A' ' 83' ' ' GLY . 3.7 m -59.96 -50.06 75.25 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.577 -0.702 . . . . 0.0 110.095 -179.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -60.48 -36.4 78.21 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 120.498 -1.377 . . . . 0.0 108.852 179.046 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 22.3 tttp -69.37 -47.29 64.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.405 -0.809 . . . . 0.0 110.929 -179.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.7 p -111.98 -29.72 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.18 0 O-C-N 121.245 -0.909 . . . . 0.0 111.817 -177.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.601 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.62 164.49 40.14 Favored Glycine 0 N--CA 1.49 2.279 0 O-C-N 120.705 -1.247 . . . . 0.0 110.696 179.053 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 82.6 t -109.86 130.82 62.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 48.0 tp60 -79.94 -67.37 0.77 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.228 -0.92 . . . . 0.0 110.254 -179.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -115.35 146.24 41.74 Favored 'General case' 0 N--CA 1.503 2.184 0 O-C-N 121.453 -0.78 . . . . 0.0 111.152 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -119.73 131.67 55.44 Favored 'General case' 0 N--CA 1.499 1.989 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 14.0 tpp85 -137.62 136.15 37.24 Favored 'General case' 0 N--CA 1.504 2.266 0 O-C-N 120.932 -1.105 . . . . 0.0 111.057 -178.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.97 137.69 54.57 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 10.4 mp -119.84 126.17 50.33 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 16.9 p -127.01 125.09 40.84 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.301 -0.874 . . . . 0.0 110.447 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -132.13 147.44 52.43 Favored 'General case' 0 N--CA 1.5 2.039 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 75.1 m95 -70.72 139.27 51.11 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.913 -1.117 . . . . 0.0 109.593 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.8 t -111.37 123.76 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.976 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.444 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 108.02 -14.21 37.39 Favored Glycine 0 N--CA 1.496 2.652 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 89.4 p -70.99 149.96 46.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.262 -1.14 . . . . 0.0 109.414 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -96.07 -5.61 40.54 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.295 -0.878 . . . . 0.0 109.222 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 7.1 p . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 117.938 -1.03 . . . . 0.0 109.984 179.811 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.811 0 N-CA-C 119.54 2.576 . . . . 0.0 119.54 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 80.6 -166.83 49.65 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.3 t -83.23 130.24 35.07 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.323 -1.104 . . . . 0.0 109.392 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -90.53 24.45 17.04 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . 0.407 ' CG ' ' NE2' ' A' ' 34' ' ' GLN . 87.2 t90 -59.88 118.25 6.0 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.325 -1.103 . . . . 0.0 110.178 -179.403 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . 0.556 ' C ' ' H ' ' A' ' 8' ' ' ASP . 96.3 m-20 -131.56 20.03 4.72 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 178.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 54.81 2.83 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.841 -0.537 . . . . 0.0 109.655 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.556 ' H ' ' C ' ' A' ' 6' ' ' ASN . 34.0 p-10 -86.49 -20.06 28.62 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.038 -1.039 . . . . 0.0 109.172 179.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 57.0 t30 -95.36 1.68 54.39 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.411 -0.806 . . . . 0.0 109.045 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.6 t -116.41 126.19 73.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.749 -0.594 . . . . 0.0 109.903 -178.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -83.49 139.83 41.4 Favored Pre-proline 0 N--CA 1.489 1.499 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 178.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -75.65 -14.17 19.86 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 121.762 1.641 . . . . 0.0 111.868 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 77.6 p -60.21 -39.96 88.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.367 -0.833 . . . . 0.0 109.722 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 88.6 mm-40 -84.24 -11.88 55.72 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.139 -0.976 . . . . 0.0 109.725 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.813 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 29.9 t -69.69 -31.45 69.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.146 -0.971 . . . . 0.0 108.677 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.5 pp -123.58 146.15 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.413 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.5 mttt -111.31 145.18 39.26 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.285 -0.884 . . . . 0.0 109.885 -178.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.454 ' NE2' ' CZ ' ' A' ' 87' ' ' TYR . 63.3 tt0 -97.65 114.81 26.84 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.438 ' O ' ' N ' ' A' ' 21' ' ' VAL . 48.0 m -115.13 130.12 56.84 Favored 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.67 -98.27 0.01 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.438 ' N ' ' O ' ' A' ' 19' ' ' SER . 3.9 m -137.57 27.46 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.369 -1.077 . . . . 0.0 109.836 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 -130.72 162.98 28.27 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 121.196 -0.94 . . . . 0.0 109.956 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -116.95 140.02 49.96 Favored 'General case' 0 N--CA 1.5 2.07 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.028 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 71.3 p -130.53 145.75 51.92 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.38 -0.825 . . . . 0.0 109.446 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -80.78 126.18 31.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.189 -0.944 . . . . 0.0 108.521 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -85.76 83.48 7.84 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.176 -0.953 . . . . 0.0 110.422 -179.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.9 p -81.07 -9.07 59.88 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.132 -0.98 . . . . 0.0 109.614 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -57.42 -39.18 90.14 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.5 m -80.84 136.89 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.106 -1.232 . . . . 0.0 108.984 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 24.1 t -67.54 -30.28 69.89 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.359 -0.838 . . . . 0.0 111.178 -178.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.1 p -60.0 -40.06 82.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.818 -1.176 . . . . 0.0 110.419 -178.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.813 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 67.3 m -64.17 -40.17 95.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.786 -1.196 . . . . 0.0 110.14 -179.806 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 97.1 mmm -86.36 -14.96 41.95 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.892 -1.13 . . . . 0.0 109.77 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.407 ' NE2' ' CG ' ' A' ' 5' ' ' TRP . 30.1 tt0 -60.21 -40.27 89.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.985 -1.072 . . . . 0.0 108.127 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -79.2 -45.48 8.85 Favored Glycine 0 N--CA 1.485 1.902 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.9 tp -60.42 -43.67 96.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.243 -1.151 . . . . 0.0 109.737 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -67.32 -39.81 85.92 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.202 -0.936 . . . . 0.0 110.055 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -60.39 -31.09 70.03 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.03 -1.044 . . . . 0.0 109.349 -179.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.52 23.42 23.97 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 64.5 mmtt -109.73 -0.57 18.44 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 178.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.414 HG13 ' H ' ' A' ' 43' ' ' GLY . 86.9 t -135.37 158.12 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 121.671 0.748 . . . . 0.0 109.259 -179.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 67.4 mtp180 -119.9 -9.66 9.63 Favored 'General case' 0 N--CA 1.497 1.925 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.414 ' H ' HG13 ' A' ' 41' ' ' VAL . . . 137.75 -159.96 25.11 Favored Glycine 0 N--CA 1.497 2.72 0 N-CA-C 108.009 -2.037 . . . . 0.0 108.009 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 90.1 t -118.61 129.73 74.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.143 0 O-C-N 121.18 -1.189 . . . . 0.0 109.315 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.2 t -85.91 138.76 31.79 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.324 -0.86 . . . . 0.0 108.883 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.7 p -130.13 132.49 65.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.785 0.802 . . . . 0.0 109.544 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.4 p -123.78 146.06 48.59 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -141.77 138.7 8.82 Favored Glycine 0 N--CA 1.5 2.954 0 C-N-CA 119.362 -1.399 . . . . 0.0 111.471 -178.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 55.1 t -120.11 122.6 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 178.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.518 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 0.3 OUTLIER -100.06 126.18 46.23 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 179.875 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -98.53 121.39 40.4 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.156 -0.965 . . . . 0.0 109.444 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.532 ' O ' ' N ' ' A' ' 54' ' ' ASP . 91.7 m-85 -105.47 125.58 51.14 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.382 -0.824 . . . . 0.0 109.356 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.645 HD21 ' NE2' ' A' ' 85' ' ' GLN . 20.9 t-20 -45.53 -16.62 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.147 -0.971 . . . . 0.0 109.49 179.543 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 52' ' ' TYR . 7.4 t70 -67.79 2.52 1.91 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.378 -0.826 . . . . 0.0 109.275 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.44 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 77.39 18.83 77.47 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.529 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 16.3 p -116.65 148.36 41.07 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.555 -0.968 . . . . 0.0 110.067 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 69.6 p -129.99 138.07 50.63 Favored 'General case' 0 N--CA 1.496 1.872 0 CA-C-O 121.589 0.709 . . . . 0.0 109.665 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.5 t -118.65 142.37 47.71 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 107.224 -1.399 . . . . 0.0 107.224 178.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . 0.439 ' O ' ' OD1' ' A' ' 59' ' ' ASN . 39.7 p-10 -135.05 117.04 15.28 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.025 -1.047 . . . . 0.0 109.691 -179.443 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -116.83 130.43 56.71 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 27.2 ttpp -113.69 141.95 46.61 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -160.08 161.29 32.35 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 49.1 t -108.74 124.17 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.47 -1.017 . . . . 0.0 108.769 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 53.3 t -97.64 119.18 45.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.326 -0.859 . . . . 0.0 110.214 -179.147 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.65 ' O ' ' N ' ' A' ' 67' ' ' SER . 15.4 p -137.36 159.15 70.62 Favored Pre-proline 0 N--CA 1.491 1.616 0 N-CA-C 107.043 -1.466 . . . . 0.0 107.043 178.562 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_exo -51.2 58.73 0.02 OUTLIER 'Trans proline' 0 N--CA 1.504 2.147 0 C-N-CA 122.247 1.965 . . . . 0.0 113.688 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.65 ' N ' ' O ' ' A' ' 65' ' ' THR . 3.1 m -140.98 -64.07 0.46 Allowed 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.762 -1.211 . . . . 0.0 109.417 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 30.4 p -141.76 149.97 55.2 Favored Pre-proline 0 N--CA 1.5 2.064 0 O-C-N 121.212 -0.93 . . . . 0.0 109.501 179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -84.57 164.11 12.44 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 122.707 2.271 . . . . 0.0 112.717 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.5 t -122.26 130.12 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 74.6 m-80 -96.77 136.08 37.82 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 120.806 -1.184 . . . . 0.0 111.11 -178.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.495 ' O ' ' CZ ' ' A' ' 50' ' ' PHE . 1.6 p -81.11 -51.55 8.34 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 178.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.466 ' N ' ' OG1' ' A' ' 72' ' ' THR . 78.9 m-20 -81.46 56.1 2.83 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 66.4 tt0 -47.69 -47.23 29.81 Favored 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 119.843 -0.743 . . . . 0.0 109.553 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -106.12 97.68 7.46 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 82.2 mt -80.31 -23.83 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.228 -0.92 . . . . 0.0 109.834 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 22.9 m120 -60.13 -48.82 80.11 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 120.95 -1.094 . . . . 0.0 109.537 -178.265 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 13.8 ptpt -68.28 -38.63 81.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.676 -1.265 . . . . 0.0 109.223 179.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.609 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.4 OUTLIER -62.2 -45.7 92.21 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.012 -1.055 . . . . 0.0 108.834 179.47 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 9.5 t-20 -60.05 -34.17 73.03 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.63 -1.293 . . . . 0.0 109.499 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.3 tmtt? -64.86 -50.02 68.26 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.197 -0.939 . . . . 0.0 110.727 -179.055 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.4 p -113.2 -27.66 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.229 -0.919 . . . . 0.0 111.545 -178.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.609 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.37 157.69 26.82 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 179.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.0 t -103.52 116.49 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 179.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.645 ' NE2' HD21 ' A' ' 53' ' ' ASN . 97.7 mt-30 -70.9 -47.83 57.01 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.101 -1.0 . . . . 0.0 111.904 -178.641 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 58.6 tttp -115.58 142.81 46.23 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.239 -0.913 . . . . 0.0 110.798 -178.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.454 ' CZ ' ' NE2' ' A' ' 18' ' ' GLN . 62.3 t80 -120.66 130.07 53.96 Favored 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 178.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 2.2 tpp180 -139.44 127.51 22.38 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.082 -1.011 . . . . 0.0 110.422 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -125.45 135.36 52.26 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.875 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 9.8 mp -119.93 129.7 54.46 Favored 'General case' 0 N--CA 1.504 2.231 0 O-C-N 121.306 -0.871 . . . . 0.0 108.745 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 25.2 p -129.28 127.33 40.96 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 121.267 -0.896 . . . . 0.0 110.821 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -133.15 156.21 47.89 Favored 'General case' 0 N--CA 1.502 2.157 0 CA-C-O 121.222 0.534 . . . . 0.0 110.169 179.479 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 69.0 m95 -70.4 138.45 51.3 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.201 -0.937 . . . . 0.0 108.679 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 27.7 t -111.26 120.03 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.382 -0.824 . . . . 0.0 109.89 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 162.37 -176.41 38.73 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 47.1 t -64.84 129.93 41.57 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.064 -1.257 . . . . 0.0 108.519 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 35.2 ttm180 -89.17 132.35 34.88 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.286 -0.884 . . . . 0.0 109.636 -179.605 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 20.2 t . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.536 -179.968 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.856 0 N-CA-C 119.436 2.534 . . . . 0.0 119.436 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.04 -143.65 48.62 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.0 m -80.64 -9.21 59.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.393 -1.063 . . . . 0.0 109.181 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.87 168.32 18.64 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.091 -1.604 . . . . 0.0 109.091 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 34.6 t90 -65.77 141.44 58.32 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.215 -1.168 . . . . 0.0 110.473 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . 0.619 ' C ' ' H ' ' A' ' 8' ' ' ASP . 10.3 m120 -131.17 123.06 27.72 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 177.542 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -61.95 2.56 0.21 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.87 -1.144 . . . . 0.0 108.369 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.619 ' H ' ' C ' ' A' ' 6' ' ' ASN . 84.0 m-20 -60.9 -39.76 90.56 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.754 -0.591 . . . . 0.0 111.346 -179.079 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -84.27 0.33 49.38 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.861 -1.149 . . . . 0.0 110.195 -178.095 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.4 t -106.1 131.54 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.252 -0.905 . . . . 0.0 108.703 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.522 ' O ' ' N ' ' A' ' 13' ' ' SER . 4.3 m-20 -99.91 108.61 52.53 Favored Pre-proline 0 N--CA 1.492 1.662 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 179.634 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -44.72 -12.01 0.05 OUTLIER 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 121.931 1.754 . . . . 0.0 112.35 -179.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.522 ' N ' ' O ' ' A' ' 11' ' ' ASP . 88.1 p -69.59 -38.61 77.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.258 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.51 ' N ' ' HG ' ' A' ' 13' ' ' SER . 98.7 mm-40 -91.14 -6.79 53.1 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 120.947 -1.095 . . . . 0.0 109.967 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.811 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 22.4 t -70.66 -24.89 62.78 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.191 -0.943 . . . . 0.0 109.804 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -120.8 151.25 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.152 0 O-C-N 121.569 -0.707 . . . . 0.0 110.27 -179.059 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -118.58 137.15 53.45 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.766 -0.584 . . . . 0.0 109.61 -179.54 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -100.35 121.63 41.81 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.205 -0.934 . . . . 0.0 110.353 -179.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 83.5 p -121.21 127.56 51.58 Favored 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.73 -111.13 1.72 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.6 m -127.88 36.51 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.084 0 O-C-N 121.451 -1.029 . . . . 0.0 109.605 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -131.6 160.02 36.57 Favored 'General case' 0 N--CA 1.5 2.051 0 CA-C-O 121.646 0.736 . . . . 0.0 110.62 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -119.67 139.96 51.4 Favored 'General case' 0 N--CA 1.498 1.966 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 80.7 p -134.94 151.13 50.58 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.328 -0.857 . . . . 0.0 109.825 -179.2 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 48.3 t80 -87.51 122.88 31.79 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.393 -0.817 . . . . 0.0 109.311 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -82.66 88.28 6.7 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.344 -0.847 . . . . 0.0 109.77 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 59.7 p -80.5 -9.9 59.75 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.106 -0.996 . . . . 0.0 109.626 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -56.66 -31.8 60.89 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -84.24 114.23 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.06 -1.259 . . . . 0.0 107.989 179.281 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.545 ' O ' ' N ' ' A' ' 34' ' ' GLN . 59.7 m -60.05 -40.04 88.04 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.237 -0.914 . . . . 0.0 111.132 -178.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 6.1 m -52.09 -40.69 30.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 120.946 -1.096 . . . . 0.0 110.653 -178.115 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.811 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 55.3 m -69.97 -44.51 69.33 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.818 -1.176 . . . . 0.0 109.869 -179.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 31.1 ttm -81.07 -13.0 59.18 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.023 -1.048 . . . . 0.0 109.623 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.545 ' N ' ' O ' ' A' ' 30' ' ' SER . 62.5 tt0 -61.44 -40.03 92.98 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 179.207 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.33 -39.96 29.79 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.0 tp -59.84 -43.52 94.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.14 -1.212 . . . . 0.0 108.407 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 44.5 t30 -62.15 -40.22 95.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.507 -0.745 . . . . 0.0 109.775 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -69.07 -26.56 65.01 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.361 -0.837 . . . . 0.0 110.308 -179.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 91.17 18.07 47.99 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.854 -1.165 . . . . 0.0 110.804 179.147 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 40.1 mtmt -97.92 -0.75 44.34 Favored 'General case' 0 N--CA 1.495 1.793 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 178.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.451 HG13 ' H ' ' A' ' 43' ' ' GLY . 59.7 t -136.12 156.72 37.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 115.021 -0.99 . . . . 0.0 108.511 -179.669 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -115.74 -10.17 11.8 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.273 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.451 ' H ' HG13 ' A' ' 41' ' ' VAL . . . 139.55 -152.14 22.34 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 108.298 -1.921 . . . . 0.0 108.298 -179.566 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.5 p -125.06 129.44 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 121.068 -1.254 . . . . 0.0 109.647 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 t -87.42 134.6 33.57 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.1 p -130.06 131.18 66.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.405 -0.81 . . . . 0.0 109.359 179.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 53.1 p -121.21 149.72 42.41 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -140.49 144.4 14.77 Favored Glycine 0 N--CA 1.502 3.051 0 C-N-CA 119.603 -1.284 . . . . 0.0 110.751 -178.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 96.0 t -126.37 128.9 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.513 -0.993 . . . . 0.0 109.429 178.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -102.21 120.4 40.4 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -95.5 126.34 40.72 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.246 -0.909 . . . . 0.0 109.314 -179.74 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.51 ' O ' ' N ' ' A' ' 54' ' ' ASP . 55.0 m-85 -109.51 126.5 53.61 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.383 -0.823 . . . . 0.0 109.257 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.447 ' C ' ' H ' ' A' ' 55' ' ' GLY . 17.9 t-20 -45.94 -17.3 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.123 -0.986 . . . . 0.0 109.167 179.263 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.51 ' N ' ' O ' ' A' ' 52' ' ' TYR . 39.9 t0 -67.67 0.96 2.74 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.501 -0.75 . . . . 0.0 109.013 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.447 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 77.76 27.77 58.19 Favored Glycine 0 N--CA 1.494 2.5 0 O-C-N 121.206 -0.934 . . . . 0.0 110.769 178.689 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.5 p -123.15 150.02 43.81 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.389 -1.065 . . . . 0.0 109.78 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 39.6 p -132.58 133.99 44.37 Favored 'General case' 0 N--CA 1.501 2.101 0 CA-C-O 121.618 0.723 . . . . 0.0 109.669 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 48.3 t -119.89 142.82 48.35 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 178.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 37.9 t-20 -132.49 125.72 31.3 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 120.994 -1.066 . . . . 0.0 109.488 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -117.72 128.27 54.73 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.0 ttpm? -110.82 143.78 40.86 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -158.03 159.34 29.91 Favored Glycine 0 C--N 1.285 -2.282 0 N-CA-C 108.763 -1.735 . . . . 0.0 108.763 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 56.0 t -109.55 124.27 66.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.487 -1.007 . . . . 0.0 108.789 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.9 t -90.21 118.94 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.421 -0.799 . . . . 0.0 109.321 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.549 ' C ' ' H ' ' A' ' 67' ' ' SER . 30.6 p -132.89 151.57 78.27 Favored Pre-proline 0 N--CA 1.492 1.659 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 178.637 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -48.75 -5.51 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 121.295 1.33 . . . . 0.0 111.39 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.549 ' H ' ' C ' ' A' ' 65' ' ' THR . 19.7 t -75.62 -57.33 3.95 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.152 -0.968 . . . . 0.0 110.422 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 56.4 p -147.68 151.82 39.95 Favored Pre-proline 0 N--CA 1.502 2.142 0 O-C-N 120.855 -1.153 . . . . 0.0 110.107 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -84.67 167.33 11.55 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.939 2.426 . . . . 0.0 112.265 178.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.2 t -102.74 131.09 51.68 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -97.39 122.98 41.06 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.334 -0.853 . . . . 0.0 111.976 -177.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 1.2 p -93.37 -0.21 56.66 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 178.125 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.43 ' O ' ' OD1' ' A' ' 73' ' ' ASN . 41.3 t-20 -75.4 54.03 0.71 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.57 -0.706 . . . . 0.0 109.254 -179.631 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -62.96 -87.18 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -114.35 84.41 2.05 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.497 -0.752 . . . . 0.0 109.226 178.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 10.1 tp -70.11 -32.85 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.121 -0.987 . . . . 0.0 109.727 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -60.02 -47.39 86.04 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.1 -178.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.421 ' CG ' ' N ' ' A' ' 79' ' ' THR . 15.1 ptmt -63.63 -39.82 95.33 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.707 -1.246 . . . . 0.0 108.215 179.288 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.582 ' O ' ' N ' ' A' ' 83' ' ' GLY . 2.0 m -59.96 -40.71 89.96 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -179.614 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -66.59 -31.8 72.74 Favored 'General case' 0 C--N 1.295 -1.792 0 O-C-N 120.579 -1.326 . . . . 0.0 109.382 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 7.6 tmtm? -69.84 -44.28 70.22 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.915 -1.116 . . . . 0.0 110.378 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -110.58 -26.44 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.377 0 O-C-N 121.206 -0.934 . . . . 0.0 111.349 -178.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.47 164.29 37.6 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 71.4 t -111.21 128.16 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 93.1 mm-40 -81.27 -65.5 1.0 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.086 -1.009 . . . . 0.0 110.996 -178.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 45.1 tptt -113.92 141.76 46.97 Favored 'General case' 0 N--CA 1.503 2.181 0 O-C-N 121.438 -0.789 . . . . 0.0 110.639 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -120.17 131.25 54.93 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 95.5 mtt180 -131.8 130.8 42.27 Favored 'General case' 0 N--CA 1.508 2.432 0 O-C-N 121.094 -1.004 . . . . 0.0 110.524 -179.231 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -122.68 137.89 54.77 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.675 -0.64 . . . . 0.0 109.894 179.649 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 60.3 tp -120.01 133.31 55.58 Favored 'General case' 0 N--CA 1.506 2.355 0 O-C-N 121.298 -0.876 . . . . 0.0 109.058 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.9 p -128.7 126.11 39.39 Favored 'General case' 0 N--CA 1.504 2.227 0 CA-C-O 121.581 0.705 . . . . 0.0 110.485 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -133.24 159.21 40.88 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.759 -0.588 . . . . 0.0 110.198 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 50.7 m95 -75.66 136.46 40.42 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.372 -0.83 . . . . 0.0 108.775 178.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 21.4 t -106.79 120.81 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.485 -0.759 . . . . 0.0 109.304 -179.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 143.81 61.03 0.02 OUTLIER Glycine 0 N--CA 1.494 2.537 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 48.3 m -69.79 148.62 48.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.194 -1.18 . . . . 0.0 109.7 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 69.5 ttp85 -63.55 136.42 57.54 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.279 -0.888 . . . . 0.0 109.283 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 24.3 p . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 118.085 -0.96 . . . . 0.0 109.432 -179.917 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.853 0 N-CA-C 119.511 2.564 . . . . 0.0 119.511 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -93.09 -3.5 65.47 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 26.4 t -112.94 125.14 54.06 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.421 -1.047 . . . . 0.0 109.776 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -174.79 -165.76 31.65 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 88.7 t90 -74.21 121.48 21.3 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.327 -1.102 . . . . 0.0 109.833 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . 0.531 ' C ' ' H ' ' A' ' 8' ' ' ASP . 77.7 m-20 -127.82 23.87 6.14 Favored 'General case' 0 N--CA 1.493 1.7 0 CA-C-O 121.419 0.628 . . . . 0.0 109.701 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 59.27 0.97 0.21 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.34 -0.85 . . . . 0.0 109.378 -179.602 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.531 ' H ' ' C ' ' A' ' 6' ' ' ASN . 96.1 m-20 -93.11 -25.7 17.77 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.113 -0.992 . . . . 0.0 110.759 -179.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -90.05 4.83 49.07 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.846 -1.159 . . . . 0.0 109.916 -179.18 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.9 t -118.16 131.05 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.379 -0.826 . . . . 0.0 109.686 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 59.0 m-20 -81.96 133.91 50.71 Favored Pre-proline 0 C--N 1.301 -1.512 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 177.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -74.79 -15.34 21.34 Favored 'Trans proline' 0 N--CA 1.494 1.535 0 C-N-CA 121.848 1.699 . . . . 0.0 112.12 -178.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 79.8 p -69.05 -28.83 66.9 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.51 -0.744 . . . . 0.0 110.4 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -78.94 -11.32 60.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.121 -0.987 . . . . 0.0 109.307 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.812 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 11.7 t -69.93 -39.89 75.85 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.062 -1.024 . . . . 0.0 109.81 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -121.38 142.22 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.108 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 179.504 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -115.85 147.48 40.99 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.476 -0.765 . . . . 0.0 109.697 -178.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -85.05 113.0 21.14 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.43 -0.793 . . . . 0.0 108.953 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.5 m -103.36 120.04 40.03 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.92 -99.78 0.04 OUTLIER Glycine 0 N--CA 1.488 2.148 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 -179.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 t -128.32 20.2 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.456 -1.026 . . . . 0.0 109.195 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -129.61 167.88 17.27 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 121.357 -0.839 . . . . 0.0 110.732 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -124.31 145.21 49.55 Favored 'General case' 0 N--CA 1.501 2.079 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 40.5 p -136.8 153.65 50.76 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.272 -0.893 . . . . 0.0 110.051 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.414 ' HH ' ' CD1' ' A' ' 36' ' ' LEU . 44.2 t80 -85.59 123.28 30.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.584 -0.698 . . . . 0.0 109.695 -179.062 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -88.5 83.83 6.8 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.301 -0.875 . . . . 0.0 110.139 -179.578 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 77.7 p -79.85 -4.89 54.15 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 120.991 -1.068 . . . . 0.0 108.989 179.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.73 -40.1 96.14 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.0 m -72.97 139.97 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.008 -1.289 . . . . 0.0 108.862 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 55.2 p -69.04 -25.55 64.53 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.394 -0.816 . . . . 0.0 110.587 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 54.0 t -60.03 -43.11 91.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.011 -1.056 . . . . 0.0 110.089 -179.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.812 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.0 m -60.99 -39.95 91.62 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.067 -1.02 . . . . 0.0 110.464 -179.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.2 mmt -80.47 -14.44 58.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.934 -1.104 . . . . 0.0 110.037 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -61.07 -42.56 98.72 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.058 -1.026 . . . . 0.0 108.914 179.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.2 -47.42 9.17 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.414 ' CD1' ' HH ' ' A' ' 25' ' ' TYR . 11.7 mt -61.26 -41.66 97.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.074 -1.251 . . . . 0.0 110.14 -179.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -65.52 -39.86 92.31 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.166 -0.959 . . . . 0.0 109.333 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -66.86 -29.66 69.62 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.379 -0.826 . . . . 0.0 109.494 -179.601 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.28 22.29 54.76 Favored Glycine 0 N--CA 1.494 2.557 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 31.2 ttmt -107.61 -3.51 19.21 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 179.218 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 43' ' ' GLY . 86.3 t -133.68 160.27 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.305 -179.183 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 81.5 mtt85 -121.79 -8.1 8.97 Favored 'General case' 0 N--CA 1.499 2.023 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 178.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.426 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.34 -152.86 23.14 Favored Glycine 0 N--CA 1.499 2.86 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 99.2 t -126.53 130.0 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.322 0 O-C-N 121.066 -1.255 . . . . 0.0 109.667 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.1 t -84.43 137.86 33.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.319 -0.863 . . . . 0.0 109.608 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 7.5 p -132.7 134.19 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.43 -0.794 . . . . 0.0 108.943 179.034 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 86.7 p -121.93 146.91 46.67 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 179.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -135.99 131.24 5.64 Favored Glycine 0 N--CA 1.498 2.811 0 C-N-CA 119.964 -1.112 . . . . 0.0 110.525 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 53.7 t -120.96 127.02 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.43 ' CE1' ' OG1' ' A' ' 72' ' ' THR . 23.8 m-85 -105.47 116.05 31.3 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -92.97 137.53 32.28 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.361 -0.837 . . . . 0.0 109.879 -178.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.42 ' OH ' ' OE1' ' A' ' 74' ' ' GLN . 74.0 m-85 -120.11 137.08 54.35 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.367 -0.833 . . . . 0.0 109.676 179.347 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.422 ' C ' ' H ' ' A' ' 55' ' ' GLY . 18.7 t-20 -47.29 -21.32 0.27 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.475 -0.766 . . . . 0.0 109.531 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.414 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 10.4 t70 -68.47 0.95 3.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.267 -0.896 . . . . 0.0 109.208 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.422 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 75.61 17.93 79.94 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.09 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.9 p -111.65 154.39 24.98 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.444 -1.033 . . . . 0.0 108.932 179.329 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 32.7 p -140.44 148.01 40.53 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.38 -0.825 . . . . 0.0 110.525 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 54.9 m -117.86 147.58 42.94 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 106.046 -1.835 . . . . 0.0 106.046 177.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -139.97 116.17 10.5 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.974 -1.079 . . . . 0.0 109.705 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -115.99 122.42 45.2 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 178.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -112.26 145.57 39.71 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -165.92 178.9 40.42 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 -179.466 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 30.4 t -119.42 127.53 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.487 -1.008 . . . . 0.0 109.593 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 t -89.46 118.9 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.436 -0.79 . . . . 0.0 109.875 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.45 ' O ' ' N ' ' A' ' 67' ' ' SER . 26.6 p -138.14 150.05 65.7 Favored Pre-proline 0 N--CA 1.494 1.727 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -44.55 -19.7 0.28 Allowed 'Trans proline' 0 C--N 1.311 -1.4 0 C-N-CA 121.111 1.207 . . . . 0.0 111.414 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.45 ' N ' ' O ' ' A' ' 65' ' ' THR . 69.9 m -70.05 -46.16 65.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.512 -0.743 . . . . 0.0 111.441 -178.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -148.47 141.31 15.25 Favored Pre-proline 0 N--CA 1.504 2.235 0 O-C-N 120.664 -1.273 . . . . 0.0 110.945 -178.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -86.95 165.09 8.74 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.087 2.524 . . . . 0.0 112.229 178.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 72.6 t -113.09 128.34 69.9 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.203 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -104.52 140.61 37.73 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.285 -0.885 . . . . 0.0 111.818 -177.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.43 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.0 OUTLIER -109.9 19.17 19.36 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.024 -1.473 . . . . 0.0 107.024 177.502 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 46.5 t-20 -71.05 55.39 0.19 Allowed 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.637 -0.664 . . . . 0.0 109.522 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.42 ' OE1' ' OH ' ' A' ' 52' ' ' TYR . 55.0 tt0 -49.61 169.35 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.051 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -59.07 123.77 17.72 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.713 -1.242 . . . . 0.0 108.939 -179.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 43.3 mm -80.16 -21.61 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.433 -0.792 . . . . 0.0 110.694 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -60.01 -47.73 84.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.673 -1.267 . . . . 0.0 110.069 -179.009 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 9.9 ptpt -64.14 -39.26 93.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.966 -1.084 . . . . 0.0 108.488 179.206 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.549 ' O ' ' N ' ' A' ' 83' ' ' GLY . 30.2 m -60.0 -45.04 94.03 Favored 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.683 0.754 . . . . 0.0 109.438 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -62.01 -36.16 80.7 Favored 'General case' 0 C--N 1.293 -1.887 0 O-C-N 120.949 -1.095 . . . . 0.0 109.972 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 15.0 tmtt? -70.31 -44.83 67.5 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.102 -0.999 . . . . 0.0 111.119 -178.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.6 p -117.51 -29.04 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.416 0 O-C-N 121.135 -0.978 . . . . 0.0 111.543 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.549 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.0 158.26 33.92 Favored Glycine 0 N--CA 1.497 2.702 0 O-C-N 120.616 -1.302 . . . . 0.0 110.571 179.35 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 56.1 t -100.04 123.44 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -77.69 -65.0 1.02 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.181 -0.949 . . . . 0.0 111.365 -178.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -115.96 152.45 33.45 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.124 -0.985 . . . . 0.0 111.814 -178.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 64.8 t80 -120.94 130.92 54.05 Favored 'General case' 0 N--CA 1.5 2.033 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -136.86 130.2 31.38 Favored 'General case' 0 N--CA 1.507 2.39 0 O-C-N 120.814 -1.179 . . . . 0.0 110.843 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.68 135.44 53.05 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.2 tt -119.77 129.1 54.31 Favored 'General case' 0 N--CA 1.504 2.228 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.5 p -129.1 121.59 28.13 Favored 'General case' 0 N--CA 1.505 2.279 0 O-C-N 121.414 -0.804 . . . . 0.0 111.433 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -133.32 159.82 39.14 Favored 'General case' 0 N--CA 1.502 2.165 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.176 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -73.6 144.06 46.13 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.918 -1.113 . . . . 0.0 109.278 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.9 t -114.2 123.71 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.344 -0.848 . . . . 0.0 109.326 179.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 116.16 -0.11 20.86 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.2 m -95.2 139.29 31.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.288 -1.125 . . . . 0.0 109.237 179.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 24.9 ttm180 -97.03 121.3 38.77 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.129 -0.982 . . . . 0.0 109.642 -179.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 43.1 t . . . . . 0 N--CA 1.492 1.656 0 CA-C-O 117.844 -1.074 . . . . 0.0 109.651 -179.773 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.914 0 N-CA-C 119.732 2.653 . . . . 0.0 119.732 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -83.29 -78.65 1.06 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 72.2 m -76.31 155.96 33.79 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.281 -1.129 . . . . 0.0 110.142 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 177.94 175.99 45.56 Favored Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 89.3 t90 -77.41 115.62 17.32 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.035 -1.274 . . . . 0.0 109.772 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -131.04 19.2 4.97 Favored 'General case' 0 N--CA 1.49 1.534 0 CA-C-O 121.614 0.721 . . . . 0.0 109.1 179.538 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 56.55 13.32 1.31 Allowed 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -93.62 -28.38 16.04 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.298 -0.876 . . . . 0.0 109.914 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -90.57 0.09 57.48 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.187 -0.946 . . . . 0.0 109.397 -179.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.5 t -109.04 127.8 65.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 O-C-N 121.495 -0.753 . . . . 0.0 109.801 -179.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 60.4 m-20 -87.06 132.12 42.66 Favored Pre-proline 0 N--CA 1.489 1.515 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 178.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -72.84 -14.51 26.73 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 121.633 1.555 . . . . 0.0 112.154 -178.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 30.3 t -61.57 -40.17 93.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.142 -0.974 . . . . 0.0 110.364 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 65.4 mt-30 -81.46 -11.29 59.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.043 -1.035 . . . . 0.0 110.302 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.801 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 35.5 m -70.11 -30.02 67.11 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.948 -1.095 . . . . 0.0 108.939 179.273 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -122.11 140.51 45.79 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -123.95 143.3 50.48 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.528 -0.732 . . . . 0.0 109.398 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -87.5 130.68 34.62 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.086 -1.009 . . . . 0.0 109.456 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 53.6 m -118.9 128.41 54.4 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 46.48 -107.12 0.17 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.7 m -121.78 19.9 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.67 -0.9 . . . . 0.0 109.977 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -130.68 164.99 23.81 Favored 'General case' 0 N--CA 1.503 2.19 0 O-C-N 121.389 -0.819 . . . . 0.0 110.266 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -117.6 140.67 49.33 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 79.2 p -139.94 150.93 45.12 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.305 -0.872 . . . . 0.0 109.044 178.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 8.8 t80 -78.53 128.78 34.03 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.375 -0.828 . . . . 0.0 109.371 -179.412 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -85.69 83.12 7.96 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.341 -0.849 . . . . 0.0 109.257 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.479 ' C ' ' H ' ' A' ' 29' ' ' VAL . 97.6 p -79.08 -5.05 53.12 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.199 -0.938 . . . . 0.0 109.3 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.17 -11.73 0.69 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.479 ' H ' ' C ' ' A' ' 27' ' ' SER . 29.0 m -108.9 127.39 65.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.518 -0.989 . . . . 0.0 108.776 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 64.5 m -70.07 -27.48 64.66 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.42 -0.8 . . . . 0.0 110.451 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.7 m -60.01 -40.3 82.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.036 -1.04 . . . . 0.0 111.204 -178.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.801 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 97.1 m -66.39 -40.24 89.54 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.546 -1.347 . . . . 0.0 110.074 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 70.5 mtp -80.98 -10.08 59.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.953 -1.092 . . . . 0.0 109.603 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -61.23 -40.46 94.1 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -80.46 -51.27 4.99 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.9 tt -60.14 -41.53 92.92 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.105 -1.232 . . . . 0.0 109.726 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 -60.1 -40.22 88.85 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.018 -1.051 . . . . 0.0 109.736 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -79.01 -6.04 55.37 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.348 -0.845 . . . . 0.0 109.487 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.56 29.25 49.37 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.941 -1.123 . . . . 0.0 110.374 178.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -104.48 -9.54 18.31 Favored 'General case' 0 N--CA 1.496 1.848 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.444 ' CG1' ' H ' ' A' ' 43' ' ' GLY . 70.9 t -136.15 161.2 37.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.427 ' N ' ' CG1' ' A' ' 41' ' ' VAL . 57.9 ttm-85 -122.95 -7.65 8.38 Favored 'General case' 0 N--CA 1.495 1.8 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.444 ' H ' ' CG1' ' A' ' 41' ' ' VAL . . . 138.3 -161.16 25.63 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 95.0 t -122.5 130.13 74.74 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.335 -1.097 . . . . 0.0 109.103 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.8 m -86.3 136.79 33.02 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.051 -1.03 . . . . 0.0 108.303 179.364 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 6.0 m -132.08 133.45 60.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.644 -0.66 . . . . 0.0 109.543 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 57.3 p -122.65 142.46 50.64 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 179.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -131.3 143.06 14.48 Favored Glycine 0 N--CA 1.503 3.151 0 C-N-CA 120.085 -1.055 . . . . 0.0 111.113 -178.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 92.6 t -126.25 129.99 72.03 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.852 -0.793 . . . . 0.0 109.405 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -103.97 120.05 40.23 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 62.6 m-85 -96.64 123.22 40.24 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.354 -0.842 . . . . 0.0 109.405 -179.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.58 ' CD1' ' NZ ' ' A' ' 78' ' ' LYS . 96.9 m-85 -109.03 128.03 54.61 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.607 -0.683 . . . . 0.0 109.634 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.474 ' C ' ' H ' ' A' ' 55' ' ' GLY . 0.5 OUTLIER -45.58 -17.27 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.27 -0.894 . . . . 0.0 109.324 179.149 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 52' ' ' TYR . 22.1 t0 -67.42 1.54 2.21 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.474 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 75.36 23.42 73.65 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.346 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.9 p -121.76 149.85 42.69 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.499 -1.001 . . . . 0.0 110.002 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.1 p -134.01 138.08 45.16 Favored 'General case' 0 N--CA 1.499 2.016 0 CA-C-O 121.824 0.821 . . . . 0.0 110.174 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.8 t -119.78 143.2 47.97 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 58.6 t-20 -134.44 129.84 35.89 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 120.624 -1.297 . . . . 0.0 110.127 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -117.06 128.69 55.4 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -113.98 142.7 45.83 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -165.42 170.58 40.39 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.9 t -113.96 126.45 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.112 0 O-C-N 121.544 -0.974 . . . . 0.0 109.408 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 72.5 t -96.45 117.92 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.075 -1.015 . . . . 0.0 109.906 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.52 ' O ' ' N ' ' A' ' 67' ' ' SER . 24.3 p -126.69 150.12 70.25 Favored Pre-proline 0 N--CA 1.501 2.088 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 179.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_exo -37.41 -22.39 0.05 OUTLIER 'Trans proline' 0 N--CA 1.49 1.306 0 C-N-CA 122.227 1.951 . . . . 0.0 112.984 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.52 ' N ' ' O ' ' A' ' 65' ' ' THR . 9.0 t -114.1 -16.06 12.16 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.275 -0.891 . . . . 0.0 111.556 -178.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 98.5 m -119.6 106.53 41.99 Favored Pre-proline 0 N--CA 1.502 2.156 0 O-C-N 120.976 -1.077 . . . . 0.0 110.193 -179.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -91.41 163.48 3.62 Favored 'Trans proline' 0 N--CA 1.492 1.416 0 C-N-CA 122.657 2.238 . . . . 0.0 112.347 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.8 t -127.22 130.03 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.293 0 N-CA-C 108.714 -0.846 . . . . 0.0 108.714 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -100.16 132.31 45.61 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 121.209 -0.932 . . . . 0.0 111.873 -178.094 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.436 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.0 OUTLIER -105.33 19.96 19.69 Favored 'General case' 0 N--CA 1.498 1.938 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.602 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -67.44 54.37 0.06 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.777 -0.577 . . . . 0.0 109.651 -179.256 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.449 ' NE2' ' O ' ' A' ' 75' ' ' ASP . 0.0 OUTLIER -48.0 166.71 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.285 -0.885 . . . . 0.0 108.831 179.517 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.449 ' O ' ' NE2' ' A' ' 74' ' ' GLN . 78.3 m-20 -57.09 117.83 4.41 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.006 -1.058 . . . . 0.0 109.538 -178.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 47.7 mm -69.59 -39.48 78.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.768 -0.582 . . . . 0.0 109.582 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -56.15 -41.47 75.44 Favored 'General case' 0 N--CA 1.488 1.425 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.58 ' NZ ' ' CD1' ' A' ' 52' ' ' TYR . 28.3 tttm -62.84 -49.47 74.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.317 -0.865 . . . . 0.0 108.884 178.323 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.582 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.0 OUTLIER -67.61 -42.16 82.84 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.535 -0.728 . . . . 0.0 110.062 -179.099 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -60.96 -34.21 74.39 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 120.641 -1.287 . . . . 0.0 110.902 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -70.99 -43.54 67.79 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.887 -1.133 . . . . 0.0 111.243 -178.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.1 p -115.98 -27.78 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.39 -0.819 . . . . 0.0 111.231 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.87 166.01 40.9 Favored Glycine 0 N--CA 1.488 2.162 0 O-C-N 120.675 -1.266 . . . . 0.0 110.371 178.742 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.9 t -111.06 124.91 68.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -81.34 -64.19 1.24 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.162 -0.962 . . . . 0.0 111.073 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -114.22 143.17 45.27 Favored 'General case' 0 N--CA 1.509 2.48 0 O-C-N 121.167 -0.958 . . . . 0.0 111.299 -178.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 74.4 t80 -120.5 134.43 55.27 Favored 'General case' 0 N--CA 1.505 2.291 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 178.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 78.9 mtp180 -136.45 129.0 30.47 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 120.968 -1.083 . . . . 0.0 110.944 -178.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.66 132.66 53.39 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.729 -0.607 . . . . 0.0 109.672 179.047 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 7.7 mp -108.83 129.46 55.4 Favored 'General case' 0 N--CA 1.503 2.206 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 179.138 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.9 p -124.2 121.46 35.15 Favored 'General case' 0 N--CA 1.507 2.384 0 O-C-N 121.313 -0.867 . . . . 0.0 110.575 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 53.4 tp10 -133.84 150.95 51.41 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.772 -0.58 . . . . 0.0 110.163 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 70.9 m95 -66.95 141.55 57.57 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.992 -1.067 . . . . 0.0 108.737 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 62.0 t -119.3 130.16 74.32 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.177 0 O-C-N 121.503 -0.748 . . . . 0.0 109.989 -179.204 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 115.83 -0.53 21.45 Favored Glycine 0 N--CA 1.501 3.0 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.338 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 54.6 p -85.34 117.98 24.6 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.237 -1.155 . . . . 0.0 108.905 179.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 78.2 mtp180 -87.94 139.95 29.99 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.159 -0.963 . . . . 0.0 109.482 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.9 t . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 118.125 -0.941 . . . . 0.0 109.556 -179.686 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.821 0 N-CA-C 119.353 2.501 . . . . 0.0 119.353 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 90.04 -10.01 75.43 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.325 -1.51 . . . . 0.0 109.325 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.4 m -61.07 144.54 53.3 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.374 -1.074 . . . . 0.0 109.088 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 177.77 -77.04 0.07 OUTLIER Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.573 -1.298 . . . . 0.0 109.936 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 14.7 t90 -60.23 139.97 57.27 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.154 -1.204 . . . . 0.0 109.874 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . 0.601 ' C ' ' H ' ' A' ' 8' ' ' ASP . 17.2 m120 -133.57 125.38 28.7 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 177.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -63.78 5.39 0.21 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.006 -1.059 . . . . 0.0 108.861 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.601 ' H ' ' C ' ' A' ' 6' ' ' ASN . 33.5 p-10 -72.81 -20.13 61.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.34 -0.85 . . . . 0.0 110.708 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.7 m120 -99.52 6.71 45.79 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.098 -1.001 . . . . 0.0 109.783 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 29.2 t -119.98 129.97 74.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.47 -0.769 . . . . 0.0 109.905 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.96 140.28 43.1 Favored Pre-proline 0 N--CA 1.489 1.486 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.21 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -71.48 -22.39 24.82 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 121.806 1.671 . . . . 0.0 111.975 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 76.9 p -69.32 -38.93 78.45 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.313 -0.867 . . . . 0.0 109.781 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 56.6 tt0 -70.04 -23.93 63.18 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.304 -0.873 . . . . 0.0 109.739 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.797 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 22.0 m -68.44 -28.54 67.14 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.888 . . . . 0.0 109.685 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.4 pp -116.49 139.1 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.402 -0.811 . . . . 0.0 109.227 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -118.04 147.84 42.84 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.553 -0.717 . . . . 0.0 109.731 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.681 HE22 ' N ' ' A' ' 22' ' ' GLN . 64.2 tp60 -99.58 117.73 34.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.649 -0.657 . . . . 0.0 109.266 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.464 ' O ' ' N ' ' A' ' 21' ' ' VAL . 14.6 t -110.45 118.29 35.88 Favored 'General case' 0 N--CA 1.497 1.902 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 179.023 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.03 -92.42 0.02 OUTLIER Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.727 -1.749 . . . . 0.0 108.727 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.464 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.4 t -140.41 30.52 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 O-C-N 121.328 -1.101 . . . . 0.0 109.564 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.681 ' N ' HE22 ' A' ' 18' ' ' GLN . 89.1 mt-30 -127.46 158.07 38.35 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.271 -0.893 . . . . 0.0 110.334 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . 0.528 ' CZ ' ' OE1' ' A' ' 18' ' ' GLN . 26.9 m-85 -119.74 134.73 55.12 Favored 'General case' 0 N--CA 1.498 1.963 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.1 p -139.97 150.45 44.5 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.225 -0.922 . . . . 0.0 109.833 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.6 t80 -78.99 127.5 32.06 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 57.9 t30 -82.81 81.52 8.51 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.068 -1.02 . . . . 0.0 109.777 -179.442 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 49.9 m -78.31 -5.98 53.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.168 -0.957 . . . . 0.0 109.068 179.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -58.36 -37.43 87.56 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.829 -1.308 . . . . 0.0 109.829 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.2 m -84.32 132.38 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.036 -1.273 . . . . 0.0 109.492 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.9 m -60.09 -39.42 86.04 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.642 -0.661 . . . . 0.0 111.622 -178.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 19.7 m -57.62 -42.99 82.56 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 120.849 -1.157 . . . . 0.0 111.369 -177.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.797 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 93.0 m -67.05 -39.99 87.05 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.45 -1.406 . . . . 0.0 109.412 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.1 tpt -79.99 -11.72 59.76 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.008 -1.058 . . . . 0.0 108.419 179.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 61.2 tt0 -65.41 -39.85 92.65 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.07 -46.59 15.79 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 23.7 mt -60.04 -50.11 75.02 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.213 -1.169 . . . . 0.0 109.943 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -61.08 -39.99 91.98 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.076 -1.015 . . . . 0.0 110.0 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.437 ' OE2' ' NZ ' ' A' ' 40' ' ' LYS . 79.3 tt0 -64.55 -29.82 70.85 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.331 -0.855 . . . . 0.0 109.297 -179.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 91.25 26.54 20.95 Favored Glycine 0 N--CA 1.496 2.638 0 O-C-N 121.161 -0.962 . . . . 0.0 110.765 179.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.437 ' NZ ' ' OE2' ' A' ' 38' ' ' GLU . 96.3 mttt -110.04 -1.86 17.35 Favored 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.444 HG12 ' H ' ' A' ' 43' ' ' GLY . 72.5 t -133.71 160.2 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 CA-C-O 121.756 0.788 . . . . 0.0 109.056 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.51 ' HE ' ' CG1' ' A' ' 94' ' ' VAL . 44.9 ttp180 -125.25 -5.98 7.18 Favored 'General case' 0 N--CA 1.494 1.772 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.673 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.444 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 134.09 -164.42 24.49 Favored Glycine 0 N--CA 1.503 3.136 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 94.6 t -120.07 130.01 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.4 0 CA-C-N 118.747 1.273 . . . . 0.0 110.126 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 38.0 t -79.63 134.08 36.43 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 14.7 p -130.04 131.3 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.382 -0.824 . . . . 0.0 109.684 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 60.7 p -122.56 147.03 46.88 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 179.288 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -142.36 136.01 6.97 Favored Glycine 0 N--CA 1.503 3.118 0 C-N-CA 119.409 -1.376 . . . . 0.0 111.04 -179.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.537 ' CG1' HH12 ' A' ' 88' ' ' ARG . 65.0 t -123.45 133.77 68.22 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.311 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -111.06 124.31 51.92 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.603 -0.686 . . . . 0.0 109.185 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.607 ' CD2' ' NH2' ' A' ' 88' ' ' ARG . 23.4 m-85 -95.1 126.06 40.17 Favored 'General case' 0 N--CA 1.504 2.266 0 O-C-N 120.807 -1.183 . . . . 0.0 109.247 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.452 ' C ' ' H ' ' A' ' 54' ' ' ASP . 37.3 m-85 -111.04 131.47 55.03 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -53.13 -14.61 0.67 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.907 -1.121 . . . . 0.0 108.184 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.452 ' H ' ' C ' ' A' ' 52' ' ' TYR . 34.2 t0 -68.72 -4.77 17.05 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.2 12.43 80.8 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.0 p -110.57 159.45 17.54 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.541 -0.976 . . . . 0.0 110.025 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 78.4 p -140.43 143.82 35.8 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.449 -0.782 . . . . 0.0 110.487 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.0 t -114.98 130.01 56.84 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 177.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 12.3 m-20 -130.55 116.94 18.85 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.946 -1.096 . . . . 0.0 109.594 -178.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.532 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 54.5 p90 -117.09 120.69 39.11 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 178.511 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.9 ttpt -110.09 144.06 39.23 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -173.39 -175.35 41.08 Favored Glycine 0 C--N 1.286 -2.226 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 66.3 t -120.53 129.77 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.658 -0.907 . . . . 0.0 109.702 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.432 ' O ' ' CG1' ' A' ' 64' ' ' VAL . 4.3 p -96.89 124.23 49.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.207 -0.933 . . . . 0.0 109.462 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.0 p -135.58 150.13 71.21 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_exo -40.77 -24.8 0.17 Allowed 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.012 1.808 . . . . 0.0 112.845 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.2 t -102.84 -22.78 13.83 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.26 -0.9 . . . . 0.0 110.983 -178.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 41.5 m -123.17 107.1 32.97 Favored Pre-proline 0 N--CA 1.504 2.255 0 O-C-N 121.146 -0.971 . . . . 0.0 109.945 -179.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -89.2 163.09 5.7 Favored 'Trans proline' 0 N--CA 1.491 1.337 0 C-N-CA 122.453 2.102 . . . . 0.0 112.445 179.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.2 t -120.04 127.66 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 -103.99 130.89 51.67 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.306 -0.871 . . . . 0.0 110.805 -178.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.27 9.68 41.6 Favored 'General case' 0 N--CA 1.5 2.057 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 178.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 48.7 t-20 -76.36 56.81 1.11 Allowed 'General case' 0 N--CA 1.486 1.338 0 O-C-N 121.598 -0.689 . . . . 0.0 109.878 -179.004 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.508 ' NE2' ' N ' ' A' ' 75' ' ' ASP . 0.0 OUTLIER -63.96 -156.07 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 178.544 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.508 ' N ' ' NE2' ' A' ' 74' ' ' GLN . 76.2 m-20 -73.4 101.39 3.46 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 120.575 -1.328 . . . . 0.0 108.583 179.571 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 90.6 mt -79.95 -9.34 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.493 -0.754 . . . . 0.0 109.959 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -59.12 -43.85 91.97 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.98 -1.075 . . . . 0.0 109.337 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 10.1 ptpt -69.94 -39.2 76.23 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.947 -1.096 . . . . 0.0 109.648 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.593 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.8 OUTLIER -60.14 -47.85 84.17 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.764 -1.21 . . . . 0.0 108.266 179.808 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 44.6 t-20 -60.04 -35.07 74.31 Favored 'General case' 0 C--N 1.296 -1.718 0 O-C-N 120.825 -1.172 . . . . 0.0 108.501 178.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 83.4 tttt -64.37 -51.52 62.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.407 -0.808 . . . . 0.0 110.817 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.4 m -115.94 -26.59 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.395 0 O-C-N 121.139 -0.976 . . . . 0.0 111.803 -178.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 93.49 166.31 37.79 Favored Glycine 0 N--CA 1.492 2.43 0 O-C-N 120.65 -1.281 . . . . 0.0 110.328 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 59.7 t -110.8 130.02 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.945 -0.738 . . . . 0.0 109.127 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 36.2 tt0 -80.0 -66.57 0.86 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.119 -0.988 . . . . 0.0 110.462 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -115.71 139.98 49.63 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 121.26 -0.9 . . . . 0.0 111.48 -178.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.446 ' CA ' ' HE ' ' A' ' 88' ' ' ARG . 80.6 t80 -121.84 133.38 54.88 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.724 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.607 ' NH2' ' CD2' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -138.5 134.07 33.48 Favored 'General case' 0 N--CA 1.507 2.415 0 O-C-N 120.933 -1.104 . . . . 0.0 110.655 -179.874 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.64 136.2 53.72 Favored 'General case' 0 N--CA 1.498 1.927 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.52 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.28 131.91 56.34 Favored 'General case' 0 N--CA 1.505 2.292 0 O-C-N 121.365 -0.834 . . . . 0.0 109.427 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 40.3 p -127.09 125.31 41.05 Favored 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.358 -0.839 . . . . 0.0 110.579 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -133.18 151.61 51.96 Favored 'General case' 0 N--CA 1.504 2.242 0 O-C-N 121.783 -0.573 . . . . 0.0 110.338 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 71.0 m95 -70.37 140.73 52.19 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.146 -0.971 . . . . 0.0 108.882 178.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.51 ' CG1' ' HE ' ' A' ' 42' ' ' ARG . 38.4 t -117.03 124.8 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 O-C-N 121.399 -0.813 . . . . 0.0 109.315 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -173.81 47.55 0.15 Allowed Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.4 t -80.21 144.11 33.22 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.169 -1.195 . . . . 0.0 109.689 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 42.8 ttm180 -87.11 -18.08 31.31 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.345 -0.847 . . . . 0.0 109.364 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 25.2 p . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 118.022 -0.99 . . . . 0.0 109.654 -179.972 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.814 0 N-CA-C 119.457 2.543 . . . . 0.0 119.457 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -146.67 -54.33 0.02 OUTLIER Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.4 t -68.69 138.69 55.14 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.446 -1.031 . . . . 0.0 109.451 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.58 141.4 48.02 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 -179.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 88.5 t90 -86.89 130.03 34.63 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.413 -1.051 . . . . 0.0 109.099 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . 0.531 ' C ' ' H ' ' A' ' 8' ' ' ASP . 99.2 m-20 -129.84 12.66 5.77 Favored 'General case' 0 N--CA 1.495 1.814 0 CA-C-O 121.701 0.762 . . . . 0.0 109.696 179.295 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 57.91 2.44 0.17 Allowed 'General case' 0 C--N 1.295 -1.792 0 O-C-N 121.517 -0.739 . . . . 0.0 109.028 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.531 ' H ' ' C ' ' A' ' 6' ' ' ASN . 55.0 t0 -84.3 -26.34 28.61 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.27 -0.894 . . . . 0.0 110.362 -179.371 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.449 ' ND2' ' O ' ' A' ' 9' ' ' ASN . 0.9 OUTLIER -86.32 1.7 50.05 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.103 -0.998 . . . . 0.0 110.077 -179.307 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 2.0 t -118.15 126.92 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.483 -0.761 . . . . 0.0 109.332 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -77.91 140.33 62.5 Favored Pre-proline 0 C--N 1.3 -1.583 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 178.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -75.21 -13.74 20.89 Favored 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 121.347 1.365 . . . . 0.0 111.549 -179.275 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 38.3 t -60.73 -40.35 92.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.639 -0.663 . . . . 0.0 110.917 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -81.97 -10.03 59.38 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.0 -1.062 . . . . 0.0 109.673 -179.254 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.796 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 18.3 t -70.93 -30.9 67.34 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.125 -0.984 . . . . 0.0 109.335 179.357 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -123.86 151.89 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.204 0 O-C-N 121.443 -0.785 . . . . 0.0 109.318 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.423 ' HZ3' ' HG1' ' A' ' 24' ' ' THR . 20.9 pttp -130.85 148.22 52.59 Favored 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.502 -0.749 . . . . 0.0 109.374 179.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 62.7 tt0 -100.7 124.95 47.03 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.203 -0.935 . . . . 0.0 109.673 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.525 ' O ' ' N ' ' A' ' 21' ' ' VAL . 34.4 p -111.8 121.53 45.31 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.68 -92.87 0.01 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.67 -1.772 . . . . 0.0 108.67 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.525 ' N ' ' O ' ' A' ' 19' ' ' SER . 4.6 m -137.24 30.6 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.356 -1.085 . . . . 0.0 109.264 179.293 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -129.55 159.67 35.6 Favored 'General case' 0 N--CA 1.504 2.226 0 CA-C-O 122.03 0.919 . . . . 0.0 111.029 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -119.89 139.95 51.6 Favored 'General case' 0 N--CA 1.499 2.004 0 N-CA-C 108.404 -0.962 . . . . 0.0 108.404 178.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.423 ' HG1' ' HZ3' ' A' ' 17' ' ' LYS . 77.0 p -138.32 147.42 43.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.28 -0.888 . . . . 0.0 109.001 179.423 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -83.17 125.65 31.76 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.606 -0.684 . . . . 0.0 109.38 -178.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.6 m120 -84.91 90.34 7.78 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.208 -0.933 . . . . 0.0 109.555 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 79.8 p -89.52 -0.87 57.8 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.223 -0.923 . . . . 0.0 108.851 179.352 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -68.33 -2.12 24.89 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.0 m -113.71 130.06 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.546 -0.973 . . . . 0.0 109.363 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 80.5 p -60.45 -28.0 67.96 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.703 -0.623 . . . . 0.0 110.497 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 71.2 t -61.22 -44.31 98.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 120.948 -1.095 . . . . 0.0 110.338 -178.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.796 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 86.1 m -69.83 -39.81 76.24 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.101 -0.999 . . . . 0.0 110.109 -179.034 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.4 mmt -74.95 -20.86 59.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.092 -1.005 . . . . 0.0 109.495 179.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -60.42 -39.61 88.03 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 120.985 -1.072 . . . . 0.0 109.073 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.97 -49.13 7.2 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 17.8 mt -62.64 -39.92 95.37 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.333 -1.098 . . . . 0.0 109.737 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -66.46 -39.91 89.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.055 -1.028 . . . . 0.0 109.496 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 77.0 tt0 -67.12 -30.1 70.01 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.058 -1.026 . . . . 0.0 109.348 -179.406 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.32 22.41 27.13 Favored Glycine 0 N--CA 1.497 2.743 0 O-C-N 121.112 -0.992 . . . . 0.0 110.688 179.07 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.1 mtpt -104.47 -1.52 26.57 Favored 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 178.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.438 HG12 ' H ' ' A' ' 43' ' ' GLY . 78.3 t -131.08 158.4 43.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-O 121.639 0.733 . . . . 0.0 109.447 -179.53 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.404 ' N ' ' O ' ' A' ' 94' ' ' VAL . 62.5 ttm-85 -123.38 -6.84 8.17 Favored 'General case' 0 N--CA 1.498 1.965 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.438 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.54 -163.19 26.52 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 108.563 -1.815 . . . . 0.0 108.563 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.8 t -119.42 128.37 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.278 -1.131 . . . . 0.0 108.684 179.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.411 ' H ' ' HG ' ' A' ' 45' ' ' SER . 4.1 p -85.16 137.35 33.07 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.098 -1.001 . . . . 0.0 108.716 179.523 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 13.4 p -130.19 131.83 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 54.7 p -125.88 142.1 51.67 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -141.08 139.15 9.35 Favored Glycine 0 N--CA 1.497 2.731 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.317 -178.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 56.0 t -120.02 119.83 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -92.72 117.64 30.22 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -90.37 120.33 31.4 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -105.83 139.16 40.82 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.588 -0.695 . . . . 0.0 110.491 -179.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.529 ' C ' ' H ' ' A' ' 55' ' ' GLY . 45.0 t-20 -61.29 -14.7 28.52 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -66.48 0.82 1.97 Allowed 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.529 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 79.34 16.02 78.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 179.098 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.7 p -123.19 148.21 46.04 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.382 -1.069 . . . . 0.0 110.264 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 63.9 p -127.24 140.04 52.5 Favored 'General case' 0 N--CA 1.496 1.856 0 CA-C-O 121.648 0.737 . . . . 0.0 109.423 179.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.5 t -116.98 147.57 42.18 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 178.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -132.08 119.12 20.55 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.078 -1.014 . . . . 0.0 109.42 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.526 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 51.7 p90 -116.19 120.83 40.24 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.725 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -114.37 145.14 42.19 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 -179.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.4 171.35 43.1 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 72.7 t -110.83 126.94 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.458 -1.025 . . . . 0.0 109.966 -179.676 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 89.2 t -93.13 120.19 42.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.232 -0.918 . . . . 0.0 109.669 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.613 ' HG1' ' H ' ' A' ' 68' ' ' THR . 23.3 p -126.57 151.23 72.72 Favored Pre-proline 0 N--CA 1.495 1.811 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.038 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -53.99 -8.65 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 121.449 1.433 . . . . 0.0 111.615 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.416 ' H ' ' C ' ' A' ' 65' ' ' THR . 70.2 m -111.16 -18.65 12.94 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.476 -0.765 . . . . 0.0 110.243 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.613 ' H ' ' HG1' ' A' ' 65' ' ' THR . 10.3 p -133.91 109.37 11.86 Favored Pre-proline 0 N--CA 1.505 2.321 0 O-C-N 121.106 -0.996 . . . . 0.0 110.799 -179.016 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -86.91 163.58 8.91 Favored 'Trans proline' 0 N--CA 1.497 1.691 0 C-N-CA 122.556 2.171 . . . . 0.0 112.229 178.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 61.6 t -119.05 130.18 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.421 0 O-C-N 121.256 -0.902 . . . . 0.0 109.76 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 64.9 m-20 -100.58 123.63 45.05 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.34 -0.85 . . . . 0.0 110.717 -178.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.492 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.6 OUTLIER -90.87 0.59 57.45 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.832 -1.167 . . . . 0.0 108.665 179.051 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 -66.2 50.35 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.287 -0.883 . . . . 0.0 110.072 -179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.492 ' N ' ' O ' ' A' ' 72' ' ' THR . 98.9 mm-40 -55.04 -98.04 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.126 -0.984 . . . . 0.0 109.755 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -103.42 85.46 2.48 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.156 -0.965 . . . . 0.0 109.227 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.452 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 9.5 tp -67.38 -39.73 83.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.54 -0.725 . . . . 0.0 109.914 -179.751 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.452 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 97.6 m-20 -59.61 -40.15 86.55 Favored 'General case' 0 C--N 1.297 -1.716 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 -179.58 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 13.0 ttmm -66.71 -41.33 88.16 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.594 -0.691 . . . . 0.0 109.495 178.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.618 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -65.07 -52.3 56.42 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.281 -0.887 . . . . 0.0 110.836 -177.638 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.448 ' ND2' ' O ' ' A' ' 77' ' ' ASN . 0.5 OUTLIER -62.31 -28.17 69.55 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 119.808 -1.807 . . . . 0.0 108.976 179.677 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . 0.426 ' N ' HD21 ' A' ' 80' ' ' ASN . 34.6 ttmt -64.6 -51.09 64.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.129 -0.982 . . . . 0.0 110.496 -179.296 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 m -116.42 -22.04 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.274 0 O-C-N 121.353 -0.842 . . . . 0.0 110.72 -179.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.618 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 83.44 165.96 39.11 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 179.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 28.2 t -108.31 120.45 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -69.79 -55.08 10.82 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.998 -1.064 . . . . 0.0 110.051 -179.364 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -116.84 148.79 40.94 Favored 'General case' 0 N--CA 1.502 2.148 0 CA-C-O 121.863 0.84 . . . . 0.0 111.75 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 66.6 t80 -119.65 133.89 55.45 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 178.411 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 74.7 ttt180 -139.62 121.6 15.64 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.856 -1.152 . . . . 0.0 110.613 -178.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -125.34 137.84 54.05 Favored 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.135 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.0 tp -120.55 130.99 54.46 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 23.1 p -129.24 119.8 24.63 Favored 'General case' 0 N--CA 1.508 2.469 0 CA-C-O 121.817 0.818 . . . . 0.0 111.168 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -132.8 160.5 36.71 Favored 'General case' 0 N--CA 1.504 2.269 0 O-C-N 121.666 -0.647 . . . . 0.0 110.211 179.102 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 90.2 m95 -69.42 142.98 53.75 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.432 -0.793 . . . . 0.0 110.426 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.404 ' O ' ' N ' ' A' ' 42' ' ' ARG . 41.0 t -115.94 123.42 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 178.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 123.87 3.56 8.29 Favored Glycine 0 N--CA 1.499 2.88 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.4 m -70.04 150.29 46.78 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.335 -1.097 . . . . 0.0 109.104 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 87.1 mtm-85 -89.2 0.12 57.01 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.138 -0.976 . . . . 0.0 109.123 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 13.1 t . . . . . 0 N--CA 1.487 1.395 0 CA-C-O 117.872 -1.061 . . . . 0.0 109.405 -179.648 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.785 0 N-CA-C 119.401 2.521 . . . . 0.0 119.401 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 167.48 130.88 1.21 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.706 -1.357 . . . . 0.0 109.706 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 38.1 m -106.19 138.19 42.81 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.502 -0.999 . . . . 0.0 109.283 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 89.96 -158.82 27.32 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 41.3 t90 -60.0 139.77 57.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.423 -1.045 . . . . 0.0 110.613 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . 0.574 ' C ' ' H ' ' A' ' 8' ' ' ASP . 33.6 m120 -129.77 136.09 49.21 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.702 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -75.82 25.2 0.12 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.079 -1.013 . . . . 0.0 108.408 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.574 ' H ' ' C ' ' A' ' 6' ' ' ASN . 55.1 t0 -90.34 6.74 41.82 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.654 -0.654 . . . . 0.0 110.715 -178.725 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.43 ' OD1' ' N ' ' A' ' 9' ' ' ASN . 21.5 p-10 -137.83 17.74 2.86 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 120.913 -1.117 . . . . 0.0 109.048 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 35.0 m -126.02 129.76 72.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -94.94 142.48 24.69 Favored Pre-proline 0 N--CA 1.494 1.772 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.44 -18.05 23.28 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 121.91 1.74 . . . . 0.0 112.145 -179.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 87.9 p -70.13 -30.18 67.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 110.187 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -89.25 -14.98 34.67 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.959 -1.088 . . . . 0.0 109.952 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.811 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 35.7 t -72.44 -27.61 62.43 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.304 -0.872 . . . . 0.0 109.648 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.1 pp -118.21 132.52 67.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.534 -0.729 . . . . 0.0 109.087 -179.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -120.05 138.18 53.68 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.369 -0.832 . . . . 0.0 109.094 -179.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 -100.02 123.67 44.52 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.566 -0.709 . . . . 0.0 110.409 -178.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t -125.37 83.81 2.21 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.473 -0.767 . . . . 0.0 109.413 179.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.49 ' O ' ' N ' ' A' ' 22' ' ' GLN . . . 98.13 73.43 1.11 Allowed Glycine 0 N--CA 1.501 2.981 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.429 ' C ' ' O ' ' A' ' 20' ' ' GLY . 15.2 m 34.47 32.41 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.183 0 O-C-N 121.946 -0.738 . . . . 0.0 110.817 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.49 ' N ' ' O ' ' A' ' 20' ' ' GLY . 14.1 pt20 -130.86 161.02 32.75 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.569 -0.707 . . . . 0.0 109.55 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -124.38 131.49 53.51 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 38.7 p -134.27 152.52 51.86 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.336 -0.853 . . . . 0.0 109.381 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 39.1 t80 -81.79 130.67 35.14 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.514 -0.742 . . . . 0.0 109.256 -179.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -81.86 77.41 8.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.917 -1.114 . . . . 0.0 109.93 -179.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 54.3 p -79.57 -8.34 59.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.092 -1.005 . . . . 0.0 109.358 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.9 -39.86 96.07 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.414 ' CG2' ' SG ' ' A' ' 32' ' ' CYS . 27.0 m -82.25 138.34 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.046 -1.267 . . . . 0.0 109.305 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.744 ' HG ' HE21 ' A' ' 34' ' ' GLN . 32.6 t -63.2 -34.64 78.08 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.488 -0.758 . . . . 0.0 110.868 -179.255 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.1 t -56.83 -40.04 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.832 -1.168 . . . . 0.0 109.556 -178.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.811 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 49.1 m -63.08 -39.89 96.04 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.047 -1.033 . . . . 0.0 110.059 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 96.5 mmm -88.94 -16.8 30.91 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.769 -1.207 . . . . 0.0 110.974 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.744 HE21 ' HG ' ' A' ' 30' ' ' SER . 50.3 mt-30 -60.23 -42.68 95.74 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 120.616 -1.302 . . . . 0.0 108.984 178.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -80.34 -41.68 11.37 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.0 tp -59.99 -47.08 87.3 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.312 -1.11 . . . . 0.0 109.241 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 45.0 t30 -65.52 -39.86 92.31 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.285 -0.884 . . . . 0.0 110.184 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.5 -31.98 71.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.249 -0.907 . . . . 0.0 109.423 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.74 18.77 46.63 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 -179.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.3 tttp -97.56 -9.09 27.65 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 178.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.431 HG12 ' H ' ' A' ' 43' ' ' GLY . 97.1 t -134.72 159.87 41.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.038 -0.983 . . . . 0.0 108.665 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.472 ' N ' ' O ' ' A' ' 94' ' ' VAL . 57.9 ttm-85 -125.04 -1.69 7.74 Favored 'General case' 0 N--CA 1.497 1.917 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 179.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.431 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 129.65 -163.96 22.59 Favored Glycine 0 N--CA 1.499 2.855 0 N-CA-C 107.719 -2.153 . . . . 0.0 107.719 -179.236 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 47.5 t -120.56 129.79 75.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.124 0 CA-C-N 118.881 1.34 . . . . 0.0 109.486 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 63.6 p -77.43 141.94 39.47 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.456 -0.777 . . . . 0.0 108.959 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.9 p -127.38 125.32 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 CA-C-O 121.947 0.88 . . . . 0.0 108.727 179.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 2.4 p -128.06 146.65 50.61 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -154.66 147.44 16.57 Favored Glycine 0 N--CA 1.494 2.56 0 C-N-CA 118.306 -1.902 . . . . 0.0 111.237 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 53.2 t -126.4 126.28 68.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -100.56 125.82 46.95 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.267 -0.896 . . . . 0.0 108.773 179.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -95.28 126.92 40.92 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.493 -0.754 . . . . 0.0 109.965 -178.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.535 ' C ' ' H ' ' A' ' 54' ' ' ASP . 98.2 m-85 -114.02 130.33 56.55 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.543 -0.723 . . . . 0.0 109.918 -179.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -53.02 -8.19 0.09 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.507 -0.746 . . . . 0.0 109.328 179.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.535 ' H ' ' C ' ' A' ' 52' ' ' TYR . 41.3 t0 -74.44 0.81 13.42 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.773 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.68 14.55 79.63 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.2 p -123.15 147.86 46.36 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 121.487 -1.008 . . . . 0.0 109.788 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 53.0 p -129.68 140.35 51.15 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 85.0 p -107.45 155.88 19.57 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 30.1 p-10 -146.53 116.07 7.14 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.874 -1.141 . . . . 0.0 109.674 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -118.51 121.82 41.19 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -113.17 153.67 27.91 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -174.82 -177.25 43.78 Favored Glycine 0 C--N 1.282 -2.464 0 C-N-CA 119.337 -1.411 . . . . 0.0 110.847 -179.505 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -119.7 127.36 75.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.971 -0.723 . . . . 0.0 109.375 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.1 t -92.3 120.26 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.199 -0.938 . . . . 0.0 110.519 -179.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.7 p -135.76 152.08 75.35 Favored Pre-proline 0 N--CA 1.492 1.639 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.011 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -54.54 -10.18 2.18 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 121.613 1.542 . . . . 0.0 111.687 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.2 t -103.04 -26.97 12.87 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.324 -0.86 . . . . 0.0 111.23 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 78.2 p -133.34 108.87 12.38 Favored Pre-proline 0 N--CA 1.505 2.283 0 O-C-N 120.911 -1.118 . . . . 0.0 110.295 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -85.09 163.18 11.58 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 C-N-CA 122.068 1.845 . . . . 0.0 111.897 178.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.4 t -120.61 127.53 75.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.467 -0.77 . . . . 0.0 109.07 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -105.48 130.22 53.6 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.189 -0.944 . . . . 0.0 111.303 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.518 ' C ' ' H ' ' A' ' 74' ' ' GLN . 0.6 OUTLIER -92.61 4.87 52.79 Favored 'General case' 0 N--CA 1.499 1.983 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 177.703 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 48.2 p-10 -73.3 21.09 0.08 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.731 -0.605 . . . . 0.0 109.78 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.518 ' H ' ' C ' ' A' ' 72' ' ' THR . 73.5 tp60 -42.85 -83.49 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.479 -0.763 . . . . 0.0 110.744 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -113.62 74.38 0.86 Allowed 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.338 -0.851 . . . . 0.0 110.597 -179.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 83.1 mt -70.21 -34.26 58.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 120.945 -1.097 . . . . 0.0 109.303 178.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 71.3 m-20 -52.78 -43.25 65.73 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.064 -1.023 . . . . 0.0 108.698 -179.15 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 47.4 tttp -62.82 -46.37 88.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.412 -0.805 . . . . 0.0 109.051 178.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.585 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.3 OUTLIER -60.3 -46.7 88.96 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.528 -0.732 . . . . 0.0 110.103 -178.998 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -61.0 -36.75 80.28 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 120.255 -1.528 . . . . 0.0 109.406 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 38.0 tttm -66.38 -50.08 64.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.494 -0.754 . . . . 0.0 110.827 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.9 p -111.42 -26.98 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.544 -0.723 . . . . 0.0 111.805 -176.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.585 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.09 161.52 35.42 Favored Glycine 0 N--CA 1.492 2.372 0 O-C-N 120.678 -1.264 . . . . 0.0 110.294 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.46 ' CG2' ' HG1' ' A' ' 79' ' ' THR . 16.5 t -106.99 120.97 59.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.916 -0.755 . . . . 0.0 109.27 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 61.7 tt0 -72.04 -58.2 3.64 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.155 -0.966 . . . . 0.0 110.951 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 32.7 ttmt -114.81 146.39 41.08 Favored 'General case' 0 N--CA 1.509 2.476 0 O-C-N 121.226 -0.921 . . . . 0.0 111.038 -178.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -121.59 130.36 53.45 Favored 'General case' 0 N--CA 1.501 2.098 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 21.9 mmm180 -137.29 121.68 18.24 Favored 'General case' 0 N--CA 1.505 2.312 0 O-C-N 120.929 -1.107 . . . . 0.0 109.913 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.24 133.9 53.39 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.632 -0.668 . . . . 0.0 109.387 179.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 65.5 tp -117.87 131.46 56.54 Favored 'General case' 0 N--CA 1.5 2.068 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 11.3 p -128.19 124.55 37.07 Favored 'General case' 0 N--CA 1.502 2.139 0 CA-C-O 121.39 0.614 . . . . 0.0 110.334 -179.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -132.67 151.13 52.05 Favored 'General case' 0 N--CA 1.505 2.312 0 O-C-N 121.617 -0.677 . . . . 0.0 110.748 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 58.1 m95 -71.2 139.04 50.0 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.31 -0.869 . . . . 0.0 109.007 179.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.472 ' O ' ' N ' ' A' ' 42' ' ' ARG . 47.3 t -111.08 119.41 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -151.7 -58.61 0.01 OUTLIER Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.261 -1.535 . . . . 0.0 109.261 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 36.9 t -85.32 126.43 33.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.189 -1.183 . . . . 0.0 109.31 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 23.2 tpt180 -62.54 -40.0 95.39 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.228 -0.92 . . . . 0.0 109.16 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 m . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.958 -1.02 . . . . 0.0 109.455 -179.951 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.767 0 N-CA-C 119.563 2.585 . . . . 0.0 119.563 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.52 ' C ' ' H ' ' A' ' 4' ' ' GLY . . . -69.23 165.25 49.55 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.461 ' CB ' ' O ' ' A' ' 2' ' ' GLY . 1.7 p 74.47 -28.04 0.19 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.342 -1.093 . . . . 0.0 109.393 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.52 ' H ' ' C ' ' A' ' 2' ' ' GLY . . . -95.5 -1.63 62.14 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 88.1 t90 -79.03 118.11 20.72 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.298 -1.119 . . . . 0.0 110.056 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . 0.561 ' C ' ' H ' ' A' ' 8' ' ' ASP . 96.1 m-20 -128.91 19.48 6.03 Favored 'General case' 0 N--CA 1.495 1.776 0 CA-C-O 121.455 0.645 . . . . 0.0 109.947 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 56.04 3.24 0.09 Allowed 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.46 -0.775 . . . . 0.0 109.521 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.561 ' H ' ' C ' ' A' ' 6' ' ' ASN . 34.0 t0 -88.44 -28.07 21.11 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.33 -0.856 . . . . 0.0 109.566 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 53.5 t30 -89.97 -0.0 57.34 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.522 -0.736 . . . . 0.0 109.556 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.8 t -110.87 129.98 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.569 -0.707 . . . . 0.0 109.868 -178.771 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -89.14 135.07 31.96 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.147 -0.97 . . . . 0.0 108.593 179.288 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -73.37 -14.27 25.33 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 121.695 1.597 . . . . 0.0 111.603 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 23.2 t -60.64 -40.12 90.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.57 179.489 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 27.5 mt-30 -82.54 -12.97 57.39 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.989 -1.069 . . . . 0.0 109.865 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.796 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 44.3 t -64.27 -37.81 88.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.049 -1.032 . . . . 0.0 109.268 179.721 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -118.23 148.63 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 20.3 ptmt -130.61 155.07 47.16 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 121.497 -0.752 . . . . 0.0 109.508 -179.078 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -98.95 117.46 33.52 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.414 -0.804 . . . . 0.0 110.521 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.5 t -126.37 85.71 2.42 Favored 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.605 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.81 62.52 1.37 Allowed Glycine 0 N--CA 1.497 2.739 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.9 m 40.01 35.74 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.746 -0.855 . . . . 0.0 110.556 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 80.3 mt-30 -132.32 162.84 30.03 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.61 -0.681 . . . . 0.0 109.401 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 41.8 m-85 -120.03 136.34 54.6 Favored 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 178.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 49.3 p -139.57 149.76 44.24 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.411 -0.806 . . . . 0.0 109.925 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.61 ' CZ ' ' SG ' ' A' ' 32' ' ' CYS . 44.1 t80 -80.47 125.21 29.67 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -84.41 84.2 7.73 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.113 -0.992 . . . . 0.0 110.577 -178.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 83.1 p -83.18 -7.0 59.68 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.128 -0.982 . . . . 0.0 109.538 179.321 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.58 -37.76 68.76 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.4 m -85.53 136.46 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.272 -1.134 . . . . 0.0 108.719 179.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 82.9 p -69.88 -40.0 75.95 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.322 -0.861 . . . . 0.0 111.442 -178.617 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 33.7 m -50.23 -42.75 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.773 -1.204 . . . . 0.0 110.647 -178.084 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.796 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 18.9 t -61.17 -42.0 97.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.875 -1.14 . . . . 0.0 110.111 -179.505 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 18.0 mtp -82.12 -12.73 58.03 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.61 -1.306 . . . . 0.0 110.829 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 12.5 mm100 -60.18 -40.0 88.46 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.629 -1.295 . . . . 0.0 108.387 178.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.92 -50.61 6.3 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 62.6 tp -60.24 -41.31 92.87 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.279 -1.13 . . . . 0.0 109.446 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -60.19 -40.05 88.68 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.169 -0.957 . . . . 0.0 109.738 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -74.24 -9.51 58.68 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.156 -0.965 . . . . 0.0 109.999 -179.435 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.65 26.42 67.47 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 179.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 45.7 mmtm -100.17 -5.54 27.58 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 178.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.491 ' CG1' ' H ' ' A' ' 43' ' ' GLY . 55.7 t -133.3 161.01 42.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.412 ' N ' ' CG1' ' A' ' 41' ' ' VAL . 74.3 ttt180 -122.05 -6.82 8.92 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.564 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.491 ' H ' ' CG1' ' A' ' 41' ' ' VAL . . . 135.42 -164.95 24.84 Favored Glycine 0 N--CA 1.498 2.785 0 N-CA-C 108.082 -2.007 . . . . 0.0 108.082 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.3 t -120.03 129.41 75.49 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.091 -1.241 . . . . 0.0 109.415 179.593 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.9 t -83.71 135.99 34.35 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.312 -0.868 . . . . 0.0 108.768 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.0 p -131.45 133.17 62.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 CA-C-O 121.603 0.715 . . . . 0.0 109.813 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.8 p -124.73 151.12 45.45 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 178.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -146.17 147.01 17.68 Favored Glycine 0 N--CA 1.5 2.926 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.803 -179.029 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 75.0 t -129.67 127.18 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.803 -0.822 . . . . 0.0 108.989 179.32 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -102.64 112.88 25.83 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.472 ' HH ' HH21 ' A' ' 88' ' ' ARG . 23.7 m-85 -81.44 128.57 34.01 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.091 -1.006 . . . . 0.0 109.374 -179.222 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -114.72 134.21 55.27 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.481 -0.762 . . . . 0.0 109.499 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.447 ' C ' ' H ' ' A' ' 55' ' ' GLY . 95.9 m-20 -61.84 -9.34 6.46 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.262 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.442 ' OD2' ' OG1' ' A' ' 56' ' ' THR . 46.1 p-10 -68.05 0.15 3.87 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.326 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.447 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 88.27 14.38 62.24 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.247 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.442 ' OG1' ' OD2' ' A' ' 54' ' ' ASP . 35.0 p -136.03 156.75 48.27 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.03 -1.277 . . . . 0.0 110.652 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 37.3 p -131.23 132.94 45.0 Favored 'General case' 0 N--CA 1.498 1.937 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 83.7 p -91.59 160.01 15.61 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 6.0 p30 -152.15 115.01 4.62 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.822 -1.174 . . . . 0.0 109.985 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -118.01 127.77 54.13 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 178.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 78.7 tttt -115.44 145.71 42.31 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.155 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.71 170.07 42.09 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.2 t -110.56 127.53 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.521 -0.987 . . . . 0.0 109.574 -179.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 69.3 t -94.0 118.07 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.086 -1.009 . . . . 0.0 109.491 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.518 ' O ' ' N ' ' A' ' 68' ' ' THR . 12.0 p -125.62 146.25 54.16 Favored Pre-proline 0 N--CA 1.497 1.916 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 178.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_exo -35.9 -27.85 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.344 0 C-N-CA 122.433 2.089 . . . . 0.0 112.884 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.474 ' N ' ' O ' ' A' ' 65' ' ' THR . 5.8 t -106.81 -10.57 16.01 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.433 -0.792 . . . . 0.0 110.528 -179.657 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 65' ' ' THR . 88.7 m -126.33 106.58 24.33 Favored Pre-proline 0 N--CA 1.505 2.31 0 O-C-N 121.04 -1.038 . . . . 0.0 110.981 -179.175 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -90.44 162.48 4.46 Favored 'Trans proline' 0 N--CA 1.487 1.107 0 C-N-CA 122.404 2.069 . . . . 0.0 111.351 177.568 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 78.4 t -119.84 128.06 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.239 0 O-C-N 121.229 -0.92 . . . . 0.0 108.91 179.318 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -101.25 135.15 43.2 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.298 -0.876 . . . . 0.0 110.16 -179.206 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.486 ' C ' ' H ' ' A' ' 74' ' ' GLN . 0.1 OUTLIER -106.02 19.68 20.15 Favored 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 178.332 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.583 HD21 ' N ' ' A' ' 73' ' ' ASN . 1.6 m120 -64.28 42.88 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.848 -178.628 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.486 ' H ' ' C ' ' A' ' 72' ' ' THR . 25.2 mm100 -51.48 170.27 0.05 OUTLIER 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.106 -0.996 . . . . 0.0 109.114 179.213 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -53.05 114.0 1.3 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.054 -1.029 . . . . 0.0 109.621 -179.242 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 97.5 mt -86.46 -16.06 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.384 -0.823 . . . . 0.0 110.246 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -59.84 -39.66 85.92 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 179.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 71.1 mttt -63.0 -50.23 71.57 Favored 'General case' 0 N--CA 1.492 1.634 0 CA-C-O 122.496 1.141 . . . . 0.0 109.551 179.436 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.587 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -59.96 -50.68 72.79 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.515 -177.33 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -61.39 -36.11 79.35 Favored 'General case' 0 C--N 1.292 -1.9 0 O-C-N 120.208 -1.558 . . . . 0.0 109.031 178.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -65.58 -50.27 65.75 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.447 -0.783 . . . . 0.0 111.093 -179.312 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.3 m -115.77 -24.77 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.3 0 O-C-N 121.271 -0.893 . . . . 0.0 111.609 -177.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 91.52 166.55 40.23 Favored Glycine 0 N--CA 1.492 2.413 0 O-C-N 120.71 -1.244 . . . . 0.0 110.068 179.372 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.419 ' CG2' ' HG1' ' A' ' 79' ' ' THR . 49.0 t -106.96 128.54 61.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.926 -0.749 . . . . 0.0 109.057 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -79.99 -66.59 0.86 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.945 -1.097 . . . . 0.0 109.838 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 57.4 mttm -116.55 140.85 48.93 Favored 'General case' 0 N--CA 1.504 2.255 0 O-C-N 121.291 -0.881 . . . . 0.0 111.051 -179.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 70.5 t80 -121.05 132.75 55.07 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 178.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.472 HH21 ' HH ' ' A' ' 51' ' ' TYR . 42.6 mtm105 -136.85 129.97 31.07 Favored 'General case' 0 N--CA 1.504 2.258 0 O-C-N 121.119 -0.988 . . . . 0.0 110.743 -179.409 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.31 135.47 54.22 Favored 'General case' 0 N--CA 1.499 1.983 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.9 mt -118.51 130.28 55.84 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.427 -0.796 . . . . 0.0 109.599 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 20.1 p -128.61 125.07 37.41 Favored 'General case' 0 N--CA 1.503 2.218 0 CA-C-O 121.677 0.751 . . . . 0.0 110.645 -179.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -132.96 154.37 50.53 Favored 'General case' 0 N--CA 1.502 2.159 0 CA-C-O 121.412 0.625 . . . . 0.0 110.638 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 80.2 m95 -69.87 142.08 53.09 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 35.4 t -116.61 120.81 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.133 0 O-C-N 121.332 -0.855 . . . . 0.0 109.202 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 161.03 -140.14 6.48 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 89.1 p -72.27 158.69 35.37 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.076 -1.249 . . . . 0.0 109.407 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.8 mtm180 -64.52 140.01 58.82 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.301 -0.874 . . . . 0.0 109.863 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.3 m . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 117.896 -1.05 . . . . 0.0 109.219 179.586 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.886 0 N-CA-C 119.408 2.523 . . . . 0.0 119.408 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.81 143.6 32.61 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.7 m -99.74 122.83 43.3 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.368 -1.078 . . . . 0.0 109.096 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 136.36 78.67 0.09 OUTLIER Glycine 0 N--CA 1.496 2.641 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 -179.607 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 63.5 t90 -59.63 125.94 25.63 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.332 -1.099 . . . . 0.0 109.173 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 80.7 m-20 -134.91 24.16 3.6 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.765 -0.585 . . . . 0.0 109.662 179.142 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 51.86 36.97 19.49 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -178.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.555 ' CG ' ' H ' ' A' ' 9' ' ' ASN . 11.3 p-10 -47.74 -79.74 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.787 -0.571 . . . . 0.0 111.367 -178.533 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.555 ' H ' ' CG ' ' A' ' 8' ' ' ASP . 13.9 m120 -144.42 37.66 1.24 Allowed 'General case' 0 N--CA 1.497 1.899 0 O-C-N 120.898 -1.126 . . . . 0.0 109.885 -178.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -81.49 152.55 4.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 120.94 -1.1 . . . . 0.0 108.398 -179.11 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.6 m-20 -78.63 131.5 67.72 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.179 -0.951 . . . . 0.0 109.879 -178.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -80.61 -15.08 11.16 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.128 1.885 . . . . 0.0 111.812 179.438 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 94.2 p -64.46 -35.75 81.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.48 -0.763 . . . . 0.0 110.506 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -69.98 -23.7 63.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.162 -0.961 . . . . 0.0 109.812 -179.249 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.8 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 60.8 m -68.26 -27.66 66.54 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.209 -0.932 . . . . 0.0 109.64 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.7 pp -118.49 133.0 66.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.498 -0.751 . . . . 0.0 109.19 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -112.05 142.15 44.84 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.544 ' CD ' ' H ' ' A' ' 18' ' ' GLN . 0.1 OUTLIER -97.55 128.48 44.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.257 -0.902 . . . . 0.0 109.694 -179.411 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.549 ' O ' ' N ' ' A' ' 21' ' ' VAL . 25.3 t -107.4 118.6 37.15 Favored 'General case' 0 N--CA 1.495 1.825 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.42 -78.81 0.01 OUTLIER Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.549 ' N ' ' O ' ' A' ' 19' ' ' SER . 9.8 p -156.7 32.95 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.319 -1.106 . . . . 0.0 108.629 179.268 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 46.3 tt0 -129.22 161.56 29.86 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 -179.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -115.19 135.06 54.58 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.322 -0.861 . . . . 0.0 109.261 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 23.9 p -135.8 150.01 49.3 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 35.8 t80 -83.79 122.09 28.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.347 -0.846 . . . . 0.0 109.663 -179.039 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -84.55 83.63 7.94 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.362 -0.837 . . . . 0.0 109.742 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 96.3 p -78.48 -4.91 50.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.231 -0.918 . . . . 0.0 109.091 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -56.68 -39.01 85.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 -179.437 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.5 m -81.06 133.46 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 120.877 -1.366 . . . . 0.0 109.741 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.5 m -63.33 -34.47 77.77 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.544 -0.723 . . . . 0.0 111.929 -178.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.2 p -59.98 -40.01 81.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 120.608 -1.307 . . . . 0.0 110.796 -177.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.8 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 77.6 m -66.25 -40.04 89.92 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.657 -1.277 . . . . 0.0 109.719 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 7.7 mmt -78.69 -19.14 53.15 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.008 -1.058 . . . . 0.0 109.123 179.607 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -60.75 -41.04 94.62 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.216 -0.928 . . . . 0.0 108.958 179.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -73.59 -43.61 35.85 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 2.1 mt -65.85 -39.98 91.27 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.254 -1.145 . . . . 0.0 108.94 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.32 -40.03 94.98 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.07 -1.019 . . . . 0.0 109.82 179.05 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -76.63 -10.79 59.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.214 -0.929 . . . . 0.0 110.086 -179.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.28 28.49 69.86 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.404 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -103.64 -6.01 22.05 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.435 HG11 ' H ' ' A' ' 43' ' ' GLY . 45.9 t -133.72 159.88 42.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 115.51 -0.768 . . . . 0.0 108.987 -179.251 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.508 ' N ' ' O ' ' A' ' 94' ' ' VAL . 70.3 mtp85 -120.91 -7.71 9.47 Favored 'General case' 0 N--CA 1.5 2.053 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.355 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.435 ' H ' HG11 ' A' ' 41' ' ' VAL . . . 138.73 -159.85 25.51 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -179.035 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.4 t -120.67 129.74 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.145 0 O-C-N 121.297 -1.12 . . . . 0.0 109.32 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.0 t -86.65 140.02 30.22 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.303 -0.873 . . . . 0.0 108.98 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.9 p -131.9 132.46 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.74 0.781 . . . . 0.0 109.829 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 81.9 p -123.29 148.79 45.57 Favored 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -144.64 144.33 13.15 Favored Glycine 0 N--CA 1.5 2.962 0 C-N-CA 119.219 -1.467 . . . . 0.0 111.375 -178.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 85.6 t -121.59 130.01 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.545 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.531 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 9.9 m-85 -106.79 119.89 40.53 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.783 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -98.67 120.82 39.76 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.422 -0.799 . . . . 0.0 109.07 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.529 ' O ' ' N ' ' A' ' 54' ' ' ASP . 94.1 m-85 -105.56 131.33 53.09 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.345 -0.847 . . . . 0.0 109.164 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 49.2 t30 -46.6 -15.56 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.245 -0.909 . . . . 0.0 109.166 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 52' ' ' TYR . 35.9 t0 -69.71 -0.81 7.59 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.578 -0.701 . . . . 0.0 109.392 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.4 23.19 65.89 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 120.047 -1.073 . . . . 0.0 110.611 179.135 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.2 p -118.76 150.27 40.06 Favored 'General case' 0 N--CA 1.504 2.256 0 O-C-N 121.297 -1.12 . . . . 0.0 110.046 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 63.9 p -135.27 128.98 32.87 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.501 -0.75 . . . . 0.0 109.783 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 45.9 t -118.7 145.87 45.17 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 55.9 t-20 -135.8 128.08 30.12 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.753 -1.217 . . . . 0.0 109.796 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -117.15 122.15 43.27 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 178.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -107.52 144.5 34.41 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -162.68 170.99 38.4 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.634 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.7 t -113.98 125.39 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.555 -0.967 . . . . 0.0 109.42 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -90.26 117.9 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.368 -0.833 . . . . 0.0 110.232 -179.152 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.517 ' O ' ' N ' ' A' ' 67' ' ' SER . 25.9 p -125.74 144.4 48.2 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.402 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -38.4 -21.29 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.157 1.905 . . . . 0.0 113.276 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 65' ' ' THR . 10.4 m -108.64 -11.37 15.1 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.197 -0.939 . . . . 0.0 111.296 -178.845 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 55.1 p -130.69 107.87 15.63 Favored Pre-proline 0 N--CA 1.504 2.242 0 O-C-N 121.011 -1.056 . . . . 0.0 110.392 -179.201 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -91.25 164.42 3.69 Favored 'Trans proline' 0 N--CA 1.49 1.314 0 C-N-CA 122.605 2.203 . . . . 0.0 112.135 178.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 48.9 t -124.42 130.15 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.127 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 31.3 m120 -100.77 138.19 38.16 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.082 -1.012 . . . . 0.0 110.502 -178.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -98.5 -19.37 17.69 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 121.02 -1.05 . . . . 0.0 109.021 179.17 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 44.4 p-10 -87.41 44.42 1.18 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.038 -1.039 . . . . 0.0 108.442 179.118 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -59.71 -49.18 78.74 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.519 -0.872 . . . . 0.0 108.741 -179.334 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -115.17 75.8 0.96 Allowed 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 107.845 -1.168 . . . . 0.0 107.845 178.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 10.4 tt -73.33 -28.64 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.28 -0.887 . . . . 0.0 110.116 -178.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -60.06 -49.66 76.79 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.61 -178.067 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.414 ' CG ' ' N ' ' A' ' 79' ' ' THR . 0.1 OUTLIER -61.08 -39.94 91.82 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.569 -1.332 . . . . 0.0 108.34 179.353 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.586 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.4 m -60.04 -43.96 94.99 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.397 0.618 . . . . 0.0 109.772 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -61.63 -38.5 87.89 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 120.596 -1.315 . . . . 0.0 109.987 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.4 ttmm -70.04 -44.85 68.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.139 -0.976 . . . . 0.0 111.224 -179.266 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.1 p -112.08 -28.75 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.075 0 O-C-N 121.311 -0.868 . . . . 0.0 112.098 -176.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.586 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.69 161.43 33.52 Favored Glycine 0 N--CA 1.491 2.339 0 O-C-N 120.66 -1.275 . . . . 0.0 110.177 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 90.0 t -109.51 124.85 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.14 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -80.05 -58.62 3.07 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.247 -0.908 . . . . 0.0 110.952 -178.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 35.4 ttpt -114.11 137.59 51.53 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.267 -0.895 . . . . 0.0 110.809 -178.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 54.9 t80 -123.78 125.89 45.5 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.129 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 76.0 mmt-85 -130.98 132.01 44.76 Favored 'General case' 0 N--CA 1.506 2.336 0 O-C-N 121.137 -0.977 . . . . 0.0 110.525 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -121.26 138.09 54.39 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 179.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.6 tt -119.95 131.17 55.1 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 22.1 p -126.59 126.3 43.39 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.507 -0.745 . . . . 0.0 110.706 -179.243 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 -133.5 154.57 50.71 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.855 -0.528 . . . . 0.0 109.793 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -67.58 139.4 56.9 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.163 -0.961 . . . . 0.0 109.051 179.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.508 ' O ' ' N ' ' A' ' 42' ' ' ARG . 41.4 t -111.84 121.29 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.323 -0.861 . . . . 0.0 109.013 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 136.03 22.24 0.59 Allowed Glycine 0 N--CA 1.497 2.739 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 179.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 42.7 t -81.71 128.32 33.85 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.105 -1.232 . . . . 0.0 109.279 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 93.9 mtt-85 -76.74 145.17 38.79 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.206 -0.934 . . . . 0.0 109.596 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.3 t . . . . . 0 N--CA 1.489 1.506 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.422 -179.805 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.881 0 N-CA-C 119.6 2.6 . . . . 0.0 119.6 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.454 ' O ' ' OG ' ' A' ' 3' ' ' SER . . . 69.72 -119.3 8.97 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' A' ' 2' ' ' GLY . 85.3 p 49.76 49.68 19.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.375 -1.073 . . . . 0.0 109.989 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 94.93 31.15 7.87 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 179.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . 0.515 ' CE3' ' OE1' ' A' ' 34' ' ' GLN . 10.0 t90 -66.05 143.26 57.45 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.868 -1.372 . . . . 0.0 109.366 179.204 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . 0.751 ' H ' HD21 ' A' ' 6' ' ' ASN . 0.0 OUTLIER -131.65 126.82 35.61 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.073 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -61.13 -2.05 0.56 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.967 -1.083 . . . . 0.0 108.464 179.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.55 ' H ' ' C ' ' A' ' 6' ' ' ASN . 66.2 t0 -69.87 -39.84 76.09 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.681 -0.637 . . . . 0.0 110.761 -179.223 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 32.7 m120 -84.38 3.56 35.37 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.004 -1.06 . . . . 0.0 110.4 -178.312 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.0 t -116.31 129.8 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.347 -0.846 . . . . 0.0 109.129 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 -84.68 138.3 38.11 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.016 -1.053 . . . . 0.0 109.212 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -76.63 -24.74 10.07 Favored 'Trans proline' 0 N--CA 1.494 1.531 0 C-N-CA 121.938 1.758 . . . . 0.0 111.673 179.314 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 55.4 m -60.26 -39.89 88.38 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.304 -0.872 . . . . 0.0 110.566 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.7 mt-30 -77.89 -19.82 54.06 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.182 -0.949 . . . . 0.0 110.287 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.812 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 49.6 m -65.66 -29.61 70.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.005 -1.06 . . . . 0.0 109.685 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -118.6 139.64 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.132 0 O-C-N 121.427 -0.796 . . . . 0.0 109.272 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -124.31 144.25 50.1 Favored 'General case' 0 N--CA 1.498 1.955 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 -179.731 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 64.8 tt0 -96.74 124.37 40.7 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.212 -0.93 . . . . 0.0 109.676 -179.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.497 ' O ' ' N ' ' A' ' 21' ' ' VAL . 70.3 m -109.52 129.95 55.54 Favored 'General case' 0 N--CA 1.498 1.967 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.36 -94.06 0.01 OUTLIER Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.497 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.8 t -137.17 28.84 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 121.427 -1.043 . . . . 0.0 109.319 -179.386 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -131.38 163.15 28.53 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.577 -0.702 . . . . 0.0 110.359 -179.571 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -118.76 139.94 50.75 Favored 'General case' 0 N--CA 1.503 2.183 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 70.9 p -139.82 157.01 46.43 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.272 -0.893 . . . . 0.0 109.651 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -89.65 121.69 32.07 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.539 -0.726 . . . . 0.0 109.103 -179.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 -82.47 86.09 6.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.129 -0.982 . . . . 0.0 110.105 -179.368 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.516 ' C ' ' H ' ' A' ' 29' ' ' VAL . 92.1 p -81.58 -7.04 59.54 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.243 -0.91 . . . . 0.0 109.38 179.391 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.66 -8.22 0.34 Allowed Glycine 0 N--CA 1.489 2.196 0 N-CA-C 110.162 -1.175 . . . . 0.0 110.162 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.516 ' H ' ' C ' ' A' ' 27' ' ' SER . 20.4 m -113.31 132.44 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.409 -1.054 . . . . 0.0 108.992 179.529 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.8 m -69.87 -30.07 67.45 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.426 -0.796 . . . . 0.0 111.107 -178.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 18.0 m -60.16 -40.34 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 120.672 -1.268 . . . . 0.0 110.583 -178.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.812 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 96.5 m -65.81 -40.02 91.47 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.83 -1.169 . . . . 0.0 110.01 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 35.3 mtp -84.37 -11.92 55.42 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.901 -1.125 . . . . 0.0 109.303 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.515 ' OE1' ' CE3' ' A' ' 5' ' ' TRP . 12.6 tm0? -61.66 -42.19 98.57 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.8 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.83 -42.68 24.97 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 179.16 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.5 tp -60.2 -41.23 92.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.276 -1.132 . . . . 0.0 108.96 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -62.61 -40.68 97.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.306 -0.871 . . . . 0.0 109.815 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -63.07 -28.27 69.97 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.342 -0.849 . . . . 0.0 109.873 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.69 17.96 57.4 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 92.4 mttt -100.84 -1.54 34.5 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.422 HG11 ' H ' ' A' ' 43' ' ' GLY . 97.4 t -132.3 157.75 43.14 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 115.189 -0.914 . . . . 0.0 108.713 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -119.99 -7.62 9.9 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 179.149 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.422 ' H ' HG11 ' A' ' 41' ' ' VAL . . . 135.7 -160.08 24.41 Favored Glycine 0 N--CA 1.5 2.934 0 N-CA-C 108.22 -1.952 . . . . 0.0 108.22 -179.564 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.1 t -119.98 128.03 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.16 -1.2 . . . . 0.0 108.795 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.493 ' H ' ' HG ' ' A' ' 45' ' ' SER . 1.5 p -82.56 139.64 33.72 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.147 -0.971 . . . . 0.0 108.924 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.7 p -120.05 127.62 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 CA-C-O 121.827 0.822 . . . . 0.0 108.878 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.0 p -128.06 149.86 50.2 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -168.92 159.44 32.53 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 117.922 -2.085 . . . . 0.0 111.682 -179.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 89.2 t -131.32 136.84 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.943 -0.739 . . . . 0.0 109.133 179.255 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.55 ' CZ ' ' OG1' ' A' ' 72' ' ' THR . 55.7 m-85 -108.18 123.71 49.16 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.006 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -95.91 126.51 41.21 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 120.735 -1.228 . . . . 0.0 109.751 -179.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.503 ' C ' ' H ' ' A' ' 54' ' ' ASP . 78.2 m-85 -112.0 129.79 56.08 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.453 -0.779 . . . . 0.0 109.913 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.435 ' C ' ' H ' ' A' ' 55' ' ' GLY . 31.9 t-20 -52.89 -10.83 0.18 Allowed 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 178.459 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.503 ' H ' ' C ' ' A' ' 52' ' ' TYR . 9.3 t70 -67.07 -2.68 5.82 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 84.56 19.0 60.89 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.114 178.633 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.4 p -133.46 152.07 51.86 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.022 -1.281 . . . . 0.0 110.812 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 68.9 p -130.33 142.39 50.53 Favored 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.419 0.628 . . . . 0.0 109.859 -179.476 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -117.55 140.83 49.1 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 178.681 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -125.28 116.24 21.63 Favored 'General case' 0 N--CA 1.496 1.839 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -117.49 121.04 39.93 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -113.22 149.8 33.23 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 179.502 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.2 -175.99 38.88 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.317 -1.421 . . . . 0.0 110.844 -179.53 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 66.8 t -122.49 127.82 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.915 -0.756 . . . . 0.0 109.944 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 21.8 t -99.3 118.61 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.365 -0.834 . . . . 0.0 110.256 -179.267 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.413 ' O ' ' N ' ' A' ' 67' ' ' SER . 29.9 p -118.89 149.83 47.4 Favored Pre-proline 0 N--CA 1.494 1.732 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.304 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -38.51 -28.02 0.12 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 121.845 1.697 . . . . 0.0 113.013 -179.552 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.413 ' N ' ' O ' ' A' ' 65' ' ' THR . 53.5 m -108.58 -3.58 17.89 Favored 'General case' 0 N--CA 1.503 2.225 0 O-C-N 121.345 -0.847 . . . . 0.0 111.677 -178.767 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 7.5 m -124.76 106.57 29.26 Favored Pre-proline 0 N--CA 1.508 2.452 0 O-C-N 120.84 -1.163 . . . . 0.0 111.008 -179.036 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -92.61 164.76 2.83 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 122.818 2.345 . . . . 0.0 111.562 177.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.8 t -119.88 130.04 74.69 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.19 0 O-C-N 121.261 -0.899 . . . . 0.0 108.802 179.62 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -99.91 121.7 41.72 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.304 -0.872 . . . . 0.0 109.997 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.55 ' OG1' ' CZ ' ' A' ' 50' ' ' PHE . 0.2 OUTLIER -100.45 5.45 44.22 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.075 -1.016 . . . . 0.0 108.855 179.41 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.422 ' O ' ' O ' ' A' ' 74' ' ' GLN . 47.9 p-10 -73.42 46.52 0.2 Allowed 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.323 -0.861 . . . . 0.0 109.649 -179.379 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.422 ' O ' ' O ' ' A' ' 73' ' ' ASN . 65.4 tt0 -47.72 -91.9 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.132 -0.98 . . . . 0.0 109.208 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -113.78 104.49 12.25 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.481 -0.762 . . . . 0.0 109.762 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 77.6 mt -80.07 -27.02 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 120.951 -1.093 . . . . 0.0 108.765 179.084 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.408 ' HA ' HD22 ' A' ' 80' ' ' ASN . 27.0 t-20 -59.71 -40.0 86.5 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 18.5 ttmm -69.59 -48.55 59.78 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.209 -0.932 . . . . 0.0 108.791 177.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.61 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.5 OUTLIER -61.84 -51.15 69.43 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.805 -1.184 . . . . 0.0 110.801 -178.551 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 81' ' ' LYS . 29.6 p30 -66.25 -27.11 67.7 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 119.656 -1.902 . . . . 0.0 108.925 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . 0.52 ' N ' ' OD1' ' A' ' 80' ' ' ASN . 37.4 tptt -69.94 -49.05 55.65 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.348 -0.845 . . . . 0.0 110.431 179.366 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.5 m -114.73 -26.04 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.351 0 O-C-N 121.039 -1.038 . . . . 0.0 110.859 -178.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.61 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.87 161.28 36.01 Favored Glycine 0 N--CA 1.493 2.46 0 O-C-N 120.712 -1.243 . . . . 0.0 110.41 179.097 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -100.92 117.52 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -74.75 -59.28 2.8 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.115 -0.991 . . . . 0.0 111.613 -178.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 54.3 mttp -114.29 135.41 54.1 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.33 -0.856 . . . . 0.0 110.983 -177.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 61.2 t80 -122.7 131.81 53.97 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.562 -0.711 . . . . 0.0 109.599 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -139.18 130.76 27.25 Favored 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.214 -0.929 . . . . 0.0 110.576 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -126.95 133.68 50.57 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.617 -0.677 . . . . 0.0 110.309 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 64.9 tp -120.05 131.29 55.05 Favored 'General case' 0 N--CA 1.503 2.181 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -130.48 131.13 44.99 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.528 -0.732 . . . . 0.0 111.181 -179.308 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.466 ' CD ' ' N ' ' A' ' 92' ' ' GLU . 4.6 pm0 -134.22 153.49 51.82 Favored 'General case' 0 N--CA 1.505 2.289 0 CA-C-O 121.35 0.595 . . . . 0.0 110.512 179.101 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 36.7 m95 -70.0 138.97 52.66 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.7 t -110.23 119.81 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.442 -0.787 . . . . 0.0 108.891 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -177.95 -173.26 43.23 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 60.7 p -70.09 150.05 46.98 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.06 -1.259 . . . . 0.0 108.968 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 13.7 tpt180 -86.2 129.9 34.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.007 -1.058 . . . . 0.0 109.064 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.9 p . . . . . 0 N--CA 1.494 1.735 0 CA-C-O 118.026 -0.987 . . . . 0.0 109.183 179.993 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.924 0 N-CA-C 119.539 2.576 . . . . 0.0 119.539 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -84.63 -1.77 89.02 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.4 t -79.99 138.08 36.97 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.267 -1.137 . . . . 0.0 109.443 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 128.48 -128.04 5.82 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 -179.759 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 88.1 t90 -66.41 120.57 13.56 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.271 -1.135 . . . . 0.0 109.548 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 24.6 p-10 -132.45 24.84 4.45 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.092 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 51.63 40.07 26.45 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.318 -0.864 . . . . 0.0 108.678 -179.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -57.61 -72.04 0.09 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.677 -0.64 . . . . 0.0 110.892 -178.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.4 p-10 -147.38 42.33 1.08 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.051 -1.031 . . . . 0.0 108.22 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.3 m -80.5 139.95 17.4 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 O-C-N 121.463 -0.773 . . . . 0.0 109.301 -178.191 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -70.69 126.35 92.19 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.436 -0.79 . . . . 0.0 110.297 -178.442 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -82.91 -17.36 7.0 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.402 2.068 . . . . 0.0 111.53 178.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 57.3 m -60.04 -39.64 86.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.504 -0.747 . . . . 0.0 110.112 -179.427 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.3 mm-40 -65.98 -23.91 66.68 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.106 -0.997 . . . . 0.0 109.468 -179.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.816 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 36.0 t -65.26 -34.92 79.49 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.282 -0.886 . . . . 0.0 110.208 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -119.93 146.51 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.337 -0.852 . . . . 0.0 109.701 -179.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 53.4 mtmt -126.47 157.99 37.21 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 121.531 -0.73 . . . . 0.0 109.252 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -100.22 113.41 26.07 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.123 -0.986 . . . . 0.0 109.876 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.2 m -125.37 121.34 33.64 Favored 'General case' 0 N--CA 1.5 2.032 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.43 ' O ' ' N ' ' A' ' 22' ' ' GLN . . . 57.56 64.34 4.46 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' A' ' 20' ' ' GLY . 35.0 m 37.03 31.47 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.866 -0.785 . . . . 0.0 110.94 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.43 ' N ' ' O ' ' A' ' 20' ' ' GLY . 84.0 mt-30 -131.67 160.0 36.7 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.637 -0.664 . . . . 0.0 109.292 179.484 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 52.3 m-85 -119.32 140.09 50.88 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.074 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 33.7 p -135.14 148.09 49.65 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.525 -0.734 . . . . 0.0 109.314 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -84.24 120.02 25.73 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -86.23 105.85 16.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.096 -1.002 . . . . 0.0 110.516 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 79.3 p -90.78 -0.11 57.61 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.579 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -66.24 -9.75 49.93 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -103.78 124.72 58.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 179.138 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 44.1 t -59.94 -40.13 87.93 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.364 -0.835 . . . . 0.0 111.828 -178.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 p -53.51 -34.96 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.751 -1.218 . . . . 0.0 110.143 -178.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.816 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 22.1 m -61.31 -44.74 96.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.996 -1.065 . . . . 0.0 110.82 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.0 mmt -77.21 -23.48 51.39 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.838 -1.164 . . . . 0.0 110.857 -179.324 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -60.07 -39.99 87.94 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.708 -1.245 . . . . 0.0 109.748 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -74.84 -46.85 15.92 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.5 mt -66.26 -39.4 89.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.451 -1.029 . . . . 0.0 109.553 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -60.13 -39.95 88.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.262 -0.899 . . . . 0.0 110.147 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -81.5 -7.76 59.63 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.109 -0.994 . . . . 0.0 110.792 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.4 28.13 70.26 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 32.1 mmtp -101.05 -7.43 23.24 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 178.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.403 HG11 ' H ' ' A' ' 43' ' ' GLY . 41.6 t -131.93 156.98 43.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 84.3 mtp180 -118.33 -6.5 10.79 Favored 'General case' 0 N--CA 1.5 2.052 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 179.521 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.403 ' H ' HG11 ' A' ' 41' ' ' VAL . . . 137.19 -156.37 23.34 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 108.084 -2.006 . . . . 0.0 108.084 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.3 t -124.69 129.45 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 CA-C-N 118.644 1.222 . . . . 0.0 109.642 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.4 m -84.43 132.87 34.52 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.028 -1.045 . . . . 0.0 108.342 179.05 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 15.0 p -130.04 131.6 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.555 -0.715 . . . . 0.0 109.435 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 54.4 p -122.86 144.71 49.02 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.237 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -135.12 137.22 9.06 Favored Glycine 0 N--CA 1.5 2.958 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 96.4 t -123.41 130.56 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.694 -0.886 . . . . 0.0 109.321 179.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -102.82 122.47 44.58 Favored 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -98.2 127.87 44.37 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.367 -0.833 . . . . 0.0 109.149 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.522 ' O ' ' N ' ' A' ' 54' ' ' ASP . 93.1 m-85 -113.04 128.12 56.41 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.525 -0.735 . . . . 0.0 109.364 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.533 ' OD1' ' N ' ' A' ' 53' ' ' ASN . 0.8 OUTLIER -42.95 -19.83 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.528 -0.732 . . . . 0.0 109.786 179.796 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 52' ' ' TYR . 8.6 t70 -67.97 0.79 3.16 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.473 -0.767 . . . . 0.0 109.395 -179.08 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.424 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 77.72 23.35 67.35 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.554 179.011 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.5 p -119.98 146.35 45.92 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.364 -1.08 . . . . 0.0 109.617 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 38.8 p -130.89 140.01 50.17 Favored 'General case' 0 N--CA 1.497 1.884 0 CA-C-O 121.571 0.7 . . . . 0.0 109.998 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' SER . . . . . 0.434 ' C ' ' ND2' ' A' ' 59' ' ' ASN . 46.4 t -118.65 140.15 50.37 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 178.324 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . 0.673 ' N ' HD21 ' A' ' 59' ' ' ASN . 0.3 OUTLIER -129.99 118.66 21.95 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 120.973 -1.079 . . . . 0.0 109.756 -179.414 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -115.55 125.46 53.02 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 178.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -113.08 148.93 34.23 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.5 166.24 39.43 Favored Glycine 0 C--N 1.288 -2.095 0 N-CA-C 108.839 -1.704 . . . . 0.0 108.839 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.0 t -109.08 125.38 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.506 -0.997 . . . . 0.0 108.815 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.46 ' O ' ' CG1' ' A' ' 64' ' ' VAL . 3.4 p -94.35 121.8 45.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.41 -0.806 . . . . 0.0 109.984 -179.411 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.415 ' O ' ' N ' ' A' ' 68' ' ' THR . 8.2 p -127.75 149.97 71.94 Favored Pre-proline 0 N--CA 1.499 1.989 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.403 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -34.87 -38.55 0.16 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.52 2.147 . . . . 0.0 113.353 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.9 t -99.02 -6.52 28.39 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.039 -1.038 . . . . 0.0 111.026 -179.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.415 ' N ' ' O ' ' A' ' 65' ' ' THR . 34.7 m -128.07 106.89 19.93 Favored Pre-proline 0 N--CA 1.505 2.291 0 O-C-N 121.005 -1.059 . . . . 0.0 110.509 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -90.79 163.25 4.09 Favored 'Trans proline' 0 N--CA 1.488 1.201 0 C-N-CA 122.507 2.138 . . . . 0.0 111.624 178.171 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 58.6 t -120.43 130.13 74.78 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.297 0 O-C-N 121.275 -0.89 . . . . 0.0 108.783 179.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -101.33 127.78 47.8 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.126 -0.983 . . . . 0.0 111.495 -178.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.91 11.15 30.52 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 177.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.415 ' O ' ' O ' ' A' ' 74' ' ' GLN . 45.6 p-10 -77.97 57.88 1.84 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.514 -0.741 . . . . 0.0 110.214 -178.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.415 ' O ' ' O ' ' A' ' 73' ' ' ASN . 27.3 mt-30 -60.91 -158.84 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.048 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -63.68 102.13 0.42 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.722 -1.236 . . . . 0.0 108.717 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 96.8 mt -79.93 -18.1 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.422 -0.799 . . . . 0.0 110.398 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 -59.99 -40.68 90.0 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.883 -1.136 . . . . 0.0 108.413 -179.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 4.1 mtpm? -62.42 -47.93 81.94 Favored 'General case' 0 N--CA 1.495 1.786 0 CA-C-O 122.419 1.104 . . . . 0.0 108.78 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.583 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -60.04 -42.93 95.48 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.078 -0.964 . . . . 0.0 109.592 -178.284 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -62.55 -36.99 84.4 Favored 'General case' 0 C--N 1.293 -1.879 0 O-C-N 120.494 -1.379 . . . . 0.0 108.899 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 53.9 tttt -72.01 -44.49 63.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.091 -1.006 . . . . 0.0 111.107 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.3 p -112.88 -28.18 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.341 -0.85 . . . . 0.0 111.972 -176.61 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.77 165.25 40.68 Favored Glycine 0 N--CA 1.493 2.5 0 O-C-N 120.519 -1.363 . . . . 0.0 110.893 178.545 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.424 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 30.0 t -110.26 124.32 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.064 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 28.1 mt-30 -80.99 -65.17 1.05 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.004 -1.06 . . . . 0.0 110.121 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -114.77 139.94 49.31 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.363 -0.836 . . . . 0.0 110.899 -179.173 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 62.8 t80 -121.38 127.63 51.4 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.161 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -132.06 131.27 42.28 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 120.994 -1.066 . . . . 0.0 110.664 -179.424 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -122.09 131.02 53.76 Favored 'General case' 0 N--CA 1.501 2.12 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 179.229 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 8.7 mp -111.02 130.92 55.44 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.38 -0.825 . . . . 0.0 109.315 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.8 p -124.41 124.08 41.55 Favored 'General case' 0 N--CA 1.506 2.36 0 O-C-N 121.392 -0.817 . . . . 0.0 110.675 -179.625 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 -134.0 146.63 50.6 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.791 -0.568 . . . . 0.0 109.779 179.567 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 87.8 m95 -69.17 139.61 54.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.733 -1.229 . . . . 0.0 108.587 178.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 44.7 t -108.86 119.62 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.025 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 163.09 -172.83 39.19 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 108.345 -1.902 . . . . 0.0 108.345 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 28.0 m -70.19 147.18 50.13 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.965 -1.315 . . . . 0.0 109.93 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 74.9 mtp180 -92.4 -9.99 39.69 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.218 -0.926 . . . . 0.0 109.828 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.8 t . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 117.904 -1.046 . . . . 0.0 109.445 -179.581 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.772 0 N-CA-C 119.629 2.612 . . . . 0.0 119.629 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -173.13 -152.29 8.65 Favored Glycine 0 N--CA 1.486 2.011 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 77.8 p -81.28 -0.47 41.01 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.327 -1.102 . . . . 0.0 108.648 179.57 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.54 23.14 73.9 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.104 -1.598 . . . . 0.0 109.104 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 4.9 t90 -61.79 134.77 57.14 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.207 -1.172 . . . . 0.0 109.995 -179.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . 0.534 ' C ' ' H ' ' A' ' 8' ' ' ASP . 57.0 t-20 -130.71 130.27 43.62 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 177.342 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.1 -3.95 0.29 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.204 -0.935 . . . . 0.0 109.544 -179.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.534 ' H ' ' C ' ' A' ' 6' ' ' ASN . 92.9 m-20 -72.14 -36.91 69.49 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.302 -0.874 . . . . 0.0 110.51 -179.173 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -81.76 -0.91 45.23 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.922 -1.111 . . . . 0.0 109.784 -179.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.9 t -100.34 140.24 19.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.241 -0.912 . . . . 0.0 109.212 -179.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -102.04 106.44 47.75 Favored Pre-proline 0 N--CA 1.492 1.653 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -49.17 -14.42 0.49 Allowed 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 121.86 1.707 . . . . 0.0 112.066 -179.274 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.1 t -63.44 -38.51 91.43 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.465 -0.772 . . . . 0.0 110.083 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -85.22 -12.58 52.25 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.313 -0.867 . . . . 0.0 110.367 -178.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.814 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 39.2 t -68.88 -34.5 75.53 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.654 -1.279 . . . . 0.0 109.867 -179.542 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -119.82 145.43 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 11.4 ptmm? -131.57 152.58 50.67 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.226 -0.921 . . . . 0.0 108.96 -179.624 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -98.49 131.83 44.42 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.149 -0.969 . . . . 0.0 109.824 -179.591 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 29.3 t -117.71 120.07 36.87 Favored 'General case' 0 N--CA 1.496 1.871 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 178.51 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.64 -119.03 7.74 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 108.375 -1.89 . . . . 0.0 108.375 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.5 m -110.75 27.57 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.374 -1.074 . . . . 0.0 108.731 179.326 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 45.7 tt0 -128.99 155.72 44.93 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.572 -0.705 . . . . 0.0 110.244 -178.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 38.3 m-85 -118.41 138.56 52.36 Favored 'General case' 0 N--CA 1.498 1.966 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 73.3 p -138.64 153.15 48.58 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.227 -0.921 . . . . 0.0 109.359 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.569 ' CZ ' ' SG ' ' A' ' 15' ' ' CYS . 30.1 t80 -80.72 125.2 29.76 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -86.52 88.68 7.7 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.232 -0.918 . . . . 0.0 110.681 -178.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.481 ' C ' ' H ' ' A' ' 29' ' ' VAL . 7.7 m -79.66 -8.9 59.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.952 -1.093 . . . . 0.0 108.631 178.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.53 -8.12 0.78 Allowed Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.481 ' H ' ' C ' ' A' ' 27' ' ' SER . 0.1 OUTLIER -107.51 122.7 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.954 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 178.793 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 59.8 p -63.67 -37.29 86.78 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.655 -0.653 . . . . 0.0 111.613 -178.171 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.8 m -57.65 -36.93 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 120.841 -1.162 . . . . 0.0 110.622 -178.174 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.814 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 27.1 m -61.7 -42.08 98.46 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.805 -1.185 . . . . 0.0 110.461 -179.349 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 14.6 mmt -73.91 -20.63 60.33 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.965 -1.085 . . . . 0.0 110.685 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 79.6 mm-40 -60.16 -41.86 93.69 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.739 -1.226 . . . . 0.0 110.027 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.79 -47.02 8.98 Favored Glycine 0 N--CA 1.491 2.328 0 C-N-CA 119.166 -1.493 . . . . 0.0 109.872 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 20.9 tp -62.92 -43.45 98.77 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.496 -1.002 . . . . 0.0 110.822 -178.766 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -61.97 -39.7 93.07 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.975 -1.078 . . . . 0.0 110.304 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -74.95 -8.11 55.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.231 -0.918 . . . . 0.0 110.438 -178.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 73.45 24.83 74.17 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -97.86 -6.61 32.1 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 178.129 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 93.6 t -135.65 159.92 39.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.64 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 52.7 ttt85 -118.61 -8.47 10.42 Favored 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.526 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 138.34 -161.46 25.66 Favored Glycine 0 N--CA 1.502 3.081 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 90.8 t -120.62 127.23 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.023 -1.281 . . . . 0.0 109.529 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.1 m -85.29 138.28 32.42 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 10.3 m -132.32 134.29 59.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.374 -0.829 . . . . 0.0 110.148 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 51.7 p -125.33 147.8 48.99 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.514 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -151.7 142.23 9.27 Favored Glycine 0 N--CA 1.496 2.644 0 C-N-CA 118.996 -1.573 . . . . 0.0 110.836 -178.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 78.5 t -125.13 130.13 73.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.446 ' CZ ' ' OG1' ' A' ' 72' ' ' THR . 48.8 m-85 -104.52 122.01 44.67 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.451 -0.781 . . . . 0.0 108.914 -179.285 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 36.0 m-85 -92.37 125.86 37.21 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.258 -0.901 . . . . 0.0 110.488 -178.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.412 ' CB ' ' HZ2' ' A' ' 78' ' ' LYS . 97.9 m-85 -109.22 135.54 50.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.454 -0.779 . . . . 0.0 109.941 179.76 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.442 ' C ' ' H ' ' A' ' 55' ' ' GLY . 25.6 m120 -60.83 -13.86 18.16 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 179.041 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 11.3 t70 -68.72 0.68 3.97 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.442 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 82.87 15.41 72.89 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 179.059 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.2 p -119.18 152.71 36.12 Favored 'General case' 0 N--CA 1.51 2.531 0 O-C-N 121.367 -1.078 . . . . 0.0 111.153 -179.305 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 39.3 p -131.83 141.53 49.46 Favored 'General case' 0 N--CA 1.499 1.993 0 CA-C-O 121.433 0.635 . . . . 0.0 109.509 179.298 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 35.7 t -118.0 141.58 48.31 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 178.458 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -132.4 116.62 17.06 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.123 -0.986 . . . . 0.0 109.312 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.539 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 42.2 p90 -116.38 122.65 45.47 Favored 'General case' 0 N--CA 1.496 1.865 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.613 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -115.76 143.73 44.97 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.01 178.19 42.4 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.3 t -116.56 128.95 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 O-C-N 121.46 -1.023 . . . . 0.0 109.929 -179.458 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.0 t -95.81 112.0 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.151 -0.968 . . . . 0.0 109.922 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.571 ' O ' ' N ' ' A' ' 67' ' ' SER . 2.3 p -136.63 151.5 72.85 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 178.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_exo -41.14 -15.14 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.437 0 C-N-CA 121.704 1.603 . . . . 0.0 112.24 179.108 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.571 ' N ' ' O ' ' A' ' 65' ' ' THR . 67.3 p -61.53 -54.15 46.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.875 -1.141 . . . . 0.0 109.955 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -157.78 148.76 16.39 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 120.865 -1.147 . . . . 0.0 110.109 -179.649 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -82.55 163.53 16.68 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 122.23 1.953 . . . . 0.0 111.413 178.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 99.6 t -111.25 131.1 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.128 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . 0.468 ' O ' ' OD1' ' A' ' 71' ' ' ASN . 22.8 p30 -100.91 138.26 38.19 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.471 -0.768 . . . . 0.0 111.671 -177.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.458 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.1 OUTLIER -100.0 1.72 42.78 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 177.907 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 73' ' ' ASN . 0.7 OUTLIER -66.96 52.74 0.05 OUTLIER 'General case' 0 N--CA 1.488 1.461 0 CA-C-O 121.631 0.729 . . . . 0.0 109.345 -179.604 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.458 ' N ' ' O ' ' A' ' 72' ' ' THR . 77.2 mt-30 -64.82 -90.37 0.01 OUTLIER 'General case' 0 C--N 1.294 -1.824 0 O-C-N 121.456 -0.778 . . . . 0.0 109.667 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -112.04 74.83 0.88 Allowed 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.566 -0.709 . . . . 0.0 110.115 -179.563 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.441 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 10.7 tp -60.31 -38.87 79.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.441 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 17.0 t-20 -57.92 -41.19 82.17 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.412 ' HZ2' ' CB ' ' A' ' 52' ' ' TYR . 32.4 tttm -67.81 -43.33 79.9 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.365 -0.834 . . . . 0.0 109.098 178.548 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.572 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.3 OUTLIER -67.57 -40.84 84.89 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.088 -1.007 . . . . 0.0 109.445 -179.365 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -66.79 -25.92 66.7 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 120.441 -1.412 . . . . 0.0 109.156 179.336 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -68.63 -47.52 66.41 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 120.89 -1.131 . . . . 0.0 110.379 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.7 m -121.25 -18.8 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 121.337 -0.852 . . . . 0.0 111.669 -177.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.11 170.37 46.91 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.413 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 46.5 t -108.3 127.17 64.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 62.5 tt0 -80.45 -66.8 0.83 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 120.999 -1.063 . . . . 0.0 111.149 -179.381 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 34.8 ttpt -114.82 140.02 49.27 Favored 'General case' 0 N--CA 1.506 2.342 0 O-C-N 121.179 -0.951 . . . . 0.0 110.919 -178.267 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 84.5 t80 -120.97 136.26 55.02 Favored 'General case' 0 N--CA 1.505 2.293 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.24 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 -136.49 124.13 22.37 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.204 -0.935 . . . . 0.0 110.18 179.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -125.01 140.77 52.61 Favored 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.421 -0.799 . . . . 0.0 110.426 179.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.0 mt -118.93 129.82 55.38 Favored 'General case' 0 N--CA 1.504 2.26 0 O-C-N 121.501 -0.749 . . . . 0.0 109.464 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 31.8 p -126.57 117.18 22.28 Favored 'General case' 0 N--CA 1.508 2.439 0 CA-C-O 121.848 0.832 . . . . 0.0 110.29 179.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -132.56 156.12 47.42 Favored 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.154 -179.109 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -70.82 144.74 50.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.4 -0.813 . . . . 0.0 109.384 179.302 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 35.5 t -120.04 127.58 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.707 -0.621 . . . . 0.0 109.343 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 96.7 -8.6 66.07 Favored Glycine 0 N--CA 1.497 2.764 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 75.2 m -78.68 144.83 34.98 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.501 -0.999 . . . . 0.0 109.419 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.7 mtm180 -71.0 150.02 46.07 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.274 -0.891 . . . . 0.0 109.538 179.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.5 m . . . . . 0 N--CA 1.493 1.684 0 O-C-N 121.075 -1.016 . . . . 0.0 109.184 -179.925 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.908 0 N-CA-C 119.529 2.571 . . . . 0.0 119.529 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 88.39 -6.83 83.12 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.042 -1.623 . . . . 0.0 109.042 -179.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 59.3 p -85.73 158.33 20.06 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.399 -1.059 . . . . 0.0 110.103 -179.746 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.35 14.15 82.83 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 179.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . 0.471 ' CD1' ' OE1' ' A' ' 34' ' ' GLN . 89.8 t90 -80.29 116.87 20.6 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.268 -1.136 . . . . 0.0 109.33 179.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 23.4 m120 -131.61 19.44 4.71 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 179.175 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 53.0 17.4 0.89 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.785 -0.572 . . . . 0.0 109.505 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' A' ' 8' ' ' ASP . 26.6 t0 -100.2 7.48 44.48 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.309 -0.869 . . . . 0.0 110.894 -178.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 71.6 m-80 -122.39 13.17 10.23 Favored 'General case' 0 N--CA 1.501 2.087 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.4 m -120.49 141.66 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 CA-C-O 121.343 0.592 . . . . 0.0 109.422 -179.175 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 36.0 t0 -103.97 111.94 65.34 Favored Pre-proline 0 N--CA 1.499 1.999 0 O-C-N 121.247 -0.908 . . . . 0.0 109.081 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_exo -40.78 -33.43 1.06 Allowed 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.232 1.955 . . . . 0.0 113.126 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 58.5 m -60.01 -39.93 87.5 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.036 -1.04 . . . . 0.0 110.711 -179.367 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 47.0 tt0 -70.03 -24.91 63.35 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.799 -1.188 . . . . 0.0 109.925 -178.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.817 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 37.3 t -68.31 -34.41 76.09 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.332 -0.855 . . . . 0.0 110.118 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.1 pt -117.17 145.88 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.409 -0.807 . . . . 0.0 109.153 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 52.7 mtpt -126.36 146.09 50.19 Favored 'General case' 0 N--CA 1.497 1.875 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 -179.47 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -87.0 119.73 27.51 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.543 -0.723 . . . . 0.0 109.208 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.512 ' O ' ' N ' ' A' ' 21' ' ' VAL . 39.3 p -102.07 119.54 38.96 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.404 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.81 -93.4 0.01 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.512 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.4 t -129.86 20.89 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.538 -0.978 . . . . 0.0 109.23 -179.641 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 75.2 mt-30 -128.55 167.93 16.42 Favored 'General case' 0 N--CA 1.5 2.067 0 CA-C-O 121.866 0.841 . . . . 0.0 110.695 -179.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 24.3 m-85 -119.74 135.15 54.96 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 107.888 -1.152 . . . . 0.0 107.888 178.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 60.9 p -131.32 149.74 52.43 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.345 -0.847 . . . . 0.0 109.753 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 48.5 t80 -86.89 128.76 35.06 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.468 -0.77 . . . . 0.0 109.871 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -88.27 81.53 7.28 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.105 -0.997 . . . . 0.0 110.552 -179.362 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.404 ' C ' ' H ' ' A' ' 29' ' ' VAL . 93.2 p -77.97 -16.64 57.99 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.936 -1.102 . . . . 0.0 109.599 179.396 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -64.1 -3.68 9.48 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.363 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.404 ' H ' ' C ' ' A' ' 27' ' ' SER . 2.7 t -98.6 129.35 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.261 -1.141 . . . . 0.0 108.321 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 80.8 p -60.06 -40.24 88.8 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 110.727 -178.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.1 p -60.67 -40.4 84.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.92 -1.112 . . . . 0.0 110.402 -179.246 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.817 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.9 m -61.37 -43.36 99.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.024 -1.047 . . . . 0.0 110.11 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 9.2 mmt -80.34 -16.83 53.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.897 -1.127 . . . . 0.0 109.824 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.471 ' OE1' ' CD1' ' A' ' 5' ' ' TRP . 55.9 tt0 -60.32 -40.28 90.02 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.053 -1.029 . . . . 0.0 108.744 179.372 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -78.49 -47.47 8.03 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 mt -64.86 -42.67 94.68 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.196 -1.179 . . . . 0.0 110.159 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -62.79 -40.39 97.2 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.015 -1.053 . . . . 0.0 110.002 -179.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 63.5 mm-40 -67.78 -29.29 68.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.199 -0.938 . . . . 0.0 109.61 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.02 22.75 44.01 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 110.09 -1.204 . . . . 0.0 110.09 179.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 17.2 mmmt -102.55 -0.31 32.32 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 178.475 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.427 HG11 ' H ' ' A' ' 43' ' ' GLY . 14.4 t -136.53 157.46 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.512 ' N ' ' O ' ' A' ' 94' ' ' VAL . 70.7 mtp85 -118.18 -10.19 10.33 Favored 'General case' 0 N--CA 1.5 2.045 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 178.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.427 ' H ' HG11 ' A' ' 41' ' ' VAL . . . 141.55 -158.86 26.69 Favored Glycine 0 N--CA 1.497 2.717 0 N-CA-C 108.644 -1.783 . . . . 0.0 108.644 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.7 t -120.59 128.96 76.08 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.184 -1.186 . . . . 0.0 109.207 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.4 m -85.69 139.67 31.18 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.256 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 8.6 p -129.61 133.03 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 CA-C-O 121.808 0.813 . . . . 0.0 109.797 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 22.4 p -126.73 150.09 49.24 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 178.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -148.88 145.21 13.29 Favored Glycine 0 N--CA 1.494 2.548 0 C-N-CA 118.708 -1.71 . . . . 0.0 111.462 -178.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 95.4 t -118.16 125.98 74.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 178.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 2.1 m-85 -105.51 116.29 31.69 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.166 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.409 ' HH ' ' NH1' ' A' ' 88' ' ' ARG . 70.7 m-85 -91.76 124.75 36.13 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.45 -0.781 . . . . 0.0 109.137 -179.55 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.515 ' C ' ' H ' ' A' ' 54' ' ' ASP . 88.9 m-85 -109.31 134.68 51.49 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.439 ' C ' ' H ' ' A' ' 55' ' ' GLY . 86.2 m-20 -57.16 -5.96 0.34 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.905 -1.122 . . . . 0.0 108.767 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.515 ' H ' ' C ' ' A' ' 52' ' ' TYR . 46.2 t0 -73.64 3.59 6.14 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.439 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 76.59 27.41 61.21 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.286 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 22.7 p -130.12 150.87 51.19 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.416 -1.05 . . . . 0.0 110.864 -179.162 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 80.5 p -132.0 123.04 26.52 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.64 -0.663 . . . . 0.0 109.324 179.263 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' SER . . . . . 0.462 ' C ' ' ND2' ' A' ' 59' ' ' ASN . 23.2 t -104.46 153.2 21.42 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 179.23 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . 0.462 ' ND2' ' C ' ' A' ' 58' ' ' SER . 3.1 m120 -131.97 118.87 20.32 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 120.93 -1.106 . . . . 0.0 108.98 179.755 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -117.48 123.95 47.59 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.477 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -111.78 145.57 39.16 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -163.37 174.88 39.67 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.6 t -119.82 127.22 75.87 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.124 0 O-C-N 121.517 -0.99 . . . . 0.0 109.373 179.584 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 70.8 t -95.38 120.1 44.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.21 -0.931 . . . . 0.0 110.278 -179.202 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.537 ' C ' ' H ' ' A' ' 67' ' ' SER . 3.0 p -137.34 155.32 75.73 Favored Pre-proline 0 N--CA 1.492 1.635 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.097 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -49.69 -4.96 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.021 1.814 . . . . 0.0 111.624 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.537 ' H ' ' C ' ' A' ' 65' ' ' THR . 52.6 p -71.51 -52.1 20.12 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.201 -0.937 . . . . 0.0 110.414 -179.576 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.0 t -154.58 147.08 17.6 Favored Pre-proline 0 N--CA 1.497 1.902 0 O-C-N 120.843 -1.161 . . . . 0.0 110.235 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -80.89 163.91 20.47 Favored 'Trans proline' 0 N--CA 1.497 1.687 0 C-N-CA 122.373 2.048 . . . . 0.0 112.413 179.032 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 64.6 t -123.02 131.22 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.223 0 O-C-N 121.499 -0.75 . . . . 0.0 109.02 179.419 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -90.8 140.31 29.92 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 120.953 -1.092 . . . . 0.0 109.728 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.446 ' OG1' ' N ' ' A' ' 73' ' ' ASN . 1.2 p -80.34 -50.43 10.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.058 -1.026 . . . . 0.0 108.778 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.446 ' N ' ' OG1' ' A' ' 72' ' ' THR . 97.7 m-20 -79.5 58.32 2.64 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.483 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.484 ' NE2' ' OD1' ' A' ' 75' ' ' ASP . 0.0 OUTLIER -46.41 -39.56 10.68 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.965 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.484 ' OD1' ' NE2' ' A' ' 74' ' ' GLN . 95.3 m-20 -108.37 75.6 0.99 Allowed 'General case' 0 N--CA 1.496 1.841 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.739 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.425 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 9.2 tp -60.43 -39.85 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.456 -0.777 . . . . 0.0 110.435 -178.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.425 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 46.1 t30 -59.87 -46.28 89.79 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 119.02 -1.072 . . . . 0.0 108.142 -179.371 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 44.2 tttp -60.62 -50.14 74.72 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.164 -0.96 . . . . 0.0 108.938 178.345 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.535 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.1 m -62.11 -41.11 97.89 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.726 -0.609 . . . . 0.0 110.413 -178.513 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -64.92 -33.06 75.14 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 120.545 -1.347 . . . . 0.0 109.882 179.714 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 46.2 tttt -67.02 -49.86 63.93 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.116 -0.99 . . . . 0.0 110.662 -179.073 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.8 p -113.8 -26.16 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.67 -0.644 . . . . 0.0 111.967 -176.66 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 81.59 158.11 20.6 Favored Glycine 0 N--CA 1.493 2.436 0 O-C-N 120.494 -1.379 . . . . 0.0 109.713 179.703 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.5 t -105.03 120.38 55.52 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.764 -0.845 . . . . 0.0 108.988 179.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -70.0 -58.36 3.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.132 -0.98 . . . . 0.0 111.569 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -113.9 140.04 48.7 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.141 -0.975 . . . . 0.0 110.328 -178.228 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 71.6 t80 -120.24 127.75 52.7 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.409 ' NH1' ' HH ' ' A' ' 51' ' ' TYR . 99.2 mtt180 -130.78 127.12 38.06 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 121.212 -0.93 . . . . 0.0 109.869 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.68 142.83 51.1 Favored 'General case' 0 N--CA 1.505 2.296 0 O-C-N 121.557 -0.714 . . . . 0.0 110.314 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 mt -125.83 133.54 51.95 Favored 'General case' 0 N--CA 1.508 2.433 0 O-C-N 121.602 -0.686 . . . . 0.0 109.384 179.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 61.8 p -127.95 124.66 37.85 Favored 'General case' 0 N--CA 1.506 2.362 0 O-C-N 121.369 -0.832 . . . . 0.0 110.75 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -133.08 147.25 52.17 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.749 -0.594 . . . . 0.0 109.806 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 88.4 m95 -69.49 139.76 53.92 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 120.816 -1.178 . . . . 0.0 109.35 179.331 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.512 ' O ' ' N ' ' A' ' 42' ' ' ARG . 46.8 t -111.68 120.09 61.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -176.68 -177.14 45.41 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 61.0 m -70.23 133.7 47.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.316 -1.108 . . . . 0.0 109.167 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.432 ' CD ' ' N ' ' A' ' 97' ' ' ARG . 1.3 mpt_? -71.76 139.45 49.05 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.19 -0.944 . . . . 0.0 109.859 -179.597 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 96.9 p . . . . . 0 N--CA 1.488 1.448 0 CA-C-O 117.99 -1.005 . . . . 0.0 109.39 179.779 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.963 0 N-CA-C 119.728 2.651 . . . . 0.0 119.728 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -84.78 -82.76 1.02 Allowed Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.0 m 53.44 22.1 2.72 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.361 -1.082 . . . . 0.0 109.385 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 58.76 -137.27 50.48 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 27.2 t90 -60.07 140.04 57.1 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.523 -0.986 . . . . 0.0 111.228 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . 0.58 ' C ' ' H ' ' A' ' 8' ' ' ASP . 20.6 m120 -129.56 128.41 42.69 Favored 'General case' 0 C--N 1.305 -1.365 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 177.624 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -63.3 3.66 0.27 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.051 -1.031 . . . . 0.0 108.765 179.607 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.58 ' H ' ' C ' ' A' ' 6' ' ' ASN . 68.4 m-20 -82.28 -26.16 33.37 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.465 -0.772 . . . . 0.0 110.947 -178.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -94.04 3.44 55.33 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 120.858 -1.151 . . . . 0.0 110.659 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.3 t -110.83 130.04 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.296 -0.878 . . . . 0.0 110.52 -179.076 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -88.0 131.94 41.44 Favored Pre-proline 0 N--CA 1.492 1.63 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.491 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -77.18 -19.58 13.44 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 121.801 1.668 . . . . 0.0 112.477 -179.217 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 55.2 m -59.92 -39.93 87.16 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.174 -0.954 . . . . 0.0 110.374 -179.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 90.2 mm-40 -83.71 -11.15 57.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.076 -1.015 . . . . 0.0 110.054 -179.454 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.813 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 45.5 t -69.67 -31.33 69.32 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.131 -0.981 . . . . 0.0 109.142 179.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -120.07 146.06 25.43 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 61.4 pttt -125.47 149.96 47.77 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.458 -0.776 . . . . 0.0 109.384 -179.406 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -99.85 122.03 42.18 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.357 -0.839 . . . . 0.0 109.827 -178.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.1 t -107.45 100.9 10.29 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 71.72 -94.52 0.59 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.1 m -133.2 23.28 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.204 0 O-C-N 121.285 -1.126 . . . . 0.0 110.413 -179.642 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -131.66 161.56 32.46 Favored 'General case' 0 N--CA 1.504 2.275 0 O-C-N 121.209 -0.932 . . . . 0.0 109.989 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -113.26 141.41 47.02 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 37.2 p -130.01 142.04 50.67 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.36 -0.838 . . . . 0.0 109.425 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.9 t80 -81.64 126.0 31.24 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.49 -0.756 . . . . 0.0 109.897 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -90.02 85.41 6.32 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.35 -0.844 . . . . 0.0 110.447 -179.611 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.2 p -85.54 -1.43 57.09 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.933 -1.104 . . . . 0.0 109.207 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.08 -31.56 77.16 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.511 ' CG2' ' SG ' ' A' ' 32' ' ' CYS . 24.4 m -83.64 132.48 31.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.152 -1.205 . . . . 0.0 109.138 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 71.1 m -60.08 -39.92 87.76 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.325 -0.859 . . . . 0.0 111.474 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.1 m -52.96 -38.19 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 120.719 -1.238 . . . . 0.0 110.588 -178.072 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.813 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.8 m -62.85 -39.93 95.91 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.73 -1.231 . . . . 0.0 110.016 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 10.0 mmt -80.07 -14.92 58.16 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.984 -1.073 . . . . 0.0 110.263 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 -64.84 -39.97 94.43 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.884 -1.135 . . . . 0.0 109.287 179.167 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.12 -49.11 8.82 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.97 -40.16 94.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.347 -1.09 . . . . 0.0 109.998 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -61.15 -40.01 92.23 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.936 -1.103 . . . . 0.0 110.043 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -76.7 -10.19 59.21 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.017 -1.052 . . . . 0.0 109.214 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 69.93 27.23 73.36 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 54.7 tttp -98.99 -7.52 26.8 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 178.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.45 HG12 ' H ' ' A' ' 43' ' ' GLY . 4.2 t -133.71 159.03 42.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-N 115.113 -0.949 . . . . 0.0 108.885 -179.591 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.45 ' N ' ' O ' ' A' ' 94' ' ' VAL . 96.3 mtt180 -121.46 -5.96 9.28 Favored 'General case' 0 N--CA 1.504 2.265 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.211 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.45 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 142.66 -170.13 25.29 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 108.567 -1.813 . . . . 0.0 108.567 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 77.0 t -111.08 126.18 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.065 -1.256 . . . . 0.0 108.338 179.147 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.4 p -82.02 139.76 34.32 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.126 -0.984 . . . . 0.0 109.275 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.3 p -130.0 133.45 64.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 98.1 p -124.43 142.54 51.23 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.406 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -133.87 131.86 6.19 Favored Glycine 0 N--CA 1.502 3.068 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.108 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 74.4 t -121.58 129.26 75.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.732 -0.863 . . . . 0.0 108.999 178.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -104.76 122.54 45.92 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.209 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -96.16 129.82 43.37 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.284 -0.885 . . . . 0.0 109.454 -179.417 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.529 ' O ' ' N ' ' A' ' 54' ' ' ASP . 95.0 m-85 -114.66 127.57 55.84 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -179.67 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.402 ' C ' ' H ' ' A' ' 55' ' ' GLY . 49.1 t30 -43.12 -19.11 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.428 -0.795 . . . . 0.0 109.918 179.763 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 52' ' ' TYR . 50.1 t0 -68.25 1.32 2.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.459 -0.776 . . . . 0.0 109.752 -179.235 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.402 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 77.76 20.26 74.12 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.574 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.5 p -115.9 154.76 29.17 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.423 -1.046 . . . . 0.0 109.726 179.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 45.2 p -139.62 137.98 35.76 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.626 -0.671 . . . . 0.0 109.629 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 53.8 m -113.71 149.58 34.55 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 178.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 21.9 p-10 -140.79 119.07 12.08 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.023 -1.048 . . . . 0.0 110.119 -179.418 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 73.5 m-85 -114.11 121.52 44.05 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 107.678 -1.231 . . . . 0.0 107.678 178.349 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.0 ttpm? -113.17 147.33 37.63 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.64 169.2 41.55 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.4 t -110.04 127.32 67.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.416 -1.05 . . . . 0.0 109.594 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.5 t -91.3 119.99 39.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.423 -0.798 . . . . 0.0 110.017 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.515 ' O ' ' N ' ' A' ' 67' ' ' SER . 25.7 p -136.31 147.59 60.81 Favored Pre-proline 0 N--CA 1.493 1.688 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 178.515 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_exo -39.16 -21.86 0.07 OUTLIER 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 121.987 1.792 . . . . 0.0 112.538 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.515 ' N ' ' O ' ' A' ' 65' ' ' THR . 67.9 m -68.41 -45.82 71.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.115 -0.991 . . . . 0.0 111.413 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 5.8 t -154.75 142.8 14.26 Favored Pre-proline 0 N--CA 1.5 2.042 0 O-C-N 120.407 -1.433 . . . . 0.0 111.19 -179.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -81.95 166.84 16.67 Favored 'Trans proline' 0 N--CA 1.499 1.83 0 C-N-CA 122.993 2.462 . . . . 0.0 111.627 178.308 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 90.3 t -105.95 135.79 42.81 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.198 0 O-C-N 121.242 -0.911 . . . . 0.0 109.258 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 29.2 m120 -99.67 123.95 44.43 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.301 -0.874 . . . . 0.0 111.464 -178.258 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.462 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.3 OUTLIER -109.87 20.03 18.44 Favored 'General case' 0 N--CA 1.502 2.174 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.1 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.445 ' O ' ' O ' ' A' ' 74' ' ' GLN . 25.6 t-20 -78.69 60.23 2.7 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.47 -0.769 . . . . 0.0 109.927 -179.433 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.554 ' N ' ' OE1' ' A' ' 74' ' ' GLN . 0.0 OUTLIER -50.28 177.59 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 178.732 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 78.9 m-20 -66.08 119.81 12.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.469 -1.394 . . . . 0.0 108.464 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 94.5 mt -80.65 -13.11 12.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.506 -0.746 . . . . 0.0 110.409 -179.092 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 28.7 m120 -60.13 -43.89 95.33 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.827 -1.171 . . . . 0.0 109.036 -179.497 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 18.7 pttt -66.89 -40.09 87.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.877 -1.139 . . . . 0.0 109.271 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.598 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.9 OUTLIER -63.05 -41.13 99.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.239 -0.913 . . . . 0.0 108.777 179.473 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -62.19 -38.71 90.14 Favored 'General case' 0 C--N 1.295 -1.773 0 O-C-N 120.76 -1.213 . . . . 0.0 109.551 179.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 31.3 tttm -71.61 -42.51 67.61 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.07 -1.019 . . . . 0.0 111.148 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 p -112.12 -29.42 2.36 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.188 0 O-C-N 121.252 -0.905 . . . . 0.0 112.168 -176.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.598 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.98 161.09 37.15 Favored Glycine 0 N--CA 1.495 2.587 0 O-C-N 120.702 -1.249 . . . . 0.0 110.606 179.31 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 84.7 t -108.99 127.34 65.73 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.075 0 O-C-N 121.807 -0.82 . . . . 0.0 108.903 179.363 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -88.01 -63.12 1.35 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.08 -1.013 . . . . 0.0 111.181 -178.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -115.07 142.94 45.96 Favored 'General case' 0 N--CA 1.505 2.293 0 CA-C-O 121.872 0.844 . . . . 0.0 111.937 -178.002 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -120.08 130.87 54.86 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.07 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.91 128.62 32.93 Favored 'General case' 0 N--CA 1.505 2.325 0 O-C-N 121.067 -1.02 . . . . 0.0 110.104 -178.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.43 135.38 54.08 Favored 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 179.14 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -120.0 134.73 55.16 Favored 'General case' 0 N--CA 1.503 2.205 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 14.5 p -130.22 124.24 32.05 Favored 'General case' 0 N--CA 1.505 2.283 0 CA-C-O 121.571 0.7 . . . . 0.0 111.016 -179.181 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.29 156.98 47.48 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.762 -0.586 . . . . 0.0 110.131 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 65.6 m95 -69.61 149.51 48.06 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.707 -1.246 . . . . 0.0 108.135 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.45 ' O ' ' N ' ' A' ' 42' ' ' ARG . 31.7 t -117.95 123.11 71.2 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.171 0 O-C-N 121.353 -0.842 . . . . 0.0 109.394 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 116.37 -0.96 20.63 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 31.8 m -95.63 136.07 36.5 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.237 -1.155 . . . . 0.0 108.661 179.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 96.1 mtt180 -79.45 -5.09 53.98 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.152 -0.967 . . . . 0.0 109.465 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 53.7 p . . . . . 0 N--CA 1.489 1.503 0 CA-C-O 118.013 -0.994 . . . . 0.0 109.153 179.387 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 5.032 0 N-CA-C 119.933 2.733 . . . . 0.0 119.933 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.46 -178.5 45.35 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.801 -1.32 . . . . 0.0 109.801 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 51.5 p -96.38 143.33 27.53 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.233 -1.157 . . . . 0.0 109.454 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -109.79 -131.42 6.15 Favored Glycine 0 N--CA 1.502 3.041 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -179.714 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 87.8 t90 -68.73 125.31 26.17 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.407 -1.055 . . . . 0.0 109.89 -179.477 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -134.61 18.05 3.6 Favored 'General case' 0 N--CA 1.493 1.724 0 CA-C-O 121.299 0.571 . . . . 0.0 109.855 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 57.77 20.03 6.14 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.434 -0.791 . . . . 0.0 109.109 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.435 ' O ' ' OD1' ' A' ' 8' ' ' ASP . 39.2 t0 -99.19 6.09 46.51 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.296 -0.877 . . . . 0.0 111.427 -178.546 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.7 p-10 -130.01 9.3 5.3 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 120.843 -1.161 . . . . 0.0 108.908 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 2.2 m -124.68 129.96 73.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -89.81 148.25 39.41 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.016 -1.053 . . . . 0.0 108.759 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -80.15 -22.36 7.23 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.408 2.072 . . . . 0.0 111.937 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 56.0 m -60.24 -40.16 89.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.916 . . . . 0.0 110.411 -179.583 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -81.05 -13.77 58.48 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.031 -1.043 . . . . 0.0 110.239 -179.286 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.801 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 53.9 m -71.11 -29.06 64.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.11 178.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -120.46 135.05 61.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 64.0 mmtt -111.96 147.86 35.0 Favored 'General case' 0 N--CA 1.502 2.161 0 O-C-N 121.291 -0.88 . . . . 0.0 109.292 -179.318 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -97.11 119.86 36.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 108.796 179.516 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 47.8 t -107.56 116.08 31.3 Favored 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.56 -109.42 1.21 Allowed Glycine 0 N--CA 1.487 2.038 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 -178.681 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.414 ' CG2' ' HG1' ' A' ' 72' ' ' THR . 7.7 p -118.74 34.64 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.43 -1.041 . . . . 0.0 108.997 179.16 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -130.66 159.37 37.42 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 122.194 0.997 . . . . 0.0 111.567 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -120.8 136.79 54.81 Favored 'General case' 0 N--CA 1.496 1.825 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 26.5 p -137.25 154.44 50.14 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.245 -0.909 . . . . 0.0 109.279 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.8 t80 -87.67 128.06 35.29 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.266 -0.896 . . . . 0.0 109.597 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -86.01 83.21 7.83 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.929 -1.107 . . . . 0.0 109.92 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 86.4 p -84.65 -0.98 55.4 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.933 -1.104 . . . . 0.0 109.424 179.627 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.67 -39.96 95.87 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.089 -1.605 . . . . 0.0 109.089 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 33.4 m -81.83 135.28 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.332 -1.099 . . . . 0.0 108.774 179.433 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 34' ' ' GLN . 17.1 p -72.76 -26.8 61.68 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.182 -0.949 . . . . 0.0 110.873 -178.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.9 p -59.9 -40.85 83.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 120.841 -1.162 . . . . 0.0 110.774 -178.504 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.801 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 87.0 m -68.69 -39.9 80.3 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.839 -1.163 . . . . 0.0 109.228 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 99.5 mmm -80.09 -14.6 58.39 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.134 -0.979 . . . . 0.0 108.68 179.089 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.421 ' N ' ' O ' ' A' ' 30' ' ' SER . 7.2 tt0 -60.62 -41.98 95.92 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.01 -41.2 28.1 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.378 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.3 tp -67.16 -40.26 86.63 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -1.128 . . . . 0.0 108.687 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -63.07 -40.03 96.47 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.48 -0.763 . . . . 0.0 110.539 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.537 ' N ' ' OE1' ' A' ' 38' ' ' GLU . 0.4 OUTLIER -75.09 -11.41 60.09 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.831 -1.168 . . . . 0.0 109.763 -179.403 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.24 21.5 70.16 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 119.901 -1.142 . . . . 0.0 110.443 178.654 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 62.3 mttm -98.66 -3.38 36.15 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.461 HG12 ' H ' ' A' ' 43' ' ' GLY . 94.0 t -134.91 159.28 41.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 95.0 mtt-85 -122.08 -7.13 8.89 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 179.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.461 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.78 -163.22 25.88 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 -179.504 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 87.8 t -119.39 129.19 75.6 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 121.322 -1.105 . . . . 0.0 109.115 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 5.4 m -86.36 139.19 31.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.861 -1.149 . . . . 0.0 108.897 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 10.6 p -131.25 133.76 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 53.5 p -125.42 149.42 48.21 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 179.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -143.51 138.12 7.96 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 119.574 -1.298 . . . . 0.0 110.062 -179.145 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 62.4 t -122.63 127.06 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 179.064 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.594 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 0.2 OUTLIER -100.87 119.8 39.2 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -179.858 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -94.41 119.92 33.86 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.164 -0.96 . . . . 0.0 108.661 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.482 ' O ' ' N ' ' A' ' 54' ' ' ASP . 93.4 m-85 -102.22 125.79 49.02 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.424 -0.797 . . . . 0.0 109.985 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.438 ' C ' ' H ' ' A' ' 55' ' ' GLY . 20.1 t-20 -47.2 -16.43 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.104 -0.997 . . . . 0.0 109.751 179.562 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.482 ' N ' ' O ' ' A' ' 52' ' ' TYR . 47.4 t0 -70.85 4.72 2.37 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.247 -0.908 . . . . 0.0 109.223 -179.533 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.438 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 77.08 22.76 70.49 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 178.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.4 p -123.54 150.81 43.54 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.33 -1.1 . . . . 0.0 109.339 179.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.1 p -135.33 139.79 44.58 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.583 -0.698 . . . . 0.0 110.152 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.1 m -117.92 144.5 45.41 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 178.352 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.6 m-20 -128.2 118.49 23.42 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.388 -0.82 . . . . 0.0 108.953 -179.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 66.3 t80 -116.76 126.47 53.16 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.256 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -113.74 144.9 42.19 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -159.16 167.83 35.02 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.83 128.58 74.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.599 -0.942 . . . . 0.0 108.694 -179.662 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 45.7 t -92.88 117.87 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.047 -1.033 . . . . 0.0 110.088 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.579 ' HG1' ' H ' ' A' ' 67' ' ' SER . 6.4 p -134.98 153.87 78.81 Favored Pre-proline 0 N--CA 1.492 1.633 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 178.643 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_exo -43.93 -10.13 0.03 OUTLIER 'Trans proline' 0 N--CA 1.494 1.543 0 C-N-CA 121.981 1.788 . . . . 0.0 113.204 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.579 ' H ' ' HG1' ' A' ' 65' ' ' THR . 87.1 p -67.6 -59.52 3.29 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.892 -1.13 . . . . 0.0 110.687 -179.236 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -155.4 150.75 21.21 Favored Pre-proline 0 N--CA 1.498 1.933 0 O-C-N 120.596 -1.315 . . . . 0.0 110.259 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -82.81 161.24 16.25 Favored 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.522 2.148 . . . . 0.0 112.523 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.5 t -110.78 130.5 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 15.7 m-20 -100.8 144.46 29.73 Favored 'General case' 0 N--CA 1.506 2.338 0 O-C-N 120.905 -1.122 . . . . 0.0 111.069 -178.355 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.414 ' HG1' ' CG2' ' A' ' 21' ' ' VAL . 0.1 OUTLIER -93.19 -0.06 56.99 Favored 'General case' 0 N--CA 1.504 2.244 0 O-C-N 121.059 -1.026 . . . . 0.0 108.607 178.531 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 52.2 p-10 -80.43 46.67 0.86 Allowed 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.239 -0.913 . . . . 0.0 109.832 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 62.1 tt0 -48.17 -81.04 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.957 -1.09 . . . . 0.0 110.012 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -112.93 94.9 5.12 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.41 -0.806 . . . . 0.0 109.938 -179.503 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 8.8 mm -68.63 -39.89 81.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.28 -0.888 . . . . 0.0 109.733 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -59.95 -40.97 90.81 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 107.74 -1.207 . . . . 0.0 107.74 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -66.51 -43.13 86.1 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.455 -0.778 . . . . 0.0 109.156 178.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.597 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.2 m -76.1 -47.95 22.55 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.524 -0.735 . . . . 0.0 110.227 -178.721 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -60.05 -32.11 70.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.248 -1.533 . . . . 0.0 109.783 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 18.7 tptt -67.49 -53.53 27.97 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.329 -0.857 . . . . 0.0 110.694 -178.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.12 -22.14 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.172 -0.955 . . . . 0.0 111.515 -178.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.2 167.3 43.39 Favored Glycine 0 N--CA 1.487 2.086 0 O-C-N 120.896 -1.128 . . . . 0.0 110.764 178.729 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 63.8 t -109.86 129.72 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -80.03 -67.08 0.8 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.768 -1.208 . . . . 0.0 110.34 -178.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -113.73 138.78 49.76 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.418 -0.801 . . . . 0.0 109.891 -178.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 63.2 t80 -121.99 126.88 49.53 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.205 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 38.6 ptt180 -133.71 134.7 43.37 Favored 'General case' 0 N--CA 1.502 2.151 0 CA-C-O 121.96 0.886 . . . . 0.0 110.023 179.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.8 136.04 54.16 Favored 'General case' 0 N--CA 1.495 1.798 0 CA-C-O 121.164 0.507 . . . . 0.0 109.749 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 4.0 mt -113.35 131.79 55.83 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.402 -0.811 . . . . 0.0 108.815 179.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 3.8 p -126.12 121.3 32.49 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.677 0.751 . . . . 0.0 109.82 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -133.66 154.46 50.9 Favored 'General case' 0 N--CA 1.498 1.926 0 CA-C-O 121.422 0.63 . . . . 0.0 110.087 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -72.94 138.44 46.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.394 -0.816 . . . . 0.0 109.01 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 39.7 t -109.97 116.31 51.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.752 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -173.39 -48.33 0.05 OUTLIER Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 66.5 m -69.95 149.74 47.44 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.184 -1.186 . . . . 0.0 109.234 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.0 mtt85 -97.96 130.04 44.83 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.227 -0.921 . . . . 0.0 109.05 179.79 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 69.7 m . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 118.054 -0.974 . . . . 0.0 109.254 179.744 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.866 0 N-CA-C 119.563 2.585 . . . . 0.0 119.563 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.42 104.52 1.69 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.15 -1.58 . . . . 0.0 109.15 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 45.7 t -101.37 129.93 47.46 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.359 -1.083 . . . . 0.0 109.422 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.33 19.67 79.38 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.058 -1.617 . . . . 0.0 109.058 -179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 70.3 t90 -56.85 120.54 8.07 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.234 -1.157 . . . . 0.0 109.114 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . 0.503 ' C ' ' H ' ' A' ' 8' ' ' ASP . 13.0 t-20 -128.65 20.59 6.07 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 59.12 1.62 0.23 Allowed 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.759 -0.588 . . . . 0.0 109.699 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.503 ' H ' ' C ' ' A' ' 6' ' ' ASN . 36.4 p-10 -85.13 -26.17 27.04 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.233 -0.917 . . . . 0.0 110.035 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.425 ' N ' ' OD1' ' A' ' 8' ' ' ASP . 22.7 m120 -91.71 1.46 57.14 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.295 -0.878 . . . . 0.0 110.067 -179.141 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.8 t -108.98 129.96 62.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.466 -0.771 . . . . 0.0 109.562 -178.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -90.02 127.6 53.05 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.103 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -76.57 -13.84 18.09 Favored 'Trans proline' 0 N--CA 1.497 1.702 0 C-N-CA 122.082 1.855 . . . . 0.0 112.648 -179.048 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 54.5 m -62.06 -40.01 94.33 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.133 -0.979 . . . . 0.0 110.43 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.416 ' CD ' ' N ' ' A' ' 14' ' ' GLN . 28.2 mp0 -83.35 -12.52 56.47 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.076 -1.015 . . . . 0.0 110.37 -179.2 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.814 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 36.6 t -64.62 -36.62 84.83 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.182 -0.949 . . . . 0.0 110.189 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -117.48 141.1 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 121.399 -0.813 . . . . 0.0 108.887 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 20.4 pttp -118.83 145.46 45.64 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -98.11 124.77 42.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.397 -0.814 . . . . 0.0 109.409 179.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.539 ' O ' ' N ' ' A' ' 21' ' ' VAL . 65.6 m -110.17 131.12 55.34 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.38 -93.68 0.01 OUTLIER Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 -179.235 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.539 ' N ' ' O ' ' A' ' 19' ' ' SER . 26.2 m -139.6 31.39 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.308 -1.113 . . . . 0.0 109.676 179.816 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -131.53 159.41 38.24 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.417 -0.802 . . . . 0.0 109.902 179.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -114.24 139.97 48.96 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.027 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.2 p -136.53 148.79 47.79 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.143 -0.973 . . . . 0.0 109.847 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -84.55 129.92 34.8 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.169 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -90.95 103.73 16.41 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.095 -1.003 . . . . 0.0 110.159 -179.6 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 88.1 p -92.08 -5.99 51.76 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.062 -1.023 . . . . 0.0 108.981 178.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.89 -36.43 90.06 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.8 m -79.0 136.89 22.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.214 -1.168 . . . . 0.0 109.263 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.9 m -68.37 -31.49 70.89 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.409 -0.807 . . . . 0.0 111.157 -178.693 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 85.4 t -59.98 -40.07 82.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.885 -1.135 . . . . 0.0 110.556 -178.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.814 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 68.3 m -59.84 -47.0 87.51 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.629 -1.294 . . . . 0.0 110.056 -179.321 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' MET . . . . . 0.416 ' O ' ' CB ' ' A' ' 37' ' ' ASN . 29.7 mmt -70.23 -34.13 72.49 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.304 -0.873 . . . . 0.0 110.657 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 18.7 mm100 -59.55 -41.53 90.32 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.02 -1.05 . . . . 0.0 110.765 -178.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.68 -49.5 7.14 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 30.6 tp -60.01 -43.71 95.04 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.416 ' CB ' ' O ' ' A' ' 33' ' ' MET . 39.9 t30 -61.47 -39.9 92.56 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.543 -0.723 . . . . 0.0 109.963 179.19 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 49.7 tp10 -60.2 -31.4 70.11 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.329 -0.857 . . . . 0.0 109.819 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.81 15.23 56.86 Favored Glycine 0 N--CA 1.497 2.737 0 N-CA-C 110.306 -1.117 . . . . 0.0 110.306 179.33 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -101.98 -1.16 32.46 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 106.628 -1.619 . . . . 0.0 106.628 178.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.437 HG12 ' H ' ' A' ' 43' ' ' GLY . 98.9 t -130.56 159.91 42.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-N 115.172 -0.922 . . . . 0.0 108.518 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.511 ' N ' ' O ' ' A' ' 94' ' ' VAL . 42.0 ttm180 -123.71 -8.93 7.88 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.252 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.437 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.84 -159.1 26.43 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 108.215 -1.954 . . . . 0.0 108.215 -179.296 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 96.6 t -119.68 128.65 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.306 -1.114 . . . . 0.0 109.178 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.498 ' H ' ' HG ' ' A' ' 45' ' ' SER . 2.5 p -82.97 140.89 32.51 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.279 -0.888 . . . . 0.0 109.012 179.602 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 8.8 p -132.23 130.61 60.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.575 -0.703 . . . . 0.0 109.525 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 16.8 p -123.63 146.04 48.49 Favored 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -140.47 136.74 7.85 Favored Glycine 0 N--CA 1.499 2.84 0 N-CA-C 110.119 -1.193 . . . . 0.0 110.119 -179.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 90.9 t -121.39 129.1 75.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.791 -0.829 . . . . 0.0 108.973 179.113 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -100.72 119.96 39.37 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 179.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 63.6 m-85 -96.49 126.09 41.44 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.323 -0.861 . . . . 0.0 108.945 -179.535 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.545 ' CD1' ' NZ ' ' A' ' 78' ' ' LYS . 90.0 m-85 -111.45 129.42 56.04 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.446 -0.784 . . . . 0.0 110.021 -178.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.429 ' OD1' ' OE1' ' A' ' 85' ' ' GLN . 74.9 m-20 -45.46 -17.27 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.41 -0.806 . . . . 0.0 109.406 178.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.514 ' N ' ' O ' ' A' ' 52' ' ' TYR . 52.5 t0 -68.86 0.09 4.83 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.495 -0.753 . . . . 0.0 109.532 -179.552 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.55 23.96 63.86 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.019 -1.086 . . . . 0.0 110.431 179.219 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.3 p -122.76 147.47 46.46 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.37 -1.077 . . . . 0.0 110.127 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.5 p -131.56 136.27 47.69 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.608 -0.683 . . . . 0.0 109.771 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 41.2 t -118.64 142.73 47.37 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 178.439 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 35.1 p-10 -130.61 120.44 23.99 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.921 -1.112 . . . . 0.0 110.224 -179.224 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.436 ' CZ ' ' NE2' ' A' ' 74' ' ' GLN . 96.1 m-85 -114.71 120.16 39.16 Favored 'General case' 0 N--CA 1.498 1.963 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.52 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.8 ttpt -112.54 152.6 28.64 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 -179.43 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.57 174.67 43.27 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 67.6 t -115.7 126.27 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.623 -0.928 . . . . 0.0 110.04 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 38.2 t -91.23 117.76 35.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.514 -0.741 . . . . 0.0 110.013 -179.364 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.516 ' O ' ' N ' ' A' ' 67' ' ' SER . 21.7 p -121.28 150.92 55.11 Favored Pre-proline 0 N--CA 1.498 1.943 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 178.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_exo -38.34 -20.76 0.05 OUTLIER 'Trans proline' 0 C--N 1.312 -1.358 0 C-N-CA 122.01 1.807 . . . . 0.0 113.372 -179.466 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.516 ' N ' ' O ' ' A' ' 65' ' ' THR . 18.1 p -121.81 2.93 10.04 Favored 'General case' 0 N--CA 1.505 2.29 0 O-C-N 121.181 -0.949 . . . . 0.0 111.88 -179.004 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.44 ' OG1' ' OG1' ' A' ' 65' ' ' THR . 61.1 p -129.94 107.22 16.66 Favored Pre-proline 0 N--CA 1.51 2.537 0 O-C-N 120.768 -1.207 . . . . 0.0 110.687 -179.807 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -90.58 165.31 4.24 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 C-N-CA 122.781 2.32 . . . . 0.0 112.288 178.315 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.1 t -120.47 129.95 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 N-CA-C 108.79 -0.818 . . . . 0.0 108.79 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 30.1 m120 -99.99 121.65 41.68 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.22 -0.925 . . . . 0.0 111.154 -178.432 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -91.02 -0.02 57.64 Favored 'General case' 0 N--CA 1.497 1.914 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.211 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.438 ' O ' ' O ' ' A' ' 74' ' ' GLN . 51.5 p-10 -75.11 57.74 0.85 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.4 -0.813 . . . . 0.0 109.573 -179.218 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.438 ' O ' ' O ' ' A' ' 73' ' ' ASN . 9.4 tp-100 -55.47 -101.92 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.559 -0.713 . . . . 0.0 109.091 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -108.26 100.43 9.74 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 120.967 -1.083 . . . . 0.0 109.231 179.449 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.406 HG21 HD12 ' A' ' 76' ' ' ILE . 44.3 mm -69.86 -39.33 77.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.024 -1.047 . . . . 0.0 109.077 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 -58.29 -41.08 83.6 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.545 ' NZ ' ' CD1' ' A' ' 52' ' ' TYR . 54.5 tttm -60.12 -49.91 75.77 Favored 'General case' 0 N--CA 1.488 1.425 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.367 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.581 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.8 OUTLIER -63.29 -41.03 98.94 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.546 -0.722 . . . . 0.0 110.304 -179.113 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -60.4 -35.94 76.95 Favored 'General case' 0 C--N 1.294 -1.838 0 O-C-N 120.655 -1.278 . . . . 0.0 110.912 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 8.9 tmtm? -70.9 -43.94 67.28 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.701 -1.249 . . . . 0.0 111.463 -178.502 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 p -110.1 -26.0 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.281 0 O-C-N 120.872 -1.142 . . . . 0.0 110.924 -178.281 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.581 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 79.94 157.81 14.73 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.8 t -108.53 130.4 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.067 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.429 ' OE1' ' OD1' ' A' ' 53' ' ' ASN . 18.7 pt20 -97.43 -43.29 7.34 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.185 -0.947 . . . . 0.0 110.929 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -115.9 127.84 55.31 Favored 'General case' 0 N--CA 1.502 2.127 0 O-C-N 121.197 -0.939 . . . . 0.0 110.766 -178.804 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -122.17 123.62 41.94 Favored 'General case' 0 N--CA 1.499 2.003 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 93.8 mtt180 -132.2 133.75 44.54 Favored 'General case' 0 N--CA 1.507 2.387 0 O-C-N 121.073 -1.017 . . . . 0.0 110.799 -179.545 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.1 135.18 53.36 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.797 -0.564 . . . . 0.0 109.58 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 54.5 tp -117.32 137.48 52.41 Favored 'General case' 0 N--CA 1.505 2.316 0 O-C-N 121.421 -0.799 . . . . 0.0 109.73 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.7 p -129.72 123.58 31.43 Favored 'General case' 0 N--CA 1.504 2.25 0 CA-C-O 121.639 0.733 . . . . 0.0 111.241 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.4 tt0 -133.78 157.33 46.16 Favored 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.637 -0.664 . . . . 0.0 109.724 179.145 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 82.4 m95 -69.43 149.31 48.48 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.78 -1.2 . . . . 0.0 109.873 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 42' ' ' ARG . 21.7 t -122.48 127.28 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.549 -0.72 . . . . 0.0 109.629 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 127.67 -16.16 6.23 Favored Glycine 0 N--CA 1.502 3.097 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 178.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.4 p -80.46 128.9 34.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.016 -1.285 . . . . 0.0 108.44 179.35 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 20.4 ttm105 -98.93 118.93 36.82 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.187 -0.946 . . . . 0.0 109.18 -179.706 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.1 m . . . . . 0 N--CA 1.497 1.888 0 CA-C-O 117.991 -1.004 . . . . 0.0 109.403 -179.867 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.841 0 N-CA-C 119.492 2.557 . . . . 0.0 119.492 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.54 170.88 43.92 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 68.7 m -88.44 -9.3 53.01 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.248 -1.149 . . . . 0.0 110.156 -179.416 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 150.05 -157.28 27.15 Favored Glycine 0 N--CA 1.497 2.75 0 N-CA-C 109.971 -1.252 . . . . 0.0 109.971 179.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 20.0 t90 -59.21 139.31 57.07 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.233 -1.157 . . . . 0.0 109.724 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . 0.546 ' C ' ' H ' ' A' ' 8' ' ' ASP . 83.8 m-20 -133.05 128.12 35.55 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 178.065 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -67.38 8.24 0.35 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.162 -0.961 . . . . 0.0 109.252 179.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.546 ' H ' ' C ' ' A' ' 6' ' ' ASN . 94.7 m-20 -98.07 5.31 48.82 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.48 -0.763 . . . . 0.0 110.546 -178.66 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -121.02 6.58 10.33 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -134.85 139.4 47.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -179.429 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 24.5 m-20 -85.02 148.47 50.72 Favored Pre-proline 0 C--N 1.301 -1.51 0 O-C-N 121.269 -0.895 . . . . 0.0 109.264 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -75.63 -20.98 15.15 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.258 1.972 . . . . 0.0 111.655 179.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.486 ' HG ' ' N ' ' A' ' 14' ' ' GLN . 84.0 p -61.48 -37.68 84.52 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.217 -0.927 . . . . 0.0 109.801 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . 0.486 ' N ' ' HG ' ' A' ' 13' ' ' SER . 5.1 tp-100 -70.1 -25.66 63.61 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.172 -0.955 . . . . 0.0 109.384 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.801 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 77.2 m -68.42 -30.67 69.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.119 -0.988 . . . . 0.0 109.903 -179.453 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -124.06 136.66 59.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -120.91 150.65 40.74 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.597 -0.69 . . . . 0.0 109.139 -179.545 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -91.99 119.77 32.02 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.037 -1.04 . . . . 0.0 109.639 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 54.9 m -124.4 131.72 53.51 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.419 -0.8 . . . . 0.0 109.073 179.732 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 46.6 47.99 17.46 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.896 -1.145 . . . . 0.0 110.504 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.4 t 56.92 29.6 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.208 -1.172 . . . . 0.0 110.363 179.451 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 25.3 mt-30 -130.76 164.85 24.22 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.287 -0.883 . . . . 0.0 108.708 178.494 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 39.1 m-85 -120.43 136.77 54.63 Favored 'General case' 0 N--CA 1.501 2.117 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.366 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 34.7 p -139.85 152.3 46.37 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.401 -0.812 . . . . 0.0 109.612 179.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 28.5 t80 -80.81 127.08 32.12 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.638 -0.664 . . . . 0.0 109.229 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -83.6 83.63 7.83 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.342 -0.849 . . . . 0.0 109.783 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 27.9 p -76.68 -8.91 58.17 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.223 -0.923 . . . . 0.0 108.988 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.01 -39.79 70.61 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.6 m -82.27 128.61 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.036 -1.273 . . . . 0.0 108.46 179.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.463 ' O ' ' N ' ' A' ' 34' ' ' GLN . 82.2 p -66.87 -25.0 66.19 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.174 -0.954 . . . . 0.0 110.445 -178.845 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 71.3 t -59.81 -49.24 84.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.242 -0.911 . . . . 0.0 109.937 -178.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.801 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 79.8 m -61.83 -40.08 94.04 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.949 -1.094 . . . . 0.0 109.305 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 5.3 tpt -79.97 -14.87 58.26 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.079 -1.013 . . . . 0.0 108.7 179.615 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.463 ' N ' ' O ' ' A' ' 30' ' ' SER . 5.9 tp-100 -63.15 -40.04 96.43 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.05 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -73.17 -45.41 31.49 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.6 mt -61.02 -42.88 99.31 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.316 -1.108 . . . . 0.0 108.994 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -60.25 -39.91 88.42 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.622 0.725 . . . . 0.0 109.265 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -80.01 -10.01 59.74 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.627 -0.67 . . . . 0.0 109.455 -179.522 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.34 31.88 68.56 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -106.41 -5.89 18.64 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 179.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.436 HG13 ' H ' ' A' ' 43' ' ' GLY . 87.2 t -133.12 156.67 42.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.526 HH12 ' H ' ' A' ' 96' ' ' SER . 73.8 mtt85 -120.36 -7.03 9.8 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.436 ' H ' HG13 ' A' ' 41' ' ' VAL . . . 137.8 -166.02 25.21 Favored Glycine 0 N--CA 1.498 2.821 0 N-CA-C 109.042 -1.623 . . . . 0.0 109.042 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.7 t -119.95 126.18 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.282 -1.128 . . . . 0.0 109.239 -179.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 28.6 m -80.76 133.12 35.6 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.255 -0.903 . . . . 0.0 108.775 179.267 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 7.1 p -129.01 132.27 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.586 -0.696 . . . . 0.0 109.396 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.5 p -123.39 148.4 46.12 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -142.4 140.91 10.3 Favored Glycine 0 N--CA 1.503 3.157 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.981 -178.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 94.8 t -124.79 130.03 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.675 -0.897 . . . . 0.0 109.654 179.188 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 33.9 m-85 -104.18 114.36 28.55 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.823 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -86.28 131.68 34.16 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.041 -1.037 . . . . 0.0 109.192 -179.569 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.473 ' C ' ' H ' ' A' ' 54' ' ' ASP . 54.3 m-85 -116.32 134.18 55.18 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.465 -0.772 . . . . 0.0 109.713 -179.439 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.467 ' C ' ' H ' ' A' ' 55' ' ' GLY . 44.8 t30 -57.17 -11.38 1.63 Allowed 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 178.77 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.473 ' H ' ' C ' ' A' ' 52' ' ' TYR . 11.9 t70 -67.01 0.6 2.43 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.467 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 79.52 20.76 68.25 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.173 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 18.4 p -130.9 151.56 51.18 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.297 -1.119 . . . . 0.0 110.914 -179.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 79.2 p -130.05 137.58 50.3 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 56.9 m -116.24 148.89 40.01 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 179.105 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -137.49 127.33 25.58 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.302 -0.874 . . . . 0.0 109.715 179.77 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -116.41 129.13 56.07 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.013 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -114.06 144.95 42.28 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -167.44 164.54 37.99 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.1 t -109.95 128.19 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.535 -0.98 . . . . 0.0 108.932 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 21.2 t -91.91 119.1 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.191 -0.943 . . . . 0.0 110.088 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.448 ' C ' ' H ' ' A' ' 67' ' ' SER . 29.7 p -132.31 149.93 74.56 Favored Pre-proline 0 N--CA 1.492 1.639 0 N-CA-C 106.889 -1.522 . . . . 0.0 106.889 178.268 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -52.28 -9.23 0.48 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 121.443 1.429 . . . . 0.0 111.293 -179.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.448 ' H ' ' C ' ' A' ' 65' ' ' THR . 19.6 m -104.79 -24.93 12.84 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.513 -0.742 . . . . 0.0 110.31 -179.655 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 20.7 m -135.88 107.39 9.76 Favored Pre-proline 0 N--CA 1.506 2.356 0 O-C-N 121.113 -0.992 . . . . 0.0 110.652 -179.593 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -87.04 164.03 8.7 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 C-N-CA 122.148 1.899 . . . . 0.0 111.69 178.428 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.3 t -118.57 129.57 74.65 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.377 -0.827 . . . . 0.0 109.12 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -103.3 136.67 42.64 Favored 'General case' 0 N--CA 1.501 2.105 0 O-C-N 121.148 -0.97 . . . . 0.0 110.678 -178.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -93.12 -1.16 56.7 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 178.347 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.416 ' O ' ' O ' ' A' ' 74' ' ' GLN . 78.3 m-20 -70.31 51.73 0.13 Allowed 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.427 -0.796 . . . . 0.0 109.378 -179.554 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.416 ' O ' ' O ' ' A' ' 73' ' ' ASN . 59.1 tt0 -62.39 -108.47 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 179.507 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -106.32 96.12 6.24 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.137 -0.977 . . . . 0.0 108.384 178.278 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 90.4 mt -84.99 -15.22 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.0 -1.063 . . . . 0.0 110.305 -179.577 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 64.9 t-20 -59.89 -44.6 94.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.919 -1.113 . . . . 0.0 109.837 -179.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 9.7 ptmm? -68.77 -33.96 74.77 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.11 -0.994 . . . . 0.0 109.174 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.607 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.7 OUTLIER -62.89 -45.14 93.9 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.935 -1.103 . . . . 0.0 108.067 178.895 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -59.95 -35.17 74.38 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 120.776 -1.202 . . . . 0.0 108.843 178.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.4 tttp -63.99 -51.15 65.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.402 -0.811 . . . . 0.0 111.07 -178.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.9 m -117.01 -20.8 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.226 0 O-C-N 121.365 -0.835 . . . . 0.0 111.545 -177.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.607 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.28 167.48 42.84 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 179.412 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 53.6 t -108.62 126.49 65.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 57.1 tt0 -79.96 -65.33 1.02 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.892 -1.13 . . . . 0.0 109.958 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.8 tptm -114.38 140.18 48.88 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.52 -0.738 . . . . 0.0 110.554 -178.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 69.2 t80 -119.75 137.23 54.07 Favored 'General case' 0 N--CA 1.5 2.045 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.139 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -138.1 128.08 25.6 Favored 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.066 -1.021 . . . . 0.0 111.068 -178.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.57 133.43 53.29 Favored 'General case' 0 N--CA 1.503 2.177 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 59.4 tp -120.01 135.35 54.96 Favored 'General case' 0 N--CA 1.508 2.434 0 O-C-N 121.298 -0.876 . . . . 0.0 110.169 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 30.6 p -129.23 127.38 41.14 Favored 'General case' 0 N--CA 1.505 2.282 0 CA-C-O 121.679 0.752 . . . . 0.0 110.958 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -132.63 145.86 51.43 Favored 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.692 -0.63 . . . . 0.0 110.221 179.774 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 76.8 m95 -69.88 139.96 53.1 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 120.945 -1.097 . . . . 0.0 108.771 178.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 17.4 t -112.38 117.52 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.453 -0.779 . . . . 0.0 109.546 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 163.03 89.96 0.07 OUTLIER Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 179.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.526 ' H ' HH12 ' A' ' 42' ' ' ARG . 16.5 t -75.09 130.47 39.32 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.024 -1.28 . . . . 0.0 109.224 179.464 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -82.72 145.03 29.81 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.046 -1.034 . . . . 0.0 109.764 -179.616 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.6 t . . . . . 0 N--CA 1.491 1.6 0 CA-C-O 117.925 -1.036 . . . . 0.0 109.269 179.577 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -79.89 -21.73 43.65 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.475 -0.765 . . . . 0.0 110.549 -179.442 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 28.5 m120 -88.48 0.13 56.61 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.933 -1.105 . . . . 0.0 109.424 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.8 t -112.74 127.54 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.553 -0.717 . . . . 0.0 109.42 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -79.04 130.92 68.2 Favored Pre-proline 0 N--CA 1.488 1.444 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -74.49 -10.65 22.21 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 121.706 1.604 . . . . 0.0 111.832 -179.049 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 82.7 p -69.96 -29.34 66.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.301 -0.874 . . . . 0.0 109.505 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 62.9 tt0 -90.07 -19.52 24.26 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.228 -0.92 . . . . 0.0 109.502 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.581 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 48.8 t -66.34 -33.5 75.86 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.089 -1.007 . . . . 0.0 109.846 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.433 ' O ' HD12 ' A' ' 16' ' ' ILE . 2.5 pp -119.35 132.11 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.696 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -113.98 142.87 45.61 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -96.01 127.24 41.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.422 -0.799 . . . . 0.0 110.024 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 49.5 m -115.67 124.24 50.39 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.053 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.62 -103.12 0.11 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.212 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.4 m -129.76 30.5 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.086 0 O-C-N 121.559 -0.965 . . . . 0.0 109.188 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 35.7 tt0 -129.43 153.04 48.32 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.397 -0.815 . . . . 0.0 110.453 -178.362 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -114.34 136.42 53.0 Favored 'General case' 0 N--CA 1.499 1.99 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.193 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 36.9 p -135.36 145.37 47.31 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.338 -0.851 . . . . 0.0 109.553 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 45.6 t80 -80.13 124.46 28.79 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.2 m120 -82.82 86.96 6.82 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.01 -1.056 . . . . 0.0 110.267 -179.087 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 13.8 m -79.61 -13.69 59.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.044 -1.035 . . . . 0.0 109.145 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -65.78 -3.68 16.66 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.448 HG12 HG22 ' A' ' 31' ' ' VAL . 2.0 t -102.93 126.91 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 96.7 p -59.92 -40.12 87.79 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.076 -1.015 . . . . 0.0 111.279 -178.436 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.575 HG23 ' N ' ' A' ' 32' ' ' CYS . 16.2 m -60.56 -44.3 96.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 120.878 -1.139 . . . . 0.0 110.638 -178.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.581 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 89.3 m -60.14 -43.36 95.76 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.099 -1.001 . . . . 0.0 110.563 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 95.2 mmm -84.33 -12.76 54.02 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.721 -1.237 . . . . 0.0 109.121 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 -60.12 -47.44 85.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.889 . . . . 0.0 108.604 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.86 -45.04 17.85 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.2 tp -60.18 -40.01 88.47 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.242 -1.152 . . . . 0.0 109.449 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 97.7 m-20 -66.13 -39.95 90.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.319 -0.863 . . . . 0.0 110.363 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -75.62 -6.17 49.03 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.071 -1.018 . . . . 0.0 109.978 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.93 26.81 73.3 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -101.13 -5.47 25.62 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.733 HG12 ' H ' ' A' ' 43' ' ' GLY . 77.2 t -134.95 159.82 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -179.616 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.455 ' N ' HG12 ' A' ' 41' ' ' VAL . 65.0 mtp180 -122.73 -5.93 8.59 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.819 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.733 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 137.76 -164.92 25.43 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 108.429 -1.868 . . . . 0.0 108.429 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.0 t -120.34 130.0 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.226 -1.161 . . . . 0.0 109.545 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.434 ' H ' HG23 ' A' ' 94' ' ' VAL . 3.3 t -83.17 133.79 35.01 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.189 -0.944 . . . . 0.0 108.726 179.01 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.5 p -129.96 134.22 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.59 -0.694 . . . . 0.0 109.434 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 25.5 p -124.83 146.59 49.19 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.473 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -138.27 140.55 11.23 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.527 HG22 ' OD1' ' A' ' 59' ' ' ASN . 98.2 t -126.53 129.85 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.675 -0.897 . . . . 0.0 109.143 179.216 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -101.44 117.2 34.45 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.723 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 39.1 m-85 -91.96 122.61 34.64 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.403 -0.811 . . . . 0.0 109.079 -179.412 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -104.99 136.16 44.99 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.575 -0.703 . . . . 0.0 109.771 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 -57.27 -11.63 1.88 Allowed 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 11.2 t70 -74.46 2.16 10.19 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.59 21.21 69.78 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.253 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.1 p -120.47 147.02 45.66 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.405 -1.056 . . . . 0.0 110.127 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 71.8 p -130.01 140.95 50.8 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.673 0.749 . . . . 0.0 110.066 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.6 t -116.96 140.83 49.0 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 106.641 -1.614 . . . . 0.0 106.641 178.258 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ASN . . . . . 0.527 ' OD1' HG22 ' A' ' 49' ' ' VAL . 49.0 m-20 -129.96 116.69 18.97 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.035 -1.04 . . . . 0.0 109.727 -179.205 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -116.57 124.38 49.68 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -114.18 146.05 40.87 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -163.96 168.31 38.4 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.159 -1.576 . . . . 0.0 109.159 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.3 t -110.39 127.32 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.535 -0.98 . . . . 0.0 109.363 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.3 t -89.59 118.89 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.375 -0.828 . . . . 0.0 109.792 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 30.1 p -128.25 149.97 72.79 Favored Pre-proline 0 N--CA 1.494 1.732 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.89 -16.12 3.86 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 121.276 1.318 . . . . 0.0 111.414 -179.444 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 84.2 p -108.21 -13.2 14.96 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.393 -0.817 . . . . 0.0 110.697 -179.663 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 56.8 m -132.55 106.87 13.07 Favored Pre-proline 0 N--CA 1.505 2.286 0 O-C-N 121.086 -1.009 . . . . 0.0 110.561 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -88.28 162.43 6.95 Favored 'Trans proline' 0 N--CA 1.49 1.293 0 C-N-CA 122.267 1.978 . . . . 0.0 111.833 178.329 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.5 t -120.17 128.49 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.158 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -104.64 128.77 52.77 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.124 -0.985 . . . . 0.0 111.324 -178.487 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 74' ' ' GLN . 1.1 p -90.05 0.09 57.31 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 177.883 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -67.9 60.43 0.07 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-O 121.556 0.693 . . . . 0.0 109.143 -179.449 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.494 ' N ' ' O ' ' A' ' 72' ' ' THR . 59.7 tt0 -68.79 -106.5 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.169 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -103.6 94.47 5.48 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.009 -1.057 . . . . 0.0 109.74 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 79.5 mt -74.46 -29.82 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.013 -1.054 . . . . 0.0 109.698 179.351 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -59.94 -42.63 94.42 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.809 -1.182 . . . . 0.0 108.186 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 84.2 tttt -65.27 -42.16 93.49 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.277 -0.889 . . . . 0.0 108.749 178.78 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.599 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.4 OUTLIER -69.75 -42.7 73.54 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.562 -0.711 . . . . 0.0 110.179 -179.132 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -63.51 -32.76 74.3 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.168 -1.582 . . . . 0.0 109.233 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.0 tttt -69.81 -47.38 63.03 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 110.735 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.4 p -112.2 -27.55 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 O-C-N 121.504 -0.747 . . . . 0.0 111.661 -177.126 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.599 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 88.61 169.7 45.04 Favored Glycine 0 N--CA 1.49 2.244 0 O-C-N 120.715 -1.241 . . . . 0.0 110.452 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.473 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 23.5 t -115.43 129.67 71.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.892 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -80.07 -67.46 0.76 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.071 -1.018 . . . . 0.0 110.297 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -116.51 140.12 49.71 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.508 -0.745 . . . . 0.0 110.846 -179.102 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 68.9 t80 -119.96 131.8 55.3 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.036 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -131.53 132.6 44.3 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.08 -1.012 . . . . 0.0 110.788 -178.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.52 137.1 54.84 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.802 -0.561 . . . . 0.0 109.551 179.266 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 44.7 tp -117.16 133.32 56.14 Favored 'General case' 0 N--CA 1.502 2.167 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.622 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 p -129.08 122.18 29.39 Favored 'General case' 0 N--CA 1.503 2.215 0 CA-C-O 121.708 0.766 . . . . 0.0 110.733 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -132.35 152.75 51.3 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.891 -0.506 . . . . 0.0 109.846 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 78.0 m95 -70.21 139.89 52.37 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.048 -1.033 . . . . 0.0 109.07 178.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.434 HG23 ' H ' ' A' ' 45' ' ' SER . 59.7 t -112.53 120.83 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.156 0 O-C-N 121.383 -0.823 . . . . 0.0 109.397 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.487 0 N-CA-C 109.189 -1.564 . . . . 0.0 109.189 179.844 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.653 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.414 ' OD1' ' O ' ' A' ' 8' ' ' ASP . 61.1 t0 -92.13 -27.47 17.71 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.234 -0.917 . . . . 0.0 109.555 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -95.15 4.08 54.01 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.392 -0.817 . . . . 0.0 110.099 -179.276 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 19.7 t -110.61 134.08 54.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.5 -0.75 . . . . 0.0 109.88 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -90.81 131.61 37.07 Favored Pre-proline 0 N--CA 1.49 1.526 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.49 -14.16 22.5 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 121.747 1.631 . . . . 0.0 111.592 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 59.8 p -67.22 -35.83 80.42 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.518 -0.739 . . . . 0.0 109.867 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -90.05 -11.62 40.9 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.208 -0.933 . . . . 0.0 110.313 -179.095 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.668 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 8.2 t -69.63 -29.4 66.89 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.974 -1.079 . . . . 0.0 108.471 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.4 pp -120.62 145.47 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 61.1 mttp -127.09 154.14 45.09 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.402 -0.811 . . . . 0.0 110.032 -179.269 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 -96.07 120.01 35.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.463 -0.773 . . . . 0.0 109.692 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 5.9 t -110.34 115.14 29.14 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.87 -111.09 2.25 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.4 m -117.33 20.69 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.241 0 O-C-N 121.466 -1.02 . . . . 0.0 109.959 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -127.26 160.53 31.02 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.348 -0.845 . . . . 0.0 111.081 -177.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 12.5 m-85 -111.33 134.17 53.11 Favored 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.567 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 37.9 p -132.74 145.48 51.06 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.284 -0.885 . . . . 0.0 108.986 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -82.87 127.26 33.33 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.387 -0.821 . . . . 0.0 108.999 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -84.56 80.52 9.21 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.024 -1.047 . . . . 0.0 109.119 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.516 ' C ' ' H ' ' A' ' 29' ' ' VAL . 92.0 p -83.73 -8.35 59.27 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.413 -0.804 . . . . 0.0 109.485 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.67 -2.74 0.2 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.159 -1.177 . . . . 0.0 110.159 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.516 ' H ' ' C ' ' A' ' 27' ' ' SER . 34.9 m -108.32 131.35 59.03 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.328 -1.101 . . . . 0.0 108.442 179.165 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 82.8 p -63.68 -30.23 71.36 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.287 -0.883 . . . . 0.0 111.278 -178.203 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.452 HG13 ' N ' ' A' ' 32' ' ' CYS . 7.6 p -59.9 -39.9 81.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 120.87 -1.144 . . . . 0.0 110.415 -179.189 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.668 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 56.3 m -59.93 -40.17 87.99 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.95 -1.094 . . . . 0.0 110.077 -179.271 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 9.0 mmt -79.73 -14.31 58.83 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.0 -1.062 . . . . 0.0 109.415 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 -60.76 -40.56 92.98 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.876 -1.14 . . . . 0.0 108.451 179.323 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -82.99 -51.22 4.29 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.5 mt -58.27 -40.07 80.88 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.919 -1.341 . . . . 0.0 108.832 -179.436 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -59.93 -40.02 87.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.342 -0.848 . . . . 0.0 109.497 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 60.3 mm-40 -76.8 -6.76 53.64 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.989 -1.069 . . . . 0.0 109.87 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.35 32.56 68.37 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 120.066 -1.064 . . . . 0.0 110.646 178.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -102.81 -9.65 19.77 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.6 HG12 ' H ' ' A' ' 43' ' ' GLY . 5.8 t -134.19 158.16 41.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -179.087 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 94' ' ' VAL . 97.2 mtt180 -117.33 -11.08 10.63 Favored 'General case' 0 N--CA 1.501 2.087 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 178.837 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.6 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 146.09 -157.33 27.34 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 107.879 -2.088 . . . . 0.0 107.879 -179.175 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 77.2 t -120.01 128.42 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.281 -1.129 . . . . 0.0 108.538 179.239 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.8 m -86.17 132.78 33.94 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.118 -0.989 . . . . 0.0 108.351 179.454 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 46' ' ' VAL . 13.2 p -132.52 132.46 60.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.592 -0.693 . . . . 0.0 109.779 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.3 m -128.47 141.1 51.5 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 178.395 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.426 ' O ' ' OD1' ' A' ' 59' ' ' ASN . . . -130.87 149.6 19.16 Favored Glycine 0 N--CA 1.505 3.272 0 C-N-CA 120.21 -0.995 . . . . 0.0 110.872 -178.621 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 38.2 t -125.04 129.99 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.824 -0.809 . . . . 0.0 108.825 179.359 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.539 ' CE2' ' O ' ' A' ' 72' ' ' THR . 50.0 m-85 -105.45 121.89 44.86 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.475 -0.766 . . . . 0.0 109.567 179.285 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.429 ' HB2' ' H ' ' A' ' 86' ' ' LYS . 45.8 m-85 -95.76 121.59 37.65 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.045 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.444 ' C ' ' N ' ' A' ' 54' ' ' ASP . 93.3 m-85 -106.28 128.61 54.11 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.236 -0.915 . . . . 0.0 109.271 179.802 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.405 ' C ' ' H ' ' A' ' 55' ' ' GLY . 51.9 t30 -48.77 -17.13 0.15 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.067 -1.021 . . . . 0.0 109.199 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.444 ' N ' ' C ' ' A' ' 52' ' ' TYR . 62.7 m-20 -67.99 3.28 1.62 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.407 -0.808 . . . . 0.0 109.115 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.405 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 77.68 19.77 75.21 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 178.655 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.1 p -117.79 147.67 42.78 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.383 -1.069 . . . . 0.0 109.952 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 24.3 p -130.57 127.96 40.1 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.703 -0.623 . . . . 0.0 109.543 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 30.6 t -118.39 154.49 32.31 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ASN . . . . . 0.426 ' OD1' ' O ' ' A' ' 48' ' ' GLY . 57.9 t-20 -141.53 133.15 27.02 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.796 -1.19 . . . . 0.0 110.149 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -116.46 124.41 49.91 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.304 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 62.9 tttm -114.36 143.4 44.96 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.15 172.46 43.38 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 49.0 t -114.74 128.67 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.629 -0.924 . . . . 0.0 109.156 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 75.7 t -98.08 123.02 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.218 -0.927 . . . . 0.0 109.515 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.403 ' O ' ' N ' ' A' ' 67' ' ' SER . 17.0 p -121.55 151.0 56.16 Favored Pre-proline 0 N--CA 1.496 1.856 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_exo -34.49 -34.0 0.08 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.399 2.066 . . . . 0.0 113.191 -179.289 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.403 ' N ' ' O ' ' A' ' 65' ' ' THR . 63.4 m -106.76 -0.55 23.4 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.379 -0.825 . . . . 0.0 111.78 -178.626 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.1 m -124.39 106.86 30.05 Favored Pre-proline 0 N--CA 1.508 2.437 0 O-C-N 120.945 -1.097 . . . . 0.0 111.527 -178.5 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -92.61 161.2 2.89 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 C-N-CA 122.712 2.275 . . . . 0.0 111.025 177.126 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 91.1 t -134.64 139.88 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.238 0 O-C-N 120.952 -1.092 . . . . 0.0 109.825 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -95.43 138.72 32.72 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.165 -0.959 . . . . 0.0 109.158 179.198 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.539 ' O ' ' CE2' ' A' ' 50' ' ' PHE . 5.8 t -110.93 -33.83 6.4 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.321 -0.862 . . . . 0.0 109.419 -179.769 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.508 ' ND2' ' CD1' ' A' ' 76' ' ' ILE . 9.6 t30 -92.1 32.32 1.17 Allowed 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.218 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -54.13 -22.56 11.43 Favored 'General case' 0 N--CA 1.499 2.011 0 C-N-CA 120.276 -0.57 . . . . 0.0 112.246 -178.056 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -107.37 71.9 0.85 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 120.702 -1.249 . . . . 0.0 109.735 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.508 ' CD1' ' ND2' ' A' ' 73' ' ' ASN . 45.7 mm -70.1 -40.35 78.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.335 -0.853 . . . . 0.0 111.332 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -60.12 -46.9 88.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.629 -1.294 . . . . 0.0 108.551 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 29.6 ttmt -60.08 -50.03 75.33 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.293 -0.879 . . . . 0.0 108.864 179.092 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.568 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.3 m -62.36 -42.8 99.69 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.79 -0.569 . . . . 0.0 110.625 -178.554 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.424 ' OD1' HG22 ' A' ' 76' ' ' ILE . 6.0 m120 -60.47 -35.28 75.5 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.561 -1.337 . . . . 0.0 110.027 179.523 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 14.7 tmtt? -67.07 -48.55 67.91 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.089 -1.007 . . . . 0.0 111.079 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -113.45 -26.88 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.183 -0.948 . . . . 0.0 111.572 -178.753 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 90.07 168.11 42.61 Favored Glycine 0 N--CA 1.491 2.323 0 O-C-N 120.54 -1.35 . . . . 0.0 110.173 179.737 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.05 124.58 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -79.92 -65.64 0.98 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.094 -1.004 . . . . 0.0 110.286 -179.169 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.429 ' H ' ' HB2' ' A' ' 51' ' ' TYR . 44.3 tptt -115.38 142.28 46.91 Favored 'General case' 0 N--CA 1.504 2.23 0 O-C-N 121.415 -0.803 . . . . 0.0 110.526 -178.738 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.0 t80 -121.13 132.1 54.65 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 -135.01 127.18 29.98 Favored 'General case' 0 N--CA 1.503 2.199 0 O-C-N 121.126 -0.984 . . . . 0.0 110.358 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.87 134.63 52.63 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.654 -0.653 . . . . 0.0 110.017 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.6 tp -118.51 133.45 55.86 Favored 'General case' 0 N--CA 1.503 2.192 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.2 p -129.2 126.36 39.0 Favored 'General case' 0 N--CA 1.503 2.198 0 CA-C-O 121.53 0.681 . . . . 0.0 110.678 -179.21 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 58.2 mm-40 -134.4 158.46 43.79 Favored 'General case' 0 N--CA 1.504 2.235 0 CA-C-O 121.488 0.661 . . . . 0.0 110.599 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 71.9 m95 -71.15 139.21 50.15 Favored 'General case' 0 N--CA 1.494 1.774 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 178.903 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.431 ' O ' ' N ' ' A' ' 42' ' ' ARG . 44.6 t -112.41 118.79 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.289 -0.882 . . . . 0.0 109.335 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.504 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.318 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -66.72 -73.3 0.14 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.758 -0.589 . . . . 0.0 110.234 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 64.8 t-20 -145.45 47.05 1.29 Allowed 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 179.352 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.409 HG23 ' HE1' ' A' ' 93' ' ' TRP . 2.6 m -81.17 139.75 17.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.538 -0.726 . . . . 0.0 109.077 -178.704 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.447 ' N ' ' OD1' ' A' ' 11' ' ' ASP . 2.0 m-20 -76.66 130.01 77.71 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.906 . . . . 0.0 109.981 -178.724 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -81.55 -19.96 7.2 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.22 1.947 . . . . 0.0 112.079 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 81.9 p -64.87 -36.53 84.64 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.437 -0.79 . . . . 0.0 110.572 -179.574 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -68.99 -24.66 64.26 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.132 -0.98 . . . . 0.0 109.715 -179.504 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.484 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 50.1 t -65.56 -35.16 80.03 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.331 -0.856 . . . . 0.0 109.775 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -117.09 140.42 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.063 0 O-C-N 121.436 -0.79 . . . . 0.0 109.149 -179.673 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -117.82 147.17 43.3 Favored 'General case' 0 N--CA 1.5 2.026 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -93.77 122.22 36.01 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.172 -0.955 . . . . 0.0 109.746 -179.429 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.479 ' O ' ' N ' ' A' ' 21' ' ' VAL . 26.3 t -110.67 123.71 50.53 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.117 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.42 -94.28 0.01 OUTLIER Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.479 ' N ' ' O ' ' A' ' 19' ' ' SER . 24.7 m -139.4 28.03 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.945 0 O-C-N 121.236 -1.155 . . . . 0.0 109.833 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.6 pt20 -131.42 163.65 27.45 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.318 -0.864 . . . . 0.0 110.035 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 54.0 m-85 -115.69 139.97 49.63 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 76.6 p -134.15 148.67 50.98 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.388 -0.82 . . . . 0.0 109.021 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 52.1 t80 -87.54 124.92 33.99 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.441 -0.787 . . . . 0.0 110.007 -178.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -84.39 84.93 7.47 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.33 -0.856 . . . . 0.0 109.732 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 92.4 p -77.22 -9.44 58.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.141 -0.975 . . . . 0.0 109.679 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -72.9 -1.91 56.42 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -98.89 131.64 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.159 -1.2 . . . . 0.0 108.431 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 27.3 t -59.97 -42.58 94.46 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.324 -0.86 . . . . 0.0 110.643 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.451 HG13 ' N ' ' A' ' 32' ' ' CYS . 9.9 p -59.95 -40.15 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.711 -1.243 . . . . 0.0 110.327 -179.061 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.484 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 90.2 m -61.95 -48.29 81.07 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.014 -1.054 . . . . 0.0 111.244 -178.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 1.2 mmt -77.64 -24.67 49.43 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.735 -1.228 . . . . 0.0 111.358 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -60.06 -40.05 88.12 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.709 -1.244 . . . . 0.0 109.498 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -72.44 -44.2 42.53 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.518 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.2 mt -66.2 -42.58 88.58 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.309 -1.112 . . . . 0.0 109.629 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -60.88 -40.08 91.67 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.07 -1.019 . . . . 0.0 110.212 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -78.66 -12.49 60.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.354 -0.841 . . . . 0.0 109.907 -178.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.02 29.27 70.8 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 41.9 mmtm -103.26 -5.39 23.14 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.756 HG12 ' H ' ' A' ' 43' ' ' GLY . 72.4 t -135.13 160.26 40.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.444 ' N ' HG12 ' A' ' 41' ' ' VAL . 93.4 mtt-85 -120.95 -5.96 9.56 Favored 'General case' 0 N--CA 1.501 2.095 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.756 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 132.59 -158.58 23.09 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 107.939 -2.064 . . . . 0.0 107.939 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 81.3 t -121.98 128.1 75.53 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.222 -1.164 . . . . 0.0 110.194 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.6 t -83.13 134.98 34.97 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 178.165 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 7.7 p -131.22 134.57 61.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.38 -0.825 . . . . 0.0 109.963 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.8 p -125.35 141.6 51.98 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -129.61 138.1 10.01 Favored Glycine 0 N--CA 1.503 3.107 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -178.819 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.15 125.01 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.811 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.61 ' CG ' ' NE2' ' A' ' 74' ' ' GLN . 26.3 m-85 -102.31 121.78 42.95 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 77.2 m-85 -94.61 129.28 41.53 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 120.984 -1.072 . . . . 0.0 109.517 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.47 ' OH ' ' NE2' ' A' ' 74' ' ' GLN . 68.4 m-85 -109.34 130.48 55.49 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.613 -0.679 . . . . 0.0 110.433 -179.693 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 43.1 t30 -50.61 -16.72 0.41 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.347 -0.846 . . . . 0.0 108.971 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.419 ' N ' ' C ' ' A' ' 52' ' ' TYR . 29.6 t0 -73.26 1.3 9.7 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.332 -0.855 . . . . 0.0 109.352 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.16 18.98 70.62 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 179.203 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.4 p -117.34 146.74 43.18 Favored 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.482 -1.01 . . . . 0.0 110.106 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.3 p -130.23 140.25 50.73 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.65 0.738 . . . . 0.0 110.384 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 65.3 p -118.14 143.95 46.07 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 178.235 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -137.79 119.73 15.38 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.876 -1.14 . . . . 0.0 109.933 -179.04 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -115.61 125.24 52.68 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -110.55 143.5 40.83 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -161.89 161.46 33.34 Favored Glycine 0 C--N 1.284 -2.319 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 32.2 t -108.12 125.85 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.347 -1.09 . . . . 0.0 109.049 -179.705 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 55.5 t -91.77 116.7 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.318 -0.864 . . . . 0.0 109.417 -179.569 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 67' ' ' SER . 22.3 p -135.89 149.93 70.08 Favored Pre-proline 0 N--CA 1.494 1.73 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 179.244 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_exo -41.47 -18.03 0.07 OUTLIER 'Trans proline' 0 C--N 1.313 -1.307 0 C-N-CA 121.908 1.739 . . . . 0.0 112.039 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.526 ' N ' ' O ' ' A' ' 65' ' ' THR . 68.7 m -69.96 -52.12 27.05 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.277 -0.889 . . . . 0.0 111.139 -179.002 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 60.1 p -149.64 151.75 33.61 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 120.731 -1.231 . . . . 0.0 110.064 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -85.38 165.72 10.84 Favored 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.728 2.285 . . . . 0.0 112.422 178.898 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 68.8 t -111.23 134.05 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.219 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -102.36 131.78 48.76 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.121 -0.987 . . . . 0.0 112.048 -177.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.462 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.3 OUTLIER -111.01 20.07 17.85 Favored 'General case' 0 N--CA 1.503 2.217 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 177.694 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.424 ' O ' ' O ' ' A' ' 74' ' ' GLN . 51.4 p-10 -77.07 55.73 1.17 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.575 -0.703 . . . . 0.0 110.383 -178.782 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.61 ' NE2' ' CG ' ' A' ' 50' ' ' PHE . 13.2 pt20 -49.0 175.04 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.366 -0.834 . . . . 0.0 108.884 178.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -55.19 107.71 0.34 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.819 -1.176 . . . . 0.0 108.64 179.428 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.409 ' O ' HG22 ' A' ' 76' ' ' ILE . 72.2 mt -79.36 -13.83 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.181 -0.949 . . . . 0.0 110.019 -179.55 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -59.94 -45.18 93.47 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.87 -1.144 . . . . 0.0 109.254 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 1.3 ptpp? -66.23 -38.53 88.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.93 -1.107 . . . . 0.0 108.905 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.597 ' O ' ' N ' ' A' ' 83' ' ' GLY . 3.7 m -59.96 -50.06 75.25 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.577 -0.702 . . . . 0.0 110.095 -179.806 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 44.7 t30 -60.48 -36.4 78.21 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 120.498 -1.377 . . . . 0.0 108.852 179.046 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 22.3 tttp -69.37 -47.29 64.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.405 -0.809 . . . . 0.0 110.929 -179.554 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.7 p -111.98 -29.72 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.18 0 O-C-N 121.245 -0.909 . . . . 0.0 111.817 -177.153 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.62 164.49 40.14 Favored Glycine 0 N--CA 1.49 2.279 0 O-C-N 120.705 -1.247 . . . . 0.0 110.696 179.053 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 82.6 t -109.86 130.82 62.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 48.0 tp60 -79.94 -67.37 0.77 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.228 -0.92 . . . . 0.0 110.254 -179.164 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -115.35 146.24 41.74 Favored 'General case' 0 N--CA 1.503 2.184 0 O-C-N 121.453 -0.78 . . . . 0.0 111.152 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -119.73 131.67 55.44 Favored 'General case' 0 N--CA 1.499 1.989 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 14.0 tpp85 -137.62 136.15 37.24 Favored 'General case' 0 N--CA 1.504 2.266 0 O-C-N 120.932 -1.105 . . . . 0.0 111.057 -178.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.524 ' C ' HD12 ' A' ' 90' ' ' LEU . . . -123.97 137.69 54.57 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.445 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.524 HD12 ' C ' ' A' ' 89' ' ' ALA . 10.4 mp -119.84 126.17 50.33 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 16.9 p -127.01 125.09 40.84 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.301 -0.874 . . . . 0.0 110.447 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -132.13 147.44 52.43 Favored 'General case' 0 N--CA 1.5 2.039 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' TRP . . . . . 0.409 ' HE1' HG23 ' A' ' 10' ' ' VAL . 75.1 m95 -70.72 139.27 51.11 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.913 -1.117 . . . . 0.0 109.593 179.497 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.8 t -111.37 123.76 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.976 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.444 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.652 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -179.693 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.162 0.506 . . . . 0.0 109.655 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 34.0 p-10 -86.49 -20.06 28.62 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.038 -1.039 . . . . 0.0 109.172 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 57.0 t30 -95.36 1.68 54.39 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.411 -0.806 . . . . 0.0 109.045 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.6 t -116.41 126.19 73.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.749 -0.594 . . . . 0.0 109.903 -178.848 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -83.49 139.83 41.4 Favored Pre-proline 0 N--CA 1.489 1.499 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 178.514 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -75.65 -14.17 19.86 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 121.762 1.641 . . . . 0.0 111.868 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 77.6 p -60.21 -39.96 88.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.367 -0.833 . . . . 0.0 109.722 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 88.6 mm-40 -84.24 -11.88 55.72 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.139 -0.976 . . . . 0.0 109.725 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.625 ' HG ' ' HG ' ' A' ' 32' ' ' CYS . 29.9 t -69.69 -31.45 69.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.146 -0.971 . . . . 0.0 108.677 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.5 pp -123.58 146.15 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.413 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.5 mttt -111.31 145.18 39.26 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.285 -0.884 . . . . 0.0 109.885 -178.876 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.454 ' NE2' ' CZ ' ' A' ' 87' ' ' TYR . 63.3 tt0 -97.65 114.81 26.84 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.569 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.438 ' O ' ' N ' ' A' ' 21' ' ' VAL . 48.0 m -115.13 130.12 56.84 Favored 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.67 -98.27 0.01 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.438 ' N ' ' O ' ' A' ' 19' ' ' SER . 3.9 m -137.57 27.46 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.369 -1.077 . . . . 0.0 109.836 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 -130.72 162.98 28.27 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 121.196 -0.94 . . . . 0.0 109.956 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -116.95 140.02 49.96 Favored 'General case' 0 N--CA 1.5 2.07 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.028 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 71.3 p -130.53 145.75 51.92 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.38 -0.825 . . . . 0.0 109.446 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -80.78 126.18 31.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.189 -0.944 . . . . 0.0 108.521 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -85.76 83.48 7.84 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.176 -0.953 . . . . 0.0 110.422 -179.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.9 p -81.07 -9.07 59.88 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.132 -0.98 . . . . 0.0 109.614 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -57.42 -39.18 90.14 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.5 m -80.84 136.89 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.106 -1.232 . . . . 0.0 108.984 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 24.1 t -67.54 -30.28 69.89 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.359 -0.838 . . . . 0.0 111.178 -178.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.443 HG13 ' N ' ' A' ' 32' ' ' CYS . 8.1 p -60.0 -40.06 82.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.818 -1.176 . . . . 0.0 110.419 -178.266 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.625 ' HG ' ' HG ' ' A' ' 15' ' ' CYS . 67.3 m -64.17 -40.17 95.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.786 -1.196 . . . . 0.0 110.14 -179.806 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 97.1 mmm -86.36 -14.96 41.95 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.892 -1.13 . . . . 0.0 109.77 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 30.1 tt0 -60.21 -40.27 89.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.985 -1.072 . . . . 0.0 108.127 179.146 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -79.2 -45.48 8.85 Favored Glycine 0 N--CA 1.485 1.902 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.9 tp -60.42 -43.67 96.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.243 -1.151 . . . . 0.0 109.737 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 79.4 m-20 -67.32 -39.81 85.92 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.202 -0.936 . . . . 0.0 110.055 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -60.39 -31.09 70.03 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.03 -1.044 . . . . 0.0 109.349 -179.523 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.52 23.42 23.97 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 64.5 mmtt -109.73 -0.57 18.44 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 178.869 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.735 HG12 ' H ' ' A' ' 43' ' ' GLY . 86.9 t -135.37 158.12 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 121.671 0.748 . . . . 0.0 109.259 -179.501 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.439 ' N ' HG12 ' A' ' 41' ' ' VAL . 67.4 mtp180 -119.9 -9.66 9.63 Favored 'General case' 0 N--CA 1.497 1.925 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.71 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.735 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 137.75 -159.96 25.11 Favored Glycine 0 N--CA 1.497 2.72 0 N-CA-C 108.009 -2.037 . . . . 0.0 108.009 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 90.1 t -118.61 129.73 74.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.143 0 O-C-N 121.18 -1.189 . . . . 0.0 109.315 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.2 t -85.91 138.76 31.79 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.324 -0.86 . . . . 0.0 108.883 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.435 ' O ' HG13 ' A' ' 46' ' ' VAL . 12.7 p -130.13 132.49 65.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.785 0.802 . . . . 0.0 109.544 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.4 p -123.78 146.06 48.59 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -141.77 138.7 8.82 Favored Glycine 0 N--CA 1.5 2.954 0 C-N-CA 119.362 -1.399 . . . . 0.0 111.471 -178.749 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 55.1 t -120.11 122.6 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 178.467 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.518 ' N ' ' CD1' ' A' ' 50' ' ' PHE . 0.3 OUTLIER -100.06 126.18 46.23 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 179.875 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -98.53 121.39 40.4 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.156 -0.965 . . . . 0.0 109.444 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.532 ' O ' ' N ' ' A' ' 54' ' ' ASP . 91.7 m-85 -105.47 125.58 51.14 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.382 -0.824 . . . . 0.0 109.356 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -45.53 -16.62 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.147 -0.971 . . . . 0.0 109.49 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 52' ' ' TYR . 7.4 t70 -67.79 2.52 1.91 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.378 -0.826 . . . . 0.0 109.275 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.39 18.83 77.47 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 16.3 p -116.65 148.36 41.07 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.555 -0.968 . . . . 0.0 110.067 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 69.6 p -129.99 138.07 50.63 Favored 'General case' 0 N--CA 1.496 1.872 0 CA-C-O 121.589 0.709 . . . . 0.0 109.665 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.5 t -118.65 142.37 47.71 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 107.224 -1.399 . . . . 0.0 107.224 178.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ASN . . . . . 0.439 ' O ' ' OD1' ' A' ' 59' ' ' ASN . 39.7 p-10 -135.05 117.04 15.28 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.025 -1.047 . . . . 0.0 109.691 -179.443 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -116.83 130.43 56.71 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.081 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 27.2 ttpp -113.69 141.95 46.61 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.372 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -160.08 161.29 32.35 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 49.1 t -108.74 124.17 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.47 -1.017 . . . . 0.0 108.769 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 53.3 t -97.64 119.18 45.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.326 -0.859 . . . . 0.0 110.214 -179.147 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.65 ' O ' ' N ' ' A' ' 67' ' ' SER . 15.4 p -137.36 159.15 70.62 Favored Pre-proline 0 N--CA 1.491 1.616 0 N-CA-C 107.043 -1.466 . . . . 0.0 107.043 178.562 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_exo -51.2 58.73 0.02 OUTLIER 'Trans proline' 0 N--CA 1.504 2.147 0 C-N-CA 122.247 1.965 . . . . 0.0 113.688 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.65 ' N ' ' O ' ' A' ' 65' ' ' THR . 3.1 m -140.98 -64.07 0.46 Allowed 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.762 -1.211 . . . . 0.0 109.417 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 30.4 p -141.76 149.97 55.2 Favored Pre-proline 0 N--CA 1.5 2.064 0 O-C-N 121.212 -0.93 . . . . 0.0 109.501 179.877 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -84.57 164.11 12.44 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 122.707 2.271 . . . . 0.0 112.717 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.5 t -122.26 130.12 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.026 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 74.6 m-80 -96.77 136.08 37.82 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 120.806 -1.184 . . . . 0.0 111.11 -178.279 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.495 ' O ' ' CZ ' ' A' ' 50' ' ' PHE . 1.6 p -81.11 -51.55 8.34 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 178.467 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.466 ' N ' ' OG1' ' A' ' 72' ' ' THR . 23.6 m120 -81.46 56.1 2.83 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 66.4 tt0 -47.69 -47.23 29.81 Favored 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 119.843 -0.743 . . . . 0.0 109.553 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -106.12 97.68 7.46 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 82.2 mt -80.31 -23.83 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.228 -0.92 . . . . 0.0 109.834 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 22.9 m120 -60.13 -48.82 80.11 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 120.95 -1.094 . . . . 0.0 109.537 -178.265 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 13.8 ptpt -68.28 -38.63 81.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.676 -1.265 . . . . 0.0 109.223 179.581 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.609 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.4 OUTLIER -62.2 -45.7 92.21 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.012 -1.055 . . . . 0.0 108.834 179.47 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 9.5 t-20 -60.05 -34.17 73.03 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.63 -1.293 . . . . 0.0 109.499 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.3 tmtt? -64.86 -50.02 68.26 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.197 -0.939 . . . . 0.0 110.727 -179.055 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.4 p -113.2 -27.66 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.229 -0.919 . . . . 0.0 111.545 -178.471 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.609 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.37 157.69 26.82 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 179.792 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.0 t -103.52 116.49 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 179.533 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 25.3 mt-30 -70.9 -47.83 57.01 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.101 -1.0 . . . . 0.0 111.904 -178.641 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 58.6 tttp -115.58 142.81 46.23 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.239 -0.913 . . . . 0.0 110.798 -178.275 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.454 ' CZ ' ' NE2' ' A' ' 18' ' ' GLN . 62.3 t80 -120.66 130.07 53.96 Favored 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 178.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 2.2 tpp180 -139.44 127.51 22.38 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.082 -1.011 . . . . 0.0 110.422 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.476 ' C ' HD12 ' A' ' 90' ' ' LEU . . . -125.45 135.36 52.26 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.875 179.651 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.476 HD12 ' C ' ' A' ' 89' ' ' ALA . 9.8 mp -119.93 129.7 54.46 Favored 'General case' 0 N--CA 1.504 2.231 0 O-C-N 121.306 -0.871 . . . . 0.0 108.745 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 25.2 p -129.28 127.33 40.96 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 121.267 -0.896 . . . . 0.0 110.821 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -133.15 156.21 47.89 Favored 'General case' 0 N--CA 1.502 2.157 0 CA-C-O 121.222 0.534 . . . . 0.0 110.169 179.479 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 69.0 m95 -70.4 138.45 51.3 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.201 -0.937 . . . . 0.0 108.679 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 27.7 t -111.26 120.03 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.382 -0.824 . . . . 0.0 109.89 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 179.573 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.435 ' HB1' ' NE1' ' A' ' 93' ' ' TRP . . . . . . . . 0 N--CA 1.492 1.662 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -60.9 -39.76 90.56 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.754 -0.591 . . . . 0.0 111.346 -179.079 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -84.27 0.33 49.38 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.861 -1.149 . . . . 0.0 110.195 -178.095 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.4 t -106.1 131.54 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.252 -0.905 . . . . 0.0 108.703 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.522 ' O ' ' N ' ' A' ' 13' ' ' SER . 4.3 m-20 -99.91 108.61 52.53 Favored Pre-proline 0 N--CA 1.492 1.662 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 179.634 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -44.72 -12.01 0.05 OUTLIER 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 121.931 1.754 . . . . 0.0 112.35 -179.568 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.522 ' N ' ' O ' ' A' ' 11' ' ' ASP . 88.1 p -69.59 -38.61 77.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.258 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 98.7 mm-40 -91.14 -6.79 53.1 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 120.947 -1.095 . . . . 0.0 109.967 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.793 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 22.4 t -70.66 -24.89 62.78 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.191 -0.943 . . . . 0.0 109.804 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.573 ' CG2' HG11 ' A' ' 44' ' ' VAL . 1.0 OUTLIER -120.8 151.25 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.152 0 O-C-N 121.569 -0.707 . . . . 0.0 110.27 -179.059 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -118.58 137.15 53.45 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.766 -0.584 . . . . 0.0 109.61 -179.54 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -100.35 121.63 41.81 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.205 -0.934 . . . . 0.0 110.353 -179.235 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 83.5 p -121.21 127.56 51.58 Favored 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.561 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.73 -111.13 1.72 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.638 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.6 m -127.88 36.51 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.084 0 O-C-N 121.451 -1.029 . . . . 0.0 109.605 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -131.6 160.02 36.57 Favored 'General case' 0 N--CA 1.5 2.051 0 CA-C-O 121.646 0.736 . . . . 0.0 110.62 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -119.67 139.96 51.4 Favored 'General case' 0 N--CA 1.498 1.966 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 80.7 p -134.94 151.13 50.58 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.328 -0.857 . . . . 0.0 109.825 -179.2 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 48.3 t80 -87.51 122.88 31.79 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.393 -0.817 . . . . 0.0 109.311 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -82.66 88.28 6.7 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.344 -0.847 . . . . 0.0 109.77 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 59.7 p -80.5 -9.9 59.75 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.106 -0.996 . . . . 0.0 109.626 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -56.66 -31.8 60.89 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -84.24 114.23 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.06 -1.259 . . . . 0.0 107.989 179.281 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.545 ' O ' ' N ' ' A' ' 34' ' ' GLN . 59.7 m -60.05 -40.04 88.04 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.237 -0.914 . . . . 0.0 111.132 -178.87 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 6.1 m -52.09 -40.69 30.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 120.946 -1.096 . . . . 0.0 110.653 -178.115 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.793 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 55.3 m -69.97 -44.51 69.33 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.818 -1.176 . . . . 0.0 109.869 -179.902 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 31.1 ttm -81.07 -13.0 59.18 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.023 -1.048 . . . . 0.0 109.623 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLN . . . . . 0.545 ' N ' ' O ' ' A' ' 30' ' ' SER . 62.5 tt0 -61.44 -40.03 92.98 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 179.207 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.33 -39.96 29.79 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.0 tp -59.84 -43.52 94.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.14 -1.212 . . . . 0.0 108.407 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 44.5 t30 -62.15 -40.22 95.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.507 -0.745 . . . . 0.0 109.775 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -69.07 -26.56 65.01 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.361 -0.837 . . . . 0.0 110.308 -179.394 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 91.17 18.07 47.99 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.854 -1.165 . . . . 0.0 110.804 179.147 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 40.1 mtmt -97.92 -0.75 44.34 Favored 'General case' 0 N--CA 1.495 1.793 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 178.237 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.734 HG12 ' H ' ' A' ' 43' ' ' GLY . 59.7 t -136.12 156.72 37.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 115.021 -0.99 . . . . 0.0 108.511 -179.669 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -115.74 -10.17 11.8 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.273 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.734 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 139.55 -152.14 22.34 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 108.298 -1.921 . . . . 0.0 108.298 -179.566 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.573 HG11 ' CG2' ' A' ' 16' ' ' ILE . 9.5 p -125.06 129.44 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 121.068 -1.254 . . . . 0.0 109.647 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 t -87.42 134.6 33.57 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.294 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.457 HG13 ' O ' ' A' ' 46' ' ' VAL . 9.1 p -130.06 131.18 66.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.405 -0.81 . . . . 0.0 109.359 179.752 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 53.1 p -121.21 149.72 42.41 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -140.49 144.4 14.77 Favored Glycine 0 N--CA 1.502 3.051 0 C-N-CA 119.603 -1.284 . . . . 0.0 110.751 -178.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 96.0 t -126.37 128.9 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.513 -0.993 . . . . 0.0 109.429 178.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -102.21 120.4 40.4 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.836 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -95.5 126.34 40.72 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.246 -0.909 . . . . 0.0 109.314 -179.74 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.51 ' O ' ' N ' ' A' ' 54' ' ' ASP . 55.0 m-85 -109.51 126.5 53.61 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.383 -0.823 . . . . 0.0 109.257 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -45.94 -17.3 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.123 -0.986 . . . . 0.0 109.167 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.51 ' N ' ' O ' ' A' ' 52' ' ' TYR . 39.9 t0 -67.67 0.96 2.74 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.501 -0.75 . . . . 0.0 109.013 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.76 27.77 58.19 Favored Glycine 0 N--CA 1.494 2.5 0 O-C-N 121.206 -0.934 . . . . 0.0 110.769 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.5 p -123.15 150.02 43.81 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.389 -1.065 . . . . 0.0 109.78 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 39.6 p -132.58 133.99 44.37 Favored 'General case' 0 N--CA 1.501 2.101 0 CA-C-O 121.618 0.723 . . . . 0.0 109.669 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 48.3 t -119.89 142.82 48.35 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 178.688 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 37.9 t-20 -132.49 125.72 31.3 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 120.994 -1.066 . . . . 0.0 109.488 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -117.72 128.27 54.73 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.462 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.0 ttpm? -110.82 143.78 40.86 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -158.03 159.34 29.91 Favored Glycine 0 C--N 1.285 -2.282 0 N-CA-C 108.763 -1.735 . . . . 0.0 108.763 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 56.0 t -109.55 124.27 66.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.487 -1.007 . . . . 0.0 108.789 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.9 t -90.21 118.94 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.421 -0.799 . . . . 0.0 109.321 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.538 ' O ' ' N ' ' A' ' 67' ' ' SER . 30.6 p -132.89 151.57 78.27 Favored Pre-proline 0 N--CA 1.492 1.659 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 178.637 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -48.75 -5.51 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 121.295 1.33 . . . . 0.0 111.39 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.538 ' N ' ' O ' ' A' ' 65' ' ' THR . 19.7 t -75.62 -57.33 3.95 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.152 -0.968 . . . . 0.0 110.422 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 56.4 p -147.68 151.82 39.95 Favored Pre-proline 0 N--CA 1.502 2.142 0 O-C-N 120.855 -1.153 . . . . 0.0 110.107 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -84.67 167.33 11.55 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.939 2.426 . . . . 0.0 112.265 178.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.2 t -102.74 131.09 51.68 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -97.39 122.98 41.06 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.334 -0.853 . . . . 0.0 111.976 -177.727 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 1.2 p -93.37 -0.21 56.66 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 178.125 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.43 ' O ' ' OD1' ' A' ' 73' ' ' ASN . 41.3 t-20 -75.4 54.03 0.71 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.57 -0.706 . . . . 0.0 109.254 -179.631 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -62.96 -87.18 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -114.35 84.41 2.05 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.497 -0.752 . . . . 0.0 109.226 178.679 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 10.1 tp -70.11 -32.85 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.121 -0.987 . . . . 0.0 109.727 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.7 t30 -60.02 -47.39 86.04 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.1 -178.003 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.421 ' CG ' ' N ' ' A' ' 79' ' ' THR . 15.1 ptmt -63.63 -39.82 95.33 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.707 -1.246 . . . . 0.0 108.215 179.288 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.582 ' O ' ' N ' ' A' ' 83' ' ' GLY . 2.0 m -59.96 -40.71 89.96 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -179.614 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -66.59 -31.8 72.74 Favored 'General case' 0 C--N 1.295 -1.792 0 O-C-N 120.579 -1.326 . . . . 0.0 109.382 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 7.6 tmtm? -69.84 -44.28 70.22 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.915 -1.116 . . . . 0.0 110.378 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -110.58 -26.44 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.377 0 O-C-N 121.206 -0.934 . . . . 0.0 111.349 -178.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.47 164.29 37.6 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.563 HG23 HG23 ' A' ' 79' ' ' THR . 71.4 t -111.21 128.16 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.167 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 93.1 mm-40 -81.27 -65.5 1.0 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.086 -1.009 . . . . 0.0 110.996 -178.809 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 45.1 tptt -113.92 141.76 46.97 Favored 'General case' 0 N--CA 1.503 2.181 0 O-C-N 121.438 -0.789 . . . . 0.0 110.639 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -120.17 131.25 54.93 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 95.5 mtt180 -131.8 130.8 42.27 Favored 'General case' 0 N--CA 1.508 2.432 0 O-C-N 121.094 -1.004 . . . . 0.0 110.524 -179.231 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -122.68 137.89 54.77 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.675 -0.64 . . . . 0.0 109.894 179.649 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 60.3 tp -120.01 133.31 55.58 Favored 'General case' 0 N--CA 1.506 2.355 0 O-C-N 121.298 -0.876 . . . . 0.0 109.058 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.9 p -128.7 126.11 39.39 Favored 'General case' 0 N--CA 1.504 2.227 0 CA-C-O 121.581 0.705 . . . . 0.0 110.485 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -133.24 159.21 40.88 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.759 -0.588 . . . . 0.0 110.198 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' TRP . . . . . 0.435 ' NE1' ' HB1' ' A' ' 7' ' ' ALA . 50.7 m95 -75.66 136.46 40.42 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.372 -0.83 . . . . 0.0 108.775 178.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 21.4 t -106.79 120.81 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.485 -0.759 . . . . 0.0 109.304 -179.77 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.537 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 -179.771 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.61 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -93.11 -25.7 17.77 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.113 -0.992 . . . . 0.0 110.759 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -90.05 4.83 49.07 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.846 -1.159 . . . . 0.0 109.916 -179.18 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.465 HG11 HG11 ' A' ' 31' ' ' VAL . 13.9 t -118.16 131.05 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.379 -0.826 . . . . 0.0 109.686 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 59.0 m-20 -81.96 133.91 50.71 Favored Pre-proline 0 C--N 1.301 -1.512 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 177.843 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -74.79 -15.34 21.34 Favored 'Trans proline' 0 N--CA 1.494 1.535 0 C-N-CA 121.848 1.699 . . . . 0.0 112.12 -178.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 79.8 p -69.05 -28.83 66.9 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.51 -0.744 . . . . 0.0 110.4 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -78.94 -11.32 60.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.121 -0.987 . . . . 0.0 109.307 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.483 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 11.7 t -69.93 -39.89 75.85 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.062 -1.024 . . . . 0.0 109.81 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.663 HD13 ' H ' ' A' ' 16' ' ' ILE . 0.1 OUTLIER -121.38 142.22 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.108 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 179.504 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -115.85 147.48 40.99 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.476 -0.765 . . . . 0.0 109.697 -178.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -85.05 113.0 21.14 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.43 -0.793 . . . . 0.0 108.953 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.5 m -103.36 120.04 40.03 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.19 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.92 -99.78 0.04 OUTLIER Glycine 0 N--CA 1.488 2.148 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 -179.608 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 t -128.32 20.2 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.456 -1.026 . . . . 0.0 109.195 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -129.61 167.88 17.27 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 121.357 -0.839 . . . . 0.0 110.732 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -124.31 145.21 49.55 Favored 'General case' 0 N--CA 1.501 2.079 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 40.5 p -136.8 153.65 50.76 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.272 -0.893 . . . . 0.0 110.051 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -85.59 123.28 30.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.584 -0.698 . . . . 0.0 109.695 -179.062 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -88.5 83.83 6.8 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.301 -0.875 . . . . 0.0 110.139 -179.578 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 77.7 p -79.85 -4.89 54.15 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 120.991 -1.068 . . . . 0.0 108.989 179.09 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.73 -40.1 96.14 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.0 m -72.97 139.97 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.008 -1.289 . . . . 0.0 108.862 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 55.2 p -69.04 -25.55 64.53 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.394 -0.816 . . . . 0.0 110.587 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.465 HG11 HG11 ' A' ' 10' ' ' VAL . 54.0 t -60.03 -43.11 91.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.011 -1.056 . . . . 0.0 110.089 -179.037 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.483 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.0 m -60.99 -39.95 91.62 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.067 -1.02 . . . . 0.0 110.464 -179.257 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.2 mmt -80.47 -14.44 58.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.934 -1.104 . . . . 0.0 110.037 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -61.07 -42.56 98.72 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.058 -1.026 . . . . 0.0 108.914 179.207 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.2 -47.42 9.17 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.7 mt -61.26 -41.66 97.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.074 -1.251 . . . . 0.0 110.14 -179.693 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -65.52 -39.86 92.31 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.166 -0.959 . . . . 0.0 109.333 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -66.86 -29.66 69.62 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.379 -0.826 . . . . 0.0 109.494 -179.601 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.28 22.29 54.76 Favored Glycine 0 N--CA 1.494 2.557 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 31.2 ttmt -107.61 -3.51 19.21 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 179.218 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.73 HG12 ' H ' ' A' ' 43' ' ' GLY . 86.3 t -133.68 160.27 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.305 -179.183 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.451 ' N ' HG12 ' A' ' 41' ' ' VAL . 81.5 mtt85 -121.79 -8.1 8.97 Favored 'General case' 0 N--CA 1.499 2.023 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.73 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.34 -152.86 23.14 Favored Glycine 0 N--CA 1.499 2.86 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 99.2 t -126.53 130.0 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.322 0 O-C-N 121.066 -1.255 . . . . 0.0 109.667 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.406 ' H ' HG23 ' A' ' 94' ' ' VAL . 1.1 t -84.43 137.86 33.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.319 -0.863 . . . . 0.0 109.608 179.542 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 7.5 p -132.7 134.19 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.43 -0.794 . . . . 0.0 108.943 179.034 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 86.7 p -121.93 146.91 46.67 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 179.379 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -135.99 131.24 5.64 Favored Glycine 0 N--CA 1.498 2.811 0 C-N-CA 119.964 -1.112 . . . . 0.0 110.525 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 53.7 t -120.96 127.02 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.012 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -105.47 116.05 31.3 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 179.456 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -92.97 137.53 32.28 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.361 -0.837 . . . . 0.0 109.879 -178.506 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 74.0 m-85 -120.11 137.08 54.35 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.367 -0.833 . . . . 0.0 109.676 179.347 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 18.7 t-20 -47.29 -21.32 0.27 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.475 -0.766 . . . . 0.0 109.531 179.468 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.414 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 10.4 t70 -68.47 0.95 3.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.267 -0.896 . . . . 0.0 109.208 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 75.61 17.93 79.94 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.09 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.9 p -111.65 154.39 24.98 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.444 -1.033 . . . . 0.0 108.932 179.329 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 32.7 p -140.44 148.01 40.53 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.38 -0.825 . . . . 0.0 110.525 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 54.9 m -117.86 147.58 42.94 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 106.046 -1.835 . . . . 0.0 106.046 177.725 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -139.97 116.17 10.5 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.974 -1.079 . . . . 0.0 109.705 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -115.99 122.42 45.2 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 178.503 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -112.26 145.57 39.71 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -165.92 178.9 40.42 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 -179.466 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 30.4 t -119.42 127.53 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.487 -1.008 . . . . 0.0 109.593 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 t -89.46 118.9 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.436 -0.79 . . . . 0.0 109.875 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.45 ' O ' ' N ' ' A' ' 67' ' ' SER . 26.6 p -138.14 150.05 65.7 Favored Pre-proline 0 N--CA 1.494 1.727 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -44.55 -19.7 0.28 Allowed 'Trans proline' 0 C--N 1.311 -1.4 0 C-N-CA 121.111 1.207 . . . . 0.0 111.414 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.45 ' N ' ' O ' ' A' ' 65' ' ' THR . 69.9 m -70.05 -46.16 65.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.512 -0.743 . . . . 0.0 111.441 -178.931 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -148.47 141.31 15.25 Favored Pre-proline 0 N--CA 1.504 2.235 0 O-C-N 120.664 -1.273 . . . . 0.0 110.945 -178.994 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -86.95 165.09 8.74 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.087 2.524 . . . . 0.0 112.229 178.652 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 72.6 t -113.09 128.34 69.9 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.203 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.456 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 51.9 m-20 -104.52 140.61 37.73 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.285 -0.885 . . . . 0.0 111.818 -177.522 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.43 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.0 OUTLIER -109.9 19.17 19.36 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.024 -1.473 . . . . 0.0 107.024 177.502 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 46.5 t-20 -71.05 55.39 0.19 Allowed 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.637 -0.664 . . . . 0.0 109.522 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.408 ' N ' ' O ' ' A' ' 72' ' ' THR . 55.0 tt0 -49.61 169.35 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.051 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -59.07 123.77 17.72 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.713 -1.242 . . . . 0.0 108.939 -179.482 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 43.3 mm -80.16 -21.61 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.433 -0.792 . . . . 0.0 110.694 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -60.01 -47.73 84.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.673 -1.267 . . . . 0.0 110.069 -179.009 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 9.9 ptpt -64.14 -39.26 93.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.966 -1.084 . . . . 0.0 108.488 179.206 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.549 ' O ' ' N ' ' A' ' 83' ' ' GLY . 30.2 m -60.0 -45.04 94.03 Favored 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.683 0.754 . . . . 0.0 109.438 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -62.01 -36.16 80.7 Favored 'General case' 0 C--N 1.293 -1.887 0 O-C-N 120.949 -1.095 . . . . 0.0 109.972 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 15.0 tmtt? -70.31 -44.83 67.5 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.102 -0.999 . . . . 0.0 111.119 -178.641 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.6 p -117.51 -29.04 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.416 0 O-C-N 121.135 -0.978 . . . . 0.0 111.543 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.549 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.0 158.26 33.92 Favored Glycine 0 N--CA 1.497 2.702 0 O-C-N 120.616 -1.302 . . . . 0.0 110.571 179.35 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 56.1 t -100.04 123.44 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -77.69 -65.0 1.02 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.181 -0.949 . . . . 0.0 111.365 -178.169 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -115.96 152.45 33.45 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.124 -0.985 . . . . 0.0 111.814 -178.353 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 64.8 t80 -120.94 130.92 54.05 Favored 'General case' 0 N--CA 1.5 2.033 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.364 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -136.86 130.2 31.38 Favored 'General case' 0 N--CA 1.507 2.39 0 O-C-N 120.814 -1.179 . . . . 0.0 110.843 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.68 135.44 53.05 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.183 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.59 HD23 ' N ' ' A' ' 91' ' ' THR . 1.2 tt -119.77 129.1 54.31 Favored 'General case' 0 N--CA 1.504 2.228 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.495 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.59 ' N ' HD23 ' A' ' 90' ' ' LEU . 6.5 p -129.1 121.59 28.13 Favored 'General case' 0 N--CA 1.505 2.279 0 O-C-N 121.414 -0.804 . . . . 0.0 111.433 -178.651 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -133.32 159.82 39.14 Favored 'General case' 0 N--CA 1.502 2.165 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.176 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -73.6 144.06 46.13 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.918 -1.113 . . . . 0.0 109.278 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.406 HG23 ' H ' ' A' ' 45' ' ' SER . 60.9 t -114.2 123.71 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.344 -0.848 . . . . 0.0 109.326 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.681 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.621 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -93.62 -28.38 16.04 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.298 -0.876 . . . . 0.0 109.914 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -90.57 0.09 57.48 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.187 -0.946 . . . . 0.0 109.397 -179.53 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.5 t -109.04 127.8 65.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 O-C-N 121.495 -0.753 . . . . 0.0 109.801 -179.391 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 60.4 m-20 -87.06 132.12 42.66 Favored Pre-proline 0 N--CA 1.489 1.515 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 178.104 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -72.84 -14.51 26.73 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 121.633 1.555 . . . . 0.0 112.154 -178.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 30.3 t -61.57 -40.17 93.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.142 -0.974 . . . . 0.0 110.364 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 65.4 mt-30 -81.46 -11.29 59.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.043 -1.035 . . . . 0.0 110.302 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.749 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 35.5 m -70.11 -30.02 67.11 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.948 -1.095 . . . . 0.0 108.939 179.273 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -122.11 140.51 45.79 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -123.95 143.3 50.48 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.528 -0.732 . . . . 0.0 109.398 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -87.5 130.68 34.62 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.086 -1.009 . . . . 0.0 109.456 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 53.6 m -118.9 128.41 54.4 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 46.48 -107.12 0.17 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.7 m -121.78 19.9 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.67 -0.9 . . . . 0.0 109.977 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -130.68 164.99 23.81 Favored 'General case' 0 N--CA 1.503 2.19 0 O-C-N 121.389 -0.819 . . . . 0.0 110.266 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -117.6 140.67 49.33 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 79.2 p -139.94 150.93 45.12 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.305 -0.872 . . . . 0.0 109.044 178.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 8.8 t80 -78.53 128.78 34.03 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.375 -0.828 . . . . 0.0 109.371 -179.412 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -85.69 83.12 7.96 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.341 -0.849 . . . . 0.0 109.257 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.445 ' C ' ' N ' ' A' ' 29' ' ' VAL . 97.6 p -79.08 -5.05 53.12 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.199 -0.938 . . . . 0.0 109.3 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.17 -11.73 0.69 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.474 ' O ' HG23 ' A' ' 29' ' ' VAL . 29.0 m -108.9 127.39 65.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.518 -0.989 . . . . 0.0 108.776 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 64.5 m -70.07 -27.48 64.66 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.42 -0.8 . . . . 0.0 110.451 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.422 HG23 ' N ' ' A' ' 32' ' ' CYS . 3.7 m -60.01 -40.3 82.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.036 -1.04 . . . . 0.0 111.204 -178.18 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.749 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 97.1 m -66.39 -40.24 89.54 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.546 -1.347 . . . . 0.0 110.074 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 70.5 mtp -80.98 -10.08 59.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.953 -1.092 . . . . 0.0 109.603 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -61.23 -40.46 94.1 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -80.46 -51.27 4.99 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.613 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.9 tt -60.14 -41.53 92.92 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.105 -1.232 . . . . 0.0 109.726 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 -60.1 -40.22 88.85 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.018 -1.051 . . . . 0.0 109.736 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -79.01 -6.04 55.37 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.348 -0.845 . . . . 0.0 109.487 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.56 29.25 49.37 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.941 -1.123 . . . . 0.0 110.374 178.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -104.48 -9.54 18.31 Favored 'General case' 0 N--CA 1.496 1.848 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.676 HG12 ' H ' ' A' ' 43' ' ' GLY . 70.9 t -136.15 161.2 37.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.492 ' N ' HG12 ' A' ' 41' ' ' VAL . 57.9 ttm-85 -122.95 -7.65 8.38 Favored 'General case' 0 N--CA 1.495 1.8 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.676 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.3 -161.16 25.63 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 95.0 t -122.5 130.13 74.74 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.335 -1.097 . . . . 0.0 109.103 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.454 ' H ' HG23 ' A' ' 94' ' ' VAL . 1.8 m -86.3 136.79 33.02 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.051 -1.03 . . . . 0.0 108.303 179.364 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.407 ' O ' HG23 ' A' ' 46' ' ' VAL . 6.0 m -132.08 133.45 60.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.644 -0.66 . . . . 0.0 109.543 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 57.3 p -122.65 142.46 50.64 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 179.021 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -131.3 143.06 14.48 Favored Glycine 0 N--CA 1.503 3.151 0 C-N-CA 120.085 -1.055 . . . . 0.0 111.113 -178.545 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 92.6 t -126.25 129.99 72.03 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.852 -0.793 . . . . 0.0 109.405 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -103.97 120.05 40.23 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 62.6 m-85 -96.64 123.22 40.24 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.354 -0.842 . . . . 0.0 109.405 -179.477 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.58 ' CD1' ' NZ ' ' A' ' 78' ' ' LYS . 96.9 m-85 -109.03 128.03 54.61 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.607 -0.683 . . . . 0.0 109.634 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.429 ' C ' ' H ' ' A' ' 55' ' ' GLY . 50.5 t-20 -45.58 -17.27 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.27 -0.894 . . . . 0.0 109.324 179.149 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 52' ' ' TYR . 22.1 t0 -67.42 1.54 2.21 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.429 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 75.36 23.42 73.65 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.346 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.9 p -121.76 149.85 42.69 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.499 -1.001 . . . . 0.0 110.002 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.1 p -134.01 138.08 45.16 Favored 'General case' 0 N--CA 1.499 2.016 0 CA-C-O 121.824 0.821 . . . . 0.0 110.174 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.8 t -119.78 143.2 47.97 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.277 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 58.6 t-20 -134.44 129.84 35.89 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 120.624 -1.297 . . . . 0.0 110.127 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -117.06 128.69 55.4 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -113.98 142.7 45.83 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -165.42 170.58 40.39 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.9 t -113.96 126.45 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.112 0 O-C-N 121.544 -0.974 . . . . 0.0 109.408 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 72.5 t -96.45 117.92 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.075 -1.015 . . . . 0.0 109.906 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.52 ' O ' ' N ' ' A' ' 67' ' ' SER . 24.3 p -126.69 150.12 70.25 Favored Pre-proline 0 N--CA 1.501 2.088 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 179.147 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_exo -37.41 -22.39 0.05 OUTLIER 'Trans proline' 0 N--CA 1.49 1.306 0 C-N-CA 122.227 1.951 . . . . 0.0 112.984 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.52 ' N ' ' O ' ' A' ' 65' ' ' THR . 9.0 t -114.1 -16.06 12.16 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.275 -0.891 . . . . 0.0 111.556 -178.678 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 98.5 m -119.6 106.53 41.99 Favored Pre-proline 0 N--CA 1.502 2.156 0 O-C-N 120.976 -1.077 . . . . 0.0 110.193 -179.258 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -91.41 163.48 3.62 Favored 'Trans proline' 0 N--CA 1.492 1.416 0 C-N-CA 122.657 2.238 . . . . 0.0 112.347 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.8 t -127.22 130.03 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.293 0 N-CA-C 108.714 -0.846 . . . . 0.0 108.714 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -100.16 132.31 45.61 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 121.209 -0.932 . . . . 0.0 111.873 -178.094 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.488 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.0 OUTLIER -105.33 19.96 19.69 Favored 'General case' 0 N--CA 1.498 1.938 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.602 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -67.44 54.37 0.06 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.777 -0.577 . . . . 0.0 109.651 -179.256 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.488 ' N ' ' O ' ' A' ' 72' ' ' THR . 0.0 OUTLIER -48.0 166.71 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.285 -0.885 . . . . 0.0 108.831 179.517 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.449 ' O ' ' NE2' ' A' ' 74' ' ' GLN . 78.3 m-20 -57.09 117.83 4.41 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.006 -1.058 . . . . 0.0 109.538 -178.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 47.7 mm -69.59 -39.48 78.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.768 -0.582 . . . . 0.0 109.582 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -56.15 -41.47 75.44 Favored 'General case' 0 N--CA 1.488 1.425 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.58 ' NZ ' ' CD1' ' A' ' 52' ' ' TYR . 28.3 tttm -62.84 -49.47 74.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.317 -0.865 . . . . 0.0 108.884 178.323 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.582 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.0 OUTLIER -67.61 -42.16 82.84 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.535 -0.728 . . . . 0.0 110.062 -179.099 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -60.96 -34.21 74.39 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 120.641 -1.287 . . . . 0.0 110.902 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -70.99 -43.54 67.79 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.887 -1.133 . . . . 0.0 111.243 -178.615 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.1 p -115.98 -27.78 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.39 -0.819 . . . . 0.0 111.231 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.87 166.01 40.9 Favored Glycine 0 N--CA 1.488 2.162 0 O-C-N 120.675 -1.266 . . . . 0.0 110.371 178.742 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.9 t -111.06 124.91 68.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -81.34 -64.19 1.24 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.162 -0.962 . . . . 0.0 111.073 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -114.22 143.17 45.27 Favored 'General case' 0 N--CA 1.509 2.48 0 O-C-N 121.167 -0.958 . . . . 0.0 111.299 -178.582 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 74.4 t80 -120.5 134.43 55.27 Favored 'General case' 0 N--CA 1.505 2.291 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 178.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 78.9 mtp180 -136.45 129.0 30.47 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 120.968 -1.083 . . . . 0.0 110.944 -178.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.66 132.66 53.39 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.729 -0.607 . . . . 0.0 109.672 179.047 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.518 HD12 ' N ' ' A' ' 90' ' ' LEU . 7.7 mp -108.83 129.46 55.4 Favored 'General case' 0 N--CA 1.503 2.206 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 179.138 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.9 p -124.2 121.46 35.15 Favored 'General case' 0 N--CA 1.507 2.384 0 O-C-N 121.313 -0.867 . . . . 0.0 110.575 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 53.4 tp10 -133.84 150.95 51.41 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.772 -0.58 . . . . 0.0 110.163 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 70.9 m95 -66.95 141.55 57.57 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.992 -1.067 . . . . 0.0 108.737 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.454 HG23 ' H ' ' A' ' 45' ' ' SER . 62.0 t -119.3 130.16 74.32 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.177 0 O-C-N 121.503 -0.748 . . . . 0.0 109.989 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.501 3.0 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.338 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 33.5 p-10 -72.81 -20.13 61.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.34 -0.85 . . . . 0.0 110.708 -178.954 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.7 m120 -99.52 6.71 45.79 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.098 -1.001 . . . . 0.0 109.783 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 29.2 t -119.98 129.97 74.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.47 -0.769 . . . . 0.0 109.905 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.96 140.28 43.1 Favored Pre-proline 0 N--CA 1.489 1.486 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.21 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -71.48 -22.39 24.82 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 121.806 1.671 . . . . 0.0 111.975 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 76.9 p -69.32 -38.93 78.45 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.313 -0.867 . . . . 0.0 109.781 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 56.6 tt0 -70.04 -23.93 63.18 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.304 -0.873 . . . . 0.0 109.739 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.466 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 22.0 m -68.44 -28.54 67.14 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.888 . . . . 0.0 109.685 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.4 pp -116.49 139.1 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.402 -0.811 . . . . 0.0 109.227 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -118.04 147.84 42.84 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.553 -0.717 . . . . 0.0 109.731 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.681 ' NE2' ' CZ ' ' A' ' 23' ' ' TYR . 10.7 tp-100 -99.58 117.73 34.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.649 -0.657 . . . . 0.0 109.266 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.464 ' O ' ' N ' ' A' ' 21' ' ' VAL . 14.6 t -110.45 118.29 35.88 Favored 'General case' 0 N--CA 1.497 1.902 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 179.023 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.03 -92.42 0.02 OUTLIER Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.727 -1.749 . . . . 0.0 108.727 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.464 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.4 t -140.41 30.52 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 O-C-N 121.328 -1.101 . . . . 0.0 109.564 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.443 ' N ' ' OE1' ' A' ' 18' ' ' GLN . 89.1 mt-30 -127.46 158.07 38.35 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.271 -0.893 . . . . 0.0 110.334 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' TYR . . . . . 0.681 ' CZ ' ' NE2' ' A' ' 18' ' ' GLN . 26.9 m-85 -119.74 134.73 55.12 Favored 'General case' 0 N--CA 1.498 1.963 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.1 p -139.97 150.45 44.5 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.225 -0.922 . . . . 0.0 109.833 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.424 ' CZ ' HD11 ' A' ' 36' ' ' LEU . 33.6 t80 -78.99 127.5 32.06 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 179.523 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -82.81 81.52 8.51 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.068 -1.02 . . . . 0.0 109.777 -179.442 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 49.9 m -78.31 -5.98 53.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.168 -0.957 . . . . 0.0 109.068 179.638 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -58.36 -37.43 87.56 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.829 -1.308 . . . . 0.0 109.829 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.2 m -84.32 132.38 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.036 -1.273 . . . . 0.0 109.492 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.9 m -60.09 -39.42 86.04 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.642 -0.661 . . . . 0.0 111.622 -178.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.403 HG23 ' N ' ' A' ' 32' ' ' CYS . 19.7 m -57.62 -42.99 82.56 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 120.849 -1.157 . . . . 0.0 111.369 -177.336 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.466 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 93.0 m -67.05 -39.99 87.05 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.45 -1.406 . . . . 0.0 109.412 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.1 tpt -79.99 -11.72 59.76 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.008 -1.058 . . . . 0.0 108.419 179.608 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 61.2 tt0 -65.41 -39.85 92.65 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.07 -46.59 15.79 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.424 HD11 ' CZ ' ' A' ' 25' ' ' TYR . 23.7 mt -60.04 -50.11 75.02 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.213 -1.169 . . . . 0.0 109.943 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -61.08 -39.99 91.98 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.076 -1.015 . . . . 0.0 110.0 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.437 ' OE2' ' NZ ' ' A' ' 40' ' ' LYS . 79.3 tt0 -64.55 -29.82 70.85 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.331 -0.855 . . . . 0.0 109.297 -179.362 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 91.25 26.54 20.95 Favored Glycine 0 N--CA 1.496 2.638 0 O-C-N 121.161 -0.962 . . . . 0.0 110.765 179.065 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.437 ' NZ ' ' OE2' ' A' ' 38' ' ' GLU . 96.3 mttt -110.04 -1.86 17.35 Favored 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.87 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.661 HG12 ' H ' ' A' ' 43' ' ' GLY . 72.5 t -133.71 160.2 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 CA-C-O 121.756 0.788 . . . . 0.0 109.056 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.547 ' HE ' ' CG1' ' A' ' 94' ' ' VAL . 44.9 ttp180 -125.25 -5.98 7.18 Favored 'General case' 0 N--CA 1.494 1.772 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.673 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.661 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 134.09 -164.42 24.49 Favored Glycine 0 N--CA 1.503 3.136 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 94.6 t -120.07 130.01 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.4 0 CA-C-N 118.747 1.273 . . . . 0.0 110.126 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 38.0 t -79.63 134.08 36.43 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.823 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.446 HG13 ' O ' ' A' ' 46' ' ' VAL . 14.7 p -130.04 131.3 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.382 -0.824 . . . . 0.0 109.684 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 60.7 p -122.56 147.03 46.88 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 179.288 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -142.36 136.01 6.97 Favored Glycine 0 N--CA 1.503 3.118 0 C-N-CA 119.409 -1.376 . . . . 0.0 111.04 -179.138 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.561 ' CG1' HH12 ' A' ' 88' ' ' ARG . 65.0 t -123.45 133.77 68.22 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.311 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -111.06 124.31 51.92 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.603 -0.686 . . . . 0.0 109.185 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.607 ' CD2' ' NH2' ' A' ' 88' ' ' ARG . 23.4 m-85 -95.1 126.06 40.17 Favored 'General case' 0 N--CA 1.504 2.266 0 O-C-N 120.807 -1.183 . . . . 0.0 109.247 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.451 ' C ' ' N ' ' A' ' 54' ' ' ASP . 37.3 m-85 -111.04 131.47 55.03 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.783 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -53.13 -14.61 0.67 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.907 -1.121 . . . . 0.0 108.184 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.451 ' N ' ' C ' ' A' ' 52' ' ' TYR . 34.2 t0 -68.72 -4.77 17.05 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.2 12.43 80.8 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.0 p -110.57 159.45 17.54 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.541 -0.976 . . . . 0.0 110.025 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 78.4 p -140.43 143.82 35.8 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.449 -0.782 . . . . 0.0 110.487 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.0 t -114.98 130.01 56.84 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 177.843 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 12.3 m-20 -130.55 116.94 18.85 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.946 -1.096 . . . . 0.0 109.594 -178.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.532 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 54.5 p90 -117.09 120.69 39.11 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 178.511 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.9 ttpt -110.09 144.06 39.23 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -173.39 -175.35 41.08 Favored Glycine 0 C--N 1.286 -2.226 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 66.3 t -120.53 129.77 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.658 -0.907 . . . . 0.0 109.702 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.489 HG13 ' O ' ' A' ' 64' ' ' VAL . 4.3 p -96.89 124.23 49.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.207 -0.933 . . . . 0.0 109.462 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.0 p -135.58 150.13 71.21 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_exo -40.77 -24.8 0.17 Allowed 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.012 1.808 . . . . 0.0 112.845 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.2 t -102.84 -22.78 13.83 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.26 -0.9 . . . . 0.0 110.983 -178.903 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 41.5 m -123.17 107.1 32.97 Favored Pre-proline 0 N--CA 1.504 2.255 0 O-C-N 121.146 -0.971 . . . . 0.0 109.945 -179.652 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -89.2 163.09 5.7 Favored 'Trans proline' 0 N--CA 1.491 1.337 0 C-N-CA 122.453 2.102 . . . . 0.0 112.445 179.029 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.2 t -120.04 127.66 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 -103.99 130.89 51.67 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.306 -0.871 . . . . 0.0 110.805 -178.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.27 9.68 41.6 Favored 'General case' 0 N--CA 1.5 2.057 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 178.407 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 48.7 t-20 -76.36 56.81 1.11 Allowed 'General case' 0 N--CA 1.486 1.338 0 O-C-N 121.598 -0.689 . . . . 0.0 109.878 -179.004 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.469 ' NE2' ' O ' ' A' ' 75' ' ' ASP . 4.5 pp0? -63.96 -156.07 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 178.544 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.469 ' O ' ' NE2' ' A' ' 74' ' ' GLN . 76.2 m-20 -73.4 101.39 3.46 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 120.575 -1.328 . . . . 0.0 108.583 179.571 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.473 HG22 ' O ' ' A' ' 76' ' ' ILE . 90.6 mt -79.95 -9.34 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.493 -0.754 . . . . 0.0 109.959 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -59.12 -43.85 91.97 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.98 -1.075 . . . . 0.0 109.337 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 10.1 ptpt -69.94 -39.2 76.23 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.947 -1.096 . . . . 0.0 109.648 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.593 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.8 OUTLIER -60.14 -47.85 84.17 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.764 -1.21 . . . . 0.0 108.266 179.808 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 44.6 t-20 -60.04 -35.07 74.31 Favored 'General case' 0 C--N 1.296 -1.718 0 O-C-N 120.825 -1.172 . . . . 0.0 108.501 178.54 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 83.4 tttt -64.37 -51.52 62.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.407 -0.808 . . . . 0.0 110.817 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.4 m -115.94 -26.59 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.395 0 O-C-N 121.139 -0.976 . . . . 0.0 111.803 -178.334 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 93.49 166.31 37.79 Favored Glycine 0 N--CA 1.492 2.43 0 O-C-N 120.65 -1.281 . . . . 0.0 110.328 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 59.7 t -110.8 130.02 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.945 -0.738 . . . . 0.0 109.127 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 13.1 tt0 -80.0 -66.57 0.86 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.119 -0.988 . . . . 0.0 110.462 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.417 ' C ' ' HE ' ' A' ' 88' ' ' ARG . 95.0 mttt -115.71 139.98 49.63 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 121.26 -0.9 . . . . 0.0 111.48 -178.729 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.492 ' CA ' ' HE ' ' A' ' 88' ' ' ARG . 80.6 t80 -121.84 133.38 54.88 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.724 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.607 ' NH2' ' CD2' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -138.5 134.07 33.48 Favored 'General case' 0 N--CA 1.507 2.415 0 O-C-N 120.933 -1.104 . . . . 0.0 110.655 -179.874 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.64 136.2 53.72 Favored 'General case' 0 N--CA 1.498 1.927 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.52 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.28 131.91 56.34 Favored 'General case' 0 N--CA 1.505 2.292 0 O-C-N 121.365 -0.834 . . . . 0.0 109.427 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 40.3 p -127.09 125.31 41.05 Favored 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.358 -0.839 . . . . 0.0 110.579 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -133.18 151.61 51.96 Favored 'General case' 0 N--CA 1.504 2.242 0 O-C-N 121.783 -0.573 . . . . 0.0 110.338 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 71.0 m95 -70.37 140.73 52.19 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.146 -0.971 . . . . 0.0 108.882 178.773 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.547 ' CG1' ' HE ' ' A' ' 42' ' ' ARG . 38.4 t -117.03 124.8 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 O-C-N 121.399 -0.813 . . . . 0.0 109.315 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.434 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.66 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.52 ' HB1' ' CE2' ' A' ' 93' ' ' TRP . . . . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -84.3 -26.34 28.61 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.27 -0.894 . . . . 0.0 110.362 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 49.0 t-20 -86.32 1.7 50.05 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.103 -0.998 . . . . 0.0 110.077 -179.307 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.456 HG11 HG11 ' A' ' 31' ' ' VAL . 2.0 t -118.15 126.92 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.483 -0.761 . . . . 0.0 109.332 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -77.91 140.33 62.5 Favored Pre-proline 0 C--N 1.3 -1.583 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 178.123 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -75.21 -13.74 20.89 Favored 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 121.347 1.365 . . . . 0.0 111.549 -179.275 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 38.3 t -60.73 -40.35 92.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.639 -0.663 . . . . 0.0 110.917 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -81.97 -10.03 59.38 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.0 -1.062 . . . . 0.0 109.673 -179.254 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.515 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 18.3 t -70.93 -30.9 67.34 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.125 -0.984 . . . . 0.0 109.335 179.357 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -123.86 151.89 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.204 0 O-C-N 121.443 -0.785 . . . . 0.0 109.318 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 20.9 pttp -130.85 148.22 52.59 Favored 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.502 -0.749 . . . . 0.0 109.374 179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 62.7 tt0 -100.7 124.95 47.03 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.203 -0.935 . . . . 0.0 109.673 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.525 ' O ' ' N ' ' A' ' 21' ' ' VAL . 34.4 p -111.8 121.53 45.31 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.68 -92.87 0.01 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.67 -1.772 . . . . 0.0 108.67 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.525 ' N ' ' O ' ' A' ' 19' ' ' SER . 4.6 m -137.24 30.6 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.356 -1.085 . . . . 0.0 109.264 179.293 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -129.55 159.67 35.6 Favored 'General case' 0 N--CA 1.504 2.226 0 CA-C-O 122.03 0.919 . . . . 0.0 111.029 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -119.89 139.95 51.6 Favored 'General case' 0 N--CA 1.499 2.004 0 N-CA-C 108.404 -0.962 . . . . 0.0 108.404 178.606 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 77.0 p -138.32 147.42 43.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.28 -0.888 . . . . 0.0 109.001 179.423 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -83.17 125.65 31.76 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.606 -0.684 . . . . 0.0 109.38 -178.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -84.91 90.34 7.78 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.208 -0.933 . . . . 0.0 109.555 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 79.8 p -89.52 -0.87 57.8 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.223 -0.923 . . . . 0.0 108.851 179.352 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -68.33 -2.12 24.89 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.0 m -113.71 130.06 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.546 -0.973 . . . . 0.0 109.363 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 80.5 p -60.45 -28.0 67.96 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.703 -0.623 . . . . 0.0 110.497 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.456 HG11 HG11 ' A' ' 10' ' ' VAL . 71.2 t -61.22 -44.31 98.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 120.948 -1.095 . . . . 0.0 110.338 -178.82 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.515 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 86.1 m -69.83 -39.81 76.24 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.101 -0.999 . . . . 0.0 110.109 -179.034 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.4 mmt -74.95 -20.86 59.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.092 -1.005 . . . . 0.0 109.495 179.708 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -60.42 -39.61 88.03 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 120.985 -1.072 . . . . 0.0 109.073 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.97 -49.13 7.2 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 17.8 mt -62.64 -39.92 95.37 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.333 -1.098 . . . . 0.0 109.737 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -66.46 -39.91 89.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.055 -1.028 . . . . 0.0 109.496 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 77.0 tt0 -67.12 -30.1 70.01 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.058 -1.026 . . . . 0.0 109.348 -179.406 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.32 22.41 27.13 Favored Glycine 0 N--CA 1.497 2.743 0 O-C-N 121.112 -0.992 . . . . 0.0 110.688 179.07 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.1 mtpt -104.47 -1.52 26.57 Favored 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 178.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.713 HG12 ' H ' ' A' ' 43' ' ' GLY . 78.3 t -131.08 158.4 43.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-O 121.639 0.733 . . . . 0.0 109.447 -179.53 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.438 ' N ' HG12 ' A' ' 41' ' ' VAL . 62.5 ttm-85 -123.38 -6.84 8.17 Favored 'General case' 0 N--CA 1.498 1.965 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.713 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.54 -163.19 26.52 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 108.563 -1.815 . . . . 0.0 108.563 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.8 t -119.42 128.37 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.278 -1.131 . . . . 0.0 108.684 179.595 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.1 p -85.16 137.35 33.07 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.098 -1.001 . . . . 0.0 108.716 179.523 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.439 ' O ' HG13 ' A' ' 46' ' ' VAL . 13.4 p -130.19 131.83 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 54.7 p -125.88 142.1 51.67 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -141.08 139.15 9.35 Favored Glycine 0 N--CA 1.497 2.731 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.317 -178.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 56.0 t -120.02 119.83 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.559 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -92.72 117.64 30.22 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -90.37 120.33 31.4 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -105.83 139.16 40.82 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.588 -0.695 . . . . 0.0 110.491 -179.049 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.469 ' C ' ' H ' ' A' ' 55' ' ' GLY . 45.0 t-20 -61.29 -14.7 28.52 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -66.48 0.82 1.97 Allowed 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.469 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 79.34 16.02 78.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 179.098 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.7 p -123.19 148.21 46.04 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.382 -1.069 . . . . 0.0 110.264 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 63.9 p -127.24 140.04 52.5 Favored 'General case' 0 N--CA 1.496 1.856 0 CA-C-O 121.648 0.737 . . . . 0.0 109.423 179.534 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.5 t -116.98 147.57 42.18 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 178.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -132.08 119.12 20.55 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.078 -1.014 . . . . 0.0 109.42 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.526 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 51.7 p90 -116.19 120.83 40.24 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.725 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -114.37 145.14 42.19 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 -179.624 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.4 171.35 43.1 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 72.7 t -110.83 126.94 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.458 -1.025 . . . . 0.0 109.966 -179.676 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 89.2 t -93.13 120.19 42.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.232 -0.918 . . . . 0.0 109.669 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 23.3 p -126.57 151.23 72.72 Favored Pre-proline 0 N--CA 1.495 1.811 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.038 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -53.99 -8.65 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 121.449 1.433 . . . . 0.0 111.615 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 70.2 m -111.16 -18.65 12.94 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.476 -0.765 . . . . 0.0 110.243 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 10.3 p -133.91 109.37 11.86 Favored Pre-proline 0 N--CA 1.505 2.321 0 O-C-N 121.106 -0.996 . . . . 0.0 110.799 -179.016 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -86.91 163.58 8.91 Favored 'Trans proline' 0 N--CA 1.497 1.691 0 C-N-CA 122.556 2.171 . . . . 0.0 112.229 178.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 61.6 t -119.05 130.18 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.421 0 O-C-N 121.256 -0.902 . . . . 0.0 109.76 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 64.9 m-20 -100.58 123.63 45.05 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.34 -0.85 . . . . 0.0 110.717 -178.776 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.513 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.6 OUTLIER -90.87 0.59 57.45 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.832 -1.167 . . . . 0.0 108.665 179.051 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 -66.2 50.35 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.287 -0.883 . . . . 0.0 110.072 -179.474 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.513 ' N ' ' O ' ' A' ' 72' ' ' THR . 98.9 mm-40 -55.04 -98.04 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.126 -0.984 . . . . 0.0 109.755 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -103.42 85.46 2.48 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.156 -0.965 . . . . 0.0 109.227 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.452 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 9.5 tp -67.38 -39.73 83.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.54 -0.725 . . . . 0.0 109.914 -179.751 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.452 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 97.6 m-20 -59.61 -40.15 86.55 Favored 'General case' 0 C--N 1.297 -1.716 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 -179.58 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 13.0 ttmm -66.71 -41.33 88.16 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.594 -0.691 . . . . 0.0 109.495 178.401 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.618 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -65.07 -52.3 56.42 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.281 -0.887 . . . . 0.0 110.836 -177.638 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.448 ' ND2' ' O ' ' A' ' 77' ' ' ASN . 0.5 OUTLIER -62.31 -28.17 69.55 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 119.808 -1.807 . . . . 0.0 108.976 179.677 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 81' ' ' LYS . . . . . 0.445 ' N ' HD22 ' A' ' 80' ' ' ASN . 34.6 ttmt -64.6 -51.09 64.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.129 -0.982 . . . . 0.0 110.496 -179.296 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 m -116.42 -22.04 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.274 0 O-C-N 121.353 -0.842 . . . . 0.0 110.72 -179.348 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.618 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 83.44 165.96 39.11 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 179.359 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 28.2 t -108.31 120.45 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -69.79 -55.08 10.82 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.998 -1.064 . . . . 0.0 110.051 -179.364 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -116.84 148.79 40.94 Favored 'General case' 0 N--CA 1.502 2.148 0 CA-C-O 121.863 0.84 . . . . 0.0 111.75 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 66.6 t80 -119.65 133.89 55.45 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 178.411 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 74.7 ttt180 -139.62 121.6 15.64 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.856 -1.152 . . . . 0.0 110.613 -178.81 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -125.34 137.84 54.05 Favored 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.135 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.0 tp -120.55 130.99 54.46 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 23.1 p -129.24 119.8 24.63 Favored 'General case' 0 N--CA 1.508 2.469 0 CA-C-O 121.817 0.818 . . . . 0.0 111.168 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -132.8 160.5 36.71 Favored 'General case' 0 N--CA 1.504 2.269 0 O-C-N 121.666 -0.647 . . . . 0.0 110.211 179.102 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' TRP . . . . . 0.52 ' CE2' ' HB1' ' A' ' 7' ' ' ALA . 90.2 m95 -69.42 142.98 53.75 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.432 -0.793 . . . . 0.0 110.426 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.404 ' O ' ' N ' ' A' ' 42' ' ' ARG . 41.0 t -115.94 123.42 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 178.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 2.88 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 179.929 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.648 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.448 ' OD1' ' O ' ' A' ' 8' ' ' ASP . 55.1 t0 -90.34 6.74 41.82 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.654 -0.654 . . . . 0.0 110.715 -178.725 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.43 ' OD1' ' N ' ' A' ' 9' ' ' ASN . 21.5 p-10 -137.83 17.74 2.86 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 120.913 -1.117 . . . . 0.0 109.048 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.453 ' O ' HG23 ' A' ' 10' ' ' VAL . 35.0 m -126.02 129.76 72.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -94.94 142.48 24.69 Favored Pre-proline 0 N--CA 1.494 1.772 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.44 -18.05 23.28 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 121.91 1.74 . . . . 0.0 112.145 -179.686 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 87.9 p -70.13 -30.18 67.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 110.187 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -89.25 -14.98 34.67 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.959 -1.088 . . . . 0.0 109.952 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.506 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 35.7 t -72.44 -27.61 62.43 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.304 -0.872 . . . . 0.0 109.648 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.1 pp -118.21 132.52 67.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.534 -0.729 . . . . 0.0 109.087 -179.459 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -120.05 138.18 53.68 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.369 -0.832 . . . . 0.0 109.094 -179.539 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.424 ' H ' ' HG2' ' A' ' 18' ' ' GLN . 13.3 pt20 -100.02 123.67 44.52 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.566 -0.709 . . . . 0.0 110.409 -178.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t -125.37 83.81 2.21 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.473 -0.767 . . . . 0.0 109.413 179.416 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.49 ' O ' ' N ' ' A' ' 22' ' ' GLN . . . 98.13 73.43 1.11 Allowed Glycine 0 N--CA 1.501 2.981 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.429 ' C ' ' O ' ' A' ' 20' ' ' GLY . 15.2 m 34.47 32.41 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.183 0 O-C-N 121.946 -0.738 . . . . 0.0 110.817 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.49 ' N ' ' O ' ' A' ' 20' ' ' GLY . 14.1 pt20 -130.86 161.02 32.75 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.569 -0.707 . . . . 0.0 109.55 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -124.38 131.49 53.51 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 38.7 p -134.27 152.52 51.86 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.336 -0.853 . . . . 0.0 109.381 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 39.1 t80 -81.79 130.67 35.14 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.514 -0.742 . . . . 0.0 109.256 -179.708 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -81.86 77.41 8.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.917 -1.114 . . . . 0.0 109.93 -179.666 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 54.3 p -79.57 -8.34 59.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.092 -1.005 . . . . 0.0 109.358 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.9 -39.86 96.07 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.414 ' CG2' ' SG ' ' A' ' 32' ' ' CYS . 27.0 m -82.25 138.34 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.046 -1.267 . . . . 0.0 109.305 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 32.6 t -63.2 -34.64 78.08 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.488 -0.758 . . . . 0.0 110.868 -179.255 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.1 t -56.83 -40.04 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.832 -1.168 . . . . 0.0 109.556 -178.629 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.506 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 49.1 m -63.08 -39.89 96.04 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.047 -1.033 . . . . 0.0 110.059 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 96.5 mmm -88.94 -16.8 30.91 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.769 -1.207 . . . . 0.0 110.974 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 50.3 mt-30 -60.23 -42.68 95.74 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 120.616 -1.302 . . . . 0.0 108.984 178.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -80.34 -41.68 11.37 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.0 tp -59.99 -47.08 87.3 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.312 -1.11 . . . . 0.0 109.241 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 45.0 t30 -65.52 -39.86 92.31 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.285 -0.884 . . . . 0.0 110.184 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.5 -31.98 71.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.249 -0.907 . . . . 0.0 109.423 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.74 18.77 46.63 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 -179.343 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.3 tttp -97.56 -9.09 27.65 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 178.461 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.789 HG12 ' H ' ' A' ' 43' ' ' GLY . 97.1 t -134.72 159.87 41.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.038 -0.983 . . . . 0.0 108.665 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.472 ' N ' ' O ' ' A' ' 94' ' ' VAL . 57.9 ttm-85 -125.04 -1.69 7.74 Favored 'General case' 0 N--CA 1.497 1.917 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 179.651 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.789 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 129.65 -163.96 22.59 Favored Glycine 0 N--CA 1.499 2.855 0 N-CA-C 107.719 -2.153 . . . . 0.0 107.719 -179.236 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 47.5 t -120.56 129.79 75.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.124 0 CA-C-N 118.881 1.34 . . . . 0.0 109.486 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 63.6 p -77.43 141.94 39.47 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.456 -0.777 . . . . 0.0 108.959 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.464 HG13 ' O ' ' A' ' 46' ' ' VAL . 9.9 p -127.38 125.32 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 CA-C-O 121.947 0.88 . . . . 0.0 108.727 179.067 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 2.4 p -128.06 146.65 50.61 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -154.66 147.44 16.57 Favored Glycine 0 N--CA 1.494 2.56 0 C-N-CA 118.306 -1.902 . . . . 0.0 111.237 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 53.2 t -126.4 126.28 68.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -100.56 125.82 46.95 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.267 -0.896 . . . . 0.0 108.773 179.468 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -95.28 126.92 40.92 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.493 -0.754 . . . . 0.0 109.965 -178.715 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.493 ' C ' ' H ' ' A' ' 54' ' ' ASP . 98.2 m-85 -114.02 130.33 56.55 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.543 -0.723 . . . . 0.0 109.918 -179.779 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -53.02 -8.19 0.09 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.507 -0.746 . . . . 0.0 109.328 179.579 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.493 ' H ' ' C ' ' A' ' 52' ' ' TYR . 41.3 t0 -74.44 0.81 13.42 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.773 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.68 14.55 79.63 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.2 p -123.15 147.86 46.36 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 121.487 -1.008 . . . . 0.0 109.788 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 53.0 p -129.68 140.35 51.15 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 85.0 p -107.45 155.88 19.57 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.795 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 30.1 p-10 -146.53 116.07 7.14 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.874 -1.141 . . . . 0.0 109.674 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -118.51 121.82 41.19 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -113.17 153.67 27.91 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -174.82 -177.25 43.78 Favored Glycine 0 C--N 1.282 -2.464 0 C-N-CA 119.337 -1.411 . . . . 0.0 110.847 -179.505 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -119.7 127.36 75.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.971 -0.723 . . . . 0.0 109.375 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.1 t -92.3 120.26 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.199 -0.938 . . . . 0.0 110.519 -179.289 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.7 p -135.76 152.08 75.35 Favored Pre-proline 0 N--CA 1.492 1.639 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.011 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -54.54 -10.18 2.18 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 121.613 1.542 . . . . 0.0 111.687 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.2 t -103.04 -26.97 12.87 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.324 -0.86 . . . . 0.0 111.23 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 78.2 p -133.34 108.87 12.38 Favored Pre-proline 0 N--CA 1.505 2.283 0 O-C-N 120.911 -1.118 . . . . 0.0 110.295 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -85.09 163.18 11.58 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 C-N-CA 122.068 1.845 . . . . 0.0 111.897 178.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.4 t -120.61 127.53 75.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.467 -0.77 . . . . 0.0 109.07 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -105.48 130.22 53.6 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.189 -0.944 . . . . 0.0 111.303 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.468 ' C ' ' H ' ' A' ' 74' ' ' GLN . 0.6 OUTLIER -92.61 4.87 52.79 Favored 'General case' 0 N--CA 1.499 1.983 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 177.703 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 48.2 p-10 -73.3 21.09 0.08 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.731 -0.605 . . . . 0.0 109.78 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.468 ' H ' ' C ' ' A' ' 72' ' ' THR . 73.5 tp60 -42.85 -83.49 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.479 -0.763 . . . . 0.0 110.744 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -113.62 74.38 0.86 Allowed 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.338 -0.851 . . . . 0.0 110.597 -179.457 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 83.1 mt -70.21 -34.26 58.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 120.945 -1.097 . . . . 0.0 109.303 178.835 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 71.3 m-20 -52.78 -43.25 65.73 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.064 -1.023 . . . . 0.0 108.698 -179.15 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 47.4 tttp -62.82 -46.37 88.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.412 -0.805 . . . . 0.0 109.051 178.717 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.585 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.3 OUTLIER -60.3 -46.7 88.96 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.528 -0.732 . . . . 0.0 110.103 -178.998 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -61.0 -36.75 80.28 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 120.255 -1.528 . . . . 0.0 109.406 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 38.0 tttm -66.38 -50.08 64.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.494 -0.754 . . . . 0.0 110.827 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.9 p -111.42 -26.98 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.544 -0.723 . . . . 0.0 111.805 -176.549 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.585 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.09 161.52 35.42 Favored Glycine 0 N--CA 1.492 2.372 0 O-C-N 120.678 -1.264 . . . . 0.0 110.294 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.459 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 16.5 t -106.99 120.97 59.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.916 -0.755 . . . . 0.0 109.27 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 61.7 tt0 -72.04 -58.2 3.64 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.155 -0.966 . . . . 0.0 110.951 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 32.7 ttmt -114.81 146.39 41.08 Favored 'General case' 0 N--CA 1.509 2.476 0 O-C-N 121.226 -0.921 . . . . 0.0 111.038 -178.629 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -121.59 130.36 53.45 Favored 'General case' 0 N--CA 1.501 2.098 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 21.9 mmm180 -137.29 121.68 18.24 Favored 'General case' 0 N--CA 1.505 2.312 0 O-C-N 120.929 -1.107 . . . . 0.0 109.913 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.24 133.9 53.39 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.632 -0.668 . . . . 0.0 109.387 179.249 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 65.5 tp -117.87 131.46 56.54 Favored 'General case' 0 N--CA 1.5 2.068 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 11.3 p -128.19 124.55 37.07 Favored 'General case' 0 N--CA 1.502 2.139 0 CA-C-O 121.39 0.614 . . . . 0.0 110.334 -179.304 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -132.67 151.13 52.05 Favored 'General case' 0 N--CA 1.505 2.312 0 O-C-N 121.617 -0.677 . . . . 0.0 110.748 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 58.1 m95 -71.2 139.04 50.0 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.31 -0.869 . . . . 0.0 109.007 179.006 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.472 ' O ' ' N ' ' A' ' 42' ' ' ARG . 47.3 t -111.08 119.41 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.427 0 N-CA-C 109.261 -1.535 . . . . 0.0 109.261 179.834 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.623 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 8' ' ' ASP . 34.0 t0 -88.44 -28.07 21.11 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.33 -0.856 . . . . 0.0 109.566 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 53.5 t30 -89.97 -0.0 57.34 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.522 -0.736 . . . . 0.0 109.556 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.8 t -110.87 129.98 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.569 -0.707 . . . . 0.0 109.868 -178.771 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -89.14 135.07 31.96 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.147 -0.97 . . . . 0.0 108.593 179.288 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -73.37 -14.27 25.33 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 121.695 1.597 . . . . 0.0 111.603 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 23.2 t -60.64 -40.12 90.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.57 179.489 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -82.54 -12.97 57.39 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.989 -1.069 . . . . 0.0 109.865 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.796 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 44.3 t -64.27 -37.81 88.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.049 -1.032 . . . . 0.0 109.268 179.721 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -118.23 148.63 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 20.3 ptmt -130.61 155.07 47.16 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 121.497 -0.752 . . . . 0.0 109.508 -179.078 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -98.95 117.46 33.52 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.414 -0.804 . . . . 0.0 110.521 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.5 t -126.37 85.71 2.42 Favored 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.605 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.81 62.52 1.37 Allowed Glycine 0 N--CA 1.497 2.739 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.9 m 40.01 35.74 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.746 -0.855 . . . . 0.0 110.556 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 80.3 mt-30 -132.32 162.84 30.03 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.61 -0.681 . . . . 0.0 109.401 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 41.8 m-85 -120.03 136.34 54.6 Favored 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 178.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 49.3 p -139.57 149.76 44.24 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.411 -0.806 . . . . 0.0 109.925 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.598 ' CZ ' ' SG ' ' A' ' 32' ' ' CYS . 44.1 t80 -80.47 125.21 29.67 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -84.41 84.2 7.73 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.113 -0.992 . . . . 0.0 110.577 -178.615 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 83.1 p -83.18 -7.0 59.68 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.128 -0.982 . . . . 0.0 109.538 179.321 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.58 -37.76 68.76 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.4 m -85.53 136.46 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.272 -1.134 . . . . 0.0 108.719 179.515 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 82.9 p -69.88 -40.0 75.95 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.322 -0.861 . . . . 0.0 111.442 -178.617 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.511 HG23 ' N ' ' A' ' 32' ' ' CYS . 33.7 m -50.23 -42.75 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.773 -1.204 . . . . 0.0 110.647 -178.084 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.796 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 18.9 t -61.17 -42.0 97.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.875 -1.14 . . . . 0.0 110.111 -179.505 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 18.0 mtp -82.12 -12.73 58.03 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.61 -1.306 . . . . 0.0 110.829 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 12.5 mm100 -60.18 -40.0 88.46 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.629 -1.295 . . . . 0.0 108.387 178.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.92 -50.61 6.3 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 62.6 tp -60.24 -41.31 92.87 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.279 -1.13 . . . . 0.0 109.446 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 43.8 t30 -60.19 -40.05 88.68 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.169 -0.957 . . . . 0.0 109.738 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -74.24 -9.51 58.68 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.156 -0.965 . . . . 0.0 109.999 -179.435 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.65 26.42 67.47 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 179.612 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 45.7 mmtm -100.17 -5.54 27.58 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 178.875 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.697 HG12 ' H ' ' A' ' 43' ' ' GLY . 55.7 t -133.3 161.01 42.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.476 ' N ' HG12 ' A' ' 41' ' ' VAL . 74.3 ttt180 -122.05 -6.82 8.92 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.564 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.697 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 135.42 -164.95 24.84 Favored Glycine 0 N--CA 1.498 2.785 0 N-CA-C 108.082 -2.007 . . . . 0.0 108.082 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.3 t -120.03 129.41 75.49 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.091 -1.241 . . . . 0.0 109.415 179.593 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.9 t -83.71 135.99 34.35 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.312 -0.868 . . . . 0.0 108.768 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 46' ' ' VAL . 12.0 p -131.45 133.17 62.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 CA-C-O 121.603 0.715 . . . . 0.0 109.813 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.8 p -124.73 151.12 45.45 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 178.947 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -146.17 147.01 17.68 Favored Glycine 0 N--CA 1.5 2.926 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.803 -179.029 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 75.0 t -129.67 127.18 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.803 -0.822 . . . . 0.0 108.989 179.32 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -102.64 112.88 25.83 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.634 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 23.7 m-85 -81.44 128.57 34.01 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.091 -1.006 . . . . 0.0 109.374 -179.222 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -114.72 134.21 55.27 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.481 -0.762 . . . . 0.0 109.499 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -61.84 -9.34 6.46 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.262 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.442 ' OD2' ' OG1' ' A' ' 56' ' ' THR . 46.1 p-10 -68.05 0.15 3.87 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.326 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 88.27 14.38 62.24 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.442 ' OG1' ' OD2' ' A' ' 54' ' ' ASP . 35.0 p -136.03 156.75 48.27 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.03 -1.277 . . . . 0.0 110.652 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 37.3 p -131.23 132.94 45.0 Favored 'General case' 0 N--CA 1.498 1.937 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 83.7 p -91.59 160.01 15.61 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 6.0 p30 -152.15 115.01 4.62 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.822 -1.174 . . . . 0.0 109.985 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -118.01 127.77 54.13 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 178.618 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 78.7 tttt -115.44 145.71 42.31 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.155 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.71 170.07 42.09 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.2 t -110.56 127.53 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.521 -0.987 . . . . 0.0 109.574 -179.506 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 69.3 t -94.0 118.07 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.086 -1.009 . . . . 0.0 109.491 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.518 ' O ' ' N ' ' A' ' 68' ' ' THR . 12.0 p -125.62 146.25 54.16 Favored Pre-proline 0 N--CA 1.497 1.916 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 178.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_exo -35.9 -27.85 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.344 0 C-N-CA 122.433 2.089 . . . . 0.0 112.884 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.474 ' N ' ' O ' ' A' ' 65' ' ' THR . 5.8 t -106.81 -10.57 16.01 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.433 -0.792 . . . . 0.0 110.528 -179.657 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 65' ' ' THR . 88.7 m -126.33 106.58 24.33 Favored Pre-proline 0 N--CA 1.505 2.31 0 O-C-N 121.04 -1.038 . . . . 0.0 110.981 -179.175 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -90.44 162.48 4.46 Favored 'Trans proline' 0 N--CA 1.487 1.107 0 C-N-CA 122.404 2.069 . . . . 0.0 111.351 177.568 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 78.4 t -119.84 128.06 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.239 0 O-C-N 121.229 -0.92 . . . . 0.0 108.91 179.318 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -101.25 135.15 43.2 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.298 -0.876 . . . . 0.0 110.16 -179.206 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.479 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.1 OUTLIER -106.02 19.68 20.15 Favored 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 178.332 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 6.7 m-20 -64.28 42.88 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.848 -178.628 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.479 ' N ' ' O ' ' A' ' 72' ' ' THR . 25.2 mm100 -51.48 170.27 0.05 OUTLIER 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.106 -0.996 . . . . 0.0 109.114 179.213 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -53.05 114.0 1.3 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.054 -1.029 . . . . 0.0 109.621 -179.242 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 97.5 mt -86.46 -16.06 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.384 -0.823 . . . . 0.0 110.246 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -59.84 -39.66 85.92 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 179.653 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 71.1 mttt -63.0 -50.23 71.57 Favored 'General case' 0 N--CA 1.492 1.634 0 CA-C-O 122.496 1.141 . . . . 0.0 109.551 179.436 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.587 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -59.96 -50.68 72.79 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.515 -177.33 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -61.39 -36.11 79.35 Favored 'General case' 0 C--N 1.292 -1.9 0 O-C-N 120.208 -1.558 . . . . 0.0 109.031 178.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -65.58 -50.27 65.75 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.447 -0.783 . . . . 0.0 111.093 -179.312 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.3 m -115.77 -24.77 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.3 0 O-C-N 121.271 -0.893 . . . . 0.0 111.609 -177.698 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 91.52 166.55 40.23 Favored Glycine 0 N--CA 1.492 2.413 0 O-C-N 120.71 -1.244 . . . . 0.0 110.068 179.372 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 49.0 t -106.96 128.54 61.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.926 -0.749 . . . . 0.0 109.057 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -79.99 -66.59 0.86 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.945 -1.097 . . . . 0.0 109.838 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 57.4 mttm -116.55 140.85 48.93 Favored 'General case' 0 N--CA 1.504 2.255 0 O-C-N 121.291 -0.881 . . . . 0.0 111.051 -179.263 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 70.5 t80 -121.05 132.75 55.07 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 178.35 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 42.6 mtm105 -136.85 129.97 31.07 Favored 'General case' 0 N--CA 1.504 2.258 0 O-C-N 121.119 -0.988 . . . . 0.0 110.743 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.31 135.47 54.22 Favored 'General case' 0 N--CA 1.499 1.983 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.9 mt -118.51 130.28 55.84 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.427 -0.796 . . . . 0.0 109.599 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 20.1 p -128.61 125.07 37.41 Favored 'General case' 0 N--CA 1.503 2.218 0 CA-C-O 121.677 0.751 . . . . 0.0 110.645 -179.491 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -132.96 154.37 50.53 Favored 'General case' 0 N--CA 1.502 2.159 0 CA-C-O 121.412 0.625 . . . . 0.0 110.638 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 80.2 m95 -69.87 142.08 53.09 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 35.4 t -116.61 120.81 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.133 0 O-C-N 121.332 -0.855 . . . . 0.0 109.202 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.179 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.978 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.736 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.542 ' N ' ' OD1' ' A' ' 8' ' ' ASP . 11.3 p-10 -47.74 -79.74 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.787 -0.571 . . . . 0.0 111.367 -178.533 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.517 ' H ' ' CG ' ' A' ' 8' ' ' ASP . 13.9 m120 -144.42 37.66 1.24 Allowed 'General case' 0 N--CA 1.497 1.899 0 O-C-N 120.898 -1.126 . . . . 0.0 109.885 -178.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.446 ' H ' HG23 ' A' ' 10' ' ' VAL . 0.2 OUTLIER -81.49 152.55 4.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 120.94 -1.1 . . . . 0.0 108.398 -179.11 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.6 m-20 -78.63 131.5 67.72 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.179 -0.951 . . . . 0.0 109.879 -178.849 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -80.61 -15.08 11.16 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.128 1.885 . . . . 0.0 111.812 179.438 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 94.2 p -64.46 -35.75 81.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.48 -0.763 . . . . 0.0 110.506 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -69.98 -23.7 63.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.162 -0.961 . . . . 0.0 109.812 -179.249 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.552 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 60.8 m -68.26 -27.66 66.54 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.209 -0.932 . . . . 0.0 109.64 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.7 pp -118.49 133.0 66.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.498 -0.751 . . . . 0.0 109.19 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -112.05 142.15 44.84 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.609 ' CD ' ' H ' ' A' ' 18' ' ' GLN . 0.1 OUTLIER -97.55 128.48 44.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.257 -0.902 . . . . 0.0 109.694 -179.411 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.549 ' O ' ' N ' ' A' ' 21' ' ' VAL . 25.3 t -107.4 118.6 37.15 Favored 'General case' 0 N--CA 1.495 1.825 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.42 -78.81 0.01 OUTLIER Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.549 ' N ' ' O ' ' A' ' 19' ' ' SER . 9.8 p -156.7 32.95 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.319 -1.106 . . . . 0.0 108.629 179.268 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.446 HE21 ' HB2' ' A' ' 69' ' ' PRO . 46.3 tt0 -129.22 161.56 29.86 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -115.19 135.06 54.58 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.322 -0.861 . . . . 0.0 109.261 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 23.9 p -135.8 150.01 49.3 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.586 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 35.8 t80 -83.79 122.09 28.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.347 -0.846 . . . . 0.0 109.663 -179.039 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -84.55 83.63 7.94 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.362 -0.837 . . . . 0.0 109.742 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 96.3 p -78.48 -4.91 50.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.231 -0.918 . . . . 0.0 109.091 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -56.68 -39.01 85.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 -179.437 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.445 ' H ' HG22 ' A' ' 29' ' ' VAL . 10.5 m -81.06 133.46 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 120.877 -1.366 . . . . 0.0 109.741 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.5 m -63.33 -34.47 77.77 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.544 -0.723 . . . . 0.0 111.929 -178.726 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.455 HG13 ' N ' ' A' ' 32' ' ' CYS . 7.2 p -59.98 -40.01 81.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 120.608 -1.307 . . . . 0.0 110.796 -177.789 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.552 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 77.6 m -66.25 -40.04 89.92 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.657 -1.277 . . . . 0.0 109.719 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 7.7 mmt -78.69 -19.14 53.15 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.008 -1.058 . . . . 0.0 109.123 179.607 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -60.75 -41.04 94.62 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.216 -0.928 . . . . 0.0 108.958 179.446 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -73.59 -43.61 35.85 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 2.1 mt -65.85 -39.98 91.27 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.254 -1.145 . . . . 0.0 108.94 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.32 -40.03 94.98 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.07 -1.019 . . . . 0.0 109.82 179.05 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -76.63 -10.79 59.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.214 -0.929 . . . . 0.0 110.086 -179.028 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.28 28.49 69.86 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.404 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -103.64 -6.01 22.05 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.784 HG12 ' H ' ' A' ' 43' ' ' GLY . 45.9 t -133.72 159.88 42.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 115.51 -0.768 . . . . 0.0 108.987 -179.251 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.507 ' N ' ' O ' ' A' ' 94' ' ' VAL . 70.3 mtp85 -120.91 -7.71 9.47 Favored 'General case' 0 N--CA 1.5 2.053 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.355 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.784 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.73 -159.85 25.51 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -179.035 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.4 t -120.67 129.74 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.145 0 O-C-N 121.297 -1.12 . . . . 0.0 109.32 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.0 t -86.65 140.02 30.22 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.303 -0.873 . . . . 0.0 108.98 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.443 HG13 ' O ' ' A' ' 46' ' ' VAL . 9.9 p -131.9 132.46 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.74 0.781 . . . . 0.0 109.829 179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 81.9 p -123.29 148.79 45.57 Favored 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -144.64 144.33 13.15 Favored Glycine 0 N--CA 1.5 2.962 0 C-N-CA 119.219 -1.467 . . . . 0.0 111.375 -178.707 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 85.6 t -121.59 130.01 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.545 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.531 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 9.9 m-85 -106.79 119.89 40.53 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.783 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -98.67 120.82 39.76 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.422 -0.799 . . . . 0.0 109.07 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.529 ' O ' ' N ' ' A' ' 54' ' ' ASP . 94.1 m-85 -105.56 131.33 53.09 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.345 -0.847 . . . . 0.0 109.164 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 49.2 t30 -46.6 -15.56 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.245 -0.909 . . . . 0.0 109.166 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 52' ' ' TYR . 35.9 t0 -69.71 -0.81 7.59 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.578 -0.701 . . . . 0.0 109.392 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.4 23.19 65.89 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 120.047 -1.073 . . . . 0.0 110.611 179.135 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.2 p -118.76 150.27 40.06 Favored 'General case' 0 N--CA 1.504 2.256 0 O-C-N 121.297 -1.12 . . . . 0.0 110.046 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 63.9 p -135.27 128.98 32.87 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.501 -0.75 . . . . 0.0 109.783 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 45.9 t -118.7 145.87 45.17 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.636 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 55.9 t-20 -135.8 128.08 30.12 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.753 -1.217 . . . . 0.0 109.796 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -117.15 122.15 43.27 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 178.665 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -107.52 144.5 34.41 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -162.68 170.99 38.4 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.634 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.7 t -113.98 125.39 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.555 -0.967 . . . . 0.0 109.42 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -90.26 117.9 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.368 -0.833 . . . . 0.0 110.232 -179.152 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.517 ' O ' ' N ' ' A' ' 67' ' ' SER . 25.9 p -125.74 144.4 48.2 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.402 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -38.4 -21.29 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.157 1.905 . . . . 0.0 113.276 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 65' ' ' THR . 10.4 m -108.64 -11.37 15.1 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.197 -0.939 . . . . 0.0 111.296 -178.845 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 55.1 p -130.69 107.87 15.63 Favored Pre-proline 0 N--CA 1.504 2.242 0 O-C-N 121.011 -1.056 . . . . 0.0 110.392 -179.201 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.446 ' HB2' HE21 ' A' ' 22' ' ' GLN . 40.6 Cg_endo -91.25 164.42 3.69 Favored 'Trans proline' 0 N--CA 1.49 1.314 0 C-N-CA 122.605 2.203 . . . . 0.0 112.135 178.604 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 48.9 t -124.42 130.15 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.127 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.555 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 69.7 m-80 -100.77 138.19 38.16 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.082 -1.012 . . . . 0.0 110.502 -178.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -98.5 -19.37 17.69 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 121.02 -1.05 . . . . 0.0 109.021 179.17 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 44.4 p-10 -87.41 44.42 1.18 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.038 -1.039 . . . . 0.0 108.442 179.118 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -59.71 -49.18 78.74 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.519 -0.872 . . . . 0.0 108.741 -179.334 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -115.17 75.8 0.96 Allowed 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 107.845 -1.168 . . . . 0.0 107.845 178.213 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 10.4 tt -73.33 -28.64 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.28 -0.887 . . . . 0.0 110.116 -178.809 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -60.06 -49.66 76.79 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.61 -178.067 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.414 ' CG ' ' N ' ' A' ' 79' ' ' THR . 0.1 OUTLIER -61.08 -39.94 91.82 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.569 -1.332 . . . . 0.0 108.34 179.353 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.586 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.4 m -60.04 -43.96 94.99 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.397 0.618 . . . . 0.0 109.772 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -61.63 -38.5 87.89 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 120.596 -1.315 . . . . 0.0 109.987 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.4 ttmm -70.04 -44.85 68.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.139 -0.976 . . . . 0.0 111.224 -179.266 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.1 p -112.08 -28.75 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.075 0 O-C-N 121.311 -0.868 . . . . 0.0 112.098 -176.748 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.586 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.69 161.43 33.52 Favored Glycine 0 N--CA 1.491 2.339 0 O-C-N 120.66 -1.275 . . . . 0.0 110.177 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 90.0 t -109.51 124.85 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.14 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -80.05 -58.62 3.07 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.247 -0.908 . . . . 0.0 110.952 -178.813 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 35.4 ttpt -114.11 137.59 51.53 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.267 -0.895 . . . . 0.0 110.809 -178.747 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 54.9 t80 -123.78 125.89 45.5 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.129 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 76.0 mmt-85 -130.98 132.01 44.76 Favored 'General case' 0 N--CA 1.506 2.336 0 O-C-N 121.137 -0.977 . . . . 0.0 110.525 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -121.26 138.09 54.39 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 179.568 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.671 HD23 ' N ' ' A' ' 91' ' ' THR . 1.6 tt -119.95 131.17 55.1 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.648 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.671 ' N ' HD23 ' A' ' 90' ' ' LEU . 22.1 p -126.59 126.3 43.39 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.507 -0.745 . . . . 0.0 110.706 -179.243 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 -133.5 154.57 50.71 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.855 -0.528 . . . . 0.0 109.793 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -67.58 139.4 56.9 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.163 -0.961 . . . . 0.0 109.051 179.448 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.507 ' O ' ' N ' ' A' ' 42' ' ' ARG . 41.4 t -111.84 121.29 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.323 -0.861 . . . . 0.0 109.013 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.739 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 179.461 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.48 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -69.87 -39.84 76.09 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.681 -0.637 . . . . 0.0 110.761 -179.223 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 32.7 m120 -84.38 3.56 35.37 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.004 -1.06 . . . . 0.0 110.4 -178.312 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.0 t -116.31 129.8 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.347 -0.846 . . . . 0.0 109.129 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 -84.68 138.3 38.11 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.016 -1.053 . . . . 0.0 109.212 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -76.63 -24.74 10.07 Favored 'Trans proline' 0 N--CA 1.494 1.531 0 C-N-CA 121.938 1.758 . . . . 0.0 111.673 179.314 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 55.4 m -60.26 -39.89 88.38 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.304 -0.872 . . . . 0.0 110.566 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.7 mt-30 -77.89 -19.82 54.06 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.182 -0.949 . . . . 0.0 110.287 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.637 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 49.6 m -65.66 -29.61 70.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.005 -1.06 . . . . 0.0 109.685 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -118.6 139.64 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.132 0 O-C-N 121.427 -0.796 . . . . 0.0 109.272 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -124.31 144.25 50.1 Favored 'General case' 0 N--CA 1.498 1.955 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 -179.731 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 64.8 tt0 -96.74 124.37 40.7 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.212 -0.93 . . . . 0.0 109.676 -179.44 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.497 ' O ' ' N ' ' A' ' 21' ' ' VAL . 70.3 m -109.52 129.95 55.54 Favored 'General case' 0 N--CA 1.498 1.967 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.36 -94.06 0.01 OUTLIER Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.497 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.8 t -137.17 28.84 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 121.427 -1.043 . . . . 0.0 109.319 -179.386 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 90.7 mt-30 -131.38 163.15 28.53 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.577 -0.702 . . . . 0.0 110.359 -179.571 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -118.76 139.94 50.75 Favored 'General case' 0 N--CA 1.503 2.183 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.776 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 70.9 p -139.82 157.01 46.43 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.272 -0.893 . . . . 0.0 109.651 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -89.65 121.69 32.07 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.539 -0.726 . . . . 0.0 109.103 -179.244 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 -82.47 86.09 6.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.129 -0.982 . . . . 0.0 110.105 -179.368 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.48 ' C ' ' H ' ' A' ' 29' ' ' VAL . 92.1 p -81.58 -7.04 59.54 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.243 -0.91 . . . . 0.0 109.38 179.391 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.66 -8.22 0.34 Allowed Glycine 0 N--CA 1.489 2.196 0 N-CA-C 110.162 -1.175 . . . . 0.0 110.162 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.48 ' H ' ' C ' ' A' ' 27' ' ' SER . 20.4 m -113.31 132.44 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.409 -1.054 . . . . 0.0 108.992 179.529 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.8 m -69.87 -30.07 67.45 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.426 -0.796 . . . . 0.0 111.107 -178.814 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.493 HG23 ' N ' ' A' ' 32' ' ' CYS . 18.0 m -60.16 -40.34 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 120.672 -1.268 . . . . 0.0 110.583 -178.57 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.637 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 96.5 m -65.81 -40.02 91.47 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.83 -1.169 . . . . 0.0 110.01 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 35.3 mtp -84.37 -11.92 55.42 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.901 -1.125 . . . . 0.0 109.303 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -61.66 -42.19 98.57 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.8 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.83 -42.68 24.97 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 179.16 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.5 tp -60.2 -41.23 92.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.276 -1.132 . . . . 0.0 108.96 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -62.61 -40.68 97.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.306 -0.871 . . . . 0.0 109.815 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -63.07 -28.27 69.97 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.342 -0.849 . . . . 0.0 109.873 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.69 17.96 57.4 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 92.4 mttt -100.84 -1.54 34.5 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.742 HG12 ' H ' ' A' ' 43' ' ' GLY . 97.4 t -132.3 157.75 43.14 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 115.189 -0.914 . . . . 0.0 108.713 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.431 ' N ' HG12 ' A' ' 41' ' ' VAL . 98.4 mtt180 -119.99 -7.62 9.9 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 179.149 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.742 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 135.7 -160.08 24.41 Favored Glycine 0 N--CA 1.5 2.934 0 N-CA-C 108.22 -1.952 . . . . 0.0 108.22 -179.564 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.1 t -119.98 128.03 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.16 -1.2 . . . . 0.0 108.795 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.5 p -82.56 139.64 33.72 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.147 -0.971 . . . . 0.0 108.924 179.738 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.485 HG13 ' O ' ' A' ' 46' ' ' VAL . 12.7 p -120.05 127.62 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 CA-C-O 121.827 0.822 . . . . 0.0 108.878 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.0 p -128.06 149.86 50.2 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -168.92 159.44 32.53 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 117.922 -2.085 . . . . 0.0 111.682 -179.643 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 89.2 t -131.32 136.84 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.943 -0.739 . . . . 0.0 109.133 179.255 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.494 ' CZ ' ' OG1' ' A' ' 72' ' ' THR . 55.7 m-85 -108.18 123.71 49.16 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.006 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -95.91 126.51 41.21 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 120.735 -1.228 . . . . 0.0 109.751 -179.013 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.487 ' C ' ' N ' ' A' ' 54' ' ' ASP . 78.2 m-85 -112.0 129.79 56.08 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.453 -0.779 . . . . 0.0 109.913 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 31.9 t-20 -52.89 -10.83 0.18 Allowed 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 178.459 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.487 ' N ' ' C ' ' A' ' 52' ' ' TYR . 9.3 t70 -67.07 -2.68 5.82 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.56 19.0 60.89 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.114 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.4 p -133.46 152.07 51.86 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.022 -1.281 . . . . 0.0 110.812 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 68.9 p -130.33 142.39 50.53 Favored 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.419 0.628 . . . . 0.0 109.859 -179.476 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -117.55 140.83 49.1 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 178.681 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -125.28 116.24 21.63 Favored 'General case' 0 N--CA 1.496 1.839 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -117.49 121.04 39.93 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -113.22 149.8 33.23 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 179.502 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.2 -175.99 38.88 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.317 -1.421 . . . . 0.0 110.844 -179.53 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 66.8 t -122.49 127.82 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.915 -0.756 . . . . 0.0 109.944 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 21.8 t -99.3 118.61 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.365 -0.834 . . . . 0.0 110.256 -179.267 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.413 ' O ' ' N ' ' A' ' 67' ' ' SER . 29.9 p -118.89 149.83 47.4 Favored Pre-proline 0 N--CA 1.494 1.732 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.304 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -38.51 -28.02 0.12 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 121.845 1.697 . . . . 0.0 113.013 -179.552 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.413 ' N ' ' O ' ' A' ' 65' ' ' THR . 53.5 m -108.58 -3.58 17.89 Favored 'General case' 0 N--CA 1.503 2.225 0 O-C-N 121.345 -0.847 . . . . 0.0 111.677 -178.767 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 7.5 m -124.76 106.57 29.26 Favored Pre-proline 0 N--CA 1.508 2.452 0 O-C-N 120.84 -1.163 . . . . 0.0 111.008 -179.036 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -92.61 164.76 2.83 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 122.818 2.345 . . . . 0.0 111.562 177.765 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.8 t -119.88 130.04 74.69 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.19 0 O-C-N 121.261 -0.899 . . . . 0.0 108.802 179.62 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -99.91 121.7 41.72 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.304 -0.872 . . . . 0.0 109.997 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.494 ' OG1' ' CZ ' ' A' ' 50' ' ' PHE . 0.2 OUTLIER -100.45 5.45 44.22 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.075 -1.016 . . . . 0.0 108.855 179.41 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.422 ' O ' ' O ' ' A' ' 74' ' ' GLN . 47.9 p-10 -73.42 46.52 0.2 Allowed 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.323 -0.861 . . . . 0.0 109.649 -179.379 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.422 ' O ' ' O ' ' A' ' 73' ' ' ASN . 65.4 tt0 -47.72 -91.9 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.132 -0.98 . . . . 0.0 109.208 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -113.78 104.49 12.25 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.481 -0.762 . . . . 0.0 109.762 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 77.6 mt -80.07 -27.02 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 120.951 -1.093 . . . . 0.0 108.765 179.084 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.44 ' HA ' HD21 ' A' ' 80' ' ' ASN . 27.0 t-20 -59.71 -40.0 86.5 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.559 ' O ' HG22 ' A' ' 82' ' ' VAL . 18.5 ttmm -69.59 -48.55 59.78 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.209 -0.932 . . . . 0.0 108.791 177.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.61 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.5 OUTLIER -61.84 -51.15 69.43 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.805 -1.184 . . . . 0.0 110.801 -178.551 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 81' ' ' LYS . 29.6 p30 -66.25 -27.11 67.7 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 119.656 -1.902 . . . . 0.0 108.925 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' LYS . . . . . 0.52 ' N ' ' OD1' ' A' ' 80' ' ' ASN . 37.4 tptt -69.94 -49.05 55.65 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.348 -0.845 . . . . 0.0 110.431 179.366 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 78' ' ' LYS . 2.5 m -114.73 -26.04 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.351 0 O-C-N 121.039 -1.038 . . . . 0.0 110.859 -178.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.61 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.87 161.28 36.01 Favored Glycine 0 N--CA 1.493 2.46 0 O-C-N 120.712 -1.243 . . . . 0.0 110.41 179.097 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -100.92 117.52 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -74.75 -59.28 2.8 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.115 -0.991 . . . . 0.0 111.613 -178.868 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 54.3 mttp -114.29 135.41 54.1 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.33 -0.856 . . . . 0.0 110.983 -177.82 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 61.2 t80 -122.7 131.81 53.97 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.562 -0.711 . . . . 0.0 109.599 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -139.18 130.76 27.25 Favored 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.214 -0.929 . . . . 0.0 110.576 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -126.95 133.68 50.57 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.617 -0.677 . . . . 0.0 110.309 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 64.9 tp -120.05 131.29 55.05 Favored 'General case' 0 N--CA 1.503 2.181 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.409 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -130.48 131.13 44.99 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.528 -0.732 . . . . 0.0 111.181 -179.308 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.466 ' N ' ' CD ' ' A' ' 92' ' ' GLU . 4.6 pm0 -134.22 153.49 51.82 Favored 'General case' 0 N--CA 1.505 2.289 0 CA-C-O 121.35 0.595 . . . . 0.0 110.512 179.101 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 36.7 m95 -70.0 138.97 52.66 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.7 t -110.23 119.81 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.442 -0.787 . . . . 0.0 108.891 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.961 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.706 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -57.61 -72.04 0.09 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.677 -0.64 . . . . 0.0 110.892 -178.813 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.4 p-10 -147.38 42.33 1.08 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.051 -1.031 . . . . 0.0 108.22 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.401 HG23 ' HE1' ' A' ' 93' ' ' TRP . 10.3 m -80.5 139.95 17.4 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 O-C-N 121.463 -0.773 . . . . 0.0 109.301 -178.191 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -70.69 126.35 92.19 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.436 -0.79 . . . . 0.0 110.297 -178.442 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -82.91 -17.36 7.0 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.402 2.068 . . . . 0.0 111.53 178.764 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 57.3 m -60.04 -39.64 86.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.504 -0.747 . . . . 0.0 110.112 -179.427 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.3 mm-40 -65.98 -23.91 66.68 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.106 -0.997 . . . . 0.0 109.468 -179.386 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.615 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 36.0 t -65.26 -34.92 79.49 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.282 -0.886 . . . . 0.0 110.208 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -119.93 146.51 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.337 -0.852 . . . . 0.0 109.701 -179.364 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 53.4 mtmt -126.47 157.99 37.21 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 121.531 -0.73 . . . . 0.0 109.252 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -100.22 113.41 26.07 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.123 -0.986 . . . . 0.0 109.876 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.2 m -125.37 121.34 33.64 Favored 'General case' 0 N--CA 1.5 2.032 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.43 ' O ' ' N ' ' A' ' 22' ' ' GLN . . . 57.56 64.34 4.46 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' A' ' 20' ' ' GLY . 35.0 m 37.03 31.47 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.866 -0.785 . . . . 0.0 110.94 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.43 ' N ' ' O ' ' A' ' 20' ' ' GLY . 84.0 mt-30 -131.67 160.0 36.7 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.637 -0.664 . . . . 0.0 109.292 179.484 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 52.3 m-85 -119.32 140.09 50.88 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.074 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 33.7 p -135.14 148.09 49.65 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.525 -0.734 . . . . 0.0 109.314 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -84.24 120.02 25.73 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -86.23 105.85 16.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.096 -1.002 . . . . 0.0 110.516 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 79.3 p -90.78 -0.11 57.61 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.579 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -66.24 -9.75 49.93 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.416 HG23 ' SG ' ' A' ' 32' ' ' CYS . 0.2 OUTLIER -103.78 124.72 58.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 179.138 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 44.1 t -59.94 -40.13 87.93 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.364 -0.835 . . . . 0.0 111.828 -178.153 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 p -53.51 -34.96 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.751 -1.218 . . . . 0.0 110.143 -178.761 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.615 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 22.1 m -61.31 -44.74 96.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.996 -1.065 . . . . 0.0 110.82 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.0 mmt -77.21 -23.48 51.39 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.838 -1.164 . . . . 0.0 110.857 -179.324 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -60.07 -39.99 87.94 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.708 -1.245 . . . . 0.0 109.748 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -74.84 -46.85 15.92 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.5 mt -66.26 -39.4 89.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.451 -1.029 . . . . 0.0 109.553 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -60.13 -39.95 88.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.262 -0.899 . . . . 0.0 110.147 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -81.5 -7.76 59.63 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.109 -0.994 . . . . 0.0 110.792 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.4 28.13 70.26 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 32.1 mmtp -101.05 -7.43 23.24 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 178.529 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.791 HG12 ' H ' ' A' ' 43' ' ' GLY . 41.6 t -131.93 156.98 43.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 84.3 mtp180 -118.33 -6.5 10.79 Favored 'General case' 0 N--CA 1.5 2.052 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 179.521 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.791 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 137.19 -156.37 23.34 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 108.084 -2.006 . . . . 0.0 108.084 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.3 t -124.69 129.45 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 CA-C-N 118.644 1.222 . . . . 0.0 109.642 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.4 m -84.43 132.87 34.52 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.028 -1.045 . . . . 0.0 108.342 179.05 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.455 HG13 ' O ' ' A' ' 46' ' ' VAL . 15.0 p -130.04 131.6 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.555 -0.715 . . . . 0.0 109.435 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 54.4 p -122.86 144.71 49.02 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.237 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -135.12 137.22 9.06 Favored Glycine 0 N--CA 1.5 2.958 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.526 HG22 ' ND2' ' A' ' 59' ' ' ASN . 96.4 t -123.41 130.56 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.694 -0.886 . . . . 0.0 109.321 179.402 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -102.82 122.47 44.58 Favored 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -98.2 127.87 44.37 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.367 -0.833 . . . . 0.0 109.149 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.522 ' O ' ' N ' ' A' ' 54' ' ' ASP . 93.1 m-85 -113.04 128.12 56.41 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.525 -0.735 . . . . 0.0 109.364 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.51 ' OD1' ' N ' ' A' ' 53' ' ' ASN . 0.8 OUTLIER -42.95 -19.83 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.528 -0.732 . . . . 0.0 109.786 179.796 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 52' ' ' TYR . 8.6 t70 -67.97 0.79 3.16 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.473 -0.767 . . . . 0.0 109.395 -179.08 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.72 23.35 67.35 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.554 179.011 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.5 p -119.98 146.35 45.92 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.364 -1.08 . . . . 0.0 109.617 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 38.8 p -130.89 140.01 50.17 Favored 'General case' 0 N--CA 1.497 1.884 0 CA-C-O 121.571 0.7 . . . . 0.0 109.998 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 46.4 t -118.65 140.15 50.37 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 178.324 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ASN . . . . . 0.526 ' ND2' HG22 ' A' ' 49' ' ' VAL . 2.1 m120 -129.99 118.66 21.95 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 120.973 -1.079 . . . . 0.0 109.756 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -115.55 125.46 53.02 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 178.77 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -113.08 148.93 34.23 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.5 166.24 39.43 Favored Glycine 0 C--N 1.288 -2.095 0 N-CA-C 108.839 -1.704 . . . . 0.0 108.839 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.0 t -109.08 125.38 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.506 -0.997 . . . . 0.0 108.815 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.506 HG13 ' O ' ' A' ' 64' ' ' VAL . 3.4 p -94.35 121.8 45.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.41 -0.806 . . . . 0.0 109.984 -179.411 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.415 ' O ' ' N ' ' A' ' 68' ' ' THR . 8.2 p -127.75 149.97 71.94 Favored Pre-proline 0 N--CA 1.499 1.989 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.403 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -34.87 -38.55 0.16 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.52 2.147 . . . . 0.0 113.353 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.9 t -99.02 -6.52 28.39 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.039 -1.038 . . . . 0.0 111.026 -179.0 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.415 ' N ' ' O ' ' A' ' 65' ' ' THR . 34.7 m -128.07 106.89 19.93 Favored Pre-proline 0 N--CA 1.505 2.291 0 O-C-N 121.005 -1.059 . . . . 0.0 110.509 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -90.79 163.25 4.09 Favored 'Trans proline' 0 N--CA 1.488 1.201 0 C-N-CA 122.507 2.138 . . . . 0.0 111.624 178.171 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 58.6 t -120.43 130.13 74.78 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.297 0 O-C-N 121.275 -0.89 . . . . 0.0 108.783 179.587 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -101.33 127.78 47.8 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.126 -0.983 . . . . 0.0 111.495 -178.477 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.91 11.15 30.52 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 177.819 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.415 ' O ' ' O ' ' A' ' 74' ' ' GLN . 45.6 p-10 -77.97 57.88 1.84 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.514 -0.741 . . . . 0.0 110.214 -178.871 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.415 ' O ' ' O ' ' A' ' 73' ' ' ASN . 87.0 mt-30 -60.91 -158.84 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.048 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -63.68 102.13 0.42 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.722 -1.236 . . . . 0.0 108.717 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 96.8 mt -79.93 -18.1 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.422 -0.799 . . . . 0.0 110.398 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 -59.99 -40.68 90.0 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.883 -1.136 . . . . 0.0 108.413 -179.618 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 4.1 mtpm? -62.42 -47.93 81.94 Favored 'General case' 0 N--CA 1.495 1.786 0 CA-C-O 122.419 1.104 . . . . 0.0 108.78 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.583 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -60.04 -42.93 95.48 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.078 -0.964 . . . . 0.0 109.592 -178.284 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -62.55 -36.99 84.4 Favored 'General case' 0 C--N 1.293 -1.879 0 O-C-N 120.494 -1.379 . . . . 0.0 108.899 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 53.9 tttt -72.01 -44.49 63.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.091 -1.006 . . . . 0.0 111.107 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.3 p -112.88 -28.18 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.341 -0.85 . . . . 0.0 111.972 -176.61 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.77 165.25 40.68 Favored Glycine 0 N--CA 1.493 2.5 0 O-C-N 120.519 -1.363 . . . . 0.0 110.893 178.545 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.424 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 30.0 t -110.26 124.32 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.064 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 28.1 mt-30 -80.99 -65.17 1.05 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.004 -1.06 . . . . 0.0 110.121 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -114.77 139.94 49.31 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.363 -0.836 . . . . 0.0 110.899 -179.173 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 62.8 t80 -121.38 127.63 51.4 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.161 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -132.06 131.27 42.28 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 120.994 -1.066 . . . . 0.0 110.664 -179.424 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.485 ' C ' HD12 ' A' ' 90' ' ' LEU . . . -122.09 131.02 53.76 Favored 'General case' 0 N--CA 1.501 2.12 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 179.229 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.543 HD12 ' N ' ' A' ' 90' ' ' LEU . 8.7 mp -111.02 130.92 55.44 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.38 -0.825 . . . . 0.0 109.315 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.8 p -124.41 124.08 41.55 Favored 'General case' 0 N--CA 1.506 2.36 0 O-C-N 121.392 -0.817 . . . . 0.0 110.675 -179.625 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 -134.0 146.63 50.6 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.791 -0.568 . . . . 0.0 109.779 179.567 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' TRP . . . . . 0.401 ' HE1' HG23 ' A' ' 10' ' ' VAL . 87.8 m95 -69.17 139.61 54.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.733 -1.229 . . . . 0.0 108.587 178.649 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 44.7 t -108.86 119.62 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.025 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.749 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.193 0 N-CA-C 108.345 -1.902 . . . . 0.0 108.345 179.872 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 121.509 0.671 . . . . 0.0 109.544 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -72.14 -36.91 69.49 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.302 -0.874 . . . . 0.0 110.51 -179.173 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -81.76 -0.91 45.23 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.922 -1.111 . . . . 0.0 109.784 -179.398 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.9 t -100.34 140.24 19.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.241 -0.912 . . . . 0.0 109.212 -179.765 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -102.04 106.44 47.75 Favored Pre-proline 0 N--CA 1.492 1.653 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.827 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -49.17 -14.42 0.49 Allowed 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 121.86 1.707 . . . . 0.0 112.066 -179.274 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.1 t -63.44 -38.51 91.43 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.465 -0.772 . . . . 0.0 110.083 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -85.22 -12.58 52.25 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.313 -0.867 . . . . 0.0 110.367 -178.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 39.2 t -68.88 -34.5 75.53 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.654 -1.279 . . . . 0.0 109.867 -179.542 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -119.82 145.43 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 11.4 ptmm? -131.57 152.58 50.67 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.226 -0.921 . . . . 0.0 108.96 -179.624 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 14.0 tt0 -98.49 131.83 44.42 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.149 -0.969 . . . . 0.0 109.824 -179.591 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 29.3 t -117.71 120.07 36.87 Favored 'General case' 0 N--CA 1.496 1.871 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 178.51 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.64 -119.03 7.74 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 108.375 -1.89 . . . . 0.0 108.375 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.5 m -110.75 27.57 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.374 -1.074 . . . . 0.0 108.731 179.326 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -128.99 155.72 44.93 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.572 -0.705 . . . . 0.0 110.244 -178.467 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 38.3 m-85 -118.41 138.56 52.36 Favored 'General case' 0 N--CA 1.498 1.966 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 73.3 p -138.64 153.15 48.58 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.227 -0.921 . . . . 0.0 109.359 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.569 ' CZ ' ' SG ' ' A' ' 15' ' ' CYS . 30.1 t80 -80.72 125.2 29.76 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -86.52 88.68 7.7 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.232 -0.918 . . . . 0.0 110.681 -178.772 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.444 ' C ' ' H ' ' A' ' 29' ' ' VAL . 7.7 m -79.66 -8.9 59.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.952 -1.093 . . . . 0.0 108.631 178.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.53 -8.12 0.78 Allowed Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.444 ' H ' ' C ' ' A' ' 27' ' ' SER . 0.1 OUTLIER -107.51 122.7 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.954 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 178.793 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 59.8 p -63.67 -37.29 86.78 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.655 -0.653 . . . . 0.0 111.613 -178.171 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.8 m -57.65 -36.93 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 120.841 -1.162 . . . . 0.0 110.622 -178.174 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 27.1 m -61.7 -42.08 98.46 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.805 -1.185 . . . . 0.0 110.461 -179.349 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 14.6 mmt -73.91 -20.63 60.33 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.965 -1.085 . . . . 0.0 110.685 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 79.6 mm-40 -60.16 -41.86 93.69 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.739 -1.226 . . . . 0.0 110.027 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.79 -47.02 8.98 Favored Glycine 0 N--CA 1.491 2.328 0 C-N-CA 119.166 -1.493 . . . . 0.0 109.872 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 20.9 tp -62.92 -43.45 98.77 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.496 -1.002 . . . . 0.0 110.822 -178.766 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 -61.97 -39.7 93.07 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.975 -1.078 . . . . 0.0 110.304 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.481 ' HB3' ' HZ3' ' A' ' 40' ' ' LYS . 77.9 mm-40 -74.95 -8.11 55.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.231 -0.918 . . . . 0.0 110.438 -178.857 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 73.45 24.83 74.17 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.481 ' HZ3' ' HB3' ' A' ' 38' ' ' GLU . 59.6 mttp -97.86 -6.61 32.1 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 178.129 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.764 HG12 ' H ' ' A' ' 43' ' ' GLY . 93.6 t -135.65 159.92 39.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.64 -179.835 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.441 ' N ' HG12 ' A' ' 41' ' ' VAL . 52.7 ttt85 -118.61 -8.47 10.42 Favored 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.526 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.764 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.34 -161.46 25.66 Favored Glycine 0 N--CA 1.502 3.081 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 90.8 t -120.62 127.23 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.023 -1.281 . . . . 0.0 109.529 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.1 m -85.29 138.28 32.42 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 10.3 m -132.32 134.29 59.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.374 -0.829 . . . . 0.0 110.148 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 51.7 p -125.33 147.8 48.99 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.514 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -151.7 142.23 9.27 Favored Glycine 0 N--CA 1.496 2.644 0 C-N-CA 118.996 -1.573 . . . . 0.0 110.836 -178.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 78.5 t -125.13 130.13 73.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -104.52 122.01 44.67 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.451 -0.781 . . . . 0.0 108.914 -179.285 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 36.0 m-85 -92.37 125.86 37.21 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.258 -0.901 . . . . 0.0 110.488 -178.677 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.519 ' HE1' ' HG1' ' A' ' 79' ' ' THR . 97.9 m-85 -109.22 135.54 50.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.454 -0.779 . . . . 0.0 109.941 179.76 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 25.6 m120 -60.83 -13.86 18.16 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 179.041 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 11.3 t70 -68.72 0.68 3.97 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.87 15.41 72.89 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 179.059 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.2 p -119.18 152.71 36.12 Favored 'General case' 0 N--CA 1.51 2.531 0 O-C-N 121.367 -1.078 . . . . 0.0 111.153 -179.305 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 39.3 p -131.83 141.53 49.46 Favored 'General case' 0 N--CA 1.499 1.993 0 CA-C-O 121.433 0.635 . . . . 0.0 109.509 179.298 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 35.7 t -118.0 141.58 48.31 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 178.458 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -132.4 116.62 17.06 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.123 -0.986 . . . . 0.0 109.312 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.539 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 42.2 p90 -116.38 122.65 45.47 Favored 'General case' 0 N--CA 1.496 1.865 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.613 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -115.76 143.73 44.97 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.01 178.19 42.4 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.3 t -116.56 128.95 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 O-C-N 121.46 -1.023 . . . . 0.0 109.929 -179.458 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.0 t -95.81 112.0 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.151 -0.968 . . . . 0.0 109.922 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.571 ' O ' ' N ' ' A' ' 67' ' ' SER . 2.3 p -136.63 151.5 72.85 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 178.691 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_exo -41.14 -15.14 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.437 0 C-N-CA 121.704 1.603 . . . . 0.0 112.24 179.108 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.571 ' N ' ' O ' ' A' ' 65' ' ' THR . 67.3 p -61.53 -54.15 46.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.875 -1.141 . . . . 0.0 109.955 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -157.78 148.76 16.39 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 120.865 -1.147 . . . . 0.0 110.109 -179.649 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -82.55 163.53 16.68 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 122.23 1.953 . . . . 0.0 111.413 178.194 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 99.6 t -111.25 131.1 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.128 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ASN . . . . . 0.468 ' O ' ' OD1' ' A' ' 71' ' ' ASN . 22.8 p30 -100.91 138.26 38.19 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.471 -0.768 . . . . 0.0 111.671 -177.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.54 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.1 OUTLIER -100.0 1.72 42.78 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 177.907 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 40.9 t-20 -66.96 52.74 0.05 OUTLIER 'General case' 0 N--CA 1.488 1.461 0 CA-C-O 121.631 0.729 . . . . 0.0 109.345 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.54 ' N ' ' O ' ' A' ' 72' ' ' THR . 77.2 mt-30 -64.82 -90.37 0.01 OUTLIER 'General case' 0 C--N 1.294 -1.824 0 O-C-N 121.456 -0.778 . . . . 0.0 109.667 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -112.04 74.83 0.88 Allowed 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.566 -0.709 . . . . 0.0 110.115 -179.563 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.441 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 10.7 tp -60.31 -38.87 79.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.875 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.441 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 17.0 t-20 -57.92 -41.19 82.17 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 32.4 tttm -67.81 -43.33 79.9 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.365 -0.834 . . . . 0.0 109.098 178.548 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.572 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.3 OUTLIER -67.57 -40.84 84.89 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.088 -1.007 . . . . 0.0 109.445 -179.365 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -66.79 -25.92 66.7 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 120.441 -1.412 . . . . 0.0 109.156 179.336 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -68.63 -47.52 66.41 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 120.89 -1.131 . . . . 0.0 110.379 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.7 m -121.25 -18.8 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 121.337 -0.852 . . . . 0.0 111.669 -177.733 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.11 170.37 46.91 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.413 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 46.5 t -108.3 127.17 64.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 62.5 tt0 -80.45 -66.8 0.83 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 120.999 -1.063 . . . . 0.0 111.149 -179.381 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 34.8 ttpt -114.82 140.02 49.27 Favored 'General case' 0 N--CA 1.506 2.342 0 O-C-N 121.179 -0.951 . . . . 0.0 110.919 -178.267 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 84.5 t80 -120.97 136.26 55.02 Favored 'General case' 0 N--CA 1.505 2.293 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.24 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 -136.49 124.13 22.37 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.204 -0.935 . . . . 0.0 110.18 179.589 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -125.01 140.77 52.61 Favored 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.421 -0.799 . . . . 0.0 110.426 179.519 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.0 mt -118.93 129.82 55.38 Favored 'General case' 0 N--CA 1.504 2.26 0 O-C-N 121.501 -0.749 . . . . 0.0 109.464 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 31.8 p -126.57 117.18 22.28 Favored 'General case' 0 N--CA 1.508 2.439 0 CA-C-O 121.848 0.832 . . . . 0.0 110.29 179.708 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -132.56 156.12 47.42 Favored 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.154 -179.109 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -70.82 144.74 50.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.4 -0.813 . . . . 0.0 109.384 179.302 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 35.5 t -120.04 127.58 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.707 -0.621 . . . . 0.0 109.343 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.764 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -179.552 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' A' ' 8' ' ' ASP . 26.6 t0 -100.2 7.48 44.48 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.309 -0.869 . . . . 0.0 110.894 -178.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 71.6 m-80 -122.39 13.17 10.23 Favored 'General case' 0 N--CA 1.501 2.087 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.4 m -120.49 141.66 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 CA-C-O 121.343 0.592 . . . . 0.0 109.422 -179.175 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 36.0 t0 -103.97 111.94 65.34 Favored Pre-proline 0 N--CA 1.499 1.999 0 O-C-N 121.247 -0.908 . . . . 0.0 109.081 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_exo -40.78 -33.43 1.06 Allowed 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.232 1.955 . . . . 0.0 113.126 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 58.5 m -60.01 -39.93 87.5 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.036 -1.04 . . . . 0.0 110.711 -179.367 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 47.0 tt0 -70.03 -24.91 63.35 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.799 -1.188 . . . . 0.0 109.925 -178.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.555 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 37.3 t -68.31 -34.41 76.09 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.332 -0.855 . . . . 0.0 110.118 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.1 pt -117.17 145.88 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.409 -0.807 . . . . 0.0 109.153 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 52.7 mtpt -126.36 146.09 50.19 Favored 'General case' 0 N--CA 1.497 1.875 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 -179.47 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -87.0 119.73 27.51 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.543 -0.723 . . . . 0.0 109.208 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.512 ' O ' ' N ' ' A' ' 21' ' ' VAL . 39.3 p -102.07 119.54 38.96 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.404 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.81 -93.4 0.01 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.512 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.4 t -129.86 20.89 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.538 -0.978 . . . . 0.0 109.23 -179.641 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 75.2 mt-30 -128.55 167.93 16.42 Favored 'General case' 0 N--CA 1.5 2.067 0 CA-C-O 121.866 0.841 . . . . 0.0 110.695 -179.357 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 24.3 m-85 -119.74 135.15 54.96 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 107.888 -1.152 . . . . 0.0 107.888 178.54 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 60.9 p -131.32 149.74 52.43 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.345 -0.847 . . . . 0.0 109.753 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 48.5 t80 -86.89 128.76 35.06 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.468 -0.77 . . . . 0.0 109.871 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -88.27 81.53 7.28 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.105 -0.997 . . . . 0.0 110.552 -179.362 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.2 p -77.97 -16.64 57.99 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.936 -1.102 . . . . 0.0 109.599 179.396 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -64.1 -3.68 9.48 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.363 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.402 HG12 HG12 ' A' ' 31' ' ' VAL . 2.7 t -98.6 129.35 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.261 -1.141 . . . . 0.0 108.321 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 80.8 p -60.06 -40.24 88.8 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 110.727 -178.62 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.42 HG13 ' N ' ' A' ' 32' ' ' CYS . 8.1 p -60.67 -40.4 84.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.92 -1.112 . . . . 0.0 110.402 -179.246 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.555 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.9 m -61.37 -43.36 99.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.024 -1.047 . . . . 0.0 110.11 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 9.2 mmt -80.34 -16.83 53.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.897 -1.127 . . . . 0.0 109.824 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 55.9 tt0 -60.32 -40.28 90.02 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.053 -1.029 . . . . 0.0 108.744 179.372 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -78.49 -47.47 8.03 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.717 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 mt -64.86 -42.67 94.68 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.196 -1.179 . . . . 0.0 110.159 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -62.79 -40.39 97.2 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.015 -1.053 . . . . 0.0 110.002 -179.586 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 63.5 mm-40 -67.78 -29.29 68.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.199 -0.938 . . . . 0.0 109.61 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.02 22.75 44.01 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 110.09 -1.204 . . . . 0.0 110.09 179.703 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 17.2 mmmt -102.55 -0.31 32.32 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 178.475 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.636 HG12 ' H ' ' A' ' 43' ' ' GLY . 14.4 t -136.53 157.46 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.512 ' N ' ' O ' ' A' ' 94' ' ' VAL . 70.7 mtp85 -118.18 -10.19 10.33 Favored 'General case' 0 N--CA 1.5 2.045 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 178.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.636 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 141.55 -158.86 26.69 Favored Glycine 0 N--CA 1.497 2.717 0 N-CA-C 108.644 -1.783 . . . . 0.0 108.644 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.7 t -120.59 128.96 76.08 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.184 -1.186 . . . . 0.0 109.207 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.4 m -85.69 139.67 31.18 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.256 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.412 ' O ' HG13 ' A' ' 46' ' ' VAL . 8.6 p -129.61 133.03 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 CA-C-O 121.808 0.813 . . . . 0.0 109.797 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 22.4 p -126.73 150.09 49.24 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 178.859 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -148.88 145.21 13.29 Favored Glycine 0 N--CA 1.494 2.548 0 C-N-CA 118.708 -1.71 . . . . 0.0 111.462 -178.83 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 95.4 t -118.16 125.98 74.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 178.111 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.598 ' N ' ' CD1' ' A' ' 50' ' ' PHE . 2.1 m-85 -105.51 116.29 31.69 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.166 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -91.76 124.75 36.13 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.45 -0.781 . . . . 0.0 109.137 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.466 ' C ' ' H ' ' A' ' 54' ' ' ASP . 88.9 m-85 -109.31 134.68 51.49 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 -57.16 -5.96 0.34 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.905 -1.122 . . . . 0.0 108.767 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.466 ' H ' ' C ' ' A' ' 52' ' ' TYR . 46.2 t0 -73.64 3.59 6.14 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.868 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.59 27.41 61.21 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.286 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 22.7 p -130.12 150.87 51.19 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.416 -1.05 . . . . 0.0 110.864 -179.162 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 80.5 p -132.0 123.04 26.52 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.64 -0.663 . . . . 0.0 109.324 179.263 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 23.2 t -104.46 153.2 21.42 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 9.3 m-20 -131.97 118.87 20.32 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 120.93 -1.106 . . . . 0.0 108.98 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -117.48 123.95 47.59 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.477 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -111.78 145.57 39.16 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -163.37 174.88 39.67 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.6 t -119.82 127.22 75.87 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.124 0 O-C-N 121.517 -0.99 . . . . 0.0 109.373 179.584 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 70.8 t -95.38 120.1 44.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.21 -0.931 . . . . 0.0 110.278 -179.202 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.502 ' C ' ' H ' ' A' ' 67' ' ' SER . 3.0 p -137.34 155.32 75.73 Favored Pre-proline 0 N--CA 1.492 1.635 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.097 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -49.69 -4.96 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.021 1.814 . . . . 0.0 111.624 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.502 ' H ' ' C ' ' A' ' 65' ' ' THR . 52.6 p -71.51 -52.1 20.12 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.201 -0.937 . . . . 0.0 110.414 -179.576 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.0 t -154.58 147.08 17.6 Favored Pre-proline 0 N--CA 1.497 1.902 0 O-C-N 120.843 -1.161 . . . . 0.0 110.235 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -80.89 163.91 20.47 Favored 'Trans proline' 0 N--CA 1.497 1.687 0 C-N-CA 122.373 2.048 . . . . 0.0 112.413 179.032 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 64.6 t -123.02 131.22 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.223 0 O-C-N 121.499 -0.75 . . . . 0.0 109.02 179.419 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -90.8 140.31 29.92 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 120.953 -1.092 . . . . 0.0 109.728 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.446 ' OG1' ' N ' ' A' ' 73' ' ' ASN . 1.2 p -80.34 -50.43 10.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.058 -1.026 . . . . 0.0 108.778 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.446 ' N ' ' OG1' ' A' ' 72' ' ' THR . 97.7 m-20 -79.5 58.32 2.64 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.483 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -46.41 -39.56 10.68 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -108.37 75.6 0.99 Allowed 'General case' 0 N--CA 1.496 1.841 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.739 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.425 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 9.2 tp -60.43 -39.85 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.456 -0.777 . . . . 0.0 110.435 -178.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.425 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 46.1 t30 -59.87 -46.28 89.79 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 119.02 -1.072 . . . . 0.0 108.142 -179.371 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 44.2 tttp -60.62 -50.14 74.72 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.164 -0.96 . . . . 0.0 108.938 178.345 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.535 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.1 m -62.11 -41.11 97.89 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.726 -0.609 . . . . 0.0 110.413 -178.513 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -64.92 -33.06 75.14 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 120.545 -1.347 . . . . 0.0 109.882 179.714 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 46.2 tttt -67.02 -49.86 63.93 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.116 -0.99 . . . . 0.0 110.662 -179.073 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.8 p -113.8 -26.16 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.67 -0.644 . . . . 0.0 111.967 -176.66 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 81.59 158.11 20.6 Favored Glycine 0 N--CA 1.493 2.436 0 O-C-N 120.494 -1.379 . . . . 0.0 109.713 179.703 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.5 t -105.03 120.38 55.52 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.764 -0.845 . . . . 0.0 108.988 179.667 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -70.0 -58.36 3.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.132 -0.98 . . . . 0.0 111.569 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -113.9 140.04 48.7 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.141 -0.975 . . . . 0.0 110.328 -178.228 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 71.6 t80 -120.24 127.75 52.7 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.667 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -130.78 127.12 38.06 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 121.212 -0.93 . . . . 0.0 109.869 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.68 142.83 51.1 Favored 'General case' 0 N--CA 1.505 2.296 0 O-C-N 121.557 -0.714 . . . . 0.0 110.314 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 mt -125.83 133.54 51.95 Favored 'General case' 0 N--CA 1.508 2.433 0 O-C-N 121.602 -0.686 . . . . 0.0 109.384 179.603 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 61.8 p -127.95 124.66 37.85 Favored 'General case' 0 N--CA 1.506 2.362 0 O-C-N 121.369 -0.832 . . . . 0.0 110.75 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -133.08 147.25 52.17 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.749 -0.594 . . . . 0.0 109.806 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 88.4 m95 -69.49 139.76 53.92 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 120.816 -1.178 . . . . 0.0 109.35 179.331 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.512 ' O ' ' N ' ' A' ' 42' ' ' ARG . 46.8 t -111.68 120.09 61.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.185 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 -179.986 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.692 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 -82.28 -26.16 33.37 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.465 -0.772 . . . . 0.0 110.947 -178.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -94.04 3.44 55.33 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 120.858 -1.151 . . . . 0.0 110.659 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.3 t -110.83 130.04 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.296 -0.878 . . . . 0.0 110.52 -179.076 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -88.0 131.94 41.44 Favored Pre-proline 0 N--CA 1.492 1.63 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.491 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -77.18 -19.58 13.44 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 121.801 1.668 . . . . 0.0 112.477 -179.217 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 55.2 m -59.92 -39.93 87.16 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.174 -0.954 . . . . 0.0 110.374 -179.682 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 90.2 mm-40 -83.71 -11.15 57.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.076 -1.015 . . . . 0.0 110.054 -179.454 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.667 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 45.5 t -69.67 -31.33 69.32 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.131 -0.981 . . . . 0.0 109.142 179.779 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -120.07 146.06 25.43 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 61.4 pttt -125.47 149.96 47.77 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.458 -0.776 . . . . 0.0 109.384 -179.406 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -99.85 122.03 42.18 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.357 -0.839 . . . . 0.0 109.827 -178.631 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.1 t -107.45 100.9 10.29 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.069 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 71.72 -94.52 0.59 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.1 m -133.2 23.28 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.204 0 O-C-N 121.285 -1.126 . . . . 0.0 110.413 -179.642 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -131.66 161.56 32.46 Favored 'General case' 0 N--CA 1.504 2.275 0 O-C-N 121.209 -0.932 . . . . 0.0 109.989 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -113.26 141.41 47.02 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.903 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 37.2 p -130.01 142.04 50.67 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.36 -0.838 . . . . 0.0 109.425 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.9 t80 -81.64 126.0 31.24 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.49 -0.756 . . . . 0.0 109.897 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 48.7 t-20 -90.02 85.41 6.32 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.35 -0.844 . . . . 0.0 110.447 -179.611 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.2 p -85.54 -1.43 57.09 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.933 -1.104 . . . . 0.0 109.207 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.08 -31.56 77.16 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.511 ' CG2' ' SG ' ' A' ' 32' ' ' CYS . 24.4 m -83.64 132.48 31.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.152 -1.205 . . . . 0.0 109.138 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 71.1 m -60.08 -39.92 87.76 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.325 -0.859 . . . . 0.0 111.474 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.1 m -52.96 -38.19 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 120.719 -1.238 . . . . 0.0 110.588 -178.072 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.667 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.8 m -62.85 -39.93 95.91 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.73 -1.231 . . . . 0.0 110.016 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 10.0 mmt -80.07 -14.92 58.16 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.984 -1.073 . . . . 0.0 110.263 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -64.84 -39.97 94.43 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.884 -1.135 . . . . 0.0 109.287 179.167 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.12 -49.11 8.82 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.97 -40.16 94.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.347 -1.09 . . . . 0.0 109.998 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -61.15 -40.01 92.23 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.936 -1.103 . . . . 0.0 110.043 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -76.7 -10.19 59.21 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.017 -1.052 . . . . 0.0 109.214 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 69.93 27.23 73.36 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 54.7 tttp -98.99 -7.52 26.8 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 178.837 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.566 HG12 ' H ' ' A' ' 43' ' ' GLY . 4.2 t -133.71 159.03 42.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-N 115.113 -0.949 . . . . 0.0 108.885 -179.591 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 94' ' ' VAL . 96.3 mtt180 -121.46 -5.96 9.28 Favored 'General case' 0 N--CA 1.504 2.265 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.211 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.566 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 142.66 -170.13 25.29 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 108.567 -1.813 . . . . 0.0 108.567 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 77.0 t -111.08 126.18 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.065 -1.256 . . . . 0.0 108.338 179.147 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.4 p -82.02 139.76 34.32 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.126 -0.984 . . . . 0.0 109.275 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.431 ' O ' HG13 ' A' ' 46' ' ' VAL . 12.3 p -130.0 133.45 64.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 98.1 p -124.43 142.54 51.23 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.406 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -133.87 131.86 6.19 Favored Glycine 0 N--CA 1.502 3.068 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.108 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 74.4 t -121.58 129.26 75.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.732 -0.863 . . . . 0.0 108.999 178.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.433 ' HE2' ' HG1' ' A' ' 72' ' ' THR . 29.7 m-85 -104.76 122.54 45.92 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.209 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -96.16 129.82 43.37 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.284 -0.885 . . . . 0.0 109.454 -179.417 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.529 ' O ' ' N ' ' A' ' 54' ' ' ASP . 95.0 m-85 -114.66 127.57 55.84 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -179.67 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -43.12 -19.11 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.428 -0.795 . . . . 0.0 109.918 179.763 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 52' ' ' TYR . 50.1 t0 -68.25 1.32 2.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.459 -0.776 . . . . 0.0 109.752 -179.235 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.76 20.26 74.12 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.574 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.5 p -115.9 154.76 29.17 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.423 -1.046 . . . . 0.0 109.726 179.617 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 45.2 p -139.62 137.98 35.76 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.626 -0.671 . . . . 0.0 109.629 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 53.8 m -113.71 149.58 34.55 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 178.434 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 21.9 p-10 -140.79 119.07 12.08 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.023 -1.048 . . . . 0.0 110.119 -179.418 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 73.5 m-85 -114.11 121.52 44.05 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 107.678 -1.231 . . . . 0.0 107.678 178.349 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.0 ttpm? -113.17 147.33 37.63 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.748 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.64 169.2 41.55 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.4 t -110.04 127.32 67.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.416 -1.05 . . . . 0.0 109.594 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.5 t -91.3 119.99 39.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.423 -0.798 . . . . 0.0 110.017 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.515 ' O ' ' N ' ' A' ' 67' ' ' SER . 25.7 p -136.31 147.59 60.81 Favored Pre-proline 0 N--CA 1.493 1.688 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 178.515 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_exo -39.16 -21.86 0.07 OUTLIER 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 121.987 1.792 . . . . 0.0 112.538 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.515 ' N ' ' O ' ' A' ' 65' ' ' THR . 67.9 m -68.41 -45.82 71.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.115 -0.991 . . . . 0.0 111.413 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 5.8 t -154.75 142.8 14.26 Favored Pre-proline 0 N--CA 1.5 2.042 0 O-C-N 120.407 -1.433 . . . . 0.0 111.19 -179.384 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -81.95 166.84 16.67 Favored 'Trans proline' 0 N--CA 1.499 1.83 0 C-N-CA 122.993 2.462 . . . . 0.0 111.627 178.308 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 90.3 t -105.95 135.79 42.81 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.198 0 O-C-N 121.242 -0.911 . . . . 0.0 109.258 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 29.2 m120 -99.67 123.95 44.43 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.301 -0.874 . . . . 0.0 111.464 -178.258 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.462 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.3 OUTLIER -109.87 20.03 18.44 Favored 'General case' 0 N--CA 1.502 2.174 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.1 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.445 ' O ' ' O ' ' A' ' 74' ' ' GLN . 25.6 t-20 -78.69 60.23 2.7 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.47 -0.769 . . . . 0.0 109.927 -179.433 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.554 ' N ' ' OE1' ' A' ' 74' ' ' GLN . 0.0 OUTLIER -50.28 177.59 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 178.732 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 78.9 m-20 -66.08 119.81 12.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.469 -1.394 . . . . 0.0 108.464 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.436 HG22 ' O ' ' A' ' 76' ' ' ILE . 94.5 mt -80.65 -13.11 12.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.506 -0.746 . . . . 0.0 110.409 -179.092 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 28.7 m120 -60.13 -43.89 95.33 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.827 -1.171 . . . . 0.0 109.036 -179.497 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 18.7 pttt -66.89 -40.09 87.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.877 -1.139 . . . . 0.0 109.271 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.587 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.9 OUTLIER -63.05 -41.13 99.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.239 -0.913 . . . . 0.0 108.777 179.473 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -62.19 -38.71 90.14 Favored 'General case' 0 C--N 1.295 -1.773 0 O-C-N 120.76 -1.213 . . . . 0.0 109.551 179.236 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 31.3 tttm -71.61 -42.51 67.61 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.07 -1.019 . . . . 0.0 111.148 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 p -112.12 -29.42 2.36 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.188 0 O-C-N 121.252 -0.905 . . . . 0.0 112.168 -176.883 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.98 161.09 37.15 Favored Glycine 0 N--CA 1.495 2.587 0 O-C-N 120.702 -1.249 . . . . 0.0 110.606 179.31 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 84.7 t -108.99 127.34 65.73 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.075 0 O-C-N 121.807 -0.82 . . . . 0.0 108.903 179.363 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -88.01 -63.12 1.35 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.08 -1.013 . . . . 0.0 111.181 -178.872 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -115.07 142.94 45.96 Favored 'General case' 0 N--CA 1.505 2.293 0 CA-C-O 121.872 0.844 . . . . 0.0 111.937 -178.002 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -120.08 130.87 54.86 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.07 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.91 128.62 32.93 Favored 'General case' 0 N--CA 1.505 2.325 0 O-C-N 121.067 -1.02 . . . . 0.0 110.104 -178.966 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.43 135.38 54.08 Favored 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 179.14 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.696 HD13 ' N ' ' A' ' 91' ' ' THR . 0.2 OUTLIER -120.0 134.73 55.16 Favored 'General case' 0 N--CA 1.503 2.205 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.789 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.696 ' N ' HD13 ' A' ' 90' ' ' LEU . 14.5 p -130.22 124.24 32.05 Favored 'General case' 0 N--CA 1.505 2.283 0 CA-C-O 121.571 0.7 . . . . 0.0 111.016 -179.181 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.29 156.98 47.48 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.762 -0.586 . . . . 0.0 110.131 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 65.6 m95 -69.61 149.51 48.06 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.707 -1.246 . . . . 0.0 108.135 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.519 ' O ' ' N ' ' A' ' 42' ' ' ARG . 31.7 t -117.95 123.11 71.2 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.171 0 O-C-N 121.353 -0.842 . . . . 0.0 109.394 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 2.77 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 179.627 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.682 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.435 ' OD1' ' O ' ' A' ' 8' ' ' ASP . 39.2 t0 -99.19 6.09 46.51 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.296 -0.877 . . . . 0.0 111.427 -178.546 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.7 p-10 -130.01 9.3 5.3 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 120.843 -1.161 . . . . 0.0 108.908 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 2.2 m -124.68 129.96 73.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -89.81 148.25 39.41 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.016 -1.053 . . . . 0.0 108.759 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -80.15 -22.36 7.23 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.408 2.072 . . . . 0.0 111.937 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 56.0 m -60.24 -40.16 89.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.916 . . . . 0.0 110.411 -179.583 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -81.05 -13.77 58.48 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.031 -1.043 . . . . 0.0 110.239 -179.286 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.678 ' HG ' ' HG ' ' A' ' 32' ' ' CYS . 53.9 m -71.11 -29.06 64.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.11 178.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -120.46 135.05 61.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 64.0 mmtt -111.96 147.86 35.0 Favored 'General case' 0 N--CA 1.502 2.161 0 O-C-N 121.291 -0.88 . . . . 0.0 109.292 -179.318 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -97.11 119.86 36.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 108.796 179.516 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 47.8 t -107.56 116.08 31.3 Favored 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.805 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.56 -109.42 1.21 Allowed Glycine 0 N--CA 1.487 2.038 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 -178.681 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.435 ' O ' HG13 ' A' ' 21' ' ' VAL . 7.7 p -118.74 34.64 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.43 -1.041 . . . . 0.0 108.997 179.16 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -130.66 159.37 37.42 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 122.194 0.997 . . . . 0.0 111.567 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -120.8 136.79 54.81 Favored 'General case' 0 N--CA 1.496 1.825 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 26.5 p -137.25 154.44 50.14 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.245 -0.909 . . . . 0.0 109.279 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.8 t80 -87.67 128.06 35.29 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.266 -0.896 . . . . 0.0 109.597 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -86.01 83.21 7.83 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.929 -1.107 . . . . 0.0 109.92 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 86.4 p -84.65 -0.98 55.4 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.933 -1.104 . . . . 0.0 109.424 179.627 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.67 -39.96 95.87 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.089 -1.605 . . . . 0.0 109.089 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 33.4 m -81.83 135.28 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.332 -1.099 . . . . 0.0 108.774 179.433 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 34' ' ' GLN . 17.1 p -72.76 -26.8 61.68 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.182 -0.949 . . . . 0.0 110.873 -178.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.484 HG13 ' N ' ' A' ' 32' ' ' CYS . 10.9 p -59.9 -40.85 83.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 120.841 -1.162 . . . . 0.0 110.774 -178.504 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.678 ' HG ' ' HG ' ' A' ' 15' ' ' CYS . 87.0 m -68.69 -39.9 80.3 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.839 -1.163 . . . . 0.0 109.228 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 99.5 mmm -80.09 -14.6 58.39 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.134 -0.979 . . . . 0.0 108.68 179.089 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLN . . . . . 0.421 ' N ' ' O ' ' A' ' 30' ' ' SER . 59.8 tt0 -60.62 -41.98 95.92 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.01 -41.2 28.1 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.378 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.3 tp -67.16 -40.26 86.63 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -1.128 . . . . 0.0 108.687 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -63.07 -40.03 96.47 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.48 -0.763 . . . . 0.0 110.539 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.537 ' N ' ' OE1' ' A' ' 38' ' ' GLU . 0.4 OUTLIER -75.09 -11.41 60.09 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.831 -1.168 . . . . 0.0 109.763 -179.403 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.24 21.5 70.16 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 119.901 -1.142 . . . . 0.0 110.443 178.654 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 62.3 mttm -98.66 -3.38 36.15 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.686 HG12 ' H ' ' A' ' 43' ' ' GLY . 94.0 t -134.91 159.28 41.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.419 ' N ' HG12 ' A' ' 41' ' ' VAL . 95.0 mtt-85 -122.08 -7.13 8.89 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 179.482 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.686 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.78 -163.22 25.88 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 -179.504 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 87.8 t -119.39 129.19 75.6 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 121.322 -1.105 . . . . 0.0 109.115 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 5.4 m -86.36 139.19 31.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.861 -1.149 . . . . 0.0 108.897 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.41 ' O ' HG13 ' A' ' 46' ' ' VAL . 10.6 p -131.25 133.76 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.615 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 53.5 p -125.42 149.42 48.21 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 179.257 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -143.51 138.12 7.96 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 119.574 -1.298 . . . . 0.0 110.062 -179.145 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.426 HG21 HH21 ' A' ' 88' ' ' ARG . 62.4 t -122.63 127.06 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 179.064 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.594 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 0.2 OUTLIER -100.87 119.8 39.2 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -179.858 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -94.41 119.92 33.86 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.164 -0.96 . . . . 0.0 108.661 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.482 ' O ' ' N ' ' A' ' 54' ' ' ASP . 93.4 m-85 -102.22 125.79 49.02 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.424 -0.797 . . . . 0.0 109.985 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -47.2 -16.43 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.104 -0.997 . . . . 0.0 109.751 179.562 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.482 ' N ' ' O ' ' A' ' 52' ' ' TYR . 47.4 t0 -70.85 4.72 2.37 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.247 -0.908 . . . . 0.0 109.223 -179.533 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.08 22.76 70.49 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 178.704 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.4 p -123.54 150.81 43.54 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.33 -1.1 . . . . 0.0 109.339 179.756 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.1 p -135.33 139.79 44.58 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.583 -0.698 . . . . 0.0 110.152 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.1 m -117.92 144.5 45.41 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 178.352 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.6 m-20 -128.2 118.49 23.42 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.388 -0.82 . . . . 0.0 108.953 -179.831 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 66.3 t80 -116.76 126.47 53.16 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.256 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -113.74 144.9 42.19 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -159.16 167.83 35.02 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.83 128.58 74.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.599 -0.942 . . . . 0.0 108.694 -179.662 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 45.7 t -92.88 117.87 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.047 -1.033 . . . . 0.0 110.088 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.541 ' O ' ' N ' ' A' ' 67' ' ' SER . 6.4 p -134.98 153.87 78.81 Favored Pre-proline 0 N--CA 1.492 1.633 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 178.643 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_exo -43.93 -10.13 0.03 OUTLIER 'Trans proline' 0 N--CA 1.494 1.543 0 C-N-CA 121.981 1.788 . . . . 0.0 113.204 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.541 ' N ' ' O ' ' A' ' 65' ' ' THR . 87.1 p -67.6 -59.52 3.29 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.892 -1.13 . . . . 0.0 110.687 -179.236 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -155.4 150.75 21.21 Favored Pre-proline 0 N--CA 1.498 1.933 0 O-C-N 120.596 -1.315 . . . . 0.0 110.259 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -82.81 161.24 16.25 Favored 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.522 2.148 . . . . 0.0 112.523 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.5 t -110.78 130.5 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 15.7 m-20 -100.8 144.46 29.73 Favored 'General case' 0 N--CA 1.506 2.338 0 O-C-N 120.905 -1.122 . . . . 0.0 111.069 -178.355 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.19 -0.06 56.99 Favored 'General case' 0 N--CA 1.504 2.244 0 O-C-N 121.059 -1.026 . . . . 0.0 108.607 178.531 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.434 ' HB3' HG21 ' A' ' 21' ' ' VAL . 52.2 p-10 -80.43 46.67 0.86 Allowed 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.239 -0.913 . . . . 0.0 109.832 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 62.1 tt0 -48.17 -81.04 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.957 -1.09 . . . . 0.0 110.012 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -112.93 94.9 5.12 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.41 -0.806 . . . . 0.0 109.938 -179.503 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 8.8 mm -68.63 -39.89 81.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.28 -0.888 . . . . 0.0 109.733 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -59.95 -40.97 90.81 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 107.74 -1.207 . . . . 0.0 107.74 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -66.51 -43.13 86.1 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.455 -0.778 . . . . 0.0 109.156 178.818 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.597 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.2 m -76.1 -47.95 22.55 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.524 -0.735 . . . . 0.0 110.227 -178.721 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -60.05 -32.11 70.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.248 -1.533 . . . . 0.0 109.783 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 18.7 tptt -67.49 -53.53 27.97 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.329 -0.857 . . . . 0.0 110.694 -178.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.12 -22.14 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.172 -0.955 . . . . 0.0 111.515 -178.328 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.2 167.3 43.39 Favored Glycine 0 N--CA 1.487 2.086 0 O-C-N 120.896 -1.128 . . . . 0.0 110.764 178.729 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.401 HG23 HG23 ' A' ' 79' ' ' THR . 63.8 t -109.86 129.72 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.744 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -80.03 -67.08 0.8 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.768 -1.208 . . . . 0.0 110.34 -178.784 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -113.73 138.78 49.76 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.418 -0.801 . . . . 0.0 109.891 -178.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 63.2 t80 -121.99 126.88 49.53 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.205 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.426 HH21 HG21 ' A' ' 49' ' ' VAL . 38.6 ptt180 -133.71 134.7 43.37 Favored 'General case' 0 N--CA 1.502 2.151 0 CA-C-O 121.96 0.886 . . . . 0.0 110.023 179.711 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.8 136.04 54.16 Favored 'General case' 0 N--CA 1.495 1.798 0 CA-C-O 121.164 0.507 . . . . 0.0 109.749 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 4.0 mt -113.35 131.79 55.83 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.402 -0.811 . . . . 0.0 108.815 179.194 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 3.8 p -126.12 121.3 32.49 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.677 0.751 . . . . 0.0 109.82 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -133.66 154.46 50.9 Favored 'General case' 0 N--CA 1.498 1.926 0 CA-C-O 121.422 0.63 . . . . 0.0 110.087 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -72.94 138.44 46.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.394 -0.816 . . . . 0.0 109.01 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 39.7 t -109.97 116.31 51.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.752 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.551 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.286 0.565 . . . . 0.0 109.699 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.425 ' OD1' ' N ' ' A' ' 9' ' ' ASN . 36.4 p-10 -85.13 -26.17 27.04 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.233 -0.917 . . . . 0.0 110.035 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.425 ' N ' ' OD1' ' A' ' 8' ' ' ASP . 87.6 m-20 -91.71 1.46 57.14 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.295 -0.878 . . . . 0.0 110.067 -179.141 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.8 t -108.98 129.96 62.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.466 -0.771 . . . . 0.0 109.562 -178.765 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -90.02 127.6 53.05 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.103 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -76.57 -13.84 18.09 Favored 'Trans proline' 0 N--CA 1.497 1.702 0 C-N-CA 122.082 1.855 . . . . 0.0 112.648 -179.048 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 54.5 m -62.06 -40.01 94.33 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.133 -0.979 . . . . 0.0 110.43 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLN . . . . . 0.416 ' CD ' ' N ' ' A' ' 14' ' ' GLN . 28.2 mp0 -83.35 -12.52 56.47 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.076 -1.015 . . . . 0.0 110.37 -179.2 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.77 ' HG ' ' HG ' ' A' ' 32' ' ' CYS . 36.6 t -64.62 -36.62 84.83 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.182 -0.949 . . . . 0.0 110.189 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -117.48 141.1 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 121.399 -0.813 . . . . 0.0 108.887 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.462 ' HG2' HD22 ' A' ' 26' ' ' ASN . 20.4 pttp -118.83 145.46 45.64 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -98.11 124.77 42.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.397 -0.814 . . . . 0.0 109.409 179.815 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.539 ' O ' ' N ' ' A' ' 21' ' ' VAL . 65.6 m -110.17 131.12 55.34 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.38 -93.68 0.01 OUTLIER Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 -179.235 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.539 ' N ' ' O ' ' A' ' 19' ' ' SER . 26.2 m -139.6 31.39 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.308 -1.113 . . . . 0.0 109.676 179.816 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -131.53 159.41 38.24 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.417 -0.802 . . . . 0.0 109.902 179.456 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -114.24 139.97 48.96 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.027 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.2 p -136.53 148.79 47.79 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.143 -0.973 . . . . 0.0 109.847 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -84.55 129.92 34.8 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.169 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ASN . . . . . 0.462 HD22 ' HG2' ' A' ' 17' ' ' LYS . 67.5 m-80 -90.95 103.73 16.41 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.095 -1.003 . . . . 0.0 110.159 -179.6 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 88.1 p -92.08 -5.99 51.76 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.062 -1.023 . . . . 0.0 108.981 178.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.89 -36.43 90.06 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.8 m -79.0 136.89 22.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.214 -1.168 . . . . 0.0 109.263 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.9 m -68.37 -31.49 70.89 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.409 -0.807 . . . . 0.0 111.157 -178.693 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 85.4 t -59.98 -40.07 82.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.885 -1.135 . . . . 0.0 110.556 -178.031 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.77 ' HG ' ' HG ' ' A' ' 15' ' ' CYS . 68.3 m -59.84 -47.0 87.51 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.629 -1.294 . . . . 0.0 110.056 -179.321 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' MET . . . . . 0.416 ' O ' ' CB ' ' A' ' 37' ' ' ASN . 29.7 mmt -70.23 -34.13 72.49 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.304 -0.873 . . . . 0.0 110.657 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 18.7 mm100 -59.55 -41.53 90.32 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.02 -1.05 . . . . 0.0 110.765 -178.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.68 -49.5 7.14 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 30.6 tp -60.01 -43.71 95.04 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ASN . . . . . 0.416 ' CB ' ' O ' ' A' ' 33' ' ' MET . 39.9 t30 -61.47 -39.9 92.56 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.543 -0.723 . . . . 0.0 109.963 179.19 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 49.7 tp10 -60.2 -31.4 70.11 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.329 -0.857 . . . . 0.0 109.819 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.81 15.23 56.86 Favored Glycine 0 N--CA 1.497 2.737 0 N-CA-C 110.306 -1.117 . . . . 0.0 110.306 179.33 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -101.98 -1.16 32.46 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 106.628 -1.619 . . . . 0.0 106.628 178.556 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.688 HG12 ' H ' ' A' ' 43' ' ' GLY . 98.9 t -130.56 159.91 42.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-N 115.172 -0.922 . . . . 0.0 108.518 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.511 ' N ' ' O ' ' A' ' 94' ' ' VAL . 42.0 ttm180 -123.71 -8.93 7.88 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.252 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.688 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.84 -159.1 26.43 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 108.215 -1.954 . . . . 0.0 108.215 -179.296 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 96.6 t -119.68 128.65 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.306 -1.114 . . . . 0.0 109.178 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 p -82.97 140.89 32.51 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.279 -0.888 . . . . 0.0 109.012 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.458 ' O ' HG13 ' A' ' 46' ' ' VAL . 8.8 p -132.23 130.61 60.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.575 -0.703 . . . . 0.0 109.525 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 16.8 p -123.63 146.04 48.49 Favored 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -140.47 136.74 7.85 Favored Glycine 0 N--CA 1.499 2.84 0 N-CA-C 110.119 -1.193 . . . . 0.0 110.119 -179.394 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 90.9 t -121.39 129.1 75.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.791 -0.829 . . . . 0.0 108.973 179.113 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -100.72 119.96 39.37 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 179.34 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 63.6 m-85 -96.49 126.09 41.44 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.323 -0.861 . . . . 0.0 108.945 -179.535 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.53 ' CD1' ' NZ ' ' A' ' 78' ' ' LYS . 90.0 m-85 -111.45 129.42 56.04 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.446 -0.784 . . . . 0.0 110.021 -178.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.429 ' OD1' ' OE1' ' A' ' 85' ' ' GLN . 74.9 m-20 -45.46 -17.27 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.41 -0.806 . . . . 0.0 109.406 178.949 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.514 ' N ' ' O ' ' A' ' 52' ' ' TYR . 52.5 t0 -68.86 0.09 4.83 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.495 -0.753 . . . . 0.0 109.532 -179.552 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.55 23.96 63.86 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.019 -1.086 . . . . 0.0 110.431 179.219 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.3 p -122.76 147.47 46.46 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.37 -1.077 . . . . 0.0 110.127 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.5 p -131.56 136.27 47.69 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.608 -0.683 . . . . 0.0 109.771 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 41.2 t -118.64 142.73 47.37 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 178.439 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 35.1 p-10 -130.61 120.44 23.99 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.921 -1.112 . . . . 0.0 110.224 -179.224 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -114.71 120.16 39.16 Favored 'General case' 0 N--CA 1.498 1.963 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.52 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.8 ttpt -112.54 152.6 28.64 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 -179.43 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.57 174.67 43.27 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 67.6 t -115.7 126.27 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.623 -0.928 . . . . 0.0 110.04 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 38.2 t -91.23 117.76 35.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.514 -0.741 . . . . 0.0 110.013 -179.364 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.516 ' O ' ' N ' ' A' ' 67' ' ' SER . 21.7 p -121.28 150.92 55.11 Favored Pre-proline 0 N--CA 1.498 1.943 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 178.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_exo -38.34 -20.76 0.05 OUTLIER 'Trans proline' 0 C--N 1.312 -1.358 0 C-N-CA 122.01 1.807 . . . . 0.0 113.372 -179.466 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.516 ' N ' ' O ' ' A' ' 65' ' ' THR . 18.1 p -121.81 2.93 10.04 Favored 'General case' 0 N--CA 1.505 2.29 0 O-C-N 121.181 -0.949 . . . . 0.0 111.88 -179.004 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 61.1 p -129.94 107.22 16.66 Favored Pre-proline 0 N--CA 1.51 2.537 0 O-C-N 120.768 -1.207 . . . . 0.0 110.687 -179.807 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -90.58 165.31 4.24 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 C-N-CA 122.781 2.32 . . . . 0.0 112.288 178.315 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.1 t -120.47 129.95 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 N-CA-C 108.79 -0.818 . . . . 0.0 108.79 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 30.1 m120 -99.99 121.65 41.68 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.22 -0.925 . . . . 0.0 111.154 -178.432 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -91.02 -0.02 57.64 Favored 'General case' 0 N--CA 1.497 1.914 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.211 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.438 ' O ' ' O ' ' A' ' 74' ' ' GLN . 51.5 p-10 -75.11 57.74 0.85 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.4 -0.813 . . . . 0.0 109.573 -179.218 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.438 ' O ' ' O ' ' A' ' 73' ' ' ASN . 64.7 tp60 -55.47 -101.92 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.559 -0.713 . . . . 0.0 109.091 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -108.26 100.43 9.74 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 120.967 -1.083 . . . . 0.0 109.231 179.449 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 44.3 mm -69.86 -39.33 77.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.024 -1.047 . . . . 0.0 109.077 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 -58.29 -41.08 83.6 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.53 ' NZ ' ' CD1' ' A' ' 52' ' ' TYR . 54.5 tttm -60.12 -49.91 75.77 Favored 'General case' 0 N--CA 1.488 1.425 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.367 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.581 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.8 OUTLIER -63.29 -41.03 98.94 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.546 -0.722 . . . . 0.0 110.304 -179.113 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -60.4 -35.94 76.95 Favored 'General case' 0 C--N 1.294 -1.838 0 O-C-N 120.655 -1.278 . . . . 0.0 110.912 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 8.9 tmtm? -70.9 -43.94 67.28 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.701 -1.249 . . . . 0.0 111.463 -178.502 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 p -110.1 -26.0 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.281 0 O-C-N 120.872 -1.142 . . . . 0.0 110.924 -178.281 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.581 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 79.94 157.81 14.73 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.8 t -108.53 130.4 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.067 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.429 ' OE1' ' OD1' ' A' ' 53' ' ' ASN . 18.7 pt20 -97.43 -43.29 7.34 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.185 -0.947 . . . . 0.0 110.929 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -115.9 127.84 55.31 Favored 'General case' 0 N--CA 1.502 2.127 0 O-C-N 121.197 -0.939 . . . . 0.0 110.766 -178.804 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -122.17 123.62 41.94 Favored 'General case' 0 N--CA 1.499 2.003 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.768 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 93.8 mtt180 -132.2 133.75 44.54 Favored 'General case' 0 N--CA 1.507 2.387 0 O-C-N 121.073 -1.017 . . . . 0.0 110.799 -179.545 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.1 135.18 53.36 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.797 -0.564 . . . . 0.0 109.58 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 54.5 tp -117.32 137.48 52.41 Favored 'General case' 0 N--CA 1.505 2.316 0 O-C-N 121.421 -0.799 . . . . 0.0 109.73 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.7 p -129.72 123.58 31.43 Favored 'General case' 0 N--CA 1.504 2.25 0 CA-C-O 121.639 0.733 . . . . 0.0 111.241 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.4 tt0 -133.78 157.33 46.16 Favored 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.637 -0.664 . . . . 0.0 109.724 179.145 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 82.4 m95 -69.43 149.31 48.48 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.78 -1.2 . . . . 0.0 109.873 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 42' ' ' ARG . 21.7 t -122.48 127.28 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.549 -0.72 . . . . 0.0 109.629 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.502 3.097 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 178.847 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -98.07 5.31 48.82 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.48 -0.763 . . . . 0.0 110.546 -178.66 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -121.02 6.58 10.33 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -134.85 139.4 47.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -179.429 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 24.5 m-20 -85.02 148.47 50.72 Favored Pre-proline 0 C--N 1.301 -1.51 0 O-C-N 121.269 -0.895 . . . . 0.0 109.264 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -75.63 -20.98 15.15 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.258 1.972 . . . . 0.0 111.655 179.677 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 84.0 p -61.48 -37.68 84.52 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.217 -0.927 . . . . 0.0 109.801 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.1 tp-100 -70.1 -25.66 63.61 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.172 -0.955 . . . . 0.0 109.384 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.511 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 77.2 m -68.42 -30.67 69.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.119 -0.988 . . . . 0.0 109.903 -179.453 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -124.06 136.66 59.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -120.91 150.65 40.74 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.597 -0.69 . . . . 0.0 109.139 -179.545 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -91.99 119.77 32.02 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.037 -1.04 . . . . 0.0 109.639 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 54.9 m -124.4 131.72 53.51 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.419 -0.8 . . . . 0.0 109.073 179.732 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 46.6 47.99 17.46 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.896 -1.145 . . . . 0.0 110.504 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.406 HG11 ' OD1' ' A' ' 73' ' ' ASN . 3.4 t 56.92 29.6 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.208 -1.172 . . . . 0.0 110.363 179.451 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 89.8 mt-30 -130.76 164.85 24.22 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.287 -0.883 . . . . 0.0 108.708 178.494 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 39.1 m-85 -120.43 136.77 54.63 Favored 'General case' 0 N--CA 1.501 2.117 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.366 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 34.7 p -139.85 152.3 46.37 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.401 -0.812 . . . . 0.0 109.612 179.825 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 28.5 t80 -80.81 127.08 32.12 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.638 -0.664 . . . . 0.0 109.229 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -83.6 83.63 7.83 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.342 -0.849 . . . . 0.0 109.783 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 27.9 p -76.68 -8.91 58.17 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.223 -0.923 . . . . 0.0 108.988 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.01 -39.79 70.61 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.6 m -82.27 128.61 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.036 -1.273 . . . . 0.0 108.46 179.052 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.463 ' O ' ' N ' ' A' ' 34' ' ' GLN . 82.2 p -66.87 -25.0 66.19 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.174 -0.954 . . . . 0.0 110.445 -178.845 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 71.3 t -59.81 -49.24 84.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.242 -0.911 . . . . 0.0 109.937 -178.854 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.511 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 79.8 m -61.83 -40.08 94.04 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.949 -1.094 . . . . 0.0 109.305 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 5.3 tpt -79.97 -14.87 58.26 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.079 -1.013 . . . . 0.0 108.7 179.615 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLN . . . . . 0.463 ' N ' ' O ' ' A' ' 30' ' ' SER . 5.9 tp-100 -63.15 -40.04 96.43 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.05 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -73.17 -45.41 31.49 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.6 mt -61.02 -42.88 99.31 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.316 -1.108 . . . . 0.0 108.994 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -60.25 -39.91 88.42 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.622 0.725 . . . . 0.0 109.265 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -80.01 -10.01 59.74 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.627 -0.67 . . . . 0.0 109.455 -179.522 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.34 31.88 68.56 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -106.41 -5.89 18.64 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 179.801 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.746 HG12 ' H ' ' A' ' 43' ' ' GLY . 87.2 t -133.12 156.67 42.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.789 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.42 ' N ' HG12 ' A' ' 41' ' ' VAL . 73.8 mtt85 -120.36 -7.03 9.8 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.746 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 137.8 -166.02 25.21 Favored Glycine 0 N--CA 1.498 2.821 0 N-CA-C 109.042 -1.623 . . . . 0.0 109.042 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.7 t -119.95 126.18 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.282 -1.128 . . . . 0.0 109.239 -179.783 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 28.6 m -80.76 133.12 35.6 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.255 -0.903 . . . . 0.0 108.775 179.267 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.439 HG13 ' O ' ' A' ' 46' ' ' VAL . 7.1 p -129.01 132.27 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.586 -0.696 . . . . 0.0 109.396 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.5 p -123.39 148.4 46.12 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -142.4 140.91 10.3 Favored Glycine 0 N--CA 1.503 3.157 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.981 -178.86 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 94.8 t -124.79 130.03 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.675 -0.897 . . . . 0.0 109.654 179.188 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 33.9 m-85 -104.18 114.36 28.55 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.823 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -86.28 131.68 34.16 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.041 -1.037 . . . . 0.0 109.192 -179.569 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.429 ' C ' ' H ' ' A' ' 54' ' ' ASP . 54.3 m-85 -116.32 134.18 55.18 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.465 -0.772 . . . . 0.0 109.713 -179.439 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.426 ' C ' ' H ' ' A' ' 55' ' ' GLY . 44.8 t30 -57.17 -11.38 1.63 Allowed 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 178.77 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.429 ' H ' ' C ' ' A' ' 52' ' ' TYR . 11.9 t70 -67.01 0.6 2.43 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.426 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 79.52 20.76 68.25 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.173 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 18.4 p -130.9 151.56 51.18 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.297 -1.119 . . . . 0.0 110.914 -179.468 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 79.2 p -130.05 137.58 50.3 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 56.9 m -116.24 148.89 40.01 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 179.105 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -137.49 127.33 25.58 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.302 -0.874 . . . . 0.0 109.715 179.77 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -116.41 129.13 56.07 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.013 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -114.06 144.95 42.28 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -167.44 164.54 37.99 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.1 t -109.95 128.19 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.535 -0.98 . . . . 0.0 108.932 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 21.2 t -91.91 119.1 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.191 -0.943 . . . . 0.0 110.088 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.401 ' C ' ' H ' ' A' ' 67' ' ' SER . 29.7 p -132.31 149.93 74.56 Favored Pre-proline 0 N--CA 1.492 1.639 0 N-CA-C 106.889 -1.522 . . . . 0.0 106.889 178.268 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -52.28 -9.23 0.48 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 121.443 1.429 . . . . 0.0 111.293 -179.376 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.401 ' H ' ' C ' ' A' ' 65' ' ' THR . 19.6 m -104.79 -24.93 12.84 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.513 -0.742 . . . . 0.0 110.31 -179.655 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 20.7 m -135.88 107.39 9.76 Favored Pre-proline 0 N--CA 1.506 2.356 0 O-C-N 121.113 -0.992 . . . . 0.0 110.652 -179.593 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -87.04 164.03 8.7 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 C-N-CA 122.148 1.899 . . . . 0.0 111.69 178.428 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.3 t -118.57 129.57 74.65 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.377 -0.827 . . . . 0.0 109.12 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -103.3 136.67 42.64 Favored 'General case' 0 N--CA 1.501 2.105 0 O-C-N 121.148 -0.97 . . . . 0.0 110.678 -178.856 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.419 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.4 OUTLIER -93.12 -1.16 56.7 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 178.347 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.416 ' O ' ' O ' ' A' ' 74' ' ' GLN . 78.3 m-20 -70.31 51.73 0.13 Allowed 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.427 -0.796 . . . . 0.0 109.378 -179.554 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.419 ' N ' ' O ' ' A' ' 72' ' ' THR . 59.1 tt0 -62.39 -108.47 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 179.507 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -106.32 96.12 6.24 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.137 -0.977 . . . . 0.0 108.384 178.278 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.428 HG22 ' O ' ' A' ' 76' ' ' ILE . 90.4 mt -84.99 -15.22 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.0 -1.063 . . . . 0.0 110.305 -179.577 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 64.9 t-20 -59.89 -44.6 94.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.919 -1.113 . . . . 0.0 109.837 -179.335 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.414 ' HB2' ' HZ3' ' A' ' 78' ' ' LYS . 9.7 ptmm? -68.77 -33.96 74.77 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.11 -0.994 . . . . 0.0 109.174 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.607 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.7 OUTLIER -62.89 -45.14 93.9 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.935 -1.103 . . . . 0.0 108.067 178.895 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -59.95 -35.17 74.38 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 120.776 -1.202 . . . . 0.0 108.843 178.899 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.4 tttp -63.99 -51.15 65.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.402 -0.811 . . . . 0.0 111.07 -178.733 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.9 m -117.01 -20.8 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.226 0 O-C-N 121.365 -0.835 . . . . 0.0 111.545 -177.618 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.607 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.28 167.48 42.84 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 179.412 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 53.6 t -108.62 126.49 65.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 57.1 tt0 -79.96 -65.33 1.02 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.892 -1.13 . . . . 0.0 109.958 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.8 tptm -114.38 140.18 48.88 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.52 -0.738 . . . . 0.0 110.554 -178.842 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 69.2 t80 -119.75 137.23 54.07 Favored 'General case' 0 N--CA 1.5 2.045 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.139 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -138.1 128.08 25.6 Favored 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.066 -1.021 . . . . 0.0 111.068 -178.808 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.57 133.43 53.29 Favored 'General case' 0 N--CA 1.503 2.177 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.752 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 59.4 tp -120.01 135.35 54.96 Favored 'General case' 0 N--CA 1.508 2.434 0 O-C-N 121.298 -0.876 . . . . 0.0 110.169 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 30.6 p -129.23 127.38 41.14 Favored 'General case' 0 N--CA 1.505 2.282 0 CA-C-O 121.679 0.752 . . . . 0.0 110.958 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -132.63 145.86 51.43 Favored 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.692 -0.63 . . . . 0.0 110.221 179.774 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 76.8 m95 -69.88 139.96 53.1 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 120.945 -1.097 . . . . 0.0 108.771 178.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 17.4 t -112.38 117.52 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.453 -0.779 . . . . 0.0 109.546 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.486 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 179.785 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.879 0 N-CA-C 119.587 2.595 . . . . 0.0 119.587 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.54 138.37 26.05 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 30.0 t -91.13 -3.53 56.99 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.249 -1.148 . . . . 0.0 109.614 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 108.07 -110.01 3.03 Favored Glycine 0 N--CA 1.499 2.897 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 20.2 t90 -61.88 136.56 58.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.229 -1.16 . . . . 0.0 110.6 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ASN . . . . . 0.528 ' C ' ' H ' ' A' ' 8' ' ' ASP . 98.6 m-20 -131.57 124.42 29.98 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 177.047 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.87 -3.97 0.14 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.025 -1.047 . . . . 0.0 108.973 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.528 ' H ' ' C ' ' A' ' 6' ' ' ASN . 95.7 m-20 -79.89 -21.73 43.65 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.475 -0.765 . . . . 0.0 110.549 -179.442 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 28.5 m120 -88.48 0.13 56.61 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.933 -1.105 . . . . 0.0 109.424 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.8 t -112.74 127.54 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.553 -0.717 . . . . 0.0 109.42 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -79.04 130.92 68.2 Favored Pre-proline 0 N--CA 1.488 1.444 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -74.49 -10.65 22.21 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 121.706 1.604 . . . . 0.0 111.832 -179.049 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 82.7 p -69.96 -29.34 66.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.301 -0.874 . . . . 0.0 109.505 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 62.9 tt0 -90.07 -19.52 24.26 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.228 -0.92 . . . . 0.0 109.502 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.581 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 48.8 t -66.34 -33.5 75.86 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.089 -1.007 . . . . 0.0 109.846 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.433 ' O ' HD12 ' A' ' 16' ' ' ILE . 2.5 pp -119.35 132.11 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.696 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -113.98 142.87 45.61 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -96.01 127.24 41.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.422 -0.799 . . . . 0.0 110.024 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 49.5 m -115.67 124.24 50.39 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.053 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.62 -103.12 0.11 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.212 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.4 m -129.76 30.5 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.086 0 O-C-N 121.559 -0.965 . . . . 0.0 109.188 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 35.7 tt0 -129.43 153.04 48.32 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.397 -0.815 . . . . 0.0 110.453 -178.362 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -114.34 136.42 53.0 Favored 'General case' 0 N--CA 1.499 1.99 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.193 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 36.9 p -135.36 145.37 47.31 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.338 -0.851 . . . . 0.0 109.553 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 45.6 t80 -80.13 124.46 28.79 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.2 m120 -82.82 86.96 6.82 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.01 -1.056 . . . . 0.0 110.267 -179.087 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 13.8 m -79.61 -13.69 59.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.044 -1.035 . . . . 0.0 109.145 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -65.78 -3.68 16.66 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.448 HG12 HG22 ' A' ' 31' ' ' VAL . 2.0 t -102.93 126.91 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 96.7 p -59.92 -40.12 87.79 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.076 -1.015 . . . . 0.0 111.279 -178.436 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.575 HG23 ' N ' ' A' ' 32' ' ' CYS . 16.2 m -60.56 -44.3 96.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 120.878 -1.139 . . . . 0.0 110.638 -178.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.581 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 89.3 m -60.14 -43.36 95.76 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.099 -1.001 . . . . 0.0 110.563 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 95.2 mmm -84.33 -12.76 54.02 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.721 -1.237 . . . . 0.0 109.121 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 -60.12 -47.44 85.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.889 . . . . 0.0 108.604 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.86 -45.04 17.85 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.2 tp -60.18 -40.01 88.47 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.242 -1.152 . . . . 0.0 109.449 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 97.7 m-20 -66.13 -39.95 90.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.319 -0.863 . . . . 0.0 110.363 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -75.62 -6.17 49.03 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.071 -1.018 . . . . 0.0 109.978 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.93 26.81 73.3 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -101.13 -5.47 25.62 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.733 HG12 ' H ' ' A' ' 43' ' ' GLY . 77.2 t -134.95 159.82 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -179.616 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.455 ' N ' HG12 ' A' ' 41' ' ' VAL . 65.0 mtp180 -122.73 -5.93 8.59 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.819 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.733 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 137.76 -164.92 25.43 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 108.429 -1.868 . . . . 0.0 108.429 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.0 t -120.34 130.0 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.226 -1.161 . . . . 0.0 109.545 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.434 ' H ' HG23 ' A' ' 94' ' ' VAL . 3.3 t -83.17 133.79 35.01 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.189 -0.944 . . . . 0.0 108.726 179.01 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.5 p -129.96 134.22 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.59 -0.694 . . . . 0.0 109.434 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 25.5 p -124.83 146.59 49.19 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.473 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -138.27 140.55 11.23 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.527 HG22 ' OD1' ' A' ' 59' ' ' ASN . 98.2 t -126.53 129.85 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.675 -0.897 . . . . 0.0 109.143 179.216 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -101.44 117.2 34.45 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.723 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 39.1 m-85 -91.96 122.61 34.64 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.403 -0.811 . . . . 0.0 109.079 -179.412 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -104.99 136.16 44.99 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.575 -0.703 . . . . 0.0 109.771 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 -57.27 -11.63 1.88 Allowed 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 11.2 t70 -74.46 2.16 10.19 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.59 21.21 69.78 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.253 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.1 p -120.47 147.02 45.66 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.405 -1.056 . . . . 0.0 110.127 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 71.8 p -130.01 140.95 50.8 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.673 0.749 . . . . 0.0 110.066 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.6 t -116.96 140.83 49.0 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 106.641 -1.614 . . . . 0.0 106.641 178.258 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ASN . . . . . 0.527 ' OD1' HG22 ' A' ' 49' ' ' VAL . 49.0 m-20 -129.96 116.69 18.97 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.035 -1.04 . . . . 0.0 109.727 -179.205 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -116.57 124.38 49.68 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -114.18 146.05 40.87 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -163.96 168.31 38.4 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.159 -1.576 . . . . 0.0 109.159 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.3 t -110.39 127.32 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.535 -0.98 . . . . 0.0 109.363 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.3 t -89.59 118.89 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.375 -0.828 . . . . 0.0 109.792 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 30.1 p -128.25 149.97 72.79 Favored Pre-proline 0 N--CA 1.494 1.732 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.89 -16.12 3.86 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 121.276 1.318 . . . . 0.0 111.414 -179.444 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 84.2 p -108.21 -13.2 14.96 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.393 -0.817 . . . . 0.0 110.697 -179.663 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 56.8 m -132.55 106.87 13.07 Favored Pre-proline 0 N--CA 1.505 2.286 0 O-C-N 121.086 -1.009 . . . . 0.0 110.561 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -88.28 162.43 6.95 Favored 'Trans proline' 0 N--CA 1.49 1.293 0 C-N-CA 122.267 1.978 . . . . 0.0 111.833 178.329 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.5 t -120.17 128.49 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.158 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -104.64 128.77 52.77 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.124 -0.985 . . . . 0.0 111.324 -178.487 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 74' ' ' GLN . 1.1 p -90.05 0.09 57.31 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 177.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -67.9 60.43 0.07 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-O 121.556 0.693 . . . . 0.0 109.143 -179.449 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.494 ' N ' ' O ' ' A' ' 72' ' ' THR . 59.7 tt0 -68.79 -106.5 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.169 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -103.6 94.47 5.48 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.009 -1.057 . . . . 0.0 109.74 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 79.5 mt -74.46 -29.82 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.013 -1.054 . . . . 0.0 109.698 179.351 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -59.94 -42.63 94.42 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.809 -1.182 . . . . 0.0 108.186 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 84.2 tttt -65.27 -42.16 93.49 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.277 -0.889 . . . . 0.0 108.749 178.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.599 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.4 OUTLIER -69.75 -42.7 73.54 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.562 -0.711 . . . . 0.0 110.179 -179.132 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -63.51 -32.76 74.3 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.168 -1.582 . . . . 0.0 109.233 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.0 tttt -69.81 -47.38 63.03 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 110.735 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.4 p -112.2 -27.55 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 O-C-N 121.504 -0.747 . . . . 0.0 111.661 -177.126 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.599 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 88.61 169.7 45.04 Favored Glycine 0 N--CA 1.49 2.244 0 O-C-N 120.715 -1.241 . . . . 0.0 110.452 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.473 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 23.5 t -115.43 129.67 71.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.892 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -80.07 -67.46 0.76 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.071 -1.018 . . . . 0.0 110.297 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -116.51 140.12 49.71 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.508 -0.745 . . . . 0.0 110.846 -179.102 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 68.9 t80 -119.96 131.8 55.3 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.036 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -131.53 132.6 44.3 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.08 -1.012 . . . . 0.0 110.788 -178.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.52 137.1 54.84 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.802 -0.561 . . . . 0.0 109.551 179.266 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 44.7 tp -117.16 133.32 56.14 Favored 'General case' 0 N--CA 1.502 2.167 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.622 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 p -129.08 122.18 29.39 Favored 'General case' 0 N--CA 1.503 2.215 0 CA-C-O 121.708 0.766 . . . . 0.0 110.733 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -132.35 152.75 51.3 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.891 -0.506 . . . . 0.0 109.846 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 78.0 m95 -70.21 139.89 52.37 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.048 -1.033 . . . . 0.0 109.07 178.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.434 HG23 ' H ' ' A' ' 45' ' ' SER . 59.7 t -112.53 120.83 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.156 0 O-C-N 121.383 -0.823 . . . . 0.0 109.397 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 145.46 -124.13 2.04 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.189 -1.564 . . . . 0.0 109.189 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 47.4 t -60.47 140.0 57.47 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.346 -1.09 . . . . 0.0 109.934 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 35.7 ttm180 -61.48 136.37 58.0 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.357 -0.839 . . . . 0.0 109.0 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.583 -179.919 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.936 0 N-CA-C 119.648 2.619 . . . . 0.0 119.648 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -86.58 162.42 34.56 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.5 t -78.68 141.54 37.85 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.358 -1.084 . . . . 0.0 109.458 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -135.64 64.18 0.58 Allowed Glycine 0 N--CA 1.5 2.909 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' TRP . . . . . 0.413 ' HE1' HG21 ' A' ' 10' ' ' VAL . 79.6 t90 -75.5 127.9 34.13 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.277 -1.131 . . . . 0.0 108.775 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 39.7 p-10 -134.06 18.28 3.77 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.522 0.677 . . . . 0.0 109.911 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 57.95 13.85 2.34 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.433 -0.792 . . . . 0.0 109.464 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.414 ' OD1' ' O ' ' A' ' 8' ' ' ASP . 61.1 t0 -92.13 -27.47 17.71 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.234 -0.917 . . . . 0.0 109.555 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -95.15 4.08 54.01 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.392 -0.817 . . . . 0.0 110.099 -179.276 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.413 HG21 ' HE1' ' A' ' 5' ' ' TRP . 19.7 t -110.61 134.08 54.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.5 -0.75 . . . . 0.0 109.88 -179.492 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -90.81 131.61 37.07 Favored Pre-proline 0 N--CA 1.49 1.526 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.49 -14.16 22.5 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 121.747 1.631 . . . . 0.0 111.592 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 59.8 p -67.22 -35.83 80.42 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.518 -0.739 . . . . 0.0 109.867 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -90.05 -11.62 40.9 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.208 -0.933 . . . . 0.0 110.313 -179.095 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.668 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 8.2 t -69.63 -29.4 66.89 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.974 -1.079 . . . . 0.0 108.471 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.4 pp -120.62 145.47 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 61.1 mttp -127.09 154.14 45.09 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.402 -0.811 . . . . 0.0 110.032 -179.269 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 -96.07 120.01 35.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.463 -0.773 . . . . 0.0 109.692 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 5.9 t -110.34 115.14 29.14 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.87 -111.09 2.25 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.4 m -117.33 20.69 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.241 0 O-C-N 121.466 -1.02 . . . . 0.0 109.959 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -127.26 160.53 31.02 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.348 -0.845 . . . . 0.0 111.081 -177.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 12.5 m-85 -111.33 134.17 53.11 Favored 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.567 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 37.9 p -132.74 145.48 51.06 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.284 -0.885 . . . . 0.0 108.986 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -82.87 127.26 33.33 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.387 -0.821 . . . . 0.0 108.999 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -84.56 80.52 9.21 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.024 -1.047 . . . . 0.0 109.119 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.516 ' C ' ' H ' ' A' ' 29' ' ' VAL . 92.0 p -83.73 -8.35 59.27 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.413 -0.804 . . . . 0.0 109.485 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.67 -2.74 0.2 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.159 -1.177 . . . . 0.0 110.159 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.516 ' H ' ' C ' ' A' ' 27' ' ' SER . 34.9 m -108.32 131.35 59.03 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.328 -1.101 . . . . 0.0 108.442 179.165 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 82.8 p -63.68 -30.23 71.36 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.287 -0.883 . . . . 0.0 111.278 -178.203 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.452 HG13 ' N ' ' A' ' 32' ' ' CYS . 7.6 p -59.9 -39.9 81.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 120.87 -1.144 . . . . 0.0 110.415 -179.189 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.668 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 56.3 m -59.93 -40.17 87.99 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.95 -1.094 . . . . 0.0 110.077 -179.271 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 9.0 mmt -79.73 -14.31 58.83 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.0 -1.062 . . . . 0.0 109.415 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.4 tt0 -60.76 -40.56 92.98 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.876 -1.14 . . . . 0.0 108.451 179.323 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -82.99 -51.22 4.29 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.5 mt -58.27 -40.07 80.88 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.919 -1.341 . . . . 0.0 108.832 -179.436 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -59.93 -40.02 87.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.342 -0.848 . . . . 0.0 109.497 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 60.3 mm-40 -76.8 -6.76 53.64 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.989 -1.069 . . . . 0.0 109.87 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.35 32.56 68.37 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 120.066 -1.064 . . . . 0.0 110.646 178.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -102.81 -9.65 19.77 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.6 HG12 ' H ' ' A' ' 43' ' ' GLY . 5.8 t -134.19 158.16 41.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -179.087 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 94' ' ' VAL . 97.2 mtt180 -117.33 -11.08 10.63 Favored 'General case' 0 N--CA 1.501 2.087 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 178.837 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.6 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 146.09 -157.33 27.34 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 107.879 -2.088 . . . . 0.0 107.879 -179.175 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 77.2 t -120.01 128.42 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.281 -1.129 . . . . 0.0 108.538 179.239 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.8 m -86.17 132.78 33.94 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.118 -0.989 . . . . 0.0 108.351 179.454 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 46' ' ' VAL . 13.2 p -132.52 132.46 60.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.592 -0.693 . . . . 0.0 109.779 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.3 m -128.47 141.1 51.5 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 178.395 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.426 ' O ' ' OD1' ' A' ' 59' ' ' ASN . . . -130.87 149.6 19.16 Favored Glycine 0 N--CA 1.505 3.272 0 C-N-CA 120.21 -0.995 . . . . 0.0 110.872 -178.621 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 38.2 t -125.04 129.99 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.824 -0.809 . . . . 0.0 108.825 179.359 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.539 ' CE2' ' O ' ' A' ' 72' ' ' THR . 50.0 m-85 -105.45 121.89 44.86 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.475 -0.766 . . . . 0.0 109.567 179.285 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.429 ' HB2' ' H ' ' A' ' 86' ' ' LYS . 45.8 m-85 -95.76 121.59 37.65 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.045 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.444 ' C ' ' N ' ' A' ' 54' ' ' ASP . 93.3 m-85 -106.28 128.61 54.11 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.236 -0.915 . . . . 0.0 109.271 179.802 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.405 ' C ' ' H ' ' A' ' 55' ' ' GLY . 51.9 t30 -48.77 -17.13 0.15 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.067 -1.021 . . . . 0.0 109.199 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.444 ' N ' ' C ' ' A' ' 52' ' ' TYR . 62.7 m-20 -67.99 3.28 1.62 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.407 -0.808 . . . . 0.0 109.115 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.405 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 77.68 19.77 75.21 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 178.655 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.1 p -117.79 147.67 42.78 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.383 -1.069 . . . . 0.0 109.952 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 24.3 p -130.57 127.96 40.1 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.703 -0.623 . . . . 0.0 109.543 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 30.6 t -118.39 154.49 32.31 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ASN . . . . . 0.426 ' OD1' ' O ' ' A' ' 48' ' ' GLY . 57.9 t-20 -141.53 133.15 27.02 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.796 -1.19 . . . . 0.0 110.149 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -116.46 124.41 49.91 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.304 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 62.9 tttm -114.36 143.4 44.96 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.15 172.46 43.38 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 49.0 t -114.74 128.67 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.629 -0.924 . . . . 0.0 109.156 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 75.7 t -98.08 123.02 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.218 -0.927 . . . . 0.0 109.515 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.403 ' O ' ' N ' ' A' ' 67' ' ' SER . 17.0 p -121.55 151.0 56.16 Favored Pre-proline 0 N--CA 1.496 1.856 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_exo -34.49 -34.0 0.08 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.399 2.066 . . . . 0.0 113.191 -179.289 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.403 ' N ' ' O ' ' A' ' 65' ' ' THR . 63.4 m -106.76 -0.55 23.4 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.379 -0.825 . . . . 0.0 111.78 -178.626 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.1 m -124.39 106.86 30.05 Favored Pre-proline 0 N--CA 1.508 2.437 0 O-C-N 120.945 -1.097 . . . . 0.0 111.527 -178.5 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -92.61 161.2 2.89 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 C-N-CA 122.712 2.275 . . . . 0.0 111.025 177.126 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 91.1 t -134.64 139.88 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.238 0 O-C-N 120.952 -1.092 . . . . 0.0 109.825 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -95.43 138.72 32.72 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.165 -0.959 . . . . 0.0 109.158 179.198 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.539 ' O ' ' CE2' ' A' ' 50' ' ' PHE . 5.8 t -110.93 -33.83 6.4 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.321 -0.862 . . . . 0.0 109.419 -179.769 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.508 ' ND2' ' CD1' ' A' ' 76' ' ' ILE . 9.6 t30 -92.1 32.32 1.17 Allowed 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.218 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -54.13 -22.56 11.43 Favored 'General case' 0 N--CA 1.499 2.011 0 C-N-CA 120.276 -0.57 . . . . 0.0 112.246 -178.056 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -107.37 71.9 0.85 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 120.702 -1.249 . . . . 0.0 109.735 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.508 ' CD1' ' ND2' ' A' ' 73' ' ' ASN . 45.7 mm -70.1 -40.35 78.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.335 -0.853 . . . . 0.0 111.332 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -60.12 -46.9 88.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.629 -1.294 . . . . 0.0 108.551 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 29.6 ttmt -60.08 -50.03 75.33 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.293 -0.879 . . . . 0.0 108.864 179.092 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.568 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.3 m -62.36 -42.8 99.69 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.79 -0.569 . . . . 0.0 110.625 -178.554 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.424 ' OD1' HG22 ' A' ' 76' ' ' ILE . 6.0 m120 -60.47 -35.28 75.5 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.561 -1.337 . . . . 0.0 110.027 179.523 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 14.7 tmtt? -67.07 -48.55 67.91 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.089 -1.007 . . . . 0.0 111.079 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -113.45 -26.88 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.183 -0.948 . . . . 0.0 111.572 -178.753 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 90.07 168.11 42.61 Favored Glycine 0 N--CA 1.491 2.323 0 O-C-N 120.54 -1.35 . . . . 0.0 110.173 179.737 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.05 124.58 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -79.92 -65.64 0.98 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.094 -1.004 . . . . 0.0 110.286 -179.169 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.429 ' H ' ' HB2' ' A' ' 51' ' ' TYR . 44.3 tptt -115.38 142.28 46.91 Favored 'General case' 0 N--CA 1.504 2.23 0 O-C-N 121.415 -0.803 . . . . 0.0 110.526 -178.738 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.0 t80 -121.13 132.1 54.65 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 -135.01 127.18 29.98 Favored 'General case' 0 N--CA 1.503 2.199 0 O-C-N 121.126 -0.984 . . . . 0.0 110.358 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.87 134.63 52.63 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.654 -0.653 . . . . 0.0 110.017 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.6 tp -118.51 133.45 55.86 Favored 'General case' 0 N--CA 1.503 2.192 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.2 p -129.2 126.36 39.0 Favored 'General case' 0 N--CA 1.503 2.198 0 CA-C-O 121.53 0.681 . . . . 0.0 110.678 -179.21 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 58.2 mm-40 -134.4 158.46 43.79 Favored 'General case' 0 N--CA 1.504 2.235 0 CA-C-O 121.488 0.661 . . . . 0.0 110.599 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 71.9 m95 -71.15 139.21 50.15 Favored 'General case' 0 N--CA 1.494 1.774 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 178.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.431 ' O ' ' N ' ' A' ' 42' ' ' ARG . 44.6 t -112.41 118.79 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.289 -0.882 . . . . 0.0 109.335 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -142.18 -117.48 1.3 Allowed Glycine 0 N--CA 1.494 2.504 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.318 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 28.6 p -85.83 118.82 25.56 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.053 -1.263 . . . . 0.0 109.337 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 35.3 ptt-85 -89.31 -9.52 50.21 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.071 -1.018 . . . . 0.0 109.616 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 36.6 t . . . . . 0 N--CA 1.5 2.028 0 CA-C-O 118.049 -0.976 . . . . 0.0 109.299 179.78 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.941 0 N-CA-C 119.475 2.55 . . . . 0.0 119.475 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 93.46 -32.92 5.43 Favored Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 38.1 t -100.1 121.42 41.38 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.342 -1.093 . . . . 0.0 108.875 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -54.9 -84.63 0.03 OUTLIER Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 -179.405 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 66.7 t90 -60.02 138.86 57.76 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.16 -1.2 . . . . 0.0 109.026 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ASN . . . . . 0.45 ' O ' ' N ' ' A' ' 8' ' ' ASP . 94.5 m-20 -133.35 129.62 37.7 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -72.99 64.75 0.72 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.896 -1.127 . . . . 0.0 108.021 178.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.45 ' N ' ' O ' ' A' ' 6' ' ' ASN . 54.4 t0 -66.72 -73.3 0.14 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.758 -0.589 . . . . 0.0 110.234 -178.721 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 64.8 t-20 -145.45 47.05 1.29 Allowed 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 179.352 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.409 HG23 ' HE1' ' A' ' 93' ' ' TRP . 2.6 m -81.17 139.75 17.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.538 -0.726 . . . . 0.0 109.077 -178.704 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.447 ' N ' ' OD1' ' A' ' 11' ' ' ASP . 2.0 m-20 -76.66 130.01 77.71 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.906 . . . . 0.0 109.981 -178.724 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -81.55 -19.96 7.2 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.22 1.947 . . . . 0.0 112.079 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 81.9 p -64.87 -36.53 84.64 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.437 -0.79 . . . . 0.0 110.572 -179.574 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -68.99 -24.66 64.26 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.132 -0.98 . . . . 0.0 109.715 -179.504 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.484 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 50.1 t -65.56 -35.16 80.03 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.331 -0.856 . . . . 0.0 109.775 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -117.09 140.42 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.063 0 O-C-N 121.436 -0.79 . . . . 0.0 109.149 -179.673 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -117.82 147.17 43.3 Favored 'General case' 0 N--CA 1.5 2.026 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -93.77 122.22 36.01 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.172 -0.955 . . . . 0.0 109.746 -179.429 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.479 ' O ' ' N ' ' A' ' 21' ' ' VAL . 26.3 t -110.67 123.71 50.53 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.117 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.42 -94.28 0.01 OUTLIER Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.479 ' N ' ' O ' ' A' ' 19' ' ' SER . 24.7 m -139.4 28.03 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.945 0 O-C-N 121.236 -1.155 . . . . 0.0 109.833 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.6 pt20 -131.42 163.65 27.45 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.318 -0.864 . . . . 0.0 110.035 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 54.0 m-85 -115.69 139.97 49.63 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 76.6 p -134.15 148.67 50.98 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.388 -0.82 . . . . 0.0 109.021 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 52.1 t80 -87.54 124.92 33.99 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.441 -0.787 . . . . 0.0 110.007 -178.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -84.39 84.93 7.47 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.33 -0.856 . . . . 0.0 109.732 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 92.4 p -77.22 -9.44 58.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.141 -0.975 . . . . 0.0 109.679 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -72.9 -1.91 56.42 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -98.89 131.64 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.159 -1.2 . . . . 0.0 108.431 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 27.3 t -59.97 -42.58 94.46 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.324 -0.86 . . . . 0.0 110.643 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.451 HG13 ' N ' ' A' ' 32' ' ' CYS . 9.9 p -59.95 -40.15 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.711 -1.243 . . . . 0.0 110.327 -179.061 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.484 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 90.2 m -61.95 -48.29 81.07 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.014 -1.054 . . . . 0.0 111.244 -178.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 1.2 mmt -77.64 -24.67 49.43 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.735 -1.228 . . . . 0.0 111.358 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -60.06 -40.05 88.12 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.709 -1.244 . . . . 0.0 109.498 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -72.44 -44.2 42.53 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.518 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.2 mt -66.2 -42.58 88.58 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.309 -1.112 . . . . 0.0 109.629 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -60.88 -40.08 91.67 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.07 -1.019 . . . . 0.0 110.212 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -78.66 -12.49 60.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.354 -0.841 . . . . 0.0 109.907 -178.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.02 29.27 70.8 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 41.9 mmtm -103.26 -5.39 23.14 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.756 HG12 ' H ' ' A' ' 43' ' ' GLY . 72.4 t -135.13 160.26 40.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.444 ' N ' HG12 ' A' ' 41' ' ' VAL . 93.4 mtt-85 -120.95 -5.96 9.56 Favored 'General case' 0 N--CA 1.501 2.095 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.756 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 132.59 -158.58 23.09 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 107.939 -2.064 . . . . 0.0 107.939 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 81.3 t -121.98 128.1 75.53 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.222 -1.164 . . . . 0.0 110.194 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.6 t -83.13 134.98 34.97 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 178.165 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 7.7 p -131.22 134.57 61.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.38 -0.825 . . . . 0.0 109.963 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.8 p -125.35 141.6 51.98 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -129.61 138.1 10.01 Favored Glycine 0 N--CA 1.503 3.107 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -178.819 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.15 125.01 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.61 ' CG ' ' NE2' ' A' ' 74' ' ' GLN . 26.3 m-85 -102.31 121.78 42.95 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 77.2 m-85 -94.61 129.28 41.53 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 120.984 -1.072 . . . . 0.0 109.517 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.47 ' OH ' ' NE2' ' A' ' 74' ' ' GLN . 68.4 m-85 -109.34 130.48 55.49 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.613 -0.679 . . . . 0.0 110.433 -179.693 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 43.1 t30 -50.61 -16.72 0.41 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.347 -0.846 . . . . 0.0 108.971 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.419 ' N ' ' C ' ' A' ' 52' ' ' TYR . 29.6 t0 -73.26 1.3 9.7 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.332 -0.855 . . . . 0.0 109.352 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.16 18.98 70.62 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 179.203 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.4 p -117.34 146.74 43.18 Favored 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.482 -1.01 . . . . 0.0 110.106 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.3 p -130.23 140.25 50.73 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.65 0.738 . . . . 0.0 110.384 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 65.3 p -118.14 143.95 46.07 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 178.235 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -137.79 119.73 15.38 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.876 -1.14 . . . . 0.0 109.933 -179.04 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -115.61 125.24 52.68 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -110.55 143.5 40.83 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -161.89 161.46 33.34 Favored Glycine 0 C--N 1.284 -2.319 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 32.2 t -108.12 125.85 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.347 -1.09 . . . . 0.0 109.049 -179.705 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 55.5 t -91.77 116.7 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.318 -0.864 . . . . 0.0 109.417 -179.569 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 67' ' ' SER . 22.3 p -135.89 149.93 70.08 Favored Pre-proline 0 N--CA 1.494 1.73 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 179.244 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_exo -41.47 -18.03 0.07 OUTLIER 'Trans proline' 0 C--N 1.313 -1.307 0 C-N-CA 121.908 1.739 . . . . 0.0 112.039 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.526 ' N ' ' O ' ' A' ' 65' ' ' THR . 68.7 m -69.96 -52.12 27.05 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.277 -0.889 . . . . 0.0 111.139 -179.002 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 60.1 p -149.64 151.75 33.61 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 120.731 -1.231 . . . . 0.0 110.064 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -85.38 165.72 10.84 Favored 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.728 2.285 . . . . 0.0 112.422 178.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 68.8 t -111.23 134.05 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.219 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -102.36 131.78 48.76 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.121 -0.987 . . . . 0.0 112.048 -177.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.462 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.3 OUTLIER -111.01 20.07 17.85 Favored 'General case' 0 N--CA 1.503 2.217 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 177.694 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.424 ' O ' ' O ' ' A' ' 74' ' ' GLN . 51.4 p-10 -77.07 55.73 1.17 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.575 -0.703 . . . . 0.0 110.383 -178.782 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.61 ' NE2' ' CG ' ' A' ' 50' ' ' PHE . 13.2 pt20 -49.0 175.04 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.366 -0.834 . . . . 0.0 108.884 178.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -55.19 107.71 0.34 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.819 -1.176 . . . . 0.0 108.64 179.428 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.409 ' O ' HG22 ' A' ' 76' ' ' ILE . 72.2 mt -79.36 -13.83 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.181 -0.949 . . . . 0.0 110.019 -179.55 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -59.94 -45.18 93.47 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.87 -1.144 . . . . 0.0 109.254 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 1.3 ptpp? -66.23 -38.53 88.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.93 -1.107 . . . . 0.0 108.905 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.597 ' O ' ' N ' ' A' ' 83' ' ' GLY . 3.7 m -59.96 -50.06 75.25 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.577 -0.702 . . . . 0.0 110.095 -179.806 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 44.7 t30 -60.48 -36.4 78.21 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 120.498 -1.377 . . . . 0.0 108.852 179.046 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 22.3 tttp -69.37 -47.29 64.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.405 -0.809 . . . . 0.0 110.929 -179.554 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.7 p -111.98 -29.72 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.18 0 O-C-N 121.245 -0.909 . . . . 0.0 111.817 -177.153 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.62 164.49 40.14 Favored Glycine 0 N--CA 1.49 2.279 0 O-C-N 120.705 -1.247 . . . . 0.0 110.696 179.053 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 82.6 t -109.86 130.82 62.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 48.0 tp60 -79.94 -67.37 0.77 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.228 -0.92 . . . . 0.0 110.254 -179.164 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -115.35 146.24 41.74 Favored 'General case' 0 N--CA 1.503 2.184 0 O-C-N 121.453 -0.78 . . . . 0.0 111.152 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -119.73 131.67 55.44 Favored 'General case' 0 N--CA 1.499 1.989 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 14.0 tpp85 -137.62 136.15 37.24 Favored 'General case' 0 N--CA 1.504 2.266 0 O-C-N 120.932 -1.105 . . . . 0.0 111.057 -178.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.524 ' C ' HD12 ' A' ' 90' ' ' LEU . . . -123.97 137.69 54.57 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.445 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.524 HD12 ' C ' ' A' ' 89' ' ' ALA . 10.4 mp -119.84 126.17 50.33 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 16.9 p -127.01 125.09 40.84 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.301 -0.874 . . . . 0.0 110.447 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -132.13 147.44 52.43 Favored 'General case' 0 N--CA 1.5 2.039 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' TRP . . . . . 0.409 ' HE1' HG23 ' A' ' 10' ' ' VAL . 75.1 m95 -70.72 139.27 51.11 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.913 -1.117 . . . . 0.0 109.593 179.497 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.8 t -111.37 123.76 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.976 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.444 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 108.02 -14.21 37.39 Favored Glycine 0 N--CA 1.496 2.652 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 89.4 p -70.99 149.96 46.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.262 -1.14 . . . . 0.0 109.414 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -96.07 -5.61 40.54 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.295 -0.878 . . . . 0.0 109.222 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 7.1 p . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 117.938 -1.03 . . . . 0.0 109.984 179.811 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.811 0 N-CA-C 119.54 2.576 . . . . 0.0 119.54 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 80.6 -166.83 49.65 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.3 t -83.23 130.24 35.07 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.323 -1.104 . . . . 0.0 109.392 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -90.53 24.45 17.04 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 87.2 t90 -59.88 118.25 6.0 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.325 -1.103 . . . . 0.0 110.178 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ASN . . . . . 0.536 ' C ' ' H ' ' A' ' 8' ' ' ASP . 96.3 m-20 -131.56 20.03 4.72 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 178.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 54.81 2.83 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.841 -0.537 . . . . 0.0 109.655 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.536 ' H ' ' C ' ' A' ' 6' ' ' ASN . 34.0 p-10 -86.49 -20.06 28.62 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.038 -1.039 . . . . 0.0 109.172 179.42 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 57.0 t30 -95.36 1.68 54.39 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.411 -0.806 . . . . 0.0 109.045 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.6 t -116.41 126.19 73.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.749 -0.594 . . . . 0.0 109.903 -178.848 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -83.49 139.83 41.4 Favored Pre-proline 0 N--CA 1.489 1.499 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 178.514 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -75.65 -14.17 19.86 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 121.762 1.641 . . . . 0.0 111.868 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 77.6 p -60.21 -39.96 88.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.367 -0.833 . . . . 0.0 109.722 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 88.6 mm-40 -84.24 -11.88 55.72 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.139 -0.976 . . . . 0.0 109.725 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.625 ' HG ' ' HG ' ' A' ' 32' ' ' CYS . 29.9 t -69.69 -31.45 69.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.146 -0.971 . . . . 0.0 108.677 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.5 pp -123.58 146.15 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.413 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.5 mttt -111.31 145.18 39.26 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.285 -0.884 . . . . 0.0 109.885 -178.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.454 ' NE2' ' CZ ' ' A' ' 87' ' ' TYR . 63.3 tt0 -97.65 114.81 26.84 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.569 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.438 ' O ' ' N ' ' A' ' 21' ' ' VAL . 48.0 m -115.13 130.12 56.84 Favored 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.67 -98.27 0.01 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.438 ' N ' ' O ' ' A' ' 19' ' ' SER . 3.9 m -137.57 27.46 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.369 -1.077 . . . . 0.0 109.836 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 -130.72 162.98 28.27 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 121.196 -0.94 . . . . 0.0 109.956 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -116.95 140.02 49.96 Favored 'General case' 0 N--CA 1.5 2.07 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.028 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 71.3 p -130.53 145.75 51.92 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.38 -0.825 . . . . 0.0 109.446 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -80.78 126.18 31.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.189 -0.944 . . . . 0.0 108.521 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -85.76 83.48 7.84 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.176 -0.953 . . . . 0.0 110.422 -179.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.9 p -81.07 -9.07 59.88 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.132 -0.98 . . . . 0.0 109.614 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -57.42 -39.18 90.14 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.5 m -80.84 136.89 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.106 -1.232 . . . . 0.0 108.984 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 24.1 t -67.54 -30.28 69.89 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.359 -0.838 . . . . 0.0 111.178 -178.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.443 HG13 ' N ' ' A' ' 32' ' ' CYS . 8.1 p -60.0 -40.06 82.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.818 -1.176 . . . . 0.0 110.419 -178.266 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.625 ' HG ' ' HG ' ' A' ' 15' ' ' CYS . 67.3 m -64.17 -40.17 95.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.786 -1.196 . . . . 0.0 110.14 -179.806 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 97.1 mmm -86.36 -14.96 41.95 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.892 -1.13 . . . . 0.0 109.77 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 35.4 tt0 -60.21 -40.27 89.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.985 -1.072 . . . . 0.0 108.127 179.146 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -79.2 -45.48 8.85 Favored Glycine 0 N--CA 1.485 1.902 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.9 tp -60.42 -43.67 96.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.243 -1.151 . . . . 0.0 109.737 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 79.4 m-20 -67.32 -39.81 85.92 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.202 -0.936 . . . . 0.0 110.055 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -60.39 -31.09 70.03 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.03 -1.044 . . . . 0.0 109.349 -179.523 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.52 23.42 23.97 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 64.5 mmtt -109.73 -0.57 18.44 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 178.869 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.735 HG12 ' H ' ' A' ' 43' ' ' GLY . 86.9 t -135.37 158.12 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 121.671 0.748 . . . . 0.0 109.259 -179.501 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.439 ' N ' HG12 ' A' ' 41' ' ' VAL . 67.4 mtp180 -119.9 -9.66 9.63 Favored 'General case' 0 N--CA 1.497 1.925 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.71 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.735 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 137.75 -159.96 25.11 Favored Glycine 0 N--CA 1.497 2.72 0 N-CA-C 108.009 -2.037 . . . . 0.0 108.009 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 90.1 t -118.61 129.73 74.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.143 0 O-C-N 121.18 -1.189 . . . . 0.0 109.315 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.2 t -85.91 138.76 31.79 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.324 -0.86 . . . . 0.0 108.883 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.435 ' O ' HG13 ' A' ' 46' ' ' VAL . 12.7 p -130.13 132.49 65.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.785 0.802 . . . . 0.0 109.544 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.4 p -123.78 146.06 48.59 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -141.77 138.7 8.82 Favored Glycine 0 N--CA 1.5 2.954 0 C-N-CA 119.362 -1.399 . . . . 0.0 111.471 -178.749 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 55.1 t -120.11 122.6 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 178.467 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.518 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 0.3 OUTLIER -100.06 126.18 46.23 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 179.875 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -98.53 121.39 40.4 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.156 -0.965 . . . . 0.0 109.444 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.532 ' O ' ' N ' ' A' ' 54' ' ' ASP . 91.7 m-85 -105.47 125.58 51.14 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.382 -0.824 . . . . 0.0 109.356 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -45.53 -16.62 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.147 -0.971 . . . . 0.0 109.49 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 52' ' ' TYR . 7.4 t70 -67.79 2.52 1.91 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.378 -0.826 . . . . 0.0 109.275 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.39 18.83 77.47 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 16.3 p -116.65 148.36 41.07 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.555 -0.968 . . . . 0.0 110.067 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 69.6 p -129.99 138.07 50.63 Favored 'General case' 0 N--CA 1.496 1.872 0 CA-C-O 121.589 0.709 . . . . 0.0 109.665 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.5 t -118.65 142.37 47.71 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 107.224 -1.399 . . . . 0.0 107.224 178.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ASN . . . . . 0.439 ' OD1' ' O ' ' A' ' 59' ' ' ASN . 39.7 p-10 -135.05 117.04 15.28 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.025 -1.047 . . . . 0.0 109.691 -179.443 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -116.83 130.43 56.71 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.081 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 27.2 ttpp -113.69 141.95 46.61 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.372 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -160.08 161.29 32.35 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 49.1 t -108.74 124.17 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.47 -1.017 . . . . 0.0 108.769 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 53.3 t -97.64 119.18 45.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.326 -0.859 . . . . 0.0 110.214 -179.147 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.65 ' O ' ' N ' ' A' ' 67' ' ' SER . 15.4 p -137.36 159.15 70.62 Favored Pre-proline 0 N--CA 1.491 1.616 0 N-CA-C 107.043 -1.466 . . . . 0.0 107.043 178.562 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_exo -51.2 58.73 0.02 OUTLIER 'Trans proline' 0 N--CA 1.504 2.147 0 C-N-CA 122.247 1.965 . . . . 0.0 113.688 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.65 ' N ' ' O ' ' A' ' 65' ' ' THR . 3.1 m -140.98 -64.07 0.46 Allowed 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.762 -1.211 . . . . 0.0 109.417 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 30.4 p -141.76 149.97 55.2 Favored Pre-proline 0 N--CA 1.5 2.064 0 O-C-N 121.212 -0.93 . . . . 0.0 109.501 179.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -84.57 164.11 12.44 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 122.707 2.271 . . . . 0.0 112.717 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.5 t -122.26 130.12 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.026 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 74.6 m-80 -96.77 136.08 37.82 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 120.806 -1.184 . . . . 0.0 111.11 -178.279 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.495 ' O ' ' CZ ' ' A' ' 50' ' ' PHE . 1.6 p -81.11 -51.55 8.34 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 178.467 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.466 ' N ' ' OG1' ' A' ' 72' ' ' THR . 23.6 m120 -81.46 56.1 2.83 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 66.4 tt0 -47.69 -47.23 29.81 Favored 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 119.843 -0.743 . . . . 0.0 109.553 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -106.12 97.68 7.46 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 82.2 mt -80.31 -23.83 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.228 -0.92 . . . . 0.0 109.834 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 22.9 m120 -60.13 -48.82 80.11 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 120.95 -1.094 . . . . 0.0 109.537 -178.265 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 13.8 ptpt -68.28 -38.63 81.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.676 -1.265 . . . . 0.0 109.223 179.581 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.609 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.4 OUTLIER -62.2 -45.7 92.21 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.012 -1.055 . . . . 0.0 108.834 179.47 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 9.5 t-20 -60.05 -34.17 73.03 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.63 -1.293 . . . . 0.0 109.499 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.3 tmtt? -64.86 -50.02 68.26 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.197 -0.939 . . . . 0.0 110.727 -179.055 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.4 p -113.2 -27.66 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.229 -0.919 . . . . 0.0 111.545 -178.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.609 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.37 157.69 26.82 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 179.792 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.0 t -103.52 116.49 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 179.533 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 25.3 mt-30 -70.9 -47.83 57.01 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.101 -1.0 . . . . 0.0 111.904 -178.641 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 58.6 tttp -115.58 142.81 46.23 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.239 -0.913 . . . . 0.0 110.798 -178.275 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.454 ' CZ ' ' NE2' ' A' ' 18' ' ' GLN . 62.3 t80 -120.66 130.07 53.96 Favored 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 178.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 2.2 tpp180 -139.44 127.51 22.38 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.082 -1.011 . . . . 0.0 110.422 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.476 ' C ' HD12 ' A' ' 90' ' ' LEU . . . -125.45 135.36 52.26 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.875 179.651 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.476 HD12 ' C ' ' A' ' 89' ' ' ALA . 9.8 mp -119.93 129.7 54.46 Favored 'General case' 0 N--CA 1.504 2.231 0 O-C-N 121.306 -0.871 . . . . 0.0 108.745 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 25.2 p -129.28 127.33 40.96 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 121.267 -0.896 . . . . 0.0 110.821 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -133.15 156.21 47.89 Favored 'General case' 0 N--CA 1.502 2.157 0 CA-C-O 121.222 0.534 . . . . 0.0 110.169 179.479 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 69.0 m95 -70.4 138.45 51.3 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.201 -0.937 . . . . 0.0 108.679 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 27.7 t -111.26 120.03 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.382 -0.824 . . . . 0.0 109.89 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 162.37 -176.41 38.73 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 47.1 t -64.84 129.93 41.57 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.064 -1.257 . . . . 0.0 108.519 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 35.2 ttm180 -89.17 132.35 34.88 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.286 -0.884 . . . . 0.0 109.636 -179.605 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 20.2 t . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.536 -179.968 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.856 0 N-CA-C 119.436 2.534 . . . . 0.0 119.436 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.04 -143.65 48.62 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.0 m -80.64 -9.21 59.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.393 -1.063 . . . . 0.0 109.181 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.87 168.32 18.64 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.091 -1.604 . . . . 0.0 109.091 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 34.6 t90 -65.77 141.44 58.32 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.215 -1.168 . . . . 0.0 110.473 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ASN . . . . . 0.601 ' C ' ' H ' ' A' ' 8' ' ' ASP . 84.1 m-20 -131.17 123.06 27.72 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 177.542 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.435 ' HB1' ' NE1' ' A' ' 93' ' ' TRP . . . -61.95 2.56 0.21 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.87 -1.144 . . . . 0.0 108.369 179.161 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.601 ' H ' ' C ' ' A' ' 6' ' ' ASN . 84.0 m-20 -60.9 -39.76 90.56 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.754 -0.591 . . . . 0.0 111.346 -179.079 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -84.27 0.33 49.38 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.861 -1.149 . . . . 0.0 110.195 -178.095 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.4 t -106.1 131.54 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.252 -0.905 . . . . 0.0 108.703 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.522 ' O ' ' N ' ' A' ' 13' ' ' SER . 4.3 m-20 -99.91 108.61 52.53 Favored Pre-proline 0 N--CA 1.492 1.662 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 179.634 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -44.72 -12.01 0.05 OUTLIER 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 121.931 1.754 . . . . 0.0 112.35 -179.568 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.522 ' N ' ' O ' ' A' ' 11' ' ' ASP . 88.1 p -69.59 -38.61 77.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.258 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 98.7 mm-40 -91.14 -6.79 53.1 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 120.947 -1.095 . . . . 0.0 109.967 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.793 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 22.4 t -70.66 -24.89 62.78 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.191 -0.943 . . . . 0.0 109.804 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.573 ' CG2' HG11 ' A' ' 44' ' ' VAL . 1.0 OUTLIER -120.8 151.25 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.152 0 O-C-N 121.569 -0.707 . . . . 0.0 110.27 -179.059 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -118.58 137.15 53.45 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.766 -0.584 . . . . 0.0 109.61 -179.54 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -100.35 121.63 41.81 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.205 -0.934 . . . . 0.0 110.353 -179.235 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 83.5 p -121.21 127.56 51.58 Favored 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.561 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.73 -111.13 1.72 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.638 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.6 m -127.88 36.51 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.084 0 O-C-N 121.451 -1.029 . . . . 0.0 109.605 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -131.6 160.02 36.57 Favored 'General case' 0 N--CA 1.5 2.051 0 CA-C-O 121.646 0.736 . . . . 0.0 110.62 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -119.67 139.96 51.4 Favored 'General case' 0 N--CA 1.498 1.966 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 80.7 p -134.94 151.13 50.58 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.328 -0.857 . . . . 0.0 109.825 -179.2 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 48.3 t80 -87.51 122.88 31.79 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.393 -0.817 . . . . 0.0 109.311 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -82.66 88.28 6.7 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.344 -0.847 . . . . 0.0 109.77 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 59.7 p -80.5 -9.9 59.75 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.106 -0.996 . . . . 0.0 109.626 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -56.66 -31.8 60.89 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -84.24 114.23 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.06 -1.259 . . . . 0.0 107.989 179.281 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.545 ' O ' ' N ' ' A' ' 34' ' ' GLN . 59.7 m -60.05 -40.04 88.04 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.237 -0.914 . . . . 0.0 111.132 -178.87 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 6.1 m -52.09 -40.69 30.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 120.946 -1.096 . . . . 0.0 110.653 -178.115 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.793 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 55.3 m -69.97 -44.51 69.33 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.818 -1.176 . . . . 0.0 109.869 -179.902 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 31.1 ttm -81.07 -13.0 59.18 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.023 -1.048 . . . . 0.0 109.623 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.545 ' N ' ' O ' ' A' ' 30' ' ' SER . 62.5 tt0 -61.44 -40.03 92.98 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 179.207 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.33 -39.96 29.79 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.0 tp -59.84 -43.52 94.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.14 -1.212 . . . . 0.0 108.407 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 44.5 t30 -62.15 -40.22 95.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.507 -0.745 . . . . 0.0 109.775 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -69.07 -26.56 65.01 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.361 -0.837 . . . . 0.0 110.308 -179.394 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 91.17 18.07 47.99 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.854 -1.165 . . . . 0.0 110.804 179.147 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 40.1 mtmt -97.92 -0.75 44.34 Favored 'General case' 0 N--CA 1.495 1.793 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 178.237 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.734 HG12 ' H ' ' A' ' 43' ' ' GLY . 59.7 t -136.12 156.72 37.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 115.021 -0.99 . . . . 0.0 108.511 -179.669 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -115.74 -10.17 11.8 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.273 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.734 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 139.55 -152.14 22.34 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 108.298 -1.921 . . . . 0.0 108.298 -179.566 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.573 HG11 ' CG2' ' A' ' 16' ' ' ILE . 9.5 p -125.06 129.44 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 121.068 -1.254 . . . . 0.0 109.647 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 t -87.42 134.6 33.57 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.294 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.457 HG13 ' O ' ' A' ' 46' ' ' VAL . 9.1 p -130.06 131.18 66.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.405 -0.81 . . . . 0.0 109.359 179.752 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 53.1 p -121.21 149.72 42.41 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -140.49 144.4 14.77 Favored Glycine 0 N--CA 1.502 3.051 0 C-N-CA 119.603 -1.284 . . . . 0.0 110.751 -178.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 96.0 t -126.37 128.9 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.513 -0.993 . . . . 0.0 109.429 178.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -102.21 120.4 40.4 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.836 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -95.5 126.34 40.72 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.246 -0.909 . . . . 0.0 109.314 -179.74 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.51 ' O ' ' N ' ' A' ' 54' ' ' ASP . 55.0 m-85 -109.51 126.5 53.61 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.383 -0.823 . . . . 0.0 109.257 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -45.94 -17.3 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.123 -0.986 . . . . 0.0 109.167 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.51 ' N ' ' O ' ' A' ' 52' ' ' TYR . 39.9 t0 -67.67 0.96 2.74 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.501 -0.75 . . . . 0.0 109.013 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.76 27.77 58.19 Favored Glycine 0 N--CA 1.494 2.5 0 O-C-N 121.206 -0.934 . . . . 0.0 110.769 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.5 p -123.15 150.02 43.81 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.389 -1.065 . . . . 0.0 109.78 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 39.6 p -132.58 133.99 44.37 Favored 'General case' 0 N--CA 1.501 2.101 0 CA-C-O 121.618 0.723 . . . . 0.0 109.669 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 48.3 t -119.89 142.82 48.35 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 178.688 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 37.9 t-20 -132.49 125.72 31.3 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 120.994 -1.066 . . . . 0.0 109.488 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -117.72 128.27 54.73 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.462 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.0 ttpm? -110.82 143.78 40.86 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -158.03 159.34 29.91 Favored Glycine 0 C--N 1.285 -2.282 0 N-CA-C 108.763 -1.735 . . . . 0.0 108.763 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 56.0 t -109.55 124.27 66.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.487 -1.007 . . . . 0.0 108.789 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.9 t -90.21 118.94 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.421 -0.799 . . . . 0.0 109.321 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.538 ' O ' ' N ' ' A' ' 67' ' ' SER . 30.6 p -132.89 151.57 78.27 Favored Pre-proline 0 N--CA 1.492 1.659 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 178.637 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -48.75 -5.51 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 121.295 1.33 . . . . 0.0 111.39 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.538 ' N ' ' O ' ' A' ' 65' ' ' THR . 19.7 t -75.62 -57.33 3.95 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.152 -0.968 . . . . 0.0 110.422 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 56.4 p -147.68 151.82 39.95 Favored Pre-proline 0 N--CA 1.502 2.142 0 O-C-N 120.855 -1.153 . . . . 0.0 110.107 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -84.67 167.33 11.55 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.939 2.426 . . . . 0.0 112.265 178.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.2 t -102.74 131.09 51.68 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -97.39 122.98 41.06 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.334 -0.853 . . . . 0.0 111.976 -177.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 1.2 p -93.37 -0.21 56.66 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 178.125 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.43 ' O ' ' OD1' ' A' ' 73' ' ' ASN . 41.3 t-20 -75.4 54.03 0.71 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.57 -0.706 . . . . 0.0 109.254 -179.631 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -62.96 -87.18 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -114.35 84.41 2.05 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.497 -0.752 . . . . 0.0 109.226 178.679 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 10.1 tp -70.11 -32.85 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.121 -0.987 . . . . 0.0 109.727 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.7 t30 -60.02 -47.39 86.04 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.1 -178.003 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.421 ' CG ' ' N ' ' A' ' 79' ' ' THR . 15.1 ptmt -63.63 -39.82 95.33 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.707 -1.246 . . . . 0.0 108.215 179.288 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.582 ' O ' ' N ' ' A' ' 83' ' ' GLY . 2.0 m -59.96 -40.71 89.96 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -179.614 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -66.59 -31.8 72.74 Favored 'General case' 0 C--N 1.295 -1.792 0 O-C-N 120.579 -1.326 . . . . 0.0 109.382 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 7.6 tmtm? -69.84 -44.28 70.22 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.915 -1.116 . . . . 0.0 110.378 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -110.58 -26.44 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.377 0 O-C-N 121.206 -0.934 . . . . 0.0 111.349 -178.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.47 164.29 37.6 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.563 HG23 HG23 ' A' ' 79' ' ' THR . 71.4 t -111.21 128.16 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.167 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 93.1 mm-40 -81.27 -65.5 1.0 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.086 -1.009 . . . . 0.0 110.996 -178.809 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 45.1 tptt -113.92 141.76 46.97 Favored 'General case' 0 N--CA 1.503 2.181 0 O-C-N 121.438 -0.789 . . . . 0.0 110.639 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -120.17 131.25 54.93 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 95.5 mtt180 -131.8 130.8 42.27 Favored 'General case' 0 N--CA 1.508 2.432 0 O-C-N 121.094 -1.004 . . . . 0.0 110.524 -179.231 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -122.68 137.89 54.77 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.675 -0.64 . . . . 0.0 109.894 179.649 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 60.3 tp -120.01 133.31 55.58 Favored 'General case' 0 N--CA 1.506 2.355 0 O-C-N 121.298 -0.876 . . . . 0.0 109.058 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.9 p -128.7 126.11 39.39 Favored 'General case' 0 N--CA 1.504 2.227 0 CA-C-O 121.581 0.705 . . . . 0.0 110.485 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -133.24 159.21 40.88 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.759 -0.588 . . . . 0.0 110.198 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' TRP . . . . . 0.435 ' NE1' ' HB1' ' A' ' 7' ' ' ALA . 50.7 m95 -75.66 136.46 40.42 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.372 -0.83 . . . . 0.0 108.775 178.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 21.4 t -106.79 120.81 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.485 -0.759 . . . . 0.0 109.304 -179.77 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 143.81 61.03 0.02 OUTLIER Glycine 0 N--CA 1.494 2.537 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 48.3 m -69.79 148.62 48.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.194 -1.18 . . . . 0.0 109.7 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 69.5 ttp85 -63.55 136.42 57.54 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.279 -0.888 . . . . 0.0 109.283 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 24.3 p . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 118.085 -0.96 . . . . 0.0 109.432 -179.917 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.853 0 N-CA-C 119.511 2.564 . . . . 0.0 119.511 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -93.09 -3.5 65.47 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 26.4 t -112.94 125.14 54.06 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.421 -1.047 . . . . 0.0 109.776 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -174.79 -165.76 31.65 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' TRP . . . . . 0.504 ' HE1' HG21 ' A' ' 10' ' ' VAL . 88.7 t90 -74.21 121.48 21.3 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.327 -1.102 . . . . 0.0 109.833 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ASN . . . . . 0.5 ' C ' ' H ' ' A' ' 8' ' ' ASP . 77.7 m-20 -127.82 23.87 6.14 Favored 'General case' 0 N--CA 1.493 1.7 0 CA-C-O 121.419 0.628 . . . . 0.0 109.701 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.43 ' HB2' ' CH2' ' A' ' 5' ' ' TRP . . . 59.27 0.97 0.21 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.34 -0.85 . . . . 0.0 109.378 -179.602 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.5 ' H ' ' C ' ' A' ' 6' ' ' ASN . 96.1 m-20 -93.11 -25.7 17.77 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.113 -0.992 . . . . 0.0 110.759 -179.702 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -90.05 4.83 49.07 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.846 -1.159 . . . . 0.0 109.916 -179.18 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.504 HG21 ' HE1' ' A' ' 5' ' ' TRP . 13.9 t -118.16 131.05 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.379 -0.826 . . . . 0.0 109.686 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 59.0 m-20 -81.96 133.91 50.71 Favored Pre-proline 0 C--N 1.301 -1.512 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 177.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -74.79 -15.34 21.34 Favored 'Trans proline' 0 N--CA 1.494 1.535 0 C-N-CA 121.848 1.699 . . . . 0.0 112.12 -178.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 79.8 p -69.05 -28.83 66.9 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.51 -0.744 . . . . 0.0 110.4 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -78.94 -11.32 60.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.121 -0.987 . . . . 0.0 109.307 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.483 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 11.7 t -69.93 -39.89 75.85 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.062 -1.024 . . . . 0.0 109.81 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.663 HD13 ' H ' ' A' ' 16' ' ' ILE . 0.1 OUTLIER -121.38 142.22 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.108 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 179.504 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -115.85 147.48 40.99 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.476 -0.765 . . . . 0.0 109.697 -178.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -85.05 113.0 21.14 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.43 -0.793 . . . . 0.0 108.953 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.5 m -103.36 120.04 40.03 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.19 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.92 -99.78 0.04 OUTLIER Glycine 0 N--CA 1.488 2.148 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 -179.608 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 t -128.32 20.2 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.456 -1.026 . . . . 0.0 109.195 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -129.61 167.88 17.27 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 121.357 -0.839 . . . . 0.0 110.732 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -124.31 145.21 49.55 Favored 'General case' 0 N--CA 1.501 2.079 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 40.5 p -136.8 153.65 50.76 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.272 -0.893 . . . . 0.0 110.051 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -85.59 123.28 30.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.584 -0.698 . . . . 0.0 109.695 -179.062 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -88.5 83.83 6.8 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.301 -0.875 . . . . 0.0 110.139 -179.578 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 77.7 p -79.85 -4.89 54.15 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 120.991 -1.068 . . . . 0.0 108.989 179.09 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.73 -40.1 96.14 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.0 m -72.97 139.97 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.008 -1.289 . . . . 0.0 108.862 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 55.2 p -69.04 -25.55 64.53 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.394 -0.816 . . . . 0.0 110.587 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.465 HG11 HG11 ' A' ' 10' ' ' VAL . 54.0 t -60.03 -43.11 91.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.011 -1.056 . . . . 0.0 110.089 -179.037 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.483 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.0 m -60.99 -39.95 91.62 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.067 -1.02 . . . . 0.0 110.464 -179.257 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.2 mmt -80.47 -14.44 58.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.934 -1.104 . . . . 0.0 110.037 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.5 tt0 -61.07 -42.56 98.72 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.058 -1.026 . . . . 0.0 108.914 179.207 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.2 -47.42 9.17 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.7 mt -61.26 -41.66 97.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.074 -1.251 . . . . 0.0 110.14 -179.693 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -65.52 -39.86 92.31 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.166 -0.959 . . . . 0.0 109.333 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -66.86 -29.66 69.62 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.379 -0.826 . . . . 0.0 109.494 -179.601 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.28 22.29 54.76 Favored Glycine 0 N--CA 1.494 2.557 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 31.2 ttmt -107.61 -3.51 19.21 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 179.218 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.73 HG12 ' H ' ' A' ' 43' ' ' GLY . 86.3 t -133.68 160.27 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.305 -179.183 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.451 ' N ' HG12 ' A' ' 41' ' ' VAL . 81.5 mtt85 -121.79 -8.1 8.97 Favored 'General case' 0 N--CA 1.499 2.023 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.73 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.34 -152.86 23.14 Favored Glycine 0 N--CA 1.499 2.86 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 99.2 t -126.53 130.0 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.322 0 O-C-N 121.066 -1.255 . . . . 0.0 109.667 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.406 ' H ' HG23 ' A' ' 94' ' ' VAL . 1.1 t -84.43 137.86 33.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.319 -0.863 . . . . 0.0 109.608 179.542 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 7.5 p -132.7 134.19 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.43 -0.794 . . . . 0.0 108.943 179.034 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 86.7 p -121.93 146.91 46.67 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 179.379 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -135.99 131.24 5.64 Favored Glycine 0 N--CA 1.498 2.811 0 C-N-CA 119.964 -1.112 . . . . 0.0 110.525 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 53.7 t -120.96 127.02 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.012 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -105.47 116.05 31.3 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 179.456 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -92.97 137.53 32.28 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.361 -0.837 . . . . 0.0 109.879 -178.506 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 74.0 m-85 -120.11 137.08 54.35 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.367 -0.833 . . . . 0.0 109.676 179.347 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 18.7 t-20 -47.29 -21.32 0.27 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.475 -0.766 . . . . 0.0 109.531 179.468 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.414 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 10.4 t70 -68.47 0.95 3.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.267 -0.896 . . . . 0.0 109.208 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 75.61 17.93 79.94 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.09 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.9 p -111.65 154.39 24.98 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.444 -1.033 . . . . 0.0 108.932 179.329 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 32.7 p -140.44 148.01 40.53 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.38 -0.825 . . . . 0.0 110.525 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 54.9 m -117.86 147.58 42.94 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 106.046 -1.835 . . . . 0.0 106.046 177.725 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -139.97 116.17 10.5 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.974 -1.079 . . . . 0.0 109.705 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -115.99 122.42 45.2 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 178.503 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -112.26 145.57 39.71 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -165.92 178.9 40.42 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 -179.466 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 30.4 t -119.42 127.53 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.487 -1.008 . . . . 0.0 109.593 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 t -89.46 118.9 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.436 -0.79 . . . . 0.0 109.875 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.45 ' O ' ' N ' ' A' ' 67' ' ' SER . 26.6 p -138.14 150.05 65.7 Favored Pre-proline 0 N--CA 1.494 1.727 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -44.55 -19.7 0.28 Allowed 'Trans proline' 0 C--N 1.311 -1.4 0 C-N-CA 121.111 1.207 . . . . 0.0 111.414 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.45 ' N ' ' O ' ' A' ' 65' ' ' THR . 69.9 m -70.05 -46.16 65.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.512 -0.743 . . . . 0.0 111.441 -178.931 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -148.47 141.31 15.25 Favored Pre-proline 0 N--CA 1.504 2.235 0 O-C-N 120.664 -1.273 . . . . 0.0 110.945 -178.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -86.95 165.09 8.74 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.087 2.524 . . . . 0.0 112.229 178.652 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 72.6 t -113.09 128.34 69.9 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.203 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.456 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 51.9 m-20 -104.52 140.61 37.73 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.285 -0.885 . . . . 0.0 111.818 -177.522 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.43 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.0 OUTLIER -109.9 19.17 19.36 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.024 -1.473 . . . . 0.0 107.024 177.502 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 46.5 t-20 -71.05 55.39 0.19 Allowed 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.637 -0.664 . . . . 0.0 109.522 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.408 ' N ' ' O ' ' A' ' 72' ' ' THR . 55.0 tt0 -49.61 169.35 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.051 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -59.07 123.77 17.72 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.713 -1.242 . . . . 0.0 108.939 -179.482 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 43.3 mm -80.16 -21.61 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.433 -0.792 . . . . 0.0 110.694 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -60.01 -47.73 84.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.673 -1.267 . . . . 0.0 110.069 -179.009 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 9.9 ptpt -64.14 -39.26 93.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.966 -1.084 . . . . 0.0 108.488 179.206 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.549 ' O ' ' N ' ' A' ' 83' ' ' GLY . 30.2 m -60.0 -45.04 94.03 Favored 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.683 0.754 . . . . 0.0 109.438 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -62.01 -36.16 80.7 Favored 'General case' 0 C--N 1.293 -1.887 0 O-C-N 120.949 -1.095 . . . . 0.0 109.972 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 15.0 tmtt? -70.31 -44.83 67.5 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.102 -0.999 . . . . 0.0 111.119 -178.641 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.6 p -117.51 -29.04 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.416 0 O-C-N 121.135 -0.978 . . . . 0.0 111.543 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.549 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.0 158.26 33.92 Favored Glycine 0 N--CA 1.497 2.702 0 O-C-N 120.616 -1.302 . . . . 0.0 110.571 179.35 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 56.1 t -100.04 123.44 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -77.69 -65.0 1.02 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.181 -0.949 . . . . 0.0 111.365 -178.169 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -115.96 152.45 33.45 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.124 -0.985 . . . . 0.0 111.814 -178.353 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 64.8 t80 -120.94 130.92 54.05 Favored 'General case' 0 N--CA 1.5 2.033 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.364 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -136.86 130.2 31.38 Favored 'General case' 0 N--CA 1.507 2.39 0 O-C-N 120.814 -1.179 . . . . 0.0 110.843 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.68 135.44 53.05 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.183 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.59 HD23 ' N ' ' A' ' 91' ' ' THR . 1.2 tt -119.77 129.1 54.31 Favored 'General case' 0 N--CA 1.504 2.228 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.495 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.59 ' N ' HD23 ' A' ' 90' ' ' LEU . 6.5 p -129.1 121.59 28.13 Favored 'General case' 0 N--CA 1.505 2.279 0 O-C-N 121.414 -0.804 . . . . 0.0 111.433 -178.651 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -133.32 159.82 39.14 Favored 'General case' 0 N--CA 1.502 2.165 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.176 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -73.6 144.06 46.13 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.918 -1.113 . . . . 0.0 109.278 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.406 HG23 ' H ' ' A' ' 45' ' ' SER . 60.9 t -114.2 123.71 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.344 -0.848 . . . . 0.0 109.326 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 116.16 -0.11 20.86 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.2 m -95.2 139.29 31.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.288 -1.125 . . . . 0.0 109.237 179.692 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 24.9 ttm180 -97.03 121.3 38.77 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.129 -0.982 . . . . 0.0 109.642 -179.708 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 43.1 t . . . . . 0 N--CA 1.492 1.656 0 CA-C-O 117.844 -1.074 . . . . 0.0 109.651 -179.773 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.914 0 N-CA-C 119.732 2.653 . . . . 0.0 119.732 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -83.29 -78.65 1.06 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 72.2 m -76.31 155.96 33.79 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.281 -1.129 . . . . 0.0 110.142 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 177.94 175.99 45.56 Favored Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 89.3 t90 -77.41 115.62 17.32 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.035 -1.274 . . . . 0.0 109.772 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -131.04 19.2 4.97 Favored 'General case' 0 N--CA 1.49 1.534 0 CA-C-O 121.614 0.721 . . . . 0.0 109.1 179.538 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 56.55 13.32 1.31 Allowed 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -93.62 -28.38 16.04 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.298 -0.876 . . . . 0.0 109.914 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -90.57 0.09 57.48 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.187 -0.946 . . . . 0.0 109.397 -179.53 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.5 t -109.04 127.8 65.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 O-C-N 121.495 -0.753 . . . . 0.0 109.801 -179.391 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 60.4 m-20 -87.06 132.12 42.66 Favored Pre-proline 0 N--CA 1.489 1.515 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 178.104 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -72.84 -14.51 26.73 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 121.633 1.555 . . . . 0.0 112.154 -178.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 30.3 t -61.57 -40.17 93.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.142 -0.974 . . . . 0.0 110.364 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 65.4 mt-30 -81.46 -11.29 59.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.043 -1.035 . . . . 0.0 110.302 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.749 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 35.5 m -70.11 -30.02 67.11 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.948 -1.095 . . . . 0.0 108.939 179.273 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -122.11 140.51 45.79 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -123.95 143.3 50.48 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.528 -0.732 . . . . 0.0 109.398 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -87.5 130.68 34.62 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.086 -1.009 . . . . 0.0 109.456 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 53.6 m -118.9 128.41 54.4 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 46.48 -107.12 0.17 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.7 m -121.78 19.9 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.67 -0.9 . . . . 0.0 109.977 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -130.68 164.99 23.81 Favored 'General case' 0 N--CA 1.503 2.19 0 O-C-N 121.389 -0.819 . . . . 0.0 110.266 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -117.6 140.67 49.33 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 79.2 p -139.94 150.93 45.12 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.305 -0.872 . . . . 0.0 109.044 178.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 8.8 t80 -78.53 128.78 34.03 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.375 -0.828 . . . . 0.0 109.371 -179.412 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -85.69 83.12 7.96 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.341 -0.849 . . . . 0.0 109.257 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.445 ' C ' ' N ' ' A' ' 29' ' ' VAL . 97.6 p -79.08 -5.05 53.12 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.199 -0.938 . . . . 0.0 109.3 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.17 -11.73 0.69 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.474 ' O ' HG23 ' A' ' 29' ' ' VAL . 29.0 m -108.9 127.39 65.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.518 -0.989 . . . . 0.0 108.776 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 64.5 m -70.07 -27.48 64.66 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.42 -0.8 . . . . 0.0 110.451 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.422 HG23 ' N ' ' A' ' 32' ' ' CYS . 3.7 m -60.01 -40.3 82.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.036 -1.04 . . . . 0.0 111.204 -178.18 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.749 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 97.1 m -66.39 -40.24 89.54 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.546 -1.347 . . . . 0.0 110.074 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 70.5 mtp -80.98 -10.08 59.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.953 -1.092 . . . . 0.0 109.603 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -61.23 -40.46 94.1 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -80.46 -51.27 4.99 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.613 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.9 tt -60.14 -41.53 92.92 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.105 -1.232 . . . . 0.0 109.726 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 -60.1 -40.22 88.85 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.018 -1.051 . . . . 0.0 109.736 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -79.01 -6.04 55.37 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.348 -0.845 . . . . 0.0 109.487 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.56 29.25 49.37 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.941 -1.123 . . . . 0.0 110.374 178.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -104.48 -9.54 18.31 Favored 'General case' 0 N--CA 1.496 1.848 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.676 HG12 ' H ' ' A' ' 43' ' ' GLY . 70.9 t -136.15 161.2 37.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.492 ' N ' HG12 ' A' ' 41' ' ' VAL . 57.9 ttm-85 -122.95 -7.65 8.38 Favored 'General case' 0 N--CA 1.495 1.8 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.676 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.3 -161.16 25.63 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 95.0 t -122.5 130.13 74.74 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.335 -1.097 . . . . 0.0 109.103 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.454 ' H ' HG23 ' A' ' 94' ' ' VAL . 1.8 m -86.3 136.79 33.02 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.051 -1.03 . . . . 0.0 108.303 179.364 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.407 ' O ' HG23 ' A' ' 46' ' ' VAL . 6.0 m -132.08 133.45 60.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.644 -0.66 . . . . 0.0 109.543 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 57.3 p -122.65 142.46 50.64 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 179.021 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -131.3 143.06 14.48 Favored Glycine 0 N--CA 1.503 3.151 0 C-N-CA 120.085 -1.055 . . . . 0.0 111.113 -178.545 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 92.6 t -126.25 129.99 72.03 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.852 -0.793 . . . . 0.0 109.405 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -103.97 120.05 40.23 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 62.6 m-85 -96.64 123.22 40.24 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.354 -0.842 . . . . 0.0 109.405 -179.477 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.58 ' CD1' ' NZ ' ' A' ' 78' ' ' LYS . 96.9 m-85 -109.03 128.03 54.61 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.607 -0.683 . . . . 0.0 109.634 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.429 ' C ' ' H ' ' A' ' 55' ' ' GLY . 50.5 t-20 -45.58 -17.27 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.27 -0.894 . . . . 0.0 109.324 179.149 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 52' ' ' TYR . 22.1 t0 -67.42 1.54 2.21 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.429 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 75.36 23.42 73.65 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.346 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.9 p -121.76 149.85 42.69 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.499 -1.001 . . . . 0.0 110.002 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.1 p -134.01 138.08 45.16 Favored 'General case' 0 N--CA 1.499 2.016 0 CA-C-O 121.824 0.821 . . . . 0.0 110.174 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.8 t -119.78 143.2 47.97 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.277 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 58.6 t-20 -134.44 129.84 35.89 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 120.624 -1.297 . . . . 0.0 110.127 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -117.06 128.69 55.4 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -113.98 142.7 45.83 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -165.42 170.58 40.39 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.9 t -113.96 126.45 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.112 0 O-C-N 121.544 -0.974 . . . . 0.0 109.408 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 72.5 t -96.45 117.92 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.075 -1.015 . . . . 0.0 109.906 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.52 ' O ' ' N ' ' A' ' 67' ' ' SER . 24.3 p -126.69 150.12 70.25 Favored Pre-proline 0 N--CA 1.501 2.088 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 179.147 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_exo -37.41 -22.39 0.05 OUTLIER 'Trans proline' 0 N--CA 1.49 1.306 0 C-N-CA 122.227 1.951 . . . . 0.0 112.984 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.52 ' N ' ' O ' ' A' ' 65' ' ' THR . 9.0 t -114.1 -16.06 12.16 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.275 -0.891 . . . . 0.0 111.556 -178.678 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 98.5 m -119.6 106.53 41.99 Favored Pre-proline 0 N--CA 1.502 2.156 0 O-C-N 120.976 -1.077 . . . . 0.0 110.193 -179.258 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -91.41 163.48 3.62 Favored 'Trans proline' 0 N--CA 1.492 1.416 0 C-N-CA 122.657 2.238 . . . . 0.0 112.347 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.8 t -127.22 130.03 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.293 0 N-CA-C 108.714 -0.846 . . . . 0.0 108.714 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -100.16 132.31 45.61 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 121.209 -0.932 . . . . 0.0 111.873 -178.094 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.488 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.0 OUTLIER -105.33 19.96 19.69 Favored 'General case' 0 N--CA 1.498 1.938 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.602 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -67.44 54.37 0.06 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.777 -0.577 . . . . 0.0 109.651 -179.256 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.488 ' N ' ' O ' ' A' ' 72' ' ' THR . 0.0 OUTLIER -48.0 166.71 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.285 -0.885 . . . . 0.0 108.831 179.517 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.449 ' O ' ' NE2' ' A' ' 74' ' ' GLN . 78.3 m-20 -57.09 117.83 4.41 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.006 -1.058 . . . . 0.0 109.538 -178.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 47.7 mm -69.59 -39.48 78.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.768 -0.582 . . . . 0.0 109.582 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -56.15 -41.47 75.44 Favored 'General case' 0 N--CA 1.488 1.425 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.58 ' NZ ' ' CD1' ' A' ' 52' ' ' TYR . 28.3 tttm -62.84 -49.47 74.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.317 -0.865 . . . . 0.0 108.884 178.323 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.582 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.0 OUTLIER -67.61 -42.16 82.84 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.535 -0.728 . . . . 0.0 110.062 -179.099 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -60.96 -34.21 74.39 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 120.641 -1.287 . . . . 0.0 110.902 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -70.99 -43.54 67.79 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.887 -1.133 . . . . 0.0 111.243 -178.615 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.1 p -115.98 -27.78 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.39 -0.819 . . . . 0.0 111.231 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.87 166.01 40.9 Favored Glycine 0 N--CA 1.488 2.162 0 O-C-N 120.675 -1.266 . . . . 0.0 110.371 178.742 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.9 t -111.06 124.91 68.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -81.34 -64.19 1.24 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.162 -0.962 . . . . 0.0 111.073 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -114.22 143.17 45.27 Favored 'General case' 0 N--CA 1.509 2.48 0 O-C-N 121.167 -0.958 . . . . 0.0 111.299 -178.582 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 74.4 t80 -120.5 134.43 55.27 Favored 'General case' 0 N--CA 1.505 2.291 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 178.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 78.9 mtp180 -136.45 129.0 30.47 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 120.968 -1.083 . . . . 0.0 110.944 -178.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.66 132.66 53.39 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.729 -0.607 . . . . 0.0 109.672 179.047 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.518 HD12 ' N ' ' A' ' 90' ' ' LEU . 7.7 mp -108.83 129.46 55.4 Favored 'General case' 0 N--CA 1.503 2.206 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 179.138 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.9 p -124.2 121.46 35.15 Favored 'General case' 0 N--CA 1.507 2.384 0 O-C-N 121.313 -0.867 . . . . 0.0 110.575 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 53.4 tp10 -133.84 150.95 51.41 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.772 -0.58 . . . . 0.0 110.163 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 70.9 m95 -66.95 141.55 57.57 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.992 -1.067 . . . . 0.0 108.737 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.454 HG23 ' H ' ' A' ' 45' ' ' SER . 62.0 t -119.3 130.16 74.32 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.177 0 O-C-N 121.503 -0.748 . . . . 0.0 109.989 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 115.83 -0.53 21.45 Favored Glycine 0 N--CA 1.501 3.0 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.338 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 54.6 p -85.34 117.98 24.6 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.237 -1.155 . . . . 0.0 108.905 179.704 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 78.2 mtp180 -87.94 139.95 29.99 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.159 -0.963 . . . . 0.0 109.482 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.9 t . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 118.125 -0.941 . . . . 0.0 109.556 -179.686 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.821 0 N-CA-C 119.353 2.501 . . . . 0.0 119.353 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 90.04 -10.01 75.43 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.325 -1.51 . . . . 0.0 109.325 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.4 m -61.07 144.54 53.3 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.374 -1.074 . . . . 0.0 109.088 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 177.77 -77.04 0.07 OUTLIER Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.573 -1.298 . . . . 0.0 109.936 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 14.7 t90 -60.23 139.97 57.27 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.154 -1.204 . . . . 0.0 109.874 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ASN . . . . . 0.565 ' C ' ' H ' ' A' ' 8' ' ' ASP . 78.1 m-20 -133.57 125.38 28.7 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 177.533 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -63.78 5.39 0.21 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.006 -1.059 . . . . 0.0 108.861 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.565 ' H ' ' C ' ' A' ' 6' ' ' ASN . 33.5 p-10 -72.81 -20.13 61.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.34 -0.85 . . . . 0.0 110.708 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.7 m120 -99.52 6.71 45.79 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.098 -1.001 . . . . 0.0 109.783 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 29.2 t -119.98 129.97 74.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.47 -0.769 . . . . 0.0 109.905 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.96 140.28 43.1 Favored Pre-proline 0 N--CA 1.489 1.486 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.21 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -71.48 -22.39 24.82 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 121.806 1.671 . . . . 0.0 111.975 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 76.9 p -69.32 -38.93 78.45 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.313 -0.867 . . . . 0.0 109.781 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 56.6 tt0 -70.04 -23.93 63.18 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.304 -0.873 . . . . 0.0 109.739 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.466 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 22.0 m -68.44 -28.54 67.14 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.888 . . . . 0.0 109.685 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.4 pp -116.49 139.1 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.402 -0.811 . . . . 0.0 109.227 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -118.04 147.84 42.84 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.553 -0.717 . . . . 0.0 109.731 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.681 ' NE2' ' CZ ' ' A' ' 23' ' ' TYR . 10.7 tp-100 -99.58 117.73 34.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.649 -0.657 . . . . 0.0 109.266 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.464 ' O ' ' N ' ' A' ' 21' ' ' VAL . 14.6 t -110.45 118.29 35.88 Favored 'General case' 0 N--CA 1.497 1.902 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 179.023 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.03 -92.42 0.02 OUTLIER Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.727 -1.749 . . . . 0.0 108.727 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.464 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.4 t -140.41 30.52 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 O-C-N 121.328 -1.101 . . . . 0.0 109.564 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.443 ' N ' ' OE1' ' A' ' 18' ' ' GLN . 89.1 mt-30 -127.46 158.07 38.35 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.271 -0.893 . . . . 0.0 110.334 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' TYR . . . . . 0.681 ' CZ ' ' NE2' ' A' ' 18' ' ' GLN . 26.9 m-85 -119.74 134.73 55.12 Favored 'General case' 0 N--CA 1.498 1.963 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.1 p -139.97 150.45 44.5 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.225 -0.922 . . . . 0.0 109.833 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.424 ' CZ ' HD11 ' A' ' 36' ' ' LEU . 33.6 t80 -78.99 127.5 32.06 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 179.523 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -82.81 81.52 8.51 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.068 -1.02 . . . . 0.0 109.777 -179.442 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 49.9 m -78.31 -5.98 53.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.168 -0.957 . . . . 0.0 109.068 179.638 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -58.36 -37.43 87.56 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.829 -1.308 . . . . 0.0 109.829 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.2 m -84.32 132.38 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.036 -1.273 . . . . 0.0 109.492 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.9 m -60.09 -39.42 86.04 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.642 -0.661 . . . . 0.0 111.622 -178.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.403 HG23 ' N ' ' A' ' 32' ' ' CYS . 19.7 m -57.62 -42.99 82.56 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 120.849 -1.157 . . . . 0.0 111.369 -177.336 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.466 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 93.0 m -67.05 -39.99 87.05 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.45 -1.406 . . . . 0.0 109.412 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.1 tpt -79.99 -11.72 59.76 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.008 -1.058 . . . . 0.0 108.419 179.608 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 61.2 tt0 -65.41 -39.85 92.65 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.07 -46.59 15.79 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.424 HD11 ' CZ ' ' A' ' 25' ' ' TYR . 23.7 mt -60.04 -50.11 75.02 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.213 -1.169 . . . . 0.0 109.943 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -61.08 -39.99 91.98 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.076 -1.015 . . . . 0.0 110.0 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.437 ' OE2' ' NZ ' ' A' ' 40' ' ' LYS . 79.3 tt0 -64.55 -29.82 70.85 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.331 -0.855 . . . . 0.0 109.297 -179.362 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 91.25 26.54 20.95 Favored Glycine 0 N--CA 1.496 2.638 0 O-C-N 121.161 -0.962 . . . . 0.0 110.765 179.065 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.437 ' NZ ' ' OE2' ' A' ' 38' ' ' GLU . 96.3 mttt -110.04 -1.86 17.35 Favored 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.87 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.661 HG12 ' H ' ' A' ' 43' ' ' GLY . 72.5 t -133.71 160.2 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 CA-C-O 121.756 0.788 . . . . 0.0 109.056 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.547 ' HE ' ' CG1' ' A' ' 94' ' ' VAL . 44.9 ttp180 -125.25 -5.98 7.18 Favored 'General case' 0 N--CA 1.494 1.772 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.673 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.661 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 134.09 -164.42 24.49 Favored Glycine 0 N--CA 1.503 3.136 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 94.6 t -120.07 130.01 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.4 0 CA-C-N 118.747 1.273 . . . . 0.0 110.126 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 38.0 t -79.63 134.08 36.43 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.823 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.446 HG13 ' O ' ' A' ' 46' ' ' VAL . 14.7 p -130.04 131.3 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.382 -0.824 . . . . 0.0 109.684 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 60.7 p -122.56 147.03 46.88 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 179.288 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -142.36 136.01 6.97 Favored Glycine 0 N--CA 1.503 3.118 0 C-N-CA 119.409 -1.376 . . . . 0.0 111.04 -179.138 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.561 ' CG1' HH12 ' A' ' 88' ' ' ARG . 65.0 t -123.45 133.77 68.22 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.311 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -111.06 124.31 51.92 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.603 -0.686 . . . . 0.0 109.185 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.607 ' CD2' ' NH2' ' A' ' 88' ' ' ARG . 23.4 m-85 -95.1 126.06 40.17 Favored 'General case' 0 N--CA 1.504 2.266 0 O-C-N 120.807 -1.183 . . . . 0.0 109.247 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.451 ' C ' ' N ' ' A' ' 54' ' ' ASP . 37.3 m-85 -111.04 131.47 55.03 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.783 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -53.13 -14.61 0.67 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.907 -1.121 . . . . 0.0 108.184 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.451 ' N ' ' C ' ' A' ' 52' ' ' TYR . 34.2 t0 -68.72 -4.77 17.05 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.2 12.43 80.8 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.0 p -110.57 159.45 17.54 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.541 -0.976 . . . . 0.0 110.025 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 78.4 p -140.43 143.82 35.8 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.449 -0.782 . . . . 0.0 110.487 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.0 t -114.98 130.01 56.84 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 177.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 12.3 m-20 -130.55 116.94 18.85 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.946 -1.096 . . . . 0.0 109.594 -178.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.532 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 54.5 p90 -117.09 120.69 39.11 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 178.511 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.9 ttpt -110.09 144.06 39.23 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -173.39 -175.35 41.08 Favored Glycine 0 C--N 1.286 -2.226 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 66.3 t -120.53 129.77 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.658 -0.907 . . . . 0.0 109.702 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.489 HG13 ' O ' ' A' ' 64' ' ' VAL . 4.3 p -96.89 124.23 49.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.207 -0.933 . . . . 0.0 109.462 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.0 p -135.58 150.13 71.21 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_exo -40.77 -24.8 0.17 Allowed 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.012 1.808 . . . . 0.0 112.845 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.2 t -102.84 -22.78 13.83 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.26 -0.9 . . . . 0.0 110.983 -178.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 41.5 m -123.17 107.1 32.97 Favored Pre-proline 0 N--CA 1.504 2.255 0 O-C-N 121.146 -0.971 . . . . 0.0 109.945 -179.652 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -89.2 163.09 5.7 Favored 'Trans proline' 0 N--CA 1.491 1.337 0 C-N-CA 122.453 2.102 . . . . 0.0 112.445 179.029 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.2 t -120.04 127.66 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 -103.99 130.89 51.67 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.306 -0.871 . . . . 0.0 110.805 -178.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.27 9.68 41.6 Favored 'General case' 0 N--CA 1.5 2.057 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 178.407 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 48.7 t-20 -76.36 56.81 1.11 Allowed 'General case' 0 N--CA 1.486 1.338 0 O-C-N 121.598 -0.689 . . . . 0.0 109.878 -179.004 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.469 ' NE2' ' O ' ' A' ' 75' ' ' ASP . 4.5 pp0? -63.96 -156.07 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 178.544 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.469 ' O ' ' NE2' ' A' ' 74' ' ' GLN . 76.2 m-20 -73.4 101.39 3.46 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 120.575 -1.328 . . . . 0.0 108.583 179.571 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.473 HG22 ' O ' ' A' ' 76' ' ' ILE . 90.6 mt -79.95 -9.34 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.493 -0.754 . . . . 0.0 109.959 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -59.12 -43.85 91.97 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.98 -1.075 . . . . 0.0 109.337 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 10.1 ptpt -69.94 -39.2 76.23 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.947 -1.096 . . . . 0.0 109.648 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.593 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.8 OUTLIER -60.14 -47.85 84.17 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.764 -1.21 . . . . 0.0 108.266 179.808 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 44.6 t-20 -60.04 -35.07 74.31 Favored 'General case' 0 C--N 1.296 -1.718 0 O-C-N 120.825 -1.172 . . . . 0.0 108.501 178.54 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 83.4 tttt -64.37 -51.52 62.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.407 -0.808 . . . . 0.0 110.817 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.4 m -115.94 -26.59 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.395 0 O-C-N 121.139 -0.976 . . . . 0.0 111.803 -178.334 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 93.49 166.31 37.79 Favored Glycine 0 N--CA 1.492 2.43 0 O-C-N 120.65 -1.281 . . . . 0.0 110.328 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 59.7 t -110.8 130.02 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.945 -0.738 . . . . 0.0 109.127 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 13.1 tt0 -80.0 -66.57 0.86 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.119 -0.988 . . . . 0.0 110.462 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.417 ' C ' ' HE ' ' A' ' 88' ' ' ARG . 95.0 mttt -115.71 139.98 49.63 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 121.26 -0.9 . . . . 0.0 111.48 -178.729 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.492 ' CA ' ' HE ' ' A' ' 88' ' ' ARG . 80.6 t80 -121.84 133.38 54.88 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.724 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.607 ' NH2' ' CD2' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -138.5 134.07 33.48 Favored 'General case' 0 N--CA 1.507 2.415 0 O-C-N 120.933 -1.104 . . . . 0.0 110.655 -179.874 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.64 136.2 53.72 Favored 'General case' 0 N--CA 1.498 1.927 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.52 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.28 131.91 56.34 Favored 'General case' 0 N--CA 1.505 2.292 0 O-C-N 121.365 -0.834 . . . . 0.0 109.427 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 40.3 p -127.09 125.31 41.05 Favored 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.358 -0.839 . . . . 0.0 110.579 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -133.18 151.61 51.96 Favored 'General case' 0 N--CA 1.504 2.242 0 O-C-N 121.783 -0.573 . . . . 0.0 110.338 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 71.0 m95 -70.37 140.73 52.19 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.146 -0.971 . . . . 0.0 108.882 178.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.547 ' CG1' ' HE ' ' A' ' 42' ' ' ARG . 38.4 t -117.03 124.8 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 O-C-N 121.399 -0.813 . . . . 0.0 109.315 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -173.81 47.55 0.15 Allowed Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.4 t -80.21 144.11 33.22 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.169 -1.195 . . . . 0.0 109.689 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 42.8 ttm180 -87.11 -18.08 31.31 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.345 -0.847 . . . . 0.0 109.364 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 25.2 p . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 118.022 -0.99 . . . . 0.0 109.654 -179.972 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.814 0 N-CA-C 119.457 2.543 . . . . 0.0 119.457 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -146.67 -54.33 0.02 OUTLIER Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.4 t -68.69 138.69 55.14 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.446 -1.031 . . . . 0.0 109.451 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.58 141.4 48.02 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 -179.358 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' TRP . . . . . 0.843 ' CH2' ' HB2' ' A' ' 7' ' ' ALA . 88.5 t90 -86.89 130.03 34.63 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.413 -1.051 . . . . 0.0 109.099 179.447 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ASN . . . . . 0.496 ' C ' ' H ' ' A' ' 8' ' ' ASP . 99.2 m-20 -129.84 12.66 5.77 Favored 'General case' 0 N--CA 1.495 1.814 0 CA-C-O 121.701 0.762 . . . . 0.0 109.696 179.295 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.843 ' HB2' ' CH2' ' A' ' 5' ' ' TRP . . . 57.91 2.44 0.17 Allowed 'General case' 0 C--N 1.295 -1.792 0 O-C-N 121.517 -0.739 . . . . 0.0 109.028 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.496 ' H ' ' C ' ' A' ' 6' ' ' ASN . 55.0 t0 -84.3 -26.34 28.61 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.27 -0.894 . . . . 0.0 110.362 -179.371 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 49.0 t-20 -86.32 1.7 50.05 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.103 -0.998 . . . . 0.0 110.077 -179.307 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.456 HG11 HG11 ' A' ' 31' ' ' VAL . 2.0 t -118.15 126.92 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.483 -0.761 . . . . 0.0 109.332 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -77.91 140.33 62.5 Favored Pre-proline 0 C--N 1.3 -1.583 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 178.123 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -75.21 -13.74 20.89 Favored 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 121.347 1.365 . . . . 0.0 111.549 -179.275 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 38.3 t -60.73 -40.35 92.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.639 -0.663 . . . . 0.0 110.917 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -81.97 -10.03 59.38 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.0 -1.062 . . . . 0.0 109.673 -179.254 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.515 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 18.3 t -70.93 -30.9 67.34 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.125 -0.984 . . . . 0.0 109.335 179.357 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -123.86 151.89 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.204 0 O-C-N 121.443 -0.785 . . . . 0.0 109.318 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 20.9 pttp -130.85 148.22 52.59 Favored 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.502 -0.749 . . . . 0.0 109.374 179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 62.7 tt0 -100.7 124.95 47.03 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.203 -0.935 . . . . 0.0 109.673 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.525 ' O ' ' N ' ' A' ' 21' ' ' VAL . 34.4 p -111.8 121.53 45.31 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.68 -92.87 0.01 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.67 -1.772 . . . . 0.0 108.67 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.525 ' N ' ' O ' ' A' ' 19' ' ' SER . 4.6 m -137.24 30.6 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.356 -1.085 . . . . 0.0 109.264 179.293 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -129.55 159.67 35.6 Favored 'General case' 0 N--CA 1.504 2.226 0 CA-C-O 122.03 0.919 . . . . 0.0 111.029 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -119.89 139.95 51.6 Favored 'General case' 0 N--CA 1.499 2.004 0 N-CA-C 108.404 -0.962 . . . . 0.0 108.404 178.606 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 77.0 p -138.32 147.42 43.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.28 -0.888 . . . . 0.0 109.001 179.423 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -83.17 125.65 31.76 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.606 -0.684 . . . . 0.0 109.38 -178.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -84.91 90.34 7.78 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.208 -0.933 . . . . 0.0 109.555 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 79.8 p -89.52 -0.87 57.8 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.223 -0.923 . . . . 0.0 108.851 179.352 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -68.33 -2.12 24.89 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.0 m -113.71 130.06 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.546 -0.973 . . . . 0.0 109.363 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 80.5 p -60.45 -28.0 67.96 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.703 -0.623 . . . . 0.0 110.497 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.456 HG11 HG11 ' A' ' 10' ' ' VAL . 71.2 t -61.22 -44.31 98.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 120.948 -1.095 . . . . 0.0 110.338 -178.82 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.515 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 86.1 m -69.83 -39.81 76.24 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.101 -0.999 . . . . 0.0 110.109 -179.034 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.4 mmt -74.95 -20.86 59.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.092 -1.005 . . . . 0.0 109.495 179.708 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -60.42 -39.61 88.03 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 120.985 -1.072 . . . . 0.0 109.073 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.97 -49.13 7.2 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 17.8 mt -62.64 -39.92 95.37 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.333 -1.098 . . . . 0.0 109.737 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -66.46 -39.91 89.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.055 -1.028 . . . . 0.0 109.496 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 77.0 tt0 -67.12 -30.1 70.01 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.058 -1.026 . . . . 0.0 109.348 -179.406 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.32 22.41 27.13 Favored Glycine 0 N--CA 1.497 2.743 0 O-C-N 121.112 -0.992 . . . . 0.0 110.688 179.07 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.1 mtpt -104.47 -1.52 26.57 Favored 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 178.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.713 HG12 ' H ' ' A' ' 43' ' ' GLY . 78.3 t -131.08 158.4 43.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-O 121.639 0.733 . . . . 0.0 109.447 -179.53 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.438 ' N ' HG12 ' A' ' 41' ' ' VAL . 62.5 ttm-85 -123.38 -6.84 8.17 Favored 'General case' 0 N--CA 1.498 1.965 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.713 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.54 -163.19 26.52 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 108.563 -1.815 . . . . 0.0 108.563 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.8 t -119.42 128.37 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.278 -1.131 . . . . 0.0 108.684 179.595 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.1 p -85.16 137.35 33.07 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.098 -1.001 . . . . 0.0 108.716 179.523 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.439 ' O ' HG13 ' A' ' 46' ' ' VAL . 13.4 p -130.19 131.83 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 54.7 p -125.88 142.1 51.67 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -141.08 139.15 9.35 Favored Glycine 0 N--CA 1.497 2.731 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.317 -178.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 56.0 t -120.02 119.83 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.559 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -92.72 117.64 30.22 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -90.37 120.33 31.4 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -105.83 139.16 40.82 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.588 -0.695 . . . . 0.0 110.491 -179.049 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.469 ' C ' ' H ' ' A' ' 55' ' ' GLY . 45.0 t-20 -61.29 -14.7 28.52 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -66.48 0.82 1.97 Allowed 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.469 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 79.34 16.02 78.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 179.098 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.7 p -123.19 148.21 46.04 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.382 -1.069 . . . . 0.0 110.264 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 63.9 p -127.24 140.04 52.5 Favored 'General case' 0 N--CA 1.496 1.856 0 CA-C-O 121.648 0.737 . . . . 0.0 109.423 179.534 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.5 t -116.98 147.57 42.18 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 178.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -132.08 119.12 20.55 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.078 -1.014 . . . . 0.0 109.42 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.526 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 51.7 p90 -116.19 120.83 40.24 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.725 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -114.37 145.14 42.19 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 -179.624 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.4 171.35 43.1 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 72.7 t -110.83 126.94 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.458 -1.025 . . . . 0.0 109.966 -179.676 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 89.2 t -93.13 120.19 42.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.232 -0.918 . . . . 0.0 109.669 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 23.3 p -126.57 151.23 72.72 Favored Pre-proline 0 N--CA 1.495 1.811 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.038 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -53.99 -8.65 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 121.449 1.433 . . . . 0.0 111.615 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 70.2 m -111.16 -18.65 12.94 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.476 -0.765 . . . . 0.0 110.243 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 10.3 p -133.91 109.37 11.86 Favored Pre-proline 0 N--CA 1.505 2.321 0 O-C-N 121.106 -0.996 . . . . 0.0 110.799 -179.016 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -86.91 163.58 8.91 Favored 'Trans proline' 0 N--CA 1.497 1.691 0 C-N-CA 122.556 2.171 . . . . 0.0 112.229 178.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 61.6 t -119.05 130.18 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.421 0 O-C-N 121.256 -0.902 . . . . 0.0 109.76 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 64.9 m-20 -100.58 123.63 45.05 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.34 -0.85 . . . . 0.0 110.717 -178.776 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.513 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.6 OUTLIER -90.87 0.59 57.45 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.832 -1.167 . . . . 0.0 108.665 179.051 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 -66.2 50.35 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.287 -0.883 . . . . 0.0 110.072 -179.474 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.513 ' N ' ' O ' ' A' ' 72' ' ' THR . 98.9 mm-40 -55.04 -98.04 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.126 -0.984 . . . . 0.0 109.755 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -103.42 85.46 2.48 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.156 -0.965 . . . . 0.0 109.227 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.452 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 9.5 tp -67.38 -39.73 83.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.54 -0.725 . . . . 0.0 109.914 -179.751 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.452 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 97.6 m-20 -59.61 -40.15 86.55 Favored 'General case' 0 C--N 1.297 -1.716 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 -179.58 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 13.0 ttmm -66.71 -41.33 88.16 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.594 -0.691 . . . . 0.0 109.495 178.401 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.618 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -65.07 -52.3 56.42 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.281 -0.887 . . . . 0.0 110.836 -177.638 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.448 ' ND2' ' O ' ' A' ' 77' ' ' ASN . 0.5 OUTLIER -62.31 -28.17 69.55 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 119.808 -1.807 . . . . 0.0 108.976 179.677 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 81' ' ' LYS . . . . . 0.445 ' N ' HD22 ' A' ' 80' ' ' ASN . 34.6 ttmt -64.6 -51.09 64.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.129 -0.982 . . . . 0.0 110.496 -179.296 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 m -116.42 -22.04 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.274 0 O-C-N 121.353 -0.842 . . . . 0.0 110.72 -179.348 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.618 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 83.44 165.96 39.11 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 179.359 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 28.2 t -108.31 120.45 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -69.79 -55.08 10.82 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.998 -1.064 . . . . 0.0 110.051 -179.364 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -116.84 148.79 40.94 Favored 'General case' 0 N--CA 1.502 2.148 0 CA-C-O 121.863 0.84 . . . . 0.0 111.75 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 66.6 t80 -119.65 133.89 55.45 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 178.411 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 74.7 ttt180 -139.62 121.6 15.64 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.856 -1.152 . . . . 0.0 110.613 -178.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -125.34 137.84 54.05 Favored 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.135 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.0 tp -120.55 130.99 54.46 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 23.1 p -129.24 119.8 24.63 Favored 'General case' 0 N--CA 1.508 2.469 0 CA-C-O 121.817 0.818 . . . . 0.0 111.168 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -132.8 160.5 36.71 Favored 'General case' 0 N--CA 1.504 2.269 0 O-C-N 121.666 -0.647 . . . . 0.0 110.211 179.102 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' TRP . . . . . 0.52 ' CE2' ' HB1' ' A' ' 7' ' ' ALA . 90.2 m95 -69.42 142.98 53.75 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.432 -0.793 . . . . 0.0 110.426 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.404 ' O ' ' N ' ' A' ' 42' ' ' ARG . 41.0 t -115.94 123.42 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 178.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 123.87 3.56 8.29 Favored Glycine 0 N--CA 1.499 2.88 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.4 m -70.04 150.29 46.78 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.335 -1.097 . . . . 0.0 109.104 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 87.1 mtm-85 -89.2 0.12 57.01 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.138 -0.976 . . . . 0.0 109.123 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 13.1 t . . . . . 0 N--CA 1.487 1.395 0 CA-C-O 117.872 -1.061 . . . . 0.0 109.405 -179.648 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.785 0 N-CA-C 119.401 2.521 . . . . 0.0 119.401 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 167.48 130.88 1.21 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.706 -1.357 . . . . 0.0 109.706 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 38.1 m -106.19 138.19 42.81 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.502 -0.999 . . . . 0.0 109.283 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 89.96 -158.82 27.32 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 41.3 t90 -60.0 139.77 57.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.423 -1.045 . . . . 0.0 110.613 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ASN . . . . . 0.538 ' C ' ' H ' ' A' ' 8' ' ' ASP . 33.6 m120 -129.77 136.09 49.21 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.702 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -75.82 25.2 0.12 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.079 -1.013 . . . . 0.0 108.408 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.538 ' H ' ' C ' ' A' ' 6' ' ' ASN . 55.1 t0 -90.34 6.74 41.82 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.654 -0.654 . . . . 0.0 110.715 -178.725 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.43 ' OD1' ' N ' ' A' ' 9' ' ' ASN . 21.5 p-10 -137.83 17.74 2.86 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 120.913 -1.117 . . . . 0.0 109.048 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.453 ' O ' HG23 ' A' ' 10' ' ' VAL . 35.0 m -126.02 129.76 72.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -94.94 142.48 24.69 Favored Pre-proline 0 N--CA 1.494 1.772 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.44 -18.05 23.28 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 121.91 1.74 . . . . 0.0 112.145 -179.686 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 87.9 p -70.13 -30.18 67.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 110.187 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -89.25 -14.98 34.67 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.959 -1.088 . . . . 0.0 109.952 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.506 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 35.7 t -72.44 -27.61 62.43 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.304 -0.872 . . . . 0.0 109.648 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.1 pp -118.21 132.52 67.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.534 -0.729 . . . . 0.0 109.087 -179.459 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -120.05 138.18 53.68 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.369 -0.832 . . . . 0.0 109.094 -179.539 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.424 ' H ' ' HG2' ' A' ' 18' ' ' GLN . 13.3 pt20 -100.02 123.67 44.52 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.566 -0.709 . . . . 0.0 110.409 -178.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t -125.37 83.81 2.21 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.473 -0.767 . . . . 0.0 109.413 179.416 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.49 ' O ' ' N ' ' A' ' 22' ' ' GLN . . . 98.13 73.43 1.11 Allowed Glycine 0 N--CA 1.501 2.981 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.429 ' C ' ' O ' ' A' ' 20' ' ' GLY . 15.2 m 34.47 32.41 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.183 0 O-C-N 121.946 -0.738 . . . . 0.0 110.817 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.49 ' N ' ' O ' ' A' ' 20' ' ' GLY . 14.1 pt20 -130.86 161.02 32.75 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.569 -0.707 . . . . 0.0 109.55 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -124.38 131.49 53.51 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 38.7 p -134.27 152.52 51.86 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.336 -0.853 . . . . 0.0 109.381 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 39.1 t80 -81.79 130.67 35.14 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.514 -0.742 . . . . 0.0 109.256 -179.708 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -81.86 77.41 8.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.917 -1.114 . . . . 0.0 109.93 -179.666 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 54.3 p -79.57 -8.34 59.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.092 -1.005 . . . . 0.0 109.358 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.9 -39.86 96.07 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.414 ' CG2' ' SG ' ' A' ' 32' ' ' CYS . 27.0 m -82.25 138.34 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.046 -1.267 . . . . 0.0 109.305 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 32.6 t -63.2 -34.64 78.08 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.488 -0.758 . . . . 0.0 110.868 -179.255 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.1 t -56.83 -40.04 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.832 -1.168 . . . . 0.0 109.556 -178.629 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.506 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 49.1 m -63.08 -39.89 96.04 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.047 -1.033 . . . . 0.0 110.059 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 96.5 mmm -88.94 -16.8 30.91 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.769 -1.207 . . . . 0.0 110.974 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 50.3 mt-30 -60.23 -42.68 95.74 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 120.616 -1.302 . . . . 0.0 108.984 178.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -80.34 -41.68 11.37 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.0 tp -59.99 -47.08 87.3 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.312 -1.11 . . . . 0.0 109.241 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 45.0 t30 -65.52 -39.86 92.31 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.285 -0.884 . . . . 0.0 110.184 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.5 -31.98 71.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.249 -0.907 . . . . 0.0 109.423 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.74 18.77 46.63 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 -179.343 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.3 tttp -97.56 -9.09 27.65 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 178.461 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.789 HG12 ' H ' ' A' ' 43' ' ' GLY . 97.1 t -134.72 159.87 41.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.038 -0.983 . . . . 0.0 108.665 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.472 ' N ' ' O ' ' A' ' 94' ' ' VAL . 57.9 ttm-85 -125.04 -1.69 7.74 Favored 'General case' 0 N--CA 1.497 1.917 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 179.651 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.789 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 129.65 -163.96 22.59 Favored Glycine 0 N--CA 1.499 2.855 0 N-CA-C 107.719 -2.153 . . . . 0.0 107.719 -179.236 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 47.5 t -120.56 129.79 75.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.124 0 CA-C-N 118.881 1.34 . . . . 0.0 109.486 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 63.6 p -77.43 141.94 39.47 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.456 -0.777 . . . . 0.0 108.959 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.464 HG13 ' O ' ' A' ' 46' ' ' VAL . 9.9 p -127.38 125.32 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 CA-C-O 121.947 0.88 . . . . 0.0 108.727 179.067 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 2.4 p -128.06 146.65 50.61 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -154.66 147.44 16.57 Favored Glycine 0 N--CA 1.494 2.56 0 C-N-CA 118.306 -1.902 . . . . 0.0 111.237 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 53.2 t -126.4 126.28 68.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -100.56 125.82 46.95 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.267 -0.896 . . . . 0.0 108.773 179.468 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -95.28 126.92 40.92 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.493 -0.754 . . . . 0.0 109.965 -178.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.493 ' C ' ' H ' ' A' ' 54' ' ' ASP . 98.2 m-85 -114.02 130.33 56.55 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.543 -0.723 . . . . 0.0 109.918 -179.779 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -53.02 -8.19 0.09 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.507 -0.746 . . . . 0.0 109.328 179.579 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.493 ' H ' ' C ' ' A' ' 52' ' ' TYR . 41.3 t0 -74.44 0.81 13.42 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.773 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.68 14.55 79.63 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.2 p -123.15 147.86 46.36 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 121.487 -1.008 . . . . 0.0 109.788 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 53.0 p -129.68 140.35 51.15 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 85.0 p -107.45 155.88 19.57 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.795 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 30.1 p-10 -146.53 116.07 7.14 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.874 -1.141 . . . . 0.0 109.674 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -118.51 121.82 41.19 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -113.17 153.67 27.91 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -174.82 -177.25 43.78 Favored Glycine 0 C--N 1.282 -2.464 0 C-N-CA 119.337 -1.411 . . . . 0.0 110.847 -179.505 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -119.7 127.36 75.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.971 -0.723 . . . . 0.0 109.375 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.1 t -92.3 120.26 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.199 -0.938 . . . . 0.0 110.519 -179.289 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.7 p -135.76 152.08 75.35 Favored Pre-proline 0 N--CA 1.492 1.639 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.011 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -54.54 -10.18 2.18 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 121.613 1.542 . . . . 0.0 111.687 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.2 t -103.04 -26.97 12.87 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.324 -0.86 . . . . 0.0 111.23 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 78.2 p -133.34 108.87 12.38 Favored Pre-proline 0 N--CA 1.505 2.283 0 O-C-N 120.911 -1.118 . . . . 0.0 110.295 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -85.09 163.18 11.58 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 C-N-CA 122.068 1.845 . . . . 0.0 111.897 178.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.4 t -120.61 127.53 75.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.467 -0.77 . . . . 0.0 109.07 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -105.48 130.22 53.6 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.189 -0.944 . . . . 0.0 111.303 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.468 ' C ' ' H ' ' A' ' 74' ' ' GLN . 0.6 OUTLIER -92.61 4.87 52.79 Favored 'General case' 0 N--CA 1.499 1.983 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 177.703 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 48.2 p-10 -73.3 21.09 0.08 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.731 -0.605 . . . . 0.0 109.78 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.468 ' H ' ' C ' ' A' ' 72' ' ' THR . 73.5 tp60 -42.85 -83.49 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.479 -0.763 . . . . 0.0 110.744 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -113.62 74.38 0.86 Allowed 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.338 -0.851 . . . . 0.0 110.597 -179.457 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 83.1 mt -70.21 -34.26 58.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 120.945 -1.097 . . . . 0.0 109.303 178.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 71.3 m-20 -52.78 -43.25 65.73 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.064 -1.023 . . . . 0.0 108.698 -179.15 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 47.4 tttp -62.82 -46.37 88.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.412 -0.805 . . . . 0.0 109.051 178.717 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.585 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.3 OUTLIER -60.3 -46.7 88.96 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.528 -0.732 . . . . 0.0 110.103 -178.998 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -61.0 -36.75 80.28 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 120.255 -1.528 . . . . 0.0 109.406 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 38.0 tttm -66.38 -50.08 64.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.494 -0.754 . . . . 0.0 110.827 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.9 p -111.42 -26.98 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.544 -0.723 . . . . 0.0 111.805 -176.549 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.585 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.09 161.52 35.42 Favored Glycine 0 N--CA 1.492 2.372 0 O-C-N 120.678 -1.264 . . . . 0.0 110.294 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.459 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 16.5 t -106.99 120.97 59.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.916 -0.755 . . . . 0.0 109.27 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 61.7 tt0 -72.04 -58.2 3.64 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.155 -0.966 . . . . 0.0 110.951 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 32.7 ttmt -114.81 146.39 41.08 Favored 'General case' 0 N--CA 1.509 2.476 0 O-C-N 121.226 -0.921 . . . . 0.0 111.038 -178.629 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -121.59 130.36 53.45 Favored 'General case' 0 N--CA 1.501 2.098 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 21.9 mmm180 -137.29 121.68 18.24 Favored 'General case' 0 N--CA 1.505 2.312 0 O-C-N 120.929 -1.107 . . . . 0.0 109.913 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.24 133.9 53.39 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.632 -0.668 . . . . 0.0 109.387 179.249 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 65.5 tp -117.87 131.46 56.54 Favored 'General case' 0 N--CA 1.5 2.068 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 11.3 p -128.19 124.55 37.07 Favored 'General case' 0 N--CA 1.502 2.139 0 CA-C-O 121.39 0.614 . . . . 0.0 110.334 -179.304 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -132.67 151.13 52.05 Favored 'General case' 0 N--CA 1.505 2.312 0 O-C-N 121.617 -0.677 . . . . 0.0 110.748 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 58.1 m95 -71.2 139.04 50.0 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.31 -0.869 . . . . 0.0 109.007 179.006 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.472 ' O ' ' N ' ' A' ' 42' ' ' ARG . 47.3 t -111.08 119.41 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -151.7 -58.61 0.01 OUTLIER Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.261 -1.535 . . . . 0.0 109.261 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 36.9 t -85.32 126.43 33.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.189 -1.183 . . . . 0.0 109.31 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 23.2 tpt180 -62.54 -40.0 95.39 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.228 -0.92 . . . . 0.0 109.16 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 m . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.958 -1.02 . . . . 0.0 109.455 -179.951 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.767 0 N-CA-C 119.563 2.585 . . . . 0.0 119.563 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.478 ' C ' ' H ' ' A' ' 4' ' ' GLY . . . -69.23 165.25 49.55 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.461 ' CB ' ' O ' ' A' ' 2' ' ' GLY . 1.7 p 74.47 -28.04 0.19 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.342 -1.093 . . . . 0.0 109.393 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.478 ' H ' ' C ' ' A' ' 2' ' ' GLY . . . -95.5 -1.63 62.14 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 88.1 t90 -79.03 118.11 20.72 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.298 -1.119 . . . . 0.0 110.056 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ASN . . . . . 0.516 ' C ' ' H ' ' A' ' 8' ' ' ASP . 96.1 m-20 -128.91 19.48 6.03 Favored 'General case' 0 N--CA 1.495 1.776 0 CA-C-O 121.455 0.645 . . . . 0.0 109.947 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 56.04 3.24 0.09 Allowed 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.46 -0.775 . . . . 0.0 109.521 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.516 ' H ' ' C ' ' A' ' 6' ' ' ASN . 34.0 t0 -88.44 -28.07 21.11 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.33 -0.856 . . . . 0.0 109.566 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 53.5 t30 -89.97 -0.0 57.34 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.522 -0.736 . . . . 0.0 109.556 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.8 t -110.87 129.98 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.569 -0.707 . . . . 0.0 109.868 -178.771 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -89.14 135.07 31.96 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.147 -0.97 . . . . 0.0 108.593 179.288 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -73.37 -14.27 25.33 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 121.695 1.597 . . . . 0.0 111.603 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 23.2 t -60.64 -40.12 90.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.57 179.489 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -82.54 -12.97 57.39 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.989 -1.069 . . . . 0.0 109.865 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.796 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 44.3 t -64.27 -37.81 88.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.049 -1.032 . . . . 0.0 109.268 179.721 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -118.23 148.63 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 20.3 ptmt -130.61 155.07 47.16 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 121.497 -0.752 . . . . 0.0 109.508 -179.078 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -98.95 117.46 33.52 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.414 -0.804 . . . . 0.0 110.521 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.5 t -126.37 85.71 2.42 Favored 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.605 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.81 62.52 1.37 Allowed Glycine 0 N--CA 1.497 2.739 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.9 m 40.01 35.74 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.746 -0.855 . . . . 0.0 110.556 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 80.3 mt-30 -132.32 162.84 30.03 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.61 -0.681 . . . . 0.0 109.401 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 41.8 m-85 -120.03 136.34 54.6 Favored 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 178.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 49.3 p -139.57 149.76 44.24 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.411 -0.806 . . . . 0.0 109.925 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.598 ' CZ ' ' SG ' ' A' ' 32' ' ' CYS . 44.1 t80 -80.47 125.21 29.67 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -84.41 84.2 7.73 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.113 -0.992 . . . . 0.0 110.577 -178.615 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 83.1 p -83.18 -7.0 59.68 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.128 -0.982 . . . . 0.0 109.538 179.321 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.58 -37.76 68.76 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.4 m -85.53 136.46 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.272 -1.134 . . . . 0.0 108.719 179.515 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 82.9 p -69.88 -40.0 75.95 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.322 -0.861 . . . . 0.0 111.442 -178.617 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.511 HG23 ' N ' ' A' ' 32' ' ' CYS . 33.7 m -50.23 -42.75 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.773 -1.204 . . . . 0.0 110.647 -178.084 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.796 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 18.9 t -61.17 -42.0 97.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.875 -1.14 . . . . 0.0 110.111 -179.505 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 18.0 mtp -82.12 -12.73 58.03 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.61 -1.306 . . . . 0.0 110.829 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 12.5 mm100 -60.18 -40.0 88.46 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.629 -1.295 . . . . 0.0 108.387 178.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.92 -50.61 6.3 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 62.6 tp -60.24 -41.31 92.87 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.279 -1.13 . . . . 0.0 109.446 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 43.8 t30 -60.19 -40.05 88.68 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.169 -0.957 . . . . 0.0 109.738 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -74.24 -9.51 58.68 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.156 -0.965 . . . . 0.0 109.999 -179.435 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.65 26.42 67.47 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 179.612 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 45.7 mmtm -100.17 -5.54 27.58 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 178.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.697 HG12 ' H ' ' A' ' 43' ' ' GLY . 55.7 t -133.3 161.01 42.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.476 ' N ' HG12 ' A' ' 41' ' ' VAL . 74.3 ttt180 -122.05 -6.82 8.92 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.564 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.697 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 135.42 -164.95 24.84 Favored Glycine 0 N--CA 1.498 2.785 0 N-CA-C 108.082 -2.007 . . . . 0.0 108.082 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.3 t -120.03 129.41 75.49 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.091 -1.241 . . . . 0.0 109.415 179.593 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.9 t -83.71 135.99 34.35 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.312 -0.868 . . . . 0.0 108.768 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 46' ' ' VAL . 12.0 p -131.45 133.17 62.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 CA-C-O 121.603 0.715 . . . . 0.0 109.813 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.8 p -124.73 151.12 45.45 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 178.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -146.17 147.01 17.68 Favored Glycine 0 N--CA 1.5 2.926 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.803 -179.029 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 75.0 t -129.67 127.18 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.803 -0.822 . . . . 0.0 108.989 179.32 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -102.64 112.88 25.83 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.634 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 23.7 m-85 -81.44 128.57 34.01 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.091 -1.006 . . . . 0.0 109.374 -179.222 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -114.72 134.21 55.27 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.481 -0.762 . . . . 0.0 109.499 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -61.84 -9.34 6.46 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.262 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.442 ' OD2' ' OG1' ' A' ' 56' ' ' THR . 46.1 p-10 -68.05 0.15 3.87 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.326 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 88.27 14.38 62.24 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.442 ' OG1' ' OD2' ' A' ' 54' ' ' ASP . 35.0 p -136.03 156.75 48.27 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.03 -1.277 . . . . 0.0 110.652 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 37.3 p -131.23 132.94 45.0 Favored 'General case' 0 N--CA 1.498 1.937 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 83.7 p -91.59 160.01 15.61 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 6.0 p30 -152.15 115.01 4.62 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.822 -1.174 . . . . 0.0 109.985 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -118.01 127.77 54.13 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 178.618 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 78.7 tttt -115.44 145.71 42.31 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.155 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.71 170.07 42.09 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.2 t -110.56 127.53 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.521 -0.987 . . . . 0.0 109.574 -179.506 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 69.3 t -94.0 118.07 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.086 -1.009 . . . . 0.0 109.491 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.518 ' O ' ' N ' ' A' ' 68' ' ' THR . 12.0 p -125.62 146.25 54.16 Favored Pre-proline 0 N--CA 1.497 1.916 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 178.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_exo -35.9 -27.85 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.344 0 C-N-CA 122.433 2.089 . . . . 0.0 112.884 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.474 ' N ' ' O ' ' A' ' 65' ' ' THR . 5.8 t -106.81 -10.57 16.01 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.433 -0.792 . . . . 0.0 110.528 -179.657 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 65' ' ' THR . 88.7 m -126.33 106.58 24.33 Favored Pre-proline 0 N--CA 1.505 2.31 0 O-C-N 121.04 -1.038 . . . . 0.0 110.981 -179.175 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -90.44 162.48 4.46 Favored 'Trans proline' 0 N--CA 1.487 1.107 0 C-N-CA 122.404 2.069 . . . . 0.0 111.351 177.568 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 78.4 t -119.84 128.06 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.239 0 O-C-N 121.229 -0.92 . . . . 0.0 108.91 179.318 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -101.25 135.15 43.2 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.298 -0.876 . . . . 0.0 110.16 -179.206 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.479 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.1 OUTLIER -106.02 19.68 20.15 Favored 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 178.332 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 6.7 m-20 -64.28 42.88 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.848 -178.628 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.479 ' N ' ' O ' ' A' ' 72' ' ' THR . 25.2 mm100 -51.48 170.27 0.05 OUTLIER 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.106 -0.996 . . . . 0.0 109.114 179.213 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -53.05 114.0 1.3 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.054 -1.029 . . . . 0.0 109.621 -179.242 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 97.5 mt -86.46 -16.06 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.384 -0.823 . . . . 0.0 110.246 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -59.84 -39.66 85.92 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 179.653 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 71.1 mttt -63.0 -50.23 71.57 Favored 'General case' 0 N--CA 1.492 1.634 0 CA-C-O 122.496 1.141 . . . . 0.0 109.551 179.436 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.587 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -59.96 -50.68 72.79 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.515 -177.33 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -61.39 -36.11 79.35 Favored 'General case' 0 C--N 1.292 -1.9 0 O-C-N 120.208 -1.558 . . . . 0.0 109.031 178.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -65.58 -50.27 65.75 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.447 -0.783 . . . . 0.0 111.093 -179.312 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.3 m -115.77 -24.77 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.3 0 O-C-N 121.271 -0.893 . . . . 0.0 111.609 -177.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 91.52 166.55 40.23 Favored Glycine 0 N--CA 1.492 2.413 0 O-C-N 120.71 -1.244 . . . . 0.0 110.068 179.372 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 49.0 t -106.96 128.54 61.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.926 -0.749 . . . . 0.0 109.057 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -79.99 -66.59 0.86 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.945 -1.097 . . . . 0.0 109.838 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 57.4 mttm -116.55 140.85 48.93 Favored 'General case' 0 N--CA 1.504 2.255 0 O-C-N 121.291 -0.881 . . . . 0.0 111.051 -179.263 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 70.5 t80 -121.05 132.75 55.07 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 178.35 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 42.6 mtm105 -136.85 129.97 31.07 Favored 'General case' 0 N--CA 1.504 2.258 0 O-C-N 121.119 -0.988 . . . . 0.0 110.743 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.31 135.47 54.22 Favored 'General case' 0 N--CA 1.499 1.983 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.9 mt -118.51 130.28 55.84 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.427 -0.796 . . . . 0.0 109.599 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 20.1 p -128.61 125.07 37.41 Favored 'General case' 0 N--CA 1.503 2.218 0 CA-C-O 121.677 0.751 . . . . 0.0 110.645 -179.491 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -132.96 154.37 50.53 Favored 'General case' 0 N--CA 1.502 2.159 0 CA-C-O 121.412 0.625 . . . . 0.0 110.638 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 80.2 m95 -69.87 142.08 53.09 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 35.4 t -116.61 120.81 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.133 0 O-C-N 121.332 -0.855 . . . . 0.0 109.202 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 161.03 -140.14 6.48 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 89.1 p -72.27 158.69 35.37 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.076 -1.249 . . . . 0.0 109.407 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.8 mtm180 -64.52 140.01 58.82 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.301 -0.874 . . . . 0.0 109.863 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.3 m . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 117.896 -1.05 . . . . 0.0 109.219 179.586 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.886 0 N-CA-C 119.408 2.523 . . . . 0.0 119.408 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.81 143.6 32.61 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.7 m -99.74 122.83 43.3 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.368 -1.078 . . . . 0.0 109.096 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 136.36 78.67 0.09 OUTLIER Glycine 0 N--CA 1.496 2.641 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 -179.607 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 63.5 t90 -59.63 125.94 25.63 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.332 -1.099 . . . . 0.0 109.173 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 80.7 m-20 -134.91 24.16 3.6 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.765 -0.585 . . . . 0.0 109.662 179.142 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 51.86 36.97 19.49 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -178.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.542 ' N ' ' OD1' ' A' ' 8' ' ' ASP . 11.3 p-10 -47.74 -79.74 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.787 -0.571 . . . . 0.0 111.367 -178.533 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.517 ' H ' ' CG ' ' A' ' 8' ' ' ASP . 13.9 m120 -144.42 37.66 1.24 Allowed 'General case' 0 N--CA 1.497 1.899 0 O-C-N 120.898 -1.126 . . . . 0.0 109.885 -178.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.446 ' H ' HG23 ' A' ' 10' ' ' VAL . 0.2 OUTLIER -81.49 152.55 4.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 120.94 -1.1 . . . . 0.0 108.398 -179.11 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.6 m-20 -78.63 131.5 67.72 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.179 -0.951 . . . . 0.0 109.879 -178.849 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -80.61 -15.08 11.16 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.128 1.885 . . . . 0.0 111.812 179.438 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 94.2 p -64.46 -35.75 81.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.48 -0.763 . . . . 0.0 110.506 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -69.98 -23.7 63.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.162 -0.961 . . . . 0.0 109.812 -179.249 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.552 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 60.8 m -68.26 -27.66 66.54 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.209 -0.932 . . . . 0.0 109.64 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.7 pp -118.49 133.0 66.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.498 -0.751 . . . . 0.0 109.19 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -112.05 142.15 44.84 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.609 ' CD ' ' H ' ' A' ' 18' ' ' GLN . 0.1 OUTLIER -97.55 128.48 44.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.257 -0.902 . . . . 0.0 109.694 -179.411 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.549 ' O ' ' N ' ' A' ' 21' ' ' VAL . 25.3 t -107.4 118.6 37.15 Favored 'General case' 0 N--CA 1.495 1.825 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.42 -78.81 0.01 OUTLIER Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.549 ' N ' ' O ' ' A' ' 19' ' ' SER . 9.8 p -156.7 32.95 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.319 -1.106 . . . . 0.0 108.629 179.268 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.446 HE21 ' HB2' ' A' ' 69' ' ' PRO . 46.3 tt0 -129.22 161.56 29.86 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -115.19 135.06 54.58 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.322 -0.861 . . . . 0.0 109.261 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 23.9 p -135.8 150.01 49.3 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.586 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 35.8 t80 -83.79 122.09 28.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.347 -0.846 . . . . 0.0 109.663 -179.039 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -84.55 83.63 7.94 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.362 -0.837 . . . . 0.0 109.742 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 96.3 p -78.48 -4.91 50.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.231 -0.918 . . . . 0.0 109.091 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -56.68 -39.01 85.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 -179.437 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.445 ' H ' HG22 ' A' ' 29' ' ' VAL . 10.5 m -81.06 133.46 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 120.877 -1.366 . . . . 0.0 109.741 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.5 m -63.33 -34.47 77.77 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.544 -0.723 . . . . 0.0 111.929 -178.726 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.455 HG13 ' N ' ' A' ' 32' ' ' CYS . 7.2 p -59.98 -40.01 81.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 120.608 -1.307 . . . . 0.0 110.796 -177.789 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.552 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 77.6 m -66.25 -40.04 89.92 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.657 -1.277 . . . . 0.0 109.719 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 7.7 mmt -78.69 -19.14 53.15 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.008 -1.058 . . . . 0.0 109.123 179.607 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -60.75 -41.04 94.62 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.216 -0.928 . . . . 0.0 108.958 179.446 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -73.59 -43.61 35.85 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 2.1 mt -65.85 -39.98 91.27 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.254 -1.145 . . . . 0.0 108.94 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.32 -40.03 94.98 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.07 -1.019 . . . . 0.0 109.82 179.05 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -76.63 -10.79 59.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.214 -0.929 . . . . 0.0 110.086 -179.028 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.28 28.49 69.86 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.404 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -103.64 -6.01 22.05 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.784 HG12 ' H ' ' A' ' 43' ' ' GLY . 45.9 t -133.72 159.88 42.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 115.51 -0.768 . . . . 0.0 108.987 -179.251 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.507 ' N ' ' O ' ' A' ' 94' ' ' VAL . 70.3 mtp85 -120.91 -7.71 9.47 Favored 'General case' 0 N--CA 1.5 2.053 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.355 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.784 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.73 -159.85 25.51 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -179.035 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.4 t -120.67 129.74 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.145 0 O-C-N 121.297 -1.12 . . . . 0.0 109.32 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.0 t -86.65 140.02 30.22 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.303 -0.873 . . . . 0.0 108.98 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.443 HG13 ' O ' ' A' ' 46' ' ' VAL . 9.9 p -131.9 132.46 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.74 0.781 . . . . 0.0 109.829 179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 81.9 p -123.29 148.79 45.57 Favored 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -144.64 144.33 13.15 Favored Glycine 0 N--CA 1.5 2.962 0 C-N-CA 119.219 -1.467 . . . . 0.0 111.375 -178.707 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 85.6 t -121.59 130.01 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.545 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.531 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 9.9 m-85 -106.79 119.89 40.53 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.783 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -98.67 120.82 39.76 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.422 -0.799 . . . . 0.0 109.07 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.529 ' O ' ' N ' ' A' ' 54' ' ' ASP . 94.1 m-85 -105.56 131.33 53.09 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.345 -0.847 . . . . 0.0 109.164 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 49.2 t30 -46.6 -15.56 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.245 -0.909 . . . . 0.0 109.166 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 52' ' ' TYR . 35.9 t0 -69.71 -0.81 7.59 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.578 -0.701 . . . . 0.0 109.392 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.4 23.19 65.89 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 120.047 -1.073 . . . . 0.0 110.611 179.135 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.2 p -118.76 150.27 40.06 Favored 'General case' 0 N--CA 1.504 2.256 0 O-C-N 121.297 -1.12 . . . . 0.0 110.046 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 63.9 p -135.27 128.98 32.87 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.501 -0.75 . . . . 0.0 109.783 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 45.9 t -118.7 145.87 45.17 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.636 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 55.9 t-20 -135.8 128.08 30.12 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.753 -1.217 . . . . 0.0 109.796 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -117.15 122.15 43.27 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 178.665 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -107.52 144.5 34.41 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -162.68 170.99 38.4 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.634 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.7 t -113.98 125.39 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.555 -0.967 . . . . 0.0 109.42 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -90.26 117.9 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.368 -0.833 . . . . 0.0 110.232 -179.152 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.517 ' O ' ' N ' ' A' ' 67' ' ' SER . 25.9 p -125.74 144.4 48.2 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.402 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -38.4 -21.29 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.157 1.905 . . . . 0.0 113.276 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 65' ' ' THR . 10.4 m -108.64 -11.37 15.1 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.197 -0.939 . . . . 0.0 111.296 -178.845 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 55.1 p -130.69 107.87 15.63 Favored Pre-proline 0 N--CA 1.504 2.242 0 O-C-N 121.011 -1.056 . . . . 0.0 110.392 -179.201 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.446 ' HB2' HE21 ' A' ' 22' ' ' GLN . 40.6 Cg_endo -91.25 164.42 3.69 Favored 'Trans proline' 0 N--CA 1.49 1.314 0 C-N-CA 122.605 2.203 . . . . 0.0 112.135 178.604 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 48.9 t -124.42 130.15 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.127 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.555 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 69.7 m-80 -100.77 138.19 38.16 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.082 -1.012 . . . . 0.0 110.502 -178.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -98.5 -19.37 17.69 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 121.02 -1.05 . . . . 0.0 109.021 179.17 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 44.4 p-10 -87.41 44.42 1.18 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.038 -1.039 . . . . 0.0 108.442 179.118 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -59.71 -49.18 78.74 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.519 -0.872 . . . . 0.0 108.741 -179.334 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -115.17 75.8 0.96 Allowed 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 107.845 -1.168 . . . . 0.0 107.845 178.213 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 10.4 tt -73.33 -28.64 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.28 -0.887 . . . . 0.0 110.116 -178.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -60.06 -49.66 76.79 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.61 -178.067 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.414 ' CG ' ' N ' ' A' ' 79' ' ' THR . 0.1 OUTLIER -61.08 -39.94 91.82 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.569 -1.332 . . . . 0.0 108.34 179.353 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.586 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.4 m -60.04 -43.96 94.99 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.397 0.618 . . . . 0.0 109.772 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -61.63 -38.5 87.89 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 120.596 -1.315 . . . . 0.0 109.987 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.4 ttmm -70.04 -44.85 68.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.139 -0.976 . . . . 0.0 111.224 -179.266 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.1 p -112.08 -28.75 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.075 0 O-C-N 121.311 -0.868 . . . . 0.0 112.098 -176.748 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.586 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.69 161.43 33.52 Favored Glycine 0 N--CA 1.491 2.339 0 O-C-N 120.66 -1.275 . . . . 0.0 110.177 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 90.0 t -109.51 124.85 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.14 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -80.05 -58.62 3.07 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.247 -0.908 . . . . 0.0 110.952 -178.813 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 35.4 ttpt -114.11 137.59 51.53 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.267 -0.895 . . . . 0.0 110.809 -178.747 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 54.9 t80 -123.78 125.89 45.5 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.129 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 76.0 mmt-85 -130.98 132.01 44.76 Favored 'General case' 0 N--CA 1.506 2.336 0 O-C-N 121.137 -0.977 . . . . 0.0 110.525 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -121.26 138.09 54.39 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 179.568 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.671 HD23 ' N ' ' A' ' 91' ' ' THR . 1.6 tt -119.95 131.17 55.1 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.648 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.671 ' N ' HD23 ' A' ' 90' ' ' LEU . 22.1 p -126.59 126.3 43.39 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.507 -0.745 . . . . 0.0 110.706 -179.243 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 -133.5 154.57 50.71 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.855 -0.528 . . . . 0.0 109.793 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -67.58 139.4 56.9 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.163 -0.961 . . . . 0.0 109.051 179.448 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.507 ' O ' ' N ' ' A' ' 42' ' ' ARG . 41.4 t -111.84 121.29 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.323 -0.861 . . . . 0.0 109.013 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 136.03 22.24 0.59 Allowed Glycine 0 N--CA 1.497 2.739 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 179.461 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 42.7 t -81.71 128.32 33.85 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.105 -1.232 . . . . 0.0 109.279 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 93.9 mtt-85 -76.74 145.17 38.79 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.206 -0.934 . . . . 0.0 109.596 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.3 t . . . . . 0 N--CA 1.489 1.506 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.422 -179.805 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.881 0 N-CA-C 119.6 2.6 . . . . 0.0 119.6 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 69.72 -119.3 8.97 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 85.3 p 49.76 49.68 19.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.375 -1.073 . . . . 0.0 109.989 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 94.93 31.15 7.87 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 179.371 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' TRP . . . . . 0.654 ' CE3' ' NE2' ' A' ' 34' ' ' GLN . 10.0 t90 -66.05 143.26 57.45 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.868 -1.372 . . . . 0.0 109.366 179.204 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ASN . . . . . 0.509 ' C ' ' H ' ' A' ' 8' ' ' ASP . 36.0 p-10 -131.65 126.82 35.61 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.073 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -61.13 -2.05 0.56 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.967 -1.083 . . . . 0.0 108.464 179.655 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.509 ' H ' ' C ' ' A' ' 6' ' ' ASN . 66.2 t0 -69.87 -39.84 76.09 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.681 -0.637 . . . . 0.0 110.761 -179.223 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 32.7 m120 -84.38 3.56 35.37 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.004 -1.06 . . . . 0.0 110.4 -178.312 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.0 t -116.31 129.8 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.347 -0.846 . . . . 0.0 109.129 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 -84.68 138.3 38.11 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.016 -1.053 . . . . 0.0 109.212 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -76.63 -24.74 10.07 Favored 'Trans proline' 0 N--CA 1.494 1.531 0 C-N-CA 121.938 1.758 . . . . 0.0 111.673 179.314 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 55.4 m -60.26 -39.89 88.38 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.304 -0.872 . . . . 0.0 110.566 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.7 mt-30 -77.89 -19.82 54.06 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.182 -0.949 . . . . 0.0 110.287 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.637 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 49.6 m -65.66 -29.61 70.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.005 -1.06 . . . . 0.0 109.685 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -118.6 139.64 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.132 0 O-C-N 121.427 -0.796 . . . . 0.0 109.272 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -124.31 144.25 50.1 Favored 'General case' 0 N--CA 1.498 1.955 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 -179.731 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 64.8 tt0 -96.74 124.37 40.7 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.212 -0.93 . . . . 0.0 109.676 -179.44 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.497 ' O ' ' N ' ' A' ' 21' ' ' VAL . 70.3 m -109.52 129.95 55.54 Favored 'General case' 0 N--CA 1.498 1.967 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.36 -94.06 0.01 OUTLIER Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.497 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.8 t -137.17 28.84 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 121.427 -1.043 . . . . 0.0 109.319 -179.386 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 90.7 mt-30 -131.38 163.15 28.53 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.577 -0.702 . . . . 0.0 110.359 -179.571 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -118.76 139.94 50.75 Favored 'General case' 0 N--CA 1.503 2.183 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 70.9 p -139.82 157.01 46.43 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.272 -0.893 . . . . 0.0 109.651 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -89.65 121.69 32.07 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.539 -0.726 . . . . 0.0 109.103 -179.244 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 -82.47 86.09 6.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.129 -0.982 . . . . 0.0 110.105 -179.368 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.48 ' C ' ' H ' ' A' ' 29' ' ' VAL . 92.1 p -81.58 -7.04 59.54 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.243 -0.91 . . . . 0.0 109.38 179.391 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.66 -8.22 0.34 Allowed Glycine 0 N--CA 1.489 2.196 0 N-CA-C 110.162 -1.175 . . . . 0.0 110.162 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.48 ' H ' ' C ' ' A' ' 27' ' ' SER . 20.4 m -113.31 132.44 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.409 -1.054 . . . . 0.0 108.992 179.529 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.8 m -69.87 -30.07 67.45 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.426 -0.796 . . . . 0.0 111.107 -178.814 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.493 HG23 ' N ' ' A' ' 32' ' ' CYS . 18.0 m -60.16 -40.34 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 120.672 -1.268 . . . . 0.0 110.583 -178.57 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.637 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 96.5 m -65.81 -40.02 91.47 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.83 -1.169 . . . . 0.0 110.01 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 35.3 mtp -84.37 -11.92 55.42 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.901 -1.125 . . . . 0.0 109.303 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.654 ' NE2' ' CE3' ' A' ' 5' ' ' TRP . 1.3 tm0? -61.66 -42.19 98.57 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.8 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.83 -42.68 24.97 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 179.16 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.5 tp -60.2 -41.23 92.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.276 -1.132 . . . . 0.0 108.96 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -62.61 -40.68 97.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.306 -0.871 . . . . 0.0 109.815 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -63.07 -28.27 69.97 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.342 -0.849 . . . . 0.0 109.873 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.69 17.96 57.4 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 92.4 mttt -100.84 -1.54 34.5 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.742 HG12 ' H ' ' A' ' 43' ' ' GLY . 97.4 t -132.3 157.75 43.14 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 115.189 -0.914 . . . . 0.0 108.713 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.431 ' N ' HG12 ' A' ' 41' ' ' VAL . 98.4 mtt180 -119.99 -7.62 9.9 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 179.149 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.742 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 135.7 -160.08 24.41 Favored Glycine 0 N--CA 1.5 2.934 0 N-CA-C 108.22 -1.952 . . . . 0.0 108.22 -179.564 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.1 t -119.98 128.03 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.16 -1.2 . . . . 0.0 108.795 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.5 p -82.56 139.64 33.72 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.147 -0.971 . . . . 0.0 108.924 179.738 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.485 HG13 ' O ' ' A' ' 46' ' ' VAL . 12.7 p -120.05 127.62 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 CA-C-O 121.827 0.822 . . . . 0.0 108.878 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.0 p -128.06 149.86 50.2 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -168.92 159.44 32.53 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 117.922 -2.085 . . . . 0.0 111.682 -179.643 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 89.2 t -131.32 136.84 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.943 -0.739 . . . . 0.0 109.133 179.255 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.494 ' CZ ' ' OG1' ' A' ' 72' ' ' THR . 55.7 m-85 -108.18 123.71 49.16 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.006 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -95.91 126.51 41.21 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 120.735 -1.228 . . . . 0.0 109.751 -179.013 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.487 ' C ' ' N ' ' A' ' 54' ' ' ASP . 78.2 m-85 -112.0 129.79 56.08 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.453 -0.779 . . . . 0.0 109.913 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 31.9 t-20 -52.89 -10.83 0.18 Allowed 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 178.459 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.487 ' N ' ' C ' ' A' ' 52' ' ' TYR . 9.3 t70 -67.07 -2.68 5.82 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.56 19.0 60.89 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.114 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.4 p -133.46 152.07 51.86 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.022 -1.281 . . . . 0.0 110.812 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 68.9 p -130.33 142.39 50.53 Favored 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.419 0.628 . . . . 0.0 109.859 -179.476 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -117.55 140.83 49.1 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 178.681 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -125.28 116.24 21.63 Favored 'General case' 0 N--CA 1.496 1.839 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -117.49 121.04 39.93 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -113.22 149.8 33.23 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 179.502 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.2 -175.99 38.88 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.317 -1.421 . . . . 0.0 110.844 -179.53 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 66.8 t -122.49 127.82 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.915 -0.756 . . . . 0.0 109.944 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 21.8 t -99.3 118.61 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.365 -0.834 . . . . 0.0 110.256 -179.267 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.413 ' O ' ' N ' ' A' ' 67' ' ' SER . 29.9 p -118.89 149.83 47.4 Favored Pre-proline 0 N--CA 1.494 1.732 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.304 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -38.51 -28.02 0.12 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 121.845 1.697 . . . . 0.0 113.013 -179.552 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.413 ' N ' ' O ' ' A' ' 65' ' ' THR . 53.5 m -108.58 -3.58 17.89 Favored 'General case' 0 N--CA 1.503 2.225 0 O-C-N 121.345 -0.847 . . . . 0.0 111.677 -178.767 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 7.5 m -124.76 106.57 29.26 Favored Pre-proline 0 N--CA 1.508 2.452 0 O-C-N 120.84 -1.163 . . . . 0.0 111.008 -179.036 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -92.61 164.76 2.83 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 122.818 2.345 . . . . 0.0 111.562 177.765 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.8 t -119.88 130.04 74.69 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.19 0 O-C-N 121.261 -0.899 . . . . 0.0 108.802 179.62 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -99.91 121.7 41.72 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.304 -0.872 . . . . 0.0 109.997 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.494 ' OG1' ' CZ ' ' A' ' 50' ' ' PHE . 0.2 OUTLIER -100.45 5.45 44.22 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.075 -1.016 . . . . 0.0 108.855 179.41 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.422 ' O ' ' O ' ' A' ' 74' ' ' GLN . 47.9 p-10 -73.42 46.52 0.2 Allowed 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.323 -0.861 . . . . 0.0 109.649 -179.379 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.422 ' O ' ' O ' ' A' ' 73' ' ' ASN . 65.4 tt0 -47.72 -91.9 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.132 -0.98 . . . . 0.0 109.208 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -113.78 104.49 12.25 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.481 -0.762 . . . . 0.0 109.762 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 77.6 mt -80.07 -27.02 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 120.951 -1.093 . . . . 0.0 108.765 179.084 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.44 ' HA ' HD21 ' A' ' 80' ' ' ASN . 27.0 t-20 -59.71 -40.0 86.5 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.559 ' O ' HG22 ' A' ' 82' ' ' VAL . 18.5 ttmm -69.59 -48.55 59.78 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.209 -0.932 . . . . 0.0 108.791 177.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.61 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.5 OUTLIER -61.84 -51.15 69.43 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.805 -1.184 . . . . 0.0 110.801 -178.551 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 81' ' ' LYS . 29.6 p30 -66.25 -27.11 67.7 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 119.656 -1.902 . . . . 0.0 108.925 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' LYS . . . . . 0.52 ' N ' ' OD1' ' A' ' 80' ' ' ASN . 37.4 tptt -69.94 -49.05 55.65 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.348 -0.845 . . . . 0.0 110.431 179.366 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 78' ' ' LYS . 2.5 m -114.73 -26.04 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.351 0 O-C-N 121.039 -1.038 . . . . 0.0 110.859 -178.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.61 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.87 161.28 36.01 Favored Glycine 0 N--CA 1.493 2.46 0 O-C-N 120.712 -1.243 . . . . 0.0 110.41 179.097 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -100.92 117.52 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -74.75 -59.28 2.8 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.115 -0.991 . . . . 0.0 111.613 -178.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 54.3 mttp -114.29 135.41 54.1 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.33 -0.856 . . . . 0.0 110.983 -177.82 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 61.2 t80 -122.7 131.81 53.97 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.562 -0.711 . . . . 0.0 109.599 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -139.18 130.76 27.25 Favored 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.214 -0.929 . . . . 0.0 110.576 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -126.95 133.68 50.57 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.617 -0.677 . . . . 0.0 110.309 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 64.9 tp -120.05 131.29 55.05 Favored 'General case' 0 N--CA 1.503 2.181 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.409 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -130.48 131.13 44.99 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.528 -0.732 . . . . 0.0 111.181 -179.308 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.466 ' N ' ' CD ' ' A' ' 92' ' ' GLU . 4.6 pm0 -134.22 153.49 51.82 Favored 'General case' 0 N--CA 1.505 2.289 0 CA-C-O 121.35 0.595 . . . . 0.0 110.512 179.101 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 36.7 m95 -70.0 138.97 52.66 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.7 t -110.23 119.81 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.442 -0.787 . . . . 0.0 108.891 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -177.95 -173.26 43.23 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 60.7 p -70.09 150.05 46.98 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.06 -1.259 . . . . 0.0 108.968 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 13.7 tpt180 -86.2 129.9 34.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.007 -1.058 . . . . 0.0 109.064 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.9 p . . . . . 0 N--CA 1.494 1.735 0 CA-C-O 118.026 -0.987 . . . . 0.0 109.183 179.993 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.924 0 N-CA-C 119.539 2.576 . . . . 0.0 119.539 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -84.63 -1.77 89.02 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.4 t -79.99 138.08 36.97 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.267 -1.137 . . . . 0.0 109.443 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 128.48 -128.04 5.82 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 -179.759 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 88.1 t90 -66.41 120.57 13.56 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.271 -1.135 . . . . 0.0 109.548 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 24.6 p-10 -132.45 24.84 4.45 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.092 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 51.63 40.07 26.45 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.318 -0.864 . . . . 0.0 108.678 -179.53 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -57.61 -72.04 0.09 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.677 -0.64 . . . . 0.0 110.892 -178.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.4 p-10 -147.38 42.33 1.08 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.051 -1.031 . . . . 0.0 108.22 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.401 HG23 ' HE1' ' A' ' 93' ' ' TRP . 10.3 m -80.5 139.95 17.4 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 O-C-N 121.463 -0.773 . . . . 0.0 109.301 -178.191 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -70.69 126.35 92.19 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.436 -0.79 . . . . 0.0 110.297 -178.442 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -82.91 -17.36 7.0 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.402 2.068 . . . . 0.0 111.53 178.764 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 57.3 m -60.04 -39.64 86.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.504 -0.747 . . . . 0.0 110.112 -179.427 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.3 mm-40 -65.98 -23.91 66.68 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.106 -0.997 . . . . 0.0 109.468 -179.386 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.615 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 36.0 t -65.26 -34.92 79.49 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.282 -0.886 . . . . 0.0 110.208 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -119.93 146.51 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.337 -0.852 . . . . 0.0 109.701 -179.364 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 53.4 mtmt -126.47 157.99 37.21 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 121.531 -0.73 . . . . 0.0 109.252 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -100.22 113.41 26.07 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.123 -0.986 . . . . 0.0 109.876 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.2 m -125.37 121.34 33.64 Favored 'General case' 0 N--CA 1.5 2.032 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.43 ' O ' ' N ' ' A' ' 22' ' ' GLN . . . 57.56 64.34 4.46 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' A' ' 20' ' ' GLY . 35.0 m 37.03 31.47 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.866 -0.785 . . . . 0.0 110.94 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.43 ' N ' ' O ' ' A' ' 20' ' ' GLY . 84.0 mt-30 -131.67 160.0 36.7 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.637 -0.664 . . . . 0.0 109.292 179.484 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 52.3 m-85 -119.32 140.09 50.88 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.074 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 33.7 p -135.14 148.09 49.65 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.525 -0.734 . . . . 0.0 109.314 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -84.24 120.02 25.73 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -86.23 105.85 16.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.096 -1.002 . . . . 0.0 110.516 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 79.3 p -90.78 -0.11 57.61 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.579 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -66.24 -9.75 49.93 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.416 HG23 ' SG ' ' A' ' 32' ' ' CYS . 0.2 OUTLIER -103.78 124.72 58.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 179.138 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 44.1 t -59.94 -40.13 87.93 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.364 -0.835 . . . . 0.0 111.828 -178.153 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 p -53.51 -34.96 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.751 -1.218 . . . . 0.0 110.143 -178.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.615 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 22.1 m -61.31 -44.74 96.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.996 -1.065 . . . . 0.0 110.82 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.0 mmt -77.21 -23.48 51.39 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.838 -1.164 . . . . 0.0 110.857 -179.324 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -60.07 -39.99 87.94 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.708 -1.245 . . . . 0.0 109.748 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -74.84 -46.85 15.92 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.5 mt -66.26 -39.4 89.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.451 -1.029 . . . . 0.0 109.553 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -60.13 -39.95 88.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.262 -0.899 . . . . 0.0 110.147 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -81.5 -7.76 59.63 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.109 -0.994 . . . . 0.0 110.792 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.4 28.13 70.26 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 32.1 mmtp -101.05 -7.43 23.24 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 178.529 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.791 HG12 ' H ' ' A' ' 43' ' ' GLY . 41.6 t -131.93 156.98 43.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 84.3 mtp180 -118.33 -6.5 10.79 Favored 'General case' 0 N--CA 1.5 2.052 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 179.521 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.791 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 137.19 -156.37 23.34 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 108.084 -2.006 . . . . 0.0 108.084 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.3 t -124.69 129.45 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 CA-C-N 118.644 1.222 . . . . 0.0 109.642 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.4 m -84.43 132.87 34.52 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.028 -1.045 . . . . 0.0 108.342 179.05 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.455 HG13 ' O ' ' A' ' 46' ' ' VAL . 15.0 p -130.04 131.6 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.555 -0.715 . . . . 0.0 109.435 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 54.4 p -122.86 144.71 49.02 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.237 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -135.12 137.22 9.06 Favored Glycine 0 N--CA 1.5 2.958 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.526 HG22 ' ND2' ' A' ' 59' ' ' ASN . 96.4 t -123.41 130.56 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.694 -0.886 . . . . 0.0 109.321 179.402 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -102.82 122.47 44.58 Favored 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -98.2 127.87 44.37 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.367 -0.833 . . . . 0.0 109.149 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.522 ' O ' ' N ' ' A' ' 54' ' ' ASP . 93.1 m-85 -113.04 128.12 56.41 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.525 -0.735 . . . . 0.0 109.364 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.51 ' OD1' ' N ' ' A' ' 53' ' ' ASN . 0.8 OUTLIER -42.95 -19.83 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.528 -0.732 . . . . 0.0 109.786 179.796 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 52' ' ' TYR . 8.6 t70 -67.97 0.79 3.16 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.473 -0.767 . . . . 0.0 109.395 -179.08 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.72 23.35 67.35 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.554 179.011 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.5 p -119.98 146.35 45.92 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.364 -1.08 . . . . 0.0 109.617 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 38.8 p -130.89 140.01 50.17 Favored 'General case' 0 N--CA 1.497 1.884 0 CA-C-O 121.571 0.7 . . . . 0.0 109.998 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 46.4 t -118.65 140.15 50.37 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 178.324 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ASN . . . . . 0.526 ' ND2' HG22 ' A' ' 49' ' ' VAL . 2.1 m120 -129.99 118.66 21.95 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 120.973 -1.079 . . . . 0.0 109.756 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -115.55 125.46 53.02 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 178.77 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -113.08 148.93 34.23 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.5 166.24 39.43 Favored Glycine 0 C--N 1.288 -2.095 0 N-CA-C 108.839 -1.704 . . . . 0.0 108.839 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.0 t -109.08 125.38 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.506 -0.997 . . . . 0.0 108.815 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.506 HG13 ' O ' ' A' ' 64' ' ' VAL . 3.4 p -94.35 121.8 45.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.41 -0.806 . . . . 0.0 109.984 -179.411 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.415 ' O ' ' N ' ' A' ' 68' ' ' THR . 8.2 p -127.75 149.97 71.94 Favored Pre-proline 0 N--CA 1.499 1.989 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.403 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -34.87 -38.55 0.16 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.52 2.147 . . . . 0.0 113.353 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.9 t -99.02 -6.52 28.39 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.039 -1.038 . . . . 0.0 111.026 -179.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.415 ' N ' ' O ' ' A' ' 65' ' ' THR . 34.7 m -128.07 106.89 19.93 Favored Pre-proline 0 N--CA 1.505 2.291 0 O-C-N 121.005 -1.059 . . . . 0.0 110.509 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -90.79 163.25 4.09 Favored 'Trans proline' 0 N--CA 1.488 1.201 0 C-N-CA 122.507 2.138 . . . . 0.0 111.624 178.171 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 58.6 t -120.43 130.13 74.78 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.297 0 O-C-N 121.275 -0.89 . . . . 0.0 108.783 179.587 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -101.33 127.78 47.8 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.126 -0.983 . . . . 0.0 111.495 -178.477 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.91 11.15 30.52 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 177.819 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.415 ' O ' ' O ' ' A' ' 74' ' ' GLN . 45.6 p-10 -77.97 57.88 1.84 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.514 -0.741 . . . . 0.0 110.214 -178.871 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.415 ' O ' ' O ' ' A' ' 73' ' ' ASN . 87.0 mt-30 -60.91 -158.84 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.048 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -63.68 102.13 0.42 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.722 -1.236 . . . . 0.0 108.717 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 96.8 mt -79.93 -18.1 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.422 -0.799 . . . . 0.0 110.398 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 -59.99 -40.68 90.0 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.883 -1.136 . . . . 0.0 108.413 -179.618 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 4.1 mtpm? -62.42 -47.93 81.94 Favored 'General case' 0 N--CA 1.495 1.786 0 CA-C-O 122.419 1.104 . . . . 0.0 108.78 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.583 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -60.04 -42.93 95.48 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.078 -0.964 . . . . 0.0 109.592 -178.284 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -62.55 -36.99 84.4 Favored 'General case' 0 C--N 1.293 -1.879 0 O-C-N 120.494 -1.379 . . . . 0.0 108.899 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 53.9 tttt -72.01 -44.49 63.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.091 -1.006 . . . . 0.0 111.107 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.3 p -112.88 -28.18 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.341 -0.85 . . . . 0.0 111.972 -176.61 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.77 165.25 40.68 Favored Glycine 0 N--CA 1.493 2.5 0 O-C-N 120.519 -1.363 . . . . 0.0 110.893 178.545 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.424 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 30.0 t -110.26 124.32 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.064 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 28.1 mt-30 -80.99 -65.17 1.05 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.004 -1.06 . . . . 0.0 110.121 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -114.77 139.94 49.31 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.363 -0.836 . . . . 0.0 110.899 -179.173 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 62.8 t80 -121.38 127.63 51.4 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.161 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -132.06 131.27 42.28 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 120.994 -1.066 . . . . 0.0 110.664 -179.424 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.485 ' C ' HD12 ' A' ' 90' ' ' LEU . . . -122.09 131.02 53.76 Favored 'General case' 0 N--CA 1.501 2.12 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 179.229 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.543 HD12 ' N ' ' A' ' 90' ' ' LEU . 8.7 mp -111.02 130.92 55.44 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.38 -0.825 . . . . 0.0 109.315 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.8 p -124.41 124.08 41.55 Favored 'General case' 0 N--CA 1.506 2.36 0 O-C-N 121.392 -0.817 . . . . 0.0 110.675 -179.625 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 -134.0 146.63 50.6 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.791 -0.568 . . . . 0.0 109.779 179.567 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' TRP . . . . . 0.401 ' HE1' HG23 ' A' ' 10' ' ' VAL . 87.8 m95 -69.17 139.61 54.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.733 -1.229 . . . . 0.0 108.587 178.649 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 44.7 t -108.86 119.62 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.025 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.749 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 163.09 -172.83 39.19 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 108.345 -1.902 . . . . 0.0 108.345 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 28.0 m -70.19 147.18 50.13 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.965 -1.315 . . . . 0.0 109.93 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 74.9 mtp180 -92.4 -9.99 39.69 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.218 -0.926 . . . . 0.0 109.828 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.8 t . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 117.904 -1.046 . . . . 0.0 109.445 -179.581 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.772 0 N-CA-C 119.629 2.612 . . . . 0.0 119.629 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -173.13 -152.29 8.65 Favored Glycine 0 N--CA 1.486 2.011 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 77.8 p -81.28 -0.47 41.01 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.327 -1.102 . . . . 0.0 108.648 179.57 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.54 23.14 73.9 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.104 -1.598 . . . . 0.0 109.104 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' TRP . . . . . 0.443 ' HE1' HG21 ' A' ' 10' ' ' VAL . 4.9 t90 -61.79 134.77 57.14 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.207 -1.172 . . . . 0.0 109.995 -179.633 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ASN . . . . . 0.497 ' C ' ' H ' ' A' ' 8' ' ' ASP . 57.0 t-20 -130.71 130.27 43.62 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 177.342 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.1 -3.95 0.29 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.204 -0.935 . . . . 0.0 109.544 -179.356 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.497 ' H ' ' C ' ' A' ' 6' ' ' ASN . 92.9 m-20 -72.14 -36.91 69.49 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.302 -0.874 . . . . 0.0 110.51 -179.173 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -81.76 -0.91 45.23 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.922 -1.111 . . . . 0.0 109.784 -179.398 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.443 HG21 ' HE1' ' A' ' 5' ' ' TRP . 3.9 t -100.34 140.24 19.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.241 -0.912 . . . . 0.0 109.212 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -102.04 106.44 47.75 Favored Pre-proline 0 N--CA 1.492 1.653 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.827 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -49.17 -14.42 0.49 Allowed 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 121.86 1.707 . . . . 0.0 112.066 -179.274 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.1 t -63.44 -38.51 91.43 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.465 -0.772 . . . . 0.0 110.083 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -85.22 -12.58 52.25 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.313 -0.867 . . . . 0.0 110.367 -178.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 39.2 t -68.88 -34.5 75.53 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.654 -1.279 . . . . 0.0 109.867 -179.542 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -119.82 145.43 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 11.4 ptmm? -131.57 152.58 50.67 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.226 -0.921 . . . . 0.0 108.96 -179.624 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 14.0 tt0 -98.49 131.83 44.42 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.149 -0.969 . . . . 0.0 109.824 -179.591 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 29.3 t -117.71 120.07 36.87 Favored 'General case' 0 N--CA 1.496 1.871 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 178.51 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.64 -119.03 7.74 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 108.375 -1.89 . . . . 0.0 108.375 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.5 m -110.75 27.57 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.374 -1.074 . . . . 0.0 108.731 179.326 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -128.99 155.72 44.93 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.572 -0.705 . . . . 0.0 110.244 -178.467 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 38.3 m-85 -118.41 138.56 52.36 Favored 'General case' 0 N--CA 1.498 1.966 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 73.3 p -138.64 153.15 48.58 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.227 -0.921 . . . . 0.0 109.359 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.569 ' CZ ' ' SG ' ' A' ' 15' ' ' CYS . 30.1 t80 -80.72 125.2 29.76 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -86.52 88.68 7.7 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.232 -0.918 . . . . 0.0 110.681 -178.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.444 ' C ' ' H ' ' A' ' 29' ' ' VAL . 7.7 m -79.66 -8.9 59.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.952 -1.093 . . . . 0.0 108.631 178.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.53 -8.12 0.78 Allowed Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.444 ' H ' ' C ' ' A' ' 27' ' ' SER . 0.1 OUTLIER -107.51 122.7 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.954 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 178.793 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 59.8 p -63.67 -37.29 86.78 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.655 -0.653 . . . . 0.0 111.613 -178.171 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.8 m -57.65 -36.93 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 120.841 -1.162 . . . . 0.0 110.622 -178.174 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 27.1 m -61.7 -42.08 98.46 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.805 -1.185 . . . . 0.0 110.461 -179.349 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 14.6 mmt -73.91 -20.63 60.33 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.965 -1.085 . . . . 0.0 110.685 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 79.6 mm-40 -60.16 -41.86 93.69 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.739 -1.226 . . . . 0.0 110.027 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.79 -47.02 8.98 Favored Glycine 0 N--CA 1.491 2.328 0 C-N-CA 119.166 -1.493 . . . . 0.0 109.872 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 20.9 tp -62.92 -43.45 98.77 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.496 -1.002 . . . . 0.0 110.822 -178.766 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 -61.97 -39.7 93.07 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.975 -1.078 . . . . 0.0 110.304 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.481 ' HB3' ' HZ3' ' A' ' 40' ' ' LYS . 77.9 mm-40 -74.95 -8.11 55.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.231 -0.918 . . . . 0.0 110.438 -178.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 73.45 24.83 74.17 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.481 ' HZ3' ' HB3' ' A' ' 38' ' ' GLU . 59.6 mttp -97.86 -6.61 32.1 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 178.129 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.764 HG12 ' H ' ' A' ' 43' ' ' GLY . 93.6 t -135.65 159.92 39.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.64 -179.835 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.441 ' N ' HG12 ' A' ' 41' ' ' VAL . 52.7 ttt85 -118.61 -8.47 10.42 Favored 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.526 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.764 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.34 -161.46 25.66 Favored Glycine 0 N--CA 1.502 3.081 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 90.8 t -120.62 127.23 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.023 -1.281 . . . . 0.0 109.529 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.1 m -85.29 138.28 32.42 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 10.3 m -132.32 134.29 59.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.374 -0.829 . . . . 0.0 110.148 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 51.7 p -125.33 147.8 48.99 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.514 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -151.7 142.23 9.27 Favored Glycine 0 N--CA 1.496 2.644 0 C-N-CA 118.996 -1.573 . . . . 0.0 110.836 -178.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 78.5 t -125.13 130.13 73.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -104.52 122.01 44.67 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.451 -0.781 . . . . 0.0 108.914 -179.285 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 36.0 m-85 -92.37 125.86 37.21 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.258 -0.901 . . . . 0.0 110.488 -178.677 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.519 ' HE1' ' HG1' ' A' ' 79' ' ' THR . 97.9 m-85 -109.22 135.54 50.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.454 -0.779 . . . . 0.0 109.941 179.76 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 25.6 m120 -60.83 -13.86 18.16 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 179.041 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 11.3 t70 -68.72 0.68 3.97 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.87 15.41 72.89 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 179.059 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.2 p -119.18 152.71 36.12 Favored 'General case' 0 N--CA 1.51 2.531 0 O-C-N 121.367 -1.078 . . . . 0.0 111.153 -179.305 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 39.3 p -131.83 141.53 49.46 Favored 'General case' 0 N--CA 1.499 1.993 0 CA-C-O 121.433 0.635 . . . . 0.0 109.509 179.298 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 35.7 t -118.0 141.58 48.31 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 178.458 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -132.4 116.62 17.06 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.123 -0.986 . . . . 0.0 109.312 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.539 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 42.2 p90 -116.38 122.65 45.47 Favored 'General case' 0 N--CA 1.496 1.865 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.613 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -115.76 143.73 44.97 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.01 178.19 42.4 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.3 t -116.56 128.95 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 O-C-N 121.46 -1.023 . . . . 0.0 109.929 -179.458 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.0 t -95.81 112.0 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.151 -0.968 . . . . 0.0 109.922 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.571 ' O ' ' N ' ' A' ' 67' ' ' SER . 2.3 p -136.63 151.5 72.85 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 178.691 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_exo -41.14 -15.14 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.437 0 C-N-CA 121.704 1.603 . . . . 0.0 112.24 179.108 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.571 ' N ' ' O ' ' A' ' 65' ' ' THR . 67.3 p -61.53 -54.15 46.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.875 -1.141 . . . . 0.0 109.955 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -157.78 148.76 16.39 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 120.865 -1.147 . . . . 0.0 110.109 -179.649 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -82.55 163.53 16.68 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 122.23 1.953 . . . . 0.0 111.413 178.194 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 99.6 t -111.25 131.1 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.128 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ASN . . . . . 0.468 ' O ' ' OD1' ' A' ' 71' ' ' ASN . 22.8 p30 -100.91 138.26 38.19 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.471 -0.768 . . . . 0.0 111.671 -177.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.54 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.1 OUTLIER -100.0 1.72 42.78 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 177.907 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 40.9 t-20 -66.96 52.74 0.05 OUTLIER 'General case' 0 N--CA 1.488 1.461 0 CA-C-O 121.631 0.729 . . . . 0.0 109.345 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.54 ' N ' ' O ' ' A' ' 72' ' ' THR . 77.2 mt-30 -64.82 -90.37 0.01 OUTLIER 'General case' 0 C--N 1.294 -1.824 0 O-C-N 121.456 -0.778 . . . . 0.0 109.667 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -112.04 74.83 0.88 Allowed 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.566 -0.709 . . . . 0.0 110.115 -179.563 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.441 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 10.7 tp -60.31 -38.87 79.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.875 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.441 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 17.0 t-20 -57.92 -41.19 82.17 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 32.4 tttm -67.81 -43.33 79.9 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.365 -0.834 . . . . 0.0 109.098 178.548 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.572 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.3 OUTLIER -67.57 -40.84 84.89 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.088 -1.007 . . . . 0.0 109.445 -179.365 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -66.79 -25.92 66.7 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 120.441 -1.412 . . . . 0.0 109.156 179.336 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -68.63 -47.52 66.41 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 120.89 -1.131 . . . . 0.0 110.379 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.7 m -121.25 -18.8 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 121.337 -0.852 . . . . 0.0 111.669 -177.733 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.11 170.37 46.91 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.413 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 46.5 t -108.3 127.17 64.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 62.5 tt0 -80.45 -66.8 0.83 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 120.999 -1.063 . . . . 0.0 111.149 -179.381 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 34.8 ttpt -114.82 140.02 49.27 Favored 'General case' 0 N--CA 1.506 2.342 0 O-C-N 121.179 -0.951 . . . . 0.0 110.919 -178.267 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 84.5 t80 -120.97 136.26 55.02 Favored 'General case' 0 N--CA 1.505 2.293 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.24 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 -136.49 124.13 22.37 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.204 -0.935 . . . . 0.0 110.18 179.589 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -125.01 140.77 52.61 Favored 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.421 -0.799 . . . . 0.0 110.426 179.519 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.0 mt -118.93 129.82 55.38 Favored 'General case' 0 N--CA 1.504 2.26 0 O-C-N 121.501 -0.749 . . . . 0.0 109.464 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 31.8 p -126.57 117.18 22.28 Favored 'General case' 0 N--CA 1.508 2.439 0 CA-C-O 121.848 0.832 . . . . 0.0 110.29 179.708 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -132.56 156.12 47.42 Favored 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.154 -179.109 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -70.82 144.74 50.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.4 -0.813 . . . . 0.0 109.384 179.302 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 35.5 t -120.04 127.58 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.707 -0.621 . . . . 0.0 109.343 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 96.7 -8.6 66.07 Favored Glycine 0 N--CA 1.497 2.764 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 75.2 m -78.68 144.83 34.98 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.501 -0.999 . . . . 0.0 109.419 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.7 mtm180 -71.0 150.02 46.07 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.274 -0.891 . . . . 0.0 109.538 179.777 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.5 m . . . . . 0 N--CA 1.493 1.684 0 O-C-N 121.075 -1.016 . . . . 0.0 109.184 -179.925 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.908 0 N-CA-C 119.529 2.571 . . . . 0.0 119.529 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 88.39 -6.83 83.12 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.042 -1.623 . . . . 0.0 109.042 -179.629 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 59.3 p -85.73 158.33 20.06 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.399 -1.059 . . . . 0.0 110.103 -179.746 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.35 14.15 82.83 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 179.532 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' TRP . . . . . 0.471 ' CD1' ' OE1' ' A' ' 34' ' ' GLN . 89.8 t90 -80.29 116.87 20.6 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.268 -1.136 . . . . 0.0 109.33 179.829 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 23.4 m120 -131.61 19.44 4.71 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 179.175 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 53.0 17.4 0.89 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.785 -0.572 . . . . 0.0 109.505 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' A' ' 8' ' ' ASP . 26.6 t0 -100.2 7.48 44.48 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.309 -0.869 . . . . 0.0 110.894 -178.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 71.6 m-80 -122.39 13.17 10.23 Favored 'General case' 0 N--CA 1.501 2.087 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.4 m -120.49 141.66 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 CA-C-O 121.343 0.592 . . . . 0.0 109.422 -179.175 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 36.0 t0 -103.97 111.94 65.34 Favored Pre-proline 0 N--CA 1.499 1.999 0 O-C-N 121.247 -0.908 . . . . 0.0 109.081 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_exo -40.78 -33.43 1.06 Allowed 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.232 1.955 . . . . 0.0 113.126 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 58.5 m -60.01 -39.93 87.5 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.036 -1.04 . . . . 0.0 110.711 -179.367 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 47.0 tt0 -70.03 -24.91 63.35 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.799 -1.188 . . . . 0.0 109.925 -178.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.555 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 37.3 t -68.31 -34.41 76.09 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.332 -0.855 . . . . 0.0 110.118 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.1 pt -117.17 145.88 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.409 -0.807 . . . . 0.0 109.153 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 52.7 mtpt -126.36 146.09 50.19 Favored 'General case' 0 N--CA 1.497 1.875 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 -179.47 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -87.0 119.73 27.51 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.543 -0.723 . . . . 0.0 109.208 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.512 ' O ' ' N ' ' A' ' 21' ' ' VAL . 39.3 p -102.07 119.54 38.96 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.404 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.81 -93.4 0.01 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.512 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.4 t -129.86 20.89 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.538 -0.978 . . . . 0.0 109.23 -179.641 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 75.2 mt-30 -128.55 167.93 16.42 Favored 'General case' 0 N--CA 1.5 2.067 0 CA-C-O 121.866 0.841 . . . . 0.0 110.695 -179.357 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 24.3 m-85 -119.74 135.15 54.96 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 107.888 -1.152 . . . . 0.0 107.888 178.54 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 60.9 p -131.32 149.74 52.43 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.345 -0.847 . . . . 0.0 109.753 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 48.5 t80 -86.89 128.76 35.06 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.468 -0.77 . . . . 0.0 109.871 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -88.27 81.53 7.28 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.105 -0.997 . . . . 0.0 110.552 -179.362 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.2 p -77.97 -16.64 57.99 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.936 -1.102 . . . . 0.0 109.599 179.396 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -64.1 -3.68 9.48 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.363 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.402 HG12 HG12 ' A' ' 31' ' ' VAL . 2.7 t -98.6 129.35 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.261 -1.141 . . . . 0.0 108.321 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 80.8 p -60.06 -40.24 88.8 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 110.727 -178.62 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.42 HG13 ' N ' ' A' ' 32' ' ' CYS . 8.1 p -60.67 -40.4 84.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.92 -1.112 . . . . 0.0 110.402 -179.246 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.555 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.9 m -61.37 -43.36 99.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.024 -1.047 . . . . 0.0 110.11 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 9.2 mmt -80.34 -16.83 53.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.897 -1.127 . . . . 0.0 109.824 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.471 ' OE1' ' CD1' ' A' ' 5' ' ' TRP . 55.9 tt0 -60.32 -40.28 90.02 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.053 -1.029 . . . . 0.0 108.744 179.372 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -78.49 -47.47 8.03 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.717 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 mt -64.86 -42.67 94.68 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.196 -1.179 . . . . 0.0 110.159 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -62.79 -40.39 97.2 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.015 -1.053 . . . . 0.0 110.002 -179.586 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 63.5 mm-40 -67.78 -29.29 68.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.199 -0.938 . . . . 0.0 109.61 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.02 22.75 44.01 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 110.09 -1.204 . . . . 0.0 110.09 179.703 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 17.2 mmmt -102.55 -0.31 32.32 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 178.475 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.636 HG12 ' H ' ' A' ' 43' ' ' GLY . 14.4 t -136.53 157.46 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.512 ' N ' ' O ' ' A' ' 94' ' ' VAL . 70.7 mtp85 -118.18 -10.19 10.33 Favored 'General case' 0 N--CA 1.5 2.045 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 178.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.636 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 141.55 -158.86 26.69 Favored Glycine 0 N--CA 1.497 2.717 0 N-CA-C 108.644 -1.783 . . . . 0.0 108.644 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.7 t -120.59 128.96 76.08 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.184 -1.186 . . . . 0.0 109.207 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.4 m -85.69 139.67 31.18 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.256 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.412 ' O ' HG13 ' A' ' 46' ' ' VAL . 8.6 p -129.61 133.03 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 CA-C-O 121.808 0.813 . . . . 0.0 109.797 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 22.4 p -126.73 150.09 49.24 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 178.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -148.88 145.21 13.29 Favored Glycine 0 N--CA 1.494 2.548 0 C-N-CA 118.708 -1.71 . . . . 0.0 111.462 -178.83 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 95.4 t -118.16 125.98 74.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 178.111 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 2.1 m-85 -105.51 116.29 31.69 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.166 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -91.76 124.75 36.13 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.45 -0.781 . . . . 0.0 109.137 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.466 ' C ' ' H ' ' A' ' 54' ' ' ASP . 88.9 m-85 -109.31 134.68 51.49 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 -57.16 -5.96 0.34 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.905 -1.122 . . . . 0.0 108.767 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.466 ' H ' ' C ' ' A' ' 52' ' ' TYR . 46.2 t0 -73.64 3.59 6.14 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.59 27.41 61.21 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.286 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 22.7 p -130.12 150.87 51.19 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.416 -1.05 . . . . 0.0 110.864 -179.162 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 80.5 p -132.0 123.04 26.52 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.64 -0.663 . . . . 0.0 109.324 179.263 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 23.2 t -104.46 153.2 21.42 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 9.3 m-20 -131.97 118.87 20.32 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 120.93 -1.106 . . . . 0.0 108.98 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -117.48 123.95 47.59 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.477 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -111.78 145.57 39.16 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -163.37 174.88 39.67 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.6 t -119.82 127.22 75.87 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.124 0 O-C-N 121.517 -0.99 . . . . 0.0 109.373 179.584 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 70.8 t -95.38 120.1 44.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.21 -0.931 . . . . 0.0 110.278 -179.202 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.502 ' C ' ' H ' ' A' ' 67' ' ' SER . 3.0 p -137.34 155.32 75.73 Favored Pre-proline 0 N--CA 1.492 1.635 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.097 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -49.69 -4.96 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.021 1.814 . . . . 0.0 111.624 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.502 ' H ' ' C ' ' A' ' 65' ' ' THR . 52.6 p -71.51 -52.1 20.12 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.201 -0.937 . . . . 0.0 110.414 -179.576 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.0 t -154.58 147.08 17.6 Favored Pre-proline 0 N--CA 1.497 1.902 0 O-C-N 120.843 -1.161 . . . . 0.0 110.235 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -80.89 163.91 20.47 Favored 'Trans proline' 0 N--CA 1.497 1.687 0 C-N-CA 122.373 2.048 . . . . 0.0 112.413 179.032 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 64.6 t -123.02 131.22 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.223 0 O-C-N 121.499 -0.75 . . . . 0.0 109.02 179.419 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -90.8 140.31 29.92 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 120.953 -1.092 . . . . 0.0 109.728 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.446 ' OG1' ' N ' ' A' ' 73' ' ' ASN . 1.2 p -80.34 -50.43 10.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.058 -1.026 . . . . 0.0 108.778 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.446 ' N ' ' OG1' ' A' ' 72' ' ' THR . 97.7 m-20 -79.5 58.32 2.64 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.483 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -46.41 -39.56 10.68 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -108.37 75.6 0.99 Allowed 'General case' 0 N--CA 1.496 1.841 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.739 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.425 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 9.2 tp -60.43 -39.85 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.456 -0.777 . . . . 0.0 110.435 -178.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.425 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 46.1 t30 -59.87 -46.28 89.79 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 119.02 -1.072 . . . . 0.0 108.142 -179.371 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 44.2 tttp -60.62 -50.14 74.72 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.164 -0.96 . . . . 0.0 108.938 178.345 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.535 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.1 m -62.11 -41.11 97.89 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.726 -0.609 . . . . 0.0 110.413 -178.513 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -64.92 -33.06 75.14 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 120.545 -1.347 . . . . 0.0 109.882 179.714 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 46.2 tttt -67.02 -49.86 63.93 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.116 -0.99 . . . . 0.0 110.662 -179.073 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.8 p -113.8 -26.16 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.67 -0.644 . . . . 0.0 111.967 -176.66 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 81.59 158.11 20.6 Favored Glycine 0 N--CA 1.493 2.436 0 O-C-N 120.494 -1.379 . . . . 0.0 109.713 179.703 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.5 t -105.03 120.38 55.52 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.764 -0.845 . . . . 0.0 108.988 179.667 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -70.0 -58.36 3.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.132 -0.98 . . . . 0.0 111.569 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -113.9 140.04 48.7 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.141 -0.975 . . . . 0.0 110.328 -178.228 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 71.6 t80 -120.24 127.75 52.7 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.667 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -130.78 127.12 38.06 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 121.212 -0.93 . . . . 0.0 109.869 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.68 142.83 51.1 Favored 'General case' 0 N--CA 1.505 2.296 0 O-C-N 121.557 -0.714 . . . . 0.0 110.314 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 mt -125.83 133.54 51.95 Favored 'General case' 0 N--CA 1.508 2.433 0 O-C-N 121.602 -0.686 . . . . 0.0 109.384 179.603 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 61.8 p -127.95 124.66 37.85 Favored 'General case' 0 N--CA 1.506 2.362 0 O-C-N 121.369 -0.832 . . . . 0.0 110.75 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -133.08 147.25 52.17 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.749 -0.594 . . . . 0.0 109.806 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 88.4 m95 -69.49 139.76 53.92 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 120.816 -1.178 . . . . 0.0 109.35 179.331 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.512 ' O ' ' N ' ' A' ' 42' ' ' ARG . 46.8 t -111.68 120.09 61.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -176.68 -177.14 45.41 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 61.0 m -70.23 133.7 47.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.316 -1.108 . . . . 0.0 109.167 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.432 ' N ' ' CD ' ' A' ' 97' ' ' ARG . 1.3 mpt_? -71.76 139.45 49.05 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.19 -0.944 . . . . 0.0 109.859 -179.597 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 96.9 p . . . . . 0 N--CA 1.488 1.448 0 CA-C-O 117.99 -1.005 . . . . 0.0 109.39 179.779 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.963 0 N-CA-C 119.728 2.651 . . . . 0.0 119.728 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -84.78 -82.76 1.02 Allowed Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.0 m 53.44 22.1 2.72 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.361 -1.082 . . . . 0.0 109.385 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 58.76 -137.27 50.48 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.425 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 27.2 t90 -60.07 140.04 57.1 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.523 -0.986 . . . . 0.0 111.228 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ASN . . . . . 0.552 ' C ' ' H ' ' A' ' 8' ' ' ASP . 80.8 m-20 -129.56 128.41 42.69 Favored 'General case' 0 C--N 1.305 -1.365 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 177.624 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -63.3 3.66 0.27 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.051 -1.031 . . . . 0.0 108.765 179.607 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.552 ' H ' ' C ' ' A' ' 6' ' ' ASN . 68.4 m-20 -82.28 -26.16 33.37 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.465 -0.772 . . . . 0.0 110.947 -178.963 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -94.04 3.44 55.33 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 120.858 -1.151 . . . . 0.0 110.659 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.3 t -110.83 130.04 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.296 -0.878 . . . . 0.0 110.52 -179.076 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -88.0 131.94 41.44 Favored Pre-proline 0 N--CA 1.492 1.63 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.491 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -77.18 -19.58 13.44 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 121.801 1.668 . . . . 0.0 112.477 -179.217 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 55.2 m -59.92 -39.93 87.16 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.174 -0.954 . . . . 0.0 110.374 -179.682 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 90.2 mm-40 -83.71 -11.15 57.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.076 -1.015 . . . . 0.0 110.054 -179.454 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.667 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 45.5 t -69.67 -31.33 69.32 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.131 -0.981 . . . . 0.0 109.142 179.779 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -120.07 146.06 25.43 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 61.4 pttt -125.47 149.96 47.77 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.458 -0.776 . . . . 0.0 109.384 -179.406 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -99.85 122.03 42.18 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.357 -0.839 . . . . 0.0 109.827 -178.631 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.1 t -107.45 100.9 10.29 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.069 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 71.72 -94.52 0.59 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.1 m -133.2 23.28 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.204 0 O-C-N 121.285 -1.126 . . . . 0.0 110.413 -179.642 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -131.66 161.56 32.46 Favored 'General case' 0 N--CA 1.504 2.275 0 O-C-N 121.209 -0.932 . . . . 0.0 109.989 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -113.26 141.41 47.02 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 37.2 p -130.01 142.04 50.67 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.36 -0.838 . . . . 0.0 109.425 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.9 t80 -81.64 126.0 31.24 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.49 -0.756 . . . . 0.0 109.897 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 48.7 t-20 -90.02 85.41 6.32 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.35 -0.844 . . . . 0.0 110.447 -179.611 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.2 p -85.54 -1.43 57.09 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.933 -1.104 . . . . 0.0 109.207 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.08 -31.56 77.16 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.511 ' CG2' ' SG ' ' A' ' 32' ' ' CYS . 24.4 m -83.64 132.48 31.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.152 -1.205 . . . . 0.0 109.138 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 71.1 m -60.08 -39.92 87.76 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.325 -0.859 . . . . 0.0 111.474 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.1 m -52.96 -38.19 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 120.719 -1.238 . . . . 0.0 110.588 -178.072 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.667 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.8 m -62.85 -39.93 95.91 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.73 -1.231 . . . . 0.0 110.016 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 10.0 mmt -80.07 -14.92 58.16 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.984 -1.073 . . . . 0.0 110.263 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -64.84 -39.97 94.43 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.884 -1.135 . . . . 0.0 109.287 179.167 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.12 -49.11 8.82 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.97 -40.16 94.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.347 -1.09 . . . . 0.0 109.998 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -61.15 -40.01 92.23 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.936 -1.103 . . . . 0.0 110.043 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -76.7 -10.19 59.21 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.017 -1.052 . . . . 0.0 109.214 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 69.93 27.23 73.36 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 54.7 tttp -98.99 -7.52 26.8 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 178.837 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.566 HG12 ' H ' ' A' ' 43' ' ' GLY . 4.2 t -133.71 159.03 42.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-N 115.113 -0.949 . . . . 0.0 108.885 -179.591 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 94' ' ' VAL . 96.3 mtt180 -121.46 -5.96 9.28 Favored 'General case' 0 N--CA 1.504 2.265 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.211 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.566 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 142.66 -170.13 25.29 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 108.567 -1.813 . . . . 0.0 108.567 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 77.0 t -111.08 126.18 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.065 -1.256 . . . . 0.0 108.338 179.147 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.4 p -82.02 139.76 34.32 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.126 -0.984 . . . . 0.0 109.275 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.431 ' O ' HG13 ' A' ' 46' ' ' VAL . 12.3 p -130.0 133.45 64.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 98.1 p -124.43 142.54 51.23 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.406 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -133.87 131.86 6.19 Favored Glycine 0 N--CA 1.502 3.068 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.108 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 74.4 t -121.58 129.26 75.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.732 -0.863 . . . . 0.0 108.999 178.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.433 ' HE2' ' HG1' ' A' ' 72' ' ' THR . 29.7 m-85 -104.76 122.54 45.92 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.209 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -96.16 129.82 43.37 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.284 -0.885 . . . . 0.0 109.454 -179.417 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.529 ' O ' ' N ' ' A' ' 54' ' ' ASP . 95.0 m-85 -114.66 127.57 55.84 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -179.67 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -43.12 -19.11 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.428 -0.795 . . . . 0.0 109.918 179.763 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 52' ' ' TYR . 50.1 t0 -68.25 1.32 2.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.459 -0.776 . . . . 0.0 109.752 -179.235 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.76 20.26 74.12 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.574 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.5 p -115.9 154.76 29.17 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.423 -1.046 . . . . 0.0 109.726 179.617 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 45.2 p -139.62 137.98 35.76 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.626 -0.671 . . . . 0.0 109.629 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 53.8 m -113.71 149.58 34.55 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 178.434 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 21.9 p-10 -140.79 119.07 12.08 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.023 -1.048 . . . . 0.0 110.119 -179.418 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 73.5 m-85 -114.11 121.52 44.05 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 107.678 -1.231 . . . . 0.0 107.678 178.349 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.0 ttpm? -113.17 147.33 37.63 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.748 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.64 169.2 41.55 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.4 t -110.04 127.32 67.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.416 -1.05 . . . . 0.0 109.594 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.5 t -91.3 119.99 39.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.423 -0.798 . . . . 0.0 110.017 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.515 ' O ' ' N ' ' A' ' 67' ' ' SER . 25.7 p -136.31 147.59 60.81 Favored Pre-proline 0 N--CA 1.493 1.688 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 178.515 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_exo -39.16 -21.86 0.07 OUTLIER 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 121.987 1.792 . . . . 0.0 112.538 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.515 ' N ' ' O ' ' A' ' 65' ' ' THR . 67.9 m -68.41 -45.82 71.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.115 -0.991 . . . . 0.0 111.413 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 5.8 t -154.75 142.8 14.26 Favored Pre-proline 0 N--CA 1.5 2.042 0 O-C-N 120.407 -1.433 . . . . 0.0 111.19 -179.384 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -81.95 166.84 16.67 Favored 'Trans proline' 0 N--CA 1.499 1.83 0 C-N-CA 122.993 2.462 . . . . 0.0 111.627 178.308 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 90.3 t -105.95 135.79 42.81 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.198 0 O-C-N 121.242 -0.911 . . . . 0.0 109.258 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 29.2 m120 -99.67 123.95 44.43 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.301 -0.874 . . . . 0.0 111.464 -178.258 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.462 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.3 OUTLIER -109.87 20.03 18.44 Favored 'General case' 0 N--CA 1.502 2.174 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.1 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.445 ' O ' ' O ' ' A' ' 74' ' ' GLN . 25.6 t-20 -78.69 60.23 2.7 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.47 -0.769 . . . . 0.0 109.927 -179.433 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.554 ' OE1' ' N ' ' A' ' 74' ' ' GLN . 0.0 OUTLIER -50.28 177.59 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 178.732 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 78.9 m-20 -66.08 119.81 12.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.469 -1.394 . . . . 0.0 108.464 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.436 HG22 ' O ' ' A' ' 76' ' ' ILE . 94.5 mt -80.65 -13.11 12.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.506 -0.746 . . . . 0.0 110.409 -179.092 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 28.7 m120 -60.13 -43.89 95.33 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.827 -1.171 . . . . 0.0 109.036 -179.497 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 18.7 pttt -66.89 -40.09 87.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.877 -1.139 . . . . 0.0 109.271 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.587 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.9 OUTLIER -63.05 -41.13 99.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.239 -0.913 . . . . 0.0 108.777 179.473 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -62.19 -38.71 90.14 Favored 'General case' 0 C--N 1.295 -1.773 0 O-C-N 120.76 -1.213 . . . . 0.0 109.551 179.236 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 31.3 tttm -71.61 -42.51 67.61 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.07 -1.019 . . . . 0.0 111.148 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 p -112.12 -29.42 2.36 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.188 0 O-C-N 121.252 -0.905 . . . . 0.0 112.168 -176.883 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.98 161.09 37.15 Favored Glycine 0 N--CA 1.495 2.587 0 O-C-N 120.702 -1.249 . . . . 0.0 110.606 179.31 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 84.7 t -108.99 127.34 65.73 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.075 0 O-C-N 121.807 -0.82 . . . . 0.0 108.903 179.363 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -88.01 -63.12 1.35 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.08 -1.013 . . . . 0.0 111.181 -178.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -115.07 142.94 45.96 Favored 'General case' 0 N--CA 1.505 2.293 0 CA-C-O 121.872 0.844 . . . . 0.0 111.937 -178.002 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -120.08 130.87 54.86 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.07 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.91 128.62 32.93 Favored 'General case' 0 N--CA 1.505 2.325 0 O-C-N 121.067 -1.02 . . . . 0.0 110.104 -178.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.43 135.38 54.08 Favored 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 179.14 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.696 HD13 ' N ' ' A' ' 91' ' ' THR . 0.2 OUTLIER -120.0 134.73 55.16 Favored 'General case' 0 N--CA 1.503 2.205 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.789 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.696 ' N ' HD13 ' A' ' 90' ' ' LEU . 14.5 p -130.22 124.24 32.05 Favored 'General case' 0 N--CA 1.505 2.283 0 CA-C-O 121.571 0.7 . . . . 0.0 111.016 -179.181 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.29 156.98 47.48 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.762 -0.586 . . . . 0.0 110.131 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 65.6 m95 -69.61 149.51 48.06 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.707 -1.246 . . . . 0.0 108.135 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.519 ' O ' ' N ' ' A' ' 42' ' ' ARG . 31.7 t -117.95 123.11 71.2 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.171 0 O-C-N 121.353 -0.842 . . . . 0.0 109.394 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 116.37 -0.96 20.63 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 31.8 m -95.63 136.07 36.5 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.237 -1.155 . . . . 0.0 108.661 179.311 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 96.1 mtt180 -79.45 -5.09 53.98 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.152 -0.967 . . . . 0.0 109.465 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 53.7 p . . . . . 0 N--CA 1.489 1.503 0 CA-C-O 118.013 -0.994 . . . . 0.0 109.153 179.387 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 5.032 0 N-CA-C 119.933 2.733 . . . . 0.0 119.933 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.46 -178.5 45.35 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.801 -1.32 . . . . 0.0 109.801 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 51.5 p -96.38 143.33 27.53 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.233 -1.157 . . . . 0.0 109.454 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -109.79 -131.42 6.15 Favored Glycine 0 N--CA 1.502 3.041 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -179.714 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 87.8 t90 -68.73 125.31 26.17 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.407 -1.055 . . . . 0.0 109.89 -179.477 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -134.61 18.05 3.6 Favored 'General case' 0 N--CA 1.493 1.724 0 CA-C-O 121.299 0.571 . . . . 0.0 109.855 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 57.77 20.03 6.14 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.434 -0.791 . . . . 0.0 109.109 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.435 ' OD1' ' O ' ' A' ' 8' ' ' ASP . 39.2 t0 -99.19 6.09 46.51 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.296 -0.877 . . . . 0.0 111.427 -178.546 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.7 p-10 -130.01 9.3 5.3 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 120.843 -1.161 . . . . 0.0 108.908 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 2.2 m -124.68 129.96 73.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -89.81 148.25 39.41 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.016 -1.053 . . . . 0.0 108.759 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -80.15 -22.36 7.23 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.408 2.072 . . . . 0.0 111.937 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 56.0 m -60.24 -40.16 89.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.916 . . . . 0.0 110.411 -179.583 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -81.05 -13.77 58.48 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.031 -1.043 . . . . 0.0 110.239 -179.286 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.678 ' HG ' ' HG ' ' A' ' 32' ' ' CYS . 53.9 m -71.11 -29.06 64.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.11 178.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -120.46 135.05 61.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 64.0 mmtt -111.96 147.86 35.0 Favored 'General case' 0 N--CA 1.502 2.161 0 O-C-N 121.291 -0.88 . . . . 0.0 109.292 -179.318 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -97.11 119.86 36.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 108.796 179.516 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 47.8 t -107.56 116.08 31.3 Favored 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.805 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.56 -109.42 1.21 Allowed Glycine 0 N--CA 1.487 2.038 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 -178.681 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.435 ' O ' HG13 ' A' ' 21' ' ' VAL . 7.7 p -118.74 34.64 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.43 -1.041 . . . . 0.0 108.997 179.16 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -130.66 159.37 37.42 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 122.194 0.997 . . . . 0.0 111.567 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -120.8 136.79 54.81 Favored 'General case' 0 N--CA 1.496 1.825 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 26.5 p -137.25 154.44 50.14 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.245 -0.909 . . . . 0.0 109.279 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.8 t80 -87.67 128.06 35.29 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.266 -0.896 . . . . 0.0 109.597 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -86.01 83.21 7.83 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.929 -1.107 . . . . 0.0 109.92 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 86.4 p -84.65 -0.98 55.4 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.933 -1.104 . . . . 0.0 109.424 179.627 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.67 -39.96 95.87 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.089 -1.605 . . . . 0.0 109.089 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 33.4 m -81.83 135.28 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.332 -1.099 . . . . 0.0 108.774 179.433 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 34' ' ' GLN . 17.1 p -72.76 -26.8 61.68 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.182 -0.949 . . . . 0.0 110.873 -178.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.484 HG13 ' N ' ' A' ' 32' ' ' CYS . 10.9 p -59.9 -40.85 83.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 120.841 -1.162 . . . . 0.0 110.774 -178.504 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.678 ' HG ' ' HG ' ' A' ' 15' ' ' CYS . 87.0 m -68.69 -39.9 80.3 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.839 -1.163 . . . . 0.0 109.228 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 99.5 mmm -80.09 -14.6 58.39 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.134 -0.979 . . . . 0.0 108.68 179.089 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.421 ' N ' ' O ' ' A' ' 30' ' ' SER . 59.8 tt0 -60.62 -41.98 95.92 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.01 -41.2 28.1 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.378 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.3 tp -67.16 -40.26 86.63 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -1.128 . . . . 0.0 108.687 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -63.07 -40.03 96.47 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.48 -0.763 . . . . 0.0 110.539 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.537 ' N ' ' OE1' ' A' ' 38' ' ' GLU . 0.4 OUTLIER -75.09 -11.41 60.09 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.831 -1.168 . . . . 0.0 109.763 -179.403 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.24 21.5 70.16 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 119.901 -1.142 . . . . 0.0 110.443 178.654 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 62.3 mttm -98.66 -3.38 36.15 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.686 HG12 ' H ' ' A' ' 43' ' ' GLY . 94.0 t -134.91 159.28 41.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.419 ' N ' HG12 ' A' ' 41' ' ' VAL . 95.0 mtt-85 -122.08 -7.13 8.89 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 179.482 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.686 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.78 -163.22 25.88 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 -179.504 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 87.8 t -119.39 129.19 75.6 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 121.322 -1.105 . . . . 0.0 109.115 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 5.4 m -86.36 139.19 31.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.861 -1.149 . . . . 0.0 108.897 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.41 ' O ' HG13 ' A' ' 46' ' ' VAL . 10.6 p -131.25 133.76 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.615 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 53.5 p -125.42 149.42 48.21 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 179.257 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -143.51 138.12 7.96 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 119.574 -1.298 . . . . 0.0 110.062 -179.145 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.426 HG21 HH21 ' A' ' 88' ' ' ARG . 62.4 t -122.63 127.06 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 179.064 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.594 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 0.2 OUTLIER -100.87 119.8 39.2 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -179.858 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -94.41 119.92 33.86 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.164 -0.96 . . . . 0.0 108.661 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.482 ' O ' ' N ' ' A' ' 54' ' ' ASP . 93.4 m-85 -102.22 125.79 49.02 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.424 -0.797 . . . . 0.0 109.985 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -47.2 -16.43 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.104 -0.997 . . . . 0.0 109.751 179.562 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.482 ' N ' ' O ' ' A' ' 52' ' ' TYR . 47.4 t0 -70.85 4.72 2.37 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.247 -0.908 . . . . 0.0 109.223 -179.533 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.08 22.76 70.49 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 178.704 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.4 p -123.54 150.81 43.54 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.33 -1.1 . . . . 0.0 109.339 179.756 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.1 p -135.33 139.79 44.58 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.583 -0.698 . . . . 0.0 110.152 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.1 m -117.92 144.5 45.41 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 178.352 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.6 m-20 -128.2 118.49 23.42 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.388 -0.82 . . . . 0.0 108.953 -179.831 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 66.3 t80 -116.76 126.47 53.16 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.256 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -113.74 144.9 42.19 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -159.16 167.83 35.02 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.83 128.58 74.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.599 -0.942 . . . . 0.0 108.694 -179.662 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 45.7 t -92.88 117.87 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.047 -1.033 . . . . 0.0 110.088 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.541 ' O ' ' N ' ' A' ' 67' ' ' SER . 6.4 p -134.98 153.87 78.81 Favored Pre-proline 0 N--CA 1.492 1.633 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 178.643 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_exo -43.93 -10.13 0.03 OUTLIER 'Trans proline' 0 N--CA 1.494 1.543 0 C-N-CA 121.981 1.788 . . . . 0.0 113.204 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.541 ' N ' ' O ' ' A' ' 65' ' ' THR . 87.1 p -67.6 -59.52 3.29 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.892 -1.13 . . . . 0.0 110.687 -179.236 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -155.4 150.75 21.21 Favored Pre-proline 0 N--CA 1.498 1.933 0 O-C-N 120.596 -1.315 . . . . 0.0 110.259 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -82.81 161.24 16.25 Favored 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.522 2.148 . . . . 0.0 112.523 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.5 t -110.78 130.5 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 15.7 m-20 -100.8 144.46 29.73 Favored 'General case' 0 N--CA 1.506 2.338 0 O-C-N 120.905 -1.122 . . . . 0.0 111.069 -178.355 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.19 -0.06 56.99 Favored 'General case' 0 N--CA 1.504 2.244 0 O-C-N 121.059 -1.026 . . . . 0.0 108.607 178.531 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.434 ' HB3' HG21 ' A' ' 21' ' ' VAL . 52.2 p-10 -80.43 46.67 0.86 Allowed 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.239 -0.913 . . . . 0.0 109.832 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 62.1 tt0 -48.17 -81.04 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.957 -1.09 . . . . 0.0 110.012 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -112.93 94.9 5.12 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.41 -0.806 . . . . 0.0 109.938 -179.503 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 8.8 mm -68.63 -39.89 81.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.28 -0.888 . . . . 0.0 109.733 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -59.95 -40.97 90.81 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 107.74 -1.207 . . . . 0.0 107.74 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -66.51 -43.13 86.1 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.455 -0.778 . . . . 0.0 109.156 178.818 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.597 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.2 m -76.1 -47.95 22.55 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.524 -0.735 . . . . 0.0 110.227 -178.721 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -60.05 -32.11 70.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.248 -1.533 . . . . 0.0 109.783 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 18.7 tptt -67.49 -53.53 27.97 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.329 -0.857 . . . . 0.0 110.694 -178.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.12 -22.14 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.172 -0.955 . . . . 0.0 111.515 -178.328 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.2 167.3 43.39 Favored Glycine 0 N--CA 1.487 2.086 0 O-C-N 120.896 -1.128 . . . . 0.0 110.764 178.729 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.401 HG23 HG23 ' A' ' 79' ' ' THR . 63.8 t -109.86 129.72 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.744 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -80.03 -67.08 0.8 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.768 -1.208 . . . . 0.0 110.34 -178.784 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -113.73 138.78 49.76 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.418 -0.801 . . . . 0.0 109.891 -178.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 63.2 t80 -121.99 126.88 49.53 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.205 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.426 HH21 HG21 ' A' ' 49' ' ' VAL . 38.6 ptt180 -133.71 134.7 43.37 Favored 'General case' 0 N--CA 1.502 2.151 0 CA-C-O 121.96 0.886 . . . . 0.0 110.023 179.711 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.8 136.04 54.16 Favored 'General case' 0 N--CA 1.495 1.798 0 CA-C-O 121.164 0.507 . . . . 0.0 109.749 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 4.0 mt -113.35 131.79 55.83 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.402 -0.811 . . . . 0.0 108.815 179.194 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 3.8 p -126.12 121.3 32.49 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.677 0.751 . . . . 0.0 109.82 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -133.66 154.46 50.9 Favored 'General case' 0 N--CA 1.498 1.926 0 CA-C-O 121.422 0.63 . . . . 0.0 110.087 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -72.94 138.44 46.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.394 -0.816 . . . . 0.0 109.01 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 39.7 t -109.97 116.31 51.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.752 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -173.39 -48.33 0.05 OUTLIER Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 66.5 m -69.95 149.74 47.44 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.184 -1.186 . . . . 0.0 109.234 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.0 mtt85 -97.96 130.04 44.83 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.227 -0.921 . . . . 0.0 109.05 179.79 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 69.7 m . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 118.054 -0.974 . . . . 0.0 109.254 179.744 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.866 0 N-CA-C 119.563 2.585 . . . . 0.0 119.563 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.42 104.52 1.69 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.15 -1.58 . . . . 0.0 109.15 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 45.7 t -101.37 129.93 47.46 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.359 -1.083 . . . . 0.0 109.422 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.33 19.67 79.38 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.058 -1.617 . . . . 0.0 109.058 -179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 70.3 t90 -56.85 120.54 8.07 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.234 -1.157 . . . . 0.0 109.114 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ASN . . . . . 0.484 ' C ' ' H ' ' A' ' 8' ' ' ASP . 1.8 t30 -128.65 20.59 6.07 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 59.12 1.62 0.23 Allowed 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.759 -0.588 . . . . 0.0 109.699 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.484 ' H ' ' C ' ' A' ' 6' ' ' ASN . 36.4 p-10 -85.13 -26.17 27.04 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.233 -0.917 . . . . 0.0 110.035 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.425 ' N ' ' OD1' ' A' ' 8' ' ' ASP . 87.6 m-20 -91.71 1.46 57.14 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.295 -0.878 . . . . 0.0 110.067 -179.141 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.8 t -108.98 129.96 62.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.466 -0.771 . . . . 0.0 109.562 -178.765 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -90.02 127.6 53.05 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.103 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -76.57 -13.84 18.09 Favored 'Trans proline' 0 N--CA 1.497 1.702 0 C-N-CA 122.082 1.855 . . . . 0.0 112.648 -179.048 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 54.5 m -62.06 -40.01 94.33 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.133 -0.979 . . . . 0.0 110.43 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLN . . . . . 0.416 ' CD ' ' N ' ' A' ' 14' ' ' GLN . 28.2 mp0 -83.35 -12.52 56.47 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.076 -1.015 . . . . 0.0 110.37 -179.2 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.77 ' HG ' ' HG ' ' A' ' 32' ' ' CYS . 36.6 t -64.62 -36.62 84.83 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.182 -0.949 . . . . 0.0 110.189 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -117.48 141.1 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 121.399 -0.813 . . . . 0.0 108.887 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.462 ' HG2' HD22 ' A' ' 26' ' ' ASN . 20.4 pttp -118.83 145.46 45.64 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -98.11 124.77 42.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.397 -0.814 . . . . 0.0 109.409 179.815 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.539 ' O ' ' N ' ' A' ' 21' ' ' VAL . 65.6 m -110.17 131.12 55.34 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.38 -93.68 0.01 OUTLIER Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 -179.235 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.539 ' N ' ' O ' ' A' ' 19' ' ' SER . 26.2 m -139.6 31.39 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.308 -1.113 . . . . 0.0 109.676 179.816 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -131.53 159.41 38.24 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.417 -0.802 . . . . 0.0 109.902 179.456 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -114.24 139.97 48.96 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.027 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.2 p -136.53 148.79 47.79 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.143 -0.973 . . . . 0.0 109.847 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -84.55 129.92 34.8 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.169 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ASN . . . . . 0.462 HD22 ' HG2' ' A' ' 17' ' ' LYS . 67.5 m-80 -90.95 103.73 16.41 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.095 -1.003 . . . . 0.0 110.159 -179.6 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 88.1 p -92.08 -5.99 51.76 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.062 -1.023 . . . . 0.0 108.981 178.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.89 -36.43 90.06 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.8 m -79.0 136.89 22.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.214 -1.168 . . . . 0.0 109.263 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.9 m -68.37 -31.49 70.89 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.409 -0.807 . . . . 0.0 111.157 -178.693 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 85.4 t -59.98 -40.07 82.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.885 -1.135 . . . . 0.0 110.556 -178.031 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.77 ' HG ' ' HG ' ' A' ' 15' ' ' CYS . 68.3 m -59.84 -47.0 87.51 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.629 -1.294 . . . . 0.0 110.056 -179.321 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' MET . . . . . 0.416 ' O ' ' CB ' ' A' ' 37' ' ' ASN . 29.7 mmt -70.23 -34.13 72.49 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.304 -0.873 . . . . 0.0 110.657 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 18.7 mm100 -59.55 -41.53 90.32 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.02 -1.05 . . . . 0.0 110.765 -178.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.68 -49.5 7.14 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 30.6 tp -60.01 -43.71 95.04 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.416 ' CB ' ' O ' ' A' ' 33' ' ' MET . 39.9 t30 -61.47 -39.9 92.56 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.543 -0.723 . . . . 0.0 109.963 179.19 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 49.7 tp10 -60.2 -31.4 70.11 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.329 -0.857 . . . . 0.0 109.819 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.81 15.23 56.86 Favored Glycine 0 N--CA 1.497 2.737 0 N-CA-C 110.306 -1.117 . . . . 0.0 110.306 179.33 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -101.98 -1.16 32.46 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 106.628 -1.619 . . . . 0.0 106.628 178.556 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.688 HG12 ' H ' ' A' ' 43' ' ' GLY . 98.9 t -130.56 159.91 42.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-N 115.172 -0.922 . . . . 0.0 108.518 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.511 ' N ' ' O ' ' A' ' 94' ' ' VAL . 42.0 ttm180 -123.71 -8.93 7.88 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.252 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.688 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.84 -159.1 26.43 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 108.215 -1.954 . . . . 0.0 108.215 -179.296 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 96.6 t -119.68 128.65 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.306 -1.114 . . . . 0.0 109.178 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 p -82.97 140.89 32.51 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.279 -0.888 . . . . 0.0 109.012 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.458 ' O ' HG13 ' A' ' 46' ' ' VAL . 8.8 p -132.23 130.61 60.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.575 -0.703 . . . . 0.0 109.525 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 16.8 p -123.63 146.04 48.49 Favored 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -140.47 136.74 7.85 Favored Glycine 0 N--CA 1.499 2.84 0 N-CA-C 110.119 -1.193 . . . . 0.0 110.119 -179.394 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 90.9 t -121.39 129.1 75.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.791 -0.829 . . . . 0.0 108.973 179.113 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -100.72 119.96 39.37 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 179.34 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 63.6 m-85 -96.49 126.09 41.44 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.323 -0.861 . . . . 0.0 108.945 -179.535 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.53 ' CD1' ' NZ ' ' A' ' 78' ' ' LYS . 90.0 m-85 -111.45 129.42 56.04 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.446 -0.784 . . . . 0.0 110.021 -178.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.429 ' OD1' ' OE1' ' A' ' 85' ' ' GLN . 74.9 m-20 -45.46 -17.27 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.41 -0.806 . . . . 0.0 109.406 178.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.514 ' N ' ' O ' ' A' ' 52' ' ' TYR . 52.5 t0 -68.86 0.09 4.83 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.495 -0.753 . . . . 0.0 109.532 -179.552 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.55 23.96 63.86 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.019 -1.086 . . . . 0.0 110.431 179.219 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.3 p -122.76 147.47 46.46 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.37 -1.077 . . . . 0.0 110.127 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.5 p -131.56 136.27 47.69 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.608 -0.683 . . . . 0.0 109.771 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 41.2 t -118.64 142.73 47.37 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 178.439 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 35.1 p-10 -130.61 120.44 23.99 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.921 -1.112 . . . . 0.0 110.224 -179.224 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -114.71 120.16 39.16 Favored 'General case' 0 N--CA 1.498 1.963 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.52 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.8 ttpt -112.54 152.6 28.64 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 -179.43 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.57 174.67 43.27 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 67.6 t -115.7 126.27 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.623 -0.928 . . . . 0.0 110.04 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 38.2 t -91.23 117.76 35.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.514 -0.741 . . . . 0.0 110.013 -179.364 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.516 ' O ' ' N ' ' A' ' 67' ' ' SER . 21.7 p -121.28 150.92 55.11 Favored Pre-proline 0 N--CA 1.498 1.943 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 178.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_exo -38.34 -20.76 0.05 OUTLIER 'Trans proline' 0 C--N 1.312 -1.358 0 C-N-CA 122.01 1.807 . . . . 0.0 113.372 -179.466 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.516 ' N ' ' O ' ' A' ' 65' ' ' THR . 18.1 p -121.81 2.93 10.04 Favored 'General case' 0 N--CA 1.505 2.29 0 O-C-N 121.181 -0.949 . . . . 0.0 111.88 -179.004 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 61.1 p -129.94 107.22 16.66 Favored Pre-proline 0 N--CA 1.51 2.537 0 O-C-N 120.768 -1.207 . . . . 0.0 110.687 -179.807 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -90.58 165.31 4.24 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 C-N-CA 122.781 2.32 . . . . 0.0 112.288 178.315 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.1 t -120.47 129.95 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 N-CA-C 108.79 -0.818 . . . . 0.0 108.79 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 30.1 m120 -99.99 121.65 41.68 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.22 -0.925 . . . . 0.0 111.154 -178.432 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -91.02 -0.02 57.64 Favored 'General case' 0 N--CA 1.497 1.914 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.211 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.438 ' O ' ' O ' ' A' ' 74' ' ' GLN . 51.5 p-10 -75.11 57.74 0.85 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.4 -0.813 . . . . 0.0 109.573 -179.218 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.438 ' O ' ' O ' ' A' ' 73' ' ' ASN . 64.7 tp60 -55.47 -101.92 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.559 -0.713 . . . . 0.0 109.091 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -108.26 100.43 9.74 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 120.967 -1.083 . . . . 0.0 109.231 179.449 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 44.3 mm -69.86 -39.33 77.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.024 -1.047 . . . . 0.0 109.077 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 -58.29 -41.08 83.6 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.53 ' NZ ' ' CD1' ' A' ' 52' ' ' TYR . 54.5 tttm -60.12 -49.91 75.77 Favored 'General case' 0 N--CA 1.488 1.425 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.367 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.581 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.8 OUTLIER -63.29 -41.03 98.94 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.546 -0.722 . . . . 0.0 110.304 -179.113 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -60.4 -35.94 76.95 Favored 'General case' 0 C--N 1.294 -1.838 0 O-C-N 120.655 -1.278 . . . . 0.0 110.912 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 8.9 tmtm? -70.9 -43.94 67.28 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.701 -1.249 . . . . 0.0 111.463 -178.502 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 p -110.1 -26.0 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.281 0 O-C-N 120.872 -1.142 . . . . 0.0 110.924 -178.281 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.581 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 79.94 157.81 14.73 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.8 t -108.53 130.4 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.067 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.429 ' OE1' ' OD1' ' A' ' 53' ' ' ASN . 18.7 pt20 -97.43 -43.29 7.34 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.185 -0.947 . . . . 0.0 110.929 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -115.9 127.84 55.31 Favored 'General case' 0 N--CA 1.502 2.127 0 O-C-N 121.197 -0.939 . . . . 0.0 110.766 -178.804 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -122.17 123.62 41.94 Favored 'General case' 0 N--CA 1.499 2.003 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.768 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 93.8 mtt180 -132.2 133.75 44.54 Favored 'General case' 0 N--CA 1.507 2.387 0 O-C-N 121.073 -1.017 . . . . 0.0 110.799 -179.545 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.1 135.18 53.36 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.797 -0.564 . . . . 0.0 109.58 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 54.5 tp -117.32 137.48 52.41 Favored 'General case' 0 N--CA 1.505 2.316 0 O-C-N 121.421 -0.799 . . . . 0.0 109.73 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.7 p -129.72 123.58 31.43 Favored 'General case' 0 N--CA 1.504 2.25 0 CA-C-O 121.639 0.733 . . . . 0.0 111.241 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.4 tt0 -133.78 157.33 46.16 Favored 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.637 -0.664 . . . . 0.0 109.724 179.145 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 82.4 m95 -69.43 149.31 48.48 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.78 -1.2 . . . . 0.0 109.873 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 42' ' ' ARG . 21.7 t -122.48 127.28 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.549 -0.72 . . . . 0.0 109.629 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 127.67 -16.16 6.23 Favored Glycine 0 N--CA 1.502 3.097 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 178.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.4 p -80.46 128.9 34.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.016 -1.285 . . . . 0.0 108.44 179.35 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 20.4 ttm105 -98.93 118.93 36.82 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.187 -0.946 . . . . 0.0 109.18 -179.706 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.1 m . . . . . 0 N--CA 1.497 1.888 0 CA-C-O 117.991 -1.004 . . . . 0.0 109.403 -179.867 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.841 0 N-CA-C 119.492 2.557 . . . . 0.0 119.492 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.54 170.88 43.92 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 68.7 m -88.44 -9.3 53.01 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.248 -1.149 . . . . 0.0 110.156 -179.416 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 150.05 -157.28 27.15 Favored Glycine 0 N--CA 1.497 2.75 0 N-CA-C 109.971 -1.252 . . . . 0.0 109.971 179.773 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 20.0 t90 -59.21 139.31 57.07 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.233 -1.157 . . . . 0.0 109.724 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ASN . . . . . 0.499 ' C ' ' H ' ' A' ' 8' ' ' ASP . 83.8 m-20 -133.05 128.12 35.55 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 178.065 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -67.38 8.24 0.35 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.162 -0.961 . . . . 0.0 109.252 179.716 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.499 ' H ' ' C ' ' A' ' 6' ' ' ASN . 94.7 m-20 -98.07 5.31 48.82 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.48 -0.763 . . . . 0.0 110.546 -178.66 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -121.02 6.58 10.33 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -134.85 139.4 47.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -179.429 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 24.5 m-20 -85.02 148.47 50.72 Favored Pre-proline 0 C--N 1.301 -1.51 0 O-C-N 121.269 -0.895 . . . . 0.0 109.264 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -75.63 -20.98 15.15 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.258 1.972 . . . . 0.0 111.655 179.677 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 84.0 p -61.48 -37.68 84.52 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.217 -0.927 . . . . 0.0 109.801 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.1 tp-100 -70.1 -25.66 63.61 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.172 -0.955 . . . . 0.0 109.384 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.511 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 77.2 m -68.42 -30.67 69.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.119 -0.988 . . . . 0.0 109.903 -179.453 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -124.06 136.66 59.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -120.91 150.65 40.74 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.597 -0.69 . . . . 0.0 109.139 -179.545 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -91.99 119.77 32.02 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.037 -1.04 . . . . 0.0 109.639 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 54.9 m -124.4 131.72 53.51 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.419 -0.8 . . . . 0.0 109.073 179.732 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 46.6 47.99 17.46 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.896 -1.145 . . . . 0.0 110.504 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.406 HG11 ' OD1' ' A' ' 73' ' ' ASN . 3.4 t 56.92 29.6 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.208 -1.172 . . . . 0.0 110.363 179.451 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 89.8 mt-30 -130.76 164.85 24.22 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.287 -0.883 . . . . 0.0 108.708 178.494 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 39.1 m-85 -120.43 136.77 54.63 Favored 'General case' 0 N--CA 1.501 2.117 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.366 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 34.7 p -139.85 152.3 46.37 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.401 -0.812 . . . . 0.0 109.612 179.825 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 28.5 t80 -80.81 127.08 32.12 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.638 -0.664 . . . . 0.0 109.229 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -83.6 83.63 7.83 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.342 -0.849 . . . . 0.0 109.783 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 27.9 p -76.68 -8.91 58.17 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.223 -0.923 . . . . 0.0 108.988 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.01 -39.79 70.61 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.6 m -82.27 128.61 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.036 -1.273 . . . . 0.0 108.46 179.052 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.463 ' O ' ' N ' ' A' ' 34' ' ' GLN . 82.2 p -66.87 -25.0 66.19 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.174 -0.954 . . . . 0.0 110.445 -178.845 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 71.3 t -59.81 -49.24 84.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.242 -0.911 . . . . 0.0 109.937 -178.854 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.511 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 79.8 m -61.83 -40.08 94.04 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.949 -1.094 . . . . 0.0 109.305 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 5.3 tpt -79.97 -14.87 58.26 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.079 -1.013 . . . . 0.0 108.7 179.615 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.463 ' N ' ' O ' ' A' ' 30' ' ' SER . 5.9 tp-100 -63.15 -40.04 96.43 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.05 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -73.17 -45.41 31.49 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.6 mt -61.02 -42.88 99.31 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.316 -1.108 . . . . 0.0 108.994 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -60.25 -39.91 88.42 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.622 0.725 . . . . 0.0 109.265 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -80.01 -10.01 59.74 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.627 -0.67 . . . . 0.0 109.455 -179.522 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.34 31.88 68.56 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -106.41 -5.89 18.64 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 179.801 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.746 HG12 ' H ' ' A' ' 43' ' ' GLY . 87.2 t -133.12 156.67 42.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.789 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.573 HH12 ' H ' ' A' ' 96' ' ' SER . 73.8 mtt85 -120.36 -7.03 9.8 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.746 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 137.8 -166.02 25.21 Favored Glycine 0 N--CA 1.498 2.821 0 N-CA-C 109.042 -1.623 . . . . 0.0 109.042 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.7 t -119.95 126.18 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.282 -1.128 . . . . 0.0 109.239 -179.783 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 28.6 m -80.76 133.12 35.6 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.255 -0.903 . . . . 0.0 108.775 179.267 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.439 HG13 ' O ' ' A' ' 46' ' ' VAL . 7.1 p -129.01 132.27 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.586 -0.696 . . . . 0.0 109.396 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.5 p -123.39 148.4 46.12 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -142.4 140.91 10.3 Favored Glycine 0 N--CA 1.503 3.157 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.981 -178.86 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 94.8 t -124.79 130.03 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.675 -0.897 . . . . 0.0 109.654 179.188 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 33.9 m-85 -104.18 114.36 28.55 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.823 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -86.28 131.68 34.16 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.041 -1.037 . . . . 0.0 109.192 -179.569 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.429 ' C ' ' H ' ' A' ' 54' ' ' ASP . 54.3 m-85 -116.32 134.18 55.18 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.465 -0.772 . . . . 0.0 109.713 -179.439 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.426 ' C ' ' H ' ' A' ' 55' ' ' GLY . 44.8 t30 -57.17 -11.38 1.63 Allowed 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 178.77 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.429 ' H ' ' C ' ' A' ' 52' ' ' TYR . 11.9 t70 -67.01 0.6 2.43 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.426 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 79.52 20.76 68.25 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.173 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 18.4 p -130.9 151.56 51.18 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.297 -1.119 . . . . 0.0 110.914 -179.468 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 79.2 p -130.05 137.58 50.3 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 56.9 m -116.24 148.89 40.01 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 179.105 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -137.49 127.33 25.58 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.302 -0.874 . . . . 0.0 109.715 179.77 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -116.41 129.13 56.07 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.013 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -114.06 144.95 42.28 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -167.44 164.54 37.99 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.1 t -109.95 128.19 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.535 -0.98 . . . . 0.0 108.932 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 21.2 t -91.91 119.1 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.191 -0.943 . . . . 0.0 110.088 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.401 ' C ' ' H ' ' A' ' 67' ' ' SER . 29.7 p -132.31 149.93 74.56 Favored Pre-proline 0 N--CA 1.492 1.639 0 N-CA-C 106.889 -1.522 . . . . 0.0 106.889 178.268 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -52.28 -9.23 0.48 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 121.443 1.429 . . . . 0.0 111.293 -179.376 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.401 ' H ' ' C ' ' A' ' 65' ' ' THR . 19.6 m -104.79 -24.93 12.84 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.513 -0.742 . . . . 0.0 110.31 -179.655 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 20.7 m -135.88 107.39 9.76 Favored Pre-proline 0 N--CA 1.506 2.356 0 O-C-N 121.113 -0.992 . . . . 0.0 110.652 -179.593 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -87.04 164.03 8.7 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 C-N-CA 122.148 1.899 . . . . 0.0 111.69 178.428 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.3 t -118.57 129.57 74.65 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.377 -0.827 . . . . 0.0 109.12 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -103.3 136.67 42.64 Favored 'General case' 0 N--CA 1.501 2.105 0 O-C-N 121.148 -0.97 . . . . 0.0 110.678 -178.856 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.419 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.4 OUTLIER -93.12 -1.16 56.7 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 178.347 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.416 ' O ' ' O ' ' A' ' 74' ' ' GLN . 78.3 m-20 -70.31 51.73 0.13 Allowed 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.427 -0.796 . . . . 0.0 109.378 -179.554 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.419 ' N ' ' O ' ' A' ' 72' ' ' THR . 59.1 tt0 -62.39 -108.47 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 179.507 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -106.32 96.12 6.24 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.137 -0.977 . . . . 0.0 108.384 178.278 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.428 HG22 ' O ' ' A' ' 76' ' ' ILE . 90.4 mt -84.99 -15.22 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.0 -1.063 . . . . 0.0 110.305 -179.577 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 64.9 t-20 -59.89 -44.6 94.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.919 -1.113 . . . . 0.0 109.837 -179.335 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.414 ' HB2' ' HZ3' ' A' ' 78' ' ' LYS . 9.7 ptmm? -68.77 -33.96 74.77 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.11 -0.994 . . . . 0.0 109.174 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.607 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.7 OUTLIER -62.89 -45.14 93.9 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.935 -1.103 . . . . 0.0 108.067 178.895 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -59.95 -35.17 74.38 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 120.776 -1.202 . . . . 0.0 108.843 178.899 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.4 tttp -63.99 -51.15 65.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.402 -0.811 . . . . 0.0 111.07 -178.733 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.9 m -117.01 -20.8 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.226 0 O-C-N 121.365 -0.835 . . . . 0.0 111.545 -177.618 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.607 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.28 167.48 42.84 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 179.412 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 53.6 t -108.62 126.49 65.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 57.1 tt0 -79.96 -65.33 1.02 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.892 -1.13 . . . . 0.0 109.958 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.8 tptm -114.38 140.18 48.88 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.52 -0.738 . . . . 0.0 110.554 -178.842 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 69.2 t80 -119.75 137.23 54.07 Favored 'General case' 0 N--CA 1.5 2.045 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.139 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -138.1 128.08 25.6 Favored 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.066 -1.021 . . . . 0.0 111.068 -178.808 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.57 133.43 53.29 Favored 'General case' 0 N--CA 1.503 2.177 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.752 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 59.4 tp -120.01 135.35 54.96 Favored 'General case' 0 N--CA 1.508 2.434 0 O-C-N 121.298 -0.876 . . . . 0.0 110.169 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 30.6 p -129.23 127.38 41.14 Favored 'General case' 0 N--CA 1.505 2.282 0 CA-C-O 121.679 0.752 . . . . 0.0 110.958 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -132.63 145.86 51.43 Favored 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.692 -0.63 . . . . 0.0 110.221 179.774 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 76.8 m95 -69.88 139.96 53.1 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 120.945 -1.097 . . . . 0.0 108.771 178.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 17.4 t -112.38 117.52 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.453 -0.779 . . . . 0.0 109.546 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 163.03 89.96 0.07 OUTLIER Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 179.785 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.573 ' H ' HH12 ' A' ' 42' ' ' ARG . 16.5 t -75.09 130.47 39.32 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.024 -1.28 . . . . 0.0 109.224 179.464 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -82.72 145.03 29.81 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.046 -1.034 . . . . 0.0 109.764 -179.616 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.6 t . . . . . 0 N--CA 1.491 1.6 0 CA-C-O 117.925 -1.036 . . . . 0.0 109.269 179.577 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -79.89 -21.73 43.65 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.475 -0.765 . . . . 0.0 110.549 -179.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 28.5 m120 -88.48 0.13 56.61 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.933 -1.105 . . . . 0.0 109.424 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.8 t -112.74 127.54 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.553 -0.717 . . . . 0.0 109.42 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -79.04 130.92 68.2 Favored Pre-proline 0 N--CA 1.488 1.444 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -74.49 -10.65 22.21 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 121.706 1.604 . . . . 0.0 111.832 -179.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 82.7 p -69.96 -29.34 66.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.301 -0.874 . . . . 0.0 109.505 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 62.9 tt0 -90.07 -19.52 24.26 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.228 -0.92 . . . . 0.0 109.502 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.581 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 48.8 t -66.34 -33.5 75.86 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.089 -1.007 . . . . 0.0 109.846 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.433 ' O ' HD12 ' A' ' 16' ' ' ILE . 2.5 pp -119.35 132.11 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -113.98 142.87 45.61 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -96.01 127.24 41.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.422 -0.799 . . . . 0.0 110.024 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 49.5 m -115.67 124.24 50.39 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.62 -103.12 0.11 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.4 m -129.76 30.5 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.086 0 O-C-N 121.559 -0.965 . . . . 0.0 109.188 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 14.2 tt0 -129.43 153.04 48.32 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.397 -0.815 . . . . 0.0 110.453 -178.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -114.34 136.42 53.0 Favored 'General case' 0 N--CA 1.499 1.99 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.193 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 36.9 p -135.36 145.37 47.31 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.338 -0.851 . . . . 0.0 109.553 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 45.6 t80 -80.13 124.46 28.79 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.2 m120 -82.82 86.96 6.82 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.01 -1.056 . . . . 0.0 110.267 -179.087 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 13.8 m -79.61 -13.69 59.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.044 -1.035 . . . . 0.0 109.145 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -65.78 -3.68 16.66 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.448 HG12 HG22 ' A' ' 31' ' ' VAL . 2.0 t -102.93 126.91 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 96.7 p -59.92 -40.12 87.79 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.076 -1.015 . . . . 0.0 111.279 -178.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.575 HG23 ' N ' ' A' ' 32' ' ' CYS . 16.2 m -60.56 -44.3 96.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 120.878 -1.139 . . . . 0.0 110.638 -178.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.581 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 89.3 m -60.14 -43.36 95.76 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.099 -1.001 . . . . 0.0 110.563 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 95.2 mmm -84.33 -12.76 54.02 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.721 -1.237 . . . . 0.0 109.121 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 -60.12 -47.44 85.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.889 . . . . 0.0 108.604 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.86 -45.04 17.85 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.2 tp -60.18 -40.01 88.47 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.242 -1.152 . . . . 0.0 109.449 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -66.13 -39.95 90.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.319 -0.863 . . . . 0.0 110.363 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -75.62 -6.17 49.03 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.071 -1.018 . . . . 0.0 109.978 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.93 26.81 73.3 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -101.13 -5.47 25.62 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.733 HG12 ' H ' ' A' ' 43' ' ' GLY . 77.2 t -134.95 159.82 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -179.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.455 ' N ' HG12 ' A' ' 41' ' ' VAL . 65.0 mtp180 -122.73 -5.93 8.59 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.733 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 137.76 -164.92 25.43 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 108.429 -1.868 . . . . 0.0 108.429 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.0 t -120.34 130.0 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.226 -1.161 . . . . 0.0 109.545 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.434 ' H ' HG23 ' A' ' 94' ' ' VAL . 3.3 t -83.17 133.79 35.01 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.189 -0.944 . . . . 0.0 108.726 179.01 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.5 p -129.96 134.22 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.59 -0.694 . . . . 0.0 109.434 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 25.5 p -124.83 146.59 49.19 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.473 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -138.27 140.55 11.23 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.527 HG22 ' OD1' ' A' ' 59' ' ' ASN . 98.2 t -126.53 129.85 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.675 -0.897 . . . . 0.0 109.143 179.216 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -101.44 117.2 34.45 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.723 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 39.1 m-85 -91.96 122.61 34.64 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.403 -0.811 . . . . 0.0 109.079 -179.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -104.99 136.16 44.99 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.575 -0.703 . . . . 0.0 109.771 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 -57.27 -11.63 1.88 Allowed 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 11.2 t70 -74.46 2.16 10.19 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.59 21.21 69.78 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.1 p -120.47 147.02 45.66 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.405 -1.056 . . . . 0.0 110.127 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 71.8 p -130.01 140.95 50.8 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.673 0.749 . . . . 0.0 110.066 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.6 t -116.96 140.83 49.0 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 106.641 -1.614 . . . . 0.0 106.641 178.258 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.527 ' OD1' HG22 ' A' ' 49' ' ' VAL . 49.0 m-20 -129.96 116.69 18.97 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.035 -1.04 . . . . 0.0 109.727 -179.205 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -116.57 124.38 49.68 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -114.18 146.05 40.87 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -163.96 168.31 38.4 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.159 -1.576 . . . . 0.0 109.159 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.3 t -110.39 127.32 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.535 -0.98 . . . . 0.0 109.363 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.3 t -89.59 118.89 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.375 -0.828 . . . . 0.0 109.792 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 30.1 p -128.25 149.97 72.79 Favored Pre-proline 0 N--CA 1.494 1.732 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.89 -16.12 3.86 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 121.276 1.318 . . . . 0.0 111.414 -179.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 84.2 p -108.21 -13.2 14.96 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.393 -0.817 . . . . 0.0 110.697 -179.663 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 56.8 m -132.55 106.87 13.07 Favored Pre-proline 0 N--CA 1.505 2.286 0 O-C-N 121.086 -1.009 . . . . 0.0 110.561 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -88.28 162.43 6.95 Favored 'Trans proline' 0 N--CA 1.49 1.293 0 C-N-CA 122.267 1.978 . . . . 0.0 111.833 178.329 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.5 t -120.17 128.49 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.158 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -104.64 128.77 52.77 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.124 -0.985 . . . . 0.0 111.324 -178.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 74' ' ' GLN . 1.1 p -90.05 0.09 57.31 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 177.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -67.9 60.43 0.07 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-O 121.556 0.693 . . . . 0.0 109.143 -179.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.494 ' N ' ' O ' ' A' ' 72' ' ' THR . 7.3 tt0 -68.79 -106.5 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.169 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -103.6 94.47 5.48 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.009 -1.057 . . . . 0.0 109.74 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 79.5 mt -74.46 -29.82 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.013 -1.054 . . . . 0.0 109.698 179.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -59.94 -42.63 94.42 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.809 -1.182 . . . . 0.0 108.186 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 84.2 tttt -65.27 -42.16 93.49 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.277 -0.889 . . . . 0.0 108.749 178.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.599 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.4 OUTLIER -69.75 -42.7 73.54 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.562 -0.711 . . . . 0.0 110.179 -179.132 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -63.51 -32.76 74.3 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.168 -1.582 . . . . 0.0 109.233 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.0 tttt -69.81 -47.38 63.03 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 110.735 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.4 p -112.2 -27.55 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 O-C-N 121.504 -0.747 . . . . 0.0 111.661 -177.126 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.599 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 88.61 169.7 45.04 Favored Glycine 0 N--CA 1.49 2.244 0 O-C-N 120.715 -1.241 . . . . 0.0 110.452 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.473 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 23.5 t -115.43 129.67 71.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.892 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -80.07 -67.46 0.76 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.071 -1.018 . . . . 0.0 110.297 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -116.51 140.12 49.71 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.508 -0.745 . . . . 0.0 110.846 -179.102 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 68.9 t80 -119.96 131.8 55.3 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -131.53 132.6 44.3 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.08 -1.012 . . . . 0.0 110.788 -178.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.52 137.1 54.84 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.802 -0.561 . . . . 0.0 109.551 179.266 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 44.7 tp -117.16 133.32 56.14 Favored 'General case' 0 N--CA 1.502 2.167 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 p -129.08 122.18 29.39 Favored 'General case' 0 N--CA 1.503 2.215 0 CA-C-O 121.708 0.766 . . . . 0.0 110.733 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -132.35 152.75 51.3 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.891 -0.506 . . . . 0.0 109.846 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 78.0 m95 -70.21 139.89 52.37 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.048 -1.033 . . . . 0.0 109.07 178.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.434 HG23 ' H ' ' A' ' 45' ' ' SER . 59.7 t -112.53 120.83 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.156 0 O-C-N 121.383 -0.823 . . . . 0.0 109.397 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.487 0 N-CA-C 109.189 -1.564 . . . . 0.0 109.189 179.844 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.653 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.414 ' OD1' ' O ' ' A' ' 8' ' ' ASP . 61.1 t0 -92.13 -27.47 17.71 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.234 -0.917 . . . . 0.0 109.555 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -95.15 4.08 54.01 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.392 -0.817 . . . . 0.0 110.099 -179.276 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 19.7 t -110.61 134.08 54.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.5 -0.75 . . . . 0.0 109.88 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -90.81 131.61 37.07 Favored Pre-proline 0 N--CA 1.49 1.526 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.49 -14.16 22.5 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 121.747 1.631 . . . . 0.0 111.592 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 59.8 p -67.22 -35.83 80.42 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.518 -0.739 . . . . 0.0 109.867 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -90.05 -11.62 40.9 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.208 -0.933 . . . . 0.0 110.313 -179.095 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.668 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 8.2 t -69.63 -29.4 66.89 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.974 -1.079 . . . . 0.0 108.471 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.4 pp -120.62 145.47 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 61.1 mttp -127.09 154.14 45.09 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.402 -0.811 . . . . 0.0 110.032 -179.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.441 ' NE2' ' OH ' ' A' ' 23' ' ' TYR . 83.4 mt-30 -96.07 120.01 35.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.463 -0.773 . . . . 0.0 109.692 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 5.9 t -110.34 115.14 29.14 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.87 -111.09 2.25 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.4 m -117.33 20.69 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.241 0 O-C-N 121.466 -1.02 . . . . 0.0 109.959 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -127.26 160.53 31.02 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.348 -0.845 . . . . 0.0 111.081 -177.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . 0.441 ' OH ' ' NE2' ' A' ' 18' ' ' GLN . 12.5 m-85 -111.33 134.17 53.11 Favored 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.567 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 37.9 p -132.74 145.48 51.06 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.284 -0.885 . . . . 0.0 108.986 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -82.87 127.26 33.33 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.387 -0.821 . . . . 0.0 108.999 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -84.56 80.52 9.21 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.024 -1.047 . . . . 0.0 109.119 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.516 ' C ' ' H ' ' A' ' 29' ' ' VAL . 92.0 p -83.73 -8.35 59.27 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.413 -0.804 . . . . 0.0 109.485 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.67 -2.74 0.2 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.159 -1.177 . . . . 0.0 110.159 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.516 ' H ' ' C ' ' A' ' 27' ' ' SER . 34.9 m -108.32 131.35 59.03 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.328 -1.101 . . . . 0.0 108.442 179.165 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 82.8 p -63.68 -30.23 71.36 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.287 -0.883 . . . . 0.0 111.278 -178.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.452 HG13 ' N ' ' A' ' 32' ' ' CYS . 7.6 p -59.9 -39.9 81.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 120.87 -1.144 . . . . 0.0 110.415 -179.189 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.668 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 56.3 m -59.93 -40.17 87.99 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.95 -1.094 . . . . 0.0 110.077 -179.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 9.0 mmt -79.73 -14.31 58.83 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.0 -1.062 . . . . 0.0 109.415 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 -60.76 -40.56 92.98 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.876 -1.14 . . . . 0.0 108.451 179.323 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -82.99 -51.22 4.29 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.5 mt -58.27 -40.07 80.88 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.919 -1.341 . . . . 0.0 108.832 -179.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -59.93 -40.02 87.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.342 -0.848 . . . . 0.0 109.497 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 60.3 mm-40 -76.8 -6.76 53.64 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.989 -1.069 . . . . 0.0 109.87 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.35 32.56 68.37 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 120.066 -1.064 . . . . 0.0 110.646 178.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -102.81 -9.65 19.77 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.6 HG12 ' H ' ' A' ' 43' ' ' GLY . 5.8 t -134.19 158.16 41.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -179.087 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 94' ' ' VAL . 97.2 mtt180 -117.33 -11.08 10.63 Favored 'General case' 0 N--CA 1.501 2.087 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 178.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.6 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 146.09 -157.33 27.34 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 107.879 -2.088 . . . . 0.0 107.879 -179.175 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 77.2 t -120.01 128.42 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.281 -1.129 . . . . 0.0 108.538 179.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.8 m -86.17 132.78 33.94 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.118 -0.989 . . . . 0.0 108.351 179.454 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 46' ' ' VAL . 13.2 p -132.52 132.46 60.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.592 -0.693 . . . . 0.0 109.779 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.3 m -128.47 141.1 51.5 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 178.395 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.426 ' O ' ' OD1' ' A' ' 59' ' ' ASN . . . -130.87 149.6 19.16 Favored Glycine 0 N--CA 1.505 3.272 0 C-N-CA 120.21 -0.995 . . . . 0.0 110.872 -178.621 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 38.2 t -125.04 129.99 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.824 -0.809 . . . . 0.0 108.825 179.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.539 ' CE2' ' O ' ' A' ' 72' ' ' THR . 50.0 m-85 -105.45 121.89 44.86 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.475 -0.766 . . . . 0.0 109.567 179.285 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.429 ' HB2' ' H ' ' A' ' 86' ' ' LYS . 45.8 m-85 -95.76 121.59 37.65 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.045 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.444 ' C ' ' N ' ' A' ' 54' ' ' ASP . 93.3 m-85 -106.28 128.61 54.11 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.236 -0.915 . . . . 0.0 109.271 179.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.405 ' C ' ' H ' ' A' ' 55' ' ' GLY . 51.9 t30 -48.77 -17.13 0.15 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.067 -1.021 . . . . 0.0 109.199 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.444 ' N ' ' C ' ' A' ' 52' ' ' TYR . 62.7 m-20 -67.99 3.28 1.62 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.407 -0.808 . . . . 0.0 109.115 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.405 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 77.68 19.77 75.21 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 178.655 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.1 p -117.79 147.67 42.78 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.383 -1.069 . . . . 0.0 109.952 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 24.3 p -130.57 127.96 40.1 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.703 -0.623 . . . . 0.0 109.543 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 30.6 t -118.39 154.49 32.31 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.426 ' OD1' ' O ' ' A' ' 48' ' ' GLY . 57.9 t-20 -141.53 133.15 27.02 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.796 -1.19 . . . . 0.0 110.149 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.438 ' CZ ' ' NE2' ' A' ' 74' ' ' GLN . 58.6 m-85 -116.46 124.41 49.91 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.304 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 62.9 tttm -114.36 143.4 44.96 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.15 172.46 43.38 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 49.0 t -114.74 128.67 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.629 -0.924 . . . . 0.0 109.156 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 75.7 t -98.08 123.02 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.218 -0.927 . . . . 0.0 109.515 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.403 ' O ' ' N ' ' A' ' 67' ' ' SER . 17.0 p -121.55 151.0 56.16 Favored Pre-proline 0 N--CA 1.496 1.856 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_exo -34.49 -34.0 0.08 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.399 2.066 . . . . 0.0 113.191 -179.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.403 ' N ' ' O ' ' A' ' 65' ' ' THR . 63.4 m -106.76 -0.55 23.4 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.379 -0.825 . . . . 0.0 111.78 -178.626 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.1 m -124.39 106.86 30.05 Favored Pre-proline 0 N--CA 1.508 2.437 0 O-C-N 120.945 -1.097 . . . . 0.0 111.527 -178.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -92.61 161.2 2.89 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 C-N-CA 122.712 2.275 . . . . 0.0 111.025 177.126 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 91.1 t -134.64 139.88 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.238 0 O-C-N 120.952 -1.092 . . . . 0.0 109.825 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -95.43 138.72 32.72 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.165 -0.959 . . . . 0.0 109.158 179.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.539 ' O ' ' CE2' ' A' ' 50' ' ' PHE . 5.8 t -110.93 -33.83 6.4 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.321 -0.862 . . . . 0.0 109.419 -179.769 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.508 ' ND2' ' CD1' ' A' ' 76' ' ' ILE . 9.6 t30 -92.1 32.32 1.17 Allowed 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.218 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.438 ' NE2' ' CZ ' ' A' ' 60' ' ' PHE . 13.8 pt20 -54.13 -22.56 11.43 Favored 'General case' 0 N--CA 1.499 2.011 0 C-N-CA 120.276 -0.57 . . . . 0.0 112.246 -178.056 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -107.37 71.9 0.85 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 120.702 -1.249 . . . . 0.0 109.735 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.508 ' CD1' ' ND2' ' A' ' 73' ' ' ASN . 45.7 mm -70.1 -40.35 78.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.335 -0.853 . . . . 0.0 111.332 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -60.12 -46.9 88.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.629 -1.294 . . . . 0.0 108.551 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 29.6 ttmt -60.08 -50.03 75.33 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.293 -0.879 . . . . 0.0 108.864 179.092 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.568 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.3 m -62.36 -42.8 99.69 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.79 -0.569 . . . . 0.0 110.625 -178.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.424 ' OD1' HG22 ' A' ' 76' ' ' ILE . 6.0 m120 -60.47 -35.28 75.5 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.561 -1.337 . . . . 0.0 110.027 179.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 14.7 tmtt? -67.07 -48.55 67.91 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.089 -1.007 . . . . 0.0 111.079 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -113.45 -26.88 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.183 -0.948 . . . . 0.0 111.572 -178.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 90.07 168.11 42.61 Favored Glycine 0 N--CA 1.491 2.323 0 O-C-N 120.54 -1.35 . . . . 0.0 110.173 179.737 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.05 124.58 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -79.92 -65.64 0.98 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.094 -1.004 . . . . 0.0 110.286 -179.169 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.429 ' H ' ' HB2' ' A' ' 51' ' ' TYR . 44.3 tptt -115.38 142.28 46.91 Favored 'General case' 0 N--CA 1.504 2.23 0 O-C-N 121.415 -0.803 . . . . 0.0 110.526 -178.738 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.0 t80 -121.13 132.1 54.65 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 -135.01 127.18 29.98 Favored 'General case' 0 N--CA 1.503 2.199 0 O-C-N 121.126 -0.984 . . . . 0.0 110.358 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.87 134.63 52.63 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.654 -0.653 . . . . 0.0 110.017 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.6 tp -118.51 133.45 55.86 Favored 'General case' 0 N--CA 1.503 2.192 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.2 p -129.2 126.36 39.0 Favored 'General case' 0 N--CA 1.503 2.198 0 CA-C-O 121.53 0.681 . . . . 0.0 110.678 -179.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 58.2 mm-40 -134.4 158.46 43.79 Favored 'General case' 0 N--CA 1.504 2.235 0 CA-C-O 121.488 0.661 . . . . 0.0 110.599 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 71.9 m95 -71.15 139.21 50.15 Favored 'General case' 0 N--CA 1.494 1.774 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 178.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.431 ' O ' ' N ' ' A' ' 42' ' ' ARG . 44.6 t -112.41 118.79 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.289 -0.882 . . . . 0.0 109.335 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.504 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.318 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -66.72 -73.3 0.14 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.758 -0.589 . . . . 0.0 110.234 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 64.8 t-20 -145.45 47.05 1.29 Allowed 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 179.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.409 HG23 ' HE1' ' A' ' 93' ' ' TRP . 2.6 m -81.17 139.75 17.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.538 -0.726 . . . . 0.0 109.077 -178.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.447 ' N ' ' OD1' ' A' ' 11' ' ' ASP . 2.0 m-20 -76.66 130.01 77.71 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.906 . . . . 0.0 109.981 -178.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -81.55 -19.96 7.2 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.22 1.947 . . . . 0.0 112.079 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 81.9 p -64.87 -36.53 84.64 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.437 -0.79 . . . . 0.0 110.572 -179.574 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -68.99 -24.66 64.26 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.132 -0.98 . . . . 0.0 109.715 -179.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.484 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 50.1 t -65.56 -35.16 80.03 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.331 -0.856 . . . . 0.0 109.775 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -117.09 140.42 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.063 0 O-C-N 121.436 -0.79 . . . . 0.0 109.149 -179.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -117.82 147.17 43.3 Favored 'General case' 0 N--CA 1.5 2.026 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -93.77 122.22 36.01 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.172 -0.955 . . . . 0.0 109.746 -179.429 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.479 ' O ' ' N ' ' A' ' 21' ' ' VAL . 26.3 t -110.67 123.71 50.53 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.117 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.42 -94.28 0.01 OUTLIER Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.479 ' N ' ' O ' ' A' ' 19' ' ' SER . 24.7 m -139.4 28.03 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.945 0 O-C-N 121.236 -1.155 . . . . 0.0 109.833 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.6 pt20 -131.42 163.65 27.45 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.318 -0.864 . . . . 0.0 110.035 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 54.0 m-85 -115.69 139.97 49.63 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 76.6 p -134.15 148.67 50.98 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.388 -0.82 . . . . 0.0 109.021 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 52.1 t80 -87.54 124.92 33.99 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.441 -0.787 . . . . 0.0 110.007 -178.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -84.39 84.93 7.47 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.33 -0.856 . . . . 0.0 109.732 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 92.4 p -77.22 -9.44 58.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.141 -0.975 . . . . 0.0 109.679 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -72.9 -1.91 56.42 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -98.89 131.64 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.159 -1.2 . . . . 0.0 108.431 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 27.3 t -59.97 -42.58 94.46 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.324 -0.86 . . . . 0.0 110.643 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.451 HG13 ' N ' ' A' ' 32' ' ' CYS . 9.9 p -59.95 -40.15 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.711 -1.243 . . . . 0.0 110.327 -179.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.484 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 90.2 m -61.95 -48.29 81.07 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.014 -1.054 . . . . 0.0 111.244 -178.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 1.2 mmt -77.64 -24.67 49.43 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.735 -1.228 . . . . 0.0 111.358 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -60.06 -40.05 88.12 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.709 -1.244 . . . . 0.0 109.498 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -72.44 -44.2 42.53 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.2 mt -66.2 -42.58 88.58 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.309 -1.112 . . . . 0.0 109.629 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -60.88 -40.08 91.67 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.07 -1.019 . . . . 0.0 110.212 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -78.66 -12.49 60.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.354 -0.841 . . . . 0.0 109.907 -178.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.02 29.27 70.8 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 41.9 mmtm -103.26 -5.39 23.14 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.756 HG12 ' H ' ' A' ' 43' ' ' GLY . 72.4 t -135.13 160.26 40.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.444 ' N ' HG12 ' A' ' 41' ' ' VAL . 93.4 mtt-85 -120.95 -5.96 9.56 Favored 'General case' 0 N--CA 1.501 2.095 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.756 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 132.59 -158.58 23.09 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 107.939 -2.064 . . . . 0.0 107.939 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 81.3 t -121.98 128.1 75.53 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.222 -1.164 . . . . 0.0 110.194 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.6 t -83.13 134.98 34.97 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 178.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 7.7 p -131.22 134.57 61.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.38 -0.825 . . . . 0.0 109.963 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.8 p -125.35 141.6 51.98 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -129.61 138.1 10.01 Favored Glycine 0 N--CA 1.503 3.107 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -178.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.15 125.01 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.61 ' CG ' ' NE2' ' A' ' 74' ' ' GLN . 26.3 m-85 -102.31 121.78 42.95 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 77.2 m-85 -94.61 129.28 41.53 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 120.984 -1.072 . . . . 0.0 109.517 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.47 ' OH ' ' NE2' ' A' ' 74' ' ' GLN . 68.4 m-85 -109.34 130.48 55.49 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.613 -0.679 . . . . 0.0 110.433 -179.693 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 43.1 t30 -50.61 -16.72 0.41 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.347 -0.846 . . . . 0.0 108.971 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.419 ' N ' ' C ' ' A' ' 52' ' ' TYR . 29.6 t0 -73.26 1.3 9.7 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.332 -0.855 . . . . 0.0 109.352 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.16 18.98 70.62 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 179.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.4 p -117.34 146.74 43.18 Favored 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.482 -1.01 . . . . 0.0 110.106 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.3 p -130.23 140.25 50.73 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.65 0.738 . . . . 0.0 110.384 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 65.3 p -118.14 143.95 46.07 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 178.235 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -137.79 119.73 15.38 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.876 -1.14 . . . . 0.0 109.933 -179.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -115.61 125.24 52.68 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -110.55 143.5 40.83 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -161.89 161.46 33.34 Favored Glycine 0 C--N 1.284 -2.319 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 32.2 t -108.12 125.85 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.347 -1.09 . . . . 0.0 109.049 -179.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 55.5 t -91.77 116.7 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.318 -0.864 . . . . 0.0 109.417 -179.569 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 67' ' ' SER . 22.3 p -135.89 149.93 70.08 Favored Pre-proline 0 N--CA 1.494 1.73 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 179.244 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_exo -41.47 -18.03 0.07 OUTLIER 'Trans proline' 0 C--N 1.313 -1.307 0 C-N-CA 121.908 1.739 . . . . 0.0 112.039 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.526 ' N ' ' O ' ' A' ' 65' ' ' THR . 68.7 m -69.96 -52.12 27.05 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.277 -0.889 . . . . 0.0 111.139 -179.002 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 60.1 p -149.64 151.75 33.61 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 120.731 -1.231 . . . . 0.0 110.064 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -85.38 165.72 10.84 Favored 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.728 2.285 . . . . 0.0 112.422 178.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 68.8 t -111.23 134.05 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.219 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -102.36 131.78 48.76 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.121 -0.987 . . . . 0.0 112.048 -177.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.462 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.3 OUTLIER -111.01 20.07 17.85 Favored 'General case' 0 N--CA 1.503 2.217 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 177.694 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.509 HD22 ' N ' ' A' ' 73' ' ' ASN . 0.0 OUTLIER -77.07 55.73 1.17 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.575 -0.703 . . . . 0.0 110.383 -178.782 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.61 ' NE2' ' CG ' ' A' ' 50' ' ' PHE . 13.2 pt20 -49.0 175.04 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.366 -0.834 . . . . 0.0 108.884 178.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -55.19 107.71 0.34 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.819 -1.176 . . . . 0.0 108.64 179.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.409 ' O ' HG22 ' A' ' 76' ' ' ILE . 72.2 mt -79.36 -13.83 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.181 -0.949 . . . . 0.0 110.019 -179.55 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -59.94 -45.18 93.47 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.87 -1.144 . . . . 0.0 109.254 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 1.3 ptpp? -66.23 -38.53 88.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.93 -1.107 . . . . 0.0 108.905 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.597 ' O ' ' N ' ' A' ' 83' ' ' GLY . 3.7 m -59.96 -50.06 75.25 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.577 -0.702 . . . . 0.0 110.095 -179.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -60.48 -36.4 78.21 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 120.498 -1.377 . . . . 0.0 108.852 179.046 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 22.3 tttp -69.37 -47.29 64.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.405 -0.809 . . . . 0.0 110.929 -179.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.7 p -111.98 -29.72 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.18 0 O-C-N 121.245 -0.909 . . . . 0.0 111.817 -177.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.62 164.49 40.14 Favored Glycine 0 N--CA 1.49 2.279 0 O-C-N 120.705 -1.247 . . . . 0.0 110.696 179.053 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 82.6 t -109.86 130.82 62.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 48.0 tp60 -79.94 -67.37 0.77 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.228 -0.92 . . . . 0.0 110.254 -179.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -115.35 146.24 41.74 Favored 'General case' 0 N--CA 1.503 2.184 0 O-C-N 121.453 -0.78 . . . . 0.0 111.152 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -119.73 131.67 55.44 Favored 'General case' 0 N--CA 1.499 1.989 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 14.0 tpp85 -137.62 136.15 37.24 Favored 'General case' 0 N--CA 1.504 2.266 0 O-C-N 120.932 -1.105 . . . . 0.0 111.057 -178.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.524 ' C ' HD12 ' A' ' 90' ' ' LEU . . . -123.97 137.69 54.57 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.445 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.524 HD12 ' C ' ' A' ' 89' ' ' ALA . 10.4 mp -119.84 126.17 50.33 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 16.9 p -127.01 125.09 40.84 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.301 -0.874 . . . . 0.0 110.447 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -132.13 147.44 52.43 Favored 'General case' 0 N--CA 1.5 2.039 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . 0.409 ' HE1' HG23 ' A' ' 10' ' ' VAL . 75.1 m95 -70.72 139.27 51.11 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.913 -1.117 . . . . 0.0 109.593 179.497 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.8 t -111.37 123.76 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.976 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.444 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.652 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -179.693 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.162 0.506 . . . . 0.0 109.655 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 34.0 p-10 -86.49 -20.06 28.62 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.038 -1.039 . . . . 0.0 109.172 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 57.0 t30 -95.36 1.68 54.39 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.411 -0.806 . . . . 0.0 109.045 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.6 t -116.41 126.19 73.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.749 -0.594 . . . . 0.0 109.903 -178.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -83.49 139.83 41.4 Favored Pre-proline 0 N--CA 1.489 1.499 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 178.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -75.65 -14.17 19.86 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 121.762 1.641 . . . . 0.0 111.868 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 77.6 p -60.21 -39.96 88.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.367 -0.833 . . . . 0.0 109.722 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 88.6 mm-40 -84.24 -11.88 55.72 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.139 -0.976 . . . . 0.0 109.725 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.625 ' HG ' ' HG ' ' A' ' 32' ' ' CYS . 29.9 t -69.69 -31.45 69.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.146 -0.971 . . . . 0.0 108.677 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.5 pp -123.58 146.15 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.413 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.5 mttt -111.31 145.18 39.26 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.285 -0.884 . . . . 0.0 109.885 -178.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.454 ' NE2' ' CZ ' ' A' ' 87' ' ' TYR . 63.3 tt0 -97.65 114.81 26.84 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.438 ' O ' ' N ' ' A' ' 21' ' ' VAL . 48.0 m -115.13 130.12 56.84 Favored 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.67 -98.27 0.01 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.467 ' CG1' HD22 ' A' ' 73' ' ' ASN . 3.9 m -137.57 27.46 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.369 -1.077 . . . . 0.0 109.836 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 -130.72 162.98 28.27 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 121.196 -0.94 . . . . 0.0 109.956 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -116.95 140.02 49.96 Favored 'General case' 0 N--CA 1.5 2.07 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.028 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 71.3 p -130.53 145.75 51.92 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.38 -0.825 . . . . 0.0 109.446 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -80.78 126.18 31.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.189 -0.944 . . . . 0.0 108.521 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -85.76 83.48 7.84 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.176 -0.953 . . . . 0.0 110.422 -179.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.9 p -81.07 -9.07 59.88 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.132 -0.98 . . . . 0.0 109.614 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -57.42 -39.18 90.14 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.5 m -80.84 136.89 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.106 -1.232 . . . . 0.0 108.984 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 24.1 t -67.54 -30.28 69.89 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.359 -0.838 . . . . 0.0 111.178 -178.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.443 HG13 ' N ' ' A' ' 32' ' ' CYS . 8.1 p -60.0 -40.06 82.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.818 -1.176 . . . . 0.0 110.419 -178.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.625 ' HG ' ' HG ' ' A' ' 15' ' ' CYS . 67.3 m -64.17 -40.17 95.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.786 -1.196 . . . . 0.0 110.14 -179.806 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 97.1 mmm -86.36 -14.96 41.95 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.892 -1.13 . . . . 0.0 109.77 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 30.1 tt0 -60.21 -40.27 89.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.985 -1.072 . . . . 0.0 108.127 179.146 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -79.2 -45.48 8.85 Favored Glycine 0 N--CA 1.485 1.902 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.9 tp -60.42 -43.67 96.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.243 -1.151 . . . . 0.0 109.737 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -67.32 -39.81 85.92 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.202 -0.936 . . . . 0.0 110.055 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -60.39 -31.09 70.03 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.03 -1.044 . . . . 0.0 109.349 -179.523 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.52 23.42 23.97 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 64.5 mmtt -109.73 -0.57 18.44 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 178.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.735 HG12 ' H ' ' A' ' 43' ' ' GLY . 86.9 t -135.37 158.12 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 121.671 0.748 . . . . 0.0 109.259 -179.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.439 ' N ' HG12 ' A' ' 41' ' ' VAL . 67.4 mtp180 -119.9 -9.66 9.63 Favored 'General case' 0 N--CA 1.497 1.925 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.735 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 137.75 -159.96 25.11 Favored Glycine 0 N--CA 1.497 2.72 0 N-CA-C 108.009 -2.037 . . . . 0.0 108.009 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 90.1 t -118.61 129.73 74.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.143 0 O-C-N 121.18 -1.189 . . . . 0.0 109.315 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.2 t -85.91 138.76 31.79 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.324 -0.86 . . . . 0.0 108.883 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.435 ' O ' HG13 ' A' ' 46' ' ' VAL . 12.7 p -130.13 132.49 65.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.785 0.802 . . . . 0.0 109.544 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.4 p -123.78 146.06 48.59 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -141.77 138.7 8.82 Favored Glycine 0 N--CA 1.5 2.954 0 C-N-CA 119.362 -1.399 . . . . 0.0 111.471 -178.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 55.1 t -120.11 122.6 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 178.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.518 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 0.3 OUTLIER -100.06 126.18 46.23 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 179.875 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -98.53 121.39 40.4 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.156 -0.965 . . . . 0.0 109.444 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.532 ' O ' ' N ' ' A' ' 54' ' ' ASP . 91.7 m-85 -105.47 125.58 51.14 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.382 -0.824 . . . . 0.0 109.356 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.671 HD22 ' NE2' ' A' ' 85' ' ' GLN . 20.9 t-20 -45.53 -16.62 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.147 -0.971 . . . . 0.0 109.49 179.543 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 52' ' ' TYR . 7.4 t70 -67.79 2.52 1.91 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.378 -0.826 . . . . 0.0 109.275 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.39 18.83 77.47 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 16.3 p -116.65 148.36 41.07 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.555 -0.968 . . . . 0.0 110.067 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 69.6 p -129.99 138.07 50.63 Favored 'General case' 0 N--CA 1.496 1.872 0 CA-C-O 121.589 0.709 . . . . 0.0 109.665 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.5 t -118.65 142.37 47.71 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 107.224 -1.399 . . . . 0.0 107.224 178.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.439 ' OD1' ' O ' ' A' ' 59' ' ' ASN . 39.7 p-10 -135.05 117.04 15.28 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.025 -1.047 . . . . 0.0 109.691 -179.443 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -116.83 130.43 56.71 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.081 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 27.2 ttpp -113.69 141.95 46.61 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -160.08 161.29 32.35 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 49.1 t -108.74 124.17 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.47 -1.017 . . . . 0.0 108.769 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 53.3 t -97.64 119.18 45.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.326 -0.859 . . . . 0.0 110.214 -179.147 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.65 ' O ' ' N ' ' A' ' 67' ' ' SER . 15.4 p -137.36 159.15 70.62 Favored Pre-proline 0 N--CA 1.491 1.616 0 N-CA-C 107.043 -1.466 . . . . 0.0 107.043 178.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_exo -51.2 58.73 0.02 OUTLIER 'Trans proline' 0 N--CA 1.504 2.147 0 C-N-CA 122.247 1.965 . . . . 0.0 113.688 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.65 ' N ' ' O ' ' A' ' 65' ' ' THR . 3.1 m -140.98 -64.07 0.46 Allowed 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.762 -1.211 . . . . 0.0 109.417 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 30.4 p -141.76 149.97 55.2 Favored Pre-proline 0 N--CA 1.5 2.064 0 O-C-N 121.212 -0.93 . . . . 0.0 109.501 179.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -84.57 164.11 12.44 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 122.707 2.271 . . . . 0.0 112.717 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.5 t -122.26 130.12 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.026 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 74.6 m-80 -96.77 136.08 37.82 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 120.806 -1.184 . . . . 0.0 111.11 -178.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.495 ' O ' ' CZ ' ' A' ' 50' ' ' PHE . 1.6 p -81.11 -51.55 8.34 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 178.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.467 HD22 ' CG1' ' A' ' 21' ' ' VAL . 78.9 m-20 -81.46 56.1 2.83 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 66.4 tt0 -47.69 -47.23 29.81 Favored 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 119.843 -0.743 . . . . 0.0 109.553 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -106.12 97.68 7.46 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 82.2 mt -80.31 -23.83 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.228 -0.92 . . . . 0.0 109.834 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 22.9 m120 -60.13 -48.82 80.11 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 120.95 -1.094 . . . . 0.0 109.537 -178.265 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 13.8 ptpt -68.28 -38.63 81.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.676 -1.265 . . . . 0.0 109.223 179.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.609 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.4 OUTLIER -62.2 -45.7 92.21 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.012 -1.055 . . . . 0.0 108.834 179.47 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 9.5 t-20 -60.05 -34.17 73.03 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.63 -1.293 . . . . 0.0 109.499 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.3 tmtt? -64.86 -50.02 68.26 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.197 -0.939 . . . . 0.0 110.727 -179.055 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.4 p -113.2 -27.66 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.229 -0.919 . . . . 0.0 111.545 -178.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.609 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.37 157.69 26.82 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 179.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.0 t -103.52 116.49 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 179.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.671 ' NE2' HD22 ' A' ' 53' ' ' ASN . 97.7 mt-30 -70.9 -47.83 57.01 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.101 -1.0 . . . . 0.0 111.904 -178.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 58.6 tttp -115.58 142.81 46.23 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.239 -0.913 . . . . 0.0 110.798 -178.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.454 ' CZ ' ' NE2' ' A' ' 18' ' ' GLN . 62.3 t80 -120.66 130.07 53.96 Favored 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 178.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 2.2 tpp180 -139.44 127.51 22.38 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.082 -1.011 . . . . 0.0 110.422 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.476 ' C ' HD12 ' A' ' 90' ' ' LEU . . . -125.45 135.36 52.26 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.875 179.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.476 HD12 ' C ' ' A' ' 89' ' ' ALA . 9.8 mp -119.93 129.7 54.46 Favored 'General case' 0 N--CA 1.504 2.231 0 O-C-N 121.306 -0.871 . . . . 0.0 108.745 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 25.2 p -129.28 127.33 40.96 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 121.267 -0.896 . . . . 0.0 110.821 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -133.15 156.21 47.89 Favored 'General case' 0 N--CA 1.502 2.157 0 CA-C-O 121.222 0.534 . . . . 0.0 110.169 179.479 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 69.0 m95 -70.4 138.45 51.3 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.201 -0.937 . . . . 0.0 108.679 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 27.7 t -111.26 120.03 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.382 -0.824 . . . . 0.0 109.89 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 179.573 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.435 ' HB1' ' NE1' ' A' ' 93' ' ' TRP . . . . . . . . 0 N--CA 1.492 1.662 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -60.9 -39.76 90.56 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.754 -0.591 . . . . 0.0 111.346 -179.079 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -84.27 0.33 49.38 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.861 -1.149 . . . . 0.0 110.195 -178.095 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.4 t -106.1 131.54 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.252 -0.905 . . . . 0.0 108.703 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.522 ' O ' ' N ' ' A' ' 13' ' ' SER . 4.3 m-20 -99.91 108.61 52.53 Favored Pre-proline 0 N--CA 1.492 1.662 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 179.634 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -44.72 -12.01 0.05 OUTLIER 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 121.931 1.754 . . . . 0.0 112.35 -179.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.522 ' N ' ' O ' ' A' ' 11' ' ' ASP . 88.1 p -69.59 -38.61 77.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.258 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 98.7 mm-40 -91.14 -6.79 53.1 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 120.947 -1.095 . . . . 0.0 109.967 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.793 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 22.4 t -70.66 -24.89 62.78 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.191 -0.943 . . . . 0.0 109.804 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.573 ' CG2' HG11 ' A' ' 44' ' ' VAL . 1.0 OUTLIER -120.8 151.25 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.152 0 O-C-N 121.569 -0.707 . . . . 0.0 110.27 -179.059 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -118.58 137.15 53.45 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.766 -0.584 . . . . 0.0 109.61 -179.54 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -100.35 121.63 41.81 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.205 -0.934 . . . . 0.0 110.353 -179.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 83.5 p -121.21 127.56 51.58 Favored 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.73 -111.13 1.72 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.6 m -127.88 36.51 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.084 0 O-C-N 121.451 -1.029 . . . . 0.0 109.605 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -131.6 160.02 36.57 Favored 'General case' 0 N--CA 1.5 2.051 0 CA-C-O 121.646 0.736 . . . . 0.0 110.62 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -119.67 139.96 51.4 Favored 'General case' 0 N--CA 1.498 1.966 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 80.7 p -134.94 151.13 50.58 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.328 -0.857 . . . . 0.0 109.825 -179.2 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 48.3 t80 -87.51 122.88 31.79 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.393 -0.817 . . . . 0.0 109.311 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -82.66 88.28 6.7 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.344 -0.847 . . . . 0.0 109.77 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 59.7 p -80.5 -9.9 59.75 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.106 -0.996 . . . . 0.0 109.626 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -56.66 -31.8 60.89 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -84.24 114.23 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.06 -1.259 . . . . 0.0 107.989 179.281 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.545 ' O ' ' N ' ' A' ' 34' ' ' GLN . 59.7 m -60.05 -40.04 88.04 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.237 -0.914 . . . . 0.0 111.132 -178.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 6.1 m -52.09 -40.69 30.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 120.946 -1.096 . . . . 0.0 110.653 -178.115 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.793 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 55.3 m -69.97 -44.51 69.33 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.818 -1.176 . . . . 0.0 109.869 -179.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 31.1 ttm -81.07 -13.0 59.18 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.023 -1.048 . . . . 0.0 109.623 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.545 ' N ' ' O ' ' A' ' 30' ' ' SER . 62.5 tt0 -61.44 -40.03 92.98 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 179.207 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.33 -39.96 29.79 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.0 tp -59.84 -43.52 94.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.14 -1.212 . . . . 0.0 108.407 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 44.5 t30 -62.15 -40.22 95.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.507 -0.745 . . . . 0.0 109.775 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -69.07 -26.56 65.01 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.361 -0.837 . . . . 0.0 110.308 -179.394 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 91.17 18.07 47.99 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.854 -1.165 . . . . 0.0 110.804 179.147 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 40.1 mtmt -97.92 -0.75 44.34 Favored 'General case' 0 N--CA 1.495 1.793 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 178.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.734 HG12 ' H ' ' A' ' 43' ' ' GLY . 59.7 t -136.12 156.72 37.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 115.021 -0.99 . . . . 0.0 108.511 -179.669 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -115.74 -10.17 11.8 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.273 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.734 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 139.55 -152.14 22.34 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 108.298 -1.921 . . . . 0.0 108.298 -179.566 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.573 HG11 ' CG2' ' A' ' 16' ' ' ILE . 9.5 p -125.06 129.44 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 121.068 -1.254 . . . . 0.0 109.647 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 t -87.42 134.6 33.57 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.294 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.457 HG13 ' O ' ' A' ' 46' ' ' VAL . 9.1 p -130.06 131.18 66.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.405 -0.81 . . . . 0.0 109.359 179.752 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 53.1 p -121.21 149.72 42.41 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -140.49 144.4 14.77 Favored Glycine 0 N--CA 1.502 3.051 0 C-N-CA 119.603 -1.284 . . . . 0.0 110.751 -178.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 96.0 t -126.37 128.9 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.513 -0.993 . . . . 0.0 109.429 178.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -102.21 120.4 40.4 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -95.5 126.34 40.72 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.246 -0.909 . . . . 0.0 109.314 -179.74 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.51 ' O ' ' N ' ' A' ' 54' ' ' ASP . 55.0 m-85 -109.51 126.5 53.61 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.383 -0.823 . . . . 0.0 109.257 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -45.94 -17.3 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.123 -0.986 . . . . 0.0 109.167 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.51 ' N ' ' O ' ' A' ' 52' ' ' TYR . 39.9 t0 -67.67 0.96 2.74 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.501 -0.75 . . . . 0.0 109.013 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.76 27.77 58.19 Favored Glycine 0 N--CA 1.494 2.5 0 O-C-N 121.206 -0.934 . . . . 0.0 110.769 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.5 p -123.15 150.02 43.81 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.389 -1.065 . . . . 0.0 109.78 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 39.6 p -132.58 133.99 44.37 Favored 'General case' 0 N--CA 1.501 2.101 0 CA-C-O 121.618 0.723 . . . . 0.0 109.669 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 48.3 t -119.89 142.82 48.35 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 178.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 37.9 t-20 -132.49 125.72 31.3 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 120.994 -1.066 . . . . 0.0 109.488 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -117.72 128.27 54.73 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.0 ttpm? -110.82 143.78 40.86 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -158.03 159.34 29.91 Favored Glycine 0 C--N 1.285 -2.282 0 N-CA-C 108.763 -1.735 . . . . 0.0 108.763 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 56.0 t -109.55 124.27 66.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.487 -1.007 . . . . 0.0 108.789 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.9 t -90.21 118.94 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.421 -0.799 . . . . 0.0 109.321 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.538 ' O ' ' N ' ' A' ' 67' ' ' SER . 30.6 p -132.89 151.57 78.27 Favored Pre-proline 0 N--CA 1.492 1.659 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 178.637 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -48.75 -5.51 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 121.295 1.33 . . . . 0.0 111.39 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.538 ' N ' ' O ' ' A' ' 65' ' ' THR . 19.7 t -75.62 -57.33 3.95 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.152 -0.968 . . . . 0.0 110.422 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 56.4 p -147.68 151.82 39.95 Favored Pre-proline 0 N--CA 1.502 2.142 0 O-C-N 120.855 -1.153 . . . . 0.0 110.107 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -84.67 167.33 11.55 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.939 2.426 . . . . 0.0 112.265 178.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.2 t -102.74 131.09 51.68 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -97.39 122.98 41.06 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.334 -0.853 . . . . 0.0 111.976 -177.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 1.2 p -93.37 -0.21 56.66 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 178.125 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.43 ' O ' ' OD1' ' A' ' 73' ' ' ASN . 41.3 t-20 -75.4 54.03 0.71 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.57 -0.706 . . . . 0.0 109.254 -179.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -62.96 -87.18 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -114.35 84.41 2.05 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.497 -0.752 . . . . 0.0 109.226 178.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 10.1 tp -70.11 -32.85 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.121 -0.987 . . . . 0.0 109.727 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -60.02 -47.39 86.04 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.1 -178.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.421 ' CG ' ' N ' ' A' ' 79' ' ' THR . 15.1 ptmt -63.63 -39.82 95.33 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.707 -1.246 . . . . 0.0 108.215 179.288 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.582 ' O ' ' N ' ' A' ' 83' ' ' GLY . 2.0 m -59.96 -40.71 89.96 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -179.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -66.59 -31.8 72.74 Favored 'General case' 0 C--N 1.295 -1.792 0 O-C-N 120.579 -1.326 . . . . 0.0 109.382 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 7.6 tmtm? -69.84 -44.28 70.22 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.915 -1.116 . . . . 0.0 110.378 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -110.58 -26.44 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.377 0 O-C-N 121.206 -0.934 . . . . 0.0 111.349 -178.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.47 164.29 37.6 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.563 HG23 HG23 ' A' ' 79' ' ' THR . 71.4 t -111.21 128.16 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.167 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 93.1 mm-40 -81.27 -65.5 1.0 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.086 -1.009 . . . . 0.0 110.996 -178.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 45.1 tptt -113.92 141.76 46.97 Favored 'General case' 0 N--CA 1.503 2.181 0 O-C-N 121.438 -0.789 . . . . 0.0 110.639 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -120.17 131.25 54.93 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 95.5 mtt180 -131.8 130.8 42.27 Favored 'General case' 0 N--CA 1.508 2.432 0 O-C-N 121.094 -1.004 . . . . 0.0 110.524 -179.231 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -122.68 137.89 54.77 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.675 -0.64 . . . . 0.0 109.894 179.649 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 60.3 tp -120.01 133.31 55.58 Favored 'General case' 0 N--CA 1.506 2.355 0 O-C-N 121.298 -0.876 . . . . 0.0 109.058 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.9 p -128.7 126.11 39.39 Favored 'General case' 0 N--CA 1.504 2.227 0 CA-C-O 121.581 0.705 . . . . 0.0 110.485 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -133.24 159.21 40.88 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.759 -0.588 . . . . 0.0 110.198 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . 0.435 ' NE1' ' HB1' ' A' ' 7' ' ' ALA . 50.7 m95 -75.66 136.46 40.42 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.372 -0.83 . . . . 0.0 108.775 178.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 21.4 t -106.79 120.81 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.485 -0.759 . . . . 0.0 109.304 -179.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.537 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 -179.771 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.61 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -93.11 -25.7 17.77 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.113 -0.992 . . . . 0.0 110.759 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -90.05 4.83 49.07 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.846 -1.159 . . . . 0.0 109.916 -179.18 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.465 HG11 HG11 ' A' ' 31' ' ' VAL . 13.9 t -118.16 131.05 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.379 -0.826 . . . . 0.0 109.686 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 59.0 m-20 -81.96 133.91 50.71 Favored Pre-proline 0 C--N 1.301 -1.512 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 177.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -74.79 -15.34 21.34 Favored 'Trans proline' 0 N--CA 1.494 1.535 0 C-N-CA 121.848 1.699 . . . . 0.0 112.12 -178.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 79.8 p -69.05 -28.83 66.9 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.51 -0.744 . . . . 0.0 110.4 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -78.94 -11.32 60.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.121 -0.987 . . . . 0.0 109.307 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.483 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 11.7 t -69.93 -39.89 75.85 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.062 -1.024 . . . . 0.0 109.81 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.663 HD13 ' H ' ' A' ' 16' ' ' ILE . 0.1 OUTLIER -121.38 142.22 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.108 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 179.504 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -115.85 147.48 40.99 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.476 -0.765 . . . . 0.0 109.697 -178.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -85.05 113.0 21.14 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.43 -0.793 . . . . 0.0 108.953 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.5 m -103.36 120.04 40.03 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.92 -99.78 0.04 OUTLIER Glycine 0 N--CA 1.488 2.148 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 -179.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 t -128.32 20.2 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.456 -1.026 . . . . 0.0 109.195 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -129.61 167.88 17.27 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 121.357 -0.839 . . . . 0.0 110.732 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -124.31 145.21 49.55 Favored 'General case' 0 N--CA 1.501 2.079 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 40.5 p -136.8 153.65 50.76 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.272 -0.893 . . . . 0.0 110.051 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -85.59 123.28 30.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.584 -0.698 . . . . 0.0 109.695 -179.062 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -88.5 83.83 6.8 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.301 -0.875 . . . . 0.0 110.139 -179.578 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 77.7 p -79.85 -4.89 54.15 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 120.991 -1.068 . . . . 0.0 108.989 179.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.73 -40.1 96.14 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.0 m -72.97 139.97 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.008 -1.289 . . . . 0.0 108.862 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 55.2 p -69.04 -25.55 64.53 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.394 -0.816 . . . . 0.0 110.587 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.465 HG11 HG11 ' A' ' 10' ' ' VAL . 54.0 t -60.03 -43.11 91.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.011 -1.056 . . . . 0.0 110.089 -179.037 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.483 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.0 m -60.99 -39.95 91.62 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.067 -1.02 . . . . 0.0 110.464 -179.257 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.2 mmt -80.47 -14.44 58.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.934 -1.104 . . . . 0.0 110.037 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -61.07 -42.56 98.72 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.058 -1.026 . . . . 0.0 108.914 179.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.2 -47.42 9.17 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.7 mt -61.26 -41.66 97.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.074 -1.251 . . . . 0.0 110.14 -179.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -65.52 -39.86 92.31 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.166 -0.959 . . . . 0.0 109.333 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -66.86 -29.66 69.62 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.379 -0.826 . . . . 0.0 109.494 -179.601 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.28 22.29 54.76 Favored Glycine 0 N--CA 1.494 2.557 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 31.2 ttmt -107.61 -3.51 19.21 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 179.218 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.73 HG12 ' H ' ' A' ' 43' ' ' GLY . 86.3 t -133.68 160.27 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.305 -179.183 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.451 ' N ' HG12 ' A' ' 41' ' ' VAL . 81.5 mtt85 -121.79 -8.1 8.97 Favored 'General case' 0 N--CA 1.499 2.023 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.73 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.34 -152.86 23.14 Favored Glycine 0 N--CA 1.499 2.86 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 99.2 t -126.53 130.0 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.322 0 O-C-N 121.066 -1.255 . . . . 0.0 109.667 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.406 ' H ' HG23 ' A' ' 94' ' ' VAL . 1.1 t -84.43 137.86 33.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.319 -0.863 . . . . 0.0 109.608 179.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 7.5 p -132.7 134.19 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.43 -0.794 . . . . 0.0 108.943 179.034 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 86.7 p -121.93 146.91 46.67 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 179.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -135.99 131.24 5.64 Favored Glycine 0 N--CA 1.498 2.811 0 C-N-CA 119.964 -1.112 . . . . 0.0 110.525 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 53.7 t -120.96 127.02 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -105.47 116.05 31.3 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 179.456 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -92.97 137.53 32.28 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.361 -0.837 . . . . 0.0 109.879 -178.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 74.0 m-85 -120.11 137.08 54.35 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.367 -0.833 . . . . 0.0 109.676 179.347 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 18.7 t-20 -47.29 -21.32 0.27 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.475 -0.766 . . . . 0.0 109.531 179.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.414 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 10.4 t70 -68.47 0.95 3.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.267 -0.896 . . . . 0.0 109.208 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 75.61 17.93 79.94 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.9 p -111.65 154.39 24.98 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.444 -1.033 . . . . 0.0 108.932 179.329 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 32.7 p -140.44 148.01 40.53 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.38 -0.825 . . . . 0.0 110.525 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 54.9 m -117.86 147.58 42.94 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 106.046 -1.835 . . . . 0.0 106.046 177.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -139.97 116.17 10.5 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.974 -1.079 . . . . 0.0 109.705 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -115.99 122.42 45.2 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 178.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -112.26 145.57 39.71 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -165.92 178.9 40.42 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 -179.466 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 30.4 t -119.42 127.53 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.487 -1.008 . . . . 0.0 109.593 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 t -89.46 118.9 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.436 -0.79 . . . . 0.0 109.875 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.45 ' O ' ' N ' ' A' ' 67' ' ' SER . 26.6 p -138.14 150.05 65.7 Favored Pre-proline 0 N--CA 1.494 1.727 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -44.55 -19.7 0.28 Allowed 'Trans proline' 0 C--N 1.311 -1.4 0 C-N-CA 121.111 1.207 . . . . 0.0 111.414 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.45 ' N ' ' O ' ' A' ' 65' ' ' THR . 69.9 m -70.05 -46.16 65.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.512 -0.743 . . . . 0.0 111.441 -178.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -148.47 141.31 15.25 Favored Pre-proline 0 N--CA 1.504 2.235 0 O-C-N 120.664 -1.273 . . . . 0.0 110.945 -178.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -86.95 165.09 8.74 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.087 2.524 . . . . 0.0 112.229 178.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 72.6 t -113.09 128.34 69.9 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.203 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.456 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -104.52 140.61 37.73 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.285 -0.885 . . . . 0.0 111.818 -177.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.43 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.0 OUTLIER -109.9 19.17 19.36 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.024 -1.473 . . . . 0.0 107.024 177.502 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 46.5 t-20 -71.05 55.39 0.19 Allowed 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.637 -0.664 . . . . 0.0 109.522 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.408 ' N ' ' O ' ' A' ' 72' ' ' THR . 55.0 tt0 -49.61 169.35 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.051 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -59.07 123.77 17.72 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.713 -1.242 . . . . 0.0 108.939 -179.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 43.3 mm -80.16 -21.61 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.433 -0.792 . . . . 0.0 110.694 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -60.01 -47.73 84.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.673 -1.267 . . . . 0.0 110.069 -179.009 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 9.9 ptpt -64.14 -39.26 93.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.966 -1.084 . . . . 0.0 108.488 179.206 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.549 ' O ' ' N ' ' A' ' 83' ' ' GLY . 30.2 m -60.0 -45.04 94.03 Favored 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.683 0.754 . . . . 0.0 109.438 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -62.01 -36.16 80.7 Favored 'General case' 0 C--N 1.293 -1.887 0 O-C-N 120.949 -1.095 . . . . 0.0 109.972 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 15.0 tmtt? -70.31 -44.83 67.5 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.102 -0.999 . . . . 0.0 111.119 -178.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.6 p -117.51 -29.04 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.416 0 O-C-N 121.135 -0.978 . . . . 0.0 111.543 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.549 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.0 158.26 33.92 Favored Glycine 0 N--CA 1.497 2.702 0 O-C-N 120.616 -1.302 . . . . 0.0 110.571 179.35 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 56.1 t -100.04 123.44 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -77.69 -65.0 1.02 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.181 -0.949 . . . . 0.0 111.365 -178.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -115.96 152.45 33.45 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.124 -0.985 . . . . 0.0 111.814 -178.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 64.8 t80 -120.94 130.92 54.05 Favored 'General case' 0 N--CA 1.5 2.033 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.364 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -136.86 130.2 31.38 Favored 'General case' 0 N--CA 1.507 2.39 0 O-C-N 120.814 -1.179 . . . . 0.0 110.843 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.68 135.44 53.05 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.59 HD23 ' N ' ' A' ' 91' ' ' THR . 1.2 tt -119.77 129.1 54.31 Favored 'General case' 0 N--CA 1.504 2.228 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.495 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.59 ' N ' HD23 ' A' ' 90' ' ' LEU . 6.5 p -129.1 121.59 28.13 Favored 'General case' 0 N--CA 1.505 2.279 0 O-C-N 121.414 -0.804 . . . . 0.0 111.433 -178.651 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -133.32 159.82 39.14 Favored 'General case' 0 N--CA 1.502 2.165 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.176 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -73.6 144.06 46.13 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.918 -1.113 . . . . 0.0 109.278 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.406 HG23 ' H ' ' A' ' 45' ' ' SER . 60.9 t -114.2 123.71 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.344 -0.848 . . . . 0.0 109.326 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.681 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.621 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -93.62 -28.38 16.04 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.298 -0.876 . . . . 0.0 109.914 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -90.57 0.09 57.48 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.187 -0.946 . . . . 0.0 109.397 -179.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.5 t -109.04 127.8 65.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 O-C-N 121.495 -0.753 . . . . 0.0 109.801 -179.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 60.4 m-20 -87.06 132.12 42.66 Favored Pre-proline 0 N--CA 1.489 1.515 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 178.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -72.84 -14.51 26.73 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 121.633 1.555 . . . . 0.0 112.154 -178.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 30.3 t -61.57 -40.17 93.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.142 -0.974 . . . . 0.0 110.364 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 65.4 mt-30 -81.46 -11.29 59.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.043 -1.035 . . . . 0.0 110.302 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.749 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 35.5 m -70.11 -30.02 67.11 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.948 -1.095 . . . . 0.0 108.939 179.273 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -122.11 140.51 45.79 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -123.95 143.3 50.48 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.528 -0.732 . . . . 0.0 109.398 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -87.5 130.68 34.62 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.086 -1.009 . . . . 0.0 109.456 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 53.6 m -118.9 128.41 54.4 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 46.48 -107.12 0.17 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.7 m -121.78 19.9 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.67 -0.9 . . . . 0.0 109.977 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -130.68 164.99 23.81 Favored 'General case' 0 N--CA 1.503 2.19 0 O-C-N 121.389 -0.819 . . . . 0.0 110.266 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -117.6 140.67 49.33 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 79.2 p -139.94 150.93 45.12 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.305 -0.872 . . . . 0.0 109.044 178.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 8.8 t80 -78.53 128.78 34.03 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.375 -0.828 . . . . 0.0 109.371 -179.412 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -85.69 83.12 7.96 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.341 -0.849 . . . . 0.0 109.257 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.445 ' C ' ' N ' ' A' ' 29' ' ' VAL . 97.6 p -79.08 -5.05 53.12 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.199 -0.938 . . . . 0.0 109.3 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.17 -11.73 0.69 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.474 ' O ' HG23 ' A' ' 29' ' ' VAL . 29.0 m -108.9 127.39 65.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.518 -0.989 . . . . 0.0 108.776 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 64.5 m -70.07 -27.48 64.66 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.42 -0.8 . . . . 0.0 110.451 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.422 HG23 ' N ' ' A' ' 32' ' ' CYS . 3.7 m -60.01 -40.3 82.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.036 -1.04 . . . . 0.0 111.204 -178.18 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.749 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 97.1 m -66.39 -40.24 89.54 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.546 -1.347 . . . . 0.0 110.074 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 70.5 mtp -80.98 -10.08 59.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.953 -1.092 . . . . 0.0 109.603 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -61.23 -40.46 94.1 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -80.46 -51.27 4.99 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.9 tt -60.14 -41.53 92.92 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.105 -1.232 . . . . 0.0 109.726 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 -60.1 -40.22 88.85 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.018 -1.051 . . . . 0.0 109.736 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -79.01 -6.04 55.37 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.348 -0.845 . . . . 0.0 109.487 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.56 29.25 49.37 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.941 -1.123 . . . . 0.0 110.374 178.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -104.48 -9.54 18.31 Favored 'General case' 0 N--CA 1.496 1.848 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.676 HG12 ' H ' ' A' ' 43' ' ' GLY . 70.9 t -136.15 161.2 37.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.492 ' N ' HG12 ' A' ' 41' ' ' VAL . 57.9 ttm-85 -122.95 -7.65 8.38 Favored 'General case' 0 N--CA 1.495 1.8 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.676 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.3 -161.16 25.63 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 95.0 t -122.5 130.13 74.74 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.335 -1.097 . . . . 0.0 109.103 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.454 ' H ' HG23 ' A' ' 94' ' ' VAL . 1.8 m -86.3 136.79 33.02 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.051 -1.03 . . . . 0.0 108.303 179.364 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.407 ' O ' HG23 ' A' ' 46' ' ' VAL . 6.0 m -132.08 133.45 60.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.644 -0.66 . . . . 0.0 109.543 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 57.3 p -122.65 142.46 50.64 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 179.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -131.3 143.06 14.48 Favored Glycine 0 N--CA 1.503 3.151 0 C-N-CA 120.085 -1.055 . . . . 0.0 111.113 -178.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 92.6 t -126.25 129.99 72.03 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.852 -0.793 . . . . 0.0 109.405 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -103.97 120.05 40.23 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 62.6 m-85 -96.64 123.22 40.24 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.354 -0.842 . . . . 0.0 109.405 -179.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.58 ' CD1' ' NZ ' ' A' ' 78' ' ' LYS . 96.9 m-85 -109.03 128.03 54.61 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.607 -0.683 . . . . 0.0 109.634 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.46 ' ND2' ' O ' ' A' ' 53' ' ' ASN . 0.5 OUTLIER -45.58 -17.27 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.27 -0.894 . . . . 0.0 109.324 179.149 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 52' ' ' TYR . 22.1 t0 -67.42 1.54 2.21 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.429 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 75.36 23.42 73.65 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.346 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.9 p -121.76 149.85 42.69 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.499 -1.001 . . . . 0.0 110.002 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.1 p -134.01 138.08 45.16 Favored 'General case' 0 N--CA 1.499 2.016 0 CA-C-O 121.824 0.821 . . . . 0.0 110.174 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.8 t -119.78 143.2 47.97 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 58.6 t-20 -134.44 129.84 35.89 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 120.624 -1.297 . . . . 0.0 110.127 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -117.06 128.69 55.4 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -113.98 142.7 45.83 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -165.42 170.58 40.39 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.9 t -113.96 126.45 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.112 0 O-C-N 121.544 -0.974 . . . . 0.0 109.408 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 72.5 t -96.45 117.92 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.075 -1.015 . . . . 0.0 109.906 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.52 ' O ' ' N ' ' A' ' 67' ' ' SER . 24.3 p -126.69 150.12 70.25 Favored Pre-proline 0 N--CA 1.501 2.088 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 179.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_exo -37.41 -22.39 0.05 OUTLIER 'Trans proline' 0 N--CA 1.49 1.306 0 C-N-CA 122.227 1.951 . . . . 0.0 112.984 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.52 ' N ' ' O ' ' A' ' 65' ' ' THR . 9.0 t -114.1 -16.06 12.16 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.275 -0.891 . . . . 0.0 111.556 -178.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 98.5 m -119.6 106.53 41.99 Favored Pre-proline 0 N--CA 1.502 2.156 0 O-C-N 120.976 -1.077 . . . . 0.0 110.193 -179.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -91.41 163.48 3.62 Favored 'Trans proline' 0 N--CA 1.492 1.416 0 C-N-CA 122.657 2.238 . . . . 0.0 112.347 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.8 t -127.22 130.03 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.293 0 N-CA-C 108.714 -0.846 . . . . 0.0 108.714 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -100.16 132.31 45.61 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 121.209 -0.932 . . . . 0.0 111.873 -178.094 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.488 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.0 OUTLIER -105.33 19.96 19.69 Favored 'General case' 0 N--CA 1.498 1.938 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.602 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -67.44 54.37 0.06 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.777 -0.577 . . . . 0.0 109.651 -179.256 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.488 ' N ' ' O ' ' A' ' 72' ' ' THR . 0.0 OUTLIER -48.0 166.71 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.285 -0.885 . . . . 0.0 108.831 179.517 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.449 ' O ' ' NE2' ' A' ' 74' ' ' GLN . 78.3 m-20 -57.09 117.83 4.41 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.006 -1.058 . . . . 0.0 109.538 -178.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 47.7 mm -69.59 -39.48 78.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.768 -0.582 . . . . 0.0 109.582 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -56.15 -41.47 75.44 Favored 'General case' 0 N--CA 1.488 1.425 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.58 ' NZ ' ' CD1' ' A' ' 52' ' ' TYR . 28.3 tttm -62.84 -49.47 74.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.317 -0.865 . . . . 0.0 108.884 178.323 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.582 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.0 OUTLIER -67.61 -42.16 82.84 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.535 -0.728 . . . . 0.0 110.062 -179.099 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -60.96 -34.21 74.39 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 120.641 -1.287 . . . . 0.0 110.902 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -70.99 -43.54 67.79 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.887 -1.133 . . . . 0.0 111.243 -178.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.1 p -115.98 -27.78 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.39 -0.819 . . . . 0.0 111.231 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.87 166.01 40.9 Favored Glycine 0 N--CA 1.488 2.162 0 O-C-N 120.675 -1.266 . . . . 0.0 110.371 178.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.9 t -111.06 124.91 68.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -81.34 -64.19 1.24 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.162 -0.962 . . . . 0.0 111.073 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -114.22 143.17 45.27 Favored 'General case' 0 N--CA 1.509 2.48 0 O-C-N 121.167 -0.958 . . . . 0.0 111.299 -178.582 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 74.4 t80 -120.5 134.43 55.27 Favored 'General case' 0 N--CA 1.505 2.291 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 178.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 78.9 mtp180 -136.45 129.0 30.47 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 120.968 -1.083 . . . . 0.0 110.944 -178.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.66 132.66 53.39 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.729 -0.607 . . . . 0.0 109.672 179.047 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.518 HD12 ' N ' ' A' ' 90' ' ' LEU . 7.7 mp -108.83 129.46 55.4 Favored 'General case' 0 N--CA 1.503 2.206 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 179.138 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.9 p -124.2 121.46 35.15 Favored 'General case' 0 N--CA 1.507 2.384 0 O-C-N 121.313 -0.867 . . . . 0.0 110.575 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 53.4 tp10 -133.84 150.95 51.41 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.772 -0.58 . . . . 0.0 110.163 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 70.9 m95 -66.95 141.55 57.57 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.992 -1.067 . . . . 0.0 108.737 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.454 HG23 ' H ' ' A' ' 45' ' ' SER . 62.0 t -119.3 130.16 74.32 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.177 0 O-C-N 121.503 -0.748 . . . . 0.0 109.989 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.501 3.0 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.338 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 33.5 p-10 -72.81 -20.13 61.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.34 -0.85 . . . . 0.0 110.708 -178.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.7 m120 -99.52 6.71 45.79 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.098 -1.001 . . . . 0.0 109.783 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 29.2 t -119.98 129.97 74.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.47 -0.769 . . . . 0.0 109.905 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.96 140.28 43.1 Favored Pre-proline 0 N--CA 1.489 1.486 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.21 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -71.48 -22.39 24.82 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 121.806 1.671 . . . . 0.0 111.975 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 76.9 p -69.32 -38.93 78.45 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.313 -0.867 . . . . 0.0 109.781 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 56.6 tt0 -70.04 -23.93 63.18 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.304 -0.873 . . . . 0.0 109.739 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.466 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 22.0 m -68.44 -28.54 67.14 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.888 . . . . 0.0 109.685 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.4 pp -116.49 139.1 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.402 -0.811 . . . . 0.0 109.227 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -118.04 147.84 42.84 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.553 -0.717 . . . . 0.0 109.731 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.701 HE22 ' N ' ' A' ' 22' ' ' GLN . 64.2 tp60 -99.58 117.73 34.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.649 -0.657 . . . . 0.0 109.266 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.464 ' O ' ' N ' ' A' ' 21' ' ' VAL . 14.6 t -110.45 118.29 35.88 Favored 'General case' 0 N--CA 1.497 1.902 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 179.023 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.03 -92.42 0.02 OUTLIER Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.727 -1.749 . . . . 0.0 108.727 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.464 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.4 t -140.41 30.52 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 O-C-N 121.328 -1.101 . . . . 0.0 109.564 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.701 ' N ' HE22 ' A' ' 18' ' ' GLN . 89.1 mt-30 -127.46 158.07 38.35 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.271 -0.893 . . . . 0.0 110.334 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . 0.528 ' CZ ' ' OE1' ' A' ' 18' ' ' GLN . 26.9 m-85 -119.74 134.73 55.12 Favored 'General case' 0 N--CA 1.498 1.963 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.1 p -139.97 150.45 44.5 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.225 -0.922 . . . . 0.0 109.833 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.424 ' CZ ' HD11 ' A' ' 36' ' ' LEU . 33.6 t80 -78.99 127.5 32.06 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 179.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . 0.51 HD21 HG13 ' A' ' 29' ' ' VAL . 57.9 t30 -82.81 81.52 8.51 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.068 -1.02 . . . . 0.0 109.777 -179.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 49.9 m -78.31 -5.98 53.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.168 -0.957 . . . . 0.0 109.068 179.638 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -58.36 -37.43 87.56 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.829 -1.308 . . . . 0.0 109.829 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.51 HG13 HD21 ' A' ' 26' ' ' ASN . 28.2 m -84.32 132.38 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.036 -1.273 . . . . 0.0 109.492 -179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.9 m -60.09 -39.42 86.04 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.642 -0.661 . . . . 0.0 111.622 -178.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.403 HG23 ' N ' ' A' ' 32' ' ' CYS . 19.7 m -57.62 -42.99 82.56 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 120.849 -1.157 . . . . 0.0 111.369 -177.336 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.466 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 93.0 m -67.05 -39.99 87.05 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.45 -1.406 . . . . 0.0 109.412 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.1 tpt -79.99 -11.72 59.76 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.008 -1.058 . . . . 0.0 108.419 179.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 61.2 tt0 -65.41 -39.85 92.65 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.07 -46.59 15.79 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.424 HD11 ' CZ ' ' A' ' 25' ' ' TYR . 23.7 mt -60.04 -50.11 75.02 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.213 -1.169 . . . . 0.0 109.943 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -61.08 -39.99 91.98 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.076 -1.015 . . . . 0.0 110.0 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.437 ' OE2' ' NZ ' ' A' ' 40' ' ' LYS . 79.3 tt0 -64.55 -29.82 70.85 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.331 -0.855 . . . . 0.0 109.297 -179.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 91.25 26.54 20.95 Favored Glycine 0 N--CA 1.496 2.638 0 O-C-N 121.161 -0.962 . . . . 0.0 110.765 179.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.437 ' NZ ' ' OE2' ' A' ' 38' ' ' GLU . 96.3 mttt -110.04 -1.86 17.35 Favored 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.661 HG12 ' H ' ' A' ' 43' ' ' GLY . 72.5 t -133.71 160.2 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 CA-C-O 121.756 0.788 . . . . 0.0 109.056 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.547 ' HE ' ' CG1' ' A' ' 94' ' ' VAL . 44.9 ttp180 -125.25 -5.98 7.18 Favored 'General case' 0 N--CA 1.494 1.772 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.673 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.661 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 134.09 -164.42 24.49 Favored Glycine 0 N--CA 1.503 3.136 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 94.6 t -120.07 130.01 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.4 0 CA-C-N 118.747 1.273 . . . . 0.0 110.126 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 38.0 t -79.63 134.08 36.43 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.446 HG13 ' O ' ' A' ' 46' ' ' VAL . 14.7 p -130.04 131.3 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.382 -0.824 . . . . 0.0 109.684 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 60.7 p -122.56 147.03 46.88 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 179.288 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -142.36 136.01 6.97 Favored Glycine 0 N--CA 1.503 3.118 0 C-N-CA 119.409 -1.376 . . . . 0.0 111.04 -179.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.561 ' CG1' HH12 ' A' ' 88' ' ' ARG . 65.0 t -123.45 133.77 68.22 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.311 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -111.06 124.31 51.92 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.603 -0.686 . . . . 0.0 109.185 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.607 ' CD2' ' NH2' ' A' ' 88' ' ' ARG . 23.4 m-85 -95.1 126.06 40.17 Favored 'General case' 0 N--CA 1.504 2.266 0 O-C-N 120.807 -1.183 . . . . 0.0 109.247 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.451 ' C ' ' N ' ' A' ' 54' ' ' ASP . 37.3 m-85 -111.04 131.47 55.03 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -53.13 -14.61 0.67 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.907 -1.121 . . . . 0.0 108.184 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.451 ' N ' ' C ' ' A' ' 52' ' ' TYR . 34.2 t0 -68.72 -4.77 17.05 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.2 12.43 80.8 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.0 p -110.57 159.45 17.54 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.541 -0.976 . . . . 0.0 110.025 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 78.4 p -140.43 143.82 35.8 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.449 -0.782 . . . . 0.0 110.487 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.0 t -114.98 130.01 56.84 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 177.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 12.3 m-20 -130.55 116.94 18.85 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.946 -1.096 . . . . 0.0 109.594 -178.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.532 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 54.5 p90 -117.09 120.69 39.11 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 178.511 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.9 ttpt -110.09 144.06 39.23 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -173.39 -175.35 41.08 Favored Glycine 0 C--N 1.286 -2.226 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 66.3 t -120.53 129.77 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.658 -0.907 . . . . 0.0 109.702 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.489 HG13 ' O ' ' A' ' 64' ' ' VAL . 4.3 p -96.89 124.23 49.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.207 -0.933 . . . . 0.0 109.462 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.0 p -135.58 150.13 71.21 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_exo -40.77 -24.8 0.17 Allowed 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.012 1.808 . . . . 0.0 112.845 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.2 t -102.84 -22.78 13.83 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.26 -0.9 . . . . 0.0 110.983 -178.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 41.5 m -123.17 107.1 32.97 Favored Pre-proline 0 N--CA 1.504 2.255 0 O-C-N 121.146 -0.971 . . . . 0.0 109.945 -179.652 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -89.2 163.09 5.7 Favored 'Trans proline' 0 N--CA 1.491 1.337 0 C-N-CA 122.453 2.102 . . . . 0.0 112.445 179.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.2 t -120.04 127.66 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 -103.99 130.89 51.67 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.306 -0.871 . . . . 0.0 110.805 -178.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.27 9.68 41.6 Favored 'General case' 0 N--CA 1.5 2.057 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 178.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 48.7 t-20 -76.36 56.81 1.11 Allowed 'General case' 0 N--CA 1.486 1.338 0 O-C-N 121.598 -0.689 . . . . 0.0 109.878 -179.004 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.508 ' NE2' ' N ' ' A' ' 75' ' ' ASP . 0.0 OUTLIER -63.96 -156.07 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 178.544 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.508 ' N ' ' NE2' ' A' ' 74' ' ' GLN . 76.2 m-20 -73.4 101.39 3.46 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 120.575 -1.328 . . . . 0.0 108.583 179.571 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.473 HG22 ' O ' ' A' ' 76' ' ' ILE . 90.6 mt -79.95 -9.34 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.493 -0.754 . . . . 0.0 109.959 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -59.12 -43.85 91.97 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.98 -1.075 . . . . 0.0 109.337 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 10.1 ptpt -69.94 -39.2 76.23 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.947 -1.096 . . . . 0.0 109.648 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.593 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.8 OUTLIER -60.14 -47.85 84.17 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.764 -1.21 . . . . 0.0 108.266 179.808 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 44.6 t-20 -60.04 -35.07 74.31 Favored 'General case' 0 C--N 1.296 -1.718 0 O-C-N 120.825 -1.172 . . . . 0.0 108.501 178.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 83.4 tttt -64.37 -51.52 62.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.407 -0.808 . . . . 0.0 110.817 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.4 m -115.94 -26.59 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.395 0 O-C-N 121.139 -0.976 . . . . 0.0 111.803 -178.334 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 93.49 166.31 37.79 Favored Glycine 0 N--CA 1.492 2.43 0 O-C-N 120.65 -1.281 . . . . 0.0 110.328 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 59.7 t -110.8 130.02 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.945 -0.738 . . . . 0.0 109.127 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 36.2 tt0 -80.0 -66.57 0.86 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.119 -0.988 . . . . 0.0 110.462 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.417 ' C ' ' HE ' ' A' ' 88' ' ' ARG . 95.0 mttt -115.71 139.98 49.63 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 121.26 -0.9 . . . . 0.0 111.48 -178.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.492 ' CA ' ' HE ' ' A' ' 88' ' ' ARG . 80.6 t80 -121.84 133.38 54.88 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.607 ' NH2' ' CD2' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -138.5 134.07 33.48 Favored 'General case' 0 N--CA 1.507 2.415 0 O-C-N 120.933 -1.104 . . . . 0.0 110.655 -179.874 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.64 136.2 53.72 Favored 'General case' 0 N--CA 1.498 1.927 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.52 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.28 131.91 56.34 Favored 'General case' 0 N--CA 1.505 2.292 0 O-C-N 121.365 -0.834 . . . . 0.0 109.427 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 40.3 p -127.09 125.31 41.05 Favored 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.358 -0.839 . . . . 0.0 110.579 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -133.18 151.61 51.96 Favored 'General case' 0 N--CA 1.504 2.242 0 O-C-N 121.783 -0.573 . . . . 0.0 110.338 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 71.0 m95 -70.37 140.73 52.19 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.146 -0.971 . . . . 0.0 108.882 178.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.547 ' CG1' ' HE ' ' A' ' 42' ' ' ARG . 38.4 t -117.03 124.8 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 O-C-N 121.399 -0.813 . . . . 0.0 109.315 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.434 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.66 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.52 ' HB1' ' CE2' ' A' ' 93' ' ' TRP . . . . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -84.3 -26.34 28.61 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.27 -0.894 . . . . 0.0 110.362 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.449 ' ND2' ' O ' ' A' ' 9' ' ' ASN . 0.9 OUTLIER -86.32 1.7 50.05 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.103 -0.998 . . . . 0.0 110.077 -179.307 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.456 HG11 HG11 ' A' ' 31' ' ' VAL . 2.0 t -118.15 126.92 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.483 -0.761 . . . . 0.0 109.332 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -77.91 140.33 62.5 Favored Pre-proline 0 C--N 1.3 -1.583 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 178.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -75.21 -13.74 20.89 Favored 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 121.347 1.365 . . . . 0.0 111.549 -179.275 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 38.3 t -60.73 -40.35 92.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.639 -0.663 . . . . 0.0 110.917 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -81.97 -10.03 59.38 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.0 -1.062 . . . . 0.0 109.673 -179.254 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.515 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 18.3 t -70.93 -30.9 67.34 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.125 -0.984 . . . . 0.0 109.335 179.357 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -123.86 151.89 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.204 0 O-C-N 121.443 -0.785 . . . . 0.0 109.318 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.404 ' CD ' HD21 ' A' ' 26' ' ' ASN . 20.9 pttp -130.85 148.22 52.59 Favored 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.502 -0.749 . . . . 0.0 109.374 179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 62.7 tt0 -100.7 124.95 47.03 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.203 -0.935 . . . . 0.0 109.673 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.525 ' O ' ' N ' ' A' ' 21' ' ' VAL . 34.4 p -111.8 121.53 45.31 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.68 -92.87 0.01 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.67 -1.772 . . . . 0.0 108.67 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.525 ' N ' ' O ' ' A' ' 19' ' ' SER . 4.6 m -137.24 30.6 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.356 -1.085 . . . . 0.0 109.264 179.293 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -129.55 159.67 35.6 Favored 'General case' 0 N--CA 1.504 2.226 0 CA-C-O 122.03 0.919 . . . . 0.0 111.029 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -119.89 139.95 51.6 Favored 'General case' 0 N--CA 1.499 2.004 0 N-CA-C 108.404 -0.962 . . . . 0.0 108.404 178.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 77.0 p -138.32 147.42 43.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.28 -0.888 . . . . 0.0 109.001 179.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -83.17 125.65 31.76 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.606 -0.684 . . . . 0.0 109.38 -178.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . 0.404 HD21 ' CD ' ' A' ' 17' ' ' LYS . 9.6 m120 -84.91 90.34 7.78 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.208 -0.933 . . . . 0.0 109.555 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 79.8 p -89.52 -0.87 57.8 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.223 -0.923 . . . . 0.0 108.851 179.352 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -68.33 -2.12 24.89 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.0 m -113.71 130.06 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.546 -0.973 . . . . 0.0 109.363 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 80.5 p -60.45 -28.0 67.96 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.703 -0.623 . . . . 0.0 110.497 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.456 HG11 HG11 ' A' ' 10' ' ' VAL . 71.2 t -61.22 -44.31 98.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 120.948 -1.095 . . . . 0.0 110.338 -178.82 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.515 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 86.1 m -69.83 -39.81 76.24 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.101 -0.999 . . . . 0.0 110.109 -179.034 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.4 mmt -74.95 -20.86 59.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.092 -1.005 . . . . 0.0 109.495 179.708 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -60.42 -39.61 88.03 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 120.985 -1.072 . . . . 0.0 109.073 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.97 -49.13 7.2 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 17.8 mt -62.64 -39.92 95.37 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.333 -1.098 . . . . 0.0 109.737 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -66.46 -39.91 89.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.055 -1.028 . . . . 0.0 109.496 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 77.0 tt0 -67.12 -30.1 70.01 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.058 -1.026 . . . . 0.0 109.348 -179.406 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.32 22.41 27.13 Favored Glycine 0 N--CA 1.497 2.743 0 O-C-N 121.112 -0.992 . . . . 0.0 110.688 179.07 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.1 mtpt -104.47 -1.52 26.57 Favored 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 178.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.713 HG12 ' H ' ' A' ' 43' ' ' GLY . 78.3 t -131.08 158.4 43.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-O 121.639 0.733 . . . . 0.0 109.447 -179.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.438 ' N ' HG12 ' A' ' 41' ' ' VAL . 62.5 ttm-85 -123.38 -6.84 8.17 Favored 'General case' 0 N--CA 1.498 1.965 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.713 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.54 -163.19 26.52 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 108.563 -1.815 . . . . 0.0 108.563 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.8 t -119.42 128.37 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.278 -1.131 . . . . 0.0 108.684 179.595 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.1 p -85.16 137.35 33.07 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.098 -1.001 . . . . 0.0 108.716 179.523 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.439 ' O ' HG13 ' A' ' 46' ' ' VAL . 13.4 p -130.19 131.83 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 54.7 p -125.88 142.1 51.67 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -141.08 139.15 9.35 Favored Glycine 0 N--CA 1.497 2.731 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.317 -178.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 56.0 t -120.02 119.83 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -92.72 117.64 30.22 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -90.37 120.33 31.4 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -105.83 139.16 40.82 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.588 -0.695 . . . . 0.0 110.491 -179.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.469 ' C ' ' H ' ' A' ' 55' ' ' GLY . 45.0 t-20 -61.29 -14.7 28.52 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -66.48 0.82 1.97 Allowed 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.469 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 79.34 16.02 78.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 179.098 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.7 p -123.19 148.21 46.04 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.382 -1.069 . . . . 0.0 110.264 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 63.9 p -127.24 140.04 52.5 Favored 'General case' 0 N--CA 1.496 1.856 0 CA-C-O 121.648 0.737 . . . . 0.0 109.423 179.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.5 t -116.98 147.57 42.18 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 178.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -132.08 119.12 20.55 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.078 -1.014 . . . . 0.0 109.42 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.526 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 51.7 p90 -116.19 120.83 40.24 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.725 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -114.37 145.14 42.19 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 -179.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.4 171.35 43.1 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 72.7 t -110.83 126.94 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.458 -1.025 . . . . 0.0 109.966 -179.676 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 89.2 t -93.13 120.19 42.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.232 -0.918 . . . . 0.0 109.669 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 23.3 p -126.57 151.23 72.72 Favored Pre-proline 0 N--CA 1.495 1.811 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -53.99 -8.65 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 121.449 1.433 . . . . 0.0 111.615 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 70.2 m -111.16 -18.65 12.94 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.476 -0.765 . . . . 0.0 110.243 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 10.3 p -133.91 109.37 11.86 Favored Pre-proline 0 N--CA 1.505 2.321 0 O-C-N 121.106 -0.996 . . . . 0.0 110.799 -179.016 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -86.91 163.58 8.91 Favored 'Trans proline' 0 N--CA 1.497 1.691 0 C-N-CA 122.556 2.171 . . . . 0.0 112.229 178.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 61.6 t -119.05 130.18 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.421 0 O-C-N 121.256 -0.902 . . . . 0.0 109.76 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 64.9 m-20 -100.58 123.63 45.05 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.34 -0.85 . . . . 0.0 110.717 -178.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.513 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.6 OUTLIER -90.87 0.59 57.45 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.832 -1.167 . . . . 0.0 108.665 179.051 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 -66.2 50.35 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.287 -0.883 . . . . 0.0 110.072 -179.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.513 ' N ' ' O ' ' A' ' 72' ' ' THR . 98.9 mm-40 -55.04 -98.04 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.126 -0.984 . . . . 0.0 109.755 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -103.42 85.46 2.48 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.156 -0.965 . . . . 0.0 109.227 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.452 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 9.5 tp -67.38 -39.73 83.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.54 -0.725 . . . . 0.0 109.914 -179.751 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.452 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 97.6 m-20 -59.61 -40.15 86.55 Favored 'General case' 0 C--N 1.297 -1.716 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 -179.58 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 13.0 ttmm -66.71 -41.33 88.16 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.594 -0.691 . . . . 0.0 109.495 178.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.618 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -65.07 -52.3 56.42 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.281 -0.887 . . . . 0.0 110.836 -177.638 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.448 ' ND2' ' O ' ' A' ' 77' ' ' ASN . 0.5 OUTLIER -62.31 -28.17 69.55 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 119.808 -1.807 . . . . 0.0 108.976 179.677 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . 0.445 ' N ' HD22 ' A' ' 80' ' ' ASN . 34.6 ttmt -64.6 -51.09 64.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.129 -0.982 . . . . 0.0 110.496 -179.296 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 m -116.42 -22.04 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.274 0 O-C-N 121.353 -0.842 . . . . 0.0 110.72 -179.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.618 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 83.44 165.96 39.11 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 179.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 28.2 t -108.31 120.45 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -69.79 -55.08 10.82 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.998 -1.064 . . . . 0.0 110.051 -179.364 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -116.84 148.79 40.94 Favored 'General case' 0 N--CA 1.502 2.148 0 CA-C-O 121.863 0.84 . . . . 0.0 111.75 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 66.6 t80 -119.65 133.89 55.45 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 178.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 74.7 ttt180 -139.62 121.6 15.64 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.856 -1.152 . . . . 0.0 110.613 -178.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -125.34 137.84 54.05 Favored 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.135 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.0 tp -120.55 130.99 54.46 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 23.1 p -129.24 119.8 24.63 Favored 'General case' 0 N--CA 1.508 2.469 0 CA-C-O 121.817 0.818 . . . . 0.0 111.168 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -132.8 160.5 36.71 Favored 'General case' 0 N--CA 1.504 2.269 0 O-C-N 121.666 -0.647 . . . . 0.0 110.211 179.102 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . 0.52 ' CE2' ' HB1' ' A' ' 7' ' ' ALA . 90.2 m95 -69.42 142.98 53.75 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.432 -0.793 . . . . 0.0 110.426 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.404 ' O ' ' N ' ' A' ' 42' ' ' ARG . 41.0 t -115.94 123.42 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 178.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 2.88 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 179.929 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.648 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.448 ' OD1' ' O ' ' A' ' 8' ' ' ASP . 55.1 t0 -90.34 6.74 41.82 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.654 -0.654 . . . . 0.0 110.715 -178.725 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.43 ' OD1' ' N ' ' A' ' 9' ' ' ASN . 21.5 p-10 -137.83 17.74 2.86 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 120.913 -1.117 . . . . 0.0 109.048 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.453 ' O ' HG23 ' A' ' 10' ' ' VAL . 35.0 m -126.02 129.76 72.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -94.94 142.48 24.69 Favored Pre-proline 0 N--CA 1.494 1.772 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.44 -18.05 23.28 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 121.91 1.74 . . . . 0.0 112.145 -179.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 87.9 p -70.13 -30.18 67.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 110.187 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -89.25 -14.98 34.67 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.959 -1.088 . . . . 0.0 109.952 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.506 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 35.7 t -72.44 -27.61 62.43 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.304 -0.872 . . . . 0.0 109.648 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.1 pp -118.21 132.52 67.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.534 -0.729 . . . . 0.0 109.087 -179.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -120.05 138.18 53.68 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.369 -0.832 . . . . 0.0 109.094 -179.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.424 ' H ' ' HG2' ' A' ' 18' ' ' GLN . 13.3 pt20 -100.02 123.67 44.52 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.566 -0.709 . . . . 0.0 110.409 -178.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t -125.37 83.81 2.21 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.473 -0.767 . . . . 0.0 109.413 179.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.49 ' O ' ' N ' ' A' ' 22' ' ' GLN . . . 98.13 73.43 1.11 Allowed Glycine 0 N--CA 1.501 2.981 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.429 ' C ' ' O ' ' A' ' 20' ' ' GLY . 15.2 m 34.47 32.41 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.183 0 O-C-N 121.946 -0.738 . . . . 0.0 110.817 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.49 ' N ' ' O ' ' A' ' 20' ' ' GLY . 14.1 pt20 -130.86 161.02 32.75 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.569 -0.707 . . . . 0.0 109.55 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -124.38 131.49 53.51 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 38.7 p -134.27 152.52 51.86 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.336 -0.853 . . . . 0.0 109.381 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 39.1 t80 -81.79 130.67 35.14 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.514 -0.742 . . . . 0.0 109.256 -179.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -81.86 77.41 8.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.917 -1.114 . . . . 0.0 109.93 -179.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 54.3 p -79.57 -8.34 59.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.092 -1.005 . . . . 0.0 109.358 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.9 -39.86 96.07 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.414 ' CG2' ' SG ' ' A' ' 32' ' ' CYS . 27.0 m -82.25 138.34 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.046 -1.267 . . . . 0.0 109.305 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 32.6 t -63.2 -34.64 78.08 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.488 -0.758 . . . . 0.0 110.868 -179.255 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.1 t -56.83 -40.04 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.832 -1.168 . . . . 0.0 109.556 -178.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.506 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 49.1 m -63.08 -39.89 96.04 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.047 -1.033 . . . . 0.0 110.059 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 96.5 mmm -88.94 -16.8 30.91 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.769 -1.207 . . . . 0.0 110.974 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 50.3 mt-30 -60.23 -42.68 95.74 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 120.616 -1.302 . . . . 0.0 108.984 178.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -80.34 -41.68 11.37 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.0 tp -59.99 -47.08 87.3 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.312 -1.11 . . . . 0.0 109.241 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 45.0 t30 -65.52 -39.86 92.31 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.285 -0.884 . . . . 0.0 110.184 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.5 -31.98 71.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.249 -0.907 . . . . 0.0 109.423 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.74 18.77 46.63 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 -179.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.3 tttp -97.56 -9.09 27.65 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 178.461 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.789 HG12 ' H ' ' A' ' 43' ' ' GLY . 97.1 t -134.72 159.87 41.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.038 -0.983 . . . . 0.0 108.665 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.472 ' N ' ' O ' ' A' ' 94' ' ' VAL . 57.9 ttm-85 -125.04 -1.69 7.74 Favored 'General case' 0 N--CA 1.497 1.917 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 179.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.789 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 129.65 -163.96 22.59 Favored Glycine 0 N--CA 1.499 2.855 0 N-CA-C 107.719 -2.153 . . . . 0.0 107.719 -179.236 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 47.5 t -120.56 129.79 75.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.124 0 CA-C-N 118.881 1.34 . . . . 0.0 109.486 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 63.6 p -77.43 141.94 39.47 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.456 -0.777 . . . . 0.0 108.959 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.464 HG13 ' O ' ' A' ' 46' ' ' VAL . 9.9 p -127.38 125.32 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 CA-C-O 121.947 0.88 . . . . 0.0 108.727 179.067 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 2.4 p -128.06 146.65 50.61 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -154.66 147.44 16.57 Favored Glycine 0 N--CA 1.494 2.56 0 C-N-CA 118.306 -1.902 . . . . 0.0 111.237 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 53.2 t -126.4 126.28 68.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -100.56 125.82 46.95 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.267 -0.896 . . . . 0.0 108.773 179.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -95.28 126.92 40.92 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.493 -0.754 . . . . 0.0 109.965 -178.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.493 ' C ' ' H ' ' A' ' 54' ' ' ASP . 98.2 m-85 -114.02 130.33 56.55 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.543 -0.723 . . . . 0.0 109.918 -179.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -53.02 -8.19 0.09 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.507 -0.746 . . . . 0.0 109.328 179.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.493 ' H ' ' C ' ' A' ' 52' ' ' TYR . 41.3 t0 -74.44 0.81 13.42 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.773 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.68 14.55 79.63 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.2 p -123.15 147.86 46.36 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 121.487 -1.008 . . . . 0.0 109.788 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 53.0 p -129.68 140.35 51.15 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 85.0 p -107.45 155.88 19.57 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 30.1 p-10 -146.53 116.07 7.14 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.874 -1.141 . . . . 0.0 109.674 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -118.51 121.82 41.19 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -113.17 153.67 27.91 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -174.82 -177.25 43.78 Favored Glycine 0 C--N 1.282 -2.464 0 C-N-CA 119.337 -1.411 . . . . 0.0 110.847 -179.505 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -119.7 127.36 75.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.971 -0.723 . . . . 0.0 109.375 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.1 t -92.3 120.26 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.199 -0.938 . . . . 0.0 110.519 -179.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.7 p -135.76 152.08 75.35 Favored Pre-proline 0 N--CA 1.492 1.639 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.011 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -54.54 -10.18 2.18 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 121.613 1.542 . . . . 0.0 111.687 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.2 t -103.04 -26.97 12.87 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.324 -0.86 . . . . 0.0 111.23 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 78.2 p -133.34 108.87 12.38 Favored Pre-proline 0 N--CA 1.505 2.283 0 O-C-N 120.911 -1.118 . . . . 0.0 110.295 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -85.09 163.18 11.58 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 C-N-CA 122.068 1.845 . . . . 0.0 111.897 178.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.4 t -120.61 127.53 75.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.467 -0.77 . . . . 0.0 109.07 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -105.48 130.22 53.6 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.189 -0.944 . . . . 0.0 111.303 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.468 ' C ' ' H ' ' A' ' 74' ' ' GLN . 0.6 OUTLIER -92.61 4.87 52.79 Favored 'General case' 0 N--CA 1.499 1.983 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 177.703 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 48.2 p-10 -73.3 21.09 0.08 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.731 -0.605 . . . . 0.0 109.78 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.468 ' H ' ' C ' ' A' ' 72' ' ' THR . 73.5 tp60 -42.85 -83.49 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.479 -0.763 . . . . 0.0 110.744 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -113.62 74.38 0.86 Allowed 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.338 -0.851 . . . . 0.0 110.597 -179.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 83.1 mt -70.21 -34.26 58.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 120.945 -1.097 . . . . 0.0 109.303 178.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 71.3 m-20 -52.78 -43.25 65.73 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.064 -1.023 . . . . 0.0 108.698 -179.15 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 47.4 tttp -62.82 -46.37 88.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.412 -0.805 . . . . 0.0 109.051 178.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.585 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.3 OUTLIER -60.3 -46.7 88.96 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.528 -0.732 . . . . 0.0 110.103 -178.998 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -61.0 -36.75 80.28 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 120.255 -1.528 . . . . 0.0 109.406 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 38.0 tttm -66.38 -50.08 64.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.494 -0.754 . . . . 0.0 110.827 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.9 p -111.42 -26.98 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.544 -0.723 . . . . 0.0 111.805 -176.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.585 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.09 161.52 35.42 Favored Glycine 0 N--CA 1.492 2.372 0 O-C-N 120.678 -1.264 . . . . 0.0 110.294 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.459 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 16.5 t -106.99 120.97 59.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.916 -0.755 . . . . 0.0 109.27 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 61.7 tt0 -72.04 -58.2 3.64 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.155 -0.966 . . . . 0.0 110.951 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 32.7 ttmt -114.81 146.39 41.08 Favored 'General case' 0 N--CA 1.509 2.476 0 O-C-N 121.226 -0.921 . . . . 0.0 111.038 -178.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -121.59 130.36 53.45 Favored 'General case' 0 N--CA 1.501 2.098 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 21.9 mmm180 -137.29 121.68 18.24 Favored 'General case' 0 N--CA 1.505 2.312 0 O-C-N 120.929 -1.107 . . . . 0.0 109.913 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.24 133.9 53.39 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.632 -0.668 . . . . 0.0 109.387 179.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 65.5 tp -117.87 131.46 56.54 Favored 'General case' 0 N--CA 1.5 2.068 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 11.3 p -128.19 124.55 37.07 Favored 'General case' 0 N--CA 1.502 2.139 0 CA-C-O 121.39 0.614 . . . . 0.0 110.334 -179.304 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -132.67 151.13 52.05 Favored 'General case' 0 N--CA 1.505 2.312 0 O-C-N 121.617 -0.677 . . . . 0.0 110.748 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 58.1 m95 -71.2 139.04 50.0 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.31 -0.869 . . . . 0.0 109.007 179.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.472 ' O ' ' N ' ' A' ' 42' ' ' ARG . 47.3 t -111.08 119.41 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.427 0 N-CA-C 109.261 -1.535 . . . . 0.0 109.261 179.834 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.623 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 8' ' ' ASP . 34.0 t0 -88.44 -28.07 21.11 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.33 -0.856 . . . . 0.0 109.566 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 53.5 t30 -89.97 -0.0 57.34 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.522 -0.736 . . . . 0.0 109.556 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.8 t -110.87 129.98 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.569 -0.707 . . . . 0.0 109.868 -178.771 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -89.14 135.07 31.96 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.147 -0.97 . . . . 0.0 108.593 179.288 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -73.37 -14.27 25.33 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 121.695 1.597 . . . . 0.0 111.603 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 23.2 t -60.64 -40.12 90.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.57 179.489 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 27.5 mt-30 -82.54 -12.97 57.39 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.989 -1.069 . . . . 0.0 109.865 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.796 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 44.3 t -64.27 -37.81 88.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.049 -1.032 . . . . 0.0 109.268 179.721 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -118.23 148.63 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 20.3 ptmt -130.61 155.07 47.16 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 121.497 -0.752 . . . . 0.0 109.508 -179.078 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -98.95 117.46 33.52 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.414 -0.804 . . . . 0.0 110.521 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.5 t -126.37 85.71 2.42 Favored 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.605 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.81 62.52 1.37 Allowed Glycine 0 N--CA 1.497 2.739 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.478 HG23 ' ND2' ' A' ' 73' ' ' ASN . 33.9 m 40.01 35.74 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.746 -0.855 . . . . 0.0 110.556 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 80.3 mt-30 -132.32 162.84 30.03 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.61 -0.681 . . . . 0.0 109.401 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 41.8 m-85 -120.03 136.34 54.6 Favored 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 178.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 49.3 p -139.57 149.76 44.24 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.411 -0.806 . . . . 0.0 109.925 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.598 ' CZ ' ' SG ' ' A' ' 32' ' ' CYS . 44.1 t80 -80.47 125.21 29.67 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -84.41 84.2 7.73 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.113 -0.992 . . . . 0.0 110.577 -178.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 83.1 p -83.18 -7.0 59.68 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.128 -0.982 . . . . 0.0 109.538 179.321 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.58 -37.76 68.76 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.4 m -85.53 136.46 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.272 -1.134 . . . . 0.0 108.719 179.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 82.9 p -69.88 -40.0 75.95 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.322 -0.861 . . . . 0.0 111.442 -178.617 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.511 HG23 ' N ' ' A' ' 32' ' ' CYS . 33.7 m -50.23 -42.75 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.773 -1.204 . . . . 0.0 110.647 -178.084 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.796 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 18.9 t -61.17 -42.0 97.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.875 -1.14 . . . . 0.0 110.111 -179.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 18.0 mtp -82.12 -12.73 58.03 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.61 -1.306 . . . . 0.0 110.829 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 12.5 mm100 -60.18 -40.0 88.46 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.629 -1.295 . . . . 0.0 108.387 178.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.92 -50.61 6.3 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 62.6 tp -60.24 -41.31 92.87 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.279 -1.13 . . . . 0.0 109.446 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -60.19 -40.05 88.68 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.169 -0.957 . . . . 0.0 109.738 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -74.24 -9.51 58.68 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.156 -0.965 . . . . 0.0 109.999 -179.435 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.65 26.42 67.47 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 179.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 45.7 mmtm -100.17 -5.54 27.58 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 178.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.697 HG12 ' H ' ' A' ' 43' ' ' GLY . 55.7 t -133.3 161.01 42.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.476 ' N ' HG12 ' A' ' 41' ' ' VAL . 74.3 ttt180 -122.05 -6.82 8.92 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.564 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.697 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 135.42 -164.95 24.84 Favored Glycine 0 N--CA 1.498 2.785 0 N-CA-C 108.082 -2.007 . . . . 0.0 108.082 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.3 t -120.03 129.41 75.49 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.091 -1.241 . . . . 0.0 109.415 179.593 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.9 t -83.71 135.99 34.35 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.312 -0.868 . . . . 0.0 108.768 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 46' ' ' VAL . 12.0 p -131.45 133.17 62.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 CA-C-O 121.603 0.715 . . . . 0.0 109.813 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.8 p -124.73 151.12 45.45 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 178.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -146.17 147.01 17.68 Favored Glycine 0 N--CA 1.5 2.926 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.803 -179.029 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 75.0 t -129.67 127.18 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.803 -0.822 . . . . 0.0 108.989 179.32 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -102.64 112.88 25.83 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 23.7 m-85 -81.44 128.57 34.01 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.091 -1.006 . . . . 0.0 109.374 -179.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -114.72 134.21 55.27 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.481 -0.762 . . . . 0.0 109.499 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -61.84 -9.34 6.46 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.262 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.442 ' OD2' ' OG1' ' A' ' 56' ' ' THR . 46.1 p-10 -68.05 0.15 3.87 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.326 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 88.27 14.38 62.24 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.442 ' OG1' ' OD2' ' A' ' 54' ' ' ASP . 35.0 p -136.03 156.75 48.27 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.03 -1.277 . . . . 0.0 110.652 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 37.3 p -131.23 132.94 45.0 Favored 'General case' 0 N--CA 1.498 1.937 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 83.7 p -91.59 160.01 15.61 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 6.0 p30 -152.15 115.01 4.62 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.822 -1.174 . . . . 0.0 109.985 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -118.01 127.77 54.13 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 178.618 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 78.7 tttt -115.44 145.71 42.31 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.155 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.71 170.07 42.09 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.2 t -110.56 127.53 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.521 -0.987 . . . . 0.0 109.574 -179.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 69.3 t -94.0 118.07 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.086 -1.009 . . . . 0.0 109.491 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.518 ' O ' ' N ' ' A' ' 68' ' ' THR . 12.0 p -125.62 146.25 54.16 Favored Pre-proline 0 N--CA 1.497 1.916 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 178.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_exo -35.9 -27.85 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.344 0 C-N-CA 122.433 2.089 . . . . 0.0 112.884 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.474 ' N ' ' O ' ' A' ' 65' ' ' THR . 5.8 t -106.81 -10.57 16.01 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.433 -0.792 . . . . 0.0 110.528 -179.657 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 65' ' ' THR . 88.7 m -126.33 106.58 24.33 Favored Pre-proline 0 N--CA 1.505 2.31 0 O-C-N 121.04 -1.038 . . . . 0.0 110.981 -179.175 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -90.44 162.48 4.46 Favored 'Trans proline' 0 N--CA 1.487 1.107 0 C-N-CA 122.404 2.069 . . . . 0.0 111.351 177.568 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 78.4 t -119.84 128.06 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.239 0 O-C-N 121.229 -0.92 . . . . 0.0 108.91 179.318 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -101.25 135.15 43.2 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.298 -0.876 . . . . 0.0 110.16 -179.206 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.479 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.1 OUTLIER -106.02 19.68 20.15 Favored 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 178.332 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.585 ' N ' HD22 ' A' ' 73' ' ' ASN . 1.6 m120 -64.28 42.88 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.848 -178.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.479 ' N ' ' O ' ' A' ' 72' ' ' THR . 25.2 mm100 -51.48 170.27 0.05 OUTLIER 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.106 -0.996 . . . . 0.0 109.114 179.213 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -53.05 114.0 1.3 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.054 -1.029 . . . . 0.0 109.621 -179.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 97.5 mt -86.46 -16.06 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.384 -0.823 . . . . 0.0 110.246 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -59.84 -39.66 85.92 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 179.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 71.1 mttt -63.0 -50.23 71.57 Favored 'General case' 0 N--CA 1.492 1.634 0 CA-C-O 122.496 1.141 . . . . 0.0 109.551 179.436 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.587 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -59.96 -50.68 72.79 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.515 -177.33 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -61.39 -36.11 79.35 Favored 'General case' 0 C--N 1.292 -1.9 0 O-C-N 120.208 -1.558 . . . . 0.0 109.031 178.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -65.58 -50.27 65.75 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.447 -0.783 . . . . 0.0 111.093 -179.312 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.3 m -115.77 -24.77 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.3 0 O-C-N 121.271 -0.893 . . . . 0.0 111.609 -177.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 91.52 166.55 40.23 Favored Glycine 0 N--CA 1.492 2.413 0 O-C-N 120.71 -1.244 . . . . 0.0 110.068 179.372 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 49.0 t -106.96 128.54 61.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.926 -0.749 . . . . 0.0 109.057 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -79.99 -66.59 0.86 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.945 -1.097 . . . . 0.0 109.838 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 57.4 mttm -116.55 140.85 48.93 Favored 'General case' 0 N--CA 1.504 2.255 0 O-C-N 121.291 -0.881 . . . . 0.0 111.051 -179.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 70.5 t80 -121.05 132.75 55.07 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 178.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 42.6 mtm105 -136.85 129.97 31.07 Favored 'General case' 0 N--CA 1.504 2.258 0 O-C-N 121.119 -0.988 . . . . 0.0 110.743 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.31 135.47 54.22 Favored 'General case' 0 N--CA 1.499 1.983 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.9 mt -118.51 130.28 55.84 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.427 -0.796 . . . . 0.0 109.599 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 20.1 p -128.61 125.07 37.41 Favored 'General case' 0 N--CA 1.503 2.218 0 CA-C-O 121.677 0.751 . . . . 0.0 110.645 -179.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -132.96 154.37 50.53 Favored 'General case' 0 N--CA 1.502 2.159 0 CA-C-O 121.412 0.625 . . . . 0.0 110.638 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 80.2 m95 -69.87 142.08 53.09 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 35.4 t -116.61 120.81 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.133 0 O-C-N 121.332 -0.855 . . . . 0.0 109.202 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.179 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.978 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.736 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.542 ' N ' ' OD1' ' A' ' 8' ' ' ASP . 11.3 p-10 -47.74 -79.74 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.787 -0.571 . . . . 0.0 111.367 -178.533 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.517 ' H ' ' CG ' ' A' ' 8' ' ' ASP . 13.9 m120 -144.42 37.66 1.24 Allowed 'General case' 0 N--CA 1.497 1.899 0 O-C-N 120.898 -1.126 . . . . 0.0 109.885 -178.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.446 ' H ' HG23 ' A' ' 10' ' ' VAL . 0.2 OUTLIER -81.49 152.55 4.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 120.94 -1.1 . . . . 0.0 108.398 -179.11 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.6 m-20 -78.63 131.5 67.72 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.179 -0.951 . . . . 0.0 109.879 -178.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -80.61 -15.08 11.16 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.128 1.885 . . . . 0.0 111.812 179.438 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 94.2 p -64.46 -35.75 81.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.48 -0.763 . . . . 0.0 110.506 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -69.98 -23.7 63.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.162 -0.961 . . . . 0.0 109.812 -179.249 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.552 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 60.8 m -68.26 -27.66 66.54 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.209 -0.932 . . . . 0.0 109.64 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.7 pp -118.49 133.0 66.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.498 -0.751 . . . . 0.0 109.19 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -112.05 142.15 44.84 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.609 ' CD ' ' H ' ' A' ' 18' ' ' GLN . 0.1 OUTLIER -97.55 128.48 44.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.257 -0.902 . . . . 0.0 109.694 -179.411 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.549 ' O ' ' N ' ' A' ' 21' ' ' VAL . 25.3 t -107.4 118.6 37.15 Favored 'General case' 0 N--CA 1.495 1.825 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.42 -78.81 0.01 OUTLIER Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.549 ' N ' ' O ' ' A' ' 19' ' ' SER . 9.8 p -156.7 32.95 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.319 -1.106 . . . . 0.0 108.629 179.268 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.446 HE21 ' HB2' ' A' ' 69' ' ' PRO . 46.3 tt0 -129.22 161.56 29.86 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -115.19 135.06 54.58 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.322 -0.861 . . . . 0.0 109.261 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 23.9 p -135.8 150.01 49.3 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 35.8 t80 -83.79 122.09 28.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.347 -0.846 . . . . 0.0 109.663 -179.039 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -84.55 83.63 7.94 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.362 -0.837 . . . . 0.0 109.742 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 96.3 p -78.48 -4.91 50.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.231 -0.918 . . . . 0.0 109.091 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -56.68 -39.01 85.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 -179.437 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.445 ' H ' HG22 ' A' ' 29' ' ' VAL . 10.5 m -81.06 133.46 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 120.877 -1.366 . . . . 0.0 109.741 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.5 m -63.33 -34.47 77.77 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.544 -0.723 . . . . 0.0 111.929 -178.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.455 HG13 ' N ' ' A' ' 32' ' ' CYS . 7.2 p -59.98 -40.01 81.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 120.608 -1.307 . . . . 0.0 110.796 -177.789 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.552 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 77.6 m -66.25 -40.04 89.92 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.657 -1.277 . . . . 0.0 109.719 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 7.7 mmt -78.69 -19.14 53.15 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.008 -1.058 . . . . 0.0 109.123 179.607 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -60.75 -41.04 94.62 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.216 -0.928 . . . . 0.0 108.958 179.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -73.59 -43.61 35.85 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 2.1 mt -65.85 -39.98 91.27 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.254 -1.145 . . . . 0.0 108.94 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.32 -40.03 94.98 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.07 -1.019 . . . . 0.0 109.82 179.05 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -76.63 -10.79 59.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.214 -0.929 . . . . 0.0 110.086 -179.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.28 28.49 69.86 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.404 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -103.64 -6.01 22.05 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.784 HG12 ' H ' ' A' ' 43' ' ' GLY . 45.9 t -133.72 159.88 42.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 115.51 -0.768 . . . . 0.0 108.987 -179.251 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.507 ' N ' ' O ' ' A' ' 94' ' ' VAL . 70.3 mtp85 -120.91 -7.71 9.47 Favored 'General case' 0 N--CA 1.5 2.053 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.355 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.784 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.73 -159.85 25.51 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -179.035 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.4 t -120.67 129.74 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.145 0 O-C-N 121.297 -1.12 . . . . 0.0 109.32 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.0 t -86.65 140.02 30.22 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.303 -0.873 . . . . 0.0 108.98 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.443 HG13 ' O ' ' A' ' 46' ' ' VAL . 9.9 p -131.9 132.46 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.74 0.781 . . . . 0.0 109.829 179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 81.9 p -123.29 148.79 45.57 Favored 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -144.64 144.33 13.15 Favored Glycine 0 N--CA 1.5 2.962 0 C-N-CA 119.219 -1.467 . . . . 0.0 111.375 -178.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 85.6 t -121.59 130.01 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.545 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.531 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 9.9 m-85 -106.79 119.89 40.53 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.783 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -98.67 120.82 39.76 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.422 -0.799 . . . . 0.0 109.07 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.529 ' O ' ' N ' ' A' ' 54' ' ' ASP . 94.1 m-85 -105.56 131.33 53.09 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.345 -0.847 . . . . 0.0 109.164 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 49.2 t30 -46.6 -15.56 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.245 -0.909 . . . . 0.0 109.166 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 52' ' ' TYR . 35.9 t0 -69.71 -0.81 7.59 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.578 -0.701 . . . . 0.0 109.392 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.4 23.19 65.89 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 120.047 -1.073 . . . . 0.0 110.611 179.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.2 p -118.76 150.27 40.06 Favored 'General case' 0 N--CA 1.504 2.256 0 O-C-N 121.297 -1.12 . . . . 0.0 110.046 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 63.9 p -135.27 128.98 32.87 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.501 -0.75 . . . . 0.0 109.783 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 45.9 t -118.7 145.87 45.17 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 55.9 t-20 -135.8 128.08 30.12 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.753 -1.217 . . . . 0.0 109.796 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -117.15 122.15 43.27 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 178.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -107.52 144.5 34.41 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -162.68 170.99 38.4 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.634 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.7 t -113.98 125.39 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.555 -0.967 . . . . 0.0 109.42 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -90.26 117.9 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.368 -0.833 . . . . 0.0 110.232 -179.152 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.517 ' O ' ' N ' ' A' ' 67' ' ' SER . 25.9 p -125.74 144.4 48.2 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.402 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -38.4 -21.29 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.157 1.905 . . . . 0.0 113.276 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 65' ' ' THR . 10.4 m -108.64 -11.37 15.1 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.197 -0.939 . . . . 0.0 111.296 -178.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 55.1 p -130.69 107.87 15.63 Favored Pre-proline 0 N--CA 1.504 2.242 0 O-C-N 121.011 -1.056 . . . . 0.0 110.392 -179.201 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.446 ' HB2' HE21 ' A' ' 22' ' ' GLN . 40.6 Cg_endo -91.25 164.42 3.69 Favored 'Trans proline' 0 N--CA 1.49 1.314 0 C-N-CA 122.605 2.203 . . . . 0.0 112.135 178.604 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 48.9 t -124.42 130.15 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.127 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 31.3 m120 -100.77 138.19 38.16 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.082 -1.012 . . . . 0.0 110.502 -178.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -98.5 -19.37 17.69 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 121.02 -1.05 . . . . 0.0 109.021 179.17 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 44.4 p-10 -87.41 44.42 1.18 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.038 -1.039 . . . . 0.0 108.442 179.118 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -59.71 -49.18 78.74 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.519 -0.872 . . . . 0.0 108.741 -179.334 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -115.17 75.8 0.96 Allowed 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 107.845 -1.168 . . . . 0.0 107.845 178.213 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 10.4 tt -73.33 -28.64 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.28 -0.887 . . . . 0.0 110.116 -178.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -60.06 -49.66 76.79 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.61 -178.067 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.414 ' CG ' ' N ' ' A' ' 79' ' ' THR . 0.1 OUTLIER -61.08 -39.94 91.82 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.569 -1.332 . . . . 0.0 108.34 179.353 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.586 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.4 m -60.04 -43.96 94.99 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.397 0.618 . . . . 0.0 109.772 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -61.63 -38.5 87.89 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 120.596 -1.315 . . . . 0.0 109.987 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.4 ttmm -70.04 -44.85 68.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.139 -0.976 . . . . 0.0 111.224 -179.266 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.1 p -112.08 -28.75 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.075 0 O-C-N 121.311 -0.868 . . . . 0.0 112.098 -176.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.586 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.69 161.43 33.52 Favored Glycine 0 N--CA 1.491 2.339 0 O-C-N 120.66 -1.275 . . . . 0.0 110.177 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 90.0 t -109.51 124.85 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.14 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -80.05 -58.62 3.07 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.247 -0.908 . . . . 0.0 110.952 -178.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 35.4 ttpt -114.11 137.59 51.53 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.267 -0.895 . . . . 0.0 110.809 -178.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 54.9 t80 -123.78 125.89 45.5 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.129 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 76.0 mmt-85 -130.98 132.01 44.76 Favored 'General case' 0 N--CA 1.506 2.336 0 O-C-N 121.137 -0.977 . . . . 0.0 110.525 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -121.26 138.09 54.39 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 179.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.671 HD23 ' N ' ' A' ' 91' ' ' THR . 1.6 tt -119.95 131.17 55.1 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.671 ' N ' HD23 ' A' ' 90' ' ' LEU . 22.1 p -126.59 126.3 43.39 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.507 -0.745 . . . . 0.0 110.706 -179.243 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 -133.5 154.57 50.71 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.855 -0.528 . . . . 0.0 109.793 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -67.58 139.4 56.9 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.163 -0.961 . . . . 0.0 109.051 179.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.507 ' O ' ' N ' ' A' ' 42' ' ' ARG . 41.4 t -111.84 121.29 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.323 -0.861 . . . . 0.0 109.013 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.739 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 179.461 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.48 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -69.87 -39.84 76.09 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.681 -0.637 . . . . 0.0 110.761 -179.223 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 32.7 m120 -84.38 3.56 35.37 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.004 -1.06 . . . . 0.0 110.4 -178.312 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.0 t -116.31 129.8 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.347 -0.846 . . . . 0.0 109.129 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 -84.68 138.3 38.11 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.016 -1.053 . . . . 0.0 109.212 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -76.63 -24.74 10.07 Favored 'Trans proline' 0 N--CA 1.494 1.531 0 C-N-CA 121.938 1.758 . . . . 0.0 111.673 179.314 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 55.4 m -60.26 -39.89 88.38 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.304 -0.872 . . . . 0.0 110.566 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.7 mt-30 -77.89 -19.82 54.06 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.182 -0.949 . . . . 0.0 110.287 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.637 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 49.6 m -65.66 -29.61 70.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.005 -1.06 . . . . 0.0 109.685 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -118.6 139.64 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.132 0 O-C-N 121.427 -0.796 . . . . 0.0 109.272 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -124.31 144.25 50.1 Favored 'General case' 0 N--CA 1.498 1.955 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 -179.731 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 64.8 tt0 -96.74 124.37 40.7 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.212 -0.93 . . . . 0.0 109.676 -179.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.497 ' O ' ' N ' ' A' ' 21' ' ' VAL . 70.3 m -109.52 129.95 55.54 Favored 'General case' 0 N--CA 1.498 1.967 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.36 -94.06 0.01 OUTLIER Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.497 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.8 t -137.17 28.84 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 121.427 -1.043 . . . . 0.0 109.319 -179.386 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -131.38 163.15 28.53 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.577 -0.702 . . . . 0.0 110.359 -179.571 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -118.76 139.94 50.75 Favored 'General case' 0 N--CA 1.503 2.183 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 70.9 p -139.82 157.01 46.43 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.272 -0.893 . . . . 0.0 109.651 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -89.65 121.69 32.07 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.539 -0.726 . . . . 0.0 109.103 -179.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 -82.47 86.09 6.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.129 -0.982 . . . . 0.0 110.105 -179.368 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.48 ' C ' ' H ' ' A' ' 29' ' ' VAL . 92.1 p -81.58 -7.04 59.54 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.243 -0.91 . . . . 0.0 109.38 179.391 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.66 -8.22 0.34 Allowed Glycine 0 N--CA 1.489 2.196 0 N-CA-C 110.162 -1.175 . . . . 0.0 110.162 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.48 ' H ' ' C ' ' A' ' 27' ' ' SER . 20.4 m -113.31 132.44 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.409 -1.054 . . . . 0.0 108.992 179.529 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.8 m -69.87 -30.07 67.45 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.426 -0.796 . . . . 0.0 111.107 -178.814 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.493 HG23 ' N ' ' A' ' 32' ' ' CYS . 18.0 m -60.16 -40.34 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 120.672 -1.268 . . . . 0.0 110.583 -178.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.637 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 96.5 m -65.81 -40.02 91.47 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.83 -1.169 . . . . 0.0 110.01 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 35.3 mtp -84.37 -11.92 55.42 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.901 -1.125 . . . . 0.0 109.303 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 12.6 tm0? -61.66 -42.19 98.57 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.83 -42.68 24.97 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 179.16 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.5 tp -60.2 -41.23 92.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.276 -1.132 . . . . 0.0 108.96 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -62.61 -40.68 97.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.306 -0.871 . . . . 0.0 109.815 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -63.07 -28.27 69.97 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.342 -0.849 . . . . 0.0 109.873 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.69 17.96 57.4 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 92.4 mttt -100.84 -1.54 34.5 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.742 HG12 ' H ' ' A' ' 43' ' ' GLY . 97.4 t -132.3 157.75 43.14 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 115.189 -0.914 . . . . 0.0 108.713 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.431 ' N ' HG12 ' A' ' 41' ' ' VAL . 98.4 mtt180 -119.99 -7.62 9.9 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 179.149 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.742 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 135.7 -160.08 24.41 Favored Glycine 0 N--CA 1.5 2.934 0 N-CA-C 108.22 -1.952 . . . . 0.0 108.22 -179.564 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.1 t -119.98 128.03 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.16 -1.2 . . . . 0.0 108.795 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.5 p -82.56 139.64 33.72 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.147 -0.971 . . . . 0.0 108.924 179.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.485 HG13 ' O ' ' A' ' 46' ' ' VAL . 12.7 p -120.05 127.62 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 CA-C-O 121.827 0.822 . . . . 0.0 108.878 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.0 p -128.06 149.86 50.2 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -168.92 159.44 32.53 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 117.922 -2.085 . . . . 0.0 111.682 -179.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 89.2 t -131.32 136.84 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.943 -0.739 . . . . 0.0 109.133 179.255 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.494 ' CZ ' ' OG1' ' A' ' 72' ' ' THR . 55.7 m-85 -108.18 123.71 49.16 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.006 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -95.91 126.51 41.21 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 120.735 -1.228 . . . . 0.0 109.751 -179.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.487 ' C ' ' N ' ' A' ' 54' ' ' ASP . 78.2 m-85 -112.0 129.79 56.08 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.453 -0.779 . . . . 0.0 109.913 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 31.9 t-20 -52.89 -10.83 0.18 Allowed 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 178.459 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.487 ' N ' ' C ' ' A' ' 52' ' ' TYR . 9.3 t70 -67.07 -2.68 5.82 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.56 19.0 60.89 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.114 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.4 p -133.46 152.07 51.86 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.022 -1.281 . . . . 0.0 110.812 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 68.9 p -130.33 142.39 50.53 Favored 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.419 0.628 . . . . 0.0 109.859 -179.476 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -117.55 140.83 49.1 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 178.681 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -125.28 116.24 21.63 Favored 'General case' 0 N--CA 1.496 1.839 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -117.49 121.04 39.93 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -113.22 149.8 33.23 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 179.502 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.2 -175.99 38.88 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.317 -1.421 . . . . 0.0 110.844 -179.53 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 66.8 t -122.49 127.82 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.915 -0.756 . . . . 0.0 109.944 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 21.8 t -99.3 118.61 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.365 -0.834 . . . . 0.0 110.256 -179.267 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.413 ' O ' ' N ' ' A' ' 67' ' ' SER . 29.9 p -118.89 149.83 47.4 Favored Pre-proline 0 N--CA 1.494 1.732 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.304 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -38.51 -28.02 0.12 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 121.845 1.697 . . . . 0.0 113.013 -179.552 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.413 ' N ' ' O ' ' A' ' 65' ' ' THR . 53.5 m -108.58 -3.58 17.89 Favored 'General case' 0 N--CA 1.503 2.225 0 O-C-N 121.345 -0.847 . . . . 0.0 111.677 -178.767 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 7.5 m -124.76 106.57 29.26 Favored Pre-proline 0 N--CA 1.508 2.452 0 O-C-N 120.84 -1.163 . . . . 0.0 111.008 -179.036 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -92.61 164.76 2.83 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 122.818 2.345 . . . . 0.0 111.562 177.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.8 t -119.88 130.04 74.69 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.19 0 O-C-N 121.261 -0.899 . . . . 0.0 108.802 179.62 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -99.91 121.7 41.72 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.304 -0.872 . . . . 0.0 109.997 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.494 ' OG1' ' CZ ' ' A' ' 50' ' ' PHE . 0.2 OUTLIER -100.45 5.45 44.22 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.075 -1.016 . . . . 0.0 108.855 179.41 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.422 ' O ' ' O ' ' A' ' 74' ' ' GLN . 47.9 p-10 -73.42 46.52 0.2 Allowed 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.323 -0.861 . . . . 0.0 109.649 -179.379 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.422 ' O ' ' O ' ' A' ' 73' ' ' ASN . 65.4 tt0 -47.72 -91.9 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.132 -0.98 . . . . 0.0 109.208 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -113.78 104.49 12.25 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.481 -0.762 . . . . 0.0 109.762 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 77.6 mt -80.07 -27.02 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 120.951 -1.093 . . . . 0.0 108.765 179.084 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.44 ' HA ' HD21 ' A' ' 80' ' ' ASN . 27.0 t-20 -59.71 -40.0 86.5 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.559 ' O ' HG22 ' A' ' 82' ' ' VAL . 18.5 ttmm -69.59 -48.55 59.78 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.209 -0.932 . . . . 0.0 108.791 177.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.61 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.5 OUTLIER -61.84 -51.15 69.43 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.805 -1.184 . . . . 0.0 110.801 -178.551 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 81' ' ' LYS . 29.6 p30 -66.25 -27.11 67.7 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 119.656 -1.902 . . . . 0.0 108.925 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . 0.52 ' N ' ' OD1' ' A' ' 80' ' ' ASN . 37.4 tptt -69.94 -49.05 55.65 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.348 -0.845 . . . . 0.0 110.431 179.366 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 78' ' ' LYS . 2.5 m -114.73 -26.04 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.351 0 O-C-N 121.039 -1.038 . . . . 0.0 110.859 -178.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.61 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.87 161.28 36.01 Favored Glycine 0 N--CA 1.493 2.46 0 O-C-N 120.712 -1.243 . . . . 0.0 110.41 179.097 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -100.92 117.52 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -74.75 -59.28 2.8 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.115 -0.991 . . . . 0.0 111.613 -178.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 54.3 mttp -114.29 135.41 54.1 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.33 -0.856 . . . . 0.0 110.983 -177.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 61.2 t80 -122.7 131.81 53.97 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.562 -0.711 . . . . 0.0 109.599 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -139.18 130.76 27.25 Favored 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.214 -0.929 . . . . 0.0 110.576 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -126.95 133.68 50.57 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.617 -0.677 . . . . 0.0 110.309 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 64.9 tp -120.05 131.29 55.05 Favored 'General case' 0 N--CA 1.503 2.181 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -130.48 131.13 44.99 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.528 -0.732 . . . . 0.0 111.181 -179.308 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.466 ' N ' ' CD ' ' A' ' 92' ' ' GLU . 4.6 pm0 -134.22 153.49 51.82 Favored 'General case' 0 N--CA 1.505 2.289 0 CA-C-O 121.35 0.595 . . . . 0.0 110.512 179.101 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 36.7 m95 -70.0 138.97 52.66 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.7 t -110.23 119.81 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.442 -0.787 . . . . 0.0 108.891 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.961 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.706 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -57.61 -72.04 0.09 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.677 -0.64 . . . . 0.0 110.892 -178.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.4 p-10 -147.38 42.33 1.08 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.051 -1.031 . . . . 0.0 108.22 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.401 HG23 ' HE1' ' A' ' 93' ' ' TRP . 10.3 m -80.5 139.95 17.4 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 O-C-N 121.463 -0.773 . . . . 0.0 109.301 -178.191 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -70.69 126.35 92.19 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.436 -0.79 . . . . 0.0 110.297 -178.442 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -82.91 -17.36 7.0 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.402 2.068 . . . . 0.0 111.53 178.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 57.3 m -60.04 -39.64 86.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.504 -0.747 . . . . 0.0 110.112 -179.427 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.3 mm-40 -65.98 -23.91 66.68 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.106 -0.997 . . . . 0.0 109.468 -179.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.615 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 36.0 t -65.26 -34.92 79.49 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.282 -0.886 . . . . 0.0 110.208 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -119.93 146.51 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.337 -0.852 . . . . 0.0 109.701 -179.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 53.4 mtmt -126.47 157.99 37.21 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 121.531 -0.73 . . . . 0.0 109.252 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -100.22 113.41 26.07 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.123 -0.986 . . . . 0.0 109.876 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.2 m -125.37 121.34 33.64 Favored 'General case' 0 N--CA 1.5 2.032 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.43 ' O ' ' N ' ' A' ' 22' ' ' GLN . . . 57.56 64.34 4.46 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' A' ' 20' ' ' GLY . 35.0 m 37.03 31.47 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.866 -0.785 . . . . 0.0 110.94 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.43 ' N ' ' O ' ' A' ' 20' ' ' GLY . 84.0 mt-30 -131.67 160.0 36.7 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.637 -0.664 . . . . 0.0 109.292 179.484 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 52.3 m-85 -119.32 140.09 50.88 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.074 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 33.7 p -135.14 148.09 49.65 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.525 -0.734 . . . . 0.0 109.314 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -84.24 120.02 25.73 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -86.23 105.85 16.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.096 -1.002 . . . . 0.0 110.516 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 79.3 p -90.78 -0.11 57.61 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.579 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -66.24 -9.75 49.93 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.416 HG23 ' SG ' ' A' ' 32' ' ' CYS . 0.2 OUTLIER -103.78 124.72 58.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 179.138 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 44.1 t -59.94 -40.13 87.93 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.364 -0.835 . . . . 0.0 111.828 -178.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 p -53.51 -34.96 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.751 -1.218 . . . . 0.0 110.143 -178.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.615 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 22.1 m -61.31 -44.74 96.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.996 -1.065 . . . . 0.0 110.82 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.0 mmt -77.21 -23.48 51.39 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.838 -1.164 . . . . 0.0 110.857 -179.324 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -60.07 -39.99 87.94 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.708 -1.245 . . . . 0.0 109.748 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -74.84 -46.85 15.92 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.5 mt -66.26 -39.4 89.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.451 -1.029 . . . . 0.0 109.553 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -60.13 -39.95 88.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.262 -0.899 . . . . 0.0 110.147 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -81.5 -7.76 59.63 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.109 -0.994 . . . . 0.0 110.792 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.4 28.13 70.26 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 32.1 mmtp -101.05 -7.43 23.24 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 178.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.791 HG12 ' H ' ' A' ' 43' ' ' GLY . 41.6 t -131.93 156.98 43.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 84.3 mtp180 -118.33 -6.5 10.79 Favored 'General case' 0 N--CA 1.5 2.052 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 179.521 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.791 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 137.19 -156.37 23.34 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 108.084 -2.006 . . . . 0.0 108.084 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.3 t -124.69 129.45 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 CA-C-N 118.644 1.222 . . . . 0.0 109.642 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.4 m -84.43 132.87 34.52 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.028 -1.045 . . . . 0.0 108.342 179.05 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.455 HG13 ' O ' ' A' ' 46' ' ' VAL . 15.0 p -130.04 131.6 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.555 -0.715 . . . . 0.0 109.435 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 54.4 p -122.86 144.71 49.02 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.237 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -135.12 137.22 9.06 Favored Glycine 0 N--CA 1.5 2.958 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 96.4 t -123.41 130.56 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.694 -0.886 . . . . 0.0 109.321 179.402 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -102.82 122.47 44.58 Favored 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -98.2 127.87 44.37 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.367 -0.833 . . . . 0.0 109.149 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.522 ' O ' ' N ' ' A' ' 54' ' ' ASP . 93.1 m-85 -113.04 128.12 56.41 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.525 -0.735 . . . . 0.0 109.364 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.51 ' OD1' ' N ' ' A' ' 53' ' ' ASN . 0.8 OUTLIER -42.95 -19.83 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.528 -0.732 . . . . 0.0 109.786 179.796 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 52' ' ' TYR . 8.6 t70 -67.97 0.79 3.16 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.473 -0.767 . . . . 0.0 109.395 -179.08 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.72 23.35 67.35 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.554 179.011 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.5 p -119.98 146.35 45.92 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.364 -1.08 . . . . 0.0 109.617 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 38.8 p -130.89 140.01 50.17 Favored 'General case' 0 N--CA 1.497 1.884 0 CA-C-O 121.571 0.7 . . . . 0.0 109.998 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . 0.434 ' C ' ' ND2' ' A' ' 59' ' ' ASN . 46.4 t -118.65 140.15 50.37 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 178.324 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.692 HD22 ' N ' ' A' ' 59' ' ' ASN . 0.3 OUTLIER -129.99 118.66 21.95 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 120.973 -1.079 . . . . 0.0 109.756 -179.414 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -115.55 125.46 53.02 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 178.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -113.08 148.93 34.23 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.5 166.24 39.43 Favored Glycine 0 C--N 1.288 -2.095 0 N-CA-C 108.839 -1.704 . . . . 0.0 108.839 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.0 t -109.08 125.38 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.506 -0.997 . . . . 0.0 108.815 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.506 HG13 ' O ' ' A' ' 64' ' ' VAL . 3.4 p -94.35 121.8 45.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.41 -0.806 . . . . 0.0 109.984 -179.411 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.415 ' O ' ' N ' ' A' ' 68' ' ' THR . 8.2 p -127.75 149.97 71.94 Favored Pre-proline 0 N--CA 1.499 1.989 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.403 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -34.87 -38.55 0.16 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.52 2.147 . . . . 0.0 113.353 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.9 t -99.02 -6.52 28.39 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.039 -1.038 . . . . 0.0 111.026 -179.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.415 ' N ' ' O ' ' A' ' 65' ' ' THR . 34.7 m -128.07 106.89 19.93 Favored Pre-proline 0 N--CA 1.505 2.291 0 O-C-N 121.005 -1.059 . . . . 0.0 110.509 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -90.79 163.25 4.09 Favored 'Trans proline' 0 N--CA 1.488 1.201 0 C-N-CA 122.507 2.138 . . . . 0.0 111.624 178.171 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 58.6 t -120.43 130.13 74.78 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.297 0 O-C-N 121.275 -0.89 . . . . 0.0 108.783 179.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -101.33 127.78 47.8 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.126 -0.983 . . . . 0.0 111.495 -178.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.91 11.15 30.52 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 177.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.415 ' O ' ' O ' ' A' ' 74' ' ' GLN . 45.6 p-10 -77.97 57.88 1.84 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.514 -0.741 . . . . 0.0 110.214 -178.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.415 ' O ' ' O ' ' A' ' 73' ' ' ASN . 27.3 mt-30 -60.91 -158.84 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.048 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -63.68 102.13 0.42 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.722 -1.236 . . . . 0.0 108.717 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 96.8 mt -79.93 -18.1 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.422 -0.799 . . . . 0.0 110.398 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 -59.99 -40.68 90.0 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.883 -1.136 . . . . 0.0 108.413 -179.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 4.1 mtpm? -62.42 -47.93 81.94 Favored 'General case' 0 N--CA 1.495 1.786 0 CA-C-O 122.419 1.104 . . . . 0.0 108.78 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.583 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -60.04 -42.93 95.48 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.078 -0.964 . . . . 0.0 109.592 -178.284 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -62.55 -36.99 84.4 Favored 'General case' 0 C--N 1.293 -1.879 0 O-C-N 120.494 -1.379 . . . . 0.0 108.899 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 53.9 tttt -72.01 -44.49 63.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.091 -1.006 . . . . 0.0 111.107 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.3 p -112.88 -28.18 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.341 -0.85 . . . . 0.0 111.972 -176.61 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.77 165.25 40.68 Favored Glycine 0 N--CA 1.493 2.5 0 O-C-N 120.519 -1.363 . . . . 0.0 110.893 178.545 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.424 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 30.0 t -110.26 124.32 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.064 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 28.1 mt-30 -80.99 -65.17 1.05 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.004 -1.06 . . . . 0.0 110.121 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -114.77 139.94 49.31 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.363 -0.836 . . . . 0.0 110.899 -179.173 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 62.8 t80 -121.38 127.63 51.4 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.161 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -132.06 131.27 42.28 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 120.994 -1.066 . . . . 0.0 110.664 -179.424 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.485 ' C ' HD12 ' A' ' 90' ' ' LEU . . . -122.09 131.02 53.76 Favored 'General case' 0 N--CA 1.501 2.12 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 179.229 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.543 HD12 ' N ' ' A' ' 90' ' ' LEU . 8.7 mp -111.02 130.92 55.44 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.38 -0.825 . . . . 0.0 109.315 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.8 p -124.41 124.08 41.55 Favored 'General case' 0 N--CA 1.506 2.36 0 O-C-N 121.392 -0.817 . . . . 0.0 110.675 -179.625 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 -134.0 146.63 50.6 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.791 -0.568 . . . . 0.0 109.779 179.567 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . 0.401 ' HE1' HG23 ' A' ' 10' ' ' VAL . 87.8 m95 -69.17 139.61 54.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.733 -1.229 . . . . 0.0 108.587 178.649 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 44.7 t -108.86 119.62 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.025 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.749 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.193 0 N-CA-C 108.345 -1.902 . . . . 0.0 108.345 179.872 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 121.509 0.671 . . . . 0.0 109.544 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -72.14 -36.91 69.49 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.302 -0.874 . . . . 0.0 110.51 -179.173 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -81.76 -0.91 45.23 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.922 -1.111 . . . . 0.0 109.784 -179.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.9 t -100.34 140.24 19.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.241 -0.912 . . . . 0.0 109.212 -179.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -102.04 106.44 47.75 Favored Pre-proline 0 N--CA 1.492 1.653 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -49.17 -14.42 0.49 Allowed 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 121.86 1.707 . . . . 0.0 112.066 -179.274 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.1 t -63.44 -38.51 91.43 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.465 -0.772 . . . . 0.0 110.083 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -85.22 -12.58 52.25 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.313 -0.867 . . . . 0.0 110.367 -178.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 39.2 t -68.88 -34.5 75.53 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.654 -1.279 . . . . 0.0 109.867 -179.542 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -119.82 145.43 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 11.4 ptmm? -131.57 152.58 50.67 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.226 -0.921 . . . . 0.0 108.96 -179.624 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -98.49 131.83 44.42 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.149 -0.969 . . . . 0.0 109.824 -179.591 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 29.3 t -117.71 120.07 36.87 Favored 'General case' 0 N--CA 1.496 1.871 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 178.51 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.64 -119.03 7.74 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 108.375 -1.89 . . . . 0.0 108.375 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.5 m -110.75 27.57 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.374 -1.074 . . . . 0.0 108.731 179.326 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 45.7 tt0 -128.99 155.72 44.93 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.572 -0.705 . . . . 0.0 110.244 -178.467 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 38.3 m-85 -118.41 138.56 52.36 Favored 'General case' 0 N--CA 1.498 1.966 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 73.3 p -138.64 153.15 48.58 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.227 -0.921 . . . . 0.0 109.359 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.569 ' CZ ' ' SG ' ' A' ' 15' ' ' CYS . 30.1 t80 -80.72 125.2 29.76 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -86.52 88.68 7.7 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.232 -0.918 . . . . 0.0 110.681 -178.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.444 ' C ' ' H ' ' A' ' 29' ' ' VAL . 7.7 m -79.66 -8.9 59.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.952 -1.093 . . . . 0.0 108.631 178.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.53 -8.12 0.78 Allowed Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.444 ' H ' ' C ' ' A' ' 27' ' ' SER . 0.1 OUTLIER -107.51 122.7 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.954 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 178.793 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 59.8 p -63.67 -37.29 86.78 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.655 -0.653 . . . . 0.0 111.613 -178.171 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.8 m -57.65 -36.93 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 120.841 -1.162 . . . . 0.0 110.622 -178.174 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 27.1 m -61.7 -42.08 98.46 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.805 -1.185 . . . . 0.0 110.461 -179.349 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 14.6 mmt -73.91 -20.63 60.33 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.965 -1.085 . . . . 0.0 110.685 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 79.6 mm-40 -60.16 -41.86 93.69 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.739 -1.226 . . . . 0.0 110.027 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.79 -47.02 8.98 Favored Glycine 0 N--CA 1.491 2.328 0 C-N-CA 119.166 -1.493 . . . . 0.0 109.872 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 20.9 tp -62.92 -43.45 98.77 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.496 -1.002 . . . . 0.0 110.822 -178.766 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -61.97 -39.7 93.07 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.975 -1.078 . . . . 0.0 110.304 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.481 ' HB3' ' HZ3' ' A' ' 40' ' ' LYS . 77.9 mm-40 -74.95 -8.11 55.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.231 -0.918 . . . . 0.0 110.438 -178.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 73.45 24.83 74.17 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.481 ' HZ3' ' HB3' ' A' ' 38' ' ' GLU . 59.6 mttp -97.86 -6.61 32.1 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 178.129 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.764 HG12 ' H ' ' A' ' 43' ' ' GLY . 93.6 t -135.65 159.92 39.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.64 -179.835 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.441 ' N ' HG12 ' A' ' 41' ' ' VAL . 52.7 ttt85 -118.61 -8.47 10.42 Favored 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.526 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.764 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.34 -161.46 25.66 Favored Glycine 0 N--CA 1.502 3.081 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 90.8 t -120.62 127.23 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.023 -1.281 . . . . 0.0 109.529 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.1 m -85.29 138.28 32.42 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 10.3 m -132.32 134.29 59.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.374 -0.829 . . . . 0.0 110.148 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 51.7 p -125.33 147.8 48.99 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.514 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -151.7 142.23 9.27 Favored Glycine 0 N--CA 1.496 2.644 0 C-N-CA 118.996 -1.573 . . . . 0.0 110.836 -178.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 78.5 t -125.13 130.13 73.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -104.52 122.01 44.67 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.451 -0.781 . . . . 0.0 108.914 -179.285 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 36.0 m-85 -92.37 125.86 37.21 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.258 -0.901 . . . . 0.0 110.488 -178.677 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.519 ' HE1' ' HG1' ' A' ' 79' ' ' THR . 97.9 m-85 -109.22 135.54 50.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.454 -0.779 . . . . 0.0 109.941 179.76 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 25.6 m120 -60.83 -13.86 18.16 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 179.041 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 11.3 t70 -68.72 0.68 3.97 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.87 15.41 72.89 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 179.059 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.2 p -119.18 152.71 36.12 Favored 'General case' 0 N--CA 1.51 2.531 0 O-C-N 121.367 -1.078 . . . . 0.0 111.153 -179.305 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 39.3 p -131.83 141.53 49.46 Favored 'General case' 0 N--CA 1.499 1.993 0 CA-C-O 121.433 0.635 . . . . 0.0 109.509 179.298 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 35.7 t -118.0 141.58 48.31 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 178.458 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -132.4 116.62 17.06 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.123 -0.986 . . . . 0.0 109.312 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.539 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 42.2 p90 -116.38 122.65 45.47 Favored 'General case' 0 N--CA 1.496 1.865 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.613 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -115.76 143.73 44.97 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.01 178.19 42.4 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.3 t -116.56 128.95 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 O-C-N 121.46 -1.023 . . . . 0.0 109.929 -179.458 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.0 t -95.81 112.0 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.151 -0.968 . . . . 0.0 109.922 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.571 ' O ' ' N ' ' A' ' 67' ' ' SER . 2.3 p -136.63 151.5 72.85 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 178.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_exo -41.14 -15.14 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.437 0 C-N-CA 121.704 1.603 . . . . 0.0 112.24 179.108 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.571 ' N ' ' O ' ' A' ' 65' ' ' THR . 67.3 p -61.53 -54.15 46.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.875 -1.141 . . . . 0.0 109.955 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -157.78 148.76 16.39 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 120.865 -1.147 . . . . 0.0 110.109 -179.649 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -82.55 163.53 16.68 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 122.23 1.953 . . . . 0.0 111.413 178.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 99.6 t -111.25 131.1 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.128 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.468 ' O ' ' OD1' ' A' ' 71' ' ' ASN . 22.8 p30 -100.91 138.26 38.19 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.471 -0.768 . . . . 0.0 111.671 -177.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.54 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.1 OUTLIER -100.0 1.72 42.78 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 177.907 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 73' ' ' ASN . 0.7 OUTLIER -66.96 52.74 0.05 OUTLIER 'General case' 0 N--CA 1.488 1.461 0 CA-C-O 121.631 0.729 . . . . 0.0 109.345 -179.604 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.54 ' N ' ' O ' ' A' ' 72' ' ' THR . 77.2 mt-30 -64.82 -90.37 0.01 OUTLIER 'General case' 0 C--N 1.294 -1.824 0 O-C-N 121.456 -0.778 . . . . 0.0 109.667 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -112.04 74.83 0.88 Allowed 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.566 -0.709 . . . . 0.0 110.115 -179.563 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.441 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 10.7 tp -60.31 -38.87 79.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.441 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 17.0 t-20 -57.92 -41.19 82.17 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 32.4 tttm -67.81 -43.33 79.9 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.365 -0.834 . . . . 0.0 109.098 178.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.572 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.3 OUTLIER -67.57 -40.84 84.89 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.088 -1.007 . . . . 0.0 109.445 -179.365 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -66.79 -25.92 66.7 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 120.441 -1.412 . . . . 0.0 109.156 179.336 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -68.63 -47.52 66.41 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 120.89 -1.131 . . . . 0.0 110.379 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.7 m -121.25 -18.8 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 121.337 -0.852 . . . . 0.0 111.669 -177.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.11 170.37 46.91 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.413 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 46.5 t -108.3 127.17 64.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 62.5 tt0 -80.45 -66.8 0.83 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 120.999 -1.063 . . . . 0.0 111.149 -179.381 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 34.8 ttpt -114.82 140.02 49.27 Favored 'General case' 0 N--CA 1.506 2.342 0 O-C-N 121.179 -0.951 . . . . 0.0 110.919 -178.267 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 84.5 t80 -120.97 136.26 55.02 Favored 'General case' 0 N--CA 1.505 2.293 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.24 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 -136.49 124.13 22.37 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.204 -0.935 . . . . 0.0 110.18 179.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -125.01 140.77 52.61 Favored 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.421 -0.799 . . . . 0.0 110.426 179.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.0 mt -118.93 129.82 55.38 Favored 'General case' 0 N--CA 1.504 2.26 0 O-C-N 121.501 -0.749 . . . . 0.0 109.464 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 31.8 p -126.57 117.18 22.28 Favored 'General case' 0 N--CA 1.508 2.439 0 CA-C-O 121.848 0.832 . . . . 0.0 110.29 179.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -132.56 156.12 47.42 Favored 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.154 -179.109 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -70.82 144.74 50.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.4 -0.813 . . . . 0.0 109.384 179.302 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 35.5 t -120.04 127.58 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.707 -0.621 . . . . 0.0 109.343 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.764 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -179.552 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' A' ' 8' ' ' ASP . 26.6 t0 -100.2 7.48 44.48 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.309 -0.869 . . . . 0.0 110.894 -178.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 71.6 m-80 -122.39 13.17 10.23 Favored 'General case' 0 N--CA 1.501 2.087 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.4 m -120.49 141.66 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 CA-C-O 121.343 0.592 . . . . 0.0 109.422 -179.175 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 36.0 t0 -103.97 111.94 65.34 Favored Pre-proline 0 N--CA 1.499 1.999 0 O-C-N 121.247 -0.908 . . . . 0.0 109.081 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_exo -40.78 -33.43 1.06 Allowed 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.232 1.955 . . . . 0.0 113.126 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 58.5 m -60.01 -39.93 87.5 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.036 -1.04 . . . . 0.0 110.711 -179.367 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 47.0 tt0 -70.03 -24.91 63.35 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.799 -1.188 . . . . 0.0 109.925 -178.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.555 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 37.3 t -68.31 -34.41 76.09 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.332 -0.855 . . . . 0.0 110.118 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.1 pt -117.17 145.88 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.409 -0.807 . . . . 0.0 109.153 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 52.7 mtpt -126.36 146.09 50.19 Favored 'General case' 0 N--CA 1.497 1.875 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 -179.47 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -87.0 119.73 27.51 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.543 -0.723 . . . . 0.0 109.208 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.512 ' O ' ' N ' ' A' ' 21' ' ' VAL . 39.3 p -102.07 119.54 38.96 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.404 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.81 -93.4 0.01 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.512 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.4 t -129.86 20.89 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.538 -0.978 . . . . 0.0 109.23 -179.641 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 75.2 mt-30 -128.55 167.93 16.42 Favored 'General case' 0 N--CA 1.5 2.067 0 CA-C-O 121.866 0.841 . . . . 0.0 110.695 -179.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 24.3 m-85 -119.74 135.15 54.96 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 107.888 -1.152 . . . . 0.0 107.888 178.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 60.9 p -131.32 149.74 52.43 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.345 -0.847 . . . . 0.0 109.753 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 48.5 t80 -86.89 128.76 35.06 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.468 -0.77 . . . . 0.0 109.871 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -88.27 81.53 7.28 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.105 -0.997 . . . . 0.0 110.552 -179.362 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.2 p -77.97 -16.64 57.99 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.936 -1.102 . . . . 0.0 109.599 179.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -64.1 -3.68 9.48 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.363 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.402 HG12 HG12 ' A' ' 31' ' ' VAL . 2.7 t -98.6 129.35 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.261 -1.141 . . . . 0.0 108.321 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 80.8 p -60.06 -40.24 88.8 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 110.727 -178.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.42 HG13 ' N ' ' A' ' 32' ' ' CYS . 8.1 p -60.67 -40.4 84.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.92 -1.112 . . . . 0.0 110.402 -179.246 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.555 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.9 m -61.37 -43.36 99.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.024 -1.047 . . . . 0.0 110.11 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 9.2 mmt -80.34 -16.83 53.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.897 -1.127 . . . . 0.0 109.824 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 55.9 tt0 -60.32 -40.28 90.02 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.053 -1.029 . . . . 0.0 108.744 179.372 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -78.49 -47.47 8.03 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 mt -64.86 -42.67 94.68 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.196 -1.179 . . . . 0.0 110.159 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -62.79 -40.39 97.2 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.015 -1.053 . . . . 0.0 110.002 -179.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 63.5 mm-40 -67.78 -29.29 68.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.199 -0.938 . . . . 0.0 109.61 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.02 22.75 44.01 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 110.09 -1.204 . . . . 0.0 110.09 179.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 17.2 mmmt -102.55 -0.31 32.32 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 178.475 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.636 HG12 ' H ' ' A' ' 43' ' ' GLY . 14.4 t -136.53 157.46 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.512 ' N ' ' O ' ' A' ' 94' ' ' VAL . 70.7 mtp85 -118.18 -10.19 10.33 Favored 'General case' 0 N--CA 1.5 2.045 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 178.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.636 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 141.55 -158.86 26.69 Favored Glycine 0 N--CA 1.497 2.717 0 N-CA-C 108.644 -1.783 . . . . 0.0 108.644 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.7 t -120.59 128.96 76.08 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.184 -1.186 . . . . 0.0 109.207 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.4 m -85.69 139.67 31.18 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.256 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.412 ' O ' HG13 ' A' ' 46' ' ' VAL . 8.6 p -129.61 133.03 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 CA-C-O 121.808 0.813 . . . . 0.0 109.797 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 22.4 p -126.73 150.09 49.24 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 178.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -148.88 145.21 13.29 Favored Glycine 0 N--CA 1.494 2.548 0 C-N-CA 118.708 -1.71 . . . . 0.0 111.462 -178.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 95.4 t -118.16 125.98 74.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 178.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 2.1 m-85 -105.51 116.29 31.69 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.166 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -91.76 124.75 36.13 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.45 -0.781 . . . . 0.0 109.137 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.466 ' C ' ' H ' ' A' ' 54' ' ' ASP . 88.9 m-85 -109.31 134.68 51.49 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 -57.16 -5.96 0.34 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.905 -1.122 . . . . 0.0 108.767 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.466 ' H ' ' C ' ' A' ' 52' ' ' TYR . 46.2 t0 -73.64 3.59 6.14 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.59 27.41 61.21 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.286 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 22.7 p -130.12 150.87 51.19 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.416 -1.05 . . . . 0.0 110.864 -179.162 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 80.5 p -132.0 123.04 26.52 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.64 -0.663 . . . . 0.0 109.324 179.263 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . 0.462 ' C ' ' ND2' ' A' ' 59' ' ' ASN . 23.2 t -104.46 153.2 21.42 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 179.23 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.462 ' ND2' ' C ' ' A' ' 58' ' ' SER . 3.1 m120 -131.97 118.87 20.32 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 120.93 -1.106 . . . . 0.0 108.98 179.755 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -117.48 123.95 47.59 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.477 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -111.78 145.57 39.16 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -163.37 174.88 39.67 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.6 t -119.82 127.22 75.87 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.124 0 O-C-N 121.517 -0.99 . . . . 0.0 109.373 179.584 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 70.8 t -95.38 120.1 44.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.21 -0.931 . . . . 0.0 110.278 -179.202 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.502 ' C ' ' H ' ' A' ' 67' ' ' SER . 3.0 p -137.34 155.32 75.73 Favored Pre-proline 0 N--CA 1.492 1.635 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.097 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -49.69 -4.96 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.021 1.814 . . . . 0.0 111.624 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.502 ' H ' ' C ' ' A' ' 65' ' ' THR . 52.6 p -71.51 -52.1 20.12 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.201 -0.937 . . . . 0.0 110.414 -179.576 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.0 t -154.58 147.08 17.6 Favored Pre-proline 0 N--CA 1.497 1.902 0 O-C-N 120.843 -1.161 . . . . 0.0 110.235 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -80.89 163.91 20.47 Favored 'Trans proline' 0 N--CA 1.497 1.687 0 C-N-CA 122.373 2.048 . . . . 0.0 112.413 179.032 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 64.6 t -123.02 131.22 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.223 0 O-C-N 121.499 -0.75 . . . . 0.0 109.02 179.419 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -90.8 140.31 29.92 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 120.953 -1.092 . . . . 0.0 109.728 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.446 ' OG1' ' N ' ' A' ' 73' ' ' ASN . 1.2 p -80.34 -50.43 10.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.058 -1.026 . . . . 0.0 108.778 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.446 ' N ' ' OG1' ' A' ' 72' ' ' THR . 97.7 m-20 -79.5 58.32 2.64 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.483 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.484 ' NE2' ' OD1' ' A' ' 75' ' ' ASP . 0.0 OUTLIER -46.41 -39.56 10.68 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.965 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.484 ' OD1' ' NE2' ' A' ' 74' ' ' GLN . 95.3 m-20 -108.37 75.6 0.99 Allowed 'General case' 0 N--CA 1.496 1.841 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.425 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 9.2 tp -60.43 -39.85 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.456 -0.777 . . . . 0.0 110.435 -178.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.425 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 46.1 t30 -59.87 -46.28 89.79 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 119.02 -1.072 . . . . 0.0 108.142 -179.371 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 44.2 tttp -60.62 -50.14 74.72 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.164 -0.96 . . . . 0.0 108.938 178.345 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.535 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.1 m -62.11 -41.11 97.89 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.726 -0.609 . . . . 0.0 110.413 -178.513 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -64.92 -33.06 75.14 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 120.545 -1.347 . . . . 0.0 109.882 179.714 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 46.2 tttt -67.02 -49.86 63.93 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.116 -0.99 . . . . 0.0 110.662 -179.073 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.8 p -113.8 -26.16 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.67 -0.644 . . . . 0.0 111.967 -176.66 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 81.59 158.11 20.6 Favored Glycine 0 N--CA 1.493 2.436 0 O-C-N 120.494 -1.379 . . . . 0.0 109.713 179.703 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.5 t -105.03 120.38 55.52 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.764 -0.845 . . . . 0.0 108.988 179.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -70.0 -58.36 3.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.132 -0.98 . . . . 0.0 111.569 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -113.9 140.04 48.7 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.141 -0.975 . . . . 0.0 110.328 -178.228 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 71.6 t80 -120.24 127.75 52.7 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -130.78 127.12 38.06 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 121.212 -0.93 . . . . 0.0 109.869 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.68 142.83 51.1 Favored 'General case' 0 N--CA 1.505 2.296 0 O-C-N 121.557 -0.714 . . . . 0.0 110.314 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 mt -125.83 133.54 51.95 Favored 'General case' 0 N--CA 1.508 2.433 0 O-C-N 121.602 -0.686 . . . . 0.0 109.384 179.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 61.8 p -127.95 124.66 37.85 Favored 'General case' 0 N--CA 1.506 2.362 0 O-C-N 121.369 -0.832 . . . . 0.0 110.75 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -133.08 147.25 52.17 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.749 -0.594 . . . . 0.0 109.806 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 88.4 m95 -69.49 139.76 53.92 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 120.816 -1.178 . . . . 0.0 109.35 179.331 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.512 ' O ' ' N ' ' A' ' 42' ' ' ARG . 46.8 t -111.68 120.09 61.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.185 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 -179.986 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.692 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 -82.28 -26.16 33.37 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.465 -0.772 . . . . 0.0 110.947 -178.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -94.04 3.44 55.33 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 120.858 -1.151 . . . . 0.0 110.659 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.3 t -110.83 130.04 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.296 -0.878 . . . . 0.0 110.52 -179.076 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -88.0 131.94 41.44 Favored Pre-proline 0 N--CA 1.492 1.63 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.491 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -77.18 -19.58 13.44 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 121.801 1.668 . . . . 0.0 112.477 -179.217 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 55.2 m -59.92 -39.93 87.16 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.174 -0.954 . . . . 0.0 110.374 -179.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 90.2 mm-40 -83.71 -11.15 57.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.076 -1.015 . . . . 0.0 110.054 -179.454 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.667 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 45.5 t -69.67 -31.33 69.32 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.131 -0.981 . . . . 0.0 109.142 179.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -120.07 146.06 25.43 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 61.4 pttt -125.47 149.96 47.77 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.458 -0.776 . . . . 0.0 109.384 -179.406 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -99.85 122.03 42.18 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.357 -0.839 . . . . 0.0 109.827 -178.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.1 t -107.45 100.9 10.29 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.069 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 71.72 -94.52 0.59 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.1 m -133.2 23.28 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.204 0 O-C-N 121.285 -1.126 . . . . 0.0 110.413 -179.642 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -131.66 161.56 32.46 Favored 'General case' 0 N--CA 1.504 2.275 0 O-C-N 121.209 -0.932 . . . . 0.0 109.989 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -113.26 141.41 47.02 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 37.2 p -130.01 142.04 50.67 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.36 -0.838 . . . . 0.0 109.425 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.9 t80 -81.64 126.0 31.24 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.49 -0.756 . . . . 0.0 109.897 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -90.02 85.41 6.32 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.35 -0.844 . . . . 0.0 110.447 -179.611 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.2 p -85.54 -1.43 57.09 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.933 -1.104 . . . . 0.0 109.207 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.08 -31.56 77.16 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.511 ' CG2' ' SG ' ' A' ' 32' ' ' CYS . 24.4 m -83.64 132.48 31.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.152 -1.205 . . . . 0.0 109.138 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 71.1 m -60.08 -39.92 87.76 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.325 -0.859 . . . . 0.0 111.474 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.1 m -52.96 -38.19 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 120.719 -1.238 . . . . 0.0 110.588 -178.072 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.667 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.8 m -62.85 -39.93 95.91 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.73 -1.231 . . . . 0.0 110.016 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 10.0 mmt -80.07 -14.92 58.16 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.984 -1.073 . . . . 0.0 110.263 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 -64.84 -39.97 94.43 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.884 -1.135 . . . . 0.0 109.287 179.167 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.12 -49.11 8.82 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.97 -40.16 94.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.347 -1.09 . . . . 0.0 109.998 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -61.15 -40.01 92.23 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.936 -1.103 . . . . 0.0 110.043 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -76.7 -10.19 59.21 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.017 -1.052 . . . . 0.0 109.214 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 69.93 27.23 73.36 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 54.7 tttp -98.99 -7.52 26.8 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 178.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.566 HG12 ' H ' ' A' ' 43' ' ' GLY . 4.2 t -133.71 159.03 42.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-N 115.113 -0.949 . . . . 0.0 108.885 -179.591 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 94' ' ' VAL . 96.3 mtt180 -121.46 -5.96 9.28 Favored 'General case' 0 N--CA 1.504 2.265 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.211 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.566 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 142.66 -170.13 25.29 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 108.567 -1.813 . . . . 0.0 108.567 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 77.0 t -111.08 126.18 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.065 -1.256 . . . . 0.0 108.338 179.147 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.4 p -82.02 139.76 34.32 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.126 -0.984 . . . . 0.0 109.275 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.431 ' O ' HG13 ' A' ' 46' ' ' VAL . 12.3 p -130.0 133.45 64.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 98.1 p -124.43 142.54 51.23 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.406 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -133.87 131.86 6.19 Favored Glycine 0 N--CA 1.502 3.068 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.108 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 74.4 t -121.58 129.26 75.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.732 -0.863 . . . . 0.0 108.999 178.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.433 ' HE2' ' HG1' ' A' ' 72' ' ' THR . 29.7 m-85 -104.76 122.54 45.92 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.209 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -96.16 129.82 43.37 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.284 -0.885 . . . . 0.0 109.454 -179.417 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.529 ' O ' ' N ' ' A' ' 54' ' ' ASP . 95.0 m-85 -114.66 127.57 55.84 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -179.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -43.12 -19.11 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.428 -0.795 . . . . 0.0 109.918 179.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 52' ' ' TYR . 50.1 t0 -68.25 1.32 2.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.459 -0.776 . . . . 0.0 109.752 -179.235 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.76 20.26 74.12 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.574 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.5 p -115.9 154.76 29.17 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.423 -1.046 . . . . 0.0 109.726 179.617 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 45.2 p -139.62 137.98 35.76 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.626 -0.671 . . . . 0.0 109.629 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 53.8 m -113.71 149.58 34.55 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 178.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 21.9 p-10 -140.79 119.07 12.08 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.023 -1.048 . . . . 0.0 110.119 -179.418 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 73.5 m-85 -114.11 121.52 44.05 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 107.678 -1.231 . . . . 0.0 107.678 178.349 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.0 ttpm? -113.17 147.33 37.63 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.64 169.2 41.55 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.4 t -110.04 127.32 67.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.416 -1.05 . . . . 0.0 109.594 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.5 t -91.3 119.99 39.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.423 -0.798 . . . . 0.0 110.017 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.515 ' O ' ' N ' ' A' ' 67' ' ' SER . 25.7 p -136.31 147.59 60.81 Favored Pre-proline 0 N--CA 1.493 1.688 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 178.515 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_exo -39.16 -21.86 0.07 OUTLIER 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 121.987 1.792 . . . . 0.0 112.538 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.515 ' N ' ' O ' ' A' ' 65' ' ' THR . 67.9 m -68.41 -45.82 71.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.115 -0.991 . . . . 0.0 111.413 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 5.8 t -154.75 142.8 14.26 Favored Pre-proline 0 N--CA 1.5 2.042 0 O-C-N 120.407 -1.433 . . . . 0.0 111.19 -179.384 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -81.95 166.84 16.67 Favored 'Trans proline' 0 N--CA 1.499 1.83 0 C-N-CA 122.993 2.462 . . . . 0.0 111.627 178.308 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 90.3 t -105.95 135.79 42.81 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.198 0 O-C-N 121.242 -0.911 . . . . 0.0 109.258 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 29.2 m120 -99.67 123.95 44.43 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.301 -0.874 . . . . 0.0 111.464 -178.258 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.462 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.3 OUTLIER -109.87 20.03 18.44 Favored 'General case' 0 N--CA 1.502 2.174 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.1 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.445 ' O ' ' O ' ' A' ' 74' ' ' GLN . 25.6 t-20 -78.69 60.23 2.7 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.47 -0.769 . . . . 0.0 109.927 -179.433 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.554 ' N ' ' OE1' ' A' ' 74' ' ' GLN . 0.0 OUTLIER -50.28 177.59 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 178.732 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 78.9 m-20 -66.08 119.81 12.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.469 -1.394 . . . . 0.0 108.464 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.436 HG22 ' O ' ' A' ' 76' ' ' ILE . 94.5 mt -80.65 -13.11 12.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.506 -0.746 . . . . 0.0 110.409 -179.092 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 28.7 m120 -60.13 -43.89 95.33 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.827 -1.171 . . . . 0.0 109.036 -179.497 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 18.7 pttt -66.89 -40.09 87.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.877 -1.139 . . . . 0.0 109.271 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.587 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.9 OUTLIER -63.05 -41.13 99.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.239 -0.913 . . . . 0.0 108.777 179.473 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -62.19 -38.71 90.14 Favored 'General case' 0 C--N 1.295 -1.773 0 O-C-N 120.76 -1.213 . . . . 0.0 109.551 179.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 31.3 tttm -71.61 -42.51 67.61 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.07 -1.019 . . . . 0.0 111.148 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 p -112.12 -29.42 2.36 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.188 0 O-C-N 121.252 -0.905 . . . . 0.0 112.168 -176.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.98 161.09 37.15 Favored Glycine 0 N--CA 1.495 2.587 0 O-C-N 120.702 -1.249 . . . . 0.0 110.606 179.31 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 84.7 t -108.99 127.34 65.73 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.075 0 O-C-N 121.807 -0.82 . . . . 0.0 108.903 179.363 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -88.01 -63.12 1.35 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.08 -1.013 . . . . 0.0 111.181 -178.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -115.07 142.94 45.96 Favored 'General case' 0 N--CA 1.505 2.293 0 CA-C-O 121.872 0.844 . . . . 0.0 111.937 -178.002 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -120.08 130.87 54.86 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.07 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.91 128.62 32.93 Favored 'General case' 0 N--CA 1.505 2.325 0 O-C-N 121.067 -1.02 . . . . 0.0 110.104 -178.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.43 135.38 54.08 Favored 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 179.14 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.696 HD13 ' N ' ' A' ' 91' ' ' THR . 0.2 OUTLIER -120.0 134.73 55.16 Favored 'General case' 0 N--CA 1.503 2.205 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.789 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.696 ' N ' HD13 ' A' ' 90' ' ' LEU . 14.5 p -130.22 124.24 32.05 Favored 'General case' 0 N--CA 1.505 2.283 0 CA-C-O 121.571 0.7 . . . . 0.0 111.016 -179.181 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.29 156.98 47.48 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.762 -0.586 . . . . 0.0 110.131 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 65.6 m95 -69.61 149.51 48.06 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.707 -1.246 . . . . 0.0 108.135 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.519 ' O ' ' N ' ' A' ' 42' ' ' ARG . 31.7 t -117.95 123.11 71.2 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.171 0 O-C-N 121.353 -0.842 . . . . 0.0 109.394 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 2.77 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 179.627 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.682 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.435 ' OD1' ' O ' ' A' ' 8' ' ' ASP . 39.2 t0 -99.19 6.09 46.51 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.296 -0.877 . . . . 0.0 111.427 -178.546 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.7 p-10 -130.01 9.3 5.3 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 120.843 -1.161 . . . . 0.0 108.908 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 2.2 m -124.68 129.96 73.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -89.81 148.25 39.41 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.016 -1.053 . . . . 0.0 108.759 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -80.15 -22.36 7.23 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.408 2.072 . . . . 0.0 111.937 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 56.0 m -60.24 -40.16 89.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.916 . . . . 0.0 110.411 -179.583 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -81.05 -13.77 58.48 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.031 -1.043 . . . . 0.0 110.239 -179.286 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.678 ' HG ' ' HG ' ' A' ' 32' ' ' CYS . 53.9 m -71.11 -29.06 64.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.11 178.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -120.46 135.05 61.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 64.0 mmtt -111.96 147.86 35.0 Favored 'General case' 0 N--CA 1.502 2.161 0 O-C-N 121.291 -0.88 . . . . 0.0 109.292 -179.318 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -97.11 119.86 36.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 108.796 179.516 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 47.8 t -107.56 116.08 31.3 Favored 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.56 -109.42 1.21 Allowed Glycine 0 N--CA 1.487 2.038 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 -178.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.435 ' O ' HG13 ' A' ' 21' ' ' VAL . 7.7 p -118.74 34.64 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.43 -1.041 . . . . 0.0 108.997 179.16 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -130.66 159.37 37.42 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 122.194 0.997 . . . . 0.0 111.567 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -120.8 136.79 54.81 Favored 'General case' 0 N--CA 1.496 1.825 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 26.5 p -137.25 154.44 50.14 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.245 -0.909 . . . . 0.0 109.279 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.8 t80 -87.67 128.06 35.29 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.266 -0.896 . . . . 0.0 109.597 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -86.01 83.21 7.83 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.929 -1.107 . . . . 0.0 109.92 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 86.4 p -84.65 -0.98 55.4 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.933 -1.104 . . . . 0.0 109.424 179.627 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.67 -39.96 95.87 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.089 -1.605 . . . . 0.0 109.089 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 33.4 m -81.83 135.28 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.332 -1.099 . . . . 0.0 108.774 179.433 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 34' ' ' GLN . 17.1 p -72.76 -26.8 61.68 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.182 -0.949 . . . . 0.0 110.873 -178.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.484 HG13 ' N ' ' A' ' 32' ' ' CYS . 10.9 p -59.9 -40.85 83.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 120.841 -1.162 . . . . 0.0 110.774 -178.504 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.678 ' HG ' ' HG ' ' A' ' 15' ' ' CYS . 87.0 m -68.69 -39.9 80.3 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.839 -1.163 . . . . 0.0 109.228 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 99.5 mmm -80.09 -14.6 58.39 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.134 -0.979 . . . . 0.0 108.68 179.089 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.421 ' N ' ' O ' ' A' ' 30' ' ' SER . 7.2 tt0 -60.62 -41.98 95.92 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.01 -41.2 28.1 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.378 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.3 tp -67.16 -40.26 86.63 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -1.128 . . . . 0.0 108.687 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -63.07 -40.03 96.47 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.48 -0.763 . . . . 0.0 110.539 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.537 ' N ' ' OE1' ' A' ' 38' ' ' GLU . 0.4 OUTLIER -75.09 -11.41 60.09 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.831 -1.168 . . . . 0.0 109.763 -179.403 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.24 21.5 70.16 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 119.901 -1.142 . . . . 0.0 110.443 178.654 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 62.3 mttm -98.66 -3.38 36.15 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.686 HG12 ' H ' ' A' ' 43' ' ' GLY . 94.0 t -134.91 159.28 41.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.419 ' N ' HG12 ' A' ' 41' ' ' VAL . 95.0 mtt-85 -122.08 -7.13 8.89 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 179.482 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.686 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.78 -163.22 25.88 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 -179.504 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 87.8 t -119.39 129.19 75.6 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 121.322 -1.105 . . . . 0.0 109.115 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 5.4 m -86.36 139.19 31.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.861 -1.149 . . . . 0.0 108.897 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.41 ' O ' HG13 ' A' ' 46' ' ' VAL . 10.6 p -131.25 133.76 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 53.5 p -125.42 149.42 48.21 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 179.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -143.51 138.12 7.96 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 119.574 -1.298 . . . . 0.0 110.062 -179.145 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.426 HG21 HH21 ' A' ' 88' ' ' ARG . 62.4 t -122.63 127.06 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 179.064 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.594 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 0.2 OUTLIER -100.87 119.8 39.2 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -179.858 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -94.41 119.92 33.86 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.164 -0.96 . . . . 0.0 108.661 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.482 ' O ' ' N ' ' A' ' 54' ' ' ASP . 93.4 m-85 -102.22 125.79 49.02 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.424 -0.797 . . . . 0.0 109.985 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -47.2 -16.43 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.104 -0.997 . . . . 0.0 109.751 179.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.482 ' N ' ' O ' ' A' ' 52' ' ' TYR . 47.4 t0 -70.85 4.72 2.37 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.247 -0.908 . . . . 0.0 109.223 -179.533 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.08 22.76 70.49 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 178.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.4 p -123.54 150.81 43.54 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.33 -1.1 . . . . 0.0 109.339 179.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.1 p -135.33 139.79 44.58 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.583 -0.698 . . . . 0.0 110.152 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.1 m -117.92 144.5 45.41 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 178.352 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.6 m-20 -128.2 118.49 23.42 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.388 -0.82 . . . . 0.0 108.953 -179.831 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 66.3 t80 -116.76 126.47 53.16 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.256 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -113.74 144.9 42.19 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -159.16 167.83 35.02 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.83 128.58 74.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.599 -0.942 . . . . 0.0 108.694 -179.662 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 45.7 t -92.88 117.87 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.047 -1.033 . . . . 0.0 110.088 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.541 ' O ' ' N ' ' A' ' 67' ' ' SER . 6.4 p -134.98 153.87 78.81 Favored Pre-proline 0 N--CA 1.492 1.633 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 178.643 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_exo -43.93 -10.13 0.03 OUTLIER 'Trans proline' 0 N--CA 1.494 1.543 0 C-N-CA 121.981 1.788 . . . . 0.0 113.204 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.541 ' N ' ' O ' ' A' ' 65' ' ' THR . 87.1 p -67.6 -59.52 3.29 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.892 -1.13 . . . . 0.0 110.687 -179.236 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -155.4 150.75 21.21 Favored Pre-proline 0 N--CA 1.498 1.933 0 O-C-N 120.596 -1.315 . . . . 0.0 110.259 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -82.81 161.24 16.25 Favored 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.522 2.148 . . . . 0.0 112.523 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.5 t -110.78 130.5 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 15.7 m-20 -100.8 144.46 29.73 Favored 'General case' 0 N--CA 1.506 2.338 0 O-C-N 120.905 -1.122 . . . . 0.0 111.069 -178.355 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.19 -0.06 56.99 Favored 'General case' 0 N--CA 1.504 2.244 0 O-C-N 121.059 -1.026 . . . . 0.0 108.607 178.531 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.434 ' HB3' HG21 ' A' ' 21' ' ' VAL . 52.2 p-10 -80.43 46.67 0.86 Allowed 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.239 -0.913 . . . . 0.0 109.832 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 62.1 tt0 -48.17 -81.04 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.957 -1.09 . . . . 0.0 110.012 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -112.93 94.9 5.12 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.41 -0.806 . . . . 0.0 109.938 -179.503 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 8.8 mm -68.63 -39.89 81.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.28 -0.888 . . . . 0.0 109.733 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -59.95 -40.97 90.81 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 107.74 -1.207 . . . . 0.0 107.74 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -66.51 -43.13 86.1 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.455 -0.778 . . . . 0.0 109.156 178.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.597 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.2 m -76.1 -47.95 22.55 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.524 -0.735 . . . . 0.0 110.227 -178.721 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -60.05 -32.11 70.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.248 -1.533 . . . . 0.0 109.783 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 18.7 tptt -67.49 -53.53 27.97 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.329 -0.857 . . . . 0.0 110.694 -178.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.12 -22.14 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.172 -0.955 . . . . 0.0 111.515 -178.328 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.2 167.3 43.39 Favored Glycine 0 N--CA 1.487 2.086 0 O-C-N 120.896 -1.128 . . . . 0.0 110.764 178.729 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.401 HG23 HG23 ' A' ' 79' ' ' THR . 63.8 t -109.86 129.72 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.744 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -80.03 -67.08 0.8 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.768 -1.208 . . . . 0.0 110.34 -178.784 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -113.73 138.78 49.76 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.418 -0.801 . . . . 0.0 109.891 -178.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 63.2 t80 -121.99 126.88 49.53 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.205 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.426 HH21 HG21 ' A' ' 49' ' ' VAL . 38.6 ptt180 -133.71 134.7 43.37 Favored 'General case' 0 N--CA 1.502 2.151 0 CA-C-O 121.96 0.886 . . . . 0.0 110.023 179.711 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.8 136.04 54.16 Favored 'General case' 0 N--CA 1.495 1.798 0 CA-C-O 121.164 0.507 . . . . 0.0 109.749 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 4.0 mt -113.35 131.79 55.83 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.402 -0.811 . . . . 0.0 108.815 179.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 3.8 p -126.12 121.3 32.49 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.677 0.751 . . . . 0.0 109.82 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -133.66 154.46 50.9 Favored 'General case' 0 N--CA 1.498 1.926 0 CA-C-O 121.422 0.63 . . . . 0.0 110.087 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -72.94 138.44 46.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.394 -0.816 . . . . 0.0 109.01 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 39.7 t -109.97 116.31 51.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.752 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.551 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.286 0.565 . . . . 0.0 109.699 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.425 ' OD1' ' N ' ' A' ' 9' ' ' ASN . 36.4 p-10 -85.13 -26.17 27.04 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.233 -0.917 . . . . 0.0 110.035 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.425 ' N ' ' OD1' ' A' ' 8' ' ' ASP . 22.7 m120 -91.71 1.46 57.14 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.295 -0.878 . . . . 0.0 110.067 -179.141 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.8 t -108.98 129.96 62.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.466 -0.771 . . . . 0.0 109.562 -178.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -90.02 127.6 53.05 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.103 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -76.57 -13.84 18.09 Favored 'Trans proline' 0 N--CA 1.497 1.702 0 C-N-CA 122.082 1.855 . . . . 0.0 112.648 -179.048 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 54.5 m -62.06 -40.01 94.33 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.133 -0.979 . . . . 0.0 110.43 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . 0.416 ' CD ' ' N ' ' A' ' 14' ' ' GLN . 28.2 mp0 -83.35 -12.52 56.47 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.076 -1.015 . . . . 0.0 110.37 -179.2 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.77 ' HG ' ' HG ' ' A' ' 32' ' ' CYS . 36.6 t -64.62 -36.62 84.83 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.182 -0.949 . . . . 0.0 110.189 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -117.48 141.1 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 121.399 -0.813 . . . . 0.0 108.887 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 20.4 pttp -118.83 145.46 45.64 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -98.11 124.77 42.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.397 -0.814 . . . . 0.0 109.409 179.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.539 ' O ' ' N ' ' A' ' 21' ' ' VAL . 65.6 m -110.17 131.12 55.34 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.38 -93.68 0.01 OUTLIER Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 -179.235 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.539 ' N ' ' O ' ' A' ' 19' ' ' SER . 26.2 m -139.6 31.39 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.308 -1.113 . . . . 0.0 109.676 179.816 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -131.53 159.41 38.24 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.417 -0.802 . . . . 0.0 109.902 179.456 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -114.24 139.97 48.96 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.027 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.2 p -136.53 148.79 47.79 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.143 -0.973 . . . . 0.0 109.847 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -84.55 129.92 34.8 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.169 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -90.95 103.73 16.41 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.095 -1.003 . . . . 0.0 110.159 -179.6 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 88.1 p -92.08 -5.99 51.76 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.062 -1.023 . . . . 0.0 108.981 178.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.89 -36.43 90.06 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.8 m -79.0 136.89 22.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.214 -1.168 . . . . 0.0 109.263 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.9 m -68.37 -31.49 70.89 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.409 -0.807 . . . . 0.0 111.157 -178.693 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 85.4 t -59.98 -40.07 82.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.885 -1.135 . . . . 0.0 110.556 -178.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.77 ' HG ' ' HG ' ' A' ' 15' ' ' CYS . 68.3 m -59.84 -47.0 87.51 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.629 -1.294 . . . . 0.0 110.056 -179.321 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . 0.416 ' O ' ' CB ' ' A' ' 37' ' ' ASN . 29.7 mmt -70.23 -34.13 72.49 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.304 -0.873 . . . . 0.0 110.657 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 18.7 mm100 -59.55 -41.53 90.32 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.02 -1.05 . . . . 0.0 110.765 -178.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.68 -49.5 7.14 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 30.6 tp -60.01 -43.71 95.04 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.416 ' CB ' ' O ' ' A' ' 33' ' ' MET . 39.9 t30 -61.47 -39.9 92.56 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.543 -0.723 . . . . 0.0 109.963 179.19 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 49.7 tp10 -60.2 -31.4 70.11 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.329 -0.857 . . . . 0.0 109.819 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.81 15.23 56.86 Favored Glycine 0 N--CA 1.497 2.737 0 N-CA-C 110.306 -1.117 . . . . 0.0 110.306 179.33 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -101.98 -1.16 32.46 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 106.628 -1.619 . . . . 0.0 106.628 178.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.688 HG12 ' H ' ' A' ' 43' ' ' GLY . 98.9 t -130.56 159.91 42.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-N 115.172 -0.922 . . . . 0.0 108.518 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.511 ' N ' ' O ' ' A' ' 94' ' ' VAL . 42.0 ttm180 -123.71 -8.93 7.88 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.252 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.688 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.84 -159.1 26.43 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 108.215 -1.954 . . . . 0.0 108.215 -179.296 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 96.6 t -119.68 128.65 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.306 -1.114 . . . . 0.0 109.178 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 p -82.97 140.89 32.51 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.279 -0.888 . . . . 0.0 109.012 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.458 ' O ' HG13 ' A' ' 46' ' ' VAL . 8.8 p -132.23 130.61 60.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.575 -0.703 . . . . 0.0 109.525 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 16.8 p -123.63 146.04 48.49 Favored 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -140.47 136.74 7.85 Favored Glycine 0 N--CA 1.499 2.84 0 N-CA-C 110.119 -1.193 . . . . 0.0 110.119 -179.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 90.9 t -121.39 129.1 75.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.791 -0.829 . . . . 0.0 108.973 179.113 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -100.72 119.96 39.37 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 179.34 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 63.6 m-85 -96.49 126.09 41.44 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.323 -0.861 . . . . 0.0 108.945 -179.535 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.53 ' CD1' ' NZ ' ' A' ' 78' ' ' LYS . 90.0 m-85 -111.45 129.42 56.04 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.446 -0.784 . . . . 0.0 110.021 -178.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.429 ' OD1' ' OE1' ' A' ' 85' ' ' GLN . 74.9 m-20 -45.46 -17.27 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.41 -0.806 . . . . 0.0 109.406 178.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.514 ' N ' ' O ' ' A' ' 52' ' ' TYR . 52.5 t0 -68.86 0.09 4.83 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.495 -0.753 . . . . 0.0 109.532 -179.552 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.55 23.96 63.86 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.019 -1.086 . . . . 0.0 110.431 179.219 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.3 p -122.76 147.47 46.46 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.37 -1.077 . . . . 0.0 110.127 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.5 p -131.56 136.27 47.69 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.608 -0.683 . . . . 0.0 109.771 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 41.2 t -118.64 142.73 47.37 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 178.439 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 35.1 p-10 -130.61 120.44 23.99 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.921 -1.112 . . . . 0.0 110.224 -179.224 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.436 ' CZ ' ' NE2' ' A' ' 74' ' ' GLN . 96.1 m-85 -114.71 120.16 39.16 Favored 'General case' 0 N--CA 1.498 1.963 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.8 ttpt -112.54 152.6 28.64 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 -179.43 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.57 174.67 43.27 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 67.6 t -115.7 126.27 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.623 -0.928 . . . . 0.0 110.04 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 38.2 t -91.23 117.76 35.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.514 -0.741 . . . . 0.0 110.013 -179.364 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.516 ' O ' ' N ' ' A' ' 67' ' ' SER . 21.7 p -121.28 150.92 55.11 Favored Pre-proline 0 N--CA 1.498 1.943 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 178.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_exo -38.34 -20.76 0.05 OUTLIER 'Trans proline' 0 C--N 1.312 -1.358 0 C-N-CA 122.01 1.807 . . . . 0.0 113.372 -179.466 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.516 ' N ' ' O ' ' A' ' 65' ' ' THR . 18.1 p -121.81 2.93 10.04 Favored 'General case' 0 N--CA 1.505 2.29 0 O-C-N 121.181 -0.949 . . . . 0.0 111.88 -179.004 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 61.1 p -129.94 107.22 16.66 Favored Pre-proline 0 N--CA 1.51 2.537 0 O-C-N 120.768 -1.207 . . . . 0.0 110.687 -179.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -90.58 165.31 4.24 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 C-N-CA 122.781 2.32 . . . . 0.0 112.288 178.315 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.1 t -120.47 129.95 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 N-CA-C 108.79 -0.818 . . . . 0.0 108.79 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 30.1 m120 -99.99 121.65 41.68 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.22 -0.925 . . . . 0.0 111.154 -178.432 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -91.02 -0.02 57.64 Favored 'General case' 0 N--CA 1.497 1.914 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.211 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.438 ' O ' ' O ' ' A' ' 74' ' ' GLN . 51.5 p-10 -75.11 57.74 0.85 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.4 -0.813 . . . . 0.0 109.573 -179.218 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.438 ' O ' ' O ' ' A' ' 73' ' ' ASN . 9.4 tp-100 -55.47 -101.92 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.559 -0.713 . . . . 0.0 109.091 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -108.26 100.43 9.74 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 120.967 -1.083 . . . . 0.0 109.231 179.449 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 44.3 mm -69.86 -39.33 77.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.024 -1.047 . . . . 0.0 109.077 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 -58.29 -41.08 83.6 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.53 ' NZ ' ' CD1' ' A' ' 52' ' ' TYR . 54.5 tttm -60.12 -49.91 75.77 Favored 'General case' 0 N--CA 1.488 1.425 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.367 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.581 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.8 OUTLIER -63.29 -41.03 98.94 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.546 -0.722 . . . . 0.0 110.304 -179.113 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -60.4 -35.94 76.95 Favored 'General case' 0 C--N 1.294 -1.838 0 O-C-N 120.655 -1.278 . . . . 0.0 110.912 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 8.9 tmtm? -70.9 -43.94 67.28 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.701 -1.249 . . . . 0.0 111.463 -178.502 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 p -110.1 -26.0 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.281 0 O-C-N 120.872 -1.142 . . . . 0.0 110.924 -178.281 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.581 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 79.94 157.81 14.73 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.8 t -108.53 130.4 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.067 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.429 ' OE1' ' OD1' ' A' ' 53' ' ' ASN . 18.7 pt20 -97.43 -43.29 7.34 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.185 -0.947 . . . . 0.0 110.929 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -115.9 127.84 55.31 Favored 'General case' 0 N--CA 1.502 2.127 0 O-C-N 121.197 -0.939 . . . . 0.0 110.766 -178.804 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -122.17 123.62 41.94 Favored 'General case' 0 N--CA 1.499 2.003 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 93.8 mtt180 -132.2 133.75 44.54 Favored 'General case' 0 N--CA 1.507 2.387 0 O-C-N 121.073 -1.017 . . . . 0.0 110.799 -179.545 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.1 135.18 53.36 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.797 -0.564 . . . . 0.0 109.58 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 54.5 tp -117.32 137.48 52.41 Favored 'General case' 0 N--CA 1.505 2.316 0 O-C-N 121.421 -0.799 . . . . 0.0 109.73 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.7 p -129.72 123.58 31.43 Favored 'General case' 0 N--CA 1.504 2.25 0 CA-C-O 121.639 0.733 . . . . 0.0 111.241 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.4 tt0 -133.78 157.33 46.16 Favored 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.637 -0.664 . . . . 0.0 109.724 179.145 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 82.4 m95 -69.43 149.31 48.48 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.78 -1.2 . . . . 0.0 109.873 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 42' ' ' ARG . 21.7 t -122.48 127.28 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.549 -0.72 . . . . 0.0 109.629 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.502 3.097 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 178.847 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -98.07 5.31 48.82 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.48 -0.763 . . . . 0.0 110.546 -178.66 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -121.02 6.58 10.33 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -134.85 139.4 47.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -179.429 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 24.5 m-20 -85.02 148.47 50.72 Favored Pre-proline 0 C--N 1.301 -1.51 0 O-C-N 121.269 -0.895 . . . . 0.0 109.264 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -75.63 -20.98 15.15 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.258 1.972 . . . . 0.0 111.655 179.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 84.0 p -61.48 -37.68 84.52 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.217 -0.927 . . . . 0.0 109.801 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.1 tp-100 -70.1 -25.66 63.61 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.172 -0.955 . . . . 0.0 109.384 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.511 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 77.2 m -68.42 -30.67 69.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.119 -0.988 . . . . 0.0 109.903 -179.453 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -124.06 136.66 59.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -120.91 150.65 40.74 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.597 -0.69 . . . . 0.0 109.139 -179.545 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -91.99 119.77 32.02 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.037 -1.04 . . . . 0.0 109.639 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 54.9 m -124.4 131.72 53.51 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.419 -0.8 . . . . 0.0 109.073 179.732 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 46.6 47.99 17.46 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.896 -1.145 . . . . 0.0 110.504 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.406 HG11 ' OD1' ' A' ' 73' ' ' ASN . 3.4 t 56.92 29.6 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.208 -1.172 . . . . 0.0 110.363 179.451 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 25.3 mt-30 -130.76 164.85 24.22 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.287 -0.883 . . . . 0.0 108.708 178.494 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 39.1 m-85 -120.43 136.77 54.63 Favored 'General case' 0 N--CA 1.501 2.117 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.366 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 34.7 p -139.85 152.3 46.37 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.401 -0.812 . . . . 0.0 109.612 179.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 28.5 t80 -80.81 127.08 32.12 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.638 -0.664 . . . . 0.0 109.229 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -83.6 83.63 7.83 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.342 -0.849 . . . . 0.0 109.783 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 27.9 p -76.68 -8.91 58.17 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.223 -0.923 . . . . 0.0 108.988 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.01 -39.79 70.61 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.6 m -82.27 128.61 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.036 -1.273 . . . . 0.0 108.46 179.052 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.463 ' O ' ' N ' ' A' ' 34' ' ' GLN . 82.2 p -66.87 -25.0 66.19 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.174 -0.954 . . . . 0.0 110.445 -178.845 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 71.3 t -59.81 -49.24 84.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.242 -0.911 . . . . 0.0 109.937 -178.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.511 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 79.8 m -61.83 -40.08 94.04 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.949 -1.094 . . . . 0.0 109.305 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 5.3 tpt -79.97 -14.87 58.26 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.079 -1.013 . . . . 0.0 108.7 179.615 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.463 ' N ' ' O ' ' A' ' 30' ' ' SER . 5.9 tp-100 -63.15 -40.04 96.43 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.05 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -73.17 -45.41 31.49 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.6 mt -61.02 -42.88 99.31 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.316 -1.108 . . . . 0.0 108.994 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -60.25 -39.91 88.42 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.622 0.725 . . . . 0.0 109.265 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -80.01 -10.01 59.74 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.627 -0.67 . . . . 0.0 109.455 -179.522 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.34 31.88 68.56 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -106.41 -5.89 18.64 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 179.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.746 HG12 ' H ' ' A' ' 43' ' ' GLY . 87.2 t -133.12 156.67 42.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.42 ' N ' HG12 ' A' ' 41' ' ' VAL . 73.8 mtt85 -120.36 -7.03 9.8 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.746 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 137.8 -166.02 25.21 Favored Glycine 0 N--CA 1.498 2.821 0 N-CA-C 109.042 -1.623 . . . . 0.0 109.042 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.7 t -119.95 126.18 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.282 -1.128 . . . . 0.0 109.239 -179.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 28.6 m -80.76 133.12 35.6 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.255 -0.903 . . . . 0.0 108.775 179.267 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.439 HG13 ' O ' ' A' ' 46' ' ' VAL . 7.1 p -129.01 132.27 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.586 -0.696 . . . . 0.0 109.396 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.5 p -123.39 148.4 46.12 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -142.4 140.91 10.3 Favored Glycine 0 N--CA 1.503 3.157 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.981 -178.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 94.8 t -124.79 130.03 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.675 -0.897 . . . . 0.0 109.654 179.188 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 33.9 m-85 -104.18 114.36 28.55 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.823 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -86.28 131.68 34.16 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.041 -1.037 . . . . 0.0 109.192 -179.569 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.429 ' C ' ' H ' ' A' ' 54' ' ' ASP . 54.3 m-85 -116.32 134.18 55.18 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.465 -0.772 . . . . 0.0 109.713 -179.439 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.426 ' C ' ' H ' ' A' ' 55' ' ' GLY . 44.8 t30 -57.17 -11.38 1.63 Allowed 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 178.77 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.429 ' H ' ' C ' ' A' ' 52' ' ' TYR . 11.9 t70 -67.01 0.6 2.43 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.426 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 79.52 20.76 68.25 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.173 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 18.4 p -130.9 151.56 51.18 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.297 -1.119 . . . . 0.0 110.914 -179.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 79.2 p -130.05 137.58 50.3 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 56.9 m -116.24 148.89 40.01 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 179.105 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -137.49 127.33 25.58 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.302 -0.874 . . . . 0.0 109.715 179.77 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -116.41 129.13 56.07 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.013 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -114.06 144.95 42.28 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -167.44 164.54 37.99 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.1 t -109.95 128.19 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.535 -0.98 . . . . 0.0 108.932 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 21.2 t -91.91 119.1 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.191 -0.943 . . . . 0.0 110.088 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.401 ' C ' ' H ' ' A' ' 67' ' ' SER . 29.7 p -132.31 149.93 74.56 Favored Pre-proline 0 N--CA 1.492 1.639 0 N-CA-C 106.889 -1.522 . . . . 0.0 106.889 178.268 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -52.28 -9.23 0.48 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 121.443 1.429 . . . . 0.0 111.293 -179.376 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.401 ' H ' ' C ' ' A' ' 65' ' ' THR . 19.6 m -104.79 -24.93 12.84 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.513 -0.742 . . . . 0.0 110.31 -179.655 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 20.7 m -135.88 107.39 9.76 Favored Pre-proline 0 N--CA 1.506 2.356 0 O-C-N 121.113 -0.992 . . . . 0.0 110.652 -179.593 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -87.04 164.03 8.7 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 C-N-CA 122.148 1.899 . . . . 0.0 111.69 178.428 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.3 t -118.57 129.57 74.65 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.377 -0.827 . . . . 0.0 109.12 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -103.3 136.67 42.64 Favored 'General case' 0 N--CA 1.501 2.105 0 O-C-N 121.148 -0.97 . . . . 0.0 110.678 -178.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.419 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.4 OUTLIER -93.12 -1.16 56.7 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 178.347 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.416 ' O ' ' O ' ' A' ' 74' ' ' GLN . 78.3 m-20 -70.31 51.73 0.13 Allowed 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.427 -0.796 . . . . 0.0 109.378 -179.554 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.419 ' N ' ' O ' ' A' ' 72' ' ' THR . 59.1 tt0 -62.39 -108.47 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 179.507 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -106.32 96.12 6.24 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.137 -0.977 . . . . 0.0 108.384 178.278 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.428 HG22 ' O ' ' A' ' 76' ' ' ILE . 90.4 mt -84.99 -15.22 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.0 -1.063 . . . . 0.0 110.305 -179.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 64.9 t-20 -59.89 -44.6 94.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.919 -1.113 . . . . 0.0 109.837 -179.335 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.414 ' HB2' ' HZ3' ' A' ' 78' ' ' LYS . 9.7 ptmm? -68.77 -33.96 74.77 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.11 -0.994 . . . . 0.0 109.174 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.607 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.7 OUTLIER -62.89 -45.14 93.9 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.935 -1.103 . . . . 0.0 108.067 178.895 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -59.95 -35.17 74.38 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 120.776 -1.202 . . . . 0.0 108.843 178.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.4 tttp -63.99 -51.15 65.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.402 -0.811 . . . . 0.0 111.07 -178.733 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.9 m -117.01 -20.8 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.226 0 O-C-N 121.365 -0.835 . . . . 0.0 111.545 -177.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.607 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.28 167.48 42.84 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 179.412 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 53.6 t -108.62 126.49 65.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 57.1 tt0 -79.96 -65.33 1.02 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.892 -1.13 . . . . 0.0 109.958 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.8 tptm -114.38 140.18 48.88 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.52 -0.738 . . . . 0.0 110.554 -178.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 69.2 t80 -119.75 137.23 54.07 Favored 'General case' 0 N--CA 1.5 2.045 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.139 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -138.1 128.08 25.6 Favored 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.066 -1.021 . . . . 0.0 111.068 -178.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.57 133.43 53.29 Favored 'General case' 0 N--CA 1.503 2.177 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 59.4 tp -120.01 135.35 54.96 Favored 'General case' 0 N--CA 1.508 2.434 0 O-C-N 121.298 -0.876 . . . . 0.0 110.169 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 30.6 p -129.23 127.38 41.14 Favored 'General case' 0 N--CA 1.505 2.282 0 CA-C-O 121.679 0.752 . . . . 0.0 110.958 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -132.63 145.86 51.43 Favored 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.692 -0.63 . . . . 0.0 110.221 179.774 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 76.8 m95 -69.88 139.96 53.1 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 120.945 -1.097 . . . . 0.0 108.771 178.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 17.4 t -112.38 117.52 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.453 -0.779 . . . . 0.0 109.546 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.486 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 179.785 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.879 0 N-CA-C 119.587 2.595 . . . . 0.0 119.587 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.54 138.37 26.05 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 30.0 t -91.13 -3.53 56.99 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.249 -1.148 . . . . 0.0 109.614 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 108.07 -110.01 3.03 Favored Glycine 0 N--CA 1.499 2.897 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 20.2 t90 -61.88 136.56 58.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.229 -1.16 . . . . 0.0 110.6 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . 0.528 ' C ' ' H ' ' A' ' 8' ' ' ASP . 98.6 m-20 -131.57 124.42 29.98 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 177.047 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.87 -3.97 0.14 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.025 -1.047 . . . . 0.0 108.973 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.528 ' H ' ' C ' ' A' ' 6' ' ' ASN . 95.7 m-20 -79.89 -21.73 43.65 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.475 -0.765 . . . . 0.0 110.549 -179.442 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 28.5 m120 -88.48 0.13 56.61 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.933 -1.105 . . . . 0.0 109.424 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.8 t -112.74 127.54 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.553 -0.717 . . . . 0.0 109.42 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -79.04 130.92 68.2 Favored Pre-proline 0 N--CA 1.488 1.444 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -74.49 -10.65 22.21 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 121.706 1.604 . . . . 0.0 111.832 -179.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 82.7 p -69.96 -29.34 66.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.301 -0.874 . . . . 0.0 109.505 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 62.9 tt0 -90.07 -19.52 24.26 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.228 -0.92 . . . . 0.0 109.502 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.581 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 48.8 t -66.34 -33.5 75.86 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.089 -1.007 . . . . 0.0 109.846 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.433 ' O ' HD12 ' A' ' 16' ' ' ILE . 2.5 pp -119.35 132.11 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -113.98 142.87 45.61 Favored 'General case' 0 N--CA 1.5 2.028 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -96.01 127.24 41.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.422 -0.799 . . . . 0.0 110.024 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 49.5 m -115.67 124.24 50.39 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.62 -103.12 0.11 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.4 m -129.76 30.5 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.086 0 O-C-N 121.559 -0.965 . . . . 0.0 109.188 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 14.2 tt0 -129.43 153.04 48.32 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.397 -0.815 . . . . 0.0 110.453 -178.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -114.34 136.42 53.0 Favored 'General case' 0 N--CA 1.499 1.99 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.193 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 36.9 p -135.36 145.37 47.31 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.338 -0.851 . . . . 0.0 109.553 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 45.6 t80 -80.13 124.46 28.79 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.2 m120 -82.82 86.96 6.82 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.01 -1.056 . . . . 0.0 110.267 -179.087 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 13.8 m -79.61 -13.69 59.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.044 -1.035 . . . . 0.0 109.145 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -65.78 -3.68 16.66 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.448 HG12 HG22 ' A' ' 31' ' ' VAL . 2.0 t -102.93 126.91 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 96.7 p -59.92 -40.12 87.79 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.076 -1.015 . . . . 0.0 111.279 -178.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.575 HG23 ' N ' ' A' ' 32' ' ' CYS . 16.2 m -60.56 -44.3 96.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 120.878 -1.139 . . . . 0.0 110.638 -178.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.581 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 89.3 m -60.14 -43.36 95.76 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.099 -1.001 . . . . 0.0 110.563 -178.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 95.2 mmm -84.33 -12.76 54.02 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.721 -1.237 . . . . 0.0 109.121 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 -60.12 -47.44 85.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.889 . . . . 0.0 108.604 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.86 -45.04 17.85 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.2 tp -60.18 -40.01 88.47 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.242 -1.152 . . . . 0.0 109.449 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -66.13 -39.95 90.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.319 -0.863 . . . . 0.0 110.363 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -75.62 -6.17 49.03 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.071 -1.018 . . . . 0.0 109.978 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.93 26.81 73.3 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -101.13 -5.47 25.62 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.733 HG12 ' H ' ' A' ' 43' ' ' GLY . 77.2 t -134.95 159.82 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -179.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.455 ' N ' HG12 ' A' ' 41' ' ' VAL . 65.0 mtp180 -122.73 -5.93 8.59 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.733 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 137.76 -164.92 25.43 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 108.429 -1.868 . . . . 0.0 108.429 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.0 t -120.34 130.0 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.226 -1.161 . . . . 0.0 109.545 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.434 ' H ' HG23 ' A' ' 94' ' ' VAL . 3.3 t -83.17 133.79 35.01 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.189 -0.944 . . . . 0.0 108.726 179.01 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.5 p -129.96 134.22 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.59 -0.694 . . . . 0.0 109.434 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 25.5 p -124.83 146.59 49.19 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.473 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -138.27 140.55 11.23 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.527 HG22 ' OD1' ' A' ' 59' ' ' ASN . 98.2 t -126.53 129.85 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.675 -0.897 . . . . 0.0 109.143 179.216 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -101.44 117.2 34.45 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.723 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 39.1 m-85 -91.96 122.61 34.64 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.403 -0.811 . . . . 0.0 109.079 -179.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -104.99 136.16 44.99 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.575 -0.703 . . . . 0.0 109.771 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 -57.27 -11.63 1.88 Allowed 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 11.2 t70 -74.46 2.16 10.19 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.59 21.21 69.78 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.1 p -120.47 147.02 45.66 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.405 -1.056 . . . . 0.0 110.127 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 71.8 p -130.01 140.95 50.8 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.673 0.749 . . . . 0.0 110.066 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.6 t -116.96 140.83 49.0 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 106.641 -1.614 . . . . 0.0 106.641 178.258 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.527 ' OD1' HG22 ' A' ' 49' ' ' VAL . 49.0 m-20 -129.96 116.69 18.97 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.035 -1.04 . . . . 0.0 109.727 -179.205 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -116.57 124.38 49.68 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -114.18 146.05 40.87 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -163.96 168.31 38.4 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.159 -1.576 . . . . 0.0 109.159 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.3 t -110.39 127.32 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.535 -0.98 . . . . 0.0 109.363 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.3 t -89.59 118.89 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.375 -0.828 . . . . 0.0 109.792 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 30.1 p -128.25 149.97 72.79 Favored Pre-proline 0 N--CA 1.494 1.732 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.89 -16.12 3.86 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 121.276 1.318 . . . . 0.0 111.414 -179.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 84.2 p -108.21 -13.2 14.96 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.393 -0.817 . . . . 0.0 110.697 -179.663 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 56.8 m -132.55 106.87 13.07 Favored Pre-proline 0 N--CA 1.505 2.286 0 O-C-N 121.086 -1.009 . . . . 0.0 110.561 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -88.28 162.43 6.95 Favored 'Trans proline' 0 N--CA 1.49 1.293 0 C-N-CA 122.267 1.978 . . . . 0.0 111.833 178.329 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.5 t -120.17 128.49 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.158 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -104.64 128.77 52.77 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.124 -0.985 . . . . 0.0 111.324 -178.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 74' ' ' GLN . 1.1 p -90.05 0.09 57.31 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 177.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -67.9 60.43 0.07 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-O 121.556 0.693 . . . . 0.0 109.143 -179.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.494 ' N ' ' O ' ' A' ' 72' ' ' THR . 7.3 tt0 -68.79 -106.5 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.169 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -103.6 94.47 5.48 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.009 -1.057 . . . . 0.0 109.74 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 79.5 mt -74.46 -29.82 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.013 -1.054 . . . . 0.0 109.698 179.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -59.94 -42.63 94.42 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.809 -1.182 . . . . 0.0 108.186 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 84.2 tttt -65.27 -42.16 93.49 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.277 -0.889 . . . . 0.0 108.749 178.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.599 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.4 OUTLIER -69.75 -42.7 73.54 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.562 -0.711 . . . . 0.0 110.179 -179.132 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -63.51 -32.76 74.3 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.168 -1.582 . . . . 0.0 109.233 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.0 tttt -69.81 -47.38 63.03 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 110.735 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.4 p -112.2 -27.55 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 O-C-N 121.504 -0.747 . . . . 0.0 111.661 -177.126 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.599 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 88.61 169.7 45.04 Favored Glycine 0 N--CA 1.49 2.244 0 O-C-N 120.715 -1.241 . . . . 0.0 110.452 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.473 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 23.5 t -115.43 129.67 71.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.892 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -80.07 -67.46 0.76 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.071 -1.018 . . . . 0.0 110.297 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -116.51 140.12 49.71 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.508 -0.745 . . . . 0.0 110.846 -179.102 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 68.9 t80 -119.96 131.8 55.3 Favored 'General case' 0 N--CA 1.5 2.031 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -131.53 132.6 44.3 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.08 -1.012 . . . . 0.0 110.788 -178.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.52 137.1 54.84 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.802 -0.561 . . . . 0.0 109.551 179.266 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 44.7 tp -117.16 133.32 56.14 Favored 'General case' 0 N--CA 1.502 2.167 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 p -129.08 122.18 29.39 Favored 'General case' 0 N--CA 1.503 2.215 0 CA-C-O 121.708 0.766 . . . . 0.0 110.733 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -132.35 152.75 51.3 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.891 -0.506 . . . . 0.0 109.846 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 78.0 m95 -70.21 139.89 52.37 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.048 -1.033 . . . . 0.0 109.07 178.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.434 HG23 ' H ' ' A' ' 45' ' ' SER . 59.7 t -112.53 120.83 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.156 0 O-C-N 121.383 -0.823 . . . . 0.0 109.397 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 145.46 -124.13 2.04 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.189 -1.564 . . . . 0.0 109.189 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 47.4 t -60.47 140.0 57.47 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.346 -1.09 . . . . 0.0 109.934 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 35.7 ttm180 -61.48 136.37 58.0 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.357 -0.839 . . . . 0.0 109.0 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.583 -179.919 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.936 0 N-CA-C 119.648 2.619 . . . . 0.0 119.648 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -86.58 162.42 34.56 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.5 t -78.68 141.54 37.85 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.358 -1.084 . . . . 0.0 109.458 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -135.64 64.18 0.58 Allowed Glycine 0 N--CA 1.5 2.909 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . 0.413 ' HE1' HG21 ' A' ' 10' ' ' VAL . 79.6 t90 -75.5 127.9 34.13 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.277 -1.131 . . . . 0.0 108.775 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 39.7 p-10 -134.06 18.28 3.77 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.522 0.677 . . . . 0.0 109.911 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 57.95 13.85 2.34 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.433 -0.792 . . . . 0.0 109.464 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.414 ' OD1' ' O ' ' A' ' 8' ' ' ASP . 61.1 t0 -92.13 -27.47 17.71 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.234 -0.917 . . . . 0.0 109.555 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -95.15 4.08 54.01 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.392 -0.817 . . . . 0.0 110.099 -179.276 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.413 HG21 ' HE1' ' A' ' 5' ' ' TRP . 19.7 t -110.61 134.08 54.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.5 -0.75 . . . . 0.0 109.88 -179.492 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -90.81 131.61 37.07 Favored Pre-proline 0 N--CA 1.49 1.526 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.49 -14.16 22.5 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 121.747 1.631 . . . . 0.0 111.592 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 59.8 p -67.22 -35.83 80.42 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.518 -0.739 . . . . 0.0 109.867 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -90.05 -11.62 40.9 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.208 -0.933 . . . . 0.0 110.313 -179.095 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.668 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 8.2 t -69.63 -29.4 66.89 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.974 -1.079 . . . . 0.0 108.471 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.4 pp -120.62 145.47 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 61.1 mttp -127.09 154.14 45.09 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.402 -0.811 . . . . 0.0 110.032 -179.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.441 ' NE2' ' OH ' ' A' ' 23' ' ' TYR . 83.4 mt-30 -96.07 120.01 35.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.463 -0.773 . . . . 0.0 109.692 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 5.9 t -110.34 115.14 29.14 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.87 -111.09 2.25 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.4 m -117.33 20.69 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.241 0 O-C-N 121.466 -1.02 . . . . 0.0 109.959 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -127.26 160.53 31.02 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.348 -0.845 . . . . 0.0 111.081 -177.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . 0.441 ' OH ' ' NE2' ' A' ' 18' ' ' GLN . 12.5 m-85 -111.33 134.17 53.11 Favored 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.567 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 37.9 p -132.74 145.48 51.06 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.284 -0.885 . . . . 0.0 108.986 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -82.87 127.26 33.33 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.387 -0.821 . . . . 0.0 108.999 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -84.56 80.52 9.21 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.024 -1.047 . . . . 0.0 109.119 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.516 ' C ' ' H ' ' A' ' 29' ' ' VAL . 92.0 p -83.73 -8.35 59.27 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.413 -0.804 . . . . 0.0 109.485 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -54.67 -2.74 0.2 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.159 -1.177 . . . . 0.0 110.159 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.516 ' H ' ' C ' ' A' ' 27' ' ' SER . 34.9 m -108.32 131.35 59.03 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.328 -1.101 . . . . 0.0 108.442 179.165 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 82.8 p -63.68 -30.23 71.36 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.287 -0.883 . . . . 0.0 111.278 -178.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.452 HG13 ' N ' ' A' ' 32' ' ' CYS . 7.6 p -59.9 -39.9 81.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 120.87 -1.144 . . . . 0.0 110.415 -179.189 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.668 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 56.3 m -59.93 -40.17 87.99 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.95 -1.094 . . . . 0.0 110.077 -179.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 9.0 mmt -79.73 -14.31 58.83 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.0 -1.062 . . . . 0.0 109.415 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.408 HE22 ' HB2' ' A' ' 5' ' ' TRP . 62.2 tt0 -60.76 -40.56 92.98 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.876 -1.14 . . . . 0.0 108.451 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -82.99 -51.22 4.29 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.5 mt -58.27 -40.07 80.88 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.919 -1.341 . . . . 0.0 108.832 -179.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -59.93 -40.02 87.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.342 -0.848 . . . . 0.0 109.497 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 60.3 mm-40 -76.8 -6.76 53.64 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.989 -1.069 . . . . 0.0 109.87 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.35 32.56 68.37 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 120.066 -1.064 . . . . 0.0 110.646 178.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -102.81 -9.65 19.77 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.6 HG12 ' H ' ' A' ' 43' ' ' GLY . 5.8 t -134.19 158.16 41.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -179.087 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 94' ' ' VAL . 97.2 mtt180 -117.33 -11.08 10.63 Favored 'General case' 0 N--CA 1.501 2.087 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 178.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.6 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 146.09 -157.33 27.34 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 107.879 -2.088 . . . . 0.0 107.879 -179.175 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 77.2 t -120.01 128.42 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.281 -1.129 . . . . 0.0 108.538 179.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.8 m -86.17 132.78 33.94 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.118 -0.989 . . . . 0.0 108.351 179.454 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 46' ' ' VAL . 13.2 p -132.52 132.46 60.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.592 -0.693 . . . . 0.0 109.779 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.3 m -128.47 141.1 51.5 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 178.395 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.426 ' O ' ' OD1' ' A' ' 59' ' ' ASN . . . -130.87 149.6 19.16 Favored Glycine 0 N--CA 1.505 3.272 0 C-N-CA 120.21 -0.995 . . . . 0.0 110.872 -178.621 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 38.2 t -125.04 129.99 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.824 -0.809 . . . . 0.0 108.825 179.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.539 ' CE2' ' O ' ' A' ' 72' ' ' THR . 50.0 m-85 -105.45 121.89 44.86 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.475 -0.766 . . . . 0.0 109.567 179.285 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.429 ' HB2' ' H ' ' A' ' 86' ' ' LYS . 45.8 m-85 -95.76 121.59 37.65 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.045 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.444 ' C ' ' N ' ' A' ' 54' ' ' ASP . 93.3 m-85 -106.28 128.61 54.11 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.236 -0.915 . . . . 0.0 109.271 179.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.405 ' C ' ' H ' ' A' ' 55' ' ' GLY . 51.9 t30 -48.77 -17.13 0.15 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.067 -1.021 . . . . 0.0 109.199 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.444 ' N ' ' C ' ' A' ' 52' ' ' TYR . 62.7 m-20 -67.99 3.28 1.62 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.407 -0.808 . . . . 0.0 109.115 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.405 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 77.68 19.77 75.21 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 178.655 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.1 p -117.79 147.67 42.78 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.383 -1.069 . . . . 0.0 109.952 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 24.3 p -130.57 127.96 40.1 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.703 -0.623 . . . . 0.0 109.543 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 30.6 t -118.39 154.49 32.31 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.426 ' OD1' ' O ' ' A' ' 48' ' ' GLY . 57.9 t-20 -141.53 133.15 27.02 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.796 -1.19 . . . . 0.0 110.149 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.438 ' CZ ' ' NE2' ' A' ' 74' ' ' GLN . 58.6 m-85 -116.46 124.41 49.91 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.304 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 62.9 tttm -114.36 143.4 44.96 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.15 172.46 43.38 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 49.0 t -114.74 128.67 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.629 -0.924 . . . . 0.0 109.156 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 75.7 t -98.08 123.02 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.218 -0.927 . . . . 0.0 109.515 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.403 ' O ' ' N ' ' A' ' 67' ' ' SER . 17.0 p -121.55 151.0 56.16 Favored Pre-proline 0 N--CA 1.496 1.856 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_exo -34.49 -34.0 0.08 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.399 2.066 . . . . 0.0 113.191 -179.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.403 ' N ' ' O ' ' A' ' 65' ' ' THR . 63.4 m -106.76 -0.55 23.4 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.379 -0.825 . . . . 0.0 111.78 -178.626 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 4.1 m -124.39 106.86 30.05 Favored Pre-proline 0 N--CA 1.508 2.437 0 O-C-N 120.945 -1.097 . . . . 0.0 111.527 -178.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -92.61 161.2 2.89 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 C-N-CA 122.712 2.275 . . . . 0.0 111.025 177.126 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 91.1 t -134.64 139.88 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.238 0 O-C-N 120.952 -1.092 . . . . 0.0 109.825 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -95.43 138.72 32.72 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.165 -0.959 . . . . 0.0 109.158 179.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.539 ' O ' ' CE2' ' A' ' 50' ' ' PHE . 5.8 t -110.93 -33.83 6.4 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.321 -0.862 . . . . 0.0 109.419 -179.769 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.508 ' ND2' ' CD1' ' A' ' 76' ' ' ILE . 9.6 t30 -92.1 32.32 1.17 Allowed 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.218 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.438 ' NE2' ' CZ ' ' A' ' 60' ' ' PHE . 13.8 pt20 -54.13 -22.56 11.43 Favored 'General case' 0 N--CA 1.499 2.011 0 C-N-CA 120.276 -0.57 . . . . 0.0 112.246 -178.056 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -107.37 71.9 0.85 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 120.702 -1.249 . . . . 0.0 109.735 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.508 ' CD1' ' ND2' ' A' ' 73' ' ' ASN . 45.7 mm -70.1 -40.35 78.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.335 -0.853 . . . . 0.0 111.332 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -60.12 -46.9 88.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.629 -1.294 . . . . 0.0 108.551 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 29.6 ttmt -60.08 -50.03 75.33 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.293 -0.879 . . . . 0.0 108.864 179.092 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.568 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.3 m -62.36 -42.8 99.69 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.79 -0.569 . . . . 0.0 110.625 -178.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.424 ' OD1' HG22 ' A' ' 76' ' ' ILE . 6.0 m120 -60.47 -35.28 75.5 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.561 -1.337 . . . . 0.0 110.027 179.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 14.7 tmtt? -67.07 -48.55 67.91 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.089 -1.007 . . . . 0.0 111.079 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -113.45 -26.88 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.301 0 O-C-N 121.183 -0.948 . . . . 0.0 111.572 -178.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 90.07 168.11 42.61 Favored Glycine 0 N--CA 1.491 2.323 0 O-C-N 120.54 -1.35 . . . . 0.0 110.173 179.737 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.05 124.58 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -79.92 -65.64 0.98 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.094 -1.004 . . . . 0.0 110.286 -179.169 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.429 ' H ' ' HB2' ' A' ' 51' ' ' TYR . 44.3 tptt -115.38 142.28 46.91 Favored 'General case' 0 N--CA 1.504 2.23 0 O-C-N 121.415 -0.803 . . . . 0.0 110.526 -178.738 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.0 t80 -121.13 132.1 54.65 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 -135.01 127.18 29.98 Favored 'General case' 0 N--CA 1.503 2.199 0 O-C-N 121.126 -0.984 . . . . 0.0 110.358 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.87 134.63 52.63 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.654 -0.653 . . . . 0.0 110.017 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.6 tp -118.51 133.45 55.86 Favored 'General case' 0 N--CA 1.503 2.192 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.2 p -129.2 126.36 39.0 Favored 'General case' 0 N--CA 1.503 2.198 0 CA-C-O 121.53 0.681 . . . . 0.0 110.678 -179.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 58.2 mm-40 -134.4 158.46 43.79 Favored 'General case' 0 N--CA 1.504 2.235 0 CA-C-O 121.488 0.661 . . . . 0.0 110.599 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 71.9 m95 -71.15 139.21 50.15 Favored 'General case' 0 N--CA 1.494 1.774 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 178.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.431 ' O ' ' N ' ' A' ' 42' ' ' ARG . 44.6 t -112.41 118.79 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.289 -0.882 . . . . 0.0 109.335 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -142.18 -117.48 1.3 Allowed Glycine 0 N--CA 1.494 2.504 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.318 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 28.6 p -85.83 118.82 25.56 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.053 -1.263 . . . . 0.0 109.337 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 35.3 ptt-85 -89.31 -9.52 50.21 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.071 -1.018 . . . . 0.0 109.616 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 36.6 t . . . . . 0 N--CA 1.5 2.028 0 CA-C-O 118.049 -0.976 . . . . 0.0 109.299 179.78 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.941 0 N-CA-C 119.475 2.55 . . . . 0.0 119.475 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 93.46 -32.92 5.43 Favored Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 38.1 t -100.1 121.42 41.38 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.342 -1.093 . . . . 0.0 108.875 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -54.9 -84.63 0.03 OUTLIER Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 -179.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 66.7 t90 -60.02 138.86 57.76 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.16 -1.2 . . . . 0.0 109.026 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . 0.45 ' O ' ' N ' ' A' ' 8' ' ' ASP . 94.5 m-20 -133.35 129.62 37.7 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -72.99 64.75 0.72 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.896 -1.127 . . . . 0.0 108.021 178.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.45 ' N ' ' O ' ' A' ' 6' ' ' ASN . 54.4 t0 -66.72 -73.3 0.14 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.758 -0.589 . . . . 0.0 110.234 -178.721 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 64.8 t-20 -145.45 47.05 1.29 Allowed 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 179.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.409 HG23 ' HE1' ' A' ' 93' ' ' TRP . 2.6 m -81.17 139.75 17.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.538 -0.726 . . . . 0.0 109.077 -178.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.447 ' N ' ' OD1' ' A' ' 11' ' ' ASP . 2.0 m-20 -76.66 130.01 77.71 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.906 . . . . 0.0 109.981 -178.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -81.55 -19.96 7.2 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.22 1.947 . . . . 0.0 112.079 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 81.9 p -64.87 -36.53 84.64 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.437 -0.79 . . . . 0.0 110.572 -179.574 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -68.99 -24.66 64.26 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.132 -0.98 . . . . 0.0 109.715 -179.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.484 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 50.1 t -65.56 -35.16 80.03 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.331 -0.856 . . . . 0.0 109.775 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -117.09 140.42 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.063 0 O-C-N 121.436 -0.79 . . . . 0.0 109.149 -179.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -117.82 147.17 43.3 Favored 'General case' 0 N--CA 1.5 2.026 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -93.77 122.22 36.01 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.172 -0.955 . . . . 0.0 109.746 -179.429 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.479 ' O ' ' N ' ' A' ' 21' ' ' VAL . 26.3 t -110.67 123.71 50.53 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.117 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 52.42 -94.28 0.01 OUTLIER Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.479 ' N ' ' O ' ' A' ' 19' ' ' SER . 24.7 m -139.4 28.03 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.945 0 O-C-N 121.236 -1.155 . . . . 0.0 109.833 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 19.6 pt20 -131.42 163.65 27.45 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.318 -0.864 . . . . 0.0 110.035 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 54.0 m-85 -115.69 139.97 49.63 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 76.6 p -134.15 148.67 50.98 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.388 -0.82 . . . . 0.0 109.021 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 52.1 t80 -87.54 124.92 33.99 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.441 -0.787 . . . . 0.0 110.007 -178.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -84.39 84.93 7.47 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.33 -0.856 . . . . 0.0 109.732 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 92.4 p -77.22 -9.44 58.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.141 -0.975 . . . . 0.0 109.679 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -72.9 -1.91 56.42 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.7 t -98.89 131.64 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.159 -1.2 . . . . 0.0 108.431 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 27.3 t -59.97 -42.58 94.46 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.324 -0.86 . . . . 0.0 110.643 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.451 HG13 ' N ' ' A' ' 32' ' ' CYS . 9.9 p -59.95 -40.15 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.711 -1.243 . . . . 0.0 110.327 -179.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.484 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 90.2 m -61.95 -48.29 81.07 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.014 -1.054 . . . . 0.0 111.244 -178.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 1.2 mmt -77.64 -24.67 49.43 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.735 -1.228 . . . . 0.0 111.358 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -60.06 -40.05 88.12 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.709 -1.244 . . . . 0.0 109.498 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -72.44 -44.2 42.53 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.2 mt -66.2 -42.58 88.58 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.309 -1.112 . . . . 0.0 109.629 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -60.88 -40.08 91.67 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.07 -1.019 . . . . 0.0 110.212 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -78.66 -12.49 60.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.354 -0.841 . . . . 0.0 109.907 -178.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.02 29.27 70.8 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 41.9 mmtm -103.26 -5.39 23.14 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.756 HG12 ' H ' ' A' ' 43' ' ' GLY . 72.4 t -135.13 160.26 40.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.444 ' N ' HG12 ' A' ' 41' ' ' VAL . 93.4 mtt-85 -120.95 -5.96 9.56 Favored 'General case' 0 N--CA 1.501 2.095 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.756 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 132.59 -158.58 23.09 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 107.939 -2.064 . . . . 0.0 107.939 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 81.3 t -121.98 128.1 75.53 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.222 -1.164 . . . . 0.0 110.194 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.6 t -83.13 134.98 34.97 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 178.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 7.7 p -131.22 134.57 61.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.38 -0.825 . . . . 0.0 109.963 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.8 p -125.35 141.6 51.98 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -129.61 138.1 10.01 Favored Glycine 0 N--CA 1.503 3.107 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -178.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.15 125.01 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.61 ' CG ' ' NE2' ' A' ' 74' ' ' GLN . 26.3 m-85 -102.31 121.78 42.95 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 77.2 m-85 -94.61 129.28 41.53 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 120.984 -1.072 . . . . 0.0 109.517 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.47 ' OH ' ' NE2' ' A' ' 74' ' ' GLN . 68.4 m-85 -109.34 130.48 55.49 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.613 -0.679 . . . . 0.0 110.433 -179.693 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 43.1 t30 -50.61 -16.72 0.41 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.347 -0.846 . . . . 0.0 108.971 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.419 ' N ' ' C ' ' A' ' 52' ' ' TYR . 29.6 t0 -73.26 1.3 9.7 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.332 -0.855 . . . . 0.0 109.352 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.16 18.98 70.62 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 179.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.4 p -117.34 146.74 43.18 Favored 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.482 -1.01 . . . . 0.0 110.106 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.3 p -130.23 140.25 50.73 Favored 'General case' 0 N--CA 1.501 2.097 0 CA-C-O 121.65 0.738 . . . . 0.0 110.384 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 65.3 p -118.14 143.95 46.07 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 178.235 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -137.79 119.73 15.38 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.876 -1.14 . . . . 0.0 109.933 -179.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -115.61 125.24 52.68 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -110.55 143.5 40.83 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -161.89 161.46 33.34 Favored Glycine 0 C--N 1.284 -2.319 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 32.2 t -108.12 125.85 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.347 -1.09 . . . . 0.0 109.049 -179.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 55.5 t -91.77 116.7 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.318 -0.864 . . . . 0.0 109.417 -179.569 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.526 ' O ' ' N ' ' A' ' 67' ' ' SER . 22.3 p -135.89 149.93 70.08 Favored Pre-proline 0 N--CA 1.494 1.73 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 179.244 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_exo -41.47 -18.03 0.07 OUTLIER 'Trans proline' 0 C--N 1.313 -1.307 0 C-N-CA 121.908 1.739 . . . . 0.0 112.039 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.526 ' N ' ' O ' ' A' ' 65' ' ' THR . 68.7 m -69.96 -52.12 27.05 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.277 -0.889 . . . . 0.0 111.139 -179.002 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 60.1 p -149.64 151.75 33.61 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 120.731 -1.231 . . . . 0.0 110.064 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -85.38 165.72 10.84 Favored 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.728 2.285 . . . . 0.0 112.422 178.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 68.8 t -111.23 134.05 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.219 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -102.36 131.78 48.76 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.121 -0.987 . . . . 0.0 112.048 -177.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.462 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.3 OUTLIER -111.01 20.07 17.85 Favored 'General case' 0 N--CA 1.503 2.217 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 177.694 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.509 HD22 ' N ' ' A' ' 73' ' ' ASN . 0.0 OUTLIER -77.07 55.73 1.17 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.575 -0.703 . . . . 0.0 110.383 -178.782 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.61 ' NE2' ' CG ' ' A' ' 50' ' ' PHE . 13.2 pt20 -49.0 175.04 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.366 -0.834 . . . . 0.0 108.884 178.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -55.19 107.71 0.34 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.819 -1.176 . . . . 0.0 108.64 179.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.409 ' O ' HG22 ' A' ' 76' ' ' ILE . 72.2 mt -79.36 -13.83 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.181 -0.949 . . . . 0.0 110.019 -179.55 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -59.94 -45.18 93.47 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.87 -1.144 . . . . 0.0 109.254 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 1.3 ptpp? -66.23 -38.53 88.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.93 -1.107 . . . . 0.0 108.905 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.597 ' O ' ' N ' ' A' ' 83' ' ' GLY . 3.7 m -59.96 -50.06 75.25 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.577 -0.702 . . . . 0.0 110.095 -179.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -60.48 -36.4 78.21 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 120.498 -1.377 . . . . 0.0 108.852 179.046 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 22.3 tttp -69.37 -47.29 64.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.405 -0.809 . . . . 0.0 110.929 -179.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.7 p -111.98 -29.72 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.18 0 O-C-N 121.245 -0.909 . . . . 0.0 111.817 -177.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.62 164.49 40.14 Favored Glycine 0 N--CA 1.49 2.279 0 O-C-N 120.705 -1.247 . . . . 0.0 110.696 179.053 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 82.6 t -109.86 130.82 62.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 48.0 tp60 -79.94 -67.37 0.77 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.228 -0.92 . . . . 0.0 110.254 -179.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -115.35 146.24 41.74 Favored 'General case' 0 N--CA 1.503 2.184 0 O-C-N 121.453 -0.78 . . . . 0.0 111.152 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -119.73 131.67 55.44 Favored 'General case' 0 N--CA 1.499 1.989 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 14.0 tpp85 -137.62 136.15 37.24 Favored 'General case' 0 N--CA 1.504 2.266 0 O-C-N 120.932 -1.105 . . . . 0.0 111.057 -178.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.524 ' C ' HD12 ' A' ' 90' ' ' LEU . . . -123.97 137.69 54.57 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.445 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.524 HD12 ' C ' ' A' ' 89' ' ' ALA . 10.4 mp -119.84 126.17 50.33 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 16.9 p -127.01 125.09 40.84 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.301 -0.874 . . . . 0.0 110.447 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -132.13 147.44 52.43 Favored 'General case' 0 N--CA 1.5 2.039 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . 0.409 ' HE1' HG23 ' A' ' 10' ' ' VAL . 75.1 m95 -70.72 139.27 51.11 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.913 -1.117 . . . . 0.0 109.593 179.497 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.8 t -111.37 123.76 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.976 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.444 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 108.02 -14.21 37.39 Favored Glycine 0 N--CA 1.496 2.652 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 89.4 p -70.99 149.96 46.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.262 -1.14 . . . . 0.0 109.414 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -96.07 -5.61 40.54 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.295 -0.878 . . . . 0.0 109.222 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 7.1 p . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 117.938 -1.03 . . . . 0.0 109.984 179.811 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.811 0 N-CA-C 119.54 2.576 . . . . 0.0 119.54 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 80.6 -166.83 49.65 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.3 t -83.23 130.24 35.07 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.323 -1.104 . . . . 0.0 109.392 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -90.53 24.45 17.04 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . 0.407 ' CG ' ' NE2' ' A' ' 34' ' ' GLN . 87.2 t90 -59.88 118.25 6.0 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.325 -1.103 . . . . 0.0 110.178 -179.403 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . 0.536 ' C ' ' H ' ' A' ' 8' ' ' ASP . 96.3 m-20 -131.56 20.03 4.72 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 178.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 54.81 2.83 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.841 -0.537 . . . . 0.0 109.655 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.536 ' H ' ' C ' ' A' ' 6' ' ' ASN . 34.0 p-10 -86.49 -20.06 28.62 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.038 -1.039 . . . . 0.0 109.172 179.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 57.0 t30 -95.36 1.68 54.39 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.411 -0.806 . . . . 0.0 109.045 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.6 t -116.41 126.19 73.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.749 -0.594 . . . . 0.0 109.903 -178.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -83.49 139.83 41.4 Favored Pre-proline 0 N--CA 1.489 1.499 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 178.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -75.65 -14.17 19.86 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 121.762 1.641 . . . . 0.0 111.868 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 77.6 p -60.21 -39.96 88.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.367 -0.833 . . . . 0.0 109.722 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 88.6 mm-40 -84.24 -11.88 55.72 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.139 -0.976 . . . . 0.0 109.725 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.625 ' HG ' ' HG ' ' A' ' 32' ' ' CYS . 29.9 t -69.69 -31.45 69.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.146 -0.971 . . . . 0.0 108.677 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.5 pp -123.58 146.15 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.413 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.5 mttt -111.31 145.18 39.26 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.285 -0.884 . . . . 0.0 109.885 -178.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.454 ' NE2' ' CZ ' ' A' ' 87' ' ' TYR . 63.3 tt0 -97.65 114.81 26.84 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.438 ' O ' ' N ' ' A' ' 21' ' ' VAL . 48.0 m -115.13 130.12 56.84 Favored 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.67 -98.27 0.01 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.467 ' CG1' HD22 ' A' ' 73' ' ' ASN . 3.9 m -137.57 27.46 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.369 -1.077 . . . . 0.0 109.836 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 -130.72 162.98 28.27 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 121.196 -0.94 . . . . 0.0 109.956 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -116.95 140.02 49.96 Favored 'General case' 0 N--CA 1.5 2.07 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.028 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 71.3 p -130.53 145.75 51.92 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.38 -0.825 . . . . 0.0 109.446 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -80.78 126.18 31.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.189 -0.944 . . . . 0.0 108.521 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -85.76 83.48 7.84 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.176 -0.953 . . . . 0.0 110.422 -179.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.9 p -81.07 -9.07 59.88 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.132 -0.98 . . . . 0.0 109.614 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -57.42 -39.18 90.14 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.5 m -80.84 136.89 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.106 -1.232 . . . . 0.0 108.984 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 24.1 t -67.54 -30.28 69.89 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.359 -0.838 . . . . 0.0 111.178 -178.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.443 HG13 ' N ' ' A' ' 32' ' ' CYS . 8.1 p -60.0 -40.06 82.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.818 -1.176 . . . . 0.0 110.419 -178.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.625 ' HG ' ' HG ' ' A' ' 15' ' ' CYS . 67.3 m -64.17 -40.17 95.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.786 -1.196 . . . . 0.0 110.14 -179.806 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 97.1 mmm -86.36 -14.96 41.95 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.892 -1.13 . . . . 0.0 109.77 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.407 ' NE2' ' CG ' ' A' ' 5' ' ' TRP . 30.1 tt0 -60.21 -40.27 89.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.985 -1.072 . . . . 0.0 108.127 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -79.2 -45.48 8.85 Favored Glycine 0 N--CA 1.485 1.902 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.9 tp -60.42 -43.67 96.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.243 -1.151 . . . . 0.0 109.737 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -67.32 -39.81 85.92 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.202 -0.936 . . . . 0.0 110.055 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -60.39 -31.09 70.03 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.03 -1.044 . . . . 0.0 109.349 -179.523 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.52 23.42 23.97 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 64.5 mmtt -109.73 -0.57 18.44 Favored 'General case' 0 N--CA 1.497 1.885 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 178.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.735 HG12 ' H ' ' A' ' 43' ' ' GLY . 86.9 t -135.37 158.12 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 121.671 0.748 . . . . 0.0 109.259 -179.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.439 ' N ' HG12 ' A' ' 41' ' ' VAL . 67.4 mtp180 -119.9 -9.66 9.63 Favored 'General case' 0 N--CA 1.497 1.925 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.735 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 137.75 -159.96 25.11 Favored Glycine 0 N--CA 1.497 2.72 0 N-CA-C 108.009 -2.037 . . . . 0.0 108.009 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 90.1 t -118.61 129.73 74.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.143 0 O-C-N 121.18 -1.189 . . . . 0.0 109.315 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.2 t -85.91 138.76 31.79 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.324 -0.86 . . . . 0.0 108.883 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.435 ' O ' HG13 ' A' ' 46' ' ' VAL . 12.7 p -130.13 132.49 65.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.785 0.802 . . . . 0.0 109.544 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.4 p -123.78 146.06 48.59 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -141.77 138.7 8.82 Favored Glycine 0 N--CA 1.5 2.954 0 C-N-CA 119.362 -1.399 . . . . 0.0 111.471 -178.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 55.1 t -120.11 122.6 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 178.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.518 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 0.3 OUTLIER -100.06 126.18 46.23 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 179.875 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -98.53 121.39 40.4 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.156 -0.965 . . . . 0.0 109.444 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.532 ' O ' ' N ' ' A' ' 54' ' ' ASP . 91.7 m-85 -105.47 125.58 51.14 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.382 -0.824 . . . . 0.0 109.356 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.671 HD22 ' NE2' ' A' ' 85' ' ' GLN . 20.9 t-20 -45.53 -16.62 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.147 -0.971 . . . . 0.0 109.49 179.543 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 52' ' ' TYR . 7.4 t70 -67.79 2.52 1.91 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.378 -0.826 . . . . 0.0 109.275 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.39 18.83 77.47 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 16.3 p -116.65 148.36 41.07 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.555 -0.968 . . . . 0.0 110.067 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 69.6 p -129.99 138.07 50.63 Favored 'General case' 0 N--CA 1.496 1.872 0 CA-C-O 121.589 0.709 . . . . 0.0 109.665 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.5 t -118.65 142.37 47.71 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 107.224 -1.399 . . . . 0.0 107.224 178.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.439 ' OD1' ' O ' ' A' ' 59' ' ' ASN . 39.7 p-10 -135.05 117.04 15.28 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.025 -1.047 . . . . 0.0 109.691 -179.443 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -116.83 130.43 56.71 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.081 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 27.2 ttpp -113.69 141.95 46.61 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -160.08 161.29 32.35 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 49.1 t -108.74 124.17 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.47 -1.017 . . . . 0.0 108.769 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 53.3 t -97.64 119.18 45.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.326 -0.859 . . . . 0.0 110.214 -179.147 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.65 ' O ' ' N ' ' A' ' 67' ' ' SER . 15.4 p -137.36 159.15 70.62 Favored Pre-proline 0 N--CA 1.491 1.616 0 N-CA-C 107.043 -1.466 . . . . 0.0 107.043 178.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_exo -51.2 58.73 0.02 OUTLIER 'Trans proline' 0 N--CA 1.504 2.147 0 C-N-CA 122.247 1.965 . . . . 0.0 113.688 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.65 ' N ' ' O ' ' A' ' 65' ' ' THR . 3.1 m -140.98 -64.07 0.46 Allowed 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.762 -1.211 . . . . 0.0 109.417 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 30.4 p -141.76 149.97 55.2 Favored Pre-proline 0 N--CA 1.5 2.064 0 O-C-N 121.212 -0.93 . . . . 0.0 109.501 179.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -84.57 164.11 12.44 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 122.707 2.271 . . . . 0.0 112.717 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.5 t -122.26 130.12 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.026 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 74.6 m-80 -96.77 136.08 37.82 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 120.806 -1.184 . . . . 0.0 111.11 -178.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.495 ' O ' ' CZ ' ' A' ' 50' ' ' PHE . 1.6 p -81.11 -51.55 8.34 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 178.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.467 HD22 ' CG1' ' A' ' 21' ' ' VAL . 78.9 m-20 -81.46 56.1 2.83 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 66.4 tt0 -47.69 -47.23 29.81 Favored 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 119.843 -0.743 . . . . 0.0 109.553 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -106.12 97.68 7.46 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 82.2 mt -80.31 -23.83 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.228 -0.92 . . . . 0.0 109.834 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 22.9 m120 -60.13 -48.82 80.11 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 120.95 -1.094 . . . . 0.0 109.537 -178.265 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 13.8 ptpt -68.28 -38.63 81.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.676 -1.265 . . . . 0.0 109.223 179.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.609 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.4 OUTLIER -62.2 -45.7 92.21 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.012 -1.055 . . . . 0.0 108.834 179.47 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 9.5 t-20 -60.05 -34.17 73.03 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.63 -1.293 . . . . 0.0 109.499 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.3 tmtt? -64.86 -50.02 68.26 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.197 -0.939 . . . . 0.0 110.727 -179.055 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.4 p -113.2 -27.66 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.229 -0.919 . . . . 0.0 111.545 -178.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.609 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.37 157.69 26.82 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 179.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.0 t -103.52 116.49 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 179.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.671 ' NE2' HD22 ' A' ' 53' ' ' ASN . 97.7 mt-30 -70.9 -47.83 57.01 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.101 -1.0 . . . . 0.0 111.904 -178.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 58.6 tttp -115.58 142.81 46.23 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.239 -0.913 . . . . 0.0 110.798 -178.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.454 ' CZ ' ' NE2' ' A' ' 18' ' ' GLN . 62.3 t80 -120.66 130.07 53.96 Favored 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 178.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 2.2 tpp180 -139.44 127.51 22.38 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.082 -1.011 . . . . 0.0 110.422 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.476 ' C ' HD12 ' A' ' 90' ' ' LEU . . . -125.45 135.36 52.26 Favored 'General case' 0 N--CA 1.501 2.119 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.875 179.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.476 HD12 ' C ' ' A' ' 89' ' ' ALA . 9.8 mp -119.93 129.7 54.46 Favored 'General case' 0 N--CA 1.504 2.231 0 O-C-N 121.306 -0.871 . . . . 0.0 108.745 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 25.2 p -129.28 127.33 40.96 Favored 'General case' 0 N--CA 1.504 2.243 0 O-C-N 121.267 -0.896 . . . . 0.0 110.821 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -133.15 156.21 47.89 Favored 'General case' 0 N--CA 1.502 2.157 0 CA-C-O 121.222 0.534 . . . . 0.0 110.169 179.479 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 69.0 m95 -70.4 138.45 51.3 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.201 -0.937 . . . . 0.0 108.679 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 27.7 t -111.26 120.03 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.382 -0.824 . . . . 0.0 109.89 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 162.37 -176.41 38.73 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 47.1 t -64.84 129.93 41.57 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.064 -1.257 . . . . 0.0 108.519 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 35.2 ttm180 -89.17 132.35 34.88 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.286 -0.884 . . . . 0.0 109.636 -179.605 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 20.2 t . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.536 -179.968 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.856 0 N-CA-C 119.436 2.534 . . . . 0.0 119.436 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.04 -143.65 48.62 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.0 m -80.64 -9.21 59.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.393 -1.063 . . . . 0.0 109.181 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.87 168.32 18.64 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.091 -1.604 . . . . 0.0 109.091 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 34.6 t90 -65.77 141.44 58.32 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.215 -1.168 . . . . 0.0 110.473 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . 0.601 ' C ' ' H ' ' A' ' 8' ' ' ASP . 10.3 m120 -131.17 123.06 27.72 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 177.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.435 ' HB1' ' NE1' ' A' ' 93' ' ' TRP . . . -61.95 2.56 0.21 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.87 -1.144 . . . . 0.0 108.369 179.161 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.601 ' H ' ' C ' ' A' ' 6' ' ' ASN . 84.0 m-20 -60.9 -39.76 90.56 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.754 -0.591 . . . . 0.0 111.346 -179.079 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -84.27 0.33 49.38 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.861 -1.149 . . . . 0.0 110.195 -178.095 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.4 t -106.1 131.54 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.252 -0.905 . . . . 0.0 108.703 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.522 ' O ' ' N ' ' A' ' 13' ' ' SER . 4.3 m-20 -99.91 108.61 52.53 Favored Pre-proline 0 N--CA 1.492 1.662 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 179.634 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -44.72 -12.01 0.05 OUTLIER 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 121.931 1.754 . . . . 0.0 112.35 -179.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.522 ' N ' ' O ' ' A' ' 11' ' ' ASP . 88.1 p -69.59 -38.61 77.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.258 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 98.7 mm-40 -91.14 -6.79 53.1 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 120.947 -1.095 . . . . 0.0 109.967 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.793 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 22.4 t -70.66 -24.89 62.78 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.191 -0.943 . . . . 0.0 109.804 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.573 ' CG2' HG11 ' A' ' 44' ' ' VAL . 1.0 OUTLIER -120.8 151.25 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.152 0 O-C-N 121.569 -0.707 . . . . 0.0 110.27 -179.059 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -118.58 137.15 53.45 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.766 -0.584 . . . . 0.0 109.61 -179.54 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -100.35 121.63 41.81 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.205 -0.934 . . . . 0.0 110.353 -179.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 83.5 p -121.21 127.56 51.58 Favored 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.73 -111.13 1.72 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.6 m -127.88 36.51 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.084 0 O-C-N 121.451 -1.029 . . . . 0.0 109.605 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -131.6 160.02 36.57 Favored 'General case' 0 N--CA 1.5 2.051 0 CA-C-O 121.646 0.736 . . . . 0.0 110.62 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -119.67 139.96 51.4 Favored 'General case' 0 N--CA 1.498 1.966 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 80.7 p -134.94 151.13 50.58 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.328 -0.857 . . . . 0.0 109.825 -179.2 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 48.3 t80 -87.51 122.88 31.79 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.393 -0.817 . . . . 0.0 109.311 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -82.66 88.28 6.7 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.344 -0.847 . . . . 0.0 109.77 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 59.7 p -80.5 -9.9 59.75 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.106 -0.996 . . . . 0.0 109.626 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -56.66 -31.8 60.89 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -84.24 114.23 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.06 -1.259 . . . . 0.0 107.989 179.281 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.545 ' O ' ' N ' ' A' ' 34' ' ' GLN . 59.7 m -60.05 -40.04 88.04 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.237 -0.914 . . . . 0.0 111.132 -178.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 6.1 m -52.09 -40.69 30.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 120.946 -1.096 . . . . 0.0 110.653 -178.115 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.793 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 55.3 m -69.97 -44.51 69.33 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.818 -1.176 . . . . 0.0 109.869 -179.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 31.1 ttm -81.07 -13.0 59.18 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.023 -1.048 . . . . 0.0 109.623 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.545 ' N ' ' O ' ' A' ' 30' ' ' SER . 62.5 tt0 -61.44 -40.03 92.98 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 179.207 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.33 -39.96 29.79 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.0 tp -59.84 -43.52 94.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.14 -1.212 . . . . 0.0 108.407 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 44.5 t30 -62.15 -40.22 95.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.507 -0.745 . . . . 0.0 109.775 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -69.07 -26.56 65.01 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.361 -0.837 . . . . 0.0 110.308 -179.394 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 91.17 18.07 47.99 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.854 -1.165 . . . . 0.0 110.804 179.147 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 40.1 mtmt -97.92 -0.75 44.34 Favored 'General case' 0 N--CA 1.495 1.793 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 178.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.734 HG12 ' H ' ' A' ' 43' ' ' GLY . 59.7 t -136.12 156.72 37.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 115.021 -0.99 . . . . 0.0 108.511 -179.669 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -115.74 -10.17 11.8 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.273 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.734 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 139.55 -152.14 22.34 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 108.298 -1.921 . . . . 0.0 108.298 -179.566 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.573 HG11 ' CG2' ' A' ' 16' ' ' ILE . 9.5 p -125.06 129.44 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 121.068 -1.254 . . . . 0.0 109.647 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 t -87.42 134.6 33.57 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.294 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.457 HG13 ' O ' ' A' ' 46' ' ' VAL . 9.1 p -130.06 131.18 66.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.405 -0.81 . . . . 0.0 109.359 179.752 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 53.1 p -121.21 149.72 42.41 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -140.49 144.4 14.77 Favored Glycine 0 N--CA 1.502 3.051 0 C-N-CA 119.603 -1.284 . . . . 0.0 110.751 -178.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 96.0 t -126.37 128.9 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.513 -0.993 . . . . 0.0 109.429 178.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -102.21 120.4 40.4 Favored 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -95.5 126.34 40.72 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.246 -0.909 . . . . 0.0 109.314 -179.74 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.51 ' O ' ' N ' ' A' ' 54' ' ' ASP . 55.0 m-85 -109.51 126.5 53.61 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.383 -0.823 . . . . 0.0 109.257 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -45.94 -17.3 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.123 -0.986 . . . . 0.0 109.167 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.51 ' N ' ' O ' ' A' ' 52' ' ' TYR . 39.9 t0 -67.67 0.96 2.74 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.501 -0.75 . . . . 0.0 109.013 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.76 27.77 58.19 Favored Glycine 0 N--CA 1.494 2.5 0 O-C-N 121.206 -0.934 . . . . 0.0 110.769 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.5 p -123.15 150.02 43.81 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.389 -1.065 . . . . 0.0 109.78 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 39.6 p -132.58 133.99 44.37 Favored 'General case' 0 N--CA 1.501 2.101 0 CA-C-O 121.618 0.723 . . . . 0.0 109.669 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 48.3 t -119.89 142.82 48.35 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 178.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 37.9 t-20 -132.49 125.72 31.3 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 120.994 -1.066 . . . . 0.0 109.488 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -117.72 128.27 54.73 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.0 ttpm? -110.82 143.78 40.86 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -158.03 159.34 29.91 Favored Glycine 0 C--N 1.285 -2.282 0 N-CA-C 108.763 -1.735 . . . . 0.0 108.763 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 56.0 t -109.55 124.27 66.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.487 -1.007 . . . . 0.0 108.789 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.9 t -90.21 118.94 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.421 -0.799 . . . . 0.0 109.321 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.538 ' O ' ' N ' ' A' ' 67' ' ' SER . 30.6 p -132.89 151.57 78.27 Favored Pre-proline 0 N--CA 1.492 1.659 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 178.637 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -48.75 -5.51 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 121.295 1.33 . . . . 0.0 111.39 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.538 ' N ' ' O ' ' A' ' 65' ' ' THR . 19.7 t -75.62 -57.33 3.95 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.152 -0.968 . . . . 0.0 110.422 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 56.4 p -147.68 151.82 39.95 Favored Pre-proline 0 N--CA 1.502 2.142 0 O-C-N 120.855 -1.153 . . . . 0.0 110.107 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -84.67 167.33 11.55 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.939 2.426 . . . . 0.0 112.265 178.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.2 t -102.74 131.09 51.68 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -97.39 122.98 41.06 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.334 -0.853 . . . . 0.0 111.976 -177.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 1.2 p -93.37 -0.21 56.66 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 178.125 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.43 ' O ' ' OD1' ' A' ' 73' ' ' ASN . 41.3 t-20 -75.4 54.03 0.71 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.57 -0.706 . . . . 0.0 109.254 -179.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -62.96 -87.18 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -114.35 84.41 2.05 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.497 -0.752 . . . . 0.0 109.226 178.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 10.1 tp -70.11 -32.85 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.121 -0.987 . . . . 0.0 109.727 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -60.02 -47.39 86.04 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.1 -178.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.421 ' CG ' ' N ' ' A' ' 79' ' ' THR . 15.1 ptmt -63.63 -39.82 95.33 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.707 -1.246 . . . . 0.0 108.215 179.288 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.582 ' O ' ' N ' ' A' ' 83' ' ' GLY . 2.0 m -59.96 -40.71 89.96 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -179.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -66.59 -31.8 72.74 Favored 'General case' 0 C--N 1.295 -1.792 0 O-C-N 120.579 -1.326 . . . . 0.0 109.382 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 7.6 tmtm? -69.84 -44.28 70.22 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.915 -1.116 . . . . 0.0 110.378 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -110.58 -26.44 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.377 0 O-C-N 121.206 -0.934 . . . . 0.0 111.349 -178.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.47 164.29 37.6 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.563 HG23 HG23 ' A' ' 79' ' ' THR . 71.4 t -111.21 128.16 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.167 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 93.1 mm-40 -81.27 -65.5 1.0 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.086 -1.009 . . . . 0.0 110.996 -178.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 45.1 tptt -113.92 141.76 46.97 Favored 'General case' 0 N--CA 1.503 2.181 0 O-C-N 121.438 -0.789 . . . . 0.0 110.639 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -120.17 131.25 54.93 Favored 'General case' 0 N--CA 1.501 2.101 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 95.5 mtt180 -131.8 130.8 42.27 Favored 'General case' 0 N--CA 1.508 2.432 0 O-C-N 121.094 -1.004 . . . . 0.0 110.524 -179.231 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -122.68 137.89 54.77 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.675 -0.64 . . . . 0.0 109.894 179.649 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 60.3 tp -120.01 133.31 55.58 Favored 'General case' 0 N--CA 1.506 2.355 0 O-C-N 121.298 -0.876 . . . . 0.0 109.058 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.9 p -128.7 126.11 39.39 Favored 'General case' 0 N--CA 1.504 2.227 0 CA-C-O 121.581 0.705 . . . . 0.0 110.485 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -133.24 159.21 40.88 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.759 -0.588 . . . . 0.0 110.198 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . 0.435 ' NE1' ' HB1' ' A' ' 7' ' ' ALA . 50.7 m95 -75.66 136.46 40.42 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.372 -0.83 . . . . 0.0 108.775 178.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 21.4 t -106.79 120.81 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.485 -0.759 . . . . 0.0 109.304 -179.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 143.81 61.03 0.02 OUTLIER Glycine 0 N--CA 1.494 2.537 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 48.3 m -69.79 148.62 48.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.194 -1.18 . . . . 0.0 109.7 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 69.5 ttp85 -63.55 136.42 57.54 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.279 -0.888 . . . . 0.0 109.283 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 24.3 p . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 118.085 -0.96 . . . . 0.0 109.432 -179.917 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.853 0 N-CA-C 119.511 2.564 . . . . 0.0 119.511 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -93.09 -3.5 65.47 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 26.4 t -112.94 125.14 54.06 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.421 -1.047 . . . . 0.0 109.776 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -174.79 -165.76 31.65 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . 0.504 ' HE1' HG21 ' A' ' 10' ' ' VAL . 88.7 t90 -74.21 121.48 21.3 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.327 -1.102 . . . . 0.0 109.833 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . 0.5 ' C ' ' H ' ' A' ' 8' ' ' ASP . 77.7 m-20 -127.82 23.87 6.14 Favored 'General case' 0 N--CA 1.493 1.7 0 CA-C-O 121.419 0.628 . . . . 0.0 109.701 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.43 ' HB2' ' CH2' ' A' ' 5' ' ' TRP . . . 59.27 0.97 0.21 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.34 -0.85 . . . . 0.0 109.378 -179.602 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.5 ' H ' ' C ' ' A' ' 6' ' ' ASN . 96.1 m-20 -93.11 -25.7 17.77 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.113 -0.992 . . . . 0.0 110.759 -179.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -90.05 4.83 49.07 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.846 -1.159 . . . . 0.0 109.916 -179.18 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.504 HG21 ' HE1' ' A' ' 5' ' ' TRP . 13.9 t -118.16 131.05 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.379 -0.826 . . . . 0.0 109.686 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 59.0 m-20 -81.96 133.91 50.71 Favored Pre-proline 0 C--N 1.301 -1.512 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 177.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -74.79 -15.34 21.34 Favored 'Trans proline' 0 N--CA 1.494 1.535 0 C-N-CA 121.848 1.699 . . . . 0.0 112.12 -178.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 79.8 p -69.05 -28.83 66.9 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.51 -0.744 . . . . 0.0 110.4 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -78.94 -11.32 60.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.121 -0.987 . . . . 0.0 109.307 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.483 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 11.7 t -69.93 -39.89 75.85 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.062 -1.024 . . . . 0.0 109.81 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.663 HD13 ' H ' ' A' ' 16' ' ' ILE . 0.1 OUTLIER -121.38 142.22 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.108 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 179.504 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -115.85 147.48 40.99 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.476 -0.765 . . . . 0.0 109.697 -178.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -85.05 113.0 21.14 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.43 -0.793 . . . . 0.0 108.953 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.5 m -103.36 120.04 40.03 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.92 -99.78 0.04 OUTLIER Glycine 0 N--CA 1.488 2.148 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 -179.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 t -128.32 20.2 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.456 -1.026 . . . . 0.0 109.195 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -129.61 167.88 17.27 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 121.357 -0.839 . . . . 0.0 110.732 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -124.31 145.21 49.55 Favored 'General case' 0 N--CA 1.501 2.079 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 40.5 p -136.8 153.65 50.76 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.272 -0.893 . . . . 0.0 110.051 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -85.59 123.28 30.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.584 -0.698 . . . . 0.0 109.695 -179.062 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -88.5 83.83 6.8 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.301 -0.875 . . . . 0.0 110.139 -179.578 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 77.7 p -79.85 -4.89 54.15 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 120.991 -1.068 . . . . 0.0 108.989 179.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.73 -40.1 96.14 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.0 m -72.97 139.97 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.008 -1.289 . . . . 0.0 108.862 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 55.2 p -69.04 -25.55 64.53 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.394 -0.816 . . . . 0.0 110.587 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.465 HG11 HG11 ' A' ' 10' ' ' VAL . 54.0 t -60.03 -43.11 91.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.011 -1.056 . . . . 0.0 110.089 -179.037 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.483 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.0 m -60.99 -39.95 91.62 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.067 -1.02 . . . . 0.0 110.464 -179.257 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.2 mmt -80.47 -14.44 58.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.934 -1.104 . . . . 0.0 110.037 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -61.07 -42.56 98.72 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.058 -1.026 . . . . 0.0 108.914 179.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.2 -47.42 9.17 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.7 mt -61.26 -41.66 97.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.074 -1.251 . . . . 0.0 110.14 -179.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -65.52 -39.86 92.31 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.166 -0.959 . . . . 0.0 109.333 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -66.86 -29.66 69.62 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.379 -0.826 . . . . 0.0 109.494 -179.601 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 84.28 22.29 54.76 Favored Glycine 0 N--CA 1.494 2.557 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 31.2 ttmt -107.61 -3.51 19.21 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 179.218 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.73 HG12 ' H ' ' A' ' 43' ' ' GLY . 86.3 t -133.68 160.27 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.305 -179.183 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.451 ' N ' HG12 ' A' ' 41' ' ' VAL . 81.5 mtt85 -121.79 -8.1 8.97 Favored 'General case' 0 N--CA 1.499 2.023 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.73 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.34 -152.86 23.14 Favored Glycine 0 N--CA 1.499 2.86 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 99.2 t -126.53 130.0 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.322 0 O-C-N 121.066 -1.255 . . . . 0.0 109.667 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.406 ' H ' HG23 ' A' ' 94' ' ' VAL . 1.1 t -84.43 137.86 33.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.319 -0.863 . . . . 0.0 109.608 179.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 7.5 p -132.7 134.19 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.43 -0.794 . . . . 0.0 108.943 179.034 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 86.7 p -121.93 146.91 46.67 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 179.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -135.99 131.24 5.64 Favored Glycine 0 N--CA 1.498 2.811 0 C-N-CA 119.964 -1.112 . . . . 0.0 110.525 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 53.7 t -120.96 127.02 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -105.47 116.05 31.3 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 179.456 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -92.97 137.53 32.28 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.361 -0.837 . . . . 0.0 109.879 -178.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 74.0 m-85 -120.11 137.08 54.35 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.367 -0.833 . . . . 0.0 109.676 179.347 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 18.7 t-20 -47.29 -21.32 0.27 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.475 -0.766 . . . . 0.0 109.531 179.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.414 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 10.4 t70 -68.47 0.95 3.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.267 -0.896 . . . . 0.0 109.208 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 75.61 17.93 79.94 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.9 p -111.65 154.39 24.98 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.444 -1.033 . . . . 0.0 108.932 179.329 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 32.7 p -140.44 148.01 40.53 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.38 -0.825 . . . . 0.0 110.525 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 54.9 m -117.86 147.58 42.94 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 106.046 -1.835 . . . . 0.0 106.046 177.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -139.97 116.17 10.5 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.974 -1.079 . . . . 0.0 109.705 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -115.99 122.42 45.2 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 178.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -112.26 145.57 39.71 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -165.92 178.9 40.42 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 -179.466 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 30.4 t -119.42 127.53 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.487 -1.008 . . . . 0.0 109.593 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 t -89.46 118.9 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.436 -0.79 . . . . 0.0 109.875 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.45 ' O ' ' N ' ' A' ' 67' ' ' SER . 26.6 p -138.14 150.05 65.7 Favored Pre-proline 0 N--CA 1.494 1.727 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -44.55 -19.7 0.28 Allowed 'Trans proline' 0 C--N 1.311 -1.4 0 C-N-CA 121.111 1.207 . . . . 0.0 111.414 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.45 ' N ' ' O ' ' A' ' 65' ' ' THR . 69.9 m -70.05 -46.16 65.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.512 -0.743 . . . . 0.0 111.441 -178.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -148.47 141.31 15.25 Favored Pre-proline 0 N--CA 1.504 2.235 0 O-C-N 120.664 -1.273 . . . . 0.0 110.945 -178.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -86.95 165.09 8.74 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.087 2.524 . . . . 0.0 112.229 178.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 72.6 t -113.09 128.34 69.9 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.203 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.456 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -104.52 140.61 37.73 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.285 -0.885 . . . . 0.0 111.818 -177.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.43 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.0 OUTLIER -109.9 19.17 19.36 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.024 -1.473 . . . . 0.0 107.024 177.502 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 46.5 t-20 -71.05 55.39 0.19 Allowed 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.637 -0.664 . . . . 0.0 109.522 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.408 ' N ' ' O ' ' A' ' 72' ' ' THR . 55.0 tt0 -49.61 169.35 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.051 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -59.07 123.77 17.72 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.713 -1.242 . . . . 0.0 108.939 -179.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 43.3 mm -80.16 -21.61 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.433 -0.792 . . . . 0.0 110.694 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -60.01 -47.73 84.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.673 -1.267 . . . . 0.0 110.069 -179.009 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 9.9 ptpt -64.14 -39.26 93.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.966 -1.084 . . . . 0.0 108.488 179.206 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.549 ' O ' ' N ' ' A' ' 83' ' ' GLY . 30.2 m -60.0 -45.04 94.03 Favored 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.683 0.754 . . . . 0.0 109.438 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -62.01 -36.16 80.7 Favored 'General case' 0 C--N 1.293 -1.887 0 O-C-N 120.949 -1.095 . . . . 0.0 109.972 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 15.0 tmtt? -70.31 -44.83 67.5 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.102 -0.999 . . . . 0.0 111.119 -178.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.6 p -117.51 -29.04 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.416 0 O-C-N 121.135 -0.978 . . . . 0.0 111.543 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.549 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.0 158.26 33.92 Favored Glycine 0 N--CA 1.497 2.702 0 O-C-N 120.616 -1.302 . . . . 0.0 110.571 179.35 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 56.1 t -100.04 123.44 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -77.69 -65.0 1.02 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.181 -0.949 . . . . 0.0 111.365 -178.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -115.96 152.45 33.45 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.124 -0.985 . . . . 0.0 111.814 -178.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 64.8 t80 -120.94 130.92 54.05 Favored 'General case' 0 N--CA 1.5 2.033 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.364 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -136.86 130.2 31.38 Favored 'General case' 0 N--CA 1.507 2.39 0 O-C-N 120.814 -1.179 . . . . 0.0 110.843 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.68 135.44 53.05 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.59 HD23 ' N ' ' A' ' 91' ' ' THR . 1.2 tt -119.77 129.1 54.31 Favored 'General case' 0 N--CA 1.504 2.228 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.495 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.59 ' N ' HD23 ' A' ' 90' ' ' LEU . 6.5 p -129.1 121.59 28.13 Favored 'General case' 0 N--CA 1.505 2.279 0 O-C-N 121.414 -0.804 . . . . 0.0 111.433 -178.651 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -133.32 159.82 39.14 Favored 'General case' 0 N--CA 1.502 2.165 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.176 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -73.6 144.06 46.13 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.918 -1.113 . . . . 0.0 109.278 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.406 HG23 ' H ' ' A' ' 45' ' ' SER . 60.9 t -114.2 123.71 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.344 -0.848 . . . . 0.0 109.326 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 116.16 -0.11 20.86 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.2 m -95.2 139.29 31.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.288 -1.125 . . . . 0.0 109.237 179.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 24.9 ttm180 -97.03 121.3 38.77 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.129 -0.982 . . . . 0.0 109.642 -179.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 43.1 t . . . . . 0 N--CA 1.492 1.656 0 CA-C-O 117.844 -1.074 . . . . 0.0 109.651 -179.773 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.914 0 N-CA-C 119.732 2.653 . . . . 0.0 119.732 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -83.29 -78.65 1.06 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 72.2 m -76.31 155.96 33.79 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.281 -1.129 . . . . 0.0 110.142 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 177.94 175.99 45.56 Favored Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 89.3 t90 -77.41 115.62 17.32 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.035 -1.274 . . . . 0.0 109.772 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -131.04 19.2 4.97 Favored 'General case' 0 N--CA 1.49 1.534 0 CA-C-O 121.614 0.721 . . . . 0.0 109.1 179.538 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 56.55 13.32 1.31 Allowed 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -93.62 -28.38 16.04 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.298 -0.876 . . . . 0.0 109.914 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -90.57 0.09 57.48 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.187 -0.946 . . . . 0.0 109.397 -179.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.5 t -109.04 127.8 65.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 O-C-N 121.495 -0.753 . . . . 0.0 109.801 -179.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 60.4 m-20 -87.06 132.12 42.66 Favored Pre-proline 0 N--CA 1.489 1.515 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 178.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -72.84 -14.51 26.73 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 121.633 1.555 . . . . 0.0 112.154 -178.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 30.3 t -61.57 -40.17 93.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.142 -0.974 . . . . 0.0 110.364 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 65.4 mt-30 -81.46 -11.29 59.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.043 -1.035 . . . . 0.0 110.302 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.749 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 35.5 m -70.11 -30.02 67.11 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.948 -1.095 . . . . 0.0 108.939 179.273 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -122.11 140.51 45.79 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -123.95 143.3 50.48 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.528 -0.732 . . . . 0.0 109.398 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -87.5 130.68 34.62 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.086 -1.009 . . . . 0.0 109.456 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 53.6 m -118.9 128.41 54.4 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 46.48 -107.12 0.17 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.7 m -121.78 19.9 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.67 -0.9 . . . . 0.0 109.977 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -130.68 164.99 23.81 Favored 'General case' 0 N--CA 1.503 2.19 0 O-C-N 121.389 -0.819 . . . . 0.0 110.266 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -117.6 140.67 49.33 Favored 'General case' 0 N--CA 1.497 1.891 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 79.2 p -139.94 150.93 45.12 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.305 -0.872 . . . . 0.0 109.044 178.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 8.8 t80 -78.53 128.78 34.03 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.375 -0.828 . . . . 0.0 109.371 -179.412 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -85.69 83.12 7.96 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.341 -0.849 . . . . 0.0 109.257 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.445 ' C ' ' N ' ' A' ' 29' ' ' VAL . 97.6 p -79.08 -5.05 53.12 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.199 -0.938 . . . . 0.0 109.3 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.17 -11.73 0.69 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.474 ' O ' HG23 ' A' ' 29' ' ' VAL . 29.0 m -108.9 127.39 65.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.518 -0.989 . . . . 0.0 108.776 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 64.5 m -70.07 -27.48 64.66 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.42 -0.8 . . . . 0.0 110.451 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.422 HG23 ' N ' ' A' ' 32' ' ' CYS . 3.7 m -60.01 -40.3 82.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.036 -1.04 . . . . 0.0 111.204 -178.18 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.749 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 97.1 m -66.39 -40.24 89.54 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.546 -1.347 . . . . 0.0 110.074 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 70.5 mtp -80.98 -10.08 59.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.953 -1.092 . . . . 0.0 109.603 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -61.23 -40.46 94.1 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -80.46 -51.27 4.99 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.9 tt -60.14 -41.53 92.92 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.105 -1.232 . . . . 0.0 109.726 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 -60.1 -40.22 88.85 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.018 -1.051 . . . . 0.0 109.736 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -79.01 -6.04 55.37 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.348 -0.845 . . . . 0.0 109.487 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.56 29.25 49.37 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.941 -1.123 . . . . 0.0 110.374 178.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -104.48 -9.54 18.31 Favored 'General case' 0 N--CA 1.496 1.848 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.676 HG12 ' H ' ' A' ' 43' ' ' GLY . 70.9 t -136.15 161.2 37.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.492 ' N ' HG12 ' A' ' 41' ' ' VAL . 57.9 ttm-85 -122.95 -7.65 8.38 Favored 'General case' 0 N--CA 1.495 1.8 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.676 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.3 -161.16 25.63 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 95.0 t -122.5 130.13 74.74 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.335 -1.097 . . . . 0.0 109.103 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.454 ' H ' HG23 ' A' ' 94' ' ' VAL . 1.8 m -86.3 136.79 33.02 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.051 -1.03 . . . . 0.0 108.303 179.364 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.407 ' O ' HG23 ' A' ' 46' ' ' VAL . 6.0 m -132.08 133.45 60.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.644 -0.66 . . . . 0.0 109.543 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 57.3 p -122.65 142.46 50.64 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 179.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -131.3 143.06 14.48 Favored Glycine 0 N--CA 1.503 3.151 0 C-N-CA 120.085 -1.055 . . . . 0.0 111.113 -178.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 92.6 t -126.25 129.99 72.03 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.852 -0.793 . . . . 0.0 109.405 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -103.97 120.05 40.23 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 62.6 m-85 -96.64 123.22 40.24 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.354 -0.842 . . . . 0.0 109.405 -179.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.58 ' CD1' ' NZ ' ' A' ' 78' ' ' LYS . 96.9 m-85 -109.03 128.03 54.61 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.607 -0.683 . . . . 0.0 109.634 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.46 ' ND2' ' O ' ' A' ' 53' ' ' ASN . 0.5 OUTLIER -45.58 -17.27 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.27 -0.894 . . . . 0.0 109.324 179.149 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 52' ' ' TYR . 22.1 t0 -67.42 1.54 2.21 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.429 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 75.36 23.42 73.65 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.346 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 13.9 p -121.76 149.85 42.69 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.499 -1.001 . . . . 0.0 110.002 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.1 p -134.01 138.08 45.16 Favored 'General case' 0 N--CA 1.499 2.016 0 CA-C-O 121.824 0.821 . . . . 0.0 110.174 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.8 t -119.78 143.2 47.97 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 58.6 t-20 -134.44 129.84 35.89 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 120.624 -1.297 . . . . 0.0 110.127 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -117.06 128.69 55.4 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -113.98 142.7 45.83 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -165.42 170.58 40.39 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.9 t -113.96 126.45 71.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.112 0 O-C-N 121.544 -0.974 . . . . 0.0 109.408 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 72.5 t -96.45 117.92 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.075 -1.015 . . . . 0.0 109.906 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.52 ' O ' ' N ' ' A' ' 67' ' ' SER . 24.3 p -126.69 150.12 70.25 Favored Pre-proline 0 N--CA 1.501 2.088 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 179.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_exo -37.41 -22.39 0.05 OUTLIER 'Trans proline' 0 N--CA 1.49 1.306 0 C-N-CA 122.227 1.951 . . . . 0.0 112.984 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.52 ' N ' ' O ' ' A' ' 65' ' ' THR . 9.0 t -114.1 -16.06 12.16 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.275 -0.891 . . . . 0.0 111.556 -178.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 98.5 m -119.6 106.53 41.99 Favored Pre-proline 0 N--CA 1.502 2.156 0 O-C-N 120.976 -1.077 . . . . 0.0 110.193 -179.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -91.41 163.48 3.62 Favored 'Trans proline' 0 N--CA 1.492 1.416 0 C-N-CA 122.657 2.238 . . . . 0.0 112.347 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.8 t -127.22 130.03 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.293 0 N-CA-C 108.714 -0.846 . . . . 0.0 108.714 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 80.5 m-20 -100.16 132.31 45.61 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 121.209 -0.932 . . . . 0.0 111.873 -178.094 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.488 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.0 OUTLIER -105.33 19.96 19.69 Favored 'General case' 0 N--CA 1.498 1.938 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.602 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -67.44 54.37 0.06 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.777 -0.577 . . . . 0.0 109.651 -179.256 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.488 ' N ' ' O ' ' A' ' 72' ' ' THR . 0.0 OUTLIER -48.0 166.71 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.285 -0.885 . . . . 0.0 108.831 179.517 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.449 ' O ' ' NE2' ' A' ' 74' ' ' GLN . 78.3 m-20 -57.09 117.83 4.41 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.006 -1.058 . . . . 0.0 109.538 -178.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 47.7 mm -69.59 -39.48 78.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.768 -0.582 . . . . 0.0 109.582 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -56.15 -41.47 75.44 Favored 'General case' 0 N--CA 1.488 1.425 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.58 ' NZ ' ' CD1' ' A' ' 52' ' ' TYR . 28.3 tttm -62.84 -49.47 74.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.317 -0.865 . . . . 0.0 108.884 178.323 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.582 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.0 OUTLIER -67.61 -42.16 82.84 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.535 -0.728 . . . . 0.0 110.062 -179.099 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -60.96 -34.21 74.39 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 120.641 -1.287 . . . . 0.0 110.902 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -70.99 -43.54 67.79 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.887 -1.133 . . . . 0.0 111.243 -178.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.1 p -115.98 -27.78 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.39 -0.819 . . . . 0.0 111.231 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.87 166.01 40.9 Favored Glycine 0 N--CA 1.488 2.162 0 O-C-N 120.675 -1.266 . . . . 0.0 110.371 178.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.9 t -111.06 124.91 68.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -81.34 -64.19 1.24 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.162 -0.962 . . . . 0.0 111.073 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -114.22 143.17 45.27 Favored 'General case' 0 N--CA 1.509 2.48 0 O-C-N 121.167 -0.958 . . . . 0.0 111.299 -178.582 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 74.4 t80 -120.5 134.43 55.27 Favored 'General case' 0 N--CA 1.505 2.291 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 178.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 78.9 mtp180 -136.45 129.0 30.47 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 120.968 -1.083 . . . . 0.0 110.944 -178.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.66 132.66 53.39 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.729 -0.607 . . . . 0.0 109.672 179.047 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.518 HD12 ' N ' ' A' ' 90' ' ' LEU . 7.7 mp -108.83 129.46 55.4 Favored 'General case' 0 N--CA 1.503 2.206 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 179.138 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.9 p -124.2 121.46 35.15 Favored 'General case' 0 N--CA 1.507 2.384 0 O-C-N 121.313 -0.867 . . . . 0.0 110.575 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 53.4 tp10 -133.84 150.95 51.41 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.772 -0.58 . . . . 0.0 110.163 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 70.9 m95 -66.95 141.55 57.57 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.992 -1.067 . . . . 0.0 108.737 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.454 HG23 ' H ' ' A' ' 45' ' ' SER . 62.0 t -119.3 130.16 74.32 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.177 0 O-C-N 121.503 -0.748 . . . . 0.0 109.989 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 115.83 -0.53 21.45 Favored Glycine 0 N--CA 1.501 3.0 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.338 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 54.6 p -85.34 117.98 24.6 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.237 -1.155 . . . . 0.0 108.905 179.704 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 78.2 mtp180 -87.94 139.95 29.99 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.159 -0.963 . . . . 0.0 109.482 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.9 t . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 118.125 -0.941 . . . . 0.0 109.556 -179.686 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.821 0 N-CA-C 119.353 2.501 . . . . 0.0 119.353 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 90.04 -10.01 75.43 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.325 -1.51 . . . . 0.0 109.325 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.4 m -61.07 144.54 53.3 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.374 -1.074 . . . . 0.0 109.088 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 177.77 -77.04 0.07 OUTLIER Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.573 -1.298 . . . . 0.0 109.936 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 14.7 t90 -60.23 139.97 57.27 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.154 -1.204 . . . . 0.0 109.874 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . 0.565 ' C ' ' H ' ' A' ' 8' ' ' ASP . 17.2 m120 -133.57 125.38 28.7 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 177.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -63.78 5.39 0.21 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.006 -1.059 . . . . 0.0 108.861 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.565 ' H ' ' C ' ' A' ' 6' ' ' ASN . 33.5 p-10 -72.81 -20.13 61.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.34 -0.85 . . . . 0.0 110.708 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 33.7 m120 -99.52 6.71 45.79 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.098 -1.001 . . . . 0.0 109.783 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 29.2 t -119.98 129.97 74.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.47 -0.769 . . . . 0.0 109.905 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -82.96 140.28 43.1 Favored Pre-proline 0 N--CA 1.489 1.486 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.21 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -71.48 -22.39 24.82 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 121.806 1.671 . . . . 0.0 111.975 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 76.9 p -69.32 -38.93 78.45 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.313 -0.867 . . . . 0.0 109.781 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 56.6 tt0 -70.04 -23.93 63.18 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.304 -0.873 . . . . 0.0 109.739 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.466 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 22.0 m -68.44 -28.54 67.14 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.888 . . . . 0.0 109.685 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.4 pp -116.49 139.1 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.402 -0.811 . . . . 0.0 109.227 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -118.04 147.84 42.84 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.553 -0.717 . . . . 0.0 109.731 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.701 HE22 ' N ' ' A' ' 22' ' ' GLN . 64.2 tp60 -99.58 117.73 34.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.649 -0.657 . . . . 0.0 109.266 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.464 ' O ' ' N ' ' A' ' 21' ' ' VAL . 14.6 t -110.45 118.29 35.88 Favored 'General case' 0 N--CA 1.497 1.902 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 179.023 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.03 -92.42 0.02 OUTLIER Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.727 -1.749 . . . . 0.0 108.727 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.464 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.4 t -140.41 30.52 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 O-C-N 121.328 -1.101 . . . . 0.0 109.564 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.701 ' N ' HE22 ' A' ' 18' ' ' GLN . 89.1 mt-30 -127.46 158.07 38.35 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.271 -0.893 . . . . 0.0 110.334 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . 0.528 ' CZ ' ' OE1' ' A' ' 18' ' ' GLN . 26.9 m-85 -119.74 134.73 55.12 Favored 'General case' 0 N--CA 1.498 1.963 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.1 p -139.97 150.45 44.5 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.225 -0.922 . . . . 0.0 109.833 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.424 ' CZ ' HD11 ' A' ' 36' ' ' LEU . 33.6 t80 -78.99 127.5 32.06 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 179.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . 0.51 HD21 HG13 ' A' ' 29' ' ' VAL . 57.9 t30 -82.81 81.52 8.51 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.068 -1.02 . . . . 0.0 109.777 -179.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 49.9 m -78.31 -5.98 53.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.168 -0.957 . . . . 0.0 109.068 179.638 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -58.36 -37.43 87.56 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.829 -1.308 . . . . 0.0 109.829 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.51 HG13 HD21 ' A' ' 26' ' ' ASN . 28.2 m -84.32 132.38 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.036 -1.273 . . . . 0.0 109.492 -179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.9 m -60.09 -39.42 86.04 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.642 -0.661 . . . . 0.0 111.622 -178.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.403 HG23 ' N ' ' A' ' 32' ' ' CYS . 19.7 m -57.62 -42.99 82.56 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 120.849 -1.157 . . . . 0.0 111.369 -177.336 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.466 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 93.0 m -67.05 -39.99 87.05 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.45 -1.406 . . . . 0.0 109.412 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.1 tpt -79.99 -11.72 59.76 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.008 -1.058 . . . . 0.0 108.419 179.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 61.2 tt0 -65.41 -39.85 92.65 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.07 -46.59 15.79 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.424 HD11 ' CZ ' ' A' ' 25' ' ' TYR . 23.7 mt -60.04 -50.11 75.02 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.213 -1.169 . . . . 0.0 109.943 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -61.08 -39.99 91.98 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.076 -1.015 . . . . 0.0 110.0 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.437 ' OE2' ' NZ ' ' A' ' 40' ' ' LYS . 79.3 tt0 -64.55 -29.82 70.85 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.331 -0.855 . . . . 0.0 109.297 -179.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 91.25 26.54 20.95 Favored Glycine 0 N--CA 1.496 2.638 0 O-C-N 121.161 -0.962 . . . . 0.0 110.765 179.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.437 ' NZ ' ' OE2' ' A' ' 38' ' ' GLU . 96.3 mttt -110.04 -1.86 17.35 Favored 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.661 HG12 ' H ' ' A' ' 43' ' ' GLY . 72.5 t -133.71 160.2 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 CA-C-O 121.756 0.788 . . . . 0.0 109.056 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.547 ' HE ' ' CG1' ' A' ' 94' ' ' VAL . 44.9 ttp180 -125.25 -5.98 7.18 Favored 'General case' 0 N--CA 1.494 1.772 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.673 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.661 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 134.09 -164.42 24.49 Favored Glycine 0 N--CA 1.503 3.136 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 94.6 t -120.07 130.01 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.4 0 CA-C-N 118.747 1.273 . . . . 0.0 110.126 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 38.0 t -79.63 134.08 36.43 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.446 HG13 ' O ' ' A' ' 46' ' ' VAL . 14.7 p -130.04 131.3 66.13 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.382 -0.824 . . . . 0.0 109.684 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 60.7 p -122.56 147.03 46.88 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 179.288 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -142.36 136.01 6.97 Favored Glycine 0 N--CA 1.503 3.118 0 C-N-CA 119.409 -1.376 . . . . 0.0 111.04 -179.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.561 ' CG1' HH12 ' A' ' 88' ' ' ARG . 65.0 t -123.45 133.77 68.22 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.311 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -111.06 124.31 51.92 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.603 -0.686 . . . . 0.0 109.185 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.607 ' CD2' ' NH2' ' A' ' 88' ' ' ARG . 23.4 m-85 -95.1 126.06 40.17 Favored 'General case' 0 N--CA 1.504 2.266 0 O-C-N 120.807 -1.183 . . . . 0.0 109.247 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.451 ' C ' ' N ' ' A' ' 54' ' ' ASP . 37.3 m-85 -111.04 131.47 55.03 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -53.13 -14.61 0.67 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.907 -1.121 . . . . 0.0 108.184 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.451 ' N ' ' C ' ' A' ' 52' ' ' TYR . 34.2 t0 -68.72 -4.77 17.05 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.2 12.43 80.8 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.0 p -110.57 159.45 17.54 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.541 -0.976 . . . . 0.0 110.025 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 78.4 p -140.43 143.82 35.8 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.449 -0.782 . . . . 0.0 110.487 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.0 t -114.98 130.01 56.84 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 177.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 12.3 m-20 -130.55 116.94 18.85 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.946 -1.096 . . . . 0.0 109.594 -178.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.532 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 54.5 p90 -117.09 120.69 39.11 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 178.511 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.9 ttpt -110.09 144.06 39.23 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -173.39 -175.35 41.08 Favored Glycine 0 C--N 1.286 -2.226 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 66.3 t -120.53 129.77 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.658 -0.907 . . . . 0.0 109.702 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.489 HG13 ' O ' ' A' ' 64' ' ' VAL . 4.3 p -96.89 124.23 49.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.207 -0.933 . . . . 0.0 109.462 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 8.0 p -135.58 150.13 71.21 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_exo -40.77 -24.8 0.17 Allowed 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.012 1.808 . . . . 0.0 112.845 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.2 t -102.84 -22.78 13.83 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.26 -0.9 . . . . 0.0 110.983 -178.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 41.5 m -123.17 107.1 32.97 Favored Pre-proline 0 N--CA 1.504 2.255 0 O-C-N 121.146 -0.971 . . . . 0.0 109.945 -179.652 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -89.2 163.09 5.7 Favored 'Trans proline' 0 N--CA 1.491 1.337 0 C-N-CA 122.453 2.102 . . . . 0.0 112.445 179.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.2 t -120.04 127.66 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 -103.99 130.89 51.67 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.306 -0.871 . . . . 0.0 110.805 -178.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.27 9.68 41.6 Favored 'General case' 0 N--CA 1.5 2.057 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 178.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 48.7 t-20 -76.36 56.81 1.11 Allowed 'General case' 0 N--CA 1.486 1.338 0 O-C-N 121.598 -0.689 . . . . 0.0 109.878 -179.004 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.508 ' NE2' ' N ' ' A' ' 75' ' ' ASP . 0.0 OUTLIER -63.96 -156.07 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 178.544 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.508 ' N ' ' NE2' ' A' ' 74' ' ' GLN . 76.2 m-20 -73.4 101.39 3.46 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 120.575 -1.328 . . . . 0.0 108.583 179.571 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.473 HG22 ' O ' ' A' ' 76' ' ' ILE . 90.6 mt -79.95 -9.34 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.493 -0.754 . . . . 0.0 109.959 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -59.12 -43.85 91.97 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.98 -1.075 . . . . 0.0 109.337 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 10.1 ptpt -69.94 -39.2 76.23 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.947 -1.096 . . . . 0.0 109.648 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.593 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.8 OUTLIER -60.14 -47.85 84.17 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.764 -1.21 . . . . 0.0 108.266 179.808 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 44.6 t-20 -60.04 -35.07 74.31 Favored 'General case' 0 C--N 1.296 -1.718 0 O-C-N 120.825 -1.172 . . . . 0.0 108.501 178.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 83.4 tttt -64.37 -51.52 62.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.407 -0.808 . . . . 0.0 110.817 -179.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.4 m -115.94 -26.59 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.395 0 O-C-N 121.139 -0.976 . . . . 0.0 111.803 -178.334 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 93.49 166.31 37.79 Favored Glycine 0 N--CA 1.492 2.43 0 O-C-N 120.65 -1.281 . . . . 0.0 110.328 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 59.7 t -110.8 130.02 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.945 -0.738 . . . . 0.0 109.127 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 36.2 tt0 -80.0 -66.57 0.86 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.119 -0.988 . . . . 0.0 110.462 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.417 ' C ' ' HE ' ' A' ' 88' ' ' ARG . 95.0 mttt -115.71 139.98 49.63 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 121.26 -0.9 . . . . 0.0 111.48 -178.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.492 ' CA ' ' HE ' ' A' ' 88' ' ' ARG . 80.6 t80 -121.84 133.38 54.88 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.607 ' NH2' ' CD2' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -138.5 134.07 33.48 Favored 'General case' 0 N--CA 1.507 2.415 0 O-C-N 120.933 -1.104 . . . . 0.0 110.655 -179.874 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.64 136.2 53.72 Favored 'General case' 0 N--CA 1.498 1.927 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.52 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.28 131.91 56.34 Favored 'General case' 0 N--CA 1.505 2.292 0 O-C-N 121.365 -0.834 . . . . 0.0 109.427 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 40.3 p -127.09 125.31 41.05 Favored 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.358 -0.839 . . . . 0.0 110.579 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -133.18 151.61 51.96 Favored 'General case' 0 N--CA 1.504 2.242 0 O-C-N 121.783 -0.573 . . . . 0.0 110.338 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 71.0 m95 -70.37 140.73 52.19 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.146 -0.971 . . . . 0.0 108.882 178.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.547 ' CG1' ' HE ' ' A' ' 42' ' ' ARG . 38.4 t -117.03 124.8 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 O-C-N 121.399 -0.813 . . . . 0.0 109.315 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -173.81 47.55 0.15 Allowed Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.4 t -80.21 144.11 33.22 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.169 -1.195 . . . . 0.0 109.689 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 42.8 ttm180 -87.11 -18.08 31.31 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.345 -0.847 . . . . 0.0 109.364 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 25.2 p . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 118.022 -0.99 . . . . 0.0 109.654 -179.972 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.814 0 N-CA-C 119.457 2.543 . . . . 0.0 119.457 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -146.67 -54.33 0.02 OUTLIER Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.4 t -68.69 138.69 55.14 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.446 -1.031 . . . . 0.0 109.451 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.58 141.4 48.02 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 -179.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . 0.843 ' CH2' ' HB2' ' A' ' 7' ' ' ALA . 88.5 t90 -86.89 130.03 34.63 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.413 -1.051 . . . . 0.0 109.099 179.447 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . 0.496 ' C ' ' H ' ' A' ' 8' ' ' ASP . 99.2 m-20 -129.84 12.66 5.77 Favored 'General case' 0 N--CA 1.495 1.814 0 CA-C-O 121.701 0.762 . . . . 0.0 109.696 179.295 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.843 ' HB2' ' CH2' ' A' ' 5' ' ' TRP . . . 57.91 2.44 0.17 Allowed 'General case' 0 C--N 1.295 -1.792 0 O-C-N 121.517 -0.739 . . . . 0.0 109.028 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.496 ' H ' ' C ' ' A' ' 6' ' ' ASN . 55.0 t0 -84.3 -26.34 28.61 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.27 -0.894 . . . . 0.0 110.362 -179.371 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.449 ' ND2' ' O ' ' A' ' 9' ' ' ASN . 0.9 OUTLIER -86.32 1.7 50.05 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.103 -0.998 . . . . 0.0 110.077 -179.307 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.456 HG11 HG11 ' A' ' 31' ' ' VAL . 2.0 t -118.15 126.92 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.483 -0.761 . . . . 0.0 109.332 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -77.91 140.33 62.5 Favored Pre-proline 0 C--N 1.3 -1.583 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 178.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -75.21 -13.74 20.89 Favored 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 121.347 1.365 . . . . 0.0 111.549 -179.275 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 38.3 t -60.73 -40.35 92.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.639 -0.663 . . . . 0.0 110.917 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -81.97 -10.03 59.38 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.0 -1.062 . . . . 0.0 109.673 -179.254 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.515 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 18.3 t -70.93 -30.9 67.34 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.125 -0.984 . . . . 0.0 109.335 179.357 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -123.86 151.89 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.204 0 O-C-N 121.443 -0.785 . . . . 0.0 109.318 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.404 ' CD ' HD21 ' A' ' 26' ' ' ASN . 20.9 pttp -130.85 148.22 52.59 Favored 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.502 -0.749 . . . . 0.0 109.374 179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 62.7 tt0 -100.7 124.95 47.03 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.203 -0.935 . . . . 0.0 109.673 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.525 ' O ' ' N ' ' A' ' 21' ' ' VAL . 34.4 p -111.8 121.53 45.31 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.68 -92.87 0.01 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.67 -1.772 . . . . 0.0 108.67 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.525 ' N ' ' O ' ' A' ' 19' ' ' SER . 4.6 m -137.24 30.6 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.356 -1.085 . . . . 0.0 109.264 179.293 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -129.55 159.67 35.6 Favored 'General case' 0 N--CA 1.504 2.226 0 CA-C-O 122.03 0.919 . . . . 0.0 111.029 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -119.89 139.95 51.6 Favored 'General case' 0 N--CA 1.499 2.004 0 N-CA-C 108.404 -0.962 . . . . 0.0 108.404 178.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 77.0 p -138.32 147.42 43.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.28 -0.888 . . . . 0.0 109.001 179.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -83.17 125.65 31.76 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.606 -0.684 . . . . 0.0 109.38 -178.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . 0.404 HD21 ' CD ' ' A' ' 17' ' ' LYS . 9.6 m120 -84.91 90.34 7.78 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.208 -0.933 . . . . 0.0 109.555 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 79.8 p -89.52 -0.87 57.8 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.223 -0.923 . . . . 0.0 108.851 179.352 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -68.33 -2.12 24.89 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.0 m -113.71 130.06 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.546 -0.973 . . . . 0.0 109.363 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 80.5 p -60.45 -28.0 67.96 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.703 -0.623 . . . . 0.0 110.497 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.456 HG11 HG11 ' A' ' 10' ' ' VAL . 71.2 t -61.22 -44.31 98.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 120.948 -1.095 . . . . 0.0 110.338 -178.82 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.515 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 86.1 m -69.83 -39.81 76.24 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.101 -0.999 . . . . 0.0 110.109 -179.034 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.4 mmt -74.95 -20.86 59.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.092 -1.005 . . . . 0.0 109.495 179.708 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 60.0 tt0 -60.42 -39.61 88.03 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 120.985 -1.072 . . . . 0.0 109.073 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.97 -49.13 7.2 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 17.8 mt -62.64 -39.92 95.37 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.333 -1.098 . . . . 0.0 109.737 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -66.46 -39.91 89.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.055 -1.028 . . . . 0.0 109.496 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 77.0 tt0 -67.12 -30.1 70.01 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.058 -1.026 . . . . 0.0 109.348 -179.406 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.32 22.41 27.13 Favored Glycine 0 N--CA 1.497 2.743 0 O-C-N 121.112 -0.992 . . . . 0.0 110.688 179.07 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.1 mtpt -104.47 -1.52 26.57 Favored 'General case' 0 N--CA 1.497 1.887 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 178.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.713 HG12 ' H ' ' A' ' 43' ' ' GLY . 78.3 t -131.08 158.4 43.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-O 121.639 0.733 . . . . 0.0 109.447 -179.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.438 ' N ' HG12 ' A' ' 41' ' ' VAL . 62.5 ttm-85 -123.38 -6.84 8.17 Favored 'General case' 0 N--CA 1.498 1.965 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.713 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.54 -163.19 26.52 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 108.563 -1.815 . . . . 0.0 108.563 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.8 t -119.42 128.37 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.278 -1.131 . . . . 0.0 108.684 179.595 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.1 p -85.16 137.35 33.07 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.098 -1.001 . . . . 0.0 108.716 179.523 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.439 ' O ' HG13 ' A' ' 46' ' ' VAL . 13.4 p -130.19 131.83 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 54.7 p -125.88 142.1 51.67 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -141.08 139.15 9.35 Favored Glycine 0 N--CA 1.497 2.731 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.317 -178.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 56.0 t -120.02 119.83 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -92.72 117.64 30.22 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -90.37 120.33 31.4 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -105.83 139.16 40.82 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.588 -0.695 . . . . 0.0 110.491 -179.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.469 ' C ' ' H ' ' A' ' 55' ' ' GLY . 45.0 t-20 -61.29 -14.7 28.52 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -66.48 0.82 1.97 Allowed 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.469 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 79.34 16.02 78.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 179.098 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.7 p -123.19 148.21 46.04 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.382 -1.069 . . . . 0.0 110.264 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 63.9 p -127.24 140.04 52.5 Favored 'General case' 0 N--CA 1.496 1.856 0 CA-C-O 121.648 0.737 . . . . 0.0 109.423 179.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.5 t -116.98 147.57 42.18 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 178.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -132.08 119.12 20.55 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.078 -1.014 . . . . 0.0 109.42 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.526 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 51.7 p90 -116.19 120.83 40.24 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.725 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -114.37 145.14 42.19 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 -179.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.4 171.35 43.1 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 72.7 t -110.83 126.94 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.458 -1.025 . . . . 0.0 109.966 -179.676 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 89.2 t -93.13 120.19 42.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.232 -0.918 . . . . 0.0 109.669 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 23.3 p -126.57 151.23 72.72 Favored Pre-proline 0 N--CA 1.495 1.811 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -53.99 -8.65 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 121.449 1.433 . . . . 0.0 111.615 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 70.2 m -111.16 -18.65 12.94 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.476 -0.765 . . . . 0.0 110.243 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 10.3 p -133.91 109.37 11.86 Favored Pre-proline 0 N--CA 1.505 2.321 0 O-C-N 121.106 -0.996 . . . . 0.0 110.799 -179.016 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -86.91 163.58 8.91 Favored 'Trans proline' 0 N--CA 1.497 1.691 0 C-N-CA 122.556 2.171 . . . . 0.0 112.229 178.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 61.6 t -119.05 130.18 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.421 0 O-C-N 121.256 -0.902 . . . . 0.0 109.76 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 64.9 m-20 -100.58 123.63 45.05 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.34 -0.85 . . . . 0.0 110.717 -178.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.513 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.6 OUTLIER -90.87 0.59 57.45 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.832 -1.167 . . . . 0.0 108.665 179.051 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 -66.2 50.35 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.287 -0.883 . . . . 0.0 110.072 -179.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.513 ' N ' ' O ' ' A' ' 72' ' ' THR . 98.9 mm-40 -55.04 -98.04 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.126 -0.984 . . . . 0.0 109.755 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -103.42 85.46 2.48 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.156 -0.965 . . . . 0.0 109.227 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.452 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 9.5 tp -67.38 -39.73 83.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.54 -0.725 . . . . 0.0 109.914 -179.751 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.452 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 97.6 m-20 -59.61 -40.15 86.55 Favored 'General case' 0 C--N 1.297 -1.716 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 -179.58 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 13.0 ttmm -66.71 -41.33 88.16 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.594 -0.691 . . . . 0.0 109.495 178.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.618 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -65.07 -52.3 56.42 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.281 -0.887 . . . . 0.0 110.836 -177.638 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.448 ' ND2' ' O ' ' A' ' 77' ' ' ASN . 0.5 OUTLIER -62.31 -28.17 69.55 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 119.808 -1.807 . . . . 0.0 108.976 179.677 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . 0.445 ' N ' HD22 ' A' ' 80' ' ' ASN . 34.6 ttmt -64.6 -51.09 64.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.129 -0.982 . . . . 0.0 110.496 -179.296 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 m -116.42 -22.04 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.274 0 O-C-N 121.353 -0.842 . . . . 0.0 110.72 -179.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.618 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 83.44 165.96 39.11 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 179.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 28.2 t -108.31 120.45 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -69.79 -55.08 10.82 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.998 -1.064 . . . . 0.0 110.051 -179.364 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -116.84 148.79 40.94 Favored 'General case' 0 N--CA 1.502 2.148 0 CA-C-O 121.863 0.84 . . . . 0.0 111.75 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 66.6 t80 -119.65 133.89 55.45 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 178.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 74.7 ttt180 -139.62 121.6 15.64 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.856 -1.152 . . . . 0.0 110.613 -178.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -125.34 137.84 54.05 Favored 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.135 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.0 tp -120.55 130.99 54.46 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 23.1 p -129.24 119.8 24.63 Favored 'General case' 0 N--CA 1.508 2.469 0 CA-C-O 121.817 0.818 . . . . 0.0 111.168 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -132.8 160.5 36.71 Favored 'General case' 0 N--CA 1.504 2.269 0 O-C-N 121.666 -0.647 . . . . 0.0 110.211 179.102 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . 0.52 ' CE2' ' HB1' ' A' ' 7' ' ' ALA . 90.2 m95 -69.42 142.98 53.75 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.432 -0.793 . . . . 0.0 110.426 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.404 ' O ' ' N ' ' A' ' 42' ' ' ARG . 41.0 t -115.94 123.42 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 178.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 123.87 3.56 8.29 Favored Glycine 0 N--CA 1.499 2.88 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.4 m -70.04 150.29 46.78 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.335 -1.097 . . . . 0.0 109.104 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 87.1 mtm-85 -89.2 0.12 57.01 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.138 -0.976 . . . . 0.0 109.123 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 13.1 t . . . . . 0 N--CA 1.487 1.395 0 CA-C-O 117.872 -1.061 . . . . 0.0 109.405 -179.648 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.785 0 N-CA-C 119.401 2.521 . . . . 0.0 119.401 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 167.48 130.88 1.21 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.706 -1.357 . . . . 0.0 109.706 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 38.1 m -106.19 138.19 42.81 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.502 -0.999 . . . . 0.0 109.283 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 89.96 -158.82 27.32 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 41.3 t90 -60.0 139.77 57.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.423 -1.045 . . . . 0.0 110.613 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . 0.538 ' C ' ' H ' ' A' ' 8' ' ' ASP . 33.6 m120 -129.77 136.09 49.21 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.702 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -75.82 25.2 0.12 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.079 -1.013 . . . . 0.0 108.408 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.538 ' H ' ' C ' ' A' ' 6' ' ' ASN . 55.1 t0 -90.34 6.74 41.82 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.654 -0.654 . . . . 0.0 110.715 -178.725 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.43 ' OD1' ' N ' ' A' ' 9' ' ' ASN . 21.5 p-10 -137.83 17.74 2.86 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 120.913 -1.117 . . . . 0.0 109.048 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.453 ' O ' HG23 ' A' ' 10' ' ' VAL . 35.0 m -126.02 129.76 72.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -94.94 142.48 24.69 Favored Pre-proline 0 N--CA 1.494 1.772 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.44 -18.05 23.28 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 121.91 1.74 . . . . 0.0 112.145 -179.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 87.9 p -70.13 -30.18 67.29 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 110.187 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -89.25 -14.98 34.67 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.959 -1.088 . . . . 0.0 109.952 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.506 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 35.7 t -72.44 -27.61 62.43 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.304 -0.872 . . . . 0.0 109.648 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.1 pp -118.21 132.52 67.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.534 -0.729 . . . . 0.0 109.087 -179.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -120.05 138.18 53.68 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.369 -0.832 . . . . 0.0 109.094 -179.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.424 ' H ' ' HG2' ' A' ' 18' ' ' GLN . 13.3 pt20 -100.02 123.67 44.52 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.566 -0.709 . . . . 0.0 110.409 -178.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t -125.37 83.81 2.21 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.473 -0.767 . . . . 0.0 109.413 179.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.49 ' O ' ' N ' ' A' ' 22' ' ' GLN . . . 98.13 73.43 1.11 Allowed Glycine 0 N--CA 1.501 2.981 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.429 ' C ' ' O ' ' A' ' 20' ' ' GLY . 15.2 m 34.47 32.41 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.183 0 O-C-N 121.946 -0.738 . . . . 0.0 110.817 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.49 ' N ' ' O ' ' A' ' 20' ' ' GLY . 14.1 pt20 -130.86 161.02 32.75 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.569 -0.707 . . . . 0.0 109.55 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -124.38 131.49 53.51 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 38.7 p -134.27 152.52 51.86 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.336 -0.853 . . . . 0.0 109.381 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 39.1 t80 -81.79 130.67 35.14 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.514 -0.742 . . . . 0.0 109.256 -179.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -81.86 77.41 8.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.917 -1.114 . . . . 0.0 109.93 -179.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 54.3 p -79.57 -8.34 59.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.092 -1.005 . . . . 0.0 109.358 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.9 -39.86 96.07 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.414 ' CG2' ' SG ' ' A' ' 32' ' ' CYS . 27.0 m -82.25 138.34 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.046 -1.267 . . . . 0.0 109.305 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 32.6 t -63.2 -34.64 78.08 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.488 -0.758 . . . . 0.0 110.868 -179.255 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.1 t -56.83 -40.04 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.832 -1.168 . . . . 0.0 109.556 -178.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.506 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 49.1 m -63.08 -39.89 96.04 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.047 -1.033 . . . . 0.0 110.059 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 96.5 mmm -88.94 -16.8 30.91 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.769 -1.207 . . . . 0.0 110.974 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 50.3 mt-30 -60.23 -42.68 95.74 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 120.616 -1.302 . . . . 0.0 108.984 178.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -80.34 -41.68 11.37 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.0 tp -59.99 -47.08 87.3 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.312 -1.11 . . . . 0.0 109.241 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 45.0 t30 -65.52 -39.86 92.31 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.285 -0.884 . . . . 0.0 110.184 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.5 -31.98 71.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.249 -0.907 . . . . 0.0 109.423 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.74 18.77 46.63 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 -179.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.3 tttp -97.56 -9.09 27.65 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 178.461 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.789 HG12 ' H ' ' A' ' 43' ' ' GLY . 97.1 t -134.72 159.87 41.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.038 -0.983 . . . . 0.0 108.665 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.472 ' N ' ' O ' ' A' ' 94' ' ' VAL . 57.9 ttm-85 -125.04 -1.69 7.74 Favored 'General case' 0 N--CA 1.497 1.917 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 179.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.789 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 129.65 -163.96 22.59 Favored Glycine 0 N--CA 1.499 2.855 0 N-CA-C 107.719 -2.153 . . . . 0.0 107.719 -179.236 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 47.5 t -120.56 129.79 75.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.124 0 CA-C-N 118.881 1.34 . . . . 0.0 109.486 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 63.6 p -77.43 141.94 39.47 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.456 -0.777 . . . . 0.0 108.959 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.464 HG13 ' O ' ' A' ' 46' ' ' VAL . 9.9 p -127.38 125.32 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 CA-C-O 121.947 0.88 . . . . 0.0 108.727 179.067 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 2.4 p -128.06 146.65 50.61 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -154.66 147.44 16.57 Favored Glycine 0 N--CA 1.494 2.56 0 C-N-CA 118.306 -1.902 . . . . 0.0 111.237 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 53.2 t -126.4 126.28 68.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -100.56 125.82 46.95 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.267 -0.896 . . . . 0.0 108.773 179.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -95.28 126.92 40.92 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.493 -0.754 . . . . 0.0 109.965 -178.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.493 ' C ' ' H ' ' A' ' 54' ' ' ASP . 98.2 m-85 -114.02 130.33 56.55 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.543 -0.723 . . . . 0.0 109.918 -179.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -53.02 -8.19 0.09 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.507 -0.746 . . . . 0.0 109.328 179.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.493 ' H ' ' C ' ' A' ' 52' ' ' TYR . 41.3 t0 -74.44 0.81 13.42 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.773 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.68 14.55 79.63 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.2 p -123.15 147.86 46.36 Favored 'General case' 0 N--CA 1.503 2.203 0 O-C-N 121.487 -1.008 . . . . 0.0 109.788 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 53.0 p -129.68 140.35 51.15 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 85.0 p -107.45 155.88 19.57 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 30.1 p-10 -146.53 116.07 7.14 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.874 -1.141 . . . . 0.0 109.674 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -118.51 121.82 41.19 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -113.17 153.67 27.91 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -174.82 -177.25 43.78 Favored Glycine 0 C--N 1.282 -2.464 0 C-N-CA 119.337 -1.411 . . . . 0.0 110.847 -179.505 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -119.7 127.36 75.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.971 -0.723 . . . . 0.0 109.375 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.1 t -92.3 120.26 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.199 -0.938 . . . . 0.0 110.519 -179.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.7 p -135.76 152.08 75.35 Favored Pre-proline 0 N--CA 1.492 1.639 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.011 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -54.54 -10.18 2.18 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 121.613 1.542 . . . . 0.0 111.687 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.2 t -103.04 -26.97 12.87 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.324 -0.86 . . . . 0.0 111.23 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 78.2 p -133.34 108.87 12.38 Favored Pre-proline 0 N--CA 1.505 2.283 0 O-C-N 120.911 -1.118 . . . . 0.0 110.295 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -85.09 163.18 11.58 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 C-N-CA 122.068 1.845 . . . . 0.0 111.897 178.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.4 t -120.61 127.53 75.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.467 -0.77 . . . . 0.0 109.07 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -105.48 130.22 53.6 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.189 -0.944 . . . . 0.0 111.303 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.468 ' C ' ' H ' ' A' ' 74' ' ' GLN . 0.6 OUTLIER -92.61 4.87 52.79 Favored 'General case' 0 N--CA 1.499 1.983 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 177.703 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 48.2 p-10 -73.3 21.09 0.08 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.731 -0.605 . . . . 0.0 109.78 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.468 ' H ' ' C ' ' A' ' 72' ' ' THR . 73.5 tp60 -42.85 -83.49 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.479 -0.763 . . . . 0.0 110.744 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -113.62 74.38 0.86 Allowed 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.338 -0.851 . . . . 0.0 110.597 -179.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 83.1 mt -70.21 -34.26 58.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 120.945 -1.097 . . . . 0.0 109.303 178.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 71.3 m-20 -52.78 -43.25 65.73 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.064 -1.023 . . . . 0.0 108.698 -179.15 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 47.4 tttp -62.82 -46.37 88.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.412 -0.805 . . . . 0.0 109.051 178.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.585 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.3 OUTLIER -60.3 -46.7 88.96 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.528 -0.732 . . . . 0.0 110.103 -178.998 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -61.0 -36.75 80.28 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 120.255 -1.528 . . . . 0.0 109.406 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 38.0 tttm -66.38 -50.08 64.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.494 -0.754 . . . . 0.0 110.827 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.9 p -111.42 -26.98 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.544 -0.723 . . . . 0.0 111.805 -176.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.585 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.09 161.52 35.42 Favored Glycine 0 N--CA 1.492 2.372 0 O-C-N 120.678 -1.264 . . . . 0.0 110.294 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.459 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 16.5 t -106.99 120.97 59.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.916 -0.755 . . . . 0.0 109.27 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 61.7 tt0 -72.04 -58.2 3.64 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.155 -0.966 . . . . 0.0 110.951 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 32.7 ttmt -114.81 146.39 41.08 Favored 'General case' 0 N--CA 1.509 2.476 0 O-C-N 121.226 -0.921 . . . . 0.0 111.038 -178.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -121.59 130.36 53.45 Favored 'General case' 0 N--CA 1.501 2.098 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 21.9 mmm180 -137.29 121.68 18.24 Favored 'General case' 0 N--CA 1.505 2.312 0 O-C-N 120.929 -1.107 . . . . 0.0 109.913 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.24 133.9 53.39 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.632 -0.668 . . . . 0.0 109.387 179.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 65.5 tp -117.87 131.46 56.54 Favored 'General case' 0 N--CA 1.5 2.068 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 11.3 p -128.19 124.55 37.07 Favored 'General case' 0 N--CA 1.502 2.139 0 CA-C-O 121.39 0.614 . . . . 0.0 110.334 -179.304 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -132.67 151.13 52.05 Favored 'General case' 0 N--CA 1.505 2.312 0 O-C-N 121.617 -0.677 . . . . 0.0 110.748 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 58.1 m95 -71.2 139.04 50.0 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.31 -0.869 . . . . 0.0 109.007 179.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.472 ' O ' ' N ' ' A' ' 42' ' ' ARG . 47.3 t -111.08 119.41 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -151.7 -58.61 0.01 OUTLIER Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.261 -1.535 . . . . 0.0 109.261 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 36.9 t -85.32 126.43 33.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.189 -1.183 . . . . 0.0 109.31 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 23.2 tpt180 -62.54 -40.0 95.39 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.228 -0.92 . . . . 0.0 109.16 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 m . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.958 -1.02 . . . . 0.0 109.455 -179.951 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.767 0 N-CA-C 119.563 2.585 . . . . 0.0 119.563 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.478 ' C ' ' H ' ' A' ' 4' ' ' GLY . . . -69.23 165.25 49.55 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.461 ' CB ' ' O ' ' A' ' 2' ' ' GLY . 1.7 p 74.47 -28.04 0.19 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.342 -1.093 . . . . 0.0 109.393 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.478 ' H ' ' C ' ' A' ' 2' ' ' GLY . . . -95.5 -1.63 62.14 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 88.1 t90 -79.03 118.11 20.72 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.298 -1.119 . . . . 0.0 110.056 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . 0.516 ' C ' ' H ' ' A' ' 8' ' ' ASP . 96.1 m-20 -128.91 19.48 6.03 Favored 'General case' 0 N--CA 1.495 1.776 0 CA-C-O 121.455 0.645 . . . . 0.0 109.947 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 56.04 3.24 0.09 Allowed 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.46 -0.775 . . . . 0.0 109.521 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.516 ' H ' ' C ' ' A' ' 6' ' ' ASN . 34.0 t0 -88.44 -28.07 21.11 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.33 -0.856 . . . . 0.0 109.566 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 53.5 t30 -89.97 -0.0 57.34 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.522 -0.736 . . . . 0.0 109.556 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.8 t -110.87 129.98 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.569 -0.707 . . . . 0.0 109.868 -178.771 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -89.14 135.07 31.96 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.147 -0.97 . . . . 0.0 108.593 179.288 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -73.37 -14.27 25.33 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 121.695 1.597 . . . . 0.0 111.603 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 23.2 t -60.64 -40.12 90.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.57 179.489 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 27.5 mt-30 -82.54 -12.97 57.39 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.989 -1.069 . . . . 0.0 109.865 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.796 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 44.3 t -64.27 -37.81 88.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.049 -1.032 . . . . 0.0 109.268 179.721 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -118.23 148.63 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 20.3 ptmt -130.61 155.07 47.16 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 121.497 -0.752 . . . . 0.0 109.508 -179.078 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -98.95 117.46 33.52 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.414 -0.804 . . . . 0.0 110.521 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.5 t -126.37 85.71 2.42 Favored 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.605 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.81 62.52 1.37 Allowed Glycine 0 N--CA 1.497 2.739 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.478 HG23 ' ND2' ' A' ' 73' ' ' ASN . 33.9 m 40.01 35.74 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.746 -0.855 . . . . 0.0 110.556 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 80.3 mt-30 -132.32 162.84 30.03 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.61 -0.681 . . . . 0.0 109.401 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 41.8 m-85 -120.03 136.34 54.6 Favored 'General case' 0 N--CA 1.5 2.036 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 178.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 49.3 p -139.57 149.76 44.24 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.411 -0.806 . . . . 0.0 109.925 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.598 ' CZ ' ' SG ' ' A' ' 32' ' ' CYS . 44.1 t80 -80.47 125.21 29.67 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -84.41 84.2 7.73 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.113 -0.992 . . . . 0.0 110.577 -178.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 83.1 p -83.18 -7.0 59.68 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.128 -0.982 . . . . 0.0 109.538 179.321 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.58 -37.76 68.76 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.4 m -85.53 136.46 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.272 -1.134 . . . . 0.0 108.719 179.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 82.9 p -69.88 -40.0 75.95 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.322 -0.861 . . . . 0.0 111.442 -178.617 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.511 HG23 ' N ' ' A' ' 32' ' ' CYS . 33.7 m -50.23 -42.75 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.773 -1.204 . . . . 0.0 110.647 -178.084 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.796 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 18.9 t -61.17 -42.0 97.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.875 -1.14 . . . . 0.0 110.111 -179.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 18.0 mtp -82.12 -12.73 58.03 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.61 -1.306 . . . . 0.0 110.829 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 12.5 mm100 -60.18 -40.0 88.46 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.629 -1.295 . . . . 0.0 108.387 178.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.92 -50.61 6.3 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 62.6 tp -60.24 -41.31 92.87 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.279 -1.13 . . . . 0.0 109.446 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -60.19 -40.05 88.68 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.169 -0.957 . . . . 0.0 109.738 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -74.24 -9.51 58.68 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.156 -0.965 . . . . 0.0 109.999 -179.435 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.65 26.42 67.47 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 179.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 45.7 mmtm -100.17 -5.54 27.58 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 178.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.697 HG12 ' H ' ' A' ' 43' ' ' GLY . 55.7 t -133.3 161.01 42.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.476 ' N ' HG12 ' A' ' 41' ' ' VAL . 74.3 ttt180 -122.05 -6.82 8.92 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.564 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.697 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 135.42 -164.95 24.84 Favored Glycine 0 N--CA 1.498 2.785 0 N-CA-C 108.082 -2.007 . . . . 0.0 108.082 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.3 t -120.03 129.41 75.49 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.091 -1.241 . . . . 0.0 109.415 179.593 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.9 t -83.71 135.99 34.35 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.312 -0.868 . . . . 0.0 108.768 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 46' ' ' VAL . 12.0 p -131.45 133.17 62.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 CA-C-O 121.603 0.715 . . . . 0.0 109.813 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.8 p -124.73 151.12 45.45 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 178.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -146.17 147.01 17.68 Favored Glycine 0 N--CA 1.5 2.926 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.803 -179.029 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 75.0 t -129.67 127.18 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.803 -0.822 . . . . 0.0 108.989 179.32 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -102.64 112.88 25.83 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 23.7 m-85 -81.44 128.57 34.01 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.091 -1.006 . . . . 0.0 109.374 -179.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -114.72 134.21 55.27 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.481 -0.762 . . . . 0.0 109.499 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -61.84 -9.34 6.46 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.262 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.442 ' OD2' ' OG1' ' A' ' 56' ' ' THR . 46.1 p-10 -68.05 0.15 3.87 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.326 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 88.27 14.38 62.24 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.442 ' OG1' ' OD2' ' A' ' 54' ' ' ASP . 35.0 p -136.03 156.75 48.27 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.03 -1.277 . . . . 0.0 110.652 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 37.3 p -131.23 132.94 45.0 Favored 'General case' 0 N--CA 1.498 1.937 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 83.7 p -91.59 160.01 15.61 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 6.0 p30 -152.15 115.01 4.62 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.822 -1.174 . . . . 0.0 109.985 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -118.01 127.77 54.13 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 178.618 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 78.7 tttt -115.44 145.71 42.31 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.155 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.71 170.07 42.09 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.2 t -110.56 127.53 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.521 -0.987 . . . . 0.0 109.574 -179.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 69.3 t -94.0 118.07 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.086 -1.009 . . . . 0.0 109.491 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.518 ' O ' ' N ' ' A' ' 68' ' ' THR . 12.0 p -125.62 146.25 54.16 Favored Pre-proline 0 N--CA 1.497 1.916 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 178.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_exo -35.9 -27.85 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.344 0 C-N-CA 122.433 2.089 . . . . 0.0 112.884 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.474 ' N ' ' O ' ' A' ' 65' ' ' THR . 5.8 t -106.81 -10.57 16.01 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.433 -0.792 . . . . 0.0 110.528 -179.657 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 65' ' ' THR . 88.7 m -126.33 106.58 24.33 Favored Pre-proline 0 N--CA 1.505 2.31 0 O-C-N 121.04 -1.038 . . . . 0.0 110.981 -179.175 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -90.44 162.48 4.46 Favored 'Trans proline' 0 N--CA 1.487 1.107 0 C-N-CA 122.404 2.069 . . . . 0.0 111.351 177.568 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 78.4 t -119.84 128.06 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.239 0 O-C-N 121.229 -0.92 . . . . 0.0 108.91 179.318 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -101.25 135.15 43.2 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.298 -0.876 . . . . 0.0 110.16 -179.206 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.479 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.1 OUTLIER -106.02 19.68 20.15 Favored 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 178.332 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.585 HD22 ' N ' ' A' ' 73' ' ' ASN . 1.6 m120 -64.28 42.88 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.848 -178.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.479 ' N ' ' O ' ' A' ' 72' ' ' THR . 25.2 mm100 -51.48 170.27 0.05 OUTLIER 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.106 -0.996 . . . . 0.0 109.114 179.213 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -53.05 114.0 1.3 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.054 -1.029 . . . . 0.0 109.621 -179.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 97.5 mt -86.46 -16.06 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.384 -0.823 . . . . 0.0 110.246 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -59.84 -39.66 85.92 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 179.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 71.1 mttt -63.0 -50.23 71.57 Favored 'General case' 0 N--CA 1.492 1.634 0 CA-C-O 122.496 1.141 . . . . 0.0 109.551 179.436 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.587 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -59.96 -50.68 72.79 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.515 -177.33 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -61.39 -36.11 79.35 Favored 'General case' 0 C--N 1.292 -1.9 0 O-C-N 120.208 -1.558 . . . . 0.0 109.031 178.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -65.58 -50.27 65.75 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.447 -0.783 . . . . 0.0 111.093 -179.312 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.3 m -115.77 -24.77 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.3 0 O-C-N 121.271 -0.893 . . . . 0.0 111.609 -177.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 91.52 166.55 40.23 Favored Glycine 0 N--CA 1.492 2.413 0 O-C-N 120.71 -1.244 . . . . 0.0 110.068 179.372 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 49.0 t -106.96 128.54 61.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.926 -0.749 . . . . 0.0 109.057 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -79.99 -66.59 0.86 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.945 -1.097 . . . . 0.0 109.838 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 57.4 mttm -116.55 140.85 48.93 Favored 'General case' 0 N--CA 1.504 2.255 0 O-C-N 121.291 -0.881 . . . . 0.0 111.051 -179.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 70.5 t80 -121.05 132.75 55.07 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 178.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 42.6 mtm105 -136.85 129.97 31.07 Favored 'General case' 0 N--CA 1.504 2.258 0 O-C-N 121.119 -0.988 . . . . 0.0 110.743 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.31 135.47 54.22 Favored 'General case' 0 N--CA 1.499 1.983 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.9 mt -118.51 130.28 55.84 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.427 -0.796 . . . . 0.0 109.599 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 20.1 p -128.61 125.07 37.41 Favored 'General case' 0 N--CA 1.503 2.218 0 CA-C-O 121.677 0.751 . . . . 0.0 110.645 -179.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -132.96 154.37 50.53 Favored 'General case' 0 N--CA 1.502 2.159 0 CA-C-O 121.412 0.625 . . . . 0.0 110.638 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 80.2 m95 -69.87 142.08 53.09 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 35.4 t -116.61 120.81 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.133 0 O-C-N 121.332 -0.855 . . . . 0.0 109.202 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 161.03 -140.14 6.48 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 89.1 p -72.27 158.69 35.37 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.076 -1.249 . . . . 0.0 109.407 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.8 mtm180 -64.52 140.01 58.82 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.301 -0.874 . . . . 0.0 109.863 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.3 m . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 117.896 -1.05 . . . . 0.0 109.219 179.586 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.886 0 N-CA-C 119.408 2.523 . . . . 0.0 119.408 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.81 143.6 32.61 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.7 m -99.74 122.83 43.3 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.368 -1.078 . . . . 0.0 109.096 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 136.36 78.67 0.09 OUTLIER Glycine 0 N--CA 1.496 2.641 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 -179.607 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 63.5 t90 -59.63 125.94 25.63 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.332 -1.099 . . . . 0.0 109.173 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 80.7 m-20 -134.91 24.16 3.6 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.765 -0.585 . . . . 0.0 109.662 179.142 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 51.86 36.97 19.49 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -178.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.542 ' N ' ' OD1' ' A' ' 8' ' ' ASP . 11.3 p-10 -47.74 -79.74 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.787 -0.571 . . . . 0.0 111.367 -178.533 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.517 ' H ' ' CG ' ' A' ' 8' ' ' ASP . 13.9 m120 -144.42 37.66 1.24 Allowed 'General case' 0 N--CA 1.497 1.899 0 O-C-N 120.898 -1.126 . . . . 0.0 109.885 -178.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.446 ' H ' HG23 ' A' ' 10' ' ' VAL . 0.2 OUTLIER -81.49 152.55 4.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 120.94 -1.1 . . . . 0.0 108.398 -179.11 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.6 m-20 -78.63 131.5 67.72 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.179 -0.951 . . . . 0.0 109.879 -178.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -80.61 -15.08 11.16 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.128 1.885 . . . . 0.0 111.812 179.438 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 94.2 p -64.46 -35.75 81.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.48 -0.763 . . . . 0.0 110.506 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -69.98 -23.7 63.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.162 -0.961 . . . . 0.0 109.812 -179.249 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.552 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 60.8 m -68.26 -27.66 66.54 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.209 -0.932 . . . . 0.0 109.64 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.7 pp -118.49 133.0 66.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.498 -0.751 . . . . 0.0 109.19 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -112.05 142.15 44.84 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.609 ' CD ' ' H ' ' A' ' 18' ' ' GLN . 0.1 OUTLIER -97.55 128.48 44.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.257 -0.902 . . . . 0.0 109.694 -179.411 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.549 ' O ' ' N ' ' A' ' 21' ' ' VAL . 25.3 t -107.4 118.6 37.15 Favored 'General case' 0 N--CA 1.495 1.825 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.42 -78.81 0.01 OUTLIER Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.549 ' N ' ' O ' ' A' ' 19' ' ' SER . 9.8 p -156.7 32.95 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.319 -1.106 . . . . 0.0 108.629 179.268 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.446 HE21 ' HB2' ' A' ' 69' ' ' PRO . 46.3 tt0 -129.22 161.56 29.86 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -115.19 135.06 54.58 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.322 -0.861 . . . . 0.0 109.261 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 23.9 p -135.8 150.01 49.3 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 35.8 t80 -83.79 122.09 28.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.347 -0.846 . . . . 0.0 109.663 -179.039 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -84.55 83.63 7.94 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.362 -0.837 . . . . 0.0 109.742 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 96.3 p -78.48 -4.91 50.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.231 -0.918 . . . . 0.0 109.091 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -56.68 -39.01 85.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 -179.437 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.445 ' H ' HG22 ' A' ' 29' ' ' VAL . 10.5 m -81.06 133.46 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 120.877 -1.366 . . . . 0.0 109.741 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.5 m -63.33 -34.47 77.77 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.544 -0.723 . . . . 0.0 111.929 -178.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.455 HG13 ' N ' ' A' ' 32' ' ' CYS . 7.2 p -59.98 -40.01 81.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 120.608 -1.307 . . . . 0.0 110.796 -177.789 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.552 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 77.6 m -66.25 -40.04 89.92 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.657 -1.277 . . . . 0.0 109.719 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 7.7 mmt -78.69 -19.14 53.15 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.008 -1.058 . . . . 0.0 109.123 179.607 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -60.75 -41.04 94.62 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.216 -0.928 . . . . 0.0 108.958 179.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -73.59 -43.61 35.85 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 2.1 mt -65.85 -39.98 91.27 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.254 -1.145 . . . . 0.0 108.94 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.32 -40.03 94.98 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.07 -1.019 . . . . 0.0 109.82 179.05 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -76.63 -10.79 59.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.214 -0.929 . . . . 0.0 110.086 -179.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.28 28.49 69.86 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.404 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -103.64 -6.01 22.05 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.784 HG12 ' H ' ' A' ' 43' ' ' GLY . 45.9 t -133.72 159.88 42.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 115.51 -0.768 . . . . 0.0 108.987 -179.251 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.507 ' N ' ' O ' ' A' ' 94' ' ' VAL . 70.3 mtp85 -120.91 -7.71 9.47 Favored 'General case' 0 N--CA 1.5 2.053 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.355 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.784 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.73 -159.85 25.51 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -179.035 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.4 t -120.67 129.74 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.145 0 O-C-N 121.297 -1.12 . . . . 0.0 109.32 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.0 t -86.65 140.02 30.22 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.303 -0.873 . . . . 0.0 108.98 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.443 HG13 ' O ' ' A' ' 46' ' ' VAL . 9.9 p -131.9 132.46 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.74 0.781 . . . . 0.0 109.829 179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 81.9 p -123.29 148.79 45.57 Favored 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -144.64 144.33 13.15 Favored Glycine 0 N--CA 1.5 2.962 0 C-N-CA 119.219 -1.467 . . . . 0.0 111.375 -178.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 85.6 t -121.59 130.01 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.545 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.531 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 9.9 m-85 -106.79 119.89 40.53 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.783 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -98.67 120.82 39.76 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.422 -0.799 . . . . 0.0 109.07 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.529 ' O ' ' N ' ' A' ' 54' ' ' ASP . 94.1 m-85 -105.56 131.33 53.09 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.345 -0.847 . . . . 0.0 109.164 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 49.2 t30 -46.6 -15.56 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.245 -0.909 . . . . 0.0 109.166 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 52' ' ' TYR . 35.9 t0 -69.71 -0.81 7.59 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.578 -0.701 . . . . 0.0 109.392 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.4 23.19 65.89 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 120.047 -1.073 . . . . 0.0 110.611 179.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.2 p -118.76 150.27 40.06 Favored 'General case' 0 N--CA 1.504 2.256 0 O-C-N 121.297 -1.12 . . . . 0.0 110.046 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 63.9 p -135.27 128.98 32.87 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.501 -0.75 . . . . 0.0 109.783 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 45.9 t -118.7 145.87 45.17 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 55.9 t-20 -135.8 128.08 30.12 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.753 -1.217 . . . . 0.0 109.796 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -117.15 122.15 43.27 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 178.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -107.52 144.5 34.41 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -162.68 170.99 38.4 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.634 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.7 t -113.98 125.39 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.555 -0.967 . . . . 0.0 109.42 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -90.26 117.9 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.368 -0.833 . . . . 0.0 110.232 -179.152 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.517 ' O ' ' N ' ' A' ' 67' ' ' SER . 25.9 p -125.74 144.4 48.2 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.402 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -38.4 -21.29 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.157 1.905 . . . . 0.0 113.276 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 65' ' ' THR . 10.4 m -108.64 -11.37 15.1 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.197 -0.939 . . . . 0.0 111.296 -178.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 55.1 p -130.69 107.87 15.63 Favored Pre-proline 0 N--CA 1.504 2.242 0 O-C-N 121.011 -1.056 . . . . 0.0 110.392 -179.201 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.446 ' HB2' HE21 ' A' ' 22' ' ' GLN . 40.6 Cg_endo -91.25 164.42 3.69 Favored 'Trans proline' 0 N--CA 1.49 1.314 0 C-N-CA 122.605 2.203 . . . . 0.0 112.135 178.604 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 48.9 t -124.42 130.15 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.127 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 31.3 m120 -100.77 138.19 38.16 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.082 -1.012 . . . . 0.0 110.502 -178.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -98.5 -19.37 17.69 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 121.02 -1.05 . . . . 0.0 109.021 179.17 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 44.4 p-10 -87.41 44.42 1.18 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.038 -1.039 . . . . 0.0 108.442 179.118 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -59.71 -49.18 78.74 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.519 -0.872 . . . . 0.0 108.741 -179.334 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -115.17 75.8 0.96 Allowed 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 107.845 -1.168 . . . . 0.0 107.845 178.213 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 10.4 tt -73.33 -28.64 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.28 -0.887 . . . . 0.0 110.116 -178.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -60.06 -49.66 76.79 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.61 -178.067 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.414 ' CG ' ' N ' ' A' ' 79' ' ' THR . 0.1 OUTLIER -61.08 -39.94 91.82 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.569 -1.332 . . . . 0.0 108.34 179.353 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.586 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.4 m -60.04 -43.96 94.99 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.397 0.618 . . . . 0.0 109.772 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -61.63 -38.5 87.89 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 120.596 -1.315 . . . . 0.0 109.987 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.4 ttmm -70.04 -44.85 68.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.139 -0.976 . . . . 0.0 111.224 -179.266 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.1 p -112.08 -28.75 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.075 0 O-C-N 121.311 -0.868 . . . . 0.0 112.098 -176.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.586 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 84.69 161.43 33.52 Favored Glycine 0 N--CA 1.491 2.339 0 O-C-N 120.66 -1.275 . . . . 0.0 110.177 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 90.0 t -109.51 124.85 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.14 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -80.05 -58.62 3.07 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.247 -0.908 . . . . 0.0 110.952 -178.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 35.4 ttpt -114.11 137.59 51.53 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.267 -0.895 . . . . 0.0 110.809 -178.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 54.9 t80 -123.78 125.89 45.5 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.129 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 76.0 mmt-85 -130.98 132.01 44.76 Favored 'General case' 0 N--CA 1.506 2.336 0 O-C-N 121.137 -0.977 . . . . 0.0 110.525 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -121.26 138.09 54.39 Favored 'General case' 0 N--CA 1.499 2.018 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 179.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.671 HD23 ' N ' ' A' ' 91' ' ' THR . 1.6 tt -119.95 131.17 55.1 Favored 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.671 ' N ' HD23 ' A' ' 90' ' ' LEU . 22.1 p -126.59 126.3 43.39 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.507 -0.745 . . . . 0.0 110.706 -179.243 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 -133.5 154.57 50.71 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.855 -0.528 . . . . 0.0 109.793 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -67.58 139.4 56.9 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.163 -0.961 . . . . 0.0 109.051 179.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.507 ' O ' ' N ' ' A' ' 42' ' ' ARG . 41.4 t -111.84 121.29 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.323 -0.861 . . . . 0.0 109.013 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 136.03 22.24 0.59 Allowed Glycine 0 N--CA 1.497 2.739 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 179.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 42.7 t -81.71 128.32 33.85 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.105 -1.232 . . . . 0.0 109.279 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 93.9 mtt-85 -76.74 145.17 38.79 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.206 -0.934 . . . . 0.0 109.596 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.3 t . . . . . 0 N--CA 1.489 1.506 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.422 -179.805 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.881 0 N-CA-C 119.6 2.6 . . . . 0.0 119.6 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 69.72 -119.3 8.97 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 85.3 p 49.76 49.68 19.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.375 -1.073 . . . . 0.0 109.989 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 94.93 31.15 7.87 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 179.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . 0.515 ' CE3' ' OE1' ' A' ' 34' ' ' GLN . 10.0 t90 -66.05 143.26 57.45 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.868 -1.372 . . . . 0.0 109.366 179.204 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . 0.88 HD22 ' H ' ' A' ' 6' ' ' ASN . 0.0 OUTLIER -131.65 126.82 35.61 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.073 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -61.13 -2.05 0.56 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.967 -1.083 . . . . 0.0 108.464 179.655 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.509 ' H ' ' C ' ' A' ' 6' ' ' ASN . 66.2 t0 -69.87 -39.84 76.09 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.681 -0.637 . . . . 0.0 110.761 -179.223 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 32.7 m120 -84.38 3.56 35.37 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.004 -1.06 . . . . 0.0 110.4 -178.312 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.0 t -116.31 129.8 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.347 -0.846 . . . . 0.0 109.129 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 -84.68 138.3 38.11 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.016 -1.053 . . . . 0.0 109.212 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -76.63 -24.74 10.07 Favored 'Trans proline' 0 N--CA 1.494 1.531 0 C-N-CA 121.938 1.758 . . . . 0.0 111.673 179.314 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 55.4 m -60.26 -39.89 88.38 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.304 -0.872 . . . . 0.0 110.566 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.7 mt-30 -77.89 -19.82 54.06 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.182 -0.949 . . . . 0.0 110.287 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.637 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 49.6 m -65.66 -29.61 70.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.005 -1.06 . . . . 0.0 109.685 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -118.6 139.64 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.132 0 O-C-N 121.427 -0.796 . . . . 0.0 109.272 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -124.31 144.25 50.1 Favored 'General case' 0 N--CA 1.498 1.955 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 -179.731 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 64.8 tt0 -96.74 124.37 40.7 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.212 -0.93 . . . . 0.0 109.676 -179.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.497 ' O ' ' N ' ' A' ' 21' ' ' VAL . 70.3 m -109.52 129.95 55.54 Favored 'General case' 0 N--CA 1.498 1.967 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.36 -94.06 0.01 OUTLIER Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.497 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.8 t -137.17 28.84 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 121.427 -1.043 . . . . 0.0 109.319 -179.386 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -131.38 163.15 28.53 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.577 -0.702 . . . . 0.0 110.359 -179.571 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -118.76 139.94 50.75 Favored 'General case' 0 N--CA 1.503 2.183 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 70.9 p -139.82 157.01 46.43 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.272 -0.893 . . . . 0.0 109.651 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -89.65 121.69 32.07 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.539 -0.726 . . . . 0.0 109.103 -179.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 -82.47 86.09 6.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.129 -0.982 . . . . 0.0 110.105 -179.368 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.48 ' C ' ' H ' ' A' ' 29' ' ' VAL . 92.1 p -81.58 -7.04 59.54 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.243 -0.91 . . . . 0.0 109.38 179.391 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.66 -8.22 0.34 Allowed Glycine 0 N--CA 1.489 2.196 0 N-CA-C 110.162 -1.175 . . . . 0.0 110.162 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.48 ' H ' ' C ' ' A' ' 27' ' ' SER . 20.4 m -113.31 132.44 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.409 -1.054 . . . . 0.0 108.992 179.529 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.8 m -69.87 -30.07 67.45 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.426 -0.796 . . . . 0.0 111.107 -178.814 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.493 HG23 ' N ' ' A' ' 32' ' ' CYS . 18.0 m -60.16 -40.34 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 120.672 -1.268 . . . . 0.0 110.583 -178.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.637 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 96.5 m -65.81 -40.02 91.47 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.83 -1.169 . . . . 0.0 110.01 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 35.3 mtp -84.37 -11.92 55.42 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.901 -1.125 . . . . 0.0 109.303 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.515 ' OE1' ' CE3' ' A' ' 5' ' ' TRP . 12.6 tm0? -61.66 -42.19 98.57 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.8 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -75.83 -42.68 24.97 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 179.16 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.5 tp -60.2 -41.23 92.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.276 -1.132 . . . . 0.0 108.96 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -62.61 -40.68 97.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.306 -0.871 . . . . 0.0 109.815 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -63.07 -28.27 69.97 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.342 -0.849 . . . . 0.0 109.873 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.69 17.96 57.4 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 92.4 mttt -100.84 -1.54 34.5 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.742 HG12 ' H ' ' A' ' 43' ' ' GLY . 97.4 t -132.3 157.75 43.14 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 115.189 -0.914 . . . . 0.0 108.713 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.431 ' N ' HG12 ' A' ' 41' ' ' VAL . 98.4 mtt180 -119.99 -7.62 9.9 Favored 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 179.149 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.742 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 135.7 -160.08 24.41 Favored Glycine 0 N--CA 1.5 2.934 0 N-CA-C 108.22 -1.952 . . . . 0.0 108.22 -179.564 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.1 t -119.98 128.03 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.16 -1.2 . . . . 0.0 108.795 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.5 p -82.56 139.64 33.72 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.147 -0.971 . . . . 0.0 108.924 179.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.485 HG13 ' O ' ' A' ' 46' ' ' VAL . 12.7 p -120.05 127.62 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 CA-C-O 121.827 0.822 . . . . 0.0 108.878 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.0 p -128.06 149.86 50.2 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -168.92 159.44 32.53 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 117.922 -2.085 . . . . 0.0 111.682 -179.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 89.2 t -131.32 136.84 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.943 -0.739 . . . . 0.0 109.133 179.255 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.494 ' CZ ' ' OG1' ' A' ' 72' ' ' THR . 55.7 m-85 -108.18 123.71 49.16 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.006 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -95.91 126.51 41.21 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 120.735 -1.228 . . . . 0.0 109.751 -179.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.487 ' C ' ' N ' ' A' ' 54' ' ' ASP . 78.2 m-85 -112.0 129.79 56.08 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.453 -0.779 . . . . 0.0 109.913 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 31.9 t-20 -52.89 -10.83 0.18 Allowed 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 178.459 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.487 ' N ' ' C ' ' A' ' 52' ' ' TYR . 9.3 t70 -67.07 -2.68 5.82 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.56 19.0 60.89 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.114 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.4 p -133.46 152.07 51.86 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.022 -1.281 . . . . 0.0 110.812 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 68.9 p -130.33 142.39 50.53 Favored 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.419 0.628 . . . . 0.0 109.859 -179.476 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -117.55 140.83 49.1 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 178.681 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -125.28 116.24 21.63 Favored 'General case' 0 N--CA 1.496 1.839 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -117.49 121.04 39.93 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -113.22 149.8 33.23 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 179.502 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.2 -175.99 38.88 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.317 -1.421 . . . . 0.0 110.844 -179.53 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 66.8 t -122.49 127.82 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.915 -0.756 . . . . 0.0 109.944 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 21.8 t -99.3 118.61 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.365 -0.834 . . . . 0.0 110.256 -179.267 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.413 ' O ' ' N ' ' A' ' 67' ' ' SER . 29.9 p -118.89 149.83 47.4 Favored Pre-proline 0 N--CA 1.494 1.732 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.304 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -38.51 -28.02 0.12 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 121.845 1.697 . . . . 0.0 113.013 -179.552 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.413 ' N ' ' O ' ' A' ' 65' ' ' THR . 53.5 m -108.58 -3.58 17.89 Favored 'General case' 0 N--CA 1.503 2.225 0 O-C-N 121.345 -0.847 . . . . 0.0 111.677 -178.767 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 7.5 m -124.76 106.57 29.26 Favored Pre-proline 0 N--CA 1.508 2.452 0 O-C-N 120.84 -1.163 . . . . 0.0 111.008 -179.036 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -92.61 164.76 2.83 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 122.818 2.345 . . . . 0.0 111.562 177.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.8 t -119.88 130.04 74.69 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.19 0 O-C-N 121.261 -0.899 . . . . 0.0 108.802 179.62 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -99.91 121.7 41.72 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.304 -0.872 . . . . 0.0 109.997 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.494 ' OG1' ' CZ ' ' A' ' 50' ' ' PHE . 0.2 OUTLIER -100.45 5.45 44.22 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.075 -1.016 . . . . 0.0 108.855 179.41 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.422 ' O ' ' O ' ' A' ' 74' ' ' GLN . 47.9 p-10 -73.42 46.52 0.2 Allowed 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.323 -0.861 . . . . 0.0 109.649 -179.379 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.422 ' O ' ' O ' ' A' ' 73' ' ' ASN . 65.4 tt0 -47.72 -91.9 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.132 -0.98 . . . . 0.0 109.208 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -113.78 104.49 12.25 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.481 -0.762 . . . . 0.0 109.762 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 77.6 mt -80.07 -27.02 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 120.951 -1.093 . . . . 0.0 108.765 179.084 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.44 ' HA ' HD21 ' A' ' 80' ' ' ASN . 27.0 t-20 -59.71 -40.0 86.5 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.559 ' O ' HG22 ' A' ' 82' ' ' VAL . 18.5 ttmm -69.59 -48.55 59.78 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.209 -0.932 . . . . 0.0 108.791 177.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.61 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.5 OUTLIER -61.84 -51.15 69.43 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.805 -1.184 . . . . 0.0 110.801 -178.551 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 81' ' ' LYS . 29.6 p30 -66.25 -27.11 67.7 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 119.656 -1.902 . . . . 0.0 108.925 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . 0.52 ' N ' ' OD1' ' A' ' 80' ' ' ASN . 37.4 tptt -69.94 -49.05 55.65 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.348 -0.845 . . . . 0.0 110.431 179.366 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 78' ' ' LYS . 2.5 m -114.73 -26.04 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.351 0 O-C-N 121.039 -1.038 . . . . 0.0 110.859 -178.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.61 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.87 161.28 36.01 Favored Glycine 0 N--CA 1.493 2.46 0 O-C-N 120.712 -1.243 . . . . 0.0 110.41 179.097 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -100.92 117.52 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -74.75 -59.28 2.8 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.115 -0.991 . . . . 0.0 111.613 -178.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 54.3 mttp -114.29 135.41 54.1 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.33 -0.856 . . . . 0.0 110.983 -177.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 61.2 t80 -122.7 131.81 53.97 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.562 -0.711 . . . . 0.0 109.599 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -139.18 130.76 27.25 Favored 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.214 -0.929 . . . . 0.0 110.576 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -126.95 133.68 50.57 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.617 -0.677 . . . . 0.0 110.309 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 64.9 tp -120.05 131.29 55.05 Favored 'General case' 0 N--CA 1.503 2.181 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -130.48 131.13 44.99 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.528 -0.732 . . . . 0.0 111.181 -179.308 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.466 ' N ' ' CD ' ' A' ' 92' ' ' GLU . 4.6 pm0 -134.22 153.49 51.82 Favored 'General case' 0 N--CA 1.505 2.289 0 CA-C-O 121.35 0.595 . . . . 0.0 110.512 179.101 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 36.7 m95 -70.0 138.97 52.66 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 47.7 t -110.23 119.81 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.442 -0.787 . . . . 0.0 108.891 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -177.95 -173.26 43.23 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 60.7 p -70.09 150.05 46.98 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.06 -1.259 . . . . 0.0 108.968 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 13.7 tpt180 -86.2 129.9 34.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.007 -1.058 . . . . 0.0 109.064 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.9 p . . . . . 0 N--CA 1.494 1.735 0 CA-C-O 118.026 -0.987 . . . . 0.0 109.183 179.993 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.924 0 N-CA-C 119.539 2.576 . . . . 0.0 119.539 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -84.63 -1.77 89.02 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.4 t -79.99 138.08 36.97 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.267 -1.137 . . . . 0.0 109.443 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 128.48 -128.04 5.82 Favored Glycine 0 N--CA 1.5 2.924 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 -179.759 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 88.1 t90 -66.41 120.57 13.56 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.271 -1.135 . . . . 0.0 109.548 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 24.6 p-10 -132.45 24.84 4.45 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 51.63 40.07 26.45 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.318 -0.864 . . . . 0.0 108.678 -179.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -57.61 -72.04 0.09 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.677 -0.64 . . . . 0.0 110.892 -178.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.4 p-10 -147.38 42.33 1.08 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.051 -1.031 . . . . 0.0 108.22 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.401 HG23 ' HE1' ' A' ' 93' ' ' TRP . 10.3 m -80.5 139.95 17.4 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 O-C-N 121.463 -0.773 . . . . 0.0 109.301 -178.191 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -70.69 126.35 92.19 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.436 -0.79 . . . . 0.0 110.297 -178.442 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -82.91 -17.36 7.0 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.402 2.068 . . . . 0.0 111.53 178.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 57.3 m -60.04 -39.64 86.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.504 -0.747 . . . . 0.0 110.112 -179.427 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 95.3 mm-40 -65.98 -23.91 66.68 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.106 -0.997 . . . . 0.0 109.468 -179.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.615 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 36.0 t -65.26 -34.92 79.49 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.282 -0.886 . . . . 0.0 110.208 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -119.93 146.51 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 O-C-N 121.337 -0.852 . . . . 0.0 109.701 -179.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 53.4 mtmt -126.47 157.99 37.21 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 121.531 -0.73 . . . . 0.0 109.252 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -100.22 113.41 26.07 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.123 -0.986 . . . . 0.0 109.876 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.2 m -125.37 121.34 33.64 Favored 'General case' 0 N--CA 1.5 2.032 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.43 ' O ' ' N ' ' A' ' 22' ' ' GLN . . . 57.56 64.34 4.46 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' A' ' 20' ' ' GLY . 35.0 m 37.03 31.47 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.866 -0.785 . . . . 0.0 110.94 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.43 ' N ' ' O ' ' A' ' 20' ' ' GLY . 84.0 mt-30 -131.67 160.0 36.7 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.637 -0.664 . . . . 0.0 109.292 179.484 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 52.3 m-85 -119.32 140.09 50.88 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.074 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 33.7 p -135.14 148.09 49.65 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.525 -0.734 . . . . 0.0 109.314 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -84.24 120.02 25.73 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -86.23 105.85 16.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.096 -1.002 . . . . 0.0 110.516 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 79.3 p -90.78 -0.11 57.61 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.579 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -66.24 -9.75 49.93 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.416 HG23 ' SG ' ' A' ' 32' ' ' CYS . 0.2 OUTLIER -103.78 124.72 58.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 179.138 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 44.1 t -59.94 -40.13 87.93 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.364 -0.835 . . . . 0.0 111.828 -178.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.7 p -53.51 -34.96 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.751 -1.218 . . . . 0.0 110.143 -178.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.615 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 22.1 m -61.31 -44.74 96.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.996 -1.065 . . . . 0.0 110.82 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 8.0 mmt -77.21 -23.48 51.39 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.838 -1.164 . . . . 0.0 110.857 -179.324 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -60.07 -39.99 87.94 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.708 -1.245 . . . . 0.0 109.748 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -74.84 -46.85 15.92 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.5 mt -66.26 -39.4 89.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.451 -1.029 . . . . 0.0 109.553 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -60.13 -39.95 88.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.262 -0.899 . . . . 0.0 110.147 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -81.5 -7.76 59.63 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.109 -0.994 . . . . 0.0 110.792 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.4 28.13 70.26 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 32.1 mmtp -101.05 -7.43 23.24 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 178.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.791 HG12 ' H ' ' A' ' 43' ' ' GLY . 41.6 t -131.93 156.98 43.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 84.3 mtp180 -118.33 -6.5 10.79 Favored 'General case' 0 N--CA 1.5 2.052 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 179.521 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.791 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 137.19 -156.37 23.34 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 108.084 -2.006 . . . . 0.0 108.084 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.3 t -124.69 129.45 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 CA-C-N 118.644 1.222 . . . . 0.0 109.642 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.4 m -84.43 132.87 34.52 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.028 -1.045 . . . . 0.0 108.342 179.05 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.455 HG13 ' O ' ' A' ' 46' ' ' VAL . 15.0 p -130.04 131.6 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.555 -0.715 . . . . 0.0 109.435 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 54.4 p -122.86 144.71 49.02 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.237 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -135.12 137.22 9.06 Favored Glycine 0 N--CA 1.5 2.958 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 96.4 t -123.41 130.56 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.694 -0.886 . . . . 0.0 109.321 179.402 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -102.82 122.47 44.58 Favored 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -98.2 127.87 44.37 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.367 -0.833 . . . . 0.0 109.149 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.522 ' O ' ' N ' ' A' ' 54' ' ' ASP . 93.1 m-85 -113.04 128.12 56.41 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.525 -0.735 . . . . 0.0 109.364 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.51 ' OD1' ' N ' ' A' ' 53' ' ' ASN . 0.8 OUTLIER -42.95 -19.83 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.528 -0.732 . . . . 0.0 109.786 179.796 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 52' ' ' TYR . 8.6 t70 -67.97 0.79 3.16 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.473 -0.767 . . . . 0.0 109.395 -179.08 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.72 23.35 67.35 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.554 179.011 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.5 p -119.98 146.35 45.92 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.364 -1.08 . . . . 0.0 109.617 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 38.8 p -130.89 140.01 50.17 Favored 'General case' 0 N--CA 1.497 1.884 0 CA-C-O 121.571 0.7 . . . . 0.0 109.998 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.434 ' C ' ' ND2' ' A' ' 59' ' ' ASN . 46.4 t -118.65 140.15 50.37 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 178.324 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.692 HD22 ' N ' ' A' ' 59' ' ' ASN . 0.3 OUTLIER -129.99 118.66 21.95 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 120.973 -1.079 . . . . 0.0 109.756 -179.414 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -115.55 125.46 53.02 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 178.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -113.08 148.93 34.23 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.5 166.24 39.43 Favored Glycine 0 C--N 1.288 -2.095 0 N-CA-C 108.839 -1.704 . . . . 0.0 108.839 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.0 t -109.08 125.38 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.506 -0.997 . . . . 0.0 108.815 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.506 HG13 ' O ' ' A' ' 64' ' ' VAL . 3.4 p -94.35 121.8 45.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.41 -0.806 . . . . 0.0 109.984 -179.411 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.415 ' O ' ' N ' ' A' ' 68' ' ' THR . 8.2 p -127.75 149.97 71.94 Favored Pre-proline 0 N--CA 1.499 1.989 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.403 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -34.87 -38.55 0.16 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.52 2.147 . . . . 0.0 113.353 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.9 t -99.02 -6.52 28.39 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.039 -1.038 . . . . 0.0 111.026 -179.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.415 ' N ' ' O ' ' A' ' 65' ' ' THR . 34.7 m -128.07 106.89 19.93 Favored Pre-proline 0 N--CA 1.505 2.291 0 O-C-N 121.005 -1.059 . . . . 0.0 110.509 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -90.79 163.25 4.09 Favored 'Trans proline' 0 N--CA 1.488 1.201 0 C-N-CA 122.507 2.138 . . . . 0.0 111.624 178.171 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 58.6 t -120.43 130.13 74.78 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.297 0 O-C-N 121.275 -0.89 . . . . 0.0 108.783 179.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 -101.33 127.78 47.8 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.126 -0.983 . . . . 0.0 111.495 -178.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.91 11.15 30.52 Favored 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 177.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.415 ' O ' ' O ' ' A' ' 74' ' ' GLN . 45.6 p-10 -77.97 57.88 1.84 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.514 -0.741 . . . . 0.0 110.214 -178.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.415 ' O ' ' O ' ' A' ' 73' ' ' ASN . 27.3 mt-30 -60.91 -158.84 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.048 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -63.68 102.13 0.42 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.722 -1.236 . . . . 0.0 108.717 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 96.8 mt -79.93 -18.1 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.422 -0.799 . . . . 0.0 110.398 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 -59.99 -40.68 90.0 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.883 -1.136 . . . . 0.0 108.413 -179.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 4.1 mtpm? -62.42 -47.93 81.94 Favored 'General case' 0 N--CA 1.495 1.786 0 CA-C-O 122.419 1.104 . . . . 0.0 108.78 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.583 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER -60.04 -42.93 95.48 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.078 -0.964 . . . . 0.0 109.592 -178.284 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -62.55 -36.99 84.4 Favored 'General case' 0 C--N 1.293 -1.879 0 O-C-N 120.494 -1.379 . . . . 0.0 108.899 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 53.9 tttt -72.01 -44.49 63.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.091 -1.006 . . . . 0.0 111.107 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.3 p -112.88 -28.18 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.186 0 O-C-N 121.341 -0.85 . . . . 0.0 111.972 -176.61 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.77 165.25 40.68 Favored Glycine 0 N--CA 1.493 2.5 0 O-C-N 120.519 -1.363 . . . . 0.0 110.893 178.545 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.424 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 30.0 t -110.26 124.32 66.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.064 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 28.1 mt-30 -80.99 -65.17 1.05 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.004 -1.06 . . . . 0.0 110.121 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -114.77 139.94 49.31 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.363 -0.836 . . . . 0.0 110.899 -179.173 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 62.8 t80 -121.38 127.63 51.4 Favored 'General case' 0 N--CA 1.495 1.805 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.161 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -132.06 131.27 42.28 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 120.994 -1.066 . . . . 0.0 110.664 -179.424 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.485 ' C ' HD12 ' A' ' 90' ' ' LEU . . . -122.09 131.02 53.76 Favored 'General case' 0 N--CA 1.501 2.12 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 179.229 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.543 HD12 ' N ' ' A' ' 90' ' ' LEU . 8.7 mp -111.02 130.92 55.44 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.38 -0.825 . . . . 0.0 109.315 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.8 p -124.41 124.08 41.55 Favored 'General case' 0 N--CA 1.506 2.36 0 O-C-N 121.392 -0.817 . . . . 0.0 110.675 -179.625 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 -134.0 146.63 50.6 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.791 -0.568 . . . . 0.0 109.779 179.567 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . 0.401 ' HE1' HG23 ' A' ' 10' ' ' VAL . 87.8 m95 -69.17 139.61 54.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.733 -1.229 . . . . 0.0 108.587 178.649 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 44.7 t -108.86 119.62 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.025 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.749 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 163.09 -172.83 39.19 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 108.345 -1.902 . . . . 0.0 108.345 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 28.0 m -70.19 147.18 50.13 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.965 -1.315 . . . . 0.0 109.93 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 74.9 mtp180 -92.4 -9.99 39.69 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.218 -0.926 . . . . 0.0 109.828 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.8 t . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 117.904 -1.046 . . . . 0.0 109.445 -179.581 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.772 0 N-CA-C 119.629 2.612 . . . . 0.0 119.629 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -173.13 -152.29 8.65 Favored Glycine 0 N--CA 1.486 2.011 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 77.8 p -81.28 -0.47 41.01 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.327 -1.102 . . . . 0.0 108.648 179.57 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.54 23.14 73.9 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.104 -1.598 . . . . 0.0 109.104 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . 0.443 ' HE1' HG21 ' A' ' 10' ' ' VAL . 4.9 t90 -61.79 134.77 57.14 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.207 -1.172 . . . . 0.0 109.995 -179.633 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . 0.497 ' C ' ' H ' ' A' ' 8' ' ' ASP . 57.0 t-20 -130.71 130.27 43.62 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 177.342 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.1 -3.95 0.29 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.204 -0.935 . . . . 0.0 109.544 -179.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.497 ' H ' ' C ' ' A' ' 6' ' ' ASN . 92.9 m-20 -72.14 -36.91 69.49 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.302 -0.874 . . . . 0.0 110.51 -179.173 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -81.76 -0.91 45.23 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.922 -1.111 . . . . 0.0 109.784 -179.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.443 HG21 ' HE1' ' A' ' 5' ' ' TRP . 3.9 t -100.34 140.24 19.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.241 -0.912 . . . . 0.0 109.212 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -102.04 106.44 47.75 Favored Pre-proline 0 N--CA 1.492 1.653 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -49.17 -14.42 0.49 Allowed 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 121.86 1.707 . . . . 0.0 112.066 -179.274 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.1 t -63.44 -38.51 91.43 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.465 -0.772 . . . . 0.0 110.083 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -85.22 -12.58 52.25 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.313 -0.867 . . . . 0.0 110.367 -178.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 39.2 t -68.88 -34.5 75.53 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.654 -1.279 . . . . 0.0 109.867 -179.542 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -119.82 145.43 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 11.4 ptmm? -131.57 152.58 50.67 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.226 -0.921 . . . . 0.0 108.96 -179.624 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -98.49 131.83 44.42 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.149 -0.969 . . . . 0.0 109.824 -179.591 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 29.3 t -117.71 120.07 36.87 Favored 'General case' 0 N--CA 1.496 1.871 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 178.51 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 51.64 -119.03 7.74 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 108.375 -1.89 . . . . 0.0 108.375 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.5 m -110.75 27.57 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.374 -1.074 . . . . 0.0 108.731 179.326 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 45.7 tt0 -128.99 155.72 44.93 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.572 -0.705 . . . . 0.0 110.244 -178.467 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 38.3 m-85 -118.41 138.56 52.36 Favored 'General case' 0 N--CA 1.498 1.966 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 73.3 p -138.64 153.15 48.58 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.227 -0.921 . . . . 0.0 109.359 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.569 ' CZ ' ' SG ' ' A' ' 15' ' ' CYS . 30.1 t80 -80.72 125.2 29.76 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 179.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -86.52 88.68 7.7 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.232 -0.918 . . . . 0.0 110.681 -178.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.444 ' C ' ' H ' ' A' ' 29' ' ' VAL . 7.7 m -79.66 -8.9 59.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.952 -1.093 . . . . 0.0 108.631 178.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -53.53 -8.12 0.78 Allowed Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.444 ' H ' ' C ' ' A' ' 27' ' ' SER . 0.1 OUTLIER -107.51 122.7 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.954 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 178.793 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 59.8 p -63.67 -37.29 86.78 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.655 -0.653 . . . . 0.0 111.613 -178.171 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.8 m -57.65 -36.93 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 120.841 -1.162 . . . . 0.0 110.622 -178.174 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 27.1 m -61.7 -42.08 98.46 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.805 -1.185 . . . . 0.0 110.461 -179.349 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 14.6 mmt -73.91 -20.63 60.33 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.965 -1.085 . . . . 0.0 110.685 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 79.6 mm-40 -60.16 -41.86 93.69 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 120.739 -1.226 . . . . 0.0 110.027 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.79 -47.02 8.98 Favored Glycine 0 N--CA 1.491 2.328 0 C-N-CA 119.166 -1.493 . . . . 0.0 109.872 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 20.9 tp -62.92 -43.45 98.77 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.496 -1.002 . . . . 0.0 110.822 -178.766 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -61.97 -39.7 93.07 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.975 -1.078 . . . . 0.0 110.304 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.481 ' HB3' ' HZ3' ' A' ' 40' ' ' LYS . 77.9 mm-40 -74.95 -8.11 55.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.231 -0.918 . . . . 0.0 110.438 -178.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 73.45 24.83 74.17 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.481 ' HZ3' ' HB3' ' A' ' 38' ' ' GLU . 59.6 mttp -97.86 -6.61 32.1 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 178.129 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.764 HG12 ' H ' ' A' ' 43' ' ' GLY . 93.6 t -135.65 159.92 39.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.64 -179.835 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.441 ' N ' HG12 ' A' ' 41' ' ' VAL . 52.7 ttt85 -118.61 -8.47 10.42 Favored 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.526 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.764 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.34 -161.46 25.66 Favored Glycine 0 N--CA 1.502 3.081 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 90.8 t -120.62 127.23 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.16 0 O-C-N 121.023 -1.281 . . . . 0.0 109.529 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.1 m -85.29 138.28 32.42 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 10.3 m -132.32 134.29 59.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.374 -0.829 . . . . 0.0 110.148 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 51.7 p -125.33 147.8 48.99 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 178.514 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -151.7 142.23 9.27 Favored Glycine 0 N--CA 1.496 2.644 0 C-N-CA 118.996 -1.573 . . . . 0.0 110.836 -178.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 78.5 t -125.13 130.13 73.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -104.52 122.01 44.67 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.451 -0.781 . . . . 0.0 108.914 -179.285 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 36.0 m-85 -92.37 125.86 37.21 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.258 -0.901 . . . . 0.0 110.488 -178.677 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.519 ' HE1' ' HG1' ' A' ' 79' ' ' THR . 97.9 m-85 -109.22 135.54 50.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.454 -0.779 . . . . 0.0 109.941 179.76 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 25.6 m120 -60.83 -13.86 18.16 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 179.041 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 54' ' ' ASP . 11.3 t70 -68.72 0.68 3.97 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.87 15.41 72.89 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 179.059 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.2 p -119.18 152.71 36.12 Favored 'General case' 0 N--CA 1.51 2.531 0 O-C-N 121.367 -1.078 . . . . 0.0 111.153 -179.305 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 39.3 p -131.83 141.53 49.46 Favored 'General case' 0 N--CA 1.499 1.993 0 CA-C-O 121.433 0.635 . . . . 0.0 109.509 179.298 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 35.7 t -118.0 141.58 48.31 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 178.458 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -132.4 116.62 17.06 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.123 -0.986 . . . . 0.0 109.312 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.539 ' O ' ' CD2' ' A' ' 60' ' ' PHE . 42.2 p90 -116.38 122.65 45.47 Favored 'General case' 0 N--CA 1.496 1.865 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.613 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -115.76 143.73 44.97 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.01 178.19 42.4 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.3 t -116.56 128.95 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 O-C-N 121.46 -1.023 . . . . 0.0 109.929 -179.458 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.0 t -95.81 112.0 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.151 -0.968 . . . . 0.0 109.922 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.571 ' O ' ' N ' ' A' ' 67' ' ' SER . 2.3 p -136.63 151.5 72.85 Favored Pre-proline 0 N--CA 1.493 1.703 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 178.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_exo -41.14 -15.14 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.437 0 C-N-CA 121.704 1.603 . . . . 0.0 112.24 179.108 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.571 ' N ' ' O ' ' A' ' 65' ' ' THR . 67.3 p -61.53 -54.15 46.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.875 -1.141 . . . . 0.0 109.955 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -157.78 148.76 16.39 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 120.865 -1.147 . . . . 0.0 110.109 -179.649 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -82.55 163.53 16.68 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 122.23 1.953 . . . . 0.0 111.413 178.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 99.6 t -111.25 131.1 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.128 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.468 ' O ' ' OD1' ' A' ' 71' ' ' ASN . 22.8 p30 -100.91 138.26 38.19 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.471 -0.768 . . . . 0.0 111.671 -177.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.54 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.1 OUTLIER -100.0 1.72 42.78 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 177.907 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 73' ' ' ASN . 0.7 OUTLIER -66.96 52.74 0.05 OUTLIER 'General case' 0 N--CA 1.488 1.461 0 CA-C-O 121.631 0.729 . . . . 0.0 109.345 -179.604 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.54 ' N ' ' O ' ' A' ' 72' ' ' THR . 77.2 mt-30 -64.82 -90.37 0.01 OUTLIER 'General case' 0 C--N 1.294 -1.824 0 O-C-N 121.456 -0.778 . . . . 0.0 109.667 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -112.04 74.83 0.88 Allowed 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.566 -0.709 . . . . 0.0 110.115 -179.563 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.441 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 10.7 tp -60.31 -38.87 79.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.441 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 17.0 t-20 -57.92 -41.19 82.17 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 32.4 tttm -67.81 -43.33 79.9 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.365 -0.834 . . . . 0.0 109.098 178.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.572 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.3 OUTLIER -67.57 -40.84 84.89 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.088 -1.007 . . . . 0.0 109.445 -179.365 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -66.79 -25.92 66.7 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 120.441 -1.412 . . . . 0.0 109.156 179.336 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -68.63 -47.52 66.41 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 120.89 -1.131 . . . . 0.0 110.379 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.7 m -121.25 -18.8 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 121.337 -0.852 . . . . 0.0 111.669 -177.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.11 170.37 46.91 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.413 ' CG2' ' OG1' ' A' ' 79' ' ' THR . 46.5 t -108.3 127.17 64.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 62.5 tt0 -80.45 -66.8 0.83 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 120.999 -1.063 . . . . 0.0 111.149 -179.381 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 34.8 ttpt -114.82 140.02 49.27 Favored 'General case' 0 N--CA 1.506 2.342 0 O-C-N 121.179 -0.951 . . . . 0.0 110.919 -178.267 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 84.5 t80 -120.97 136.26 55.02 Favored 'General case' 0 N--CA 1.505 2.293 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.24 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 -136.49 124.13 22.37 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.204 -0.935 . . . . 0.0 110.18 179.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -125.01 140.77 52.61 Favored 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.421 -0.799 . . . . 0.0 110.426 179.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.0 mt -118.93 129.82 55.38 Favored 'General case' 0 N--CA 1.504 2.26 0 O-C-N 121.501 -0.749 . . . . 0.0 109.464 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 31.8 p -126.57 117.18 22.28 Favored 'General case' 0 N--CA 1.508 2.439 0 CA-C-O 121.848 0.832 . . . . 0.0 110.29 179.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -132.56 156.12 47.42 Favored 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.154 -179.109 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -70.82 144.74 50.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.4 -0.813 . . . . 0.0 109.384 179.302 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 35.5 t -120.04 127.58 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.707 -0.621 . . . . 0.0 109.343 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 96.7 -8.6 66.07 Favored Glycine 0 N--CA 1.497 2.764 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 75.2 m -78.68 144.83 34.98 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.501 -0.999 . . . . 0.0 109.419 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.7 mtm180 -71.0 150.02 46.07 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.274 -0.891 . . . . 0.0 109.538 179.777 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.5 m . . . . . 0 N--CA 1.493 1.684 0 O-C-N 121.075 -1.016 . . . . 0.0 109.184 -179.925 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.908 0 N-CA-C 119.529 2.571 . . . . 0.0 119.529 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 88.39 -6.83 83.12 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.042 -1.623 . . . . 0.0 109.042 -179.629 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 59.3 p -85.73 158.33 20.06 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.399 -1.059 . . . . 0.0 110.103 -179.746 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.35 14.15 82.83 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 179.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . 0.471 ' CD1' ' OE1' ' A' ' 34' ' ' GLN . 89.8 t90 -80.29 116.87 20.6 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.268 -1.136 . . . . 0.0 109.33 179.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 23.4 m120 -131.61 19.44 4.71 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 179.175 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 53.0 17.4 0.89 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.785 -0.572 . . . . 0.0 109.505 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' A' ' 8' ' ' ASP . 26.6 t0 -100.2 7.48 44.48 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.309 -0.869 . . . . 0.0 110.894 -178.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 71.6 m-80 -122.39 13.17 10.23 Favored 'General case' 0 N--CA 1.501 2.087 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.4 m -120.49 141.66 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 CA-C-O 121.343 0.592 . . . . 0.0 109.422 -179.175 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 36.0 t0 -103.97 111.94 65.34 Favored Pre-proline 0 N--CA 1.499 1.999 0 O-C-N 121.247 -0.908 . . . . 0.0 109.081 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_exo -40.78 -33.43 1.06 Allowed 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.232 1.955 . . . . 0.0 113.126 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 58.5 m -60.01 -39.93 87.5 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.036 -1.04 . . . . 0.0 110.711 -179.367 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 47.0 tt0 -70.03 -24.91 63.35 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.799 -1.188 . . . . 0.0 109.925 -178.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.555 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 37.3 t -68.31 -34.41 76.09 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.332 -0.855 . . . . 0.0 110.118 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 1.1 pt -117.17 145.88 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.409 -0.807 . . . . 0.0 109.153 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 52.7 mtpt -126.36 146.09 50.19 Favored 'General case' 0 N--CA 1.497 1.875 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 -179.47 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -87.0 119.73 27.51 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.543 -0.723 . . . . 0.0 109.208 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.512 ' O ' ' N ' ' A' ' 21' ' ' VAL . 39.3 p -102.07 119.54 38.96 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.404 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.81 -93.4 0.01 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.512 ' N ' ' O ' ' A' ' 19' ' ' SER . 2.4 t -129.86 20.89 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.538 -0.978 . . . . 0.0 109.23 -179.641 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 75.2 mt-30 -128.55 167.93 16.42 Favored 'General case' 0 N--CA 1.5 2.067 0 CA-C-O 121.866 0.841 . . . . 0.0 110.695 -179.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 24.3 m-85 -119.74 135.15 54.96 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 107.888 -1.152 . . . . 0.0 107.888 178.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 60.9 p -131.32 149.74 52.43 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.345 -0.847 . . . . 0.0 109.753 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 48.5 t80 -86.89 128.76 35.06 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.468 -0.77 . . . . 0.0 109.871 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -88.27 81.53 7.28 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.105 -0.997 . . . . 0.0 110.552 -179.362 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.2 p -77.97 -16.64 57.99 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.936 -1.102 . . . . 0.0 109.599 179.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -64.1 -3.68 9.48 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.363 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.402 HG12 HG12 ' A' ' 31' ' ' VAL . 2.7 t -98.6 129.35 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.261 -1.141 . . . . 0.0 108.321 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 80.8 p -60.06 -40.24 88.8 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 110.727 -178.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.42 HG13 ' N ' ' A' ' 32' ' ' CYS . 8.1 p -60.67 -40.4 84.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.92 -1.112 . . . . 0.0 110.402 -179.246 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.555 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.9 m -61.37 -43.36 99.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.024 -1.047 . . . . 0.0 110.11 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 9.2 mmt -80.34 -16.83 53.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.897 -1.127 . . . . 0.0 109.824 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.471 ' OE1' ' CD1' ' A' ' 5' ' ' TRP . 55.9 tt0 -60.32 -40.28 90.02 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.053 -1.029 . . . . 0.0 108.744 179.372 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -78.49 -47.47 8.03 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 mt -64.86 -42.67 94.68 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.196 -1.179 . . . . 0.0 110.159 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -62.79 -40.39 97.2 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.015 -1.053 . . . . 0.0 110.002 -179.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 63.5 mm-40 -67.78 -29.29 68.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.199 -0.938 . . . . 0.0 109.61 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.02 22.75 44.01 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 110.09 -1.204 . . . . 0.0 110.09 179.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 17.2 mmmt -102.55 -0.31 32.32 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 178.475 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.636 HG12 ' H ' ' A' ' 43' ' ' GLY . 14.4 t -136.53 157.46 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.512 ' N ' ' O ' ' A' ' 94' ' ' VAL . 70.7 mtp85 -118.18 -10.19 10.33 Favored 'General case' 0 N--CA 1.5 2.045 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 178.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.636 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 141.55 -158.86 26.69 Favored Glycine 0 N--CA 1.497 2.717 0 N-CA-C 108.644 -1.783 . . . . 0.0 108.644 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.7 t -120.59 128.96 76.08 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.184 -1.186 . . . . 0.0 109.207 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.4 m -85.69 139.67 31.18 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.256 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.412 ' O ' HG13 ' A' ' 46' ' ' VAL . 8.6 p -129.61 133.03 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 CA-C-O 121.808 0.813 . . . . 0.0 109.797 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 22.4 p -126.73 150.09 49.24 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 178.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -148.88 145.21 13.29 Favored Glycine 0 N--CA 1.494 2.548 0 C-N-CA 118.708 -1.71 . . . . 0.0 111.462 -178.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 95.4 t -118.16 125.98 74.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 178.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 2.1 m-85 -105.51 116.29 31.69 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.166 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -91.76 124.75 36.13 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.45 -0.781 . . . . 0.0 109.137 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.466 ' C ' ' H ' ' A' ' 54' ' ' ASP . 88.9 m-85 -109.31 134.68 51.49 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 -57.16 -5.96 0.34 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.905 -1.122 . . . . 0.0 108.767 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.466 ' H ' ' C ' ' A' ' 52' ' ' TYR . 46.2 t0 -73.64 3.59 6.14 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.59 27.41 61.21 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.286 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 22.7 p -130.12 150.87 51.19 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.416 -1.05 . . . . 0.0 110.864 -179.162 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 80.5 p -132.0 123.04 26.52 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.64 -0.663 . . . . 0.0 109.324 179.263 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.462 ' C ' ' ND2' ' A' ' 59' ' ' ASN . 23.2 t -104.46 153.2 21.42 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 179.23 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.462 ' ND2' ' C ' ' A' ' 58' ' ' SER . 3.1 m120 -131.97 118.87 20.32 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 120.93 -1.106 . . . . 0.0 108.98 179.755 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -117.48 123.95 47.59 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.477 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -111.78 145.57 39.16 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -163.37 174.88 39.67 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.6 t -119.82 127.22 75.87 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.124 0 O-C-N 121.517 -0.99 . . . . 0.0 109.373 179.584 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 70.8 t -95.38 120.1 44.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.21 -0.931 . . . . 0.0 110.278 -179.202 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.502 ' C ' ' H ' ' A' ' 67' ' ' SER . 3.0 p -137.34 155.32 75.73 Favored Pre-proline 0 N--CA 1.492 1.635 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.097 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -49.69 -4.96 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.021 1.814 . . . . 0.0 111.624 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.502 ' H ' ' C ' ' A' ' 65' ' ' THR . 52.6 p -71.51 -52.1 20.12 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.201 -0.937 . . . . 0.0 110.414 -179.576 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 2.0 t -154.58 147.08 17.6 Favored Pre-proline 0 N--CA 1.497 1.902 0 O-C-N 120.843 -1.161 . . . . 0.0 110.235 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -80.89 163.91 20.47 Favored 'Trans proline' 0 N--CA 1.497 1.687 0 C-N-CA 122.373 2.048 . . . . 0.0 112.413 179.032 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 64.6 t -123.02 131.22 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.223 0 O-C-N 121.499 -0.75 . . . . 0.0 109.02 179.419 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -90.8 140.31 29.92 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 120.953 -1.092 . . . . 0.0 109.728 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.446 ' OG1' ' N ' ' A' ' 73' ' ' ASN . 1.2 p -80.34 -50.43 10.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.058 -1.026 . . . . 0.0 108.778 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.446 ' N ' ' OG1' ' A' ' 72' ' ' THR . 97.7 m-20 -79.5 58.32 2.64 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.483 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.484 ' NE2' ' OD1' ' A' ' 75' ' ' ASP . 0.0 OUTLIER -46.41 -39.56 10.68 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.965 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.484 ' OD1' ' NE2' ' A' ' 74' ' ' GLN . 95.3 m-20 -108.37 75.6 0.99 Allowed 'General case' 0 N--CA 1.496 1.841 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.425 ' CG2' ' N ' ' A' ' 77' ' ' ASN . 9.2 tp -60.43 -39.85 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.456 -0.777 . . . . 0.0 110.435 -178.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.425 ' N ' ' CG2' ' A' ' 76' ' ' ILE . 46.1 t30 -59.87 -46.28 89.79 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 119.02 -1.072 . . . . 0.0 108.142 -179.371 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 44.2 tttp -60.62 -50.14 74.72 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.164 -0.96 . . . . 0.0 108.938 178.345 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.535 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.1 m -62.11 -41.11 97.89 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.726 -0.609 . . . . 0.0 110.413 -178.513 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -64.92 -33.06 75.14 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 120.545 -1.347 . . . . 0.0 109.882 179.714 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 46.2 tttt -67.02 -49.86 63.93 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.116 -0.99 . . . . 0.0 110.662 -179.073 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.8 p -113.8 -26.16 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.67 -0.644 . . . . 0.0 111.967 -176.66 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 81.59 158.11 20.6 Favored Glycine 0 N--CA 1.493 2.436 0 O-C-N 120.494 -1.379 . . . . 0.0 109.713 179.703 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.5 t -105.03 120.38 55.52 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.764 -0.845 . . . . 0.0 108.988 179.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -70.0 -58.36 3.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.132 -0.98 . . . . 0.0 111.569 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -113.9 140.04 48.7 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.141 -0.975 . . . . 0.0 110.328 -178.228 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 71.6 t80 -120.24 127.75 52.7 Favored 'General case' 0 N--CA 1.501 2.111 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -130.78 127.12 38.06 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 121.212 -0.93 . . . . 0.0 109.869 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.68 142.83 51.1 Favored 'General case' 0 N--CA 1.505 2.296 0 O-C-N 121.557 -0.714 . . . . 0.0 110.314 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 mt -125.83 133.54 51.95 Favored 'General case' 0 N--CA 1.508 2.433 0 O-C-N 121.602 -0.686 . . . . 0.0 109.384 179.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 61.8 p -127.95 124.66 37.85 Favored 'General case' 0 N--CA 1.506 2.362 0 O-C-N 121.369 -0.832 . . . . 0.0 110.75 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -133.08 147.25 52.17 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.749 -0.594 . . . . 0.0 109.806 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 88.4 m95 -69.49 139.76 53.92 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 120.816 -1.178 . . . . 0.0 109.35 179.331 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.512 ' O ' ' N ' ' A' ' 42' ' ' ARG . 46.8 t -111.68 120.09 61.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -176.68 -177.14 45.41 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 61.0 m -70.23 133.7 47.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.316 -1.108 . . . . 0.0 109.167 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.432 ' N ' ' CD ' ' A' ' 97' ' ' ARG . 1.3 mpt_? -71.76 139.45 49.05 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.19 -0.944 . . . . 0.0 109.859 -179.597 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 96.9 p . . . . . 0 N--CA 1.488 1.448 0 CA-C-O 117.99 -1.005 . . . . 0.0 109.39 179.779 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.963 0 N-CA-C 119.728 2.651 . . . . 0.0 119.728 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -84.78 -82.76 1.02 Allowed Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.0 m 53.44 22.1 2.72 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.361 -1.082 . . . . 0.0 109.385 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 58.76 -137.27 50.48 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.425 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 27.2 t90 -60.07 140.04 57.1 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.523 -0.986 . . . . 0.0 111.228 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . 0.552 ' C ' ' H ' ' A' ' 8' ' ' ASP . 20.6 m120 -129.56 128.41 42.69 Favored 'General case' 0 C--N 1.305 -1.365 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 177.624 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -63.3 3.66 0.27 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.051 -1.031 . . . . 0.0 108.765 179.607 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.552 ' H ' ' C ' ' A' ' 6' ' ' ASN . 68.4 m-20 -82.28 -26.16 33.37 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.465 -0.772 . . . . 0.0 110.947 -178.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -94.04 3.44 55.33 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 120.858 -1.151 . . . . 0.0 110.659 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.3 t -110.83 130.04 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.296 -0.878 . . . . 0.0 110.52 -179.076 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -88.0 131.94 41.44 Favored Pre-proline 0 N--CA 1.492 1.63 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.491 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -77.18 -19.58 13.44 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 121.801 1.668 . . . . 0.0 112.477 -179.217 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 55.2 m -59.92 -39.93 87.16 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.174 -0.954 . . . . 0.0 110.374 -179.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 90.2 mm-40 -83.71 -11.15 57.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.076 -1.015 . . . . 0.0 110.054 -179.454 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.667 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 45.5 t -69.67 -31.33 69.32 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.131 -0.981 . . . . 0.0 109.142 179.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -120.07 146.06 25.43 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 61.4 pttt -125.47 149.96 47.77 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.458 -0.776 . . . . 0.0 109.384 -179.406 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -99.85 122.03 42.18 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.357 -0.839 . . . . 0.0 109.827 -178.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.1 t -107.45 100.9 10.29 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.069 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 71.72 -94.52 0.59 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.1 m -133.2 23.28 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.204 0 O-C-N 121.285 -1.126 . . . . 0.0 110.413 -179.642 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -131.66 161.56 32.46 Favored 'General case' 0 N--CA 1.504 2.275 0 O-C-N 121.209 -0.932 . . . . 0.0 109.989 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -113.26 141.41 47.02 Favored 'General case' 0 N--CA 1.5 2.04 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 37.2 p -130.01 142.04 50.67 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.36 -0.838 . . . . 0.0 109.425 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.9 t80 -81.64 126.0 31.24 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.49 -0.756 . . . . 0.0 109.897 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -90.02 85.41 6.32 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.35 -0.844 . . . . 0.0 110.447 -179.611 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.2 p -85.54 -1.43 57.09 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.933 -1.104 . . . . 0.0 109.207 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.08 -31.56 77.16 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.511 ' CG2' ' SG ' ' A' ' 32' ' ' CYS . 24.4 m -83.64 132.48 31.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.152 -1.205 . . . . 0.0 109.138 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 71.1 m -60.08 -39.92 87.76 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.325 -0.859 . . . . 0.0 111.474 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.1 m -52.96 -38.19 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 120.719 -1.238 . . . . 0.0 110.588 -178.072 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.667 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 64.8 m -62.85 -39.93 95.91 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.73 -1.231 . . . . 0.0 110.016 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 10.0 mmt -80.07 -14.92 58.16 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.984 -1.073 . . . . 0.0 110.263 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 -64.84 -39.97 94.43 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.884 -1.135 . . . . 0.0 109.287 179.167 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.12 -49.11 8.82 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.97 -40.16 94.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.347 -1.09 . . . . 0.0 109.998 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -61.15 -40.01 92.23 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.936 -1.103 . . . . 0.0 110.043 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -76.7 -10.19 59.21 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.017 -1.052 . . . . 0.0 109.214 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 69.93 27.23 73.36 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 54.7 tttp -98.99 -7.52 26.8 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 178.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.566 HG12 ' H ' ' A' ' 43' ' ' GLY . 4.2 t -133.71 159.03 42.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-N 115.113 -0.949 . . . . 0.0 108.885 -179.591 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 94' ' ' VAL . 96.3 mtt180 -121.46 -5.96 9.28 Favored 'General case' 0 N--CA 1.504 2.265 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.211 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.566 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 142.66 -170.13 25.29 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 108.567 -1.813 . . . . 0.0 108.567 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 77.0 t -111.08 126.18 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.065 -1.256 . . . . 0.0 108.338 179.147 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.4 p -82.02 139.76 34.32 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.126 -0.984 . . . . 0.0 109.275 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.431 ' O ' HG13 ' A' ' 46' ' ' VAL . 12.3 p -130.0 133.45 64.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 98.1 p -124.43 142.54 51.23 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.406 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -133.87 131.86 6.19 Favored Glycine 0 N--CA 1.502 3.068 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.108 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 74.4 t -121.58 129.26 75.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.732 -0.863 . . . . 0.0 108.999 178.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.433 ' HE2' ' HG1' ' A' ' 72' ' ' THR . 29.7 m-85 -104.76 122.54 45.92 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.209 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -96.16 129.82 43.37 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.284 -0.885 . . . . 0.0 109.454 -179.417 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.529 ' O ' ' N ' ' A' ' 54' ' ' ASP . 95.0 m-85 -114.66 127.57 55.84 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -179.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -43.12 -19.11 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.428 -0.795 . . . . 0.0 109.918 179.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 52' ' ' TYR . 50.1 t0 -68.25 1.32 2.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.459 -0.776 . . . . 0.0 109.752 -179.235 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.76 20.26 74.12 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.574 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.5 p -115.9 154.76 29.17 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.423 -1.046 . . . . 0.0 109.726 179.617 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 45.2 p -139.62 137.98 35.76 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.626 -0.671 . . . . 0.0 109.629 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 53.8 m -113.71 149.58 34.55 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 178.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 21.9 p-10 -140.79 119.07 12.08 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.023 -1.048 . . . . 0.0 110.119 -179.418 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 73.5 m-85 -114.11 121.52 44.05 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 107.678 -1.231 . . . . 0.0 107.678 178.349 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.0 ttpm? -113.17 147.33 37.63 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.64 169.2 41.55 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.4 t -110.04 127.32 67.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.416 -1.05 . . . . 0.0 109.594 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.5 t -91.3 119.99 39.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.423 -0.798 . . . . 0.0 110.017 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.515 ' O ' ' N ' ' A' ' 67' ' ' SER . 25.7 p -136.31 147.59 60.81 Favored Pre-proline 0 N--CA 1.493 1.688 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 178.515 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_exo -39.16 -21.86 0.07 OUTLIER 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 121.987 1.792 . . . . 0.0 112.538 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.515 ' N ' ' O ' ' A' ' 65' ' ' THR . 67.9 m -68.41 -45.82 71.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.115 -0.991 . . . . 0.0 111.413 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 5.8 t -154.75 142.8 14.26 Favored Pre-proline 0 N--CA 1.5 2.042 0 O-C-N 120.407 -1.433 . . . . 0.0 111.19 -179.384 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -81.95 166.84 16.67 Favored 'Trans proline' 0 N--CA 1.499 1.83 0 C-N-CA 122.993 2.462 . . . . 0.0 111.627 178.308 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 90.3 t -105.95 135.79 42.81 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.198 0 O-C-N 121.242 -0.911 . . . . 0.0 109.258 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 29.2 m120 -99.67 123.95 44.43 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.301 -0.874 . . . . 0.0 111.464 -178.258 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.462 ' O ' ' OG1' ' A' ' 72' ' ' THR . 0.3 OUTLIER -109.87 20.03 18.44 Favored 'General case' 0 N--CA 1.502 2.174 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.1 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.445 ' O ' ' O ' ' A' ' 74' ' ' GLN . 25.6 t-20 -78.69 60.23 2.7 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.47 -0.769 . . . . 0.0 109.927 -179.433 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.554 ' OE1' ' N ' ' A' ' 74' ' ' GLN . 0.0 OUTLIER -50.28 177.59 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 178.732 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 78.9 m-20 -66.08 119.81 12.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.469 -1.394 . . . . 0.0 108.464 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.436 HG22 ' O ' ' A' ' 76' ' ' ILE . 94.5 mt -80.65 -13.11 12.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.506 -0.746 . . . . 0.0 110.409 -179.092 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 28.7 m120 -60.13 -43.89 95.33 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.827 -1.171 . . . . 0.0 109.036 -179.497 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 18.7 pttt -66.89 -40.09 87.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.877 -1.139 . . . . 0.0 109.271 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.587 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.9 OUTLIER -63.05 -41.13 99.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.239 -0.913 . . . . 0.0 108.777 179.473 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -62.19 -38.71 90.14 Favored 'General case' 0 C--N 1.295 -1.773 0 O-C-N 120.76 -1.213 . . . . 0.0 109.551 179.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 31.3 tttm -71.61 -42.51 67.61 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.07 -1.019 . . . . 0.0 111.148 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 p -112.12 -29.42 2.36 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.188 0 O-C-N 121.252 -0.905 . . . . 0.0 112.168 -176.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.98 161.09 37.15 Favored Glycine 0 N--CA 1.495 2.587 0 O-C-N 120.702 -1.249 . . . . 0.0 110.606 179.31 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 84.7 t -108.99 127.34 65.73 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.075 0 O-C-N 121.807 -0.82 . . . . 0.0 108.903 179.363 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -88.01 -63.12 1.35 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.08 -1.013 . . . . 0.0 111.181 -178.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -115.07 142.94 45.96 Favored 'General case' 0 N--CA 1.505 2.293 0 CA-C-O 121.872 0.844 . . . . 0.0 111.937 -178.002 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -120.08 130.87 54.86 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.07 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.91 128.62 32.93 Favored 'General case' 0 N--CA 1.505 2.325 0 O-C-N 121.067 -1.02 . . . . 0.0 110.104 -178.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.43 135.38 54.08 Favored 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 179.14 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.696 HD13 ' N ' ' A' ' 91' ' ' THR . 0.2 OUTLIER -120.0 134.73 55.16 Favored 'General case' 0 N--CA 1.503 2.205 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.789 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.696 ' N ' HD13 ' A' ' 90' ' ' LEU . 14.5 p -130.22 124.24 32.05 Favored 'General case' 0 N--CA 1.505 2.283 0 CA-C-O 121.571 0.7 . . . . 0.0 111.016 -179.181 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.29 156.98 47.48 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.762 -0.586 . . . . 0.0 110.131 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 65.6 m95 -69.61 149.51 48.06 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.707 -1.246 . . . . 0.0 108.135 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.519 ' O ' ' N ' ' A' ' 42' ' ' ARG . 31.7 t -117.95 123.11 71.2 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.171 0 O-C-N 121.353 -0.842 . . . . 0.0 109.394 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 116.37 -0.96 20.63 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 31.8 m -95.63 136.07 36.5 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.237 -1.155 . . . . 0.0 108.661 179.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 96.1 mtt180 -79.45 -5.09 53.98 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.152 -0.967 . . . . 0.0 109.465 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 53.7 p . . . . . 0 N--CA 1.489 1.503 0 CA-C-O 118.013 -0.994 . . . . 0.0 109.153 179.387 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 5.032 0 N-CA-C 119.933 2.733 . . . . 0.0 119.933 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.46 -178.5 45.35 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.801 -1.32 . . . . 0.0 109.801 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 51.5 p -96.38 143.33 27.53 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.233 -1.157 . . . . 0.0 109.454 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -109.79 -131.42 6.15 Favored Glycine 0 N--CA 1.502 3.041 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -179.714 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 87.8 t90 -68.73 125.31 26.17 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.407 -1.055 . . . . 0.0 109.89 -179.477 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -134.61 18.05 3.6 Favored 'General case' 0 N--CA 1.493 1.724 0 CA-C-O 121.299 0.571 . . . . 0.0 109.855 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 57.77 20.03 6.14 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.434 -0.791 . . . . 0.0 109.109 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.435 ' OD1' ' O ' ' A' ' 8' ' ' ASP . 39.2 t0 -99.19 6.09 46.51 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.296 -0.877 . . . . 0.0 111.427 -178.546 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.7 p-10 -130.01 9.3 5.3 Favored 'General case' 0 N--CA 1.506 2.359 0 O-C-N 120.843 -1.161 . . . . 0.0 108.908 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 2.2 m -124.68 129.96 73.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -89.81 148.25 39.41 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.016 -1.053 . . . . 0.0 108.759 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -80.15 -22.36 7.23 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.408 2.072 . . . . 0.0 111.937 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 56.0 m -60.24 -40.16 89.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.234 -0.916 . . . . 0.0 110.411 -179.583 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -81.05 -13.77 58.48 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.031 -1.043 . . . . 0.0 110.239 -179.286 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.678 ' HG ' ' HG ' ' A' ' 32' ' ' CYS . 53.9 m -71.11 -29.06 64.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.11 178.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -120.46 135.05 61.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 64.0 mmtt -111.96 147.86 35.0 Favored 'General case' 0 N--CA 1.502 2.161 0 O-C-N 121.291 -0.88 . . . . 0.0 109.292 -179.318 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -97.11 119.86 36.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 108.796 179.516 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 47.8 t -107.56 116.08 31.3 Favored 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.56 -109.42 1.21 Allowed Glycine 0 N--CA 1.487 2.038 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 -178.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.435 ' O ' HG13 ' A' ' 21' ' ' VAL . 7.7 p -118.74 34.64 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.43 -1.041 . . . . 0.0 108.997 179.16 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -130.66 159.37 37.42 Favored 'General case' 0 N--CA 1.501 2.111 0 CA-C-O 122.194 0.997 . . . . 0.0 111.567 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -120.8 136.79 54.81 Favored 'General case' 0 N--CA 1.496 1.825 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 26.5 p -137.25 154.44 50.14 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.245 -0.909 . . . . 0.0 109.279 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.8 t80 -87.67 128.06 35.29 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.266 -0.896 . . . . 0.0 109.597 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -86.01 83.21 7.83 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.929 -1.107 . . . . 0.0 109.92 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 86.4 p -84.65 -0.98 55.4 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.933 -1.104 . . . . 0.0 109.424 179.627 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.67 -39.96 95.87 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.089 -1.605 . . . . 0.0 109.089 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 33.4 m -81.83 135.28 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.332 -1.099 . . . . 0.0 108.774 179.433 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 34' ' ' GLN . 17.1 p -72.76 -26.8 61.68 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.182 -0.949 . . . . 0.0 110.873 -178.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.484 HG13 ' N ' ' A' ' 32' ' ' CYS . 10.9 p -59.9 -40.85 83.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 120.841 -1.162 . . . . 0.0 110.774 -178.504 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.678 ' HG ' ' HG ' ' A' ' 15' ' ' CYS . 87.0 m -68.69 -39.9 80.3 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.839 -1.163 . . . . 0.0 109.228 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 99.5 mmm -80.09 -14.6 58.39 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.134 -0.979 . . . . 0.0 108.68 179.089 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.421 ' N ' ' O ' ' A' ' 30' ' ' SER . 7.2 tt0 -60.62 -41.98 95.92 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -76.01 -41.2 28.1 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.378 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.3 tp -67.16 -40.26 86.63 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -1.128 . . . . 0.0 108.687 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -63.07 -40.03 96.47 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.48 -0.763 . . . . 0.0 110.539 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.537 ' N ' ' OE1' ' A' ' 38' ' ' GLU . 0.4 OUTLIER -75.09 -11.41 60.09 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.831 -1.168 . . . . 0.0 109.763 -179.403 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.24 21.5 70.16 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 119.901 -1.142 . . . . 0.0 110.443 178.654 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 62.3 mttm -98.66 -3.38 36.15 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.686 HG12 ' H ' ' A' ' 43' ' ' GLY . 94.0 t -134.91 159.28 41.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.419 ' N ' HG12 ' A' ' 41' ' ' VAL . 95.0 mtt-85 -122.08 -7.13 8.89 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 179.482 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.686 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 138.78 -163.22 25.88 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 -179.504 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 87.8 t -119.39 129.19 75.6 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 121.322 -1.105 . . . . 0.0 109.115 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 5.4 m -86.36 139.19 31.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.861 -1.149 . . . . 0.0 108.897 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.41 ' O ' HG13 ' A' ' 46' ' ' VAL . 10.6 p -131.25 133.76 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 53.5 p -125.42 149.42 48.21 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 179.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -143.51 138.12 7.96 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 119.574 -1.298 . . . . 0.0 110.062 -179.145 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.426 HG21 HH21 ' A' ' 88' ' ' ARG . 62.4 t -122.63 127.06 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 179.064 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.594 ' CD1' ' N ' ' A' ' 50' ' ' PHE . 0.2 OUTLIER -100.87 119.8 39.2 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -179.858 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -94.41 119.92 33.86 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.164 -0.96 . . . . 0.0 108.661 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.482 ' O ' ' N ' ' A' ' 54' ' ' ASP . 93.4 m-85 -102.22 125.79 49.02 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.424 -0.797 . . . . 0.0 109.985 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -47.2 -16.43 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.104 -0.997 . . . . 0.0 109.751 179.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.482 ' N ' ' O ' ' A' ' 52' ' ' TYR . 47.4 t0 -70.85 4.72 2.37 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.247 -0.908 . . . . 0.0 109.223 -179.533 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.08 22.76 70.49 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 178.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 7.4 p -123.54 150.81 43.54 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.33 -1.1 . . . . 0.0 109.339 179.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.1 p -135.33 139.79 44.58 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.583 -0.698 . . . . 0.0 110.152 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.1 m -117.92 144.5 45.41 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 178.352 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.6 m-20 -128.2 118.49 23.42 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.388 -0.82 . . . . 0.0 108.953 -179.831 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 66.3 t80 -116.76 126.47 53.16 Favored 'General case' 0 N--CA 1.495 1.779 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.256 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -113.74 144.9 42.19 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -159.16 167.83 35.02 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.83 128.58 74.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.599 -0.942 . . . . 0.0 108.694 -179.662 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 45.7 t -92.88 117.87 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.047 -1.033 . . . . 0.0 110.088 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.541 ' O ' ' N ' ' A' ' 67' ' ' SER . 6.4 p -134.98 153.87 78.81 Favored Pre-proline 0 N--CA 1.492 1.633 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 178.643 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_exo -43.93 -10.13 0.03 OUTLIER 'Trans proline' 0 N--CA 1.494 1.543 0 C-N-CA 121.981 1.788 . . . . 0.0 113.204 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.541 ' N ' ' O ' ' A' ' 65' ' ' THR . 87.1 p -67.6 -59.52 3.29 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.892 -1.13 . . . . 0.0 110.687 -179.236 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -155.4 150.75 21.21 Favored Pre-proline 0 N--CA 1.498 1.933 0 O-C-N 120.596 -1.315 . . . . 0.0 110.259 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -82.81 161.24 16.25 Favored 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.522 2.148 . . . . 0.0 112.523 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 59.5 t -110.78 130.5 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 15.7 m-20 -100.8 144.46 29.73 Favored 'General case' 0 N--CA 1.506 2.338 0 O-C-N 120.905 -1.122 . . . . 0.0 111.069 -178.355 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.19 -0.06 56.99 Favored 'General case' 0 N--CA 1.504 2.244 0 O-C-N 121.059 -1.026 . . . . 0.0 108.607 178.531 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.434 ' HB3' HG21 ' A' ' 21' ' ' VAL . 52.2 p-10 -80.43 46.67 0.86 Allowed 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.239 -0.913 . . . . 0.0 109.832 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 62.1 tt0 -48.17 -81.04 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.957 -1.09 . . . . 0.0 110.012 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -112.93 94.9 5.12 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.41 -0.806 . . . . 0.0 109.938 -179.503 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 8.8 mm -68.63 -39.89 81.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.28 -0.888 . . . . 0.0 109.733 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -59.95 -40.97 90.81 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 107.74 -1.207 . . . . 0.0 107.74 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -66.51 -43.13 86.1 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.455 -0.778 . . . . 0.0 109.156 178.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.597 ' O ' ' N ' ' A' ' 83' ' ' GLY . 1.2 m -76.1 -47.95 22.55 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.524 -0.735 . . . . 0.0 110.227 -178.721 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -60.05 -32.11 70.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.248 -1.533 . . . . 0.0 109.783 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 18.7 tptt -67.49 -53.53 27.97 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.329 -0.857 . . . . 0.0 110.694 -178.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.12 -22.14 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.172 -0.955 . . . . 0.0 111.515 -178.328 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 86.2 167.3 43.39 Favored Glycine 0 N--CA 1.487 2.086 0 O-C-N 120.896 -1.128 . . . . 0.0 110.764 178.729 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.401 HG23 HG23 ' A' ' 79' ' ' THR . 63.8 t -109.86 129.72 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.744 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -80.03 -67.08 0.8 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.768 -1.208 . . . . 0.0 110.34 -178.784 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -113.73 138.78 49.76 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.418 -0.801 . . . . 0.0 109.891 -178.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 63.2 t80 -121.99 126.88 49.53 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.205 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.426 HH21 HG21 ' A' ' 49' ' ' VAL . 38.6 ptt180 -133.71 134.7 43.37 Favored 'General case' 0 N--CA 1.502 2.151 0 CA-C-O 121.96 0.886 . . . . 0.0 110.023 179.711 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -123.8 136.04 54.16 Favored 'General case' 0 N--CA 1.495 1.798 0 CA-C-O 121.164 0.507 . . . . 0.0 109.749 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 4.0 mt -113.35 131.79 55.83 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.402 -0.811 . . . . 0.0 108.815 179.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 3.8 p -126.12 121.3 32.49 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.677 0.751 . . . . 0.0 109.82 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -133.66 154.46 50.9 Favored 'General case' 0 N--CA 1.498 1.926 0 CA-C-O 121.422 0.63 . . . . 0.0 110.087 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -72.94 138.44 46.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.394 -0.816 . . . . 0.0 109.01 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 39.7 t -109.97 116.31 51.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.752 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -173.39 -48.33 0.05 OUTLIER Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 66.5 m -69.95 149.74 47.44 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.184 -1.186 . . . . 0.0 109.234 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.0 mtt85 -97.96 130.04 44.83 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.227 -0.921 . . . . 0.0 109.05 179.79 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 69.7 m . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 118.054 -0.974 . . . . 0.0 109.254 179.744 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.866 0 N-CA-C 119.563 2.585 . . . . 0.0 119.563 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.42 104.52 1.69 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.15 -1.58 . . . . 0.0 109.15 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 45.7 t -101.37 129.93 47.46 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.359 -1.083 . . . . 0.0 109.422 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.33 19.67 79.38 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.058 -1.617 . . . . 0.0 109.058 -179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 70.3 t90 -56.85 120.54 8.07 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.234 -1.157 . . . . 0.0 109.114 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . 0.484 ' C ' ' H ' ' A' ' 8' ' ' ASP . 13.0 t-20 -128.65 20.59 6.07 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 59.12 1.62 0.23 Allowed 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.759 -0.588 . . . . 0.0 109.699 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.484 ' H ' ' C ' ' A' ' 6' ' ' ASN . 36.4 p-10 -85.13 -26.17 27.04 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.233 -0.917 . . . . 0.0 110.035 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.425 ' N ' ' OD1' ' A' ' 8' ' ' ASP . 22.7 m120 -91.71 1.46 57.14 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.295 -0.878 . . . . 0.0 110.067 -179.141 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.8 t -108.98 129.96 62.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.466 -0.771 . . . . 0.0 109.562 -178.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -90.02 127.6 53.05 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.103 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -76.57 -13.84 18.09 Favored 'Trans proline' 0 N--CA 1.497 1.702 0 C-N-CA 122.082 1.855 . . . . 0.0 112.648 -179.048 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 54.5 m -62.06 -40.01 94.33 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.133 -0.979 . . . . 0.0 110.43 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . 0.416 ' CD ' ' N ' ' A' ' 14' ' ' GLN . 28.2 mp0 -83.35 -12.52 56.47 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.076 -1.015 . . . . 0.0 110.37 -179.2 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.77 ' HG ' ' HG ' ' A' ' 32' ' ' CYS . 36.6 t -64.62 -36.62 84.83 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.182 -0.949 . . . . 0.0 110.189 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.2 pp -117.48 141.1 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 121.399 -0.813 . . . . 0.0 108.887 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 20.4 pttp -118.83 145.46 45.64 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -98.11 124.77 42.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.397 -0.814 . . . . 0.0 109.409 179.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.539 ' O ' ' N ' ' A' ' 21' ' ' VAL . 65.6 m -110.17 131.12 55.34 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.38 -93.68 0.01 OUTLIER Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 -179.235 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.539 ' N ' ' O ' ' A' ' 19' ' ' SER . 26.2 m -139.6 31.39 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.308 -1.113 . . . . 0.0 109.676 179.816 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -131.53 159.41 38.24 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.417 -0.802 . . . . 0.0 109.902 179.456 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -114.24 139.97 48.96 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.027 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 24.2 p -136.53 148.79 47.79 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.143 -0.973 . . . . 0.0 109.847 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -84.55 129.92 34.8 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.169 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -90.95 103.73 16.41 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.095 -1.003 . . . . 0.0 110.159 -179.6 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 88.1 p -92.08 -5.99 51.76 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.062 -1.023 . . . . 0.0 108.981 178.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -59.89 -36.43 90.06 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.8 m -79.0 136.89 22.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.214 -1.168 . . . . 0.0 109.263 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.9 m -68.37 -31.49 70.89 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.409 -0.807 . . . . 0.0 111.157 -178.693 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 85.4 t -59.98 -40.07 82.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.885 -1.135 . . . . 0.0 110.556 -178.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.77 ' HG ' ' HG ' ' A' ' 15' ' ' CYS . 68.3 m -59.84 -47.0 87.51 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.629 -1.294 . . . . 0.0 110.056 -179.321 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . 0.416 ' O ' ' CB ' ' A' ' 37' ' ' ASN . 29.7 mmt -70.23 -34.13 72.49 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.304 -0.873 . . . . 0.0 110.657 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 18.7 mm100 -59.55 -41.53 90.32 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.02 -1.05 . . . . 0.0 110.765 -178.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -77.68 -49.5 7.14 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 30.6 tp -60.01 -43.71 95.04 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.416 ' CB ' ' O ' ' A' ' 33' ' ' MET . 39.9 t30 -61.47 -39.9 92.56 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.543 -0.723 . . . . 0.0 109.963 179.19 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 49.7 tp10 -60.2 -31.4 70.11 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.329 -0.857 . . . . 0.0 109.819 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.81 15.23 56.86 Favored Glycine 0 N--CA 1.497 2.737 0 N-CA-C 110.306 -1.117 . . . . 0.0 110.306 179.33 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -101.98 -1.16 32.46 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 106.628 -1.619 . . . . 0.0 106.628 178.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.688 HG12 ' H ' ' A' ' 43' ' ' GLY . 98.9 t -130.56 159.91 42.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-N 115.172 -0.922 . . . . 0.0 108.518 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.511 ' N ' ' O ' ' A' ' 94' ' ' VAL . 42.0 ttm180 -123.71 -8.93 7.88 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.252 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.688 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 140.84 -159.1 26.43 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 108.215 -1.954 . . . . 0.0 108.215 -179.296 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 96.6 t -119.68 128.65 75.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.306 -1.114 . . . . 0.0 109.178 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 p -82.97 140.89 32.51 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.279 -0.888 . . . . 0.0 109.012 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.458 ' O ' HG13 ' A' ' 46' ' ' VAL . 8.8 p -132.23 130.61 60.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.575 -0.703 . . . . 0.0 109.525 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 16.8 p -123.63 146.04 48.49 Favored 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -140.47 136.74 7.85 Favored Glycine 0 N--CA 1.499 2.84 0 N-CA-C 110.119 -1.193 . . . . 0.0 110.119 -179.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 90.9 t -121.39 129.1 75.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.791 -0.829 . . . . 0.0 108.973 179.113 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -100.72 119.96 39.37 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 179.34 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 63.6 m-85 -96.49 126.09 41.44 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.323 -0.861 . . . . 0.0 108.945 -179.535 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.53 ' CD1' ' NZ ' ' A' ' 78' ' ' LYS . 90.0 m-85 -111.45 129.42 56.04 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.446 -0.784 . . . . 0.0 110.021 -178.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.429 ' OD1' ' OE1' ' A' ' 85' ' ' GLN . 74.9 m-20 -45.46 -17.27 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.41 -0.806 . . . . 0.0 109.406 178.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.514 ' N ' ' O ' ' A' ' 52' ' ' TYR . 52.5 t0 -68.86 0.09 4.83 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.495 -0.753 . . . . 0.0 109.532 -179.552 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.55 23.96 63.86 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.019 -1.086 . . . . 0.0 110.431 179.219 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 11.3 p -122.76 147.47 46.46 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.37 -1.077 . . . . 0.0 110.127 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 72.5 p -131.56 136.27 47.69 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.608 -0.683 . . . . 0.0 109.771 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 41.2 t -118.64 142.73 47.37 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 178.439 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 35.1 p-10 -130.61 120.44 23.99 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.921 -1.112 . . . . 0.0 110.224 -179.224 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.436 ' CZ ' ' NE2' ' A' ' 74' ' ' GLN . 96.1 m-85 -114.71 120.16 39.16 Favored 'General case' 0 N--CA 1.498 1.963 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.8 ttpt -112.54 152.6 28.64 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 -179.43 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.57 174.67 43.27 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 67.6 t -115.7 126.27 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.623 -0.928 . . . . 0.0 110.04 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 38.2 t -91.23 117.76 35.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.514 -0.741 . . . . 0.0 110.013 -179.364 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.516 ' O ' ' N ' ' A' ' 67' ' ' SER . 21.7 p -121.28 150.92 55.11 Favored Pre-proline 0 N--CA 1.498 1.943 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 178.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_exo -38.34 -20.76 0.05 OUTLIER 'Trans proline' 0 C--N 1.312 -1.358 0 C-N-CA 122.01 1.807 . . . . 0.0 113.372 -179.466 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.516 ' N ' ' O ' ' A' ' 65' ' ' THR . 18.1 p -121.81 2.93 10.04 Favored 'General case' 0 N--CA 1.505 2.29 0 O-C-N 121.181 -0.949 . . . . 0.0 111.88 -179.004 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 61.1 p -129.94 107.22 16.66 Favored Pre-proline 0 N--CA 1.51 2.537 0 O-C-N 120.768 -1.207 . . . . 0.0 110.687 -179.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -90.58 165.31 4.24 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 C-N-CA 122.781 2.32 . . . . 0.0 112.288 178.315 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 60.1 t -120.47 129.95 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 N-CA-C 108.79 -0.818 . . . . 0.0 108.79 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 30.1 m120 -99.99 121.65 41.68 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.22 -0.925 . . . . 0.0 111.154 -178.432 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -91.02 -0.02 57.64 Favored 'General case' 0 N--CA 1.497 1.914 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.211 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.438 ' O ' ' O ' ' A' ' 74' ' ' GLN . 51.5 p-10 -75.11 57.74 0.85 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.4 -0.813 . . . . 0.0 109.573 -179.218 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.438 ' O ' ' O ' ' A' ' 73' ' ' ASN . 9.4 tp-100 -55.47 -101.92 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.559 -0.713 . . . . 0.0 109.091 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -108.26 100.43 9.74 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 120.967 -1.083 . . . . 0.0 109.231 179.449 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 44.3 mm -69.86 -39.33 77.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.024 -1.047 . . . . 0.0 109.077 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 -58.29 -41.08 83.6 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.53 ' NZ ' ' CD1' ' A' ' 52' ' ' TYR . 54.5 tttm -60.12 -49.91 75.77 Favored 'General case' 0 N--CA 1.488 1.425 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.367 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.581 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.8 OUTLIER -63.29 -41.03 98.94 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.546 -0.722 . . . . 0.0 110.304 -179.113 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -60.4 -35.94 76.95 Favored 'General case' 0 C--N 1.294 -1.838 0 O-C-N 120.655 -1.278 . . . . 0.0 110.912 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 8.9 tmtm? -70.9 -43.94 67.28 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.701 -1.249 . . . . 0.0 111.463 -178.502 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 p -110.1 -26.0 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.281 0 O-C-N 120.872 -1.142 . . . . 0.0 110.924 -178.281 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.581 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 79.94 157.81 14.73 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.8 t -108.53 130.4 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.067 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.429 ' OE1' ' OD1' ' A' ' 53' ' ' ASN . 18.7 pt20 -97.43 -43.29 7.34 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.185 -0.947 . . . . 0.0 110.929 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -115.9 127.84 55.31 Favored 'General case' 0 N--CA 1.502 2.127 0 O-C-N 121.197 -0.939 . . . . 0.0 110.766 -178.804 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -122.17 123.62 41.94 Favored 'General case' 0 N--CA 1.499 2.003 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 93.8 mtt180 -132.2 133.75 44.54 Favored 'General case' 0 N--CA 1.507 2.387 0 O-C-N 121.073 -1.017 . . . . 0.0 110.799 -179.545 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.1 135.18 53.36 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 121.797 -0.564 . . . . 0.0 109.58 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 54.5 tp -117.32 137.48 52.41 Favored 'General case' 0 N--CA 1.505 2.316 0 O-C-N 121.421 -0.799 . . . . 0.0 109.73 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.7 p -129.72 123.58 31.43 Favored 'General case' 0 N--CA 1.504 2.25 0 CA-C-O 121.639 0.733 . . . . 0.0 111.241 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 87.4 tt0 -133.78 157.33 46.16 Favored 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.637 -0.664 . . . . 0.0 109.724 179.145 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 82.4 m95 -69.43 149.31 48.48 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.78 -1.2 . . . . 0.0 109.873 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' A' ' 42' ' ' ARG . 21.7 t -122.48 127.28 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.093 0 O-C-N 121.549 -0.72 . . . . 0.0 109.629 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 127.67 -16.16 6.23 Favored Glycine 0 N--CA 1.502 3.097 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 178.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.4 p -80.46 128.9 34.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.016 -1.285 . . . . 0.0 108.44 179.35 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 20.4 ttm105 -98.93 118.93 36.82 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.187 -0.946 . . . . 0.0 109.18 -179.706 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.1 m . . . . . 0 N--CA 1.497 1.888 0 CA-C-O 117.991 -1.004 . . . . 0.0 109.403 -179.867 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.841 0 N-CA-C 119.492 2.557 . . . . 0.0 119.492 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.54 170.88 43.92 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 68.7 m -88.44 -9.3 53.01 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.248 -1.149 . . . . 0.0 110.156 -179.416 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 150.05 -157.28 27.15 Favored Glycine 0 N--CA 1.497 2.75 0 N-CA-C 109.971 -1.252 . . . . 0.0 109.971 179.773 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' TRP . . . . . . . . . . . . . 20.0 t90 -59.21 139.31 57.07 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.233 -1.157 . . . . 0.0 109.724 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . 0.499 ' C ' ' H ' ' A' ' 8' ' ' ASP . 83.8 m-20 -133.05 128.12 35.55 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 178.065 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -67.38 8.24 0.35 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.162 -0.961 . . . . 0.0 109.252 179.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.499 ' H ' ' C ' ' A' ' 6' ' ' ASN . 94.7 m-20 -98.07 5.31 48.82 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.48 -0.763 . . . . 0.0 110.546 -178.66 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -121.02 6.58 10.33 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -134.85 139.4 47.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -179.429 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 24.5 m-20 -85.02 148.47 50.72 Favored Pre-proline 0 C--N 1.301 -1.51 0 O-C-N 121.269 -0.895 . . . . 0.0 109.264 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -75.63 -20.98 15.15 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.258 1.972 . . . . 0.0 111.655 179.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 84.0 p -61.48 -37.68 84.52 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.217 -0.927 . . . . 0.0 109.801 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.1 tp-100 -70.1 -25.66 63.61 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.172 -0.955 . . . . 0.0 109.384 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.511 ' SG ' ' SG ' ' A' ' 32' ' ' CYS . 77.2 m -68.42 -30.67 69.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.119 -0.988 . . . . 0.0 109.903 -179.453 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.1 pp -124.06 136.66 59.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -120.91 150.65 40.74 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.597 -0.69 . . . . 0.0 109.139 -179.545 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -91.99 119.77 32.02 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.037 -1.04 . . . . 0.0 109.639 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 54.9 m -124.4 131.72 53.51 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.419 -0.8 . . . . 0.0 109.073 179.732 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 46.6 47.99 17.46 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.896 -1.145 . . . . 0.0 110.504 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.406 HG11 ' OD1' ' A' ' 73' ' ' ASN . 3.4 t 56.92 29.6 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.208 -1.172 . . . . 0.0 110.363 179.451 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 25.3 mt-30 -130.76 164.85 24.22 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.287 -0.883 . . . . 0.0 108.708 178.494 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 39.1 m-85 -120.43 136.77 54.63 Favored 'General case' 0 N--CA 1.501 2.117 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.366 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 34.7 p -139.85 152.3 46.37 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.401 -0.812 . . . . 0.0 109.612 179.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 28.5 t80 -80.81 127.08 32.12 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.638 -0.664 . . . . 0.0 109.229 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -83.6 83.63 7.83 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.342 -0.849 . . . . 0.0 109.783 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 27.9 p -76.68 -8.91 58.17 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.223 -0.923 . . . . 0.0 108.988 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -55.01 -39.79 70.61 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.6 m -82.27 128.61 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.036 -1.273 . . . . 0.0 108.46 179.052 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.463 ' O ' ' N ' ' A' ' 34' ' ' GLN . 82.2 p -66.87 -25.0 66.19 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.174 -0.954 . . . . 0.0 110.445 -178.845 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 71.3 t -59.81 -49.24 84.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.242 -0.911 . . . . 0.0 109.937 -178.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.511 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 79.8 m -61.83 -40.08 94.04 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.949 -1.094 . . . . 0.0 109.305 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' MET . . . . . . . . . . . . . 5.3 tpt -79.97 -14.87 58.26 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.079 -1.013 . . . . 0.0 108.7 179.615 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.463 ' N ' ' O ' ' A' ' 30' ' ' SER . 5.9 tp-100 -63.15 -40.04 96.43 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.05 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -73.17 -45.41 31.49 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.6 mt -61.02 -42.88 99.31 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.316 -1.108 . . . . 0.0 108.994 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -60.25 -39.91 88.42 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.622 0.725 . . . . 0.0 109.265 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -80.01 -10.01 59.74 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.627 -0.67 . . . . 0.0 109.455 -179.522 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 70.34 31.88 68.56 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -106.41 -5.89 18.64 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 179.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.746 HG12 ' H ' ' A' ' 43' ' ' GLY . 87.2 t -133.12 156.67 42.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.573 HH12 ' H ' ' A' ' 96' ' ' SER . 73.8 mtt85 -120.36 -7.03 9.8 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.746 ' H ' HG12 ' A' ' 41' ' ' VAL . . . 137.8 -166.02 25.21 Favored Glycine 0 N--CA 1.498 2.821 0 N-CA-C 109.042 -1.623 . . . . 0.0 109.042 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.7 t -119.95 126.18 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.282 -1.128 . . . . 0.0 109.239 -179.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 28.6 m -80.76 133.12 35.6 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.255 -0.903 . . . . 0.0 108.775 179.267 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.439 HG13 ' O ' ' A' ' 46' ' ' VAL . 7.1 p -129.01 132.27 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.586 -0.696 . . . . 0.0 109.396 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.5 p -123.39 148.4 46.12 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -142.4 140.91 10.3 Favored Glycine 0 N--CA 1.503 3.157 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.981 -178.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 94.8 t -124.79 130.03 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.675 -0.897 . . . . 0.0 109.654 179.188 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 33.9 m-85 -104.18 114.36 28.55 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.823 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -86.28 131.68 34.16 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.041 -1.037 . . . . 0.0 109.192 -179.569 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.429 ' C ' ' H ' ' A' ' 54' ' ' ASP . 54.3 m-85 -116.32 134.18 55.18 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.465 -0.772 . . . . 0.0 109.713 -179.439 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.426 ' C ' ' H ' ' A' ' 55' ' ' GLY . 44.8 t30 -57.17 -11.38 1.63 Allowed 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 178.77 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.429 ' H ' ' C ' ' A' ' 52' ' ' TYR . 11.9 t70 -67.01 0.6 2.43 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.426 ' H ' ' C ' ' A' ' 53' ' ' ASN . . . 79.52 20.76 68.25 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.173 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 18.4 p -130.9 151.56 51.18 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.297 -1.119 . . . . 0.0 110.914 -179.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 79.2 p -130.05 137.58 50.3 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 56.9 m -116.24 148.89 40.01 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 179.105 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -137.49 127.33 25.58 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.302 -0.874 . . . . 0.0 109.715 179.77 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -116.41 129.13 56.07 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.013 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -114.06 144.95 42.28 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -167.44 164.54 37.99 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.1 t -109.95 128.19 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.535 -0.98 . . . . 0.0 108.932 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 21.2 t -91.91 119.1 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.191 -0.943 . . . . 0.0 110.088 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.401 ' C ' ' H ' ' A' ' 67' ' ' SER . 29.7 p -132.31 149.93 74.56 Favored Pre-proline 0 N--CA 1.492 1.639 0 N-CA-C 106.889 -1.522 . . . . 0.0 106.889 178.268 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -52.28 -9.23 0.48 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 121.443 1.429 . . . . 0.0 111.293 -179.376 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.401 ' H ' ' C ' ' A' ' 65' ' ' THR . 19.6 m -104.79 -24.93 12.84 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.513 -0.742 . . . . 0.0 110.31 -179.655 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 20.7 m -135.88 107.39 9.76 Favored Pre-proline 0 N--CA 1.506 2.356 0 O-C-N 121.113 -0.992 . . . . 0.0 110.652 -179.593 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -87.04 164.03 8.7 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 C-N-CA 122.148 1.899 . . . . 0.0 111.69 178.428 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 62.3 t -118.57 129.57 74.65 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.377 -0.827 . . . . 0.0 109.12 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -103.3 136.67 42.64 Favored 'General case' 0 N--CA 1.501 2.105 0 O-C-N 121.148 -0.97 . . . . 0.0 110.678 -178.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.419 ' O ' ' N ' ' A' ' 74' ' ' GLN . 0.4 OUTLIER -93.12 -1.16 56.7 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 178.347 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.416 ' O ' ' O ' ' A' ' 74' ' ' GLN . 78.3 m-20 -70.31 51.73 0.13 Allowed 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.427 -0.796 . . . . 0.0 109.378 -179.554 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.419 ' N ' ' O ' ' A' ' 72' ' ' THR . 59.1 tt0 -62.39 -108.47 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 179.507 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -106.32 96.12 6.24 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.137 -0.977 . . . . 0.0 108.384 178.278 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.428 HG22 ' O ' ' A' ' 76' ' ' ILE . 90.4 mt -84.99 -15.22 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.0 -1.063 . . . . 0.0 110.305 -179.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 64.9 t-20 -59.89 -44.6 94.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.919 -1.113 . . . . 0.0 109.837 -179.335 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.414 ' HB2' ' HZ3' ' A' ' 78' ' ' LYS . 9.7 ptmm? -68.77 -33.96 74.77 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.11 -0.994 . . . . 0.0 109.174 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.607 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.7 OUTLIER -62.89 -45.14 93.9 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.935 -1.103 . . . . 0.0 108.067 178.895 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -59.95 -35.17 74.38 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 120.776 -1.202 . . . . 0.0 108.843 178.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.4 tttp -63.99 -51.15 65.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.402 -0.811 . . . . 0.0 111.07 -178.733 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.9 m -117.01 -20.8 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.226 0 O-C-N 121.365 -0.835 . . . . 0.0 111.545 -177.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.607 ' N ' ' O ' ' A' ' 79' ' ' THR . . . 89.28 167.48 42.84 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 179.412 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 53.6 t -108.62 126.49 65.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 57.1 tt0 -79.96 -65.33 1.02 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.892 -1.13 . . . . 0.0 109.958 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.8 tptm -114.38 140.18 48.88 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.52 -0.738 . . . . 0.0 110.554 -178.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 69.2 t80 -119.75 137.23 54.07 Favored 'General case' 0 N--CA 1.5 2.045 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.139 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -138.1 128.08 25.6 Favored 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.066 -1.021 . . . . 0.0 111.068 -178.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -124.57 133.43 53.29 Favored 'General case' 0 N--CA 1.503 2.177 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 59.4 tp -120.01 135.35 54.96 Favored 'General case' 0 N--CA 1.508 2.434 0 O-C-N 121.298 -0.876 . . . . 0.0 110.169 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 30.6 p -129.23 127.38 41.14 Favored 'General case' 0 N--CA 1.505 2.282 0 CA-C-O 121.679 0.752 . . . . 0.0 110.958 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -132.63 145.86 51.43 Favored 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.692 -0.63 . . . . 0.0 110.221 179.774 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' TRP . . . . . . . . . . . . . 76.8 m95 -69.88 139.96 53.1 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 120.945 -1.097 . . . . 0.0 108.771 178.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 17.4 t -112.38 117.52 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.453 -0.779 . . . . 0.0 109.546 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 163.03 89.96 0.07 OUTLIER Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 179.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.573 ' H ' HH12 ' A' ' 42' ' ' ARG . 16.5 t -75.09 130.47 39.32 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.024 -1.28 . . . . 0.0 109.224 179.464 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -82.72 145.03 29.81 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.046 -1.034 . . . . 0.0 109.764 -179.616 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.6 t . . . . . 0 N--CA 1.491 1.6 0 CA-C-O 117.925 -1.036 . . . . 0.0 109.269 179.577 . . . . . . . . 0 0 . 1 stop_ save_